[
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is small cell lung carcinoma. The ICDCodes associated with this disease are D02.20, D02.21, and D02.22. The drugs being used in the trial are regorafenib (bay73-4506) - sequential / cisplatin / pemetrexed and regorafenib (bay73-4506) - continuous / cisplatin / pemetrexed. \n\nThe eligibility criteria for this trial include being at least 18 years old, having a histological or cytological diagnosis of metastatic Stage IV or locally advanced, unresectable confirmed Stage IIIB nonsquamous Non-Small Cell Lung Cancer (NSCLC) that is not amenable to local therapy with curative intent. The Eastern Cooperative Oncology Group (ECOG) Performance Status should be between 0 and 2, and the life expectancy should be at least 12 weeks. Adequate bone marrow, liver, and renal function are required, as well as controlled blood pressure. Men and women of childbearing potential must use adequate barrier birth control measures during the study.\n\nThe exclusion criteria for this trial include sensory neuropathy with sensory alterations or paresthesia, hearing impairment, persistent proteinuria of Common Toxicity Criteria (CTC) Grade 3 or higher, cardiac disease, brain metastasis, arterial or venous thrombotic or embolic events, pulmonary hemorrhage/bleeding event, bleeding diathesis or coagulopathy, centrally located tumors with radiologic evidence of local invasion of major blood vessels, and other specific conditions mentioned in the sample.\n\nAdditionally, the sample mentions that prior treatment with systemic chemotherapy for metastatic NSCLC is not allowed, but patients who underwent prior systemic treatment or radiotherapy for NSCLC in a neoadjuvant or adjuvant setting are eligible as long as they have not received chemotherapy treatment within the last 6 months prior to study entry.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in this trial are imatinib mesylate and cyclophosphamide, with three different dosing levels. \n\nThe eligibility criteria for this trial include the following inclusion criteria: the patient must have a rare tumor, metastatic or locally advanced disease that is inoperable and has no standard treatment, at least 28 days since the prior treatment, and measurable disease with at least one measurable lesion. The exclusion criteria include medullary insufficiency, cystitis or hemorrhagic cystitis, and hepatic porphyria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is diabetes mellitus, type 2. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are placebo, canagliflozin 300mg/placebo, canagliflozin 300mg/canagliflozin 150mg, and canagliflozin 300mg. The eligibility criteria for this trial include specific requirements for patients with type 2 diabetes mellitus and inadequate glycemic control. There are also exclusion criteria that specify certain medical histories or conditions that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial for the treatment of breast cancer in its metastatic or locally advanced stage, specifically targeting HER2 overexpression. The trial is a combination of phase 1 and phase 2. The diseases column indicates that the trial focuses on breast cancer. The icdcodes column provides a list of ICD-10 codes associated with the disease. The drugs column lists the medications being used in the trial, which include trastuzumab, paclitaxel, and myocet. The criteria column describes the eligibility criteria for participants in the trial, including age range, specific cancer stage, HER2 overexpression, and the presence of measurable lesions. It also lists the exclusion criteria, such as prior treatment for advanced breast cancer, previous use of Herceptin, exclusive bone or central nervous system metastasis, and a history of other malignancies within the past 5 years.",
    "The sample from the table is for a clinical trial in the early phase 1. The trial is focused on the treatment of schizophrenia and cognitive deficits. The ICD-10 codes associated with these diseases are provided. The drug being tested is papaverine or placebo. The eligibility criteria for participants include being diagnosed with schizophrenia according to the WHO ICD-10, having stable treatment for at least 6 weeks, being on mono antipsychotic treatment, and not regularly taking antidepressants or benzodiazepines. The exclusion criteria include having a dependence syndrome, severe physical illness, and having non-removable objects above the shoulders that are incompatible with MRI.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for patients with advanced solid malignancies, specifically cancer. The trial is conducted in Japan and the drug being tested is called azd4547. The eligibility criteria for inclusion in the trial include being over 25 years old and in relatively good overall health, apart from the cancer. The exclusion criteria include having poor bone marrow function, liver or kidney problems, refractory nausea and vomiting, chronic gastrointestinal diseases, or previous significant bowel resection.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"neoplasms, breast\" and its corresponding ICDCodes are ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']. The drugs being used in the trial are 'doxorubicin', 'pazopanib (gw786034)', and 'epirubicin'. The eligibility criteria include various conditions such as written informed consent, confirmed diagnosis of advanced solid tumor, age greater than or equal to 18 years, adequate organ system function, ECOG performance value of 0 or 1, and more. There are also exclusion criteria listed, such as prior use of pazopanib or anthracyclines, certain cardiovascular conditions, unstable or serious concurrent conditions, and others.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include cancer, non-small-cell lung cancer, colorectal cancer, papillary thyroid cancer, and melanoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are xl281 and famotidine. \n\nThe eligibility criteria for participants in this trial include having a histologically confirmed solid tumor that is metastatic or unresectable, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, and having adequate organ and marrow function. Other criteria include understanding the protocol and signing the informed consent document, using contraception if sexually active, having a negative pregnancy test for female subjects of childbearing potential, and having no other diagnosis of malignancy except for certain exceptions. \n\nExclusion criteria include recent anticancer treatment, recent treatment with small molecule kinase inhibitors or hormonal therapy, recent use of other investigational agents, not recovering from adverse events or baseline values, requiring certain types of treatment, having a primary brain tumor or known brain metastases, having uncontrolled intercurrent illness, being pregnant or breastfeeding, being HIV positive, having allergies or hypersensitivity to certain components, being unable or unwilling to abide by the study protocol, and receiving anticoagulation with certain compounds. \n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being used in the trial are docetaxel and epirubicin hydrochloride. The eligibility criteria for this trial include specific disease characteristics, such as histologically confirmed adenocarcinoma of the prostate, measurable or non-measurable disease with certain criteria, and progressive systemic disease despite prior standard endocrine therapy. The patient characteristics include age 18 and over, ECOG performance status 0-2, and specific hematopoietic, hepatic, renal, cardiovascular, and other health requirements. The prior concurrent therapy section outlines restrictions on biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is breast cancer. The ICD-10 codes associated with the disease are \"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", and \"D48.60\". The drugs being used in the trial are \"myocet\", \"taxotere\", and \"herceptin\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as written informed consent, specific stage and diagnosis of breast cancer, overexpression of HER2neu, absence of metastasis, certain age and performance status requirements, adequate cardiac, hepatic, and renal function, negative pregnancy test, and other exclusions such as prior treatments, comorbidities, and gender (males are excluded).",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for multiple types of cancer, including ovarian cancer, endometrial cancer, cervical cancer, and lung cancer. The ICD-10 codes associated with these diseases are also provided. The trial involves the use of two drugs, pemetrexed and topotecan. The eligibility criteria for participants are listed, including requirements such as having histologically proven advanced solid tumors, being at least 18 years old, and having adequate liver, bone marrow, and kidney function. There are also exclusion criteria, such as having received more than 3 prior chemotherapy regimens in the metastatic setting, prior treatment with topotecan or pemetrexed, and the presence of active brain metastases. The record provides detailed information about the trial phase, diseases, ICD-10 codes, drugs, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are adenocarcinoma of the pancreas, recurrent pancreatic cancer, and stage IV pancreatic cancer. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are vismodegib and gemcitabine hydrochloride. \n\nThe eligibility criteria for this trial include having histologically or cytologically confirmed adenocarcinoma of the pancreas, measurable disease, and being either newly diagnosed with chemo-na\u00efve metastatic pancreatic cancer or having recurrent disease after curative-intent surgery. Other criteria include age, life expectancy, performance status, blood counts, liver function, kidney function, and more. \n\nThere are also exclusion criteria, such as no prior chemotherapy for metastatic pancreatic cancer, no other investigational agents for metastatic disease, and no known brain metastases. Other exclusion criteria include allergies to certain compounds, certain medical conditions, and currently active second malignancy. \n\nPregnant women, breastfeeding women, and HIV-positive patients on combination antiretroviral therapy are also excluded from this study. \n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial related to pancreatic cancer.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and the disease being studied is \"healthy\" (which seems to be a control group). The ICD-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being used in the trial are \"concor 5mg(bisoprolol hemifumarate 5mg) 2tab\", \"crestor 20mg(rosuvastatin calcium 20.80mg) 1tab\", and a combination of \"concor 5mg 2t and crestor 20 mg 1tab\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Male volunteers between the ages of 20 and 55 years old.\n- Body mass index (BMI) between 18.5 and 27 kg/m2.\n- Medically healthy with normal vital signs (blood pressure and pulse rate) within specific ranges.\n- Available for the entire study period.\n- Understand the study requirements and voluntarily consent to participate.\n\nThere are also exclusion criteria for participants, including:\n- History of gastrointestinal diseases that could affect the absorption, distribution, metabolism, and excretion of medicines.\n- History of certain diseases such as arrhythmia, peripheral vascular disease, thyroid disease, bronchospasm, and asthma.\n- Allergy to bisoprolol and/or rosuvastatin.\n- History of drug abuse or abuse of caffeine, alcohol, or smoking.\n- Abnormal clinical laboratory test values for certain parameters.\n- Recent blood donation or transfusion.\n- Considered unsuitable for the trial based on medical judgment by investigators.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is mantle cell lymphoma. The ICD-10 codes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drugs being tested in this trial are pd 0332991 and bortezomib. The eligibility criteria for participants include having confirmed mantle cell lymphoma, measurable disease, prior chemotherapy and rituximab treatment, age over 18, accessible disease (such as adenopathy, bone marrow involvement, or circulating lymphoma cells), ECOG performance status of 2 or lower, normal organ and marrow function, and willingness to use contraception if applicable. Exclusion criteria include recent treatment with chemotherapy, radiotherapy, antibodies, or investigational agents, prior exposure to PD 0332991, significant hematologic or neuropathic toxicities from prior bortezomib therapy, peripheral neuropathy of grade 2 or higher, known allergies to similar compounds, contraindication to core needle biopsies, known HIV infection, malabsorption syndrome, suspected CNS involvement, uncontrolled illness, pregnancy or lactation, prolonged QTc interval, current or anticipated use of drugs that are potent CYP3A4 inhibitors or inducers, recent myocardial infarction or severe heart failure, and recent diagnosis or treatment of another malignancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with multiple myeloma are C90.01, C90.02, and C90.00. The drugs being used in the trial are dasatinib, bortezomib, and dexamethasone. The sample also includes the eligibility criteria for participants to be included or excluded from the trial. The inclusion criteria include having a confirmed diagnosis of multiple myeloma with measurable disease, evidence of relapsed or refractory disease, and having undergone at least 2 prior therapies for multiple myeloma. The exclusion criteria include having clinically significant cardiac disease, abnormal QT interval corrected for heart rate, malabsorption syndrome or uncontrolled gastrointestinal toxicities, dementia or chronic medical/psychiatric conditions, clinically significant pleural effusion or ascites, coagulation or platelet function disorder, intolerance to dasatinib and/or bortezomib, acute diffuse infiltrative pulmonary disease, and having a prior or concurrent malignancy (with some exceptions).",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 1/phase 2. The disease being studied is diabetic macular edema. The icd-10 codes associated with this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The drug being used in the trial is ranibizumab. The eligibility criteria for participants in this trial include being able to provide written informed consent, being over 18 years old, having a diagnosis of diabetes mellitus, having clinical evidence of retinal thickening due to macular edema, having a previous history of two consecutive intravitreal bevacizumab injections, having central diabetic macular edema present on examination and OCT testing, having a specific range of visual acuity, having media clarity and pupillary dilation for testing, and meeting certain exclusion criteria such as not being pregnant, not participating in another ocular investigation or trial, and not having certain medical conditions or eye conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drug mentioned is \"canagliflozin\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Patients with type 2 diabetes mellitus who are not currently receiving any anti-hyperglycemic agents (AHAs) for at least 12 weeks, or who are receiving treatment with a stable dose and regimen of metformin monotherapy for at least 12 weeks and have a hemoglobin A1c (HbA1c) level between 7% and 10%.\n\nExclusion Criteria:\n- Patients with a history of type 1 diabetes, \"brittle\" diabetes, or secondary forms of diabetes.\n- Patients with a history of one or more severe hypoglycemic episodes.\n- Patients with a history of clinically significant diabetic complications.\n- Patients with a history of or current illness considered to be clinically significant by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is type 1 diabetes. The ICDCodes associated with this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being tested in this trial are etanercept and placebo. The eligibility criteria for this trial include specific age requirements (3-18 years), positive GAD 65 and/or islet cell antibody, HbA1c at diagnosis above 6%, a specific insulin regimen, certain white blood count and platelet count ranges, normal ALT and AST levels, creatinine levels below 1.8 mg/dl, and a duration of type 1 diabetes equal to or less than 4 weeks. The exclusion criteria include recent infection requiring IV antibiotics, BMI over the 85th percentile for age and gender, unstable household, inability to comply with study drug, insulin, and study visits, evidence of psychiatric disease in the potential study subject and/or primary caregiver, and chronic diseases except euthyroid autoimmune thyroiditis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drug being tested is hll1-dox, which is the doxorubicin conjugate of milatuzumab. \n\nThe eligibility criteria for this trial include being able to provide signed, informed consent, being at least 18 years old, having multiple myeloma with measurable disease criteria, being refractory or relapsed to at least two prior standard systemic anti-myeloma treatment regimens, having adequate performance status, having a life expectancy of at least 6 months, having adequate cardiac function, having adequate hematologic status, having adequate renal function, having adequate hepatic function, and meeting various other criteria.\n\nThe exclusion criteria for this trial include being pregnant or lactating, being eligible for stem cell transplant, not practicing or unwilling to practice birth control, having received prior local radiotherapy, chemotherapy, immunotherapy, plasmapheresis, or major surgery within specific timeframes, having persistent toxicity from prior treatments, having received prior treatment with other therapeutic agents for multiple myeloma or investigational agents within a specific timeframe, having a history of allergic or adverse reactions to certain agents, having a cumulative lifetime exposure to certain agents exceeding a certain threshold, being HIV positive or having a prior hepatitis B or C infection, having a history of clinically significant autoimmune disease, having a prior history of mediastinal or pericardial external beam radiation therapy, having a prior history of treatment with trastuzumab without medical approval, having a systemic infection or requiring anti-infectives within a specific timeframe before the first dose of the study drug, and having substance abuse or other concurrent medical conditions that could confound the study or affect the patient's ability to tolerate or complete it.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include adult brain tumor, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, and recurrent adult brain tumor. The ICDCodes associated with these diseases are G47.13, J01.41, K11.22, K12.0, N96, F33.8, and G03.2. The drug being tested is tandutinib. The eligibility criteria for this trial include histologically confirmed glioblastoma, measurable disease, maintenance on a stable corticosteroid regimen, Karnofsky performance status of 60-100%, specific blood count and liver function requirements, not being pregnant or nursing, negative pregnancy test, use of effective contraception, specific cardiac and gastrointestinal health requirements, absence of certain medical conditions, absence of certain allergies, absence of ongoing or active infections, absence of psychiatric illness or social situations that would affect study compliance, absence of other serious infections or medical illnesses, specific time requirements since prior treatments, absence of certain concurrent medications or therapies, specific platelet count and heart function requirements, and specific kidney function requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-small cell lung cancer and lung cancer. The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is a combination of abt-751 and carboplatin. \n\nThe eligibility criteria for this trial include being at least 18 years old, having a confirmed diagnosis of NSCLC, having at least one measurable lesion, being in an advanced stage of the disease, and not having any known curative treatment options. Other criteria include having adequate hematologic, renal, and hepatic function, having an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1, and having previously received platinum therapy. \n\nThe exclusion criteria include having any other malignancy within the past 3 years (except in situ carcinoma), having untreated central nervous system (CNS) metastasis, having neurology category findings greater than Grade 1, receiving concurrent anti-cancer therapy or radiotherapy, and having allergies or hypersensitivity to carboplatin or sulfa. Other exclusion criteria include being pregnant or breastfeeding, not agreeing to use a contraceptive method, having received more than 2 prior chemotherapy regimens, and having clinically significant medical conditions that may compromise safety or study conduct.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on treating metastatic colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are azd2171, folfox (5-fluorouracil, leucovorin, oxaliplatin), and placebo cediranib. The eligibility criteria for this trial include having metastatic colorectal cancer, a WHO performance status of 0-1, and a life expectancy of 12 weeks or longer. The exclusion criteria include having uncontrolled brain metastases, inappropriate laboratory test values, and poorly controlled hypertension.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on the disease \"type 2 diabetes mellitus\". The associated ICD-10 codes for this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The trial involves testing several drugs, including 'mk-0893 10 mg', 'mk-0893 40 mg', 'mk-0893 200 mg', 'mk-0893 1000 mg', and a placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being in good health, having a body mass index (BMI) between 18 and 28 kg/m^2 (or up to 30 kg/m^2 with sponsor approval), being a non-smoker for at least 6 months, and being willing to avoid strenuous physical activity, alcohol, caffeine, and grapefruit juice consumption. \n\nExclusion criteria include a history of renal, neurologic, gastrointestinal, or respiratory disease, any gastrointestinal surgery, multiple and/or severe allergies to drugs or food, any cardiovascular/cardiac disease, any hepatic disease and primary biliary cirrhosis, hypoglycemia or glucose intolerance, type 1 diabetes, or type 2 diabetes. Other exclusion criteria include the use of prescription or nonprescription medications (including herbal remedies), illicit drug use or a history of drug/alcohol abuse, recent surgery, blood donation, or participation in another clinical study within 4 weeks prior to this trial. Additionally, a history of hypersensitivity to insulin, glucagon, or Sandostatine\u00ae is also an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are chronic lymphocytic leukemia and small lymphocytic leukemia. The ICDCodes associated with these diseases are C91.11, C91.12, C91.10 for chronic lymphocytic leukemia, and A87.2, K52.832, D72.111, C91.11, C91.12, C91.10 for small lymphocytic leukemia. The drugs being used in the trial are lenalidomide, fludarabine, and rituximab. The eligibility criteria for this trial include being 18 years of age or older, diagnosed with B-CLL/SLL based on specific criteria, having no prior systemic therapy for CLL/SLL, currently needing therapy based on specific criteria, having measurable disease, having an ECOG Performance Status of 0-2, having laboratory test results within specified parameters, being able to take aspirin daily as prophylactic anticoagulation. The exclusion criteria include having any serious medical condition, being pregnant or breastfeeding, having any condition that places the subject at unacceptable risk, using any other experimental drug or therapy within 28 days of baseline, having known hypersensitivity to thalidomide, developing erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs, having prior use of lenalidomide, concurrent use of other anti-cancer agents or treatments, being known positive for HIV, being a chronic active Hep B patient not on prophylactic lamivudine, and having a diagnosis of Mantle Cell Lymphoma.",
    "The sample is a phase 1 clinical trial for HIV prevention. The trial focuses on the use of various formulations of tenofovir gel for rectal and vaginal use. The eligibility criteria for participants include being at least 18 years old, able to communicate in English, and willing to provide written informed consent. Participants must also be HIV-1 negative, vaccinated for or have natural immunity to Hepatitis B, and in general good health. They must agree to abstain from certain sexual practices and use study-provided condoms throughout the trial. Female participants have additional criteria related to vaginal insertion and contraception. The exclusion criteria include various medical conditions, infections, abnormal lab results, and history of substance abuse. Pregnant and breastfeeding individuals are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are lonafarnib and paclitaxel. \n\nThe eligibility criteria for this trial include the following disease characteristics: histologically or cytologically confirmed breast cancer, stage IIIB, IIIC, or IV, HER2/neu overexpression (3+ by immunohistochemistry or 2+ if positive fluorescent in situ hybridization), and meeting specific treatment criteria (paclitaxel/trastuzumab may be appropriate therapy, anthracycline therapy is not suitable). \n\nThe patient characteristics include being 18 years or older, male or female, with no specified menopausal status. The performance status should be ECOG 0-2 or WHO 0-2, and there is no specified life expectancy. Hematopoietic requirements include a neutrophil count of at least 1,500/mm^3, platelet count of at least 100,000/mm^3, and hemoglobin level of at least 10.0 g/dL. Hepatic requirements include bilirubin no greater than 1.5 times the upper limit of normal (ULN), alkaline phosphatase less than 2.5 times ULN (5 times ULN if liver metastases are present), and AST and ALT less than 2.5 times ULN (5 times ULN if liver metastases are present). Renal requirements include a creatinine clearance of at least 40 mL/min. Cardiovascular requirements include normal cardiac ejection fraction by MUGA, QTc interval no greater than 440 msec, and no cardiac dysfunction. Other criteria include not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, having no concurrent severe/unstable systemic disease or infection, and having no circumstances that would preclude study participation. \n\nPrior concurrent therapy requirements include more than 1 year since prior trastuzumab, no concurrent prophylactic growth factors, more than 1 year since prior paclitaxel, more than 4 weeks since other prior chemotherapy, more than 1 day since prior hormonal therapy, more than 2 days since prior high-dose chronic steroids, more than 2 days since prior ethinyl estradiol, no concurrent high-dose chronic steroids or ethinyl estradiol, more than 4 weeks since prior radiotherapy, and no specified surgery. Other requirements include more than 2 days since prior administration of and no concurrent CYP3A4 inducers or inhibitors, no concurrent grapefruit juice, no other concurrent anticancer agents, and no other concurrent investigational therapy.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a phase 1 trial and includes details about the diseases being studied, the associated ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are lung cancer, breast cancer, pancreatic cancer, head and neck cancer, and gastric cancer. The corresponding ICD-10 codes for these diseases are also provided. The drug being tested is called 2-deoxy-d-glucose (2dg).\n\nThe eligibility criteria for participants in this trial include being at least 18 years old, having a confirmed diagnosis of locally advanced or metastatic solid malignancy, having received prior chemotherapy treatment or having no curative standard treatment available, and having recovered from any reversible toxicities of previous therapy. Other criteria include having a life expectancy of at least 3 months, having an ECOG performance status of 0, 1, or 2, and having measurable or nonmeasurable disease according to RECIST criteria.\n\nThere are also inclusion and exclusion criteria listed, which outline specific conditions that would make a participant eligible or ineligible for the trial. These criteria include factors such as previous or current CNS metastases, active clinically significant infections, certain medical conditions or history of certain episodes, and the use of certain medications.\n\nOverall, this sample provides a snapshot of the information contained in the table, including the phase of the trial, the diseases being studied, the associated ICD-10 codes, the drug being tested, and the eligibility criteria for participants.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of cancer. The trial focuses on non-small cell lung cancer and/or pancreatic cancer, with or without a KRAS mutation. The eligible subjects must have a solid tumor that has progressed after at least one prior standard therapy, or they refuse or have no access to standard therapy. The subjects should have a measurable tumor and be able to carry out daily activities without difficulty. They should also be able to swallow oral medication and not have significant side effects from previous anti-cancer treatment. Additionally, the subjects must have adequate organ and blood cell counts and use medically acceptable contraception if sexually active. \n\nThere are certain exclusion criteria, such as having had major surgery or certain cancer therapies within 2-3 weeks before the study, having a brain tumor, or having severe uncontrolled systemic disease. Subjects with a history of clinically significant heart, lung, or eye/vision problems, uncontrolled high blood pressure, or a permanent pacemaker are also excluded. Pregnant or breastfeeding individuals and those who test positive for Hepatitis B, Hepatitis C, or HIV are not eligible for the trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial focuses on patients with non-small-cell lung carcinoma. The trial includes eligibility criteria for patients to be included or excluded from the study. Inclusion criteria include having histologically or cytologically confirmed NSCLC, being locally advanced or metastatic, not having received prior systemic chemotherapy, and meeting certain medical and health requirements. Exclusion criteria include having received prior systemic anticancer therapy, having certain cardiac conditions, having uncontrolled hypertension, having certain infections or bleeding disorders, and having other medical or psychological conditions that may interfere with participation in the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"central retinal vein occlusion,\" and its corresponding ICDCodes are ['H34.8132', 'H34.8131', 'H34.8111', 'H34.8121', 'H34.8191', 'H34.8112', 'H34.8122']. The drug being tested is \"ranibizumab (lucentis)\". The eligibility criteria for this trial include factors such as providing written informed consent, being over 18 years old, having clinical evidence of perfused central retinal vein occlusion, having central macular edema, meeting specific visual acuity requirements, having clear media clarity and pupillary dilation, and not having certain exclusion criteria such as pregnancy, uncontrolled hypertension, or other ocular conditions.",
    "The sample is a phase 1 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of the drug exenatide once weekly compared to a placebo. The eligibility criteria for participants include having a body weight of at least 50 kg, suboptimal glycemic control as indicated by specific HbA1c levels, and being treated with diet modification and exercise or a stable regimen of certain oral antidiabetic drugs for at least 2 months prior to the study. There are also exclusion criteria, such as recent blood donation, recent treatment with unapproved drugs, previous participation in studies involving exenatide or other GLP-1 analogs, and current use of certain medications that affect gastrointestinal motility. Breastfeeding females are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on colorectal carcinoma.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31'].\n- Drugs: The drugs being tested in the trial are su011248, irinotecan, and cetuximab.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include histologic proof of adenocarcinoma of the colon or rectum with evidence of metastatic disease, prior chemotherapy regimen using specific drugs, specific time intervals since major surgery, minor surgery, and major radiotherapy, normal organ and marrow function, measurable disease according to RECIST criteria, age over 18, ECOG performance status of 0-1, and life expectancy of more than 12 weeks. The exclusion criteria include previous treatment with specific drugs, certain medical conditions within the past 12 months, brain metastases or carcinomatous meningitis, uncontrolled serious medical or psychiatric illness, grade 3 or greater hemorrhage within 4 weeks, uncontrolled hypertension, diagnosis of certain secondary malignancies within the last 5 years (with exceptions), pregnancy or breastfeeding, and concurrent treatment on another clinical trial.",
    "The sample is a phase 1 clinical trial for the treatment of macular degeneration. The trial is focused on patients diagnosed with subfoveal choroidal neovascularization caused by age-related macular degeneration. The trial aims to evaluate the effectiveness of the drug pazopanib in treating this condition. \n\nThe inclusion criteria for the trial include patients aged 50 or above with a confirmed diagnosis of subfoveal choroidal neovascularization caused by age-related macular degeneration. The patients should have specific characteristics related to the size and composition of the neovascularization lesion. They should also have a certain level of visual acuity in the study eye. \n\nFemale participants must be of non-childbearing potential or postmenopausal. All participants must be willing and able to comply with the study requirements and procedures and provide written informed consent. \n\nThere are also certain exclusion criteria, such as the presence of other eye diseases that could affect visual acuity, the presence of retinal angiomatous proliferation, and geographic atrophy involving the center of the fovea. Previous treatment for neovascular AMD, use of certain medications, and certain medical conditions are also exclusion criteria. \n\nOverall, the sample provides detailed information about the eligibility criteria for the phase 1 clinical trial, including the specific characteristics required for participation and the exclusion criteria.",
    "The sample is from a clinical trial table and represents a phase 1 trial. The disease being studied in this sample is \"healthy\", which is a bit unusual as healthy is not typically considered a disease. The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"glpg0492\", \"placebo\", and \"glpg0492\" again. The eligibility criteria for participants in this trial include being a healthy male between the ages of 18-50 years or \u226560 years, having a BMI between 18-30 kg/m\u00b2, and being a non-smoker. The exclusion criteria include having an elevated PSA level and a history of drug or alcohol abuse.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied in this trial is non-small-cell lung cancer. The corresponding ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are pemetrexed, cisplatin, and carboplatin. The eligibility criteria for participants in this trial include having inoperable non-small-cell lung cancer, no significant weight loss in the past three months, adequate kidney, liver, and lung function. The exclusion criteria include previous lung tumor surgery, previous chemotherapy or radiation therapy for lung cancer, inability to take vitamin supplementation, having had a heart attack within the past six months, and having an active infection.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on two diseases, namely pancreatic neoplasms and adenocarcinoma.\n- ICD Codes: The ICD-10 codes associated with the diseases are 'C25.3' for pancreatic neoplasms and a list of codes including 'C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', and 'C4A.31' for adenocarcinoma.\n- Drugs: The trial involves the use of two drugs, gemcitabine and etanercept.\n- Criteria: The eligibility criteria for the trial are listed, including requirements such as having a pathological diagnosis of recurring or metastatic pancreatic adenocarcinoma, no prior chemotherapy or immunology treatments, measurable disease, being over 18 years old, and only the control arm being open to accrual. There are also exclusion criteria listed, such as being pregnant or nursing, having psychiatric disorders that would interfere with consent ability, having known brain or leptomeningeal disease, having a history of myocardial infarction within the previous six months, having any concurrent illness that would be a hazard to participation, having a known sensitivity to gemcitabine or etanercept, and having prior treatment with etanercept.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the disease \"diabetes mellitus\". The ICD-10 codes associated with this disease are \"P70.2\", \"O24.92\", \"Z83.3\", \"E10.65\", \"E10.9\", \"E11.65\", and \"E11.9\". The drugs being studied are \"viaject\u00ae25\", \"viaject\u00ae7\", and \"insulin lispro\". The eligibility criteria for participants are listed, including age, body mass index, duration of Type 1 Diabetes Mellitus diagnosis, insulin antibody levels, non-smoking status, and informed consent. There are also exclusion criteria, such as having Type 2 Diabetes Mellitus, specific values for C-peptide and HbA1c, allergies to study medication components, recent use of other investigational drugs, and various medical conditions that may affect subject safety or protocol compliance.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is malignant melanoma. The ICDCodes associated with this disease are C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, and C43.10. The drug being tested is cc-5013. \n\nThe eligibility criteria for this trial include:\n1. Participants must understand and voluntarily sign an informed consent document.\n2. Participants must be 18 years or older at the time of signing the informed consent.\n3. Participants must be able to adhere to the study visit schedule and other protocol requirements.\n4. Participants must have histological documentation of malignant melanoma with evidence of metastatic disease.\n5. For the 10 patients enrolled at the Maximum Tolerated Dose (MTD), at least one measurable lesion must be present.\n6. Participants must have an ECOG performance status of 0, 1, or 2.\n7. Participants must have laboratory test results within specified ranges for absolute neutrophil count, platelet count, serum creatinine, total bilirubin, and AST/ALT levels.\n8. Women of childbearing potential must have a negative pregnancy test and agree to use at least two methods of contraception while on the study drug.\n9. Any acute adverse effects from prior therapy must have resolved to grade 1 or less.\n10. Participants must be able to take medications orally.\n\nThe exclusion criteria for this trial include:\n1. Pregnant or lactating females.\n2. Any serious medical condition or psychiatric illnesses that would prevent the patient from signing the informed consent or pose an unacceptable risk.\n3. Prior treatment with systemic chemotherapy, except for prior immunotherapy or radiotherapy.\n4. Prior history of malignancies, except for specific types, unless the patient has been disease-free for at least 3 years.\n5. Recent use of thalidomide or biologic response modifier therapy.\n6. Prior allergic reaction to thalidomide.\n7. Prior desquamating rash while taking thalidomide.\n8. Any prior use of lenalidomide.\n9. Concurrent use of any other anti-cancer agents.\n10. Recent radiation or surgical treatment of melanoma.\n11. Active infection.\n12. Central nervous system (CNS) metastases.\n13. Patients with grade-2 or higher neuropathy.\n14. Patients with known HIV positivity or AIDS-related illness.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on pancreatic cancer and is divided into different phases (phase I, phase II, phase III). The sample specifically belongs to the phase 1/phase 2 of the trial. \n\nThe record includes details about the diseases being studied, which in this case is pancreatic cancer. The ICD-10 codes associated with the disease are also provided. \n\nThe drugs being used in the trial are listed, including capecitabine and phy906. \n\nThe eligibility criteria for participants are outlined, including age requirements, previous treatment history, presence of measurable lesions, hepatic and renal function, performance status, pregnancy status, and hematologic tests. \n\nExclusion criteria are also mentioned, such as pregnancy or breastfeeding, prior capecitabine therapy for pancreatic cancer, active CNS metastases, known hypersensitivity to certain medications, and various medical conditions that could affect the patient's ability to safely participate in the trial.",
    "The sample from the table represents a clinical trial for the treatment of hepatitis C. The trial is in phase 1/phase 2, and the disease being studied is hepatitis C. The ICD-10 codes associated with the disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being tested in the trial are bavituximab and pegylated interferon (peg-ifn). \n\nThe eligibility criteria for the trial include being between the ages of 18 and 65, having chronic hepatitis C virus (HCV) genotype 1 infection, having an HCV RNA level greater than 10,000 IU/mL, and meeting the criteria for chronic HCV infection. Other criteria include having no clinically significant abnormalities in hematology, coagulation, or chemistry variables, negative urine pregnancy test for female patients, and the ability to provide informed consent.\n\nThe exclusion criteria for the trial include previous interferon-based antiviral therapy for chronic HCV infection, previous treatment with known immunogenic drugs, concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection, and having a cause of liver disease other than chronic HCV infection. Other exclusion criteria include having decompensated clinical liver disease, previous liver or solid-organ transplantation, evidence of clinically significant bleeding, history of bleeding diathesis or coagulopathy, and history of thromboembolic events.\n\nAdditional exclusion criteria include the requirement for concurrent treatment with certain medications, history of major surgery or investigational therapy within a certain timeframe, uncontrolled intercurrent disease, ongoing angina pectoris or other symptoms of coronary artery disease, history of suicidal ideation or attempt, and various other medical conditions or treatments that may affect the study.\n\nFemale patients and female partners of male patients are also excluded if they are pregnant, lactating, or unable/unwilling to practice effective contraception.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are ['G91.1', 'I42.1', 'N11.1', 'J05.0', 'G47.33', 'J44.9', 'N13.8']. The drugs being studied are glycopyrrolate, tiotropium, and placebo. The sample also includes the eligibility criteria for the trial. Inclusion criteria include being aged 40-75, having a diagnosis of moderate-severe COPD, being a current or ex-smoker with a smoking history of at least 10 pack-years, and having specific lung function measurements. Exclusion criteria include having certain allergies, abnormal laboratory or ECG findings, recent respiratory tract infections, and other significant lung diseases. Additionally, there are criteria related to medication use, alcohol or substance abuse history, and pregnancy/lactation.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is indicated as \"phase 1/phase 2\". The disease being studied in this trial is ovarian cancer. The ICD-10 codes associated with the disease are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The drug being tested in the trial is decitabine. The eligibility criteria for participants in the trial are listed, including having recurrent epithelial ovarian cancer, platinum-resistant or platinum refractory disease, and measurable or detectable disease. Other criteria include age, written informed consent, time since last treatment, absence of platinum allergy, negative pregnancy test, Eastern Cooperative Oncology Group (ECOG) performance status, and acceptable organ function. The exclusion criteria are also listed, such as not having participated in any clinical trial within the previous 3 weeks, not having grade 2 or greater neuropathy, and not having additional active cancer or uncontrolled medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"diabetes mellitus, type 2\" and \"adult.\" The ICDCodes associated with these diseases are \"E11.65,\" \"E11.9,\" \"E11.21,\" \"E11.36,\" \"E11.41,\" \"E11.42,\" and \"E11.44.\" The drugs being tested in this trial are \"ertugliflozin 2 mg single dose,\" \"ertugliflozin 2 mg split into twice daily,\" \"ertugliflozin 4 mg single dose,\" \"ertugliflozin 4 mg split into twice daily,\" and \"placebo.\"\n\nThe eligibility criteria for this trial are as follows:\n- Inclusion Criteria: Participants must have type 2 diabetes mellitus, either treatment-na\u00efve or on up to 2 acceptable oral anti-diabetes drugs for at least 8 weeks prior to the study.\n- Exclusion Criteria: Participants with type 1 diabetes mellitus, stroke, unstable angina, or a heart attack in the last 6 months, as well as those with uncontrolled blood pressure, are not eligible for this trial.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on healthy individuals, as indicated by the disease being listed as \"healthy\" and the absence of any specific diseases in the icdcodes field. The drug being tested in this trial is \"imatinib mesylate\". \n\nThe inclusion criteria for this trial include being a healthy man or woman aged 18 or older, having a body mass index (BMI) of less than 31 kg/m2, having a negative pregnancy test for female patients of childbearing potential, and providing written informed consent.\n\nThe exclusion criteria for this trial include abnormal marrow function, evidence of renal dysfunction or impaired hepatic function, taking any medications (except contraceptives) within 2 weeks of the study, receiving any other investigational agents within 28 days prior to the study, and being pregnant or breastfeeding for female subjects.\n\nOverall, this sample provides information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on kidney transplant. The associated ICD-10 codes for the diseases are ['T86.11', 'T86.12', 'T86.13', 'Z94.0', 'T86.10', 'T86.19', 'Z48.22']. The drug being studied is \"ivig and rituximab\". The eligibility criteria for the trial include having an anti-HLA antibody (Panel Reactive Antibody [PRA]) of >30% and being eligible for transplantation at Cedars-Sinai Medical Center. Other criteria include normal liver function, negative tests for hepatitis C and hepatitis B, and willingness to comply with the study protocol. There are also exclusion criteria, such as recent treatment with investigational agents, previous treatment with Rituximab, history of severe allergic reactions to monoclonal antibodies, and various medical conditions that may contraindicate the use of the investigational drug. The sample also includes laboratory exclusion criteria related to hemoglobin, platelets, liver function, and serology for hepatitis B, hepatitis C, and HIV.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are panobinostat and trastuzumab. The eligibility criteria for this trial include being over 18 years old, having confirmed HER2+ ve metastatic breast cancer, prior treatment and progression on trastuzumab, having adequate laboratory values, and having an Eastern Cooperative Oncology Group (ECOG) performance status of less than 2. The exclusion criteria include having active central nervous system (CNS) disease or brain metastases, impaired heart function or clinically significant heart disease, impairment of gastrointestinal (GI) function or GI disease that may affect the absorption of LBH589, ongoing diarrhea, liver or renal disease with impaired hepatic or renal functions, concomitant use of any anti-cancer therapy or certain drugs, being pregnant or breastfeeding for female patients, and not being willing to use an effective method of birth control.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"ulcerative colitis.\" The ICD-10 codes associated with this disease are \"K51.80,\" \"K51.813,\" \"K51.814,\" \"K51.90,\" \"K51.913,\" \"K51.914,\" and \"K51.811.\" The drugs being studied in this trial are \"placebo\" and \"rhumab beta7.\" \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must be able and willing to provide written informed consent.\n- Participants must be between 18 and 70 years of age.\n- Both males and females with reproductive potential must be willing to use a reliable method of contraception.\n- Participants must have a diagnosis of ulcerative colitis.\n- Participants must be eligible to receive biologic therapy.\n- Participants must have had the disease for at least 12 weeks.\n\nThe exclusion criteria for this trial are as follows:\n- Participants who require hospitalization due to the severity of ulcerative colitis are not eligible.\n- Participants with moderate to severe anemia are not eligible.\n- Participants with any manifestation of ulcerative colitis or other conditions likely to require treatment with more than 20 mg/day of prednisone or prednisone equivalent during the study are not eligible.\n- Pregnant or lactating individuals are not eligible.\n- Participants who lack peripheral venous access are not eligible.\n- Participants who are unable to comply with the study protocol are not eligible.\n- Participants with a history or presence of contraindicated diseases are not eligible.\n- Participants with congenital immune deficiency are not eligible.\n- Participants with active or prior infection with HIV or hepatitis B or C are not eligible.\n- Participants with a history of severe systemic bacterial, fungal, viral, or parasitic infections are not eligible.\n- Participants with a history of any other opportunistic infections within 12 weeks prior to the study are not eligible.\n- Participants who received a live attenuated vaccine within 4 weeks prior to screening are not eligible.\n- Participants who were hospitalized within 4 weeks prior to screening are not eligible.\n- Participants who received any contraindicated therapy within 12 weeks prior to screening are not eligible.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 1. The disease being studied is Alzheimer's disease, and its corresponding ICD-10 codes are G30.8, G30.9, G30.0, and G30.1. The drug being used in the trial is a placebo. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include being a Japanese male or female of non-childbearing potential, aged 50-85, having a diagnosis of probable Alzheimer's disease based on specific criteria, having a Mini-Mental Status Exam score between 16 and 26, and having a Rosen-Modified Hachinski Ischemia score of 4 or less. The exclusion criteria include having a diagnosis or history of other dementia or neurodegenerative disorders, clinically significant cerebrovascular disease, specific findings on MRI, a history of autoimmune disorders, or a history of allergic or anaphylactic reactions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is melanoma. The ICDCodes associated with melanoma are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being used in the trial are bortezomib and interferon alfa-2b. The eligibility criteria for this trial include having a histological or cytological diagnosis of cutaneous melanoma with evidence of metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease. Patients must also have measurable disease, an ECOG performance status \u2264 2, normal organ and marrow function, and meet other specified requirements. There are also exclusion criteria listed, such as having certain blood counts, creatinine clearance, brain metastases, peripheral neuropathy, hypersensitivity to the drugs, proteinuria, pregnancy or breastfeeding, recent use of other investigational drugs, and certain medical or psychiatric illnesses.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The trial involves two different drugs, everolimus, cetuximab, and irinotecan, as well as capecitabine and oxaliplatin. The eligibility criteria for the trial include obtaining written informed consent, having histologically or cytologically proven non-resectable or metastatic adenocarcinoma of the pancreas, experiencing progressive disease during adjuvant chemotherapy or within 6 months after, having previous treatment with a chemotherapeutic agent containing gemcitabine, being at least 18 years old, having an ECOG performance status of 0-1, having an absolute neutrophil count (ANC) of at least 1.5 x 10^9/l, having a platelet count of at least 75 x 10^9/l, having a total bilirubin level of no more than 1.5 x UNL (upper normal limit), having normal liver function (with no upper limit for ALAT/SPGT/alk phosph if liver metastases are present), having a creatinine clearance of at least 30 ml/min, and being capable of following the treatment and evaluation plan. The exclusion criteria include having grade 3 hyperlipidemia (>10.34 mmol/l) despite treatment, having a history of malignant neoplasm within the last 2 years, having any condition or therapy that may pose a risk or affect the purpose of the trial according to the investigator's opinion, being pregnant or breastfeeding (fertile patients must use contraceptives), having infections or other serious medical conditions that may hinder the patient's ability to receive the treatment (such as serious heart, metabolic, or lung disease), and having a known hypersensitivity to any of the components in the treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being used in the trial are taxotere and doxil. The eligibility criteria for this trial include specific requirements such as confirmed adenocarcinoma of the prostate, androgen-independent disease progression, certain levels of testosterone and PSA, previous cytotoxic therapy limitations, age over 18, adequate bone marrow, liver, and renal function, recovery from previous treatments, and other factors. There are also exclusion criteria listed, such as recent chemotherapy or radiotherapy, multiple prior chemotherapy treatments, receiving other investigational agents, symptomatic brain metastases, active second malignancy, history of cardiac disease, hypersensitivity reactions, and uncontrolled intercurrent illnesses.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are leukemia and myelodysplastic syndromes. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are arsenic trioxide and azacitidine. The eligibility criteria for participants are listed, including requirements such as a confirmed diagnosis of MDS, adequate marrow iron stores, and specific laboratory values within normal ranges. There are also exclusion criteria, such as recent treatment with growth factors or cytotoxic agents, certain medical conditions, and pregnancy or lactation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the respiratory syncytial virus disease. The ICD-10 codes associated with this disease are 'J12.1', 'J20.5', 'J21.0', 'Z29.11', and 'B97.4'. The drugs being studied in this trial are 'placebo' and 'medi-557'. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must be between 18 and 45 years old.\n- Participants must provide written informed consent.\n- Participants must have a healthy medical history and pass a physical exam.\n- Females of child-bearing potential must use two effective methods of birth control for 14 days prior to the first dose and continue using them for one year after receiving the study drug.\n- Nonsterilized, sexually active males with a female partner of child-bearing potential must also use two effective methods of birth control from Day 1 through Day 361.\n- Participants must weigh less than or equal to 110kg and have a body mass index of less than 32kg/m2.\n- Participants must be able to complete a follow-up period of approximately 360 days.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants who are unable to complete a follow-up period of 360 days.\n- Participants with any condition that, in the opinion of the investigator, would interfere with the evaluation of the investigational product or the interpretation of subject safety or study results.\n- Participants who are concurrently enrolled in another clinical study.\n- Employees of the site or individuals involved with the conduct of the study, as well as their immediate family members, are excluded from participating.\n- Participants who have received immunoglobulin or blood products within 60 days prior to randomization.\n- Participants who have received any investigational drug therapy within 6 months prior to receiving the study drug.\n- Participants with clinically abnormal electrocardiogram (ECG) results at screening.\n- Participants who have donated blood in excess of 400mL within 6 months prior to randomization.\n- Participants who have previously received biologics.\n- Participants with a history of immunodeficiency.\n- Participants with a history of allergic disease or reactions that are likely to be worsened by any component of the investigational product.\n- Participants with previous medical history or evidence of an ongoing illness that may compromise their safety.\n- Participants with positive lab test results for Hepatitis A, B, C, or HIV.\n- Participants who are pregnant or nursing mothers.\n- Participants with a history of alcohol or drug abuse within the past 2 years.\n- Participants with a positive urine test for Class A drugs.\n- Participants with an acute illness within 7 days prior to randomization.\n- Participants with a fever of 99.5\u00b0F or higher within 7 days prior to randomization.\n- Participants who have received any drug therapy within 7 days prior to randomization.\n- Participants with systolic blood pressure greater than 150mmHg and/or diastolic blood pressure greater than 90mmHg.\n- Participants who have received a vaccine within 14 days prior to randomization.\n- Participants with abnormal study laboratory results (hemoglobin, white blood cell count, platelet count, blood urea nitrogen) as specified in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"acute myeloid leukemia.\" The ICDCodes associated with this disease are \"C92.A1,\" \"C92.A2,\" \"C92.61,\" \"C92.62,\" \"C92.A0,\" and \"C92.60.\" The drugs being used in this trial are \"gemtuzumab ozogamicin,\" \"mitoxantrone,\" and \"etoposide.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being able to understand and provide written consent, being between 18 and 70 years of age, having CD33 positive de novo AML that did not respond to first-line induction therapy, having an ECOG Performance Status of 0-2, and meeting certain laboratory values and cardiac requirements. \n\nExclusion criteria include having acute promyelocytic leukemia, prior use of the specified drugs, having certain hematologic disorders or thromboembolic events, having certain infections or CNS involvement, a history of congestive heart failure or recent myocardial infarction, uncontrolled infections, certain psychiatric disorders, receiving other investigational agents, having certain coagulation or transplantation history, having other active malignancies (except for non-melanoma skin cancer or cervical intraepithelial neoplasia), and being pregnant or breastfeeding for women.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of depression, coronary artery disease (CAD), and acute coronary syndrome (ACS). The diseases are associated with specific ICD-10 codes. The drugs being tested in the trial are sertraline (Zoloft) and simvastatin (Zocor).\n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being between the ages of 18 and 60, having mild depression, and having an inflammatory marker called CRP greater than 2. Exclusion criteria include not being able to speak English or Spanish, having active suicidal or homicidal thoughts, current substance abuse, psychotic features, current personality disorder, history of bipolar depressive disorder, current psychotic disorder, current major depressive disorder, current depression treatment or treatment within the past 6 weeks, history of chronic liver and/or renal disease, current use or contraindication to any of the tested medications, absence of response to a previous trial of the tested medications, being pregnant or lactating, history of coronary artery disease, current use of statins, current regular aspirin use, antibiotic use within the past four weeks, history of diabetes, inflammatory diseases, and meeting NCEP guidelines for cholesterol lowering therapy.",
    "The sample from the table represents a clinical trial for liver cancer treatment. The trial is a combination of phase 1 and phase 2. The disease being studied is hepatocellular carcinoma, specifically in the intermediate stage B according to the Barcelona Clinic Liver Cancer classification. The trial is looking for patients who meet certain eligibility criteria.\n\nThe eligibility criteria include:\n- Histologically, cytologically, or radiologically confirmed hepatocellular carcinoma\n- Intermediate stage B (according to Barcelona Clinic Liver Cancer classification)\n- Child-Pugh score < 8\n- No tumor involvement > 50% of the whole liver\n- No advanced stage disease (portal invasion or extrahepatic spread)\n- No presence or history of metastatic disease\n- Candidate for transarterial chemoembolization after multidisciplinary discussion\n- Not on an active waiting list for liver transplantation\n\nIn addition to disease characteristics, there are patient characteristics that need to be met:\n- WHO performance status 0-1\n- Hemoglobin \u2265 90 g/L\n- Absolute neutrophil count \u2265 1.5 x 10^9/L\n- Platelet count \u2265 100 x 10^9/L\n- Bilirubin \u2264 1.5 x upper limit of normal (ULN)\n- ALT \u2264 4 x ULN\n- INR \u2264 2\n- Creatinine \u2264 1.5 x ULN\n- Not pregnant or nursing\n- Fertile patients must use effective contraception during and for 12 months after completion of study therapy\n- Negative pregnancy test\n\nThere are also various contraindications and medical conditions that would exclude a patient from participating in the trial, such as active heart disease, hypertension, thrombotic or embolic events within the past 6 months, serious non-healing wounds, bleeding diathesis, serious infections, HIV infection, and others.\n\nThe sample also includes information about prior concurrent therapy, including the time since previous treatments and the exclusion of certain drugs or therapies during the trial.\n\nOverall, the sample provides detailed information about the eligibility criteria and requirements for patients participating in the clinical trial for liver cancer treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"leukemia, lymphocytic, chronic, b-cell\", \"chronic lymphocytic leukemia\", and \"lymphoma, small lymphocytic\". The corresponding ICDCodes for these diseases are \"C91.11\", \"C91.12\", \"C91.10\", and \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\". The drug being used in the trial is \"lenalidomide, rituximab, and cyclophosphamide\". \n\nThe eligibility criteria for this trial include being at least 18 years old, being able to adhere to the study visit schedule and other protocol requirements, having relapsed/refractory B-cell CLL or SLL, having discontinued previous cancer therapy at least 2 weeks prior to treatment in this study, meeting the NCI WG Criteria for treatment of B-CLL, having an ECOG performance status of \u2264 2, and having specific laboratory test results within certain ranges. \n\nThere are also additional criteria related to disease-free status, pregnancy testing and birth control for females of childbearing potential, and the use of aspirin as prophylactic anticoagulation. \n\nThe exclusion criteria include having any serious medical condition, being pregnant or breastfeeding, having any condition that would prevent participation in the study or confound data interpretation, having evidence of laboratory tumor lysis syndrome, recent use of other experimental drugs or therapies, known hypersensitivity to thalidomide, prior use of lenalidomide, concurrent use of other anti-cancer agents or treatments, and being positive for HIV or infectious hepatitis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include recurrent non-small cell lung cancer, recurrent prostate cancer, stage III prostate cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, stage IV prostate cancer, and unspecified adult solid tumor, protocol specific. The corresponding ICDCodes for these diseases are also provided.\n\nThe drug being investigated in this trial is docetaxel. The eligibility criteria for participants in this trial include having a confirmed diagnosis of a solid tumor malignancy, prostate cancer, or non-small cell lung cancer. The disease must be recurrent, metastatic, locally advanced unresectable, or treatment-refractory. Measurable disease is required, with specific size criteria for lesions. Brain metastases are not allowed unless they are asymptomatic. Performance status, blood counts, liver and kidney function, cardiac health, and other factors are also considered in the eligibility criteria.\n\nThere are additional requirements and restrictions, such as no pregnancy or nursing, negative pregnancy test, effective contraception for fertile patients, no active peptic ulcer disease, no poorly controlled diabetes, no pre-existing grade 2 or greater neuropathy, no ongoing or active infection, and no contraindication to corticosteroids. Prior treatments, such as chemotherapy and endocrine therapy, are allowed within certain timeframes and recovery periods.\n\nConcurrent treatments, such as radiotherapy, surgery, anticoagulant therapy, and bisphosphonates, have specific guidelines and restrictions. The use of other investigational or commercial agents or therapies for treating the malignancy is not allowed, except for concurrent bisphosphonates.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on the treatment of non-small cell lung cancer. The trial involves the use of the drugs \"velcade and vorinostat\". The eligibility criteria for participants are listed, including requirements such as histologically confirmed NSCLC, planned surgical resection, age over 18, ECOG performance status 0-1, and adequate organ and marrow function. The inclusion criteria also specify certain blood counts, hemoglobin levels, and other medical parameters that need to be met. Additionally, the criteria mention the need for written informed consent and the use of contraception for female and male participants. The exclusion criteria state that previous chemotherapy or radiation therapy within 5 years, prior exposure to the drugs being tested, and certain medical conditions like peripheral neuropathy or heart failure would disqualify a participant. Other exclusions include allergies to the drugs, pregnancy or breastfeeding, participation in other trials, and the presence of serious medical or psychiatric illnesses that could interfere with the study. The criteria also mention the exclusion of individuals who have undergone certain gastrointestinal surgeries or are currently taking herbal remedies or homeopathic agents that cannot be discontinued during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are melanoma, malignant melanoma, and experimental melanoma. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial include dmf5 melanoma reactive til, cyclophosphamide, fludarabine, and aldesleukin.\n\nThe eligibility criteria for participants in this trial are listed in a bullet-point format. These criteria include having measurable metastatic melanoma that is refractory to standard treatment, being at least 18 years old, having a life expectancy of more than three months, and being willing to sign a durable power of attorney. Other criteria include having specific blood counts, serology results, and chemistry levels within certain ranges. There are also exclusion criteria, such as being pregnant or breastfeeding, having certain medical conditions or infections, and having a history of certain allergies or reactions.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the trial phase, diseases being studied, drugs used, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease schizophrenia. The ICD-10 codes associated with this disease are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being studied are aripiprazole im depot and aripiprazole tablets. The eligibility criteria for participants are listed, including requirements such as a diagnosis of schizophrenia, good physical health, ability to provide informed consent, and a body mass index (BMI) between 18 and 35 kg/m^2. There are also exclusion criteria, such as participants who are not practicing double barrier birth control, have a history of drug or alcohol abuse, or are currently using certain medications. Other exclusion criteria include pregnancy, participation in previous clinical trials involving psychotropic medication, and various medical conditions or risks.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is metastatic breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug mentioned is amrubicin. The eligibility criteria for this trial include various factors such as age, histologic diagnosis, evidence of metastatic or locally advanced breast cancer, prior chemotherapy regimens, organ function, and other medical conditions. The sample also includes exclusion criteria, which specify conditions or treatments that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial that is in both phase 1 and phase 2. The trial is focused on treating head and neck cancer. The specific diseases included in this trial are squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. The trial is intended for patients who are selected for primary surgical treatment and do not have any distant metastases or active second malignancies in the past 5 years. The trial also has various inclusion and exclusion criteria related to age, health status, pregnancy, and previous exposure to certain therapies. The drug being studied in this trial is cetuximab.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of leukemia, specifically chronic myeloid leukemia (CML) that is positive for the Philadelphia chromosome (Ph+). The eligibility criteria for the trial include being at least 18 years old, having a recent diagnosis of CML with documented Ph+ cells in the bone marrow, and either being in the chronic phase of CML with less than 15% blasts in the blood and bone marrow, or being in the advanced phase with more than 5% blasts or hematologic progression. The criteria also state that the participant must have resistance or suboptimal response to certain drugs and not have specific Abl-kinase mutations. There are also exclusion criteria, such as having certain mutations, serious medical disorders or active infections, uncontrolled cardiovascular disease, and abnormal blood counts or serum levels. The criteria also outline restrictions on prior therapies for CML or Ph+ ALL.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 1 and is focused on the disease of leukemia. The associated ICD-10 codes for this disease are ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']. The drugs being studied in this trial are 'autologous tumor cell vaccine' and 'therapeutic autologous dendritic cells'. The eligibility criteria for participants in this trial include being diagnosed with acute myeloid leukemia (AML), having adequate dendritic cells and AML blasts isolated from bone marrow and/or peripheral blood, and having no clinical evidence of CNS leukemia. There are also various patient characteristics and prior concurrent therapies specified in the eligibility criteria.",
    "The sample from the table represents a phase 1 clinical trial for advanced and/or metastatic cancer. The trial is focused on evaluating the efficacy of a drug called ly2584702. The eligibility criteria for participants include having a histological or cytological evidence of a diagnosis of advanced and/or metastatic cancer that is refractory to standard therapy or for which no standard therapy exists. Participants must also have disease amenable to efficacy assessment as defined by the Response Evaluation Criteria In Solid Tumors (RECIST). Adequate organ function, a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group scale, and an estimated life expectancy of 12 weeks or greater are also required. Participants must have discontinued all previous cancer therapies and be able to swallow capsules. There are also exclusion criteria, such as recent treatment with a drug not approved for any indication, serious preexisting medical conditions, and certain medical history or conditions related to tuberculosis, hepatitis, and central nervous system malignancy or metastasis. Hematologic malignancies or lymphoma are also excluded from the trial.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is an unspecified adult solid tumor that is specific to the protocol. The ICD-10 codes associated with the disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drug being tested is 1-methyl-d-tryptophan. \n\nThe eligibility criteria for the trial include having a histologically confirmed solid malignancy that is metastatic or unresectable and for which standard effective antineoplastic therapy does not exist or is no longer effective. Patients are eligible regardless of the types of previous therapies administered. Patients with known brain metastases can only participate if their tumors have been treated with definitive resection and/or radiotherapy and they are neurologically stable for at least 1 month off steroids. Other criteria include specific performance status, life expectancy, blood cell counts, liver function, kidney function, gastrointestinal health, pregnancy status, contraception use, history of allergic reactions, autoimmune diseases, concurrent illnesses, HIV status, prior therapy, and concurrent medications or therapies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"hypertension, pulmonary\" and \"pulmonary disease, chronic obstructive\". The corresponding ICDCodes for these diseases are \"['I27.0', 'I27.20', 'I27.21', 'I27.24', 'I27.29', 'P29.30', 'I27.22']\" and \"['J44.9', 'J44.1', 'J44.0']\" respectively.\n\nThe drugs being tested in this trial are \"riociguat (adempas, bay63-2521) 1.0 mg\" and \"riociguat (adempas, bay63-2521) 2.5 mg\".\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include patients with pulmonary hypertension due to COPD who are undergoing routine invasive measurement of hemodynamic parameters. Exclusion criteria include acute exacerbation of COPD, pre-existing lung disease other than COPD, acute or severe chronic left heart failure, severe coronary artery disease, uncontrolled arterial hypertension, severe left ventricular hypertrophy, congenital or acquired valvular or myocardial disease, systolic blood pressure < 100 mmHg, heart rate < 55 bpm or >105 bpm, PaO2/FiO2 < 50 mmHg, PaCO2 > 55 mmHg, severe hepatic insufficiency, and severe renal insufficiency.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are lung cancer and metastatic cancer. The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2 for lung cancer, and C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for metastatic cancer. The drug being tested is rad001. The eligibility criteria for this trial include specific disease characteristics, such as radiographically confirmed brain metastases with histopathologically confirmed primary non-small cell lung cancer, and measurable intracranial sites of disease. There are also patient characteristics, such as ECOG performance status, life expectancy, and various blood test results. Additionally, there are exclusions for patients with certain medical conditions or other malignancies, as well as prior and concurrent therapies that are not allowed.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on two diseases: exercise-triggered asthma and gastroesophageal reflux. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs, Nexium and a placebo. The eligibility criteria for participants are listed, including requirements such as being an athlete (specifically cyclists) with GER symptoms, experiencing certain symptoms during exercise, and exercising regularly for at least the past 6 months. There are also exclusion criteria, such as pregnancy, age restrictions, and abnormal methacholine challenge test results.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is chronic hepatitis C. The icd-10 codes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drug being tested is mp-424 (telaprevir). The eligibility criteria for this trial include being diagnosed with genotype 1b chronic hepatitis C and being naive to concomitant medications with interferon. The exclusion criteria include having decompensated cirrhosis and testing positive for HBs antigen in the test.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is esophageal cancer. The ICDCodes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drugs being used in the trial are cisplatin and fluorouracil. \n\nThe eligibility criteria for this trial are divided into three categories: disease characteristics, patient characteristics, and prior concurrent therapy. \n\nUnder disease characteristics, the inclusion criteria state that the patient must have histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus, invasive disease, and only Siewert type I gastroesophageal carcinoma is allowed. The disease must also be resectable, with specific staging criteria and no metastases or extensions compromising resectability. \n\nThe exclusion criteria for disease characteristics include inoperable disease, invasion of the tracheo-bronchial tree, recurring esophageal paralysis, esopho-tracheal fistula, cervical esophageal carcinoma, multifocal esophageal carcinoma, superficial esophageal carcinoma, esophageal carcinoma in lymph nodes that cannot be included in radiotherapy field or completely surgically resected, and proven metastatic disease. \n\nUnder patient characteristics, the inclusion criteria include specific performance status, weight loss, blood counts, creatinine levels, PTT, albumin levels, FEV1, and pregnancy/nursing status. Fertile patients must use effective contraception. \n\nThe exclusion criteria for patient characteristics include known liver cirrhosis, renal insufficiency, respiratory insufficiency, progressive coronary insufficiency, recent myocardial infarction, legal incapacitation, inability to receive study therapy due to geographical/social/psychological reasons, noncompliance with study constraints, and presence of hematologic malignancy or other cancers (except specific exceptions). \n\nUnder prior concurrent therapy, the exclusion criteria include prior anticancer chemotherapy or radiotherapy, treatment with endoprosthesis, and planned surgery (esophagectomy) without thoracotomy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drug being tested is \"pt-523 for injection.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having a metastatic or inoperable malignancy (excluding leukemia or primary CNS tumor) with no known curative or survival prolonging palliative therapy, being at least 18 years old, having a life expectancy of at least 2 months, having an ECOG performance status of 0-2, having adequate organ function and bone marrow reserve, using an appropriate contraceptive method, and providing informed consent. \n\nExclusion criteria include having active brain metastases, presence of third-space fluid collections (pleural effusion, ascites), major surgery within 3 weeks prior to dosing, prior chemotherapy or radiation therapy within 3 weeks prior to dosing (6 weeks for nitrosoureas or mitomycin-C), prior bone marrow transplantation, presence of uncontrolled serious medical or psychiatric illness, and requiring radiation therapy. \n\nThere are no limitations on the extent or type of prior therapy received by the patient, as long as the patient has fully recovered from any adverse effects and meets all relevant inclusion criteria.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on glioblastoma multiforme, glioma, astrocytoma, and brain tumor. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is \"itv depocyt + temozolomide\". \n\nThe eligibility criteria for the trial include:\n- Patients must be between 18 and 85 years old.\n- Patients must have a histological diagnosis of recurrent GBM.\n- Patients must have failed initial surgical resection followed by standard adjuvant therapy.\n- Patients must have a Karnofsky performance status (KPS) of at least 60%.\n- Patients must have recovered from the acute toxic effects of prior therapy.\n- Patients must have adequate hematologic, hepatic, and renal status.\n- Patients must provide informed consent.\n\nThe exclusion criteria for the trial include:\n- Patients younger than 18 or older than 85 years old.\n- Patients with histological diagnoses other than recurrent GBM.\n- Patients with a KPS less than 60%.\n- Patients who have received more than one other systemic or ITV adjuvant chemotherapy regimen.\n- Patients receiving other therapies specifically for recurrent GBM.\n- Patients within 8 weeks of receiving irradiation.\n- Patients with certain abnormal blood counts, liver or renal dysfunction, or abnormal serum electrolytes.\n- Patients with contraindications to having a ventricular access device.\n- Patients with hydrocephalus or increased intracranial pressure.\n- Patients with signs and symptoms of systemic infection.\n- Pregnant and breastfeeding women.\n- Patients with a ventricular-peritoneal or ventricular-atrial shunt.\n- Prisoners.\n- Patients or their legal guardians who are not willing or able to sign the informed consent document.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of irritable bowel syndrome (IBS). The ICD-10 codes associated with IBS are ['K58.2', 'K58.8', 'K58.0', 'K58.1', 'K58.9']. The drugs being studied are lubiprostone and a placebo. The eligibility criteria for participants are listed, including requirements such as a clinical diagnosis of IBS-C, meeting the Rome III diagnostic criteria for IBS-C, and being 18 years or older. There are also exclusion criteria, such as recent use of certain medications, certain medical conditions, and pregnancy.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is breast neoplasms. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs mentioned in this sample are sunitinib (sutent) and taxotere. The eligibility criteria for this trial include having breast cancer with evidence of unresectable, locally recurrent, or metastatic disease, and being a candidate for treatment with docetaxel. The exclusion criteria include having received prior chemotherapy in the advanced disease setting, having inflammatory breast cancer, and having HER2 positive disease.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column lists the names of diseases being studied in the trial. The icdcodes column contains the corresponding ICD-10 codes for each disease. The drugs column lists the names of drugs being used in the trial. The criteria column provides the eligibility criteria for participating in the trial.\n\nThe sample data in the table includes a trial that is in phase 1/phase 2. The diseases being studied in this trial are leukemia, lymphoma, neuroblastoma, immunodeficiencies, and anemia. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial include alemtuzumab, melphalan, busulfan, phenytoin, fludarabine, cyclophosphamide, horse antithymocyte globulin, rabbit antithymocyte globulin, and thiotepa. The eligibility criteria for this trial include specific requirements for renal function, liver function, cardiac function, and pulmonary function. There are also exclusion criteria, such as being pregnant or having an uncontrolled infection at the time of study entry.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is malignant melanoma. The ICDCodes associated with this disease are C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, and C43.10. The drug being tested is called pivanex. \n\nThe eligibility criteria for this trial include:\n- The patient must have a confirmed diagnosis of melanoma and have previously received chemotherapy or IL-2 treatment.\n- The disease must be recurrent or progressive after treatment.\n- The patient must have measurable disease.\n- Both males and females aged 18 years or older are eligible.\n- Adequate renal function with a creatinine level of at least 1.5 mg/dl is required.\n- Adequate liver function with specific limits for alkaline phosphatase, SGOT, SGPT, and total bilirubin.\n- Adequate bone marrow function with specific limits for platelets, hemoglobin, and absolute neutrophil count.\n- The patient must be able to provide informed consent.\n- Previous surgery, radiation therapy, or cancer chemotherapy must have been discontinued at least four weeks prior to randomization (six weeks for certain prior treatments), with recovery from treatment-associated toxicity.\n- A predicted life expectancy of at least 6 months is required.\n- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion criteria for this trial include:\n- Receipt of more than three systemic treatment regimens for malignant melanoma, including IL-2.\n- A second malignancy within the last 5 years, except for curatively treated carcinoma-in-situ or non-melanoma skin cancer.\n- Pregnant or lactating females. Females of childbearing potential must have a negative pregnancy test, and all male and female patients of reproductive potential must agree to use adequate birth control.\n- Known HIV-positive patients.\n- Acute medical problems such as ischemic heart or lung disease or uncontrolled systemic infection.\n- Patients with any underlying medical conditions or circumstances that would contraindicate therapy with the study treatment, affect compliance, or impair evaluation of study endpoints.\n- Patients receiving investigational agents within 4 weeks of randomization.\n- Known allergy to reagents in the study.\n- Symptomatic or untreated brain metastases. However, patients with stable brain metastases for at least 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife, surgical resection) and either off corticosteroids or on a stable dose of corticosteroids are eligible.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is pancreatic adenocarcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are imexon and gemcitabine. The eligibility criteria for participants in this trial include having inoperable cancer of the pancreas, blood cell counts and chemistries within normal range, ability to perform daily activities, a projected life expectancy of at least 2 months, not being pregnant or nursing (for females), willingness to use contraceptives, absence of serious illnesses, absence of other active malignancies, absence of serious infections, no current other drug therapy or steroid therapy for the cancer, and prior radiation or chemotherapy given during radiation or to prevent relapse after surgical removal of the disease is permitted. The exclusion criteria include prior chemotherapy for metastatic disease and the presence of brain metastases.",
    "The sample from the table represents a clinical trial in phase 1. The trial is focused on treating advanced solid tumors, cancer, and advanced solid malignancies. The diseases are associated with specific ICD-10 codes. The drugs being studied in this trial are azd7762 and irinotecan. The eligibility criteria for participants include having advanced solid tumors with no standard treatment available or ineffective treatment, being suitable for treatment with irinotecan, and having relatively good overall health. Exclusion criteria include poor bone marrow function, serious heart conditions, poor liver or kidney function, and any prior anthracycline treatment.",
    "The sample from the table is for a clinical trial that is in both phase 1 and phase 2. The trial is focused on the disease \"pulmonary disease, chronic obstructive\" and the corresponding ICD-10 codes are \"J44.9\", \"J44.1\", and \"J44.0\". The drug being tested is \"uk-369,003\". The eligibility criteria for this trial include meeting the GOLD criteria 2 to 4 and having a 10 pack year history of smoking. Women of childbearing potential are excluded from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is melanoma. The ICDCodes associated with melanoma are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being used in the trial are bortezomib and sorafenib. The eligibility criteria for this trial include various factors such as histological confirmation of malignant melanoma, measurable disease, prior treatments received, age, life expectancy, performance status, organ and marrow function, pregnancy test results, and more. The exclusion criteria are also listed, which include factors such as recent chemotherapy or radiotherapy, CNS disease, prior therapy with bortezomib or sorafenib, cardiac disease, uncontrolled illness, pregnancy, and various other conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1. The disease being studied is phenylketonuria (PKU), which is represented by the disease name and its corresponding ICD-10 code (E70.0). The drug being tested is ravpal-peg. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include a diagnosis of PKU, a certain blood Phe concentration, willingness to provide informed consent, ability to comply with study procedures, age between 16 and 50 years, negative pregnancy test for females of childbearing potential, and stable diet. Exclusion criteria include recent use of investigational products, pregnancy or breastfeeding, concurrent diseases or conditions that may interfere with the study, high risk of poor treatment compliance, hypersensitivity to the drug, abnormal liver or kidney function, recent blood or plasma donation, recent use of over-the-counter or prescription medications without approval, recent use of drugs known to affect liver enzymes, recent tobacco use, and positive tests or treatment for hepatitis B, hepatitis C, or HIV.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of non-small-cell lung carcinoma. The trial involves the use of two drugs, bi 2536 and pemetrexed. The eligibility criteria for participants are listed, including requirements such as confirmed diagnosis of NSCLC, measurable disease, age 18 or older, and a life expectancy of at least 3 months. There are also exclusion criteria, such as recent treatment with other investigational drugs, persisting toxicities from previous therapy, and active brain metastases. The sample provides a comprehensive list of criteria that potential participants must meet or avoid in order to be eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug being used in the trial is \"bi 2536 bs\" administered intravenously. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must have a confirmed diagnosis of advanced, non-resectable, and/or metastatic solid tumors.\n- Patients must have failed conventional treatment, or there must be no therapy of proven efficacy available, or they must not be suitable for established forms of treatment.\n- Patients must have evaluable tumor deposits.\n- Patients must be 18 years of age or older.\n- Patients must have a life expectancy of at least 6 months.\n- Patients must provide written informed consent consistent with international conference of harmonization (ICH) - good clinical practice (GCP) and local legislation.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance score of \u2264 2.\n- Patients must have fully recovered from all therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies.\n\nThe exclusion criteria for this trial are as follows:\n- Patients with serious illness or concomitant non-oncological disease that is considered incompatible with the trial protocol.\n- Patients who are pregnant or breastfeeding.\n- Patients with active infectious disease.\n- Patients with known brain metastases.\n- Patients with a second malignancy requiring therapy.\n- Patients with an absolute neutrophil count less than 1500/mm3.\n- Patients with a platelet count less than 100,000/mm3.\n- Patients with a bilirubin level greater than 1.5 mg/dL (> 26 \u03bcmol/L, SI equivalent).\n- Patients with aspartate amino transferase (AST) and/or alanine amino transferase (ALT) levels greater than 2.5 times the upper limit of normal (if related to liver metastases, greater than five times the upper limit of normal).\n- Patients with a serum creatinine level greater than 1.5 mg/dL (> 132 \u03bcmol/L, SI unit equivalent).\n- Sexually active women and men who are unwilling to use a medically acceptable method of contraception.\n- Patients who have been treated with other investigational drugs or participated in another clinical trial within the past four weeks before the start of therapy or concomitantly with this trial (except for the present trial drug).\n- Patients who have undergone chemo-, radio-, or immunotherapy within the past four weeks before the start of therapy or concomitantly with this trial.\n- Patients who are unable to comply with the trial protocol.\n- Patients with active alcohol or drug abuse.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is listed as \"phase 1/phase 2\". The diseases being studied include \"leukemia, myeloid, acute\", \"leukemia, myelogenous, chronic\", \"leukemia, lymphoblastic, acute\", \"lymphocytic leukemia, chronic\", \"myelodysplastic syndromes\", \"multiple myeloma\", \"lymphoma, non-hodgkin\", and \"hodgkin disease\". The corresponding ICD-10 codes for these diseases are also provided. The drug being tested is \"amd3100\". The eligibility criteria for participants are listed, including age requirements, HLA matching, written consent, and various health conditions that must be met. The criteria also specify that the patient must have one of the listed diagnoses. Overall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular sample belonging to phase 1. The diseases being studied in this trial include \"healthy\", \"pharmacokinetics\", \"pharmacodynamics\", and \"ilaprazole\". The diseases are also associated with specific ICD-10 codes, with the code for this sample being \"['Z76.3', 'Z76.2']\". The drugs being tested in this trial are \"ilaprazole\" and \"esomeprazole\". The eligibility criteria for participants in this trial include signing an informed consent form, being between 18 and 55 years old, having negative pregnancy test results, using a double-barrier method of birth control, having a negative breath test result for H pylori, and having a body mass index (BMI) within a specific range. The exclusion criteria include having certain medical conditions or allergies that would contraindicate taking ilaprazole or esomeprazole.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 1/phase 2, focusing on the disease \"glioblastoma multiforme.\" The associated ICD-10 codes for this disease are \"L51.0,\" \"L51.8,\" and \"L51.9.\" The trial involves the use of drugs such as \"bcnu wafer,\" \"irinotecan,\" and \"bevacizumab.\" The eligibility criteria for participants are listed, including requirements such as a histopathologically proven diagnosis of GBM, prior treatment with standard doses of Temodar, a Karnofsky Performance Status (KPS) score greater than 50, an Eastern Cooperative Oncology Group (ECOG) score less than 3, a predicted life expectancy of more than 3 months, and study entry within 5 weeks of surgical resection. The exclusion criteria include prior exposure to VEGF inhibitors or Irinotecan, recent intracranial or gastrointestinal bleeding, and uncontrolled concurrent illnesses that may limit compliance with study requirements.",
    "The sample from the table represents a clinical trial for a combination therapy for lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). The trial is in phase 1/phase 2. The diseases being targeted are lymphoma, large-cell, diffuse and lymphoma, B-cell. The corresponding ICD-10 codes for these diseases are provided. The drugs being used in the trial are bortezomib, cyclophosphamide, doxorubicin, vincristine, prednisolone, and lenograstim. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Histologically confirmed DLBCL\n- Age 70 years or less\n- Previously untreated\n- Performance status: ECOG 0-2\n- Advanced stage: stage III, IV, or non-contiguous stage II\n- Measurable disease: 1 cm or more by spiral CT\n- Normal liver function\n\nThe exclusion criteria for participants in the trial are as follows:\n- Platelet count less than 75,000/microL within 14 days before enrollment.\n- Absolute neutrophil count of less than 1,500/microlL within 14 days before enrollment.\n- Creatinine (Cr) level more than 2.0 mg/dL and/or calculated or measured creatinine clearance less than 50 mL/min within 14 days before enrollment.\n- Peripheral neuropathy of Grade 2 or worse within 14 days before enrollment.\n- Hypersensitivity to bortezomib, boron, or mannitol.\n- Female subject is pregnant or breastfeeding.\n- Use of other investigational drugs within 14 days before enrollment.\n- Presence of serious medical or psychiatric illness likely to interfere with participation in the clinical study.\n- Uncontrolled or severe cardiovascular disease, including myocardial infarction (MI) within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are prostate cancer and prostatic neoplasms. The ICDCodes associated with these diseases are provided as well. The drug being tested is \"cabazitaxel plus bavituximab\". \n\nThe eligibility criteria for this trial include: \n- Written informed consent from participants.\n- Adults aged 18 or older with a life expectancy of at least 3 months.\n- Histologically confirmed castration-resistant prostate cancer.\n- Treatment with only one prior chemotherapy regimen, which must contain docetaxel.\n- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower.\n- Adequate hematologic, renal, and hepatic function.\n- Prostate-specific antigen (PSA) level of at least 2 ng/mL.\n- New York Heart Association classification I or II.\n- Use of approved contraception for patients of reproductive potential.\n\nThe exclusion criteria include:\n- Known history of bleeding diathesis or coagulopathy.\n- History of thromboembolic events.\n- Ongoing therapy with oral or parenteral anticoagulants.\n- Grade 2 or higher peripheral neuropathy.\n- Recent radiotherapy, chemotherapy, or estrogen agonist treatment.\n- Symptomatic or clinically active brain metastases.\n- Major surgery within the past 28 days.\n- Uncontrolled intercurrent diseases such as diabetes or hypertension.\n- History of cerebrovascular accident or symptomatic coronary artery disease.\n- History of conditions requiring anti-platelet therapy, except for general cardiovascular prophylaxis with aspirin.\n- Serious non-healing wound.\n- Known chronic infection with HIV or viral hepatitis.\n- Contraindication to intravenous contrast media.\n\nThis information provides details about the phase, diseases, drugs, and eligibility criteria for this particular clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug being tested is \"bi 6727.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria include patients with confirmed diagnosis of advanced, non-resectable, and/or metastatic solid tumors who have failed conventional treatment or for whom no proven therapy exists. Other criteria include being 18 years or older, providing written informed consent, having an Eastern Cooperative Oncology Group (ECOG) performance score of 2 or higher, and having measurable tumor deposits.\n\nExclusion criteria include having a serious illness or non-oncological disease that is incompatible with the protocol, being pregnant or breastfeeding, having an active infectious disease or chronic Hepatitis B/Hepatitis C infection, having clinical evidence of active brain or leptomeningeal disease in the past 12 months, requiring active therapy for a second malignancy, and having certain abnormal blood counts or liver function tests. Other exclusion criteria include a history of relevant QT-prolongation, being sexually active without using contraception, recent treatment with other investigational drugs or participation in another clinical trial, recent chemo-, radio-, or immunotherapy, inability to comply with the protocol, and active alcohol or drug abuse.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is refractory brain tumors. The ICD-10 codes associated with these tumors are D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, and D46.22. The drug being tested in this trial is busulfan. The eligibility criteria for participants include age between 2 and 21 years, histological diagnosis of a recurrent or progressive CNS tumor, a life expectancy of at least 2 months, and no limit on the number of prior therapies received. There are specific time intervals required between different types of prior therapies. Patients taking certain medications, such as Itraconazole or Phenytoin, will be excluded from the trial. Other medications and substances that interact with the CYP3A4 substrate should also be avoided. Patients should be on Pneumocystis prophylaxis throughout the trial. Adequate organ function requirements include bone marrow function, renal function, liver function, and pulmonary function. Patients with certain neurological conditions and a stable neurologic exam are eligible. The performance level of the patients should be Karnofsky/Lansky 50 or greater. Exclusion criteria include pregnancy or breastfeeding, and patients of childbearing potential must use effective birth control methods. Female patients over 13 years of age or who have achieved menarche must have a negative pregnancy test before participating in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drugs being used in the trial are romidepsin and gemcitabine. The eligibility criteria for the trial are listed, including requirements such as confirmed advanced solid tumors, measurable or evaluable disease, written informed consent, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. There are also exclusion criteria listed, such as prior treatment with romidepsin or gemcitabine, prior chemotherapy treatment within 3 weeks, and prior radiotherapy within 4 weeks. Other exclusion criteria include cardiac abnormalities, electrolyte abnormalities, concomitant use of certain drugs, active infections, inadequate organ function, pregnancy or breastfeeding, and any significant medical or psychiatric condition that may prevent compliance with the study procedures.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is type 2 diabetes mellitus. The ICD-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are placebo and srt2104. The eligibility criteria for participants include being ambulatory, either having type 2 diabetes or being a healthy cigarette smoker, being between the ages of 18-70, having HbA1c levels below 9.0% (for diabetic subjects), having fasting plasma glucose levels below 13.875 mmol/L (for diabetic subjects), having a documented diagnosis of type 2 diabetes for at least 6 months, being on a stable hypoglycemic therapy or dietary regimen for at least 3 months, and having a non-smoking history of at least 5 years (for diabetic subjects who are also smokers). Other criteria include using reliable contraception for females of child-bearing potential, using double-barrier birth control or abstinence for male subjects, providing written informed consent, having stable concomitant treatments for other conditions, not being on certain medications or treatments that may influence coagulation, having a BMI between 18.5-38 kg/m^2, having a resting supine blood pressure below 160/90 mmHg, having no significant diseases or abnormal laboratory values, testing negative for HIV 1 and 2, testing negative for hepatitis B & C virus, having a normal electrocardiogram, comprehending the study and complying with the protocol, being able to communicate effectively, and meeting other exclusion criteria such as not having any major illnesses or ongoing chronic medical illnesses, not having renal or liver impairment, not having gastrointestinal diseases or surgeries that affect drug absorption, not having a history of drug abuse or alcoholism, not having participated in another clinical trial recently, not having difficulty donating blood or accessing veins, not having donated blood or lost a significant amount of blood recently, not using dietary or herbal supplements (except for approved vitamins) within 2 weeks prior to the study, not having a sensitivity or allergy to the study medications, not having active or recent neoplastic disease (except for certain types of skin cancer), and not testing positive on a pre-study drug screen.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is acute myelogenous leukemia. The corresponding ICD-10 codes for the disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drug being tested is azd4877. The eligibility criteria for the trial include specific inclusion and exclusion criteria. Inclusion criteria involve patients with relapsed or refractory leukemia, those who have had no more than two prior relapses or failed to achieve remission after at least one induction treatment, and patients with prior allogeneic transplants who remain clinically stable for at least two weeks off immunosuppressive therapy. Exclusion criteria include patients with promyelocytic acute myelogenous leukemia, those who have had a prior allogeneic transplant requiring immunosuppressive therapy, and patients with liver injury.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are kidney transplantation, kidney disease, and kidney failure. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are alemtuzumab, mycophenolate mofetil, sirolimus, and tacrolimus. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as a minimum weight of 40 kg, receiving a living-related primary kidney allograft, negative B-cell and T-cell cytotoxic and flow cytometry crossmatch, normal echocardiogram, completed vaccination for hepatitis B virus, willingness to comply with study visits, and willingness to use acceptable forms of contraception. \n\nExclusion criteria include factors such as previous or current organ transplant other than a kidney, ABO incompatible donor kidney, HIV infection, hepatitis C or B virus positivity, tuberculosis, current or recent history of cancer, significant liver disease, uncontrolled infections or unstable medical conditions, current or recent use of investigational drugs or immunosuppressive agents, contraindications to taking medications orally or via nasogastric tube, certain medication requirements, known hypersensitivity to study medications, certain screening laboratory values, substance abuse or psychiatric disorders, contraindication to tacrolimus administration, undergoing peritoneal dialysis, PRA value less than 10%, Graves disease (unless adequately treated), and CMV or EBV negative recipient receiving a kidney from a CMV or EBV positive donor. Pregnancy or breastfeeding is also listed as an exclusion criterion.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is an unspecified adult solid tumor that is specific to the protocol. The ICD-10 codes associated with the disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs being used in the trial are 1-methyl-d-tryptophan and docetaxel. The eligibility criteria for the trial include having histologically or cytologically confirmed metastatic solid malignancy, measurable disease, ECOG performance status \u2264 2, life expectancy of greater than 4 months, and meeting certain laboratory values. There are also criteria related to pregnancy, contraception, gastrointestinal diseases, autoimmune diseases, concurrent illnesses, HIV status, prior treatments, and use of certain medications. The sample also mentions that patients who have received prior experimental vaccines or commercially available active immunotherapies may be enrolled, and prior therapy with approved monoclonal antibodies is allowed. Additionally, it states that patients who have received docetaxel in the adjuvant setting and at least one year has elapsed since completion of adjuvant chemotherapy and disease recurrence are eligible for the trial. The sample concludes by stating that patients may not be receiving any other investigational agents or standard therapies for their malignancy while on the study, and supplements containing L-tryptophan or derivatives are not allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the disease mentioned is \"pancreatic cancer\". The ICDCodes associated with this disease are \"C25.3\". The drug mentioned is \"pioglitazone hydrochloride\". \n\nThe eligibility criteria for this trial include the following disease characteristics: \n- The patient must have histologically or cytologically confirmed adenocarcinoma of the pancreas.\n- The disease must be metastatic and previously treated.\n- Disease progression after first-line gemcitabine hydrochloride-based chemotherapy is required.\n- Radiologically measurable disease is necessary.\n\nThe patient characteristics required for eligibility are as follows:\n- ECOG performance status should be between 0-2.\n- ANC (Absolute Neutrophil Count) should be equal to or greater than 1,500/mm^3.\n- Platelet count should be equal to or greater than 100,000/mm^3.\n- Hemoglobin level should be equal to or greater than 9 g/dL.\n- Serum creatinine should be less than 1.5 times the upper limit of normal (ULN) or creatinine clearance should be greater than 45 mL/min.\n- Total bilirubin should be less than or equal to 1.5 times ULN.\n- AST and ALT should be less than or equal to 2.5 times ULN (5 times ULN if liver metastases are present).\n- The patient should not be pregnant or nursing, and a negative pregnancy test is required.\n- Fertile patients must use effective contraception during and for 3 months after completing the study treatment.\n- Patients with NYHA class III-IV congestive heart failure or unstable angina are not eligible.\n- Patients with a second malignancy, except for localized nonmelanoma skin cancer, are not eligible.\n- Patients with psychiatric or addictive disorders that would preclude giving informed consent are not eligible.\n\nRegarding prior concurrent therapy, the following conditions apply:\n- Prior systemic therapy with fluorouracil, capecitabine, oxaliplatin, or erlotinib hydrochloride is allowed.\n- More than 12 months should have passed since prior thiazolinediones, and no other concurrent use is allowed.\n- More than 6 months should have passed since prior treatment with immunosuppressive or immunomodulatory agents, and no other concurrent use is allowed.\n- No other concurrent anticancer therapy is allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on individuals without any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"canagliflozin (jnj-28431754)\" and \"placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having a body mass index (BMI) between 30.0 and 39.9 kg/m2, being non-diabetic (confirmed by fasting plasma glucose <126 mg/dL), and being a non-smoker or non-tobacco user for at least 3 months prior to screening. \n\nExclusion criteria include having a history of or currently active illness considered clinically significant by the investigator, having taken anti-obesity medications within 3 months of the screening visit or anticipating the need for such medications during the study, having a history of gastric banding, gastric bypass, or other gastric-reduction surgery, and having a history of eating disorder or recent significant changes in body weight due to dieting or nutritional treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Alzheimer's disease, and the corresponding ICDCodes are G30.8, G30.9, G30.0, and G30.1. The drugs being tested are ly2886721 and placebo. \n\nThe eligibility criteria for participants include meeting the criteria for Mild Cognitive Impairment (MCI) due to Alzheimer's disease or having mild Alzheimer's disease. Participants must also have specific scores on the Mini Mental State Examination (MMSE) scale and meet certain criteria related to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria, Clinical Dementia Rating Scale (CDR) score, and positive scan for the presence of amyloid beta.\n\nThere are additional criteria for participants with MCI due to Alzheimer's disease, including gradual and progressive change in memory function, specific scores on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR), absence of dementia, preservation of functional independence, exclusion of other potential causes of cognitive decline, and positive scan for the presence of amyloid beta.\n\nThere are also exclusion criteria, such as being enrolled in another drug or device study, having a history of certain types of dementia or movement disorders, not being on a stable standard of care, having had certain medical conditions or diseases, having certain mental health conditions or substance abuse history, having certain respiratory or breathing diseases, having HIV or syphilis, and taking blood thinners.\n\nAdditionally, women must be postmenopausal, and men must use an approved barrier method of contraception if their partners are pregnant or of childbearing potential and not using approved contraceptive methods.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being used in the trial are \"asp1941\", \"metformin\", and \"placebo\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Subjects must have type 2 diabetes.\n- Subjects must have stable disease under metformin monotherapy (between 1500-3000 mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative (SUD) for at least 3 months.\n- Fasting Serum Glucose must be between 7-11.5 mmol/l (after wash-out).\n- Stable Fasting Blood Glucose (FBG) at the end of wash-out.\n- BMI must be between 18.5 and 40.0 kg/m2, inclusive.\n\nExclusion Criteria:\n- Subjects with type 1 diabetes are not eligible.\n- Subjects with any diabetes-related macro-complications, painful diabetic neuropathy, diabetic macular edema, or diabetic proliferative retinopathy are not eligible.\n- Subjects with clinically significant renal disease (CLcr <60 ml/min as assessed during a 24h creatinine clearance on Day-2) are not eligible.\n- Subjects with recent evidence (e.g., within the last 6 months) of severe hypoglycemia, such as plasma glucose <3 mmol/l (<55 mg/dl) or requiring hospitalization, are not eligible.\n- Subjects with a pulse rate less than 40 or greater than 90, systolic blood pressure greater than 160 mmHg, or diastolic blood pressure greater than 100 mmHg are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are docetaxel and oxaliplatin. \n\nThe eligibility criteria for this trial include a diagnosis of non-small cell lung cancer (NSCLC) meeting certain criteria, such as being medically inoperable or having unresectable stage II, IIIA, or IIIB disease, or having post-resection intrathoracic tumor recurrence. Other criteria include having measurable disease by computed tomography (CT) scan, no evidence of small cell histology, no significant pleural effusion, no metastatic disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. \n\nAdditional criteria include specific blood counts, such as an absolute granulocyte count of at least 2,000/mm\u00b3, a platelet count of at least 100,000/mm\u00b3, and a hemoglobin level of at least 8.0 g/dL. Other criteria include certain levels of bilirubin, serum glutamic oxaloacetic transaminase (SGOT), and creatinine, as well as weight loss within the past 3 months, forced expiratory volume (FEV) 1, pregnancy status, and contraception use for fertile patients. \n\nThe exclusion criteria for this trial include having a synchronous or prior invasive malignancy (unless disease-free for more than 3 years), having a recent myocardial infarction, having symptomatic heart disease, having an active infection or fever, having a known hypersensitivity to the drugs being used, having prior thoracic or neck radiotherapy, or having received prior docetaxel or oxaliplatin.",
    "The sample is a phase 1 clinical trial for the drug SB705498, which is being tested for the treatment of dermatitis, atopic. The trial is looking for healthy Caucasian volunteers between the ages of 18 and 65. The participants must be non-smokers and have not used nicotine products for at least 6 months prior to the screening visit. They must also have a certain level of itch induced by cowhage and histamine, as well as a flare response with capsaicin. Participants must avoid UV exposure and use sunscreen during the study. Female participants must either be postmenopausal or use contraception methods listed in the protocol. Male participants must also use contraception methods. The participants' BMI must be within the range of 19.0 - 32.0 kg/m2. Certain liver enzyme levels and QTc values must be within specific ranges. There are also exclusion criteria, such as having skin infections or inflammation, history of regular alcohol/drug consumption, and sensitivity to the study medication or components. The sample must refrain from caffeine-containing products for 24 hours prior to each assessment visit.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on peripheral arterial disease. The ICD-10 codes associated with this disease are A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, and I73.9. The drugs being studied in this trial are atorvastatin, ascorbic acid, and a placebo. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n1. The subjects must be male or female, aged 21-99 years old.\n2. They must have peripheral arterial disease, which can be clinically diagnosed or confirmed through angiography, magnetic resonance imaging, vascular ultrasound, or an ankle brachial index less than 0.9.\n3. They must be able to provide informed consent and complete the study procedures.\n4. The patients must be scheduled for non-emergent vascular surgery or other non-cardiac surgery.\n\nExclusion Criteria:\n1. Patients requiring emergent or urgent surgery within one week of enrollment.\n2. Patients who have experienced unstable angina, myocardial infarction, stroke, coronary revascularization, or decompensated heart failure within the past month. Patients needing cardiac catheterization and coronary revascularization prior to vascular surgery will also be excluded.\n3. Patients with major illnesses in other organ systems, such as cancer, end-stage renal disease, hepatic failure, or any condition that would make participation inappropriate.\n4. Women who are lactating, pregnant, or of childbearing potential and not using a reliable contraceptive method. Pregnancy will be confirmed through a urine test.\n5. Patients with liver function tests or serum creatine kinase levels greater than three times the upper limit of normal.\n6. Patients who have received an investigational drug within 30 days of enrollment.\n7. Patients with a history of psychological illness or condition that would interfere with their ability to understand the study requirements.\n8. Patients with known occlusive atherosclerosis of the subclavian artery or upper extremity, as it would interfere with the brachial artery ultrasound studies.\n9. Patients taking vitamin C in a dose greater than twice the Recommended Daily Allowance (>120 mg/day) within one month of enrollment will also be excluded.",
    "The sample in the table is for a phase 1 clinical trial. The disease being studied is metastatic melanoma. The ICD-10 codes associated with the disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drug being tested is rituximab. The eligibility criteria for the trial include having histologically verified non-ocular melanoma stage IIIc/IV with no evidence of disease. The exclusion criteria include having an ECOG performance status greater than 2, ocular melanoma, immunodeficiency syndromes or hypogammaglobulinemia, active autoimmune diseases, treatment with immunosuppressive agents other than steroids, depressed bone marrow function, cardiac insufficiency NYHA IV, active Hepatitis B, C, or HIV infection, pregnancy or lactation, interstitial pulmonary disease, and former treatment with anti-CD20 antibody.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is breast neoplasms. The icd-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is grn163l in combination with trastuzumab. The eligibility criteria for participants include being 18 years or older, having an ECOG performance status of 0-2, having histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, having measurable or evaluable disease according to RECIST v1.1, and being HER2+ as defined by IHC 3+ or FISH ratio > 2.0. Other criteria include being resistant to trastuzumab, having prior treatment with lapatinib or investigational HER2 targeted therapies (not required), having a LVEF \u2265 Lower Limit of Normal, and being willing to use contraception. There are also exclusion criteria such as no recent investigational therapy, hormonal therapy, or cytotoxic chemotherapy, no prior treatment with GRN163L, no history of severe reaction to trastuzumab, and no history of certain cardiac or cerebrovascular conditions. Additionally, there are criteria related to CNS metastases, prior radiation therapy, breastfeeding, and active infection.",
    "The sample is a record from a table that contains information about clinical trials. It provides details about a specific trial, including the phase of the trial (phase 1), the diseases being studied (hematologic malignancies and leukemia), the corresponding ICD-10 codes for the diseases, the drug being tested (triciribine), and the eligibility criteria for participants.\n\nThe inclusion criteria state that patients must have relapsed or refractory leukemias for which standard therapies are not expected to result in a lasting remission. Patients with poor-risk myelodysplasia (MDS) and chronic myelomonocytic leukemia (CMML) are also eligible. The trial is open to patients with various types of leukemias, including acute non-lymphocytic leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML) in blast crisis. Patients with agnogenic myeloid metaplasia (AMM) are also included.\n\nOther criteria include an ECOG performance status of 0-3, the use of acceptable contraceptive methods for women of child-bearing potential, a negative pregnancy test, and written informed consent. The interval between prior treatment and the start of the study drug should be at least 2 weeks for cytotoxic agents or 5 half-lives for noncytotoxic agents. Patients on hydroxyurea must discontinue it for at least 48 hours before starting treatment. Certain laboratory values, such as creatinine, bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), must be within specified limits.\n\nThe exclusion criteria state that patients with uncontrolled intercurrent illnesses, active heart disease, or those receiving other standard or investigational treatments for their hematologic malignancy are not eligible for the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are lapatinib ditosylate and tamoxifen citrate. The eligibility criteria for participants include having histologically or cytologically confirmed advanced or metastatic breast cancer, progressive disease after aromatase inhibitor therapy, and having estrogen receptor- and/or progesterone receptor-positive tumor. There are also various patient characteristics and prior concurrent therapy requirements listed.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2, meaning it is in the early stages of testing. The diseases column specifies that the trial is focused on multiple myeloma. The icdcodes column provides the ICD-10 codes associated with the disease, which are 'C90.01', 'C90.02', and 'C90.00'. The drugs column lists the medications being used in the trial, which are bortezomib, lenalidomide, and dexamethasone. The criteria column describes the eligibility criteria for participants in the trial. It includes both inclusion criteria, which are requirements for participation, and exclusion criteria, which are factors that would disqualify someone from participating. The criteria cover various aspects such as diagnosis, prior treatment, age, performance status, medical conditions, and other factors that may affect participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are lenalidomide and dexamethasone. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having previously treated multiple myeloma, measurable levels of m-protein in serum or urine, an ECOG performance status of 0-2, and willingness to follow pregnancy precautions. Exclusion criteria include recent acute myocardial infarction or history of deep vein thrombosis or pulmonary embolism, certain infectious diseases, uncontrolled diabetes, hypertension, digestive ulcer, glaucoma, posterior subcapsular cataracts, mental illness, and other past histories or complications that make the subject inappropriate for the study. Pregnant or lactating females are also excluded, as well as those with grade 2 or worse neuropathy and certain laboratory abnormalities. \n\nAdditionally, patients with prior history of malignancies (other than multiple myeloma) within the past 3 years, recent radiation therapy, scars from a recent viscus operation, history of a desquamating rash while taking thalidomide, prior use of lenalidomide, known HIV positivity, recent use of certain medications, and known history of hypersensitivity to dexamethasone are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include acute lymphoblastic leukemia, acute myelogenous leukemia, b-cell chronic lymphocytic leukemia, chronic myelogenous leukemia, and myelodysplasia. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial include abt-348 and abt-348 in combination with azacitidine. The eligibility criteria for the trial are listed, including requirements for histological or cytological confirmation of the diseases, Eastern Cooperative Oncology Group Status, hematologic function, kidney and liver function, QTc interval, left ventricular ejection fraction, contraception use, ability to understand and comply with the protocol, and exclusion criteria such as active CNS involvement, recent anti-cancer therapy, poorly controlled diabetes, unresolved toxicities from prior therapy, major surgery, uncontrolled hypertension, proteinuria, inability to swallow or absorb oral tablets, certain infections, pregnancy or breastfeeding, high risk for toxicities, clinically significant uncontrolled conditions, advanced malignant hepatic tumors, hypersensitivity to certain drugs, recent use of CYP3A inhibitors or inducers, and hypersensitivity to drugs formulated with polyethoxylated castor oil.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is HIV infections, and the corresponding ICDCodes is \"Z21\". The drug being tested is lopinavir/ritonavir. \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be HIV infected, have a viral load greater than 10,000 copies/ml within 30 days prior to study entry, weigh more than 5.5 lbs at the time of enrollment, agree to take 2 nucleoside reverse transcriptase inhibitors (NRTIs) in addition to LPV/RTV, and have the consent of a parent or guardian willing to provide signed informed consent and have the infant followed at a PACTG site.\n\nThe exclusion criteria state that participants currently taking a nonnucleoside reverse transcriptase inhibitor or protease inhibitor (PI) while on study, previously used LPV/RTV, have certain gestational age criteria, have any laboratory toxicity of Grade 3 or greater, have newly diagnosed acute opportunistic or serious bacterial infection requiring therapy at the time of enrollment, are undergoing chemotherapy for active cancer, are taking certain medications, or have any other clinically significant conditions, other than HIV infection, that would interfere with the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of squamous cell carcinoma. The ICD-10 codes associated with this disease are C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, and C44.42. The drugs being used in the trial are azacitidine and cisplatin. The eligibility criteria for participants include having histologically proven SCCHN that is either metastatic or has persisted or recurred following surgery and/or radiation therapy. Patients must also meet certain requirements related to previous treatments, radiation, surgery, age, performance status, life expectancy, organ and marrow function, and concurrent therapy. There are also exclusion criteria, such as not planning to receive any other concurrent therapy, having known brain metastases, history of allergic reactions to certain compounds, being pregnant or nursing, having uncontrolled intercurrent illness, being HIV-positive, and having any prior malignancy except for certain types of cancer.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are \"unspecified adult solid tumor, protocol specific\" and \"solid tumor.\" The ICDCodes associated with these diseases are \"H01.009,\" \"H02.209,\" \"H02.009,\" \"H02.109,\" \"H04.209,\" \"H05.409,\" and \"H10.509.\" The drug being tested is \"bez235 + mek162.\" The eligibility criteria for this trial include the requirement of histologically/cytologically confirmed, advanced non-resectable solid tumors, and the presence of measurable or evaluable disease as determined by RECIST 1.0. There are also exclusion criteria, such as patients with primary CNS tumor or CNS tumor involvement, diabetes mellitus, and unacceptable ocular/retinal conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for the treatment of neoplasms (cancerous tumors). The trial is investigating the drug \"bms-907351 (xl184)\" as a potential treatment option. The eligibility criteria for participants include having advanced or metastatic solid tumors that are unresponsive to standard treatments, a life expectancy of at least 3 months, and an Eastern Cooperative Oncology Group performance score of 0-2. The exclusion criteria state that participants should not have any uncontrolled intercurrent illness.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for the treatment of breast neoplasms and neoplasm metastasis. The trial is focused on the drug everolimus (rad001). The eligibility criteria for this trial include being a female or male patient aged 18 or older with a WHO performance status of 1 or lower. The patient must have HER-2 overexpressing metastatic breast cancer cells confirmed by histology and must have experienced progressive disease on prior trastuzumab treatment alone or in combination with other anticancer agents, or relapsed after completing this therapy. The patient should also be neurologically stable with adequate bone marrow, liver, and renal function. There are also exclusion criteria, such as not receiving endocrine therapy for breast cancer within the past 2 weeks, not currently receiving chemotherapy, immunotherapy, or radiotherapy, and not having previously received vinorelbine or mTOR inhibitors. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on leukemia and lymphoma.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial involves the drug \"laromustine\".\n- Criteria: The eligibility criteria for participants in the trial are listed, including disease characteristics and patient characteristics. The criteria specify the types of hematologic malignancies that qualify for the trial, patient performance status, laboratory values, pregnancy status, prior therapy, and other medical conditions that would exclude participation.\n\nOverall, this sample provides a snapshot of a clinical trial that combines phase 1 and phase 2, targeting leukemia and lymphoma, using the drug laromustine, and specifying eligibility criteria for potential participants.",
    "The sample provided is for a Phase 1 clinical trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are J44.9, J44.1, and J44.0. The drugs being investigated in this trial are salbutamol and ipratropium. \n\nThe eligibility criteria for participants in this trial include having a diagnosis of COPD, being clinically stable with no recent changes in symptoms or medication, being aged 50 years or older, and meeting certain lung function criteria. Female participants must be of non-childbearing potential or postmenopausal. Participants must also have refrained from certain medications for a specified period of time prior to admission to the study. \n\nExclusion criteria for this trial include having unstable cardiac disease or a history of significant arrhythmia, having other significant respiratory disorders, having acute infections or unstable medical conditions, and having contraindications to certain medications. Other exclusion criteria include previous participation in a clinical trial within a certain time period, exposure to multiple new chemical entities within the past year, and history of sensitivity or allergy to the study medications. Participants must also abstain from certain prescription and nonprescription drugs during the study period.",
    "The sample from the table represents a phase 1 clinical trial for cancer. The disease being studied is cancer, and the associated ICD-10 codes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is triciribine phosphate monohydrate. The eligibility criteria for participants include having signed written informed consent, being p-Akt positive by immunohistochemistry, having measurable disease, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, having adequate recovery from recent surgery, chemotherapy, and radiation therapy, being accessible for treatment and follow-up, being refractory to or intolerant of established therapy, having a tumor site accessible to repetitive biopsies, having coagulation testing within normal limits, having a life expectancy of at least 3 months, being 18 years or older, and for women of childbearing potential, using adequate contraception and having a negative pregnancy test. The exclusion criteria include having a baseline prolongation of QT/QTc interval, having additional risk factors for torsades des pointes, and using concomitant medications that prolong the QT/QTc interval.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1/phase 2, and the diseases being studied are \"scleroderma, diffuse\" and \"scleroderma, systemic\". The corresponding ICD-10 codes for these diseases are \"L94.1\" and \"L94.0\". The drugs being tested in this trial are \"abatacept\" and \"placebo\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Diagnosis of diffuse systemic sclerosis\n- Age 18 years or older\n- Adequate renal, pulmonary, and cardiovascular function\n- Willingness to use effective contraception for the duration of the study if subject is of childbearing potential\n\nExclusion Criteria:\n- Other connective tissue diseases or overlap syndromes including MCTD, SLE, RA, eosinophilic fasciitis, and limited systemic sclerosis or morphea\n- Use of disease modifying agents including methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, minocycline, doxycycline, minocycline, thalidomide, penicillamine, tamoxifen, colchicine, or investigational agent within 90 days of screening visit\n- HIV, Hepatitis B or Hepatitis C infection\n- Use of prednisone greater than 10mg daily for 28 days prior to screening visit\n- Women who are breastfeeding or pregnant",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is prostate cancer. The corresponding ICD-10 codes for the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drug being tested is mdv3100. The eligibility criteria for this trial include being a male aged 18 or older, having histologically or cytologically confirmed adenocarcinoma of the prostate, and currently undergoing androgen deprivation therapy. Some exclusion criteria include having severe concurrent disease, known or suspected brain metastasis, history of another malignancy within the previous 5 years, and prior treatment with docetaxel-based chemotherapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"renal impairment,\" and the corresponding ICDCodes are ['M10.38', 'M10.30', 'M10.311', 'M10.312', 'M10.319', 'M10.321', 'M10.322']. The drug being studied is \"denosumab.\" The eligibility criteria for this trial include subjects who are at least 18 years old with severe CKD (creatinine clearance < 30 mL/min) and CKD requiring hemodialysis. There are additional inclusion and exclusion criteria mentioned, such as calcium, phosphate, and magnesium levels, as well as the absence of uncontrolled co-morbidities.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on breast neoplasms. The associated ICD-10 codes for the diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The trial involves the drugs exemestane and sunitinib malate. The eligibility criteria for participants include being at least 18 years old, having estrogen and/or progesterone receptor positive adenocarcinoma of the breast that is unresectable, locally recurrent, or metastatic, being postmenopausal, having an ECOG score of 1 or less, and having evaluable and measurable disease according to RECIST criteria. The exclusion criteria include not having previously received herceptin for HER2 positive disease, not having received any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the metastatic disease setting, and not having undergone radiation therapy within 2 weeks of the first study treatment.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is ulcerative colitis. The ICDCodes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being tested in this trial are avx 470 and placebo. The eligibility criteria for this trial include age between 18 and 75, a diagnosis of ulcerative colitis involving the sigmoid colon or proximal segments of the bowel, a Total Mayo score between 5-12 with an endoscopic subscore of the Mayo score \u2265 2 and > 15 cm of involvement beyond the anal verge. There are also exclusion criteria listed, such as pregnancy, certain diagnoses, prior surgeries, allergies, and other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are fallopian tube cancer, ovarian cancer, and peritoneal cavity cancer. The corresponding ICDCodes for these diseases are ['C57.00', 'C57.01', 'C57.02'], ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'], and ['C30.0', 'Z12.81', 'D14.0', 'C14.8', 'D37.09', 'Z86.003', 'Z85.818'] respectively.\n\nThe drug being used in the trial is topotecan hydrochloride. The eligibility criteria for participants in this trial include having a histological diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer, progressive or recurrent disease, having received at least one prior course of chemotherapy, and having measurable or evaluable disease or disease assessable by CA 125.\n\nOther criteria include specific ranges for Karnofsky performance status, absolute neutrophil count, platelet count, creatinine level, alkaline phosphatase level, total bilirubin level, and SGOT level. The trial also requires a life expectancy of at least 12 weeks, not being pregnant or nursing, having a negative pregnancy test, and fertile patients must use accepted and effective non-hormonal contraception.\n\nExclusion criteria for this trial include having had another neoplasm within the past 5 years, except for nonmetastatic, nonmelanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or chemotherapy. Other exclusion criteria include having septicemia, severe infection, acute hepatitis, or severe gastrointestinal bleeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is advanced cancer. The ICDCodes associated with this disease are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug being tested is \"zio-201-t and doxorubicin\". \n\nThe eligibility criteria for this trial include being at least 18 years old, having histological or cytological documentation of cancer, having measurable disease, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, being na\u00efve to ifosfamide and doxorubicin, having a life expectancy of at least 12 weeks, and meeting certain laboratory requirements for bone marrow, liver, and renal function. Other criteria include providing written informed consent, using adequate birth control measures, and having a negative pregnancy test for women of childbearing potential.\n\nExclusion criteria for this trial include having congestive heart failure above Class II, having serious cardiac arrhythmias, having a history of active coronary artery disease/ischemia, having serious myocardial dysfunction, having a history of HIV infection, having a prior nephrectomy or urinary tract obstruction, having an active serious infection requiring systemic therapy, having had major surgery within 3 weeks prior to treatment, having metastatic brain or meningeal tumors (unless certain conditions are met), having a history of seizure disorder, having a previous malignancy (with some exceptions), being pregnant or lactating, having substance abuse or medical/psychological/social conditions that may interfere with participation, and having any unstable condition that could jeopardize safety or compliance with the protocol requirements.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 1/phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drug being tested is cep-18770. The eligibility criteria for this trial include having relapsed multiple myeloma that has progressed following previous therapies, having measurable disease, having a life expectancy of more than 3 months, having a certain performance status, and meeting specific organ function and blood count requirements. There are also exclusion criteria listed, such as having nonmeasurable multiple myeloma, recent use of certain medications, or having certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is obesity. The icd-10 codes associated with obesity are listed as ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drug being tested is sibutramine. \n\nThe eligibility criteria for this trial include being a healthy male or female adult aged 20 to 55 years, having a BMI within the range of 30.0 to 40.0 kg/m2, being obese since the age of 18 or above, having demonstrated previous sustained weight loss for at least one month, and being a pre-menopausal female who is not pregnant or breastfeeding. The criteria also include requirements for contraception and abstinence from intercourse during the study period. \n\nThe exclusion criteria include having any previous or current medical conditions that may affect the interpretation of data, closed angle glaucoma, prostatic hypertrophy or hyperplasia, being post-menopausal, having a history of panic attacks or claustrophobia, clinically significant eating disorders, recent significant weight loss or gain, history of childhood obesity, bariatric surgical intervention for obesity, polycystic ovary syndrome, history of alcohol or substance abuse, smoking status, positive urine drug test, positive results for hepatitis C antibodies, hepatitis B surface antigen, or HIV, history of hepatobiliary disease or hepatic enzyme elevation, high fasting triglycerides, diabetes mellitus, thyroid disorder, high blood pressure, inability or unwillingness to participate in a moderate walking exercise program, pregnancy or planning a pregnancy, clinically significant abnormalities, use of certain medications, and other factors that may make the subject unfit for the study.\n\nOverall, this sample provides detailed information about the phase, disease, icd-10 codes, drug, and eligibility criteria for a clinical trial related to obesity.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participating in the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 1/phase 2\". The disease being studied is \"castrate-resistant prostate cancer\". The corresponding ICD-10 codes for this disease are listed as \"['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']\". The drugs being used in the trial are \"bez235\", \"prednisone\", and \"abiraterone acetate\". The eligibility criteria for participating in the trial are listed in a detailed format, including criteria such as age, confirmation of adenocarcinoma of the prostate, evidence of disease, testosterone levels, disease progression, performance status, organ function, and various other factors. The exclusion criteria are also provided, which outline the conditions or situations that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific trial in this sample is a combination of phase 1 and phase 2. The trial focuses on pancreatic cancer and involves the use of two drugs, hydroxychloroquine and gemcitabine. \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria.\" These criteria include having biopsy-proven adenocarcinoma of the pancreas, a certain stage of cancer determined by EUS or CT scan, a Karnofsky performance status of 70 or higher, no active second malignancy except for basal cell carcinoma of the skin, normal renal, hepatic, and hematologic function, specific blood cell counts, age over 18, and the ability to understand and sign an informed consent document.\n\nThe \"Exclusion Criteria\" list factors that would disqualify individuals from participating in the trial. These factors include being deemed surgically unresectable or unwilling to undergo surgical resection, having received chemotherapy within the past 12 months, prior use of radiotherapy or investigational agents for pancreatic cancer, evidence of metastasis to distant organs, symptomatic or endoscopic evidence of gastric outlet obstruction, concurrent malignancies with active or measurable disease, inability to adhere to study procedures, history of allergic reactions or hypersensitivity to the study drugs, concurrent experimental therapy, unknown effects of the drugs on a developing fetus, exclusion of HIV-positive patients, exclusion of patients with porphyria or uncontrolled psoriasis, exclusion of patients requiring specific anti-epileptic medication, exclusion of patients with macular degeneration or diabetic retinopathy, and a baseline EKG with a QTc interval greater than 470 msec.\n\nOverall, this sample provides information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a specific clinical trial focused on pancreatic cancer.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"diabetes mellitus, type 2.\" The ICDCodes associated with this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being tested in this trial are 'placebo' and 'ly2409021'. \n\nThe eligibility criteria for participants in this trial are as follows:\n\n- All participants must be either male or female who cannot become pregnant. They can be either healthy or have type 2 diabetes mellitus (T2DM) but should not be taking medication for diabetes.\n- Participants must have a hemoglobin A1c (HbA1c) value of less than or equal to 10% at screening.\n- Participants must have acceptable blood and urine laboratory test results for the study.\n\nAdditional criteria for healthy participants include:\n- Having a screening body mass index (BMI) between 18.5 and 29.9 kg/m^2 inclusive.\n- Having a fasting blood glucose between 3.0-5.2 millimoles/liter (mmol/L) at screening.\n- Having plasma glucose, two hours after ingesting an oral 75 g glucose load, less than 7.8 mmol/L.\n\nAdditional criteria for participants with type 2 diabetes mellitus (T2DM) include:\n- Having a screening body mass index (BMI) between 18.5 and 35 kg/m^2 inclusive.\n- Weighing 45 kg or more at screening.\n- Having a fasting blood glucose less than 11.1 mmol/L at screening.\n- Having plasma glucose, two hours after ingesting an oral 75 g glucose load, greater than or equal to 11.1 mmol/L.\n\nThere are also exclusion criteria for all participants, including:\n- Having participated in a study with a new drug in the last 30 days.\n- Having a history of significant heart, lung, liver, kidney, stomach, or brain disease, or any medical problems that may increase the risk during the study.\n- Having hypertension requiring more than single-agent therapy or having blood pressure greater than 140/90 millimeters of mercury (mmHg) on monotherapy.\n- Being allergic to LY2409021 or similar drugs.\n- Having a regular alcohol intake greater than 21 units/week (male) or 14 units/week (female), or being unwilling to stop alcohol as required by the study restrictions.\n- Intending to use other over-the-counter or prescribed medicines during 7 or 14 days respectively before the study or during the study, except for medicines for high cholesterol and high blood pressure if the participant has diabetes.\n- Having a significant blood disorder and/or donated blood (450 ml or more) in the last 3 months.\n\nAdditional exclusion criteria for participants with T2DM include:\n- Having signs of serious problems with diabetes, such as severe eye problems or poorly healing skin.\n- Having a history of being in a coma due to low blood sugar.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: A list of diseases related to the trial, including \"pancreatic neoplasms,\" \"pancreatic cancer,\" and \"adenocarcinoma.\"\n- ICD Codes: The ICD-10 codes associated with the diseases, such as \"C25.3\" for pancreatic neoplasms and \"C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31\" for adenocarcinoma.\n- Drugs: A list of drugs used in the trial, including \"nab-paclitaxel,\" \"gemcitabine,\" and \"capecitabine.\"\n- Criteria: The eligibility criteria for participants in the trial, including various conditions and requirements. These criteria include having histologically-confirmed pancreatic adenocarcinoma, being in stage IV disease, having no prior systemic therapy, having a certain performance score, being at least 18 years old, and meeting specific medical and health criteria.\n\nThe record also includes exclusion criteria, which outline conditions that would disqualify a participant from the trial. These criteria include having received prior systemic or investigational therapy for metastatic pancreatic cancer, having certain medical conditions or findings, having central nervous system or brain metastases, having a life expectancy of less than 12 weeks, being pregnant or lactating, having a history of certain malignancies, having certain cardiac conditions, and having other specific medical conditions.\n\nOverall, this record provides information about a Phase 1 clinical trial for pancreatic neoplasms, pancreatic cancer, and adenocarcinoma, including the drugs used and the eligibility and exclusion criteria for participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is advanced breast cancer. The ICD-10 codes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being tested in this trial are hki-272 and trastuzumab. The eligibility criteria for participants in this trial include having a pathologic diagnosis of breast cancer with stage IIIB, IIIC, or IV that is not curable by available therapy, progression following at least one Herceptin-containing cytotoxic chemotherapy regimen, HER2 positive breast cancer, at least one measurable target lesion, adequate performance status, adequate cardiac, kidney, and liver function, adequate blood counts, and willingness to use acceptable methods of birth control for subjects who are not surgically sterile or postmenopausal. The exclusion criteria include having more than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease, recent major surgery, chemotherapy, radiotherapy, or investigational agents, prior treatment with anthracyclines with a cumulative dose of over 400 mg/m^2, extensive visceral disease, active central nervous system metastases, being pregnant or breastfeeding, having a significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom, prior exposure to HKI-272 or other HER2 targeted agents (except Herceptin and Tykerb), significant cardiac disease or dysfunction, history of life-threatening hypersensitivity to Herceptin, inability or unwillingness to swallow HKI-272 capsules, and having any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and is focused on the disease \"infections, papillomavirus.\" The corresponding ICD-10 codes for this disease are listed as \"Z11.51,\" \"B97.7,\" \"R85.81,\" \"R85.82,\" \"R87.810,\" \"R87.811,\" and \"R87.820.\" The drug being used in this trial is \"placebo.\" \n\nThe eligibility criteria for participants in this trial are outlined in the \"criteria\" section. Inclusion criteria include subjects who can comply with the study requirements, females between the ages of 9 and 25, written informed consent/assent from the subject and their parents/legal representative, and being in good health based on medical history and examination. Female subjects of childbearing potential must practice adequate contraception and have a negative pregnancy test. \n\nExclusion criteria include the use of any investigational or non-registered products within 30 days prior to the first dose of the study vaccine, chronic administration of immunosuppressants or immune-modifying drugs within six months prior to the first vaccine dose, participation in another clinical study involving investigational or non-investigational products, planned administration of vaccines not specified in the study protocol, pregnancy or breastfeeding, previous vaccination against HPV or administration of other HPV vaccines, previous administration of components of the investigational vaccine, cancer or autoimmune disease under treatment, immunosuppressive or immunodeficient conditions, history of allergic reactions to vaccine components, hypersensitivity to latex, acute disease at the time of enrollment, clinically significant pulmonary, cardiovascular, hepatic or renal abnormalities, and administration of immunoglobulins or blood products within three months prior to the first dose of the study vaccine.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being tested are \"single subcutaneous dose (part a) of pb1023 or placebo (0.9% nacl)\" and \"multiple (four weekly) subcutaneous injections (part b) of pb1023 or placebo (0.9% nacl)\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being male or post-menopausal or surgically sterile female between the ages of 18-75, diagnosed with type 2 diabetes for at least 6 months, having specific HbA1c levels, fasting plasma glucose levels, fasting C-peptide levels, and BMI. Exclusion criteria include factors such as current use of non-oral antihyperglycemic agents, recent use of a specific type of medication, allergies to certain drugs, unstable cardiovascular disease, history of pancreatitis or severe gastrointestinal disease, and various other medical or psychiatric conditions.\n\nOverall, this sample provides information about a clinical trial that is testing the effectiveness of certain drugs on patients with type 2 diabetes, and it outlines the specific eligibility criteria that participants must meet.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The specific disease being studied in this sample is ulcerative colitis. The ICD-10 codes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being tested in the trial are placebo and he3286. The eligibility criteria for participants in the trial are listed, including age requirements, specific diagnostic criteria for ulcerative colitis, stable doses of certain medications, negative pregnancy tests for females, and other medical history and health-related factors. There are also exclusion criteria listed, which include specific medical conditions, recent treatments, and other factors that would make a participant unsuitable for the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases included are non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The ICDCodes associated with these diseases are provided as well. The drugs being studied in this trial are polatuzumab vedotin and rituximab. The eligibility criteria for participants are listed, including requirements for life expectancy, specific hematologic malignancies, measurable lesions, and contraception use for those of childbearing potential. The exclusion criteria are also mentioned, such as prior use of certain medications, recent treatments, and stem cell transplants.",
    "The sample is a phase 1 clinical trial for the treatment of chronic hepatitis C. The trial is testing the efficacy of a drug called bi 207127 na compared to a placebo. The eligibility criteria for participants include being adults between the ages of 18 and 70, having chronic HCV infection, and having a HCV genotype 1. Participants must also meet certain liver biopsy requirements and have a HCV RNA load greater than 100,000 IU RNA per ml serum. There are also exclusion criteria, such as not being willing to use contraception, having been previously treated with an HCV-polymerase inhibitor, or having other plausible causes for chronic liver disease. The sample also includes a list of laboratory values that would exclude a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is pancreatic cancer, identified by the ICDCodes ['C25.3']. The drugs being used in the trial are azd0530 and gemcitabine hydrochloride. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The disease characteristics include the requirement of histologically or cytologically confirmed pancreatic adenocarcinoma, unresectable disease, and locally advanced or metastatic disease. The patient characteristics include a performance status of ECOG 0-2, a life expectancy of more than 12 weeks, and specific hematopoietic, hepatic, renal, cardiovascular, pulmonary, gastrointestinal, immunologic, and other health requirements. The prior concurrent therapy restrictions include limitations on chemotherapy, endocrine therapy, radiotherapy, surgery, and the use of specific drugs. Additionally, there should be no other concurrent anticancer therapy or investigational agents.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and in this case, it is a combination of phase 1 and phase 2. The trial focuses on the treatment of type 2 diabetes mellitus. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for the disease.\n\nThe drugs column lists the names of the drugs being used in the trial, which in this case are \"efb0027 (metformin delayed release)\" and \"efb0026 (metformin immediate-release)\". The criteria column contains the eligibility criteria for participants in the trial.\n\nThe inclusion criteria include age requirements, specific HbA1c levels for different treatment regimens, serum creatinine and creatinine clearance levels, body mass index (BMI) range, gender-specific requirements, physical examination results, understanding and willingness to adhere to the protocol, stable thyroid medication dose, and normal thyroid-stimulating hormone (TSH) levels.\n\nThe exclusion criteria include various medical conditions that could affect participation, recent adjustments to chronic medication, use of medications affecting gastric pH, recent major surgery or blood transfusion, significant weight change, abnormal laboratory test results, unsuitability for the study based on physical, psychological, or historical findings, drug or alcohol abuse, recent blood donation, recent use of insulin, recent use of GLP-1 receptor agonists and/or thiazolidinedione treatment, intolerance to metformin, recent use of investigational drugs, known allergies or hypersensitivity to study treatment components, employment by Elcelyx Therapeutics, Inc., and excessive tobacco use.\n\nOverall, this sample provides specific details about the phase, diseases, icd codes, drugs, and eligibility criteria for participants in a clinical trial focused on type 2 diabetes mellitus.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include brain and central nervous system tumors, carcinoma of unknown primary, leukemia, lymphoma, and unspecified childhood solid tumor, protocol specific. The corresponding ICDCodes for these diseases are also provided. The drug being used in the trial is topotecan hydrochloride. The eligibility criteria for this trial include specific disease characteristics such as the diagnosis of neoplastic meningitis secondary to leukemia, lymphoma, or solid tumor, as well as certain patient characteristics such as age, performance status, and other medical conditions. The sample also includes information about prior concurrent therapies, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other investigational agents.",
    "The sample from the table is for a clinical trial with a combination of phase 1 and phase 2. The trial focuses on the disease \"seasonal allergic rhinitis\" and the associated ICD-10 code is \"J30.2\". The drug being studied is \"imatinib\". \n\nThe eligibility criteria for participants include being healthy males who are non-smokers, aged 18-55 years, and have a history of seasonal allergic rhinitis caused by Timothy grass pollen allergy. They must have a positive skin prick test to Timothy grass pollen and demonstrate symptomatic worsening within one hour after nasal allergen challenge. \n\nOther criteria include being otherwise healthy with no significant health problems, agreeing to use effective contraceptive measures, and not having respiratory diseases other than mild stable asthma. Participants should not have nasal abnormalities, recent nasal surgery, or ongoing respiratory tract infections. They should not have used medications that would affect the response to allergen challenge or influence imatinib bioavailability or clearance. \n\nExclusion criteria include acute or chronic renal insufficiency, abnormal liver function, certain heart conditions, adverse events from allergen challenge, and the use of concomitant medications that would impact the study results. \n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are carfilzomib, lenalidomide plus dexamethasone. The eligibility criteria for participants in this trial include being newly diagnosed with histologically confirmed, previously untreated Stage I, II, or III multiple myeloma requiring systemic chemotherapy. Other criteria include having measurable disease, a life expectancy of more than 3 months, a performance status of 0-2, and meeting certain laboratory and medical requirements. There are also exclusion criteria listed, such as having certain types of multiple myeloma, recent treatments, or medical conditions that may interfere with the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on the disease \"prostatic neoplasms\" (prostate cancer).\n- ICD Codes: The ICD-10 codes associated with the disease are \"B38.81\", \"N42.31\", \"Z87.430\", \"N40.0\", and \"N40.1\".\n- Drugs: The drugs being tested in the trial are \"docetaxel\", \"prednisone\", and \"su011248\".\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include confirmation of adenocarcinoma of the prostate, progressive hormone-refractory prostate cancer, measurable or non-measurable disease progression, and a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG). The exclusion criteria include prior use of certain therapies, prior chemotherapy, uncontrolled pain or complications related to bone metastasis or urinary obstruction, history of cardiac dysfunction, and central nervous system involvement.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on head and neck cancer. The ICD-10 codes associated with the disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being studied in the trial are fenretinide (4-hpr) and sch66336. The record also includes the eligibility criteria for the trial. The inclusion criteria include having histologically proven squamous cell carcinoma of the head and neck, a Karnofsky performance status of 70% or higher, adequate bone marrow and liver function, adequate renal function, and having signed a written informed consent. The exclusion criteria include having received 3 or more prior chemotherapeutic regimens, not having biopsy accessible tissue, having received radiation therapy within the past 6 months, and various other factors such as acute infection, major psychiatric illness, neurotoxicity, and uncontrolled heart disease. Pregnant women and women who are currently breastfeeding are also excluded from the trial.",
    "The sample from the table is for a phase 1 trial. The disease being studied is acute pain. The corresponding ICD-10 codes for the disease are G89.12, G89.18, G89.11, and G89.3. The drugs being tested in the trial are trv130 1.5 mg, trv130 3 mg, trv130 4.5 mg, morphine 10 mg, and placebo. The eligibility criteria for participants include providing informed consent, being healthy adult males aged 18-50 years with a BMI of 19-32 kg/m2, and having acceptable results from a cold pain test during screening. Exclusion criteria include having clinically significant medical illness or physical exam findings, active dermatological conditions or skin trauma on the non-dominant hand, peripheral vascular disease, certain ophthalmic conditions that could interfere with pupillometry, use of tobacco or nicotine within the past 6 months, and a history of recent drug or alcohol abuse within the past 6 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is diabetic macular edema. The ICDCodes associated with this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The drugs being used in the trial are efalizumab and ranibizumab. \n\nThe eligibility criteria for this trial include:\n- Signed informed consent and authorization of use and disclosure of protected health information\n- Being 18 years of age or older\n- Having a diagnosis of diabetes mellitus (type 1 or type 2)\n- Having a serum HbA1c level of 5.5% within 12 months of randomization\n- Having retinal thickening (diabetic macular edema) involving the center of the fovea, confirmed by fluorescein angiography and OCT images over 250\n- Having a best-corrected visual acuity score in the study eye of 20/40 to 20/320\n- If female and of childbearing potential, having a negative pregnancy test and committing to the use of at least two forms of effective contraception\n- If male and non-sterile, committing to the use of two forms of effective contraception\n- Demonstrating understanding of and ability to perform weekly self sub-cutaneous injections\n\nThe exclusion criteria for this trial include various factors such as recent panretinal or macular photocoagulation, use of steroids in the study eye, previous participation in a study involving anti-angiogenic drugs, current or recent treatment of psoriasis with efalizumab, proliferative diabetic retinopathy, vitreomacular traction or epiretinal membrane, structural damage to the center of the macula, concurrent diseases in the study eye, recent eye surgeries, uncontrolled glaucoma, high blood pressure, uncontrolled diabetes, renal failure, and various other conditions that may contraindicate the use of the investigational drug or pose a high risk to the subject.\n\nIt is also mentioned that participation in another simultaneous medical investigation or trial is not allowed.",
    "The sample is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is indicated as \"phase 1/phase 2\". The diseases being studied are \"leukemia\" and \"myelodysplastic syndromes\". The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in this trial are \"azacitidine\" and \"lenalidomide\". The eligibility criteria for the trial are then listed, including specific disease characteristics that qualify a patient for the trial, patient characteristics such as life expectancy and performance status, and prior concurrent therapies that are allowed or not allowed.\n\nOverall, this sample provides a snapshot of a clinical trial that focuses on leukemia and myelodysplastic syndromes, with specific eligibility criteria and information about the drugs being tested.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of acute myeloid leukemia. The trial includes patients who are newly diagnosed with AML and are eligible for intensive induction chemotherapy. The inclusion criteria specify certain characteristics that the patients must meet, such as the absence of specific genetic mutations and fusion transcripts. The patients must also provide written informed consent and have not received previous cytotoxic chemotherapy for AML, except for oral hydroxyurea. Adequate renal and hepatic functions are required, as indicated by specific laboratory values. The patients must be capable of understanding the nature and potential risks and benefits of the study. Female patients must meet certain criteria related to menopause, hormone levels, and contraception methods. Male patients also have specific criteria related to contraception methods. The exclusion criteria include current concomitant chemotherapy, radiation therapy, or immunotherapy not defined in the study protocol, recent use of investigational agents or anticancer therapy, participation in another clinical trial, bleeding disorder independent of AML, uncontrolled systemic infection, HIV infection, pregnancy or lactation, significant concurrent diseases or disorders that may compromise patient safety or compliance, and diagnosis of another malignancy unless certain conditions are met. Known hypersensitivity to any of the investigational medical products is also an exclusion criterion.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease mentioned in this sample is \"left ventricular diastolic dysfunction\". The corresponding ICD-10 codes for this disease are \"I47.2\", \"I49.01\", \"I49.02\", \"I49.3\", \"Q21.0\", \"I47.0\", and \"I50.1\". The drugs being tested in this trial are \"bnp (nesiritide)\" and \"placebo\". The sample also includes the eligibility criteria for the trial. The inclusion criteria state that subjects must have an ejection fraction greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography, and they should not have signs or symptoms of congestive heart failure or have been hospitalized for heart failure. The exclusion criteria list various conditions and factors that would disqualify a subject from participating in the trial, such as recent myocardial infarction, unstable angina, significant valvular stenosis, and abnormal levels of certain blood markers.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is HIV infections. The corresponding ICD-10 code for this disease is \"Z21\". The drugs being used in the trial are lopinavir/ritonavir and saquinavir. \n\nThe eligibility criteria for participants in this trial include being HIV infected, having an HIV RNA viral load greater than 5,000 copies/ml, having at least 6 months of continuous therapy with a protease inhibitor prior to study entry, and no change in antiretroviral therapy since genotypic resistance testing. The participant must also have specific genotypic or phenotypic resistance testing results indicating certain mutations in the HIV virus. The participant's parent or legal guardian must provide informed consent, and if sexually active, the participant must agree to use acceptable methods of contraception. The participant must have a reliable method of communication with the study staff and be able and willing to swallow the study medications.\n\nExclusion criteria for this trial include having drug toxicity greater than Grade 3 at screening, certain abnormal laboratory values, acute opportunistic or serious bacterial infection requiring treatment, chemotherapy for active cancer, any significant diseases other than HIV infection that may interfere with the study, requiring certain medications, history of heart problems, family history of prolonged QTc-Interval Syndrome or prolonged QTc-interval at study entry, and being pregnant or breastfeeding.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 combination. The trial focuses on various diseases, including graft versus host disease, leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of drugs such as busulfan, cyclophosphamide, methotrexate, and tacrolimus.\n\nThe eligibility criteria for the trial include specific disease characteristics for each disease, such as confirmed diagnosis and certain high-risk features. Patients with primary acute myeloid leukemia, secondary AML, chronic myelogenous leukemia in accelerated or blast phase, primary or secondary myelodysplastic syndromes, and primary acute lymphoblastic leukemia are eligible. Patients must not have a suitable HLA genotypically identical sibling or fully matched unrelated donor, and they should not have active CNS involvement with the disease.\n\nThe trial also specifies patient characteristics, including a Karnofsky performance status of 50-100% and no symptomatic coronary artery disease or congestive heart failure. Patients should not have hepatic disease with transaminases or bilirubin levels exceeding two times the upper limit of normal, severe hypoxemia, impaired renal function, HIV infection, or be pregnant or breastfeeding. Fertile patients must use effective contraception, and patients should not have active untreated infections.\n\nRegarding prior concurrent therapy, the inclusion criteria are the same as the disease characteristics. However, the exclusion criteria state that patients who have undergone previous allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation using a high-dose total-body irradiation regimen are not eligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of melanoma, a type of skin cancer. The trial is specifically targeting patients with locally advanced or metastatic melanoma that is resistant to standard therapy or for which no curative standard therapy exists. The eligibility criteria for participants include having a confirmed diagnosis of melanoma, having measurable disease, being at least 18 years old, meeting certain laboratory requirements, and having an ECOG performance status of 0 or 1. Participants of reproductive potential must agree to use effective contraception or be sterile. The sample also includes a list of exclusion criteria, such as concurrent therapy with any other investigational agent, uncontrolled central nervous system metastases, impaired cardiac function or significant cardiac disease, recent use of certain therapies or investigational agents, and various other medical or psychiatric conditions that may increase the risk associated with the study or interfere with the interpretation of results.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on three diseases - non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial is testing a drug called gs-9219.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as the type of disease, performance status, organ function, previous treatments, and other health conditions.\n\nOverall, this sample record provides information about a clinical trial that is testing the drug gs-9219 on patients with relapsed or refractory non-Hodgkin's lymphoma, chronic lymphocytic leukemia, or multiple myeloma. It also outlines the eligibility criteria that participants must meet to be included or excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drugs being tested in this phase are dasatinib, lenalidomide, and dexamethasone, with various dosages. \n\nThe eligibility criteria for this trial include being able to provide written informed consent, being at least 18 years old, having a confirmed diagnosis of multiple myeloma with measurable disease, and having evidence of relapsed or refractory disease with at least one prior therapy. Other criteria include having an Eastern Cooperative Oncology Group Scale (ECOG) Performance Status of 0-2, having the last treatment at least 21 days prior to the trial, and meeting certain baseline hematology and chemistry parameters. \n\nThere are also exclusion criteria, such as being pregnant or breastfeeding, having clinically significant cardiac disease, having prolonged corrected QT interval, having certain medical conditions or abnormalities, and having intolerance to dasatinib and/or lenalidomide.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on prostate cancer. The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being studied are 'abt-888' and 'temozolomide'. The eligibility criteria for participants include having confirmed prostate cancer, metastatic disease that has progressed despite previous therapies, specific PSA levels, and normal organ and bone marrow function. There are also exclusion criteria, such as a history of certain medical conditions or prior treatment with a PARP inhibitor.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has columns for \"phase\" which represents the phase of the trial (phase I, phase II, or phase III), \"diseases\" which is a list of disease names, \"icdcodes\" which is a list of ICDCodes for the diseases, \"drugs\" which is a list of drug names, and \"criteria\" which represents the eligibility criteria for the trial.\n\nThe sample data in the table shows an example for a phase 1 trial. The diseases included in this trial are breast cancer, colorectal cancer, head and neck cancer, lung cancer, mesothelioma, pancreatic cancer, prostate cancer, and sarcoma. The ICDCodes associated with these diseases are also provided. The drugs used in this trial are cisplatin, pemetrexed disodium, and sorafenib. The eligibility criteria for this trial include various conditions such as having a histologic or cytologic diagnosis of advanced non-hematologic malignancy, being at least 21 days from previous systemic therapy, having measurable or non-measurable disease as defined by RECIST criteria, having an ECOG performance status of 0 to 2, and meeting certain organ function requirements.\n\nThe exclusion criteria for this trial include having squamous cell of the lung, being pregnant or breastfeeding, having cardiac disease, having symptomatic or active brain metastases, having uncontrolled hypertension, having known allergies to the drugs used in the trial, having HIV infection or chronic Hepatitis B or C, having a second primary malignancy (except for certain cases), having active clinically serious infection, having recent thrombolic or embolic events, having pulmonary hemorrhage/bleeding events, having serious non-healing wounds or fractures, having bleeding diathesis or coagulopathy, having peripheral neuropathy, having undergone major surgery or significant traumatic injury recently, using St. John's Wort or rifampin, having conditions that impair swallowing, or having malabsorption problems.\n\nOverall, the sample provides a comprehensive overview of the schema definition and includes specific information about diseases, drugs, and eligibility criteria for a phase 1 clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include carcinoma, squamous, head and neck cancer, oral cancer, laryngeal cancer, and pharyngeal cancer. The ICDCodes associated with these diseases are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being used in the trial are bortezomib (velcade, ps-341), cetuximab, and cisplatin. The eligibility criteria for the trial are listed, including specific requirements for patients' disease stage, prior treatment, age, performance status, organ and marrow function, contraception, cognitive and neurologic function, and exclusion criteria such as previous radiation treatment, brain metastases, allergies, peripheral sensory neuropathy, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are leukemia and lymphoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are cyclophosphamide and fludarabine phosphate. The eligibility criteria for participants in this trial include having a diagnosis of non-Hodgkin Lymphoma or chronic lymphocytic leukemia (NHL or CLL) and meeting specific progression or relapse criteria. Other criteria include having an available related HLA-haploidentical NK cell adult donor, a Karnofsky performance status above 60%, measurable disease, and acceptable organ function. The sample also includes exclusion criteria and donor selection criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on treating diseases such as glioblastoma, gliosarcoma, and anaplastic astrocytoma. The diseases are identified by their corresponding ICD-10 codes. The drug being tested in this trial is a combination of oral topotecan and temodar. The eligibility criteria for participants in this trial include specific histology requirements, age above 18, a certain level of performance status, renal function within a specified range, hematologic status meeting certain criteria, hepatic function within a certain range, and other factors. The sample also includes exclusion criteria, such as pregnancy or breastfeeding, active infection requiring intravenous antibiotics, and prior failure with either topotecan or temozolomide.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is a combination of phase 1 and phase 2.\n- Diseases: The specific disease being studied, which in this case is sickle cell disease.\n- ICD Codes: The ICD-10 codes associated with the disease, which are a standardized way of classifying and coding medical diagnoses.\n- Drugs: The drug being tested in the trial, which is sodium nitrite injection, USP.\n- Criteria: The eligibility criteria for participants in the trial, including both inclusion and exclusion criteria.\n\nThe inclusion criteria state that subjects must be between 8 and 23 years old, have a diagnosis of sickle cell disease, experience sudden onset of acute pain related to vaso-occlusive crisis, require hospitalization and parenteral analgesics for severe pain, provide informed consent, and be willing to be followed for at least 30 days.\n\nThe exclusion criteria list conditions or circumstances that would disqualify subjects from participating in the trial, such as clinically significant bleeding, current drug abuse, recent hospitalization for pain, other complications of sickle cell disease, pregnancy or breastfeeding, low blood pressure, methemoglobinemia, anemia, G6PD deficiency, allergies to nitrites or other substances, recent treatment with allopurinol or any investigational drug, significant acute or chronic diseases, and being deemed inappropriate for the study by the clinical investigator or study manager.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease listed is \"unspecified adult solid tumor, protocol specific.\" The ICDCodes associated with this disease are \"H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509.\" The drug being studied is \"hsp90 inhibitor auy922.\" The eligibility criteria for this trial include various medical conditions and requirements that patients must meet in order to participate. These criteria include having a histologically proven solid tumor malignancy that is refractory to standard therapy, having at least one measurable lesion, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 1, and meeting certain blood count and organ function requirements. Additionally, male participants with partners who are of childbearing potential must agree to use double barrier method of birth control or have a history of vasectomy. The exclusion criteria include patients with central nervous system (CNS) metastasis, patients who have received prior treatment with certain inhibitors, and patients who have received systemic anti-cancer treatment within specific time frames. Other exclusion criteria include patients with impaired cardiac function, certain medical conditions, and patients who are unwilling or unable to comply with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, and myelodysplastic syndromes. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drug being tested in this trial is called \"compound 506u78\". The eligibility criteria for participants in this trial include having a histologically confirmed hematologic malignancy that has failed standard therapy or for which no standard therapy exists. Other criteria include age (18 and over), performance status, life expectancy, and various medical conditions such as hepatic and renal function, neurologic history, and HIV status.\n\nThe sample also includes information about prior concurrent therapies, such as biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery. It specifies the time intervals since prior treatments and any restrictions on concurrent therapies.\n\nOverall, this sample provides a snapshot of a clinical trial record, including the phase, diseases being studied, drugs being tested, and eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"benign prostatic hyperplasia,\" and its corresponding ICDCodes are \"N40.0\" and \"N40.1.\" The drugs being studied are \"prx302\" and \"placebo.\" The eligibility criteria for this trial include various factors such as lower urinary tract symptoms (LUTS) attributed to BPH for at least 6 months, written informed consent, IPSS score of 12 or higher, prostate volume between 30-100 mL, maximum urine flow (Qmax) between 4-15 mL/sec, refractory, intolerant or refused use of alpha-blockers and/or 5 alpha-reductase inhibitors, unwillingness or inability to undergo conventional surgical or minimally invasive treatments, and blood PSA values less than 10 ng/mL. The exclusion criteria include inability to void at least 125 mL of urine, post-void residual (PVR) volume greater than 200 mL, presence or history of certain conditions that could interfere with the study results or endanger the subject, and use of certain prescribed medications that could interfere with the study results.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"adult anaplastic astrocytoma,\" \"adult giant cell glioblastoma,\" \"adult gliosarcoma,\" and \"recurrent adult brain tumor.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are \"ixabepilone\" and \"anticonvulsant.\" The eligibility criteria for the trial are listed, including requirements such as histologically proven malignant glioma, measurable progressive or recurrent glioma, recovery from prior therapy, specific blood counts and laboratory values, performance status, prior chemotherapy regimens, birth control methods, absence of concurrent malignancy, stable corticosteroid regimen, and a minimum Mini Mental State Exam score. The exclusion criteria are also listed, including serious concurrent infection or medical illness, pregnancy or breastfeeding, more than 2 prior chemotherapy regimens, concurrent use of investigational agents, and use of specific medications known to inhibit CYP3A4.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"peritoneal neoplasms,\" and the corresponding ICDCodes are ['K65.1', 'K66.0', 'N99.4', 'N73.6', 'R88.0', 'Z49.32', 'Z49.02']. The drug mentioned is \"nanoparticulate paclitaxel.\" \n\nThe eligibility criteria for this trial include:\n- Patients must be at least 18 years of age.\n- Patients must have a histologic or cytologic diagnosis of carcinoma predominantly confined to the peritoneal cavity.\n- Patients must have failed all potentially curative therapy and have no other systemic treatment options available for extra-peritoneal disease. Patients with ovarian cancer that are platinum-sensitive must have failed primary and at least one salvage regimen. Patients may undergo surgical debulking prior to entry into the trial.\n- At least 28 days must have elapsed since completion of any other previous chemotherapy treatment received prior to registration in this study.\n- Patients may have received prior abdominal surgery greater than 2 weeks prior to registration. Patients must have recovered from all effects of the surgical procedure.\n- Patients must have a Zubrod Performance Status of 0 - 2.\n- Patients must have a pretreatment granulocyte count greater than or equal to 1,500/microliter and platelet count greater than or equal to 100,000/microliter obtained within 14 days prior to registration.\n- Patients must have adequate renal function as documented by a serum creatinine less than or equal to 1.5 times the institutional upper limit of normal obtained within 14 days prior to registration.\n- Patients must have adequate hepatic function as documented by a bilirubin of less than or equal to 2 times the institutional upper limit of normal and an SGOT less than 5 times the institutional upper limit of normal obtained within 14 days prior to registration. Patients with hepatobiliary stents are eligible for this trial if the bilirubin meets the above parameter.\n- There should be no plans for the patient to receive concomitant radiation therapy, hormonal therapy, or other chemotherapy for their tumor while on this protocol.\n\nThe exclusion criteria for this trial include:\n- Patients with active inflammatory bowel disease or chronic diarrhea.\n- Patients with uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, myocardial infarction within the previous 6 months, or serious uncontrolled cardiac arrhythmia.\n- Patients with active infection requiring systemic therapy.\n- Pregnant or nursing women.\n- Patients with Grade 2 or greater sensory neuropathy (by NCI Common Toxicity Criteria) at the time of study registration.\n- Patients taking concomitant medications demonstrated to inhibit or induce CYP3A4 or CYP2C8.\n- Patients with pre-existing conditions that prohibit the use of intravenous dexamethasone at the recommended dose.",
    "The sample provided is for a clinical trial in phase 1. The trial focuses on the disease \"stomach neoplasms\" and includes patients with a confirmed diagnosis of gastric cancer. The trial also requires patients to be chemotherapy-naive and have adequate organ function. The sample lists the icd-10 codes associated with the disease, which are ['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']. The drugs being tested in this trial are cisplatin, s-1, and sunitinib. The sample also provides the inclusion and exclusion criteria for the trial, including specific requirements and restrictions for patient eligibility.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are \"e7389 + carboplatin auc 5\", \"e7389 + carboplatin auc 6\", and \"e7389+carboplatin auc 6\". \n\nThe eligibility criteria for this trial include:\n- Patients must be 18 years of age or older.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n- Patients must have a life expectancy of at least three months.\n- Patients must have adequate renal function, as indicated by serum creatinine levels \u2264 2.0 mg/dL or calculated creatinine clearance \u2265 40 mL/min.\n- Patients must have adequate bone marrow function, with an absolute neutrophil count (ANC) \u2265 1.5 \u00d7 10^9/L, hemoglobin \u2265 10.0 g/dL, and platelet count \u2265 100 \u00d7 10^9/L.\n- Patients must have adequate liver function, with bilirubin \u2264 1.5 mg/dL and alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate aminotransferase (AST) levels \u2264 3 times the upper limits of normal (ULN).\n- Patients must be willing and able to comply with the study protocol for the duration of the trial.\n- Patients must provide written informed consent prior to any study-specific screening procedures.\n\nThere are additional inclusion and exclusion criteria specific to the dose finding phase and NSCLC patients at the MTD (maximum tolerated dose). These criteria include details about the type and stage of the disease, prior treatments, and other medical conditions that may affect eligibility.\n\nIt is important to note that this is just a sample record from the table, and there may be more records with different phases, diseases, drugs, and eligibility criteria in the actual table.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: A list of diseases being studied in the trial, including ovarian cancer, peritoneal cancer, and fallopian tube cancer.\n- ICD Codes: The corresponding ICD-10 codes for the diseases, such as C05.2, C10.0, C16.0, etc.\n- Drugs: The drugs being used in the trial, which include dasatinib, paclitaxel, and carboplatin.\n- Criteria: The eligibility criteria for participants in the trial, including requirements such as having histologic or cytologic evidence of the specified cancers, measurable disease, being over 18 years old, and having a certain expected survival rate. The criteria also include requirements for performance status, adequate organ function, no recent prior therapies, and the availability of tumor tissue for evaluation.\n\nAdditionally, the record includes exclusion criteria, which specify conditions or factors that would disqualify a participant from the trial. These include certain types of ovarian tumors, history of other invasive malignancies, specific cardiac conditions, bleeding disorders, certain medications being taken, elevated serum creatinine levels, radiation therapy to a significant portion of bone marrow, hypersensitivity to certain drugs, and severe medical conditions.\n\nOverall, this record provides information about a Phase 1 clinical trial focusing on ovarian, peritoneal, and fallopian tube cancers, using specific drugs, and with detailed eligibility and exclusion criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of recurrent ovarian carcinoma. The trial is specifically for patients who have undergone optimal cytoreductive surgery for recurrence and have received only one prior chemotherapeutic regimen. The eligibility criteria include having received platinum-based intravenous chemotherapy as the only prior therapy, evidence of recurrent cancer, specific histologic types of tumors, confinement of recurrent disease to the abdominal cavity, recurrence of tumor more than six months after completion of primary chemotherapy, and having undergone a second cytoreductive surgery to remove all gross residual disease. Other criteria include the presence of an IP catheter, adequate renal function, appropriate hematologic parameters, absence of pleural effusions, ECOG performance status less than or equal to 2, and age greater than 18 years old. The exclusion criteria include certain disease stages, absence of recurrent disease by histologic documentation, disease outside the peritoneal cavity, presence of other invasive malignancies within the last 5 years, platinum-resistant ovarian or primary peritoneal cancer, suboptimal cytoreductive surgery at first diagnosis, > 1cm residual disease after the second cytoreductive surgery, previous intraperitoneal chemotherapy, pregnancy or lactation, and peripheral neuropathy greater than grade 2 at baseline.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are cancer and non-small cell lung cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for cancer, and C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2 for non-small cell lung cancer. The drugs being used in the trial are xl147 (sar245408) and erlotinib. The eligibility criteria for this trial include various conditions such as having a confirmed solid tumor that is metastatic or unresectable, not responding to standard therapies, having measurable or non-measurable lesions, having a certain performance status, adequate organ and marrow function, and meeting other specific requirements. There are also exclusion criteria listed, which include previous treatment with a selective PI3K inhibitor, recent use of certain therapies, uncontrolled diabetes, certain medical conditions, and other factors that may limit compliance with the study requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is sorafenib. The eligibility criteria for this trial include having advanced cancer that is not eligible for curative treatment, having a measurable lesion in the thorax, abdomen, or pelvis, having normal organ and bone marrow function, and being able to receive the prescribed radiation treatment. The exclusion criteria include having overlap of treatment field with a previous radiation field, inability to meet mandated normal tissue radiation dose constraints, having brain metastases (unless previously treated and controlled), previous treatment with Sorafenib, poorly controlled hypertension, inability to swallow sorafenib tablets, intercurrent cardiac dysfunction, and uncontrolled intercurrent illness.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is obesity. The ICDCodes associated with obesity are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drugs being tested in this trial are 'zgn-440' and 'zgn-440 sterile diluent'. The eligibility criteria for participants in this trial include being obese but otherwise healthy females, having a BMI between 30 and 45 kg/m2, and having a stable body weight for the past 2 months. Exclusion criteria include recent use of weight loss agents, a history of eating disorders, type 1 or type 2 diabetes mellitus, and being a current smoker.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The sample includes a specific entry for a phase 1 trial. The diseases being studied in this trial are recurrent glioma, high-grade meningioma, and brain metastasis. The ICDCodes associated with these diseases are also provided. The drug being tested in this trial is panobinostat. The eligibility criteria for this trial include age, performance status, laboratory criteria, thyroid function, pregnancy status, and specific pathologic diagnoses for each arm of the study. The exclusion criteria include prior use of certain inhibitors, impaired cardiac function, uncontrolled hypertension, gastrointestinal issues, and other medical conditions. The sample also includes exclusion criteria specific to each arm of the trial.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is non-small-cell lung carcinoma. The corresponding ICD-10 codes for this disease are D02.20, D02.21, and D02.22. The drug being tested in this trial is celecoxib. The eligibility criteria for inclusion in the trial are having pathologically confirmed and surgically resectable non-small cell lung cancer, and being ineligible for or refusing neoadjuvant therapy. The exclusion criteria include hypersensitivity to celecoxib or NSAIDs, previous history of gastrointestinal bleeding or ulceration, chronic or concurrent use of steroids, and renal insufficiency.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is lymphoma, and the corresponding ICDCodes are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being used in the trial are rituximab, bortezomib, and ibritumomab tiuxetan. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having histologically confirmed follicular lymphoma, being CD20+ at the time of diagnosis or subsequently, and meeting certain time intervals since prior treatments, surgeries, and investigational drugs. Exclusion criteria include having AIDS-related lymphoma, history or evidence of CNS involvement, being pregnant or nursing, having known HIV positivity, having serious medical or psychiatric illnesses that would prevent study participation, recent myocardial infarction, congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, ECG evidence of acute ischemia or active conduction system abnormalities, known hypersensitivity to the drugs rituximab, bortezomib, boron, or mannitol, prior autologous or allogeneic stem cell transplantation, prior radioimmunoconjugate therapy, or prior exposure to murine antibodies, and prior external-beam irradiation to more than 25% of active bone marrow.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1 and focuses on the treatment of lymphoma. The ICD-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being tested in this trial are 'ibritumomab tiuxetan', 'rituximab', 'melphalan', and 'vinorelbine tartrate / g-csf'. \n\nThe eligibility criteria for this trial are described in detail. The disease characteristics include having histologically confirmed non-Hodgkin's lymphoma of any type, being CD20-positive, achieving a partial or complete response to salvage treatment for relapse or refractory disease within the past 10 weeks, having an indication for autologous stem cell transplantation, having bone marrow infiltration less than 25%, and having no evidence of CNS involvement.\n\nThe patient characteristics include having a WHO performance status of 0-1, bilirubin levels within 2 times the upper limit of normal (ULN), alkaline phosphatase levels within 2 times ULN, AST levels within 2 times ULN, creatinine clearance greater than 50 mL/min, no clinically significant cardiac disease, LVEF greater than 50%, no clinically significant urinary tract obstruction, no clinically significant pulmonary disease, and no serious underlying medical condition that would prevent participation in the study. Additionally, the patient should not have had any other malignancy within the past 5 years, except for nonmelanoma skin cancer or adequately treated in situ cervical cancer.\n\nThe prior concurrent therapy section states that the patient should meet the disease characteristics mentioned earlier. They should not have participated in another clinical trial within the past 30 days, should not have undergone stem cell transplantation before, should not have received prior radiolabeled antibodies for induction of disease remission, should not have received radiotherapy to \u2265 25% of the bone marrow, should not be receiving concurrent radiotherapy or other concurrent anticancer drugs, and should not be receiving other concurrent investigational drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is metastatic breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are vinorelbine oral and capecitabine.\n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically confirmed metastatic breast cancer.\n- The patient must be between the ages of 18 and 75.\n- The disease must be measurable or evaluable.\n- The patient's performance status (ECOG) must be between 0 and 2.\n- Patients with reproductive potential must use an adequate contraceptive method during treatment and for three months after completing treatment.\n- The patient must have adequate liver, renal, and bone marrow function.\n- At least three weeks must have passed since completion of irradiation.\n- The patient must have a life expectancy of at least 12 weeks.\n- The patient must be able to take oral medication.\n- The patient must provide written informed consent.\n\nThe exclusion criteria for this trial include:\n- The patient must not have an active infection.\n- The patient must not have brain metastases.\n- The patient must not have a history of significant cardiac disease.\n- The patient must not be malnourished.\n- The patient must not have a psychiatric illness or social situation that would preclude study compliance.\n- Pregnant or lactating women are excluded from the trial.",
    "The sample from the table represents a clinical trial for HIV infections. The trial is a combination of phase 1 and phase 2. The diseases being studied are HIV infections, which are identified by the ICD-10 code 'Z21'. The drugs being used in the trial include 'gpo-vir z30 tablet', 'lamivudine', 'nevirapine', and 'zidovudine'. \n\nThe eligibility criteria for participants include weighing between 6 and 30 kilograms, being HIV infected, receiving a specific HAART regimen, agreeing to use two forms of contraception, being able to swallow study drugs, and being willing to be hospitalized for a 12-hour intensive PK study. The participant's parent or legal guardian must also provide written informed consent.\n\nExclusion criteria include certain abnormal laboratory values, recent vomiting or diarrhea, history of immunologic failure, current treatment for an acute serious infection, history of dose-limiting toxicity from the study drugs, hypersensitivity to the study drugs, gastrointestinal or liver problems, recent treatment with experimental drugs, acute hepatitis, chemotherapy for active malignancy, any clinically significant diseases or findings that may interfere with the study, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes are ['Z21']. The drugs being investigated are enfuvirtide and amdoxovir. \n\nThe eligibility criteria for this study include being HIV infected, having taken at least two combination anti-HIV treatments containing three or more drugs for a minimum of 24 months, having failed two previous combination treatments, having a viral load of more than 5000 copies/ml on a stable antiretroviral regimen within 60 days prior to study entry, being willing to stay on the current failing anti-HIV treatment until starting the study treatment, using acceptable methods of contraception, having access to optimized background (OB) regimen drugs, and being able to bring OB regimen drugs to the screening visit.\n\nThe exclusion criteria for this study include prior use of DAPD or ENF, drug or alcohol use that may interfere with the study, history of any illness that may interfere with study participation, having a single kidney or a history of two or more episodes of kidney stones, being pregnant or breastfeeding, recent use of experimental anti-HIV drugs or agents that act on the immune system, active immunization within 21 days prior to study entry, undergoing acute therapy for a serious infection or illness, having an active AIDS-defining opportunistic infection requiring acute treatment, experiencing unexplained fever within 7 days prior to study entry, having cancer that requires chemotherapy, prior HIV vaccination (except for subunit vaccines that contained only gp120), certain mutations in HIV-1 reverse transcriptase, measurable loss of vision due to lens opacity, posterior subcapsular cataract, cortical cataract of Grade C3 or higher on the Lens Opacities Classification System III (LOCS III) scale, nuclear opalescence Grade NO3 (LOCS III) or higher, and having best corrected vision worse than 20/200. Diabetes mellitus is not excluded, but gestational diabetes is.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The disease being studied is carcinoma, transitional cell. The corresponding ICD-10 codes for this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being tested in this trial are pemetrexed, gemcitabine, and platinol. The eligibility criteria for participants include having biopsy-proven metastatic bladder cancer, no prior chemotherapy for metastatic disease except before or after surgery completed 6 months before enrollment, prior radiation allowed if it is not the only site of measurable disease and completed 3 weeks before enrollment, and being 18 years of age or older. The exclusion criteria include having pure adeno- or squamous urothelial cancer, brain metastases causing symptoms, not having received treatment within the last 30 days with a drug that has not received regulatory approval for any indication, inability to take dexamethasone, folic acid or vitamin B12 as per the protocol, and clinically relevant fluid collection in the lungs or abdomen that cannot be controlled.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"neoplasms\" and its corresponding ICDCodes are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being used in the trial are 'ogx-427' and 'docetaxel'. The eligibility criteria for this trial include various factors such as age, confirmed diagnosis of specific types of cancer, metastatic disease, previous failed therapies, and specific requirements for patients enrolled in Cohorts 6 and 7. The criteria also include recovery from previous treatments, laboratory requirements, willingness to continue certain medications, Karnofsky score, contraception, and consent. The exclusion criteria include limitations on the number of previous chemotherapy regimens, current treatment with certain anticancer agents, CNS metastasis, allergic reactions to specific drugs, pregnancy or lactation, second malignancy, uncontrolled or serious medical conditions, participation in other clinical trials, prior high dose chemotherapy, certain cardiac conditions, and use of drugs known to increase QTc duration.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are ipilimumab (3 mg and 10 mg), paclitaxel, and carboplatin. The eligibility criteria for participants in this trial include having histologically or cytologically documented non-small cell lung cancer, no prior chemotherapy or other treatments for NSCLC, a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group performance score of 0-1, adequate bone marrow function, and various other health requirements. There are also exclusion criteria listed, such as having symptomatic central nervous system metastasis, a history of severe autoimmune disease, or concurrent malignancies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is cervical cancer. The ICDCodes associated with this disease are M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, and M50.90. The drugs being used in the trial are cisplatin and erlotinib hydrochloride. The eligibility criteria for this trial include a diagnosis of squamous cell carcinoma of the cervix, stage IB-IVA disease, scheduled to undergo standard radiotherapy and receive weekly cisplatin, ECOG performance status 0-2, not pregnant, negative pregnancy test, fertile patients must use effective contraception, and must be able to take oral medication. The exclusion criteria include malabsorption syndrome, serious underlying medical conditions that would impair treatment, known hypersensitivity to erlotinib hydrochloride, psychological, familial, sociological, or geographical conditions that would affect study compliance, recent use of nonapproved or investigational drugs, prior chemotherapy, prior radiotherapy, prior anti-epidermal growth factor receptor treatment, prior gastrointestinal surgery that limits absorption, and concurrent use of certain agents and therapies such as other antineoplastic or antitumor agents, other chemotherapy, other investigational agents, radiotherapy, immunotherapy, and anticancer hormonal therapy.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is glioblastoma multiforme. The corresponding ICD-10 codes for this disease are 'L51.0', 'L51.8', and 'L51.9'. The drug being tested is temodar (temozolomide). The eligibility criteria for the trial include having a histologically proven glioblastoma multiforme, evidence of tumor recurrence or progression, and completion of previous radiotherapy. Other criteria include signing an informed consent, having recent brain imaging, a life expectancy of more than 8 weeks, a Karnofsky performance status of 60 or higher, recovery from prior therapy, and adequate bone marrow, liver, and renal function. Exclusion criteria include a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) within the past 3 years, active infection, pregnancy, disease that may affect drug metabolism, or serious intercurrent medical illness.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is \"neoplasms,\" and the ICDCodes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug mentioned is 'pf-00299804'. The eligibility criteria include inclusion criteria such as having a malignant solid tumor with no approved treatment and adequate bone marrow, liver, cardiac, and kidney function. The exclusion criteria include having cardiac disease, receiving anticancer therapy within 4-6 weeks, and being pregnant or breastfeeding.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 1. The disease being studied is sarcoma. The corresponding ICD-10 codes for the disease are C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, and C92.32. The drug being tested is liposomal daunorubicin citrate. The eligibility criteria for participants in this trial include having histologically confirmed Kaposi's sarcoma involving the skin, lymph nodes (palpable disease only), and oral cavity. Participants must have at least 5 measurable, previously nonirradiated, cutaneous lesions that can be used as indicator lesions, as well as 2 lesions that are accessible for a 4 mm punch biopsy. Serological confirmation of HIV positivity is required, and concurrent antiretroviral therapy is necessary, except for patients who have exhausted all available treatment options. Other patient characteristics include a life expectancy of at least 3 months, no other neoplasia requiring cytotoxic therapy, not being pregnant or nursing, and the use of effective barrier contraception for fertile patients during and for 3 months after completion of study treatment. Prior concurrent therapy and treatment history are also specified in the sample.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"graft failure\" and its corresponding ICDCodes are \"T86.831\" and \"T86.821\". The drugs being used in the trial are \"fludarabine\", \"campath 1h\", and \"fk506\". The eligibility criteria for participants in this trial include a diagnosis of engraftment failure, the availability of a healthy donor, an age between birth and 65, and a negative pregnancy test for women of childbearing potential. There are also exclusion criteria listed, such as being pregnant or lactating, having uncontrolled intercurrent infection, or having certain medical conditions like refractory AML or ALL.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on treating acute lymphoblastic leukemia (ALL). The ICD-10 codes associated with the disease are C91.01, C91.02, and C91.00. The drugs being used in the trial are vincristine sulfate liposomes injection and dexamethasone. \n\nThe inclusion criteria for the trial include having previously treated, relapsed, or refractory ALL with measurable disease, a performance status of \u22643 (ECOG), and all ages are eligible. However, patients aged 12 years or older may be counted towards the maximum tolerated dose (MTD) in the phase 1 portion of the trial. Adequate liver and renal function is required, as well as a negative pregnancy test for females of childbearing potential. Patients with a prior history of stem cell transplant are eligible if they meet all other requirements.\n\nThe exclusion criteria include having an active serious infection that is not controlled by antibiotics, recent treatment with investigational or chemotherapy agents unless there has been full recovery from side effects or the patient has rapidly progressive disease, concurrent treatment with other anti-cancer agents other than dexamethasone, and having known CNS leukemia or lymphoma that requires specific radiation therapy or has CNS neuropathy that limits the evaluation of the study drug. Patients with controlled CNS disease may be eligible after approval by the Principal Investigator. \n\nAdditional exclusion criteria include a history of grade 3 or 4 sensory or motor neuropathy related to previous chemotherapy, persistent grade 2 or greater active neuropathy, history of active neurologic disorders unrelated to chemotherapy, prior hypersensitivity reactions to vincristine or any components of VSLI, and being pregnant, lactating, or not willing to use contraception if fertile.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on rheumatoid arthritis.\n- ICD Codes: The ICD-10 codes associated with rheumatoid arthritis are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019'].\n- Drugs: The drug being studied is rituximab.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include a diagnosis of rheumatoid arthritis, positive rheumatoid factor or anticyclic citrullinated peptide, presence of arthritis symptoms for 6 weeks to 1 year, active RA with swollen and tender joints, willingness to adhere to study requirements, and use of effective contraception. The exclusion criteria include allergy to methotrexate, previous exposure to anti-CD20 monoclonal antibody or other types of mAb therapy, previous use of disease-modifying anti-rheumatic drugs or biologic agents, current use of high-dose oral steroids, recent intra-articular injections, current peptic ulcer disease, unwillingness to stop drinking alcohol, history of alcohol or substance abuse, active or chronic infections, interstitial lung disease, coronary artery disease or severe heart failure, diagnosis of another autoimmune rheumatologic disease, history of hypersensitivity to mouse proteins, history of cancer (with some exceptions), positive tuberculosis test without treatment, history of inflamed pancreas, recent live vaccine, abnormal laboratory values, requirement of certain medications, psychiatric disorders that affect informed consent, any condition or treatment that poses unacceptable risk, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Parkinson's disease, which is represented by the ICDCodes [\"G20\"]. The drugs being used in the trial are saline and carbidopa. The eligibility criteria for this sample include requirements such as having idiopathic Parkinson's disease, experiencing motor fluctuations associated with LD/CD dosing, having a Modified Hoehn and Yahr stage less than 5, being on stable levodopa/dopa decarboxylase inhibitor therapy, being postmenopausal or using adequate birth control for women, being 30 years or older, and being willing and able to give informed consent. The exclusion criteria include having a clinically significant or unstable medical or surgical condition, having clinically significant psychiatric illness, being a pre-menopausal woman not using a birth control method, having taken experimental medications within 60 days prior to baseline, and having undergone a neurosurgical intervention for Parkinson's disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes is 'Z21'. The drug being used in the trial is mifepristone. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being HIV-1 infected, having a CD4 count of 350 cells/mm3 or more, having an HIV-1 viral load of 2000 copies/ml or more, being willing to use acceptable forms of contraception, having a body weight of at least 40 kg, and being on stable doses of precautionary concomitant medications. \n\nExclusion criteria include recent antiretroviral treatment, adrenal disorders, autoimmune endocrine disease, active hepatitis B or C, liver disease, blood disorders or anticoagulant therapy, prior pituitary tumor or failure, goiters or thyroid nodules, diabetes mellitus, unusual uterine bleeding, current hormonal contraception or intrauterine use, recent pregnancy or breastfeeding, use of drugs that affect metabolism, recent use of corticosteroids or hormonal agents, recent use of immunomodulators, vaccines, or investigational therapy, recent vaccination, recent cytotoxic chemotherapy, allergy to mifepristone or study formulations, current drug or alcohol abuse, any other conditions that may interfere with participant evaluation, and serious illness requiring systemic treatment or hospitalization.\n\nOverall, this sample provides information about a clinical trial that combines phase 1 and phase 2, focusing on HIV infections and using mifepristone as the drug. It also outlines the specific eligibility criteria for participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on individuals who are not affected by any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial include \"maraviroc,\" \"fosamprenavir/ritonavir,\" and combinations of these drugs. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria state that the trial is open to healthy male and/or female subjects between the ages of 21 and 55 years, with a body mass index (BMI) ranging from 17.5 to 30.5 kg/m2, and a total body weight greater than 45 kg (99 lbs). \n\nExclusion criteria include a history of excessive alcohol consumption or tobacco/nicotine use, recent treatment with an investigational drug, and known hypersensitivity or allergy to sulfonamides.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is lymphoma, the icd-10 codes are S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, and S33.131S, the drugs are vorinostat and comparator: bexarotene, and the eligibility criteria include various inclusion and exclusion criteria. The inclusion criteria include being 18 years or older, having advanced cutaneous T-cell lymphoma, failure of at least one systemic therapy (excluding Bexarotene), and having an Eastern Cooperative Oncology Group (ECOG) status of 2 or lower. The exclusion criteria include having received investigational treatment in the past 30 days, having active hepatitis B or C or a history of HIV, prior treatment with any HDAC inhibitor, and having been disease-free from prior malignancies for more than 5 years (except for certain types of skin cancer or carcinoma in-situ of the cervix).",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drug being tested is simvastatine. The sample also includes the eligibility criteria for the trial, including requirements such as patients needing treatment for multiple myeloma, stable or progressive disease, age of 18 or older, performance status less than 3, and a life expectancy of more than 3 months. The exclusion criteria include factors such as pregnancy, inability to give personal consent, renal insufficiency with low creatinine clearance, high alanine aminotransferase levels, low thyroxine levels, known muscle diseases or previous myopathy, high creatinine kinase levels, and medication with drugs known to interact with simvastatine.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Parkinson's disease, which is represented by the ICDCodes [\"G20\"]. The drugs being tested are \"levodopa and carbidopa solution for sc administration\" and a placebo. \n\nThe eligibility criteria for this trial include:\n- Participants must have idiopathic Parkinson's disease.\n- They must experience motor fluctuations associated with LD/CD dosing.\n- The modified Hoehn and Yahr stage should be less than 5.\n- Participants must be taking optimized and stable levodopa/dopa decarboxylase inhibitor therapy.\n- Women must be postmenopausal, surgically sterilized, or using adequate birth control. Women of childbearing potential must have a negative pregnancy test at screening.\n- Participants must be 30 years of age or older.\n- They must be willing and able to give informed consent.\n\nThe exclusion criteria for this trial include:\n- Participants with clinically significant or unstable medical or surgical conditions.\n- Those with clinically significant psychiatric illness.\n- Pre-menopausal women who are not using a birth control method.\n- Participants who have taken experimental medications within 60 days prior to baseline.\n- Individuals who have undergone a neurosurgical intervention for Parkinson's disease, such as pallidotomy, thalamotomy, transplantation, and deep brain stimulation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are leukemia and solid tumors. The ICDCodes associated with these diseases are \"C95.91\", \"C95.92\", \"Z80.6\", \"Z85.6\", \"C90.11\", \"C90.12\", and \"C91.01\". The drug being tested is \"sb939\". The eligibility criteria include histological verification of malignancy, specific disease requirements for different parts of the study, disease status requirements, therapeutic options, prior systemic therapy recovery requirements, age and performance status criteria, and specific criteria for patients with solid tumors or leukemia. There are also exclusion criteria listed, such as cardiac arrhythmia, inability to take oral medication, certain infections, peripheral neuropathy, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on colorectal cancer and gastrointestinal cancer. The diseases are represented by their names and corresponding ICD-10 codes. The trial involves the drug tivozanib (av-951) plus folfox6. The eligibility criteria for participants are listed, including age requirements, confirmation of metastatic colorectal cancer or other gastrointestinal malignancy, documented progressive disease, and specific treatment history. Exclusion criteria are also provided, such as primary CNS malignancies, hematologic malignancies, abnormal laboratory values, cardiovascular disease, infections, and various other medical conditions. The sample also includes information on prior surgical procedures, bleeding history, and psychiatric disorders. Additionally, it states that pregnant or lactating women, individuals with immune suppression diseases, and those who have consumed certain herbal preparations/supplements within two weeks prior to the trial are excluded. The sample concludes with information on prior radiotherapy and the specific areas of the body that would disqualify a participant if treated within a certain timeframe.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in Phase 1, focusing on the disease of heart failure. The associated ICD-10 codes for heart failure are listed as ['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I50.9', 'T86.22', 'I11.0']. The trial involves the use of two drugs, clp and spironolactone. The eligibility criteria for participants are listed, including requirements such as having New York Heart Association (NYHA) Classification II or III, chronic kidney disease, a cardiac ejection fraction below 40%, and being on heart failure therapy with an ACEI or ARB and a BB. There are also exclusion criteria listed, such as recent hospitalization, gastrointestinal conditions, current or anticipated dialysis, and various other medical conditions that may make participation unsafe. Drug or alcohol abuse is also listed as an exclusion criterion.",
    "The sample from the table represents a phase 1 clinical trial for patients with metastatic cancer. The trial is investigating the use of the drugs carboplatin and pazopanib. The eligibility criteria for participants include being 18 years of age or older, having a histologically confirmed advanced solid tumor type that is FDA approved for treatment with Carboplatin, having a life expectancy of at least 12 weeks, and having an ECOG performance status of 0-2. Female participants must meet certain criteria related to their reproductive health, such as being post-menopausal or using contraception. The exclusion criteria include having a history or clinical evidence of central nervous system metastases, gastrointestinal abnormalities that may increase the risk of bleeding or affect absorption of the investigational product, uncontrolled infection, certain cardiovascular conditions, and other pre-existing medical or psychiatric conditions that could interfere with the study. Participants must not have received certain anti-cancer therapies within a specified timeframe prior to the trial. Any ongoing toxicity from prior anti-cancer therapy should not be greater than Grade 1, except for alopecia.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44.\n\nThe drug being tested in this trial is called asp1941. The eligibility criteria for participants in this trial include being diagnosed with Type 2 diabetes for at least 12 weeks, having a fasting plasma glucose level of less than 240 mg/dL, having a body mass index (BMI) between 20.0 and 35.0 kg/m2, and having a glomerular filtration rate (GFR) value of at least 30 ml/min/1.73m2 based on the Japanese GFR estimation equation at screening.\n\nThere are also exclusion criteria listed, which include not being a Type 1 diabetes mellitus patient, not having received insulin within 12 weeks before screening, not having diabetic ketoacidosis, not having dysuria or urinary tract infection, not having genital infection, not having significant renal, hepatic, or cardiovascular diseases, and not having severe gastrointestinal diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are topotecan and vorinostat.\n\nThe eligibility criteria for this trial are as follows:\n- The patient must have a histologically or cytologically proven diagnosis of small cell lung cancer.\n- The patient must have limited or extensive-stage disease and have received a single chemotherapy regimen or combined modality regimen (chemotherapy + chest radiotherapy) and relapsed after completion of first-line chemotherapy (sensitive relapse).\n- The patient must be at least 18 years old.\n- The patient's ECOG Performance Status must be between 0 and 2.\n- The patient must have a life expectancy of at least 12 weeks.\n- The patient must have measurable lesions according to RECIST criteria.\n- The patient must have adequate cardiac, hepatic, renal, and bone marrow function.\n- The patient must provide written informed consent.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have received prior treatment with an HDAC inhibitor.\n- The patient must not have symptomatic and/or unstable pre-existing brain metastases.\n- The patient must not have superior vena cava syndrome.\n- The patient must not have spinal cord compression.\n- The patient must not have severe or uncontrolled medical diseases such as hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of the study, chronic renal disease, or active uncontrolled infections.\n- The patient must not have any other co-existing malignancies or malignancies diagnosed within the last 5 years, except for basal cell carcinoma or cervical cancer in situ.\n- Pregnant or breastfeeding women are not eligible for this trial.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 trial design. The trial focuses on patients with heart failure as the disease of interest. The trial also includes a list of ICD-10 codes associated with heart failure. The drugs being studied in the trial include \"cxl-1020\", \"placebo for cxl-1020 cohort 1\", \"placebo for cxl-1020 cohort 2\", \"cxl-1020 dose for echo cohort a\", and \"cxl-1020 doses for echo cohort b\". \n\nThe eligibility criteria for the trial are outlined in the sample. Inclusion criteria include being a male or post-menopausal/surgically sterile female outpatient between 18 and 85 years of age, having chronic systolic heart failure due to specific causes, having a confirmed left ventricular ejection fraction \u2264 40%, and meeting certain baseline NT-Pro-BNP levels. Other inclusion criteria include being on stable doses of heart failure medications, understanding and consenting to participate in the trial, and being able to comply with the study protocol.\n\nExclusion criteria include recent participation in other drug studies or previous therapy with CXL-1020, specific heart rate and blood pressure ranges, certain cardiac conditions and history, weight and height limitations, recent worsening of heart failure, recent acute coronary syndrome or myocardial infarction, history of stroke or transient ischemic attack, and other medical conditions that may make the patient unsuitable for the trial.\n\nIt is also noted that patients receiving cardiac resynchronization therapy for heart failure are eligible if certain conditions are met.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, and secondary myelofibrosis. The corresponding ICDCodes for these diseases are also listed. The drugs being used in the trial are cyclophosphamide, cyclosporine, fludarabine phosphate, and mycophenolate mofetil. The eligibility criteria for patients to participate in the trial are also provided, including age requirements, HLA matching criteria for umbilical cord blood units, and specific disease criteria for different types of leukemia, myelodysplasia, myelofibrosis, lymphoma, and multiple myeloma. The criteria also include requirements for organ function and informed consent. The exclusion criteria are also listed, which include pregnancy, HIV infection, active infection, availability of an HLA matched sibling donor, and active blast crisis in chronic myelogenous leukemia.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is HIV-1 infection. The ICDCodes associated with this disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being used in the trial are doravirine and placebo. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as the duration of HIV-1 infection, the use of contraception, body mass index, baseline health, electrocardiogram results, previous antiretroviral treatment, and various medical history factors.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on advanced breast cancer, advanced malignant solid tumors, and breast neoplasms.\n- ICD Codes: The ICD-10 codes associated with the diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60.\n- Drugs: The drugs being studied in the trial are hki-272 and paclitaxel.\n- Criteria: The eligibility criteria for the trial are listed, including inclusion and exclusion criteria. The inclusion criteria include factors such as good performance status, normal ejection fraction, adequate cardiac, kidney, and liver function, adequate blood counts, at least one measurable target lesion, and a negative pregnancy test for female subjects. The exclusion criteria include factors such as recent major surgery, radiotherapy, chemotherapy, or investigational agents, bone or skin as the only site of disease, active central nervous system metastases, significant cardiac or gastrointestinal disorders, prior exposure to certain drugs, and various other factors.\n\nOverall, this sample record provides information about the phase, diseases, ICD codes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1. The diseases listed include \"accelerated phase chronic myelogenous leukemia,\" \"blastic phase chronic myelogenous leukemia,\" \"childhood chronic myelogenous leukemia,\" \"chronic myelogenous leukemia, bcr-abl1 positive,\" \"meningeal chronic myelogenous leukemia,\" \"recurrent childhood acute lymphoblastic leukemia,\" \"relapsing chronic myelogenous leukemia,\" and \"unspecified childhood solid tumor, protocol specific.\" The ICDCodes associated with these diseases are also provided. The drug mentioned in this sample is \"dasatinib.\" The eligibility criteria for this trial include various medical conditions, such as histologically confirmed diagnosis, measurable disease, specific blood counts, kidney function, liver function, and other factors. There are also restrictions on concurrent medications and treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"kidney transplantation\" and \"kidney disease\". The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial include \"alemtuzumab\", \"sirolimus\", \"tacrolimus\", \"methylprednisolone (or equivalent)\", \"acetaminophen\", \"diphenhydramine\", \"trimethoprim (tmp)/sulfa (bactrim, septra)\", \"valgancyclovir\", \"acyclovir\", \"pentamidine\", \"clotrimazole\", and \"nystatin\".\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as having received a kidney transplant with a primary cadaveric or non-HLA-identical living donor kidney, being able to take medications by mouth, and being willing to use acceptable methods of contraception. Exclusion criteria include factors such as having received an HLA-identical living-donor kidney transplant, having a higher HLA-antigen mismatch, having a panel reactive antibody (PRA) value greater than 10%, and having received a non-heart-beating donor allograft, among others.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial related to kidney transplantation and kidney disease.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is hematologic neoplasms. The corresponding ICD-10 codes for these diseases are E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, and T45.8X1A. The drug being tested is snx-5422. The eligibility criteria for this trial include being over 18 years old, having a Karnofsky performance status greater than 60, having a confirmed hematological malignancy, being refractory to available therapy or having no therapy available, and having adequate hepatic, renal, and hematological function. The exclusion criteria include having a CNS malignancy, being at risk for prolonged QT interval, having significant GI/liver disease, or having any other serious concurrent illness or medical condition.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease mentioned is Hepatitis C Virus. The ICDCodes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs mentioned in this sample are placebo and tmc649128. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The volunteer must have documented chronic (> 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection.\n- The volunteer must be treatment-naive, meaning they have never received (Peg)IFN, RBV, or any other approved or investigational treatment for chronic HCV infection. Alternatively, the volunteer can be a documented prior non-responder or relapser subject to previous treatment regimens but has stopped this treatment at least 6 months before screening.\n- The volunteer must have never received an HCV polymerase inhibitor, and HCV protease inhibitor treatment was stopped for at least one year.\n- The volunteer must have HCV plasma RNA levels of > 100,000 IU/mL at screening.\n- The volunteer's Body Mass Index must be between 18.0 and 35.0 kg/m2.\n- The volunteer must be deemed healthy based on a medical evaluation, including medical history, physical examination, blood tests, vital signs, and electrocardiogram.\n\nExclusion Criteria:\n- The volunteer must not have evidence of liver cirrhosis.\n- The volunteer must not have a historical liver biopsy graded as liver cirrhosis or evidence for the presence of oesophageal varices or a transient elastography (Fibroscan) result of more than 14.6 kPa within 2 years prior to screening.\n- The volunteer must not have evidence of decompensated liver disease, such as ascites, hepatic encephalopathy, bleeding oesophageal or gastric varices.\n- The volunteer must not have evidence of renal dysfunction, documented by an estimated creatinine clearance below 70 mL/min.\n- The volunteer must not have evidence of any other cause of significant liver disease in addition to hepatitis C, including hepatitis B, drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, or primary biliary cirrhosis.\n- The volunteer must not have diagnosed or suspected hepatocellular carcinoma.\n- The volunteer must not be receiving or have received any treatment for HCV during the 6 months before screening.\n- The volunteer must not be coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or hepatitis A or B virus infection, or clinically active tuberculosis at study screening.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is HCV infection. The ICDCodes associated with this disease are K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, and A31.0. The drugs mentioned in the sample are gs-5885 and placebo, with alternating occurrences. The eligibility criteria for this trial include being chronically infected with HCV genotype 1, being HCV treatment-na\u00efve, not being co-infected with HIV or HBV, having an HCV RNA viral load of at least 100,000 IU/mL, having a BMI between 19 and 35 kg/m2, and agreeing to use highly effective contraception methods if female of childbearing potential or sexually active male. The exclusion criteria include having a history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol, having decompensated liver disease or cirrhosis or evidence of hepatocellular carcinoma, having serological evidence of co-infection with HIV, HBV, or another HCV genotype, and having known current use of amphetamines and/or cocaine, taking methadone or buprenorphine (opioid replacement therapy), or ongoing alcohol abuse.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include breast cancer, male breast cancer, recurrent breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, and stage IV breast cancer. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are vorinostat and trastuzumab. The eligibility criteria for participants in the trial are listed, including requirements such as not being pregnant or nursing, having no active infections, and not having a history of allergic reactions to similar compounds. Other criteria include specific time intervals since prior treatments, certain medical conditions, and specific measurements for various health parameters.\n\nOverall, this sample provides a snapshot of a clinical trial that focuses on breast cancer patients, specifically those with metastatic or chest wall recurrent disease who have previously received trastuzumab treatment.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is head and neck cancer. The icd-10 codes associated with this disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being used in the trial are cudc-101 and cisplatin. The eligibility criteria for participants include having locally advanced squamous cell carcinoma of the head and neck, specific tumor stages and smoking history, having at least one measurable site of disease, meeting certain age and performance criteria, and having certain blood counts and organ function within normal limits. There are also exclusion criteria, such as prior radiotherapy or chemotherapy for the same indication, certain medical conditions, and prior allergic reactions to specific drugs.",
    "The sample provided is for a phase 1 trial. The only disease mentioned in this sample is \"healthy\", which seems to indicate that the trial is focused on testing a drug or treatment on generally healthy individuals. The icd-10 codes associated with the diseases are \"Z76.3\" and \"Z76.2\". The drugs being tested in this sample are \"bazedoxifene\" and \"bazedoxifene/conjugated estrogens\". The eligibility criteria for this sample include being a generally healthy postmenopausal woman with a body mass index (BMI) between 18.0 and 35.0 kg/m2 and a body weight of at least 50 kg. The exclusion criteria state that pregnant or nursing females, as well as females of childbearing potential, are not eligible for this trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include lymphoma, lymphoproliferative disorder, small intestine cancer, and unspecified adult solid tumor, protocol specific. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is a src kinase inhibitor called kx2-391. The eligibility criteria for patients participating in this trial include having a confirmed diagnosis of advanced solid tumor or lymphoma, with metastatic or unresectable disease. Other criteria include specific performance status, life expectancy, blood counts, liver function, kidney function, and exclusion of certain medical conditions. The sample also includes information about prior concurrent therapies that patients should not have received before participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is described as \"phase 1/phase 2\". The disease being studied is \"prostate cancer\". The corresponding ICD-10 codes for the disease are listed as \"['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']\". The drug being tested is \"2-deoxyglucose\". \n\nThe eligibility criteria for this trial include various conditions such as having a histologically proven metastatic solid tumor malignancy without a standard therapy option, having prostate cancer with metastatic disease and progression after initial hormonal therapy, and having either measurable disease or a PSA value > 5 ng/ml for phase II patients. Other criteria include age >18 years, estimated life expectancy of at least 6 months, ECOG performance status < 2, and specific laboratory values within normal limits.\n\nThere are also exclusion criteria listed, such as known infection with HIV, history of glucose intolerance, ongoing coagulopathies, and known brain metastases. Other exclusion criteria include certain medical conditions, history of certain diseases, recent major surgery or antitumor therapy, and inability or unwillingness to give written informed consent.\n\nOverall, this sample provides information about the phase, diseases, icd codes, drugs, and eligibility criteria for a clinical trial focused on prostate cancer and the drug 2-deoxyglucose.",
    "The sample provided is for a Phase 1 trial. The trial is focused on healthy volunteers. The ICD-10 code associated with the disease is \"Y99.2\". The drugs being tested in this trial are \"achn-975\" and \"placebo\". The eligibility criteria for this trial include having a body weight between 40 and 100 kilograms, using contraception, having stable health, and testing negative for alcohol, tobacco, and drugs of abuse. The key exclusion criteria are having a history of clinically significant disease and being pregnant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The icd-10 codes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being used in the trial are 'imatinib mesylate' and 'docetaxel'. \n\nThe eligibility criteria for this trial are listed under two categories: Inclusion and Exclusion. Inclusion criteria include requirements such as patients having histologic proof of adenocarcinoma of the prostate, bone metastases confirmed by bone scans, evidence of disease progression, minimum PSA level, specific performance status, expected survival of at least three months, and various other factors related to prior treatments and medical conditions. \n\nExclusion criteria include factors such as severe intercurrent infection, tumors containing small cell or sarcomatoid elements, certain cardiac conditions, uncontrolled CNS metastases, hypersensitivity or previous toxicity with docetaxel, certain lung diseases, contraindications to corticosteroids, uncontrolled hypertension or diabetes, second malignancies within the last three years (except non-melanoma skin cancer), overt psychosis or mental disability, and a history of non-compliance with medical regimens or unreliability.\n\nOverall, this sample provides specific details about the phase, disease, icd-10 codes, drugs, and eligibility criteria for a clinical trial focused on prostate cancer.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are fallopian tube cancer, ovarian cancer, and primary peritoneal cavity cancer. The corresponding ICDCodes for these diseases are ['C57.00', 'C57.01', 'C57.02'], ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'], and ['C30.0', 'Z12.81', 'D14.0', 'C14.8', 'D37.09', 'Z86.003', 'Z85.818'] respectively.\n\nThe drugs being used in the trial are gemcitabine hydrochloride and topotecan hydrochloride. The eligibility criteria for the trial include specific disease characteristics, patient characteristics such as age and performance status, hematopoietic, hepatic, renal, cardiovascular, and other health-related requirements. \n\nAdditionally, the sample includes information about prior concurrent therapy, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is alcohol dependence, which is identified by the ICD-10 codes ['F10.20', 'F10.24', 'F10.27', 'F10.280', 'F10.281', 'F10.282', 'F10.288']. The drug being tested is an opioid receptor kappa antagonist. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Participants must be healthy males or females.\n- Participants must have clinical laboratory tests within normal reference ranges.\n- Participants must have arterial and venous access sufficient for blood sampling.\n\nExclusion Criteria:\n- Participants currently enrolled in, or discontinued within the last 30 days from a clinical trial are not eligible.\n- Participants with a history of severe allergies or multiple adverse drug reactions are not eligible.\n- Participants with an abnormal ECG at the screening visit are not eligible.\n- Participants with abnormal sitting blood pressure are not eligible.\n- Participants with an increased risk of seizures are not eligible.\n- Participants with current suicidal ideation are not eligible.\n- Participants with a positive test for HIV, hepatitis C, or hepatitis B are not eligible.\n- Women who are breastfeeding are not eligible.\n- Participants who smoke more than 10 cigarettes per day, or equivalent, are not eligible.\n- Participants who drink more than 5 cups of coffee per day, or equivalent, are not eligible.\n- Participants with a history of head injury are not eligible.\n- Participants who are unable to undergo an MRI are not eligible.\n- Participants who suffer from claustrophobia are not eligible.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"non small cell lung cancer.\" The ICDCodes associated with this disease are \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2.\" The drugs mentioned in this sample are \"erlotinib\" and \"sunitinib.\" The eligibility criteria for this trial include various factors such as histological or cytological proof of stage IIIB or IV NSCLC, measurable disease, life expectancy of at least 12 weeks, adequate bone marrow, hepatic and renal function, ECOG performance status 0, 1, or 2, and more. There are also exclusion criteria mentioned, such as squamous cell histology, history of untreated brain metastases, prior treatment with certain medications, ongoing treatment with warfarin, and more. Additionally, there are criteria related to medical conditions, laboratory abnormalities, and HIV-positive patients. Lastly, there are criteria related to pregnancy and breastfeeding for female participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 1.\n- Diseases: The trial is specific to an unspecified adult solid tumor.\n- ICD Codes: The ICD-10 codes associated with the disease are ['H01.009', 'H02.209', 'H02.009', 'H02.109', 'H04.209', 'H05.409', 'H10.509'].\n- Drugs: The drugs being used in the trial are erlotinib hydrochloride, pemetrexed disodium, and vinflunine.\n- Criteria: The eligibility criteria for the trial are listed, including disease characteristics and patient characteristics. The disease characteristics include histologically confirmed solid tumors, advanced/unresectable or metastatic disease, refractory to standard therapy or no standard therapy exists, and specific requirements for measurable or evaluable disease. The patient characteristics include life expectancy, ECOG performance status, blood counts, kidney function, liver function, heart health, prior allergic reactions, infection or illness status, ability to receive supplementation, pregnancy or nursing status, and prior concurrent therapy.\n\nAdditionally, the record includes information about prior concurrent therapy, including the time since previous chemotherapy, investigational agents, or surgery, and the allowance or restriction of certain medications.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which means the trial is focused on healthy individuals. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"azd8418\" and \"placebo.\" The eligibility criteria for this trial include being a healthy male or a healthy non-childbearing potential female. The exclusion criteria include having a history of clinically significant medical, neurologic, or psychiatric diseases, severe allergies or hypersensitivity, or a history of hypersensitivity to drugs similar to AZD8418.",
    "The sample is a clinical trial that is in both phase 1 and phase 2. The trial is focused on the disease \"diabetes mellitus, type 2\" and the associated ICD-10 codes are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being studied in this trial are \"vildagliptin\" and \"vildagliptin\". \n\nThe eligibility criteria for this trial include being a healthy volunteer or a patient with type 2 diabetes, being a non-smoking individual of Caucasian or African American ethnicity, being between the ages of 30 and 65, and being on metformin and/or sufonylurea medication for type 2 diabetes. \n\nExclusion criteria for this trial include having a history of type 1 diabetes or insulin use, coagulation abnormalities, abnormal heart conditions, and being pregnant or breastfeeding. \n\nIt is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply to this trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, the disease is lung cancer, the ICDCodes are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2, and the drug is docetaxel. The eligibility criteria include specific disease characteristics such as the type and stage of lung cancer, as well as requirements for diagnostic tests and measurable disease. Patient characteristics include performance status, lung function, blood counts, and other medical parameters. Prior concurrent therapy restrictions are also listed, including limitations on previous treatments and concurrent medications or radiotherapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on studying the effects of different drugs on individuals with specific diseases. The diseases mentioned in this sample are \"healthy,\" \"overweight,\" and \"obesity.\" The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in this trial are \"placebo,\" \"comparator: pioglitazone,\" and \"comparator: hyperinsulinemic euglycemic clamp.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that the subjects must have a BMI (Body Mass Index) between 28 kg/m^2 and 38 kg/m^2, be nonsmokers or have not used nicotine products for at least 6 months, and be willing to avoid major dietary changes during the study. \n\nOn the other hand, the exclusion criteria specify that individuals with a history of diabetes (Type 1, Type 2, or steroid-induced), hypersensitivity to pioglitazone or other thiazolidinediones, liver disease (except non-alcoholic fatty liver disease or non-alcoholic steatohepatitis), congestive heart failure, atherosclerotic heart disease, heart failure, osteoporosis, osteopenia, recurrent bone fractures, anemia, stroke, chronic seizures, major neurological disorder, clinically significant endocrine, gastrointestinal, cardiovascular, hematological, or renal abnormalities or diseases, or neoplastic disease within the past 5 years are not eligible to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are malignant solid tumor, biliary cancer, and pancreatic cancer. The corresponding ICDCodes for these diseases are C24.9, C24.8, and C25.3. The drugs being used in the trial are gemcitabine, capecitabine, and zd6474. \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be 18 years or older.\n- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, which measures their ability to perform everyday tasks.\n- Participants must have a life expectancy of at least three months.\n\nBlood samples and other testing may be required for further eligibility assessment.\n\nThere are also exclusion criteria for this trial, which include:\n- Participants with uncontrolled illnesses, such as current infections or heart conditions, are not eligible.\n- Participants with abnormal laboratory test results, such as blood or urine tests, are not eligible.\n- Pregnant or breastfeeding women are not eligible.\n\nAdditional exclusion criteria may also apply.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on breast cancer. The trial is specifically targeting advanced or metastatic breast cancer, including inflammatory breast cancer or inoperable locally advanced disease. The eligibility criteria include having confirmed ErbB2 overexpression, being estrogen receptor positive (ER+) and/or progesterone positive (PgR+), and having measurable or non-measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria. Other criteria include having a life expectancy of more than 3 months for phase 1 and more than 6 months for phase 2, having an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less, and having normal cardiac ejection fraction. Adequate hematologic, hepatic, and renal function is also required. The trial is open to post-menopausal females or males who are at least 18 years old. Subjects must sign an IRB or EC approved informed consent. There are also exclusion criteria, such as having type 1 diabetes or uncontrolled type 2 diabetes, having certain eye conditions, having abnormal free T4 values and a history or evidence of thyroid disease, being unable or unwilling to take metformin, having uncontrolled intercurrent illness, having known or suspected HIV infection or hepatitis B or C, having inflammatory diseases of the gastrointestinal tract, having a history of other malignancy (with some exceptions), having extensive symptomatic visceral disease, having a history of prior treatment with other agents specifically targeting IGFRs, and requiring pharmacological doses of glucocorticoids beyond replacement doses. The use of topical, intra-ocular, or inhalation glucocorticoids is permitted.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves testing the effectiveness of various drugs, including sitagliptin, saxagliptin, vildagliptin, and a placebo. The eligibility criteria for participants include being a non-pregnant female of reproductive potential, having a body mass index between 18 and 43 kg/m^2, having a clinically confirmed diagnosis of type 2 diabetes, not currently receiving any oral antihyperglycemic medications, and having a screening visit hemoglobin A1c between 6.5% and 10%. Participants must also meet various other criteria, such as not having been previously treated with a DPP-4 inhibitor or glucagon-like peptide-1 analogs within 12 weeks, having fasting plasma or serum glucose \u2264200 mg/dL at screening and randomization, and being a non-smoker or not having used nicotine or nicotine-containing products for at least 6 months. Participants must also be willing to follow a specific diet and exercise program, refrain from consuming grapefruit and grapefruit juice, and refrain from consuming certain fruit juices throughout the study. There are also exclusion criteria, such as having certain psychiatric disorders, having an estimated creatinine clearance of \u226460 mL/min, having a history of stroke or major neurological disorder, having certain endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases, having been previously treated with insulin for at least 3 months, having a history of type 1 diabetes mellitus or significant diabetic complications, having a history of neoplastic disease or myeloproliferative disease, being on a weight loss program, anticipating the use of new medications or changes in dose of current medications, having donated or lost blood within 4 weeks, having had major surgery within 30 days, having uncontrolled hypertension, taking medications not permitted in the study, consuming excessive amounts of certain beverages, having significant allergies or intolerability to drugs or food, being a regular user of illicit drugs or having a history of drug abuse within the past 6 months, or being a nursing mother.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is indicated as \"phase 1/phase 2\". The diseases being studied are \"combretastatin a4 phosphate\", \"age-related macular degeneration\", \"amd\", \"cnv\", and \"choroidal neovascularization\". The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in this trial are \"combretastatin a-4 phosphate\". The eligibility criteria for the trial are listed, including age requirements, specific medical conditions, and other factors that determine if a patient can participate in the trial. There are also exclusion criteria listed, which indicate conditions or factors that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are ovarian cancer, fallopian tube cancer, and peritoneal cancer. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is low dose cyclophosphamide (oral). \n\nThe eligibility criteria for this trial include subjects with stage IIc-IV epithelial ovarian, fallopian tube, and peritoneal cancer who have completed adjuvant treatment consisting of up to 8 cycles of paclitaxel and carboplatin chemotherapy or other acceptable chemotherapy after initial debulking surgery with evidence of a complete or partial response by radiological imaging. Subjects with recurrent ovarian, fallopian tube, or peritoneal cancer who have clinical or radiologic evidence of a complete or partial response or stable disease after completion of first-line chemotherapy for their recurrent disease and are not suitable for additional cytotoxic therapy are also eligible. \n\nThere are additional inclusion and exclusion criteria listed, such as previous courses of investigational biologic therapy, time since surgery, radiotherapy or chemotherapy, and exclusion of subjects undergoing concurrent chemotherapy, radiation therapy, or immunotherapy. Other exclusion criteria include subjects who have received more than one course of chemotherapy for recurrent disease, those receiving bevacizumab for maintenance therapy, and subjects with certain medical conditions or allergies. Pregnant or nursing mothers and subjects with a medical or psychological impediment to probable compliance with the protocol are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on the treatment of colorectal cancer. The trial is specifically targeting patients with histologically confirmed primary adenocarcinoma of the rectum, with the tumor located within 12 cm of the anal verge. The disease should be clinically staged as T3-4, N1-2 (stage II or III) by various tests such as physical exam, transrectal ultrasound, pelvic CT scan, or pelvic MRI. Patients should not have any clinical evidence of metastatic disease.\n\nThe eligibility criteria for patients include being 18 years or older, having an ECOG performance status of 0-1, and having a life expectancy of more than 3 months. Hematopoietic requirements include an absolute neutrophil count of at least 1,500/mm^3 and a platelet count of at least 100,000/mm^3, with no uncontrolled coagulopathy. Hepatic requirements include bilirubin levels within 1.5 times the upper limit of normal (ULN), SGOT and SGPT levels within 1.5 times ULN, and alkaline phosphatase levels within 2.5 times ULN. Renal requirements include a creatinine level within 1.5 times the normal range and a creatinine clearance greater than 50 mL/min.\n\nPatients should not have any clinically significant cardiac disease, congestive heart failure, symptomatic coronary artery disease, poorly controlled cardiac arrhythmias, or myocardial infarction within the past year. They should also not have active inflammatory bowel disease, lack physical integrity of the upper gastrointestinal tract, or malabsorption syndrome.\n\nOther criteria include not having any other prior or concurrent malignancy except for inactive, non-invasive carcinoma of the cervix or non-melanoma skin cancer. Patients should not have any concurrent serious, uncontrolled infections, prior severe reactions to fluoropyrimidine therapy, known sensitivity to fluorouracil, uncontrolled seizures, CNS disorders that would prevent study participation, or any other medical or psychiatric condition that would preclude study participation. Pregnant or nursing individuals are not eligible, and a negative pregnancy test is required. Fertile patients must use effective contraception during and for 3 months after study participation.\n\nRegarding prior concurrent therapy, patients should not have received immunotherapy, chemotherapy, or radiotherapy for rectal cancer. They should not have undergone prior pelvic radiotherapy or surgery for rectal cancer. It should be more than 4 weeks since their last major surgery, and they should have fully recovered. Patients should not have participated in another investigational drug study within the past 4 weeks, and concurrent use of celecoxib is not allowed.",
    "The sample from the table represents a clinical trial for a contraceptive patch. The trial is a combination of phase 1 and phase 2. The specific disease being studied is contraception. The ICD-10 codes associated with this disease are Z92.0, Z30.012, and Z30.09. The drugs being tested in the trial are different variations of a levonorgestrel patch, based on the participant's body mass index (BMI). \n\nThe eligibility criteria for participants include being in good general health, aged 18-44 years, having an intact uterus with at least one ovary, and having had a recent Pap test or undergoing one at screening. Other criteria include having a cervical mucus score of >7, regular menstrual cycles, and either being abstinent or using appropriate contraception methods. Participants must also be willing to comply with the study protocol, live within the study site catchment area or a reasonable distance from the site, and sign an informed consent form.\n\nExclusion criteria include contraindications for using combined hormonal contraceptives, known hypersensitivity or contraindication to progestins, known or suspected pregnancy, prior hysterectomy or bilateral oophorectomy, history of drug or alcohol abuse, undiagnosed abnormal genital bleeding, undiagnosed vaginal discharge or lesions, uncontrolled thyroid disorder, history or presence of dermal hypersensitivity, and any Pap test finding that would require additional workup or treatment during the study. Other exclusion criteria include recent use of certain contraceptives, breastfeeding or recently discontinuing breastfeeding, planning major surgery or pregnancy during the study, smoking a certain number of cigarettes per day, history of thrombophlebitis or thromboembolic disorders, history of certain cancers or neoplasia, history of severe depression, and various other medical conditions and factors.\n\nOverall, the sample provides information about the phase, disease, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample provided is for a clinical trial in Phase 1. The trial focuses on patients with type 2 diabetes mellitus. The ICD-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The trial involves two drugs, asp1941 and placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must have had type 2 diabetes for at least 12 weeks.\n- HbA1c value must be between 7.0% and 10.0% at screening.\n- Fasting plasma glucose levels must be between 126mg/dL and 240mg/dL at screening.\n- Body Mass Index (BMI) must be between 20.0 and 45.0 kg/m2.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with type 1 diabetes mellitus.\n- Serum creatinine levels above the upper limit of normal.\n- Proteinuria, indicated by an albumin/creatinine ratio greater than 300mg/g.\n- Presence of dysuria and/or urinary tract infection.\n- Significant renal, hepatic, or cardiovascular diseases.\n- Severe gastrointestinal diseases.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"neoplasms\" and \"lymphoma, malignant\". The corresponding ICDCodes for these diseases are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", \"C17.2\" for neoplasms and \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\" for lymphoma, malignant. The drug being tested is \"e7820\". \n\nThe eligibility criteria for this trial include having a histologically or cytologically confirmed malignant solid tumor or lymphoma that requires systemic therapy and for which no standard therapy is available or the patient is not a candidate for standard therapy. Other criteria include having a Karnofsky Performance Status of at least 70%, a life expectancy of at least 3 months, being aged 18 or older, having adequate renal and bone marrow function, and giving written informed consent. \n\nThere are also exclusion criteria, such as a history of hypersensitivity to sulfonamide derivatives, recent chemotherapy or radiotherapy, major surgery, pregnancy or breastfeeding for women, and active central nervous system metastases. Other exclusion criteria include positive tests for hepatitis B or C, HIV, significant intercurrent illness/infection, unstable ischemic disease, and certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on diseases such as anemia, leukemia, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). The diseases are associated with specific ICD-10 codes. The trial involves the use of the drug lenalidomide. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of Diamond-Blackfan anemia (DBA), being transfusion-dependent for red blood cells, and meeting certain laboratory test results. There are also exclusion criteria, such as having certain medical conditions or being pregnant or breastfeeding.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 combination. The trial focuses on the disease \"carcinoma, renal cell\" and includes patients with specific icd-10 codes related to this disease. The drug being tested in the trial is a combination of gefitinib and sunitinib. The eligibility criteria for inclusion in the trial include having histologically confirmed renal cell carcinoma with metastases, evidence of measurable disease, and having failed one prior immunotherapy or having no prior systemic therapy for metastatic RCC. The exclusion criteria include having RCC without any clear (conventional) cell component, a history of or known brain metastases, and uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease of depression. The ICD-10 codes associated with depression are ['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']. The drugs being studied are vortioxetine (lu aa21004) and a placebo. The eligibility criteria for participants are listed, including specific requirements for subjects who have remitted from depression and those in the control group. There are also exclusion criteria. Overall, this sample provides details about the phase, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is obesity, the ICDCodes are E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, the drugs are azd2820 and placebo, and the eligibility criteria are listed under inclusion and exclusion criteria. The inclusion criteria include providing informed consent, being an obese male aged 18-45 with suitable veins, and having a BMI between 27 and 40 kg/m2. The exclusion criteria include having a history of clinically significant diseases or disorders, erectile dysfunction or penile abnormalities, prolonged or shortened QTcF intervals, severe allergies or hypersensitivity, and clinically significant abnormalities in lab results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"lymphoblastic leukemia, acute, childhood\" and \"myelogenous leukemia, acute, childhood.\" The corresponding ICDCodes for these diseases are \"C83.57\", \"C83.50\", \"C91.01\", \"C91.02\", \"C83.52\", \"C83.56\", and \"C83.53\". The drugs being used in the trial are \"ac220\", \"cytarabine\", \"etoposide\", and \"methotrexate\". The eligibility criteria for this sample include age restrictions, specific diagnostic criteria for different types of leukemia, Karnofsky and Lansky scores, recovery from prior treatments, adequate renal and hepatic functions, cardiac function requirements, reproductive function considerations, and exclusion criteria such as CNS 3 disease, cardiovascular disease, certain infections, concurrent treatments, and other significant concurrent diseases or disorders. Additionally, patients who are concurrently receiving CYP3A4 and 5 inhibitors and inducers are excluded from the trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on treating chronic myelogenous leukemia and acute lymphoblastic leukemia (philadelphia chromosome positive) using the drug nilotinib. The eligibility criteria for inclusion in the trial include being diagnosed with Ph+ ALL and having relapsed or being refractory to standard therapy, or being diagnosed with CML in blast crisis or accelerated phase or chronic phase and being resistant or intolerant to imatinib. The patient's performance status should be normal or ambulatory and capable of all self-care. Exclusion criteria include a history of significant or serious uncontrolled cardiovascular disease, impairment of gastrointestinal function or GI disease that may significantly alter the absorption of nilotinib, pregnancy or breastfeeding, and not employing an effective method of birth control. There are additional exclusion criteria related to cardiac function, other heart diseases, impaired gastrointestinal function, use of therapeutic warfarin, liver or renal disease, concurrent severe and/or uncontrolled medical conditions, recent treatment with certain medications or therapies, recent chemotherapy or Glivec\u00ae treatment, immunotherapy, investigational drugs or cytotoxic agents, radiotherapy, major surgery, and unwillingness or inability to comply with the protocol.",
    "The sample is from a clinical trial database and represents a phase 1 trial. The disease being studied is leukemia, specifically TdT positive acute lymphocytic leukemia or blastic chronic myelogenous leukemia. The trial is focused on patients who have failed at least one standard treatment. The eligibility criteria include being 18 years or older, having a Karnofsky performance status greater than 70%, and a life expectancy of at least 3 months. Other criteria include specific limits on bilirubin, transaminases, creatinine, and ejection fraction. The patient should not be pregnant or nursing and should not have any serious concurrent illness. The prior concurrent therapy should not include biologic therapy, chemotherapy, endocrine therapy, radiotherapy, or surgery within the specified time frames. The drugs being investigated in this trial are cordycepin and deoxycoformycin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, malignant tumor of peritoneum, and stage IV ovarian epithelial cancer. The corresponding ICDCodes for these diseases are also provided.\n\nThe drug being investigated in this trial is \"fludeoxyglucose f 18\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having persistent, metastatic, or recurrent platinum-resistant or refractory ovarian or primary peritoneal cancer, being at least 18 years old, having a life expectancy of at least 6 months, and having a Karnofsky Performance Status (KPS) of at least 60. There are also specific requirements for organ and marrow function, as well as the willingness to undergo pre- and post-treatment FDG-PET/CT scans.\n\nExclusion criteria include not having received overlapping radiation treatment, not receiving chemotherapy or other investigational agents from two weeks prior to radiation through post-therapy FDG-PET/CT, not being pregnant or nursing, not having disease larger than 8cm or greater than 3 regions, and not having concurrent malignancy other than specified exceptions.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on type 1 diabetes. The ICD-10 codes associated with the disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44']. The drugs being studied are sitagliptin and insulin. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include having a diabetes diagnosis according to the WHO report in 1999, an age at onset between 25 and 70 years, a disease duration of less than 3 years, no ketoacidosis within the first 6 months after diagnosis, being GADA positive twice within one month, and having a fasting C-peptide level of 0.2 nmol/L or more. The exclusion criteria include insulin requirements more than 0.8 units/kg/day, evidence of chronic or acute infection affecting blood glucose control within 4 weeks prior to visit 1, a history of any malignancy, pregnancy, breastfeeding, planned pregnancy within two years, secondary diabetes, congestive heart failure requiring pharmacologic treatment, renal disease or dysfunction, diabetic nephropathy suggested by abnormal creatinine levels, and any concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.",
    "The sample from the table is for a clinical trial in the early phase 1. The trial is focused on treating peripheral T-cell lymphomas and adult T-cell leukemia/lymphoma. The trial also includes other subtypes of peripheral T-cell lymphomas such as angioimmunoblastic T-cell lymphoma and anaplastic large-cell lymphoma. The trial is specifically for patients who have relapsed or refractory disease following prior anthracycline therapy.\n\nThe eligibility criteria for the trial include being 19 years or older, able to adhere to the study visit schedule and other protocol requirements, and having a confirmed diagnosis of peripheral T-cell lymphomas or cutaneous T-cell lymphoma with nodal/visceral disease. Previous cancer therapy must have been discontinued at least 4 weeks prior to treatment in this study.\n\nOther criteria include having at least one measurable lesion according to the International Working Group response criteria for non-Hodgkin's lymphoma, having an ECOG performance status of less than or equal to 2, and meeting certain laboratory test result ranges for absolute neutrophil count, platelet count, serum creatinine, total bilirubin, AST (SGOT), and ALT (SGPT).\n\nFemale participants of childbearing potential must have a negative pregnancy test and commit to using two acceptable methods of birth control. All participants must be registered into the mandatory RevAssist\u00ae program.\n\nExclusion criteria include having any serious medical condition, being pregnant or breastfeeding, having any condition that places the subject at unacceptable risk or confounds data interpretation, and having used any other experimental drug or therapy within 28 days of baseline.\n\nOther exclusion criteria include known hypersensitivity to thalidomide, prior use of lenalidomide, concurrent use of other anti-cancer agents or treatments within the past 28 days, and being known positive for HIV or infectious hepatitis.\n\nThe sample also specifies certain diseases that are not included in the trial, such as precursor T-cell lymphomas and cutaneous T-cell lymphomas with skin as the only organ of involvement. Additionally, patients with prolonged QT interval on baseline EKG, grade 3 peripheral neuropathy, or natural killer (NK) cell lymphomas are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"squamous cell carcinoma of the head and neck.\" The ICDCodes associated with this disease are \"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", and \"C4A.8\". The drugs mentioned are \"emd 1201081 + 5-fu + cisplatin + cetuximab\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN).\n- The patient must have recurrent and/or metastatic SCCHN that is not suitable for local therapy.\n- The patient must have at least one measurable lesion according to RECIST 1.0, as determined by computerized tomography (CT) scan or magnetic resonance imaging (MRI).\n- The patient must have a Karnofsky performance status (KPS) of \u2265 70 or an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at the time of trial entry.\n\nExclusion Criteria:\n- The patient must not have received prior systemic chemotherapy, unless it was part of a multimodal treatment for locally advanced disease completed more than 2 months prior to trial entry.\n- The patient must not have nasopharyngeal carcinoma.\n- The patient must not have a medical history of diagnosed interstitial lung disease.\n- The patient must not have known hypersensitivity to any of the components of the trial treatment.\n- The patient must not have received previous treatment with experimental or non-approved epidermal growth factor receptor (EGFR) targeting therapy or experimental or non-approved EGFR signal transduction inhibitors (prior treatment with cetuximab is allowed).\n- The patient must not have relevant cardiovascular co-morbidities.\n- The patient must not be receiving concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy, and must not be using steroids at a dose of \u2265 10 mg prednisone equivalent.\n- The patient must not be known to be human immunodeficiency virus (HIV) positive, have active hepatitis C, or have active hepatitis B.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is \"early phase 1\" and the disease is \"heart failure, congestive\". The ICDCodes associated with this disease are \"I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40\". The drug mentioned is \"sitagliptin\". The eligibility criteria for this trial include a diagnosis of nonischemic dilated cardiomyopathy with current NYHA class I-III congestive heart failure, treatment with a stable comprehensive heart failure regimen for at least 3 months, and age over 18 years. The exclusion criteria include cardiomyopathy primarily due to ischemic heart disease, primary valvular lesion, or hypertrophic cardiomyopathy, recent cardiac resynchronization, low creatinine clearance or end-stage renal disease, diabetes mellitus, history of heart transplantation, pregnancy or active breastfeeding, and recent hospitalization for decompensated heart failure.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and is focused on the treatment of \"head and neck cancer.\" The trial includes a list of diseases, which in this case is only \"head and neck cancer.\" The table also includes a list of ICD-10 codes associated with the diseases, with the code for \"head and neck cancer\" being \"C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11.\" Additionally, the table includes a list of drugs being used in the trial, which are \"gemcitabine\" and \"paclitaxel.\" The eligibility criteria for the trial are also provided, including various conditions that patients must meet in order to participate. These conditions include having failed previous chemotherapeutic regimens, having measurable or non-measurable disease, and meeting certain health parameters such as ANC, platelet count, hepatic function, and Zubrod Performance Status. The sample also includes exclusion criteria, such as not having any other prior malignancy except for specific exceptions, not being pregnant or nursing, and not taking certain medications that may interfere with the trial.",
    "The sample from the table represents a clinical trial with a combination of Phase 1 and Phase 2. The trial focuses on Type II Diabetes as the disease of interest. The ICD-10 codes associated with this disease are 'E23.2', 'N25.1', 'P70.2', 'O24.92', 'Z83.3', 'Z86.32', and 'E10.65'. The drugs being studied in this trial are 'placebo', 'sitagliptin', and 'lez763'. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion criteria:\n- All subjects must be male or female aged 18-65 years.\n- Subjects must weigh at least 50 kg and have a body mass index (BMI) within the range of 18-37 kg/m2.\n- Only postmenopausal females or females who have undergone surgical sterilization are allowed.\n- Subjects must have a stable conventional sleep-wake cycle.\n\nFor Normal Healthy Volunteers:\n- Healthy male or female subjects are eligible.\n- Subjects must be in good health as determined by medical history, physical examination, vital signs, electrocardiogram, and laboratory tests.\n\nFor Type II Diabetic Patients:\n- Patients must have been diagnosed with Type 2 diabetes according to the American Diabetes Association criteria for at least 3 months prior to screening.\n- Patients can be either drug na\u00efve or on a stable dose of metformin for at least 4 weeks prior to screening.\n- HbA1c levels must be between 6.5% and 9.5% at screening.\n\nExclusion criteria for all subjects include:\n- Smoking within the previous 3 months.\n- Donation or loss of 400 mL or more of blood within 8 weeks prior to the trial.\n- Significant illness within two weeks prior to dosing.\n- History of drug or alcohol abuse within the past 12 months.\n\nAdditional exclusion criteria for Normal Healthy Volunteers:\n- History of diabetes or adrenal disorders.\n\nAdditional exclusion criteria for Type II Diabetic Patients:\n- Type 1 diabetes mellitus, positive anti-GAD antibodies, or acquired/secondary forms of diabetes.\n- Evidence of clinically significant diabetic complications such as nephropathy, retinopathy, or neuropathy.\n\nIt is important to note that there may be other protocol-defined inclusion/exclusion criteria that apply to this trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors,\" and the corresponding ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drug mentioned is \"auy922.\" \n\nThe eligibility criteria for this trial include various conditions that patients must meet to be included in the study. These conditions include having an ECOG Performance Status of \u2264 2, specific laboratory values within normal limits or correctable with supplements, and meeting certain requirements for AST/SGOT, ALT/SGPT, serum bilirubin, serum albumin, and serum creatinine levels. Patients must also be able to sign informed consent and comply with the protocol.\n\nThere are also exclusion criteria listed, which specify conditions that would disqualify patients from participating in the trial. These include having brain metastasis, prior treatment with certain inhibitor compounds, being pregnant or lactating, having severe and/or uncontrolled liver or renal disease, significant heart disease, a history of long QT syndrome or other heart-related conditions, and currently receiving treatment with medications that may prolong the QTcF interval or induce Torsades de Pointes. Patients with known disorders due to a deficiency in bilirubin glucuronidation are also excluded.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific disease being studied in this sample is non-small cell lung cancer. The corresponding ICD-10 codes for this disease are provided. The trial involves the use of the drugs belinostat and erlotinib. The eligibility criteria for participants are listed, including requirements such as signed consent, specific disease diagnosis, performance status, life expectancy, age, and acceptable liver, kidney, and bone marrow function. Other criteria include acceptable coagulation levels, negative pregnancy test for women of childbearing age, and normal serum potassium levels. The exclusion criteria specify that participants should not have received experimental drugs or anti-cancer therapy within certain timeframes, should not have certain medical conditions or infections, and should not have altered mental status. The presence of a secondary malignancy or intestinal obstruction is also listed as exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is described as \"phase 1/phase 2\". The diseases being studied include \"prostate cancer\", \"prostatic neoplasms\", \"castrate-resistant prostate cancer (CRPC)\", \"androgen-insensitive prostate cancer\", \"hormone-refractory prostate cancer\", and \"metastatic disease\". The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drugs being used in the trial are \"temsirolimus\" and \"casodex (bicalutamide)\". The eligibility criteria for participants are then listed, including requirements such as having a histologically-confirmed adenocarcinoma of the prostate, a serum PSA level of at least 2 ng/mL, and a castrate level of testosterone. Other criteria include age, performance status, life expectancy, and the ability to understand and sign a written informed consent.\n\nThe exclusion criteria are also provided, which outline factors that would disqualify a participant from the trial. These include recent radiotherapy for prostate cancer, prior treatment with mTOR inhibitors or chemotherapy for prostate cancer, certain medical conditions, and participation in other experimental drug studies.\n\nOverall, this sample provides a snapshot of a clinical trial focusing on prostate cancer, its phases, the diseases being studied, the drugs being used, and the eligibility and exclusion criteria for participants.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs, and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe sample data in the table includes information for a trial that has both phase I and phase II components. For the phase I component, the trial focuses on gastrointestinal cancer. The eligibility criteria include being 18 years of age or older, having histologic confirmation of a gastrointestinal malignancy, having locally advanced or metastatic disease, and having a disease that has recurred or progressed following standard therapy or for which no standard therapy currently exists. Other criteria include specific performance status, life expectancy, organ function, and time requirements since previous treatments.\n\nFor the phase II component, the trial focuses on metastatic colorectal cancer. The eligibility criteria include being 18 years of age or older, having histologic confirmation of colorectal cancer, having stage IV disease, and having at least one site of disease measurable by RECIST criteria. Other criteria include previous treatment history, performance status, life expectancy, organ function, and time requirements since previous treatments.\n\nThe sample provides detailed inclusion and exclusion criteria for both phases of the trial, including specific medical conditions, surgeries, infections, and other factors that may affect eligibility.",
    "The sample from the table represents a phase 1 clinical trial for bladder cancer and transitional cell cancer of the renal pelvis and ureter. The diseases are identified by their respective ICD-10 codes. The trial involves the use of three drugs: cisplatin, gemcitabine hydrochloride, and lapatinib ditosylate. The eligibility criteria for patients participating in the trial include having histologically proven transitional cell carcinoma, metastatic or locally advanced disease, measurable disease according to RECIST, overexpression of HER1 and/or HER2 receptors, and no clinical signs of CNS involvement. Other patient characteristics include a WHO performance status of 0-1, specific blood cell counts within normal ranges, normal liver and kidney function, and no pregnancy or nursing. The sample also outlines various exclusion criteria related to cardiac health, peripheral neuropathy, other malignancies, infections, and medical conditions. Prior concurrent therapies, such as intravesicle therapy and neoadjuvant or adjuvant chemotherapy, are allowed, but certain time intervals must be observed. The sample specifies restrictions on prior chemotherapy for metastatic disease and recent radiotherapy. It also mentions the avoidance of certain drugs and herbal substances, as well as the exclusion of other concurrent anticancer therapies or investigational agents. The use of prophylactic antibiotics and filgrastim (G-CSF) is not allowed, and there are restrictions on the consumption of herbal or dietary supplements and grapefruit juice during the trial.",
    "The sample from the table is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial is for newly diagnosed patients who are either age 65 or older or ineligible for autologous stem cell transplantation. The trial requires patients to have measurable disease, such as quantifiable serum monoclonal protein levels or abnormal free light chain ratio. The eligibility criteria also include age 18 or older, life expectancy of at least 3 months, and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n\nIn terms of laboratory requirements, the trial specifies that patients should have adequate hepatic function, with certain limits for serum ALT and serum direct bilirubin levels. Other laboratory criteria include ANC count, corrected serum calcium level, ALT level, hemoglobin level, platelet count, and creatinine clearance.\n\nEthical and other criteria include written informed consent, agreement to ongoing pregnancy testing and contraception for females of childbearing potential, and agreement to practice contraception for male subjects.\n\nThe exclusion criteria for the trial include previous treatment with anti-myeloma therapy (excluding certain treatments), relapsed or refractory multiple myeloma, and non-secretory multiple myeloma unless abnormal serum free light chains are present. Other exclusion criteria include pregnancy or lactation, recent major surgery, active infection, HIV infection, hepatitis B or C infection, certain cardiovascular conditions, uncontrolled hypertension or diabetes, recent non-hematologic malignancy (with exceptions), significant neuropathy, allergy to Captisol\u00ae (used to solubilize carfilzomib), contraindication to required concomitant drugs or treatments, pleural effusions or ascites requiring specific procedures, and any other clinically significant medical disease or condition that may interfere with protocol adherence or informed consent.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on healthy subjects, as indicated by the \"diseases\" field containing the value \"healthy\". The trial involves the administration of multiple drugs, including \"tipranavir low dose\", \"tipranavir high dose\", \"ritonavir low dose\", \"ritonavir high dose\", and \"norethindrone-ethinyl estradiol\". The eligibility criteria for this trial include being a female between 18 and 50 years old, having a body mass index (BMI) between 18 and 29 kg/m2, providing signed informed consent, being able to swallow large capsules, having acceptable laboratory values indicating adequate organ function, passing a medical history, physical examination, ECG, and chest X-ray, abstaining from alcohol, grapefruit, certain foods and drinks, and herbal medications, having a reasonable probability of completing the study, and meeting various exclusion criteria such as not being pregnant or breastfeeding, not participating in another trial with an investigational medicine, not using certain medications, not having certain medical conditions, and not having certain allergies or sensitivities.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on two diseases, namely diabetes mellitus and diabetic nephropathy.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial involves the drug pirfenidone.\n- Criteria: The eligibility criteria for participants are listed under inclusion and exclusion categories. Inclusion criteria include having type 1 or type 2 diabetes, being 18 years or older, having abnormal kidney function, a history of proteinuria, and controlled blood pressure. Exclusion criteria include having cancer, liver disease, hepatitis, HIV, a recent history of heart attack, unstable angina, stroke, or peptic ulcer, being pregnant or planning to become pregnant during the study, having other kidney diseases besides diabetic nephropathy, and expecting to undergo dialysis or receive a kidney transplant within a year of study enrollment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is ovarian cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is paclitaxel. \n\nThe eligibility criteria for this trial include being at least 18 years old, having recurrent epithelial ovarian cancer or primary peritoneal cancer with histologic confirmation, having platinum-resistant or platinum-refractory disease, having a treatment-free interval of at least three weeks prior to the first treatment on this protocol, and having a Zubrod performance status of two or less.\n\nThe exclusion criteria for this trial include previous administration of tgDCC-E1A, progression on any taxane-containing regimen or recurrence within 6 months of receiving a weekly taxane-containing regimen, previous radiation to more than 25% of marrow-bearing areas, certain abnormal laboratory values, known HIV-positive status or active systemic infection, history of other invasive malignancies (except for non-melanoma skin cancer) within the past 5 years, grade 2 or greater neurotoxicity, unstable angina or myocardial infarction within the past six months, and an ejection fraction under 40%.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"non small cell lung cancer.\" The ICDCodes associated with this disease are \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2.\" The drugs being tested in this trial are \"rad001\" and \"erlotinib.\" The eligibility criteria for this trial include various inclusion and exclusion criteria such as age over 18 years, advanced non-small cell lung cancer that is not responding to chemotherapy, a limited number of previous chemotherapy regimens, and the ability to perform normal daily functions. Exclusion criteria include chronic steroid treatment, prior treatment with EGFR inhibitors, and other severe medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is Hepatitis C. The ICDCodes associated with this disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being used in the trial are Ribavirin and Ribavirin + Pegylated Interferon-alpha. \n\nThe eligibility criteria for this trial include being a man or woman between the ages of 18 and 65, having a confirmed positive Hepatitis C antibody status, having genotype 1 HCV confirmed, having a liver biopsy showing chronic hepatitis without cirrhosis within the past 2 years, and meeting certain blood count and hemoglobin level requirements. \n\nAdditionally, there are specific criteria for women of reproductive potential, including negative pregnancy tests and the use of reliable contraception methods. There are also exclusion criteria, such as previous therapy with certain drugs, presence of other viral hepatitis infections, certain liver function abnormalities, uncontrolled infections, and various medical conditions that would make a subject unsuitable for the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is neoplasms. The corresponding ICD-10 codes for the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are mitoxantrone hydrochloride liposome and mitoxantrone. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must comply with the requirements and restrictions listed in the consent form.\n- Patients must have a pathology and/or cytologically proven malignant solid tumor.\n- Patients must be between 18-70 years old, both male and female.\n- Patients must have failed standard chemotherapy.\n- Patients must have no better treatment options and may benefit from the use of anthracyclines.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n- Objective tumor from the last chemotherapy, biological therapy, or other experimental interval treatment should be at least 4 weeks.\n- Expected survival time should be at least 3 months.\n- Patients must agree to take effective contraceptive measures during the trial.\n- Blood routine, liver and kidney function, and cardiac function examinations should meet certain requirements.\n\nThe exclusion criteria for this trial are as follows:\n- Pregnancy and breastfeeding women.\n- Patients with multiple sclerosis.\n- Patients with a history of ischemic heart disease, heart congestive, arrhythmia that requires treatment, and significant valvular disease.\n- Patients with heart disease induced by anthracycline.\n- Patients requiring other antineoplastic treatment.\n- Patients with a temperature above 38 degrees or active infection that may affect clinical tests.\n- Patients who are allergic to anthracycline and liposomal drugs.\n- Patients who are allergic to eggs, egg products, soybean, and soybean products.\n- Patients with uncontrolled primary or metastatic brain tumors.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is heart failure, and the corresponding ICDCodes are ['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I50.9', 'T86.22', 'I11.0']. The drugs being tested are 'trv120027' and 'placebo'. The eligibility criteria for this sample include specific inclusion and exclusion criteria. Inclusion criteria include a diagnosis of congestive heart failure made at least 3 months prior to screening, NYHA Class III or IV heart failure with an ejection fraction of 35% or less, and a baseline mean PCWP of 20 mmHg or higher. Exclusion criteria include any significant disease or condition that would interfere with the study, significant valve disease, current signs or symptoms of acute myocardial ischemia or acute coronary syndrome, and sustained or uncontrolled ventricular arrhythmia.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is myelodysplastic syndrome. The ICDCodes associated with this disease are D46.9, D46.C, and D46.Z. The drugs mentioned in this sample are ezatiostat hydrochloride and lenalidomide (Revlimid\u00ae). The eligibility criteria for this trial include specific histologic diagnosis, non-del(5q) low or Intermediate-1 risk MDS, ECOG performance status of 0-1, documented significant cytopenia for at least 2 months, discontinuation of growth factors for at least 21 days prior to study entry, registration into the mandatory RevAssist\u00ae program, negative pregnancy tests for females of childbearing potential, and exclusion criteria such as hypersensitivity to Telintra\u2122, prior therapy with or hypersensitivity to thalidomide or lenalidomide, prior allogenic bone marrow transplant for MDS, history of prior malignancy (except for specific cases), MDS evolving from certain conditions, history of MDS IPSS score>1.0, pregnant or lactating women, leptomeningeal or leukemic meningitis, and prior treatment with DNA methyltransferase inhibitors (DMTI).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are lymphoma, Hodgkin disease, and non-Hodgkin lymphoma. The ICDCodes associated with these diseases are also provided. The drug being tested is called pci-24781. The eligibility criteria for this trial include age being 18 years or older, having a confirmed and previously treated lymphoma, ability to swallow oral capsules, estimated life expectancy of more than 12 weeks, ECOG performance status of 1 or lower, and willingness to provide informed consent. The exclusion criteria include having more than four prior systemic treatment regimens, recent bone marrow transplant or other therapies, major surgery, CNS lymphoma or meningeal carcinomatosis history, certain medical conditions or organ dysfunctions, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is arry-380, which is an oral HER2 inhibitor. \n\nThe eligibility criteria for this trial include having histological or cytological evidence of HER2+ cancer or HER2+ metastatic breast cancer. Patients should have received at least one previous therapeutic regimen and either no longer be candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy. Patients with HER2+ breast cancer and a clinical indication for trastuzumab or lapatinib should have received prior therapy with trastuzumab and lapatinib if available. The Eastern Cooperative Oncology Group (ECOG) performance status should be between 0 and 2. \n\nThere are also exclusion criteria, such as uncontrolled or symptomatic brain metastases, recent treatment with an investigational medicinal product or device, recent radiotherapy or chemotherapy, recent major surgery, and positive serology for HIV, hepatitis B, and/or active hepatitis C. Additional criteria may also exist.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"healthy,\" and the corresponding ICDCodes are \"Z76.3\" and \"Z76.2.\" The drugs involved in the trial are \"alo-02 weight-matched placebo,\" \"crushed alo-02 30 mg/3.6 mg,\" \"oxycodone weight-matched placebo,\" and \"crushed oxycodone ir 30 mg.\" \n\nThe eligibility criteria for this sample include the following inclusion criteria: \n- Healthy subjects\n- Non-dependent, recreational opioid users who have used opioids for non-therapeutic purposes at least 10 times within the last year and at least once in the 8 weeks before the screening visit.\n- Must have experience with intranasal opioid administration, having snorted opioid drugs at least 3 times within the last year before the screening visit.\n\nThe exclusion criteria for this sample include:\n- Diagnosis of substance and/or alcohol dependence\n- The subject has participated in, is currently participating in, or seeking treatment for substance and/or alcohol-related disorder.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is HCV infection. The ICDCodes associated with this disease are \"K94.02\", \"K94.12\", \"K94.22\", \"K94.32\", \"N99.511\", \"A02.9\", and \"A31.0\". The drugs being tested in this trial are \"ana773\" and \"placebo\". \n\nThe eligibility criteria for this trial are divided into two parts: Part A and Part B. In Part A, the inclusion criteria include being male or female between the ages of 18 and 65, having no clinically significant abnormalities, having no serious or severe chronic conditions, and being a non-smoker. The exclusion criteria for Part A include being a pregnant or breastfeeding female, having a history of significant medical conditions that could interfere with the study medication or associated assessments, and having a history of drug or alcohol abuse.\n\nIn Part B, the inclusion criteria include being male or female between the ages of 18 and 65, being diagnosed with chronic liver disease consistent with chronic hepatitis C infection for at least 6 months, having a screening HCV RNA level of at least 375,000 copies/mL or 75,000 IU/mL, and being naive to or having relapsed from prior IFN-alpha based therapy. The exclusion criteria for Part B include being a pregnant or breastfeeding female, having received anti-viral therapy or immunomodulatory therapy within 90 days prior to the first dose of study medication, using an investigational drug or participating in an investigational study with a licensed drug within 30 days, having a history of significant medical conditions that could interfere with the study medication or associated assessments, and having a history of drug or alcohol abuse.",
    "The sample provided is a phase 1 trial, involving healthy volunteers. The trial is testing the effects of a combination of drugs, including aleglitazar, aspirin, and a placebo. The eligibility criteria for participants include being between the ages of 40 and 65, having a body mass index (BMI) between 18 and 35, and being a non-smoker or smoking less than 5 cigarettes per day. Female participants of child-bearing potential must be willing to use two forms of contraception. Additionally, participants should not have any clinically abnormal laboratory test results, should not have taken any medication within 2 weeks prior to the trial, and should not have a history of certain medical conditions or disorders.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are hematologic malignancy and solid tumor. The ICDCodes associated with these diseases are ['E70.338', 'E70.339', 'P09.3', 'O28.0', 'P61.8', 'P61.9', 'T45.8X1A']. The drugs being used in the trial are voraxaze (glucarpidase) and placebo. The eligibility criteria for inclusion in the trial include having solid tumors or hematologic malignancies, receiving high dose methotrexate, and having delayed methotrexate clearance. The exclusion criteria include having medical or psychiatric illnesses that may interfere with participation, taking medications that may interfere with methotrexate excretion or enhance toxicity, having uncontrolled cardiac disease, or having known hypersensitivity to any components of the study drug.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is from phase 1/phase 2. The diseases being studied in this trial are \"non-alcoholic steatohepatitis\" and \"increased iron storage / disturbed distribution.\" The corresponding ICD-10 code for the first disease is \"K75.81.\" The drug being tested in this trial is \"exjade.\" \n\nThe record also includes eligibility criteria for the trial. The inclusion criteria state that patients must have elevated liver enzymes, elevated serum ferritin levels (females > 300 ng/ml, males > 450 ng/ml), and liver histology consistent with a diagnosis of NASH. The exclusion criteria include factors such as excessive alcohol intake, liver cirrhosis, presence of other causes of chronic liver disease, anemia, abnormal liver enzyme levels, impaired kidney function, hemochromatosis, allergy or contraindication to the drug being tested, and various other medical conditions or medications that may interfere with the study.\n\nAdditionally, the record specifies that sexually active pre-menopausal female patients must be able to use a highly effective method of birth control, unless they have undergone a total hysterectomy and/or oophorectomy or tubal ligation. Pregnant or breastfeeding patients are also excluded from the trial.\n\nOverall, this record provides information about the phase, diseases, ICD-10 codes, drug, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"head and neck cancer\" and its corresponding ICDCodes are ['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']. The drugs being studied are \"docetaxel\" and \"everolimus\". The eligibility criteria for this trial include specific disease characteristics, such as histologically confirmed squamous cell carcinoma of the head and neck, locally advanced or metastatic disease, and no evidence of central nervous system metastases. Additionally, there are patient characteristics, such as ECOG performance status 0-1, certain blood counts, normal kidney and liver function, and negative pregnancy test. The prior concurrent therapy section outlines the exclusion criteria for prior chemotherapy, taxane use, erbB inhibitors, and concurrent use of certain drugs. It also specifies the time since prior radiotherapy and investigational drug use, as well as restrictions on concurrent use of certain medications and live vaccines during everolimus therapy.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1. The disease being studied is cystic fibrosis, and the corresponding ICD-10 codes for this disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drug being tested in this trial is amiloride solution for inhalation. The eligibility criteria for participants in this trial include a diagnosis of cystic fibrosis and two positive cultures for Burkholderia dolosa lung infection. The exclusion criteria include a positive pregnancy test or currently breastfeeding (if applicable) and a known sensitivity to amiloride.",
    "The sample from the table is for a clinical trial in the field of lymphoma treatment. The trial is in phase 1/phase 2 and focuses on patients with histologically confirmed diffuse large B cell lymphoma that has relapsed or is resistant to prior systemic therapy. The trial aims to evaluate the effectiveness of the drugs azacytidine and vorinostat.\n\nThe eligibility criteria for the trial include having measurable disease on cross-sectional imaging, being at least 18 years old, having an ECOG performance status of 2 or lower, and having normal organ and marrow function. Other criteria include negative pregnancy test for women of childbearing potential, agreement to use contraception during the study, ability to understand and sign an informed consent document.\n\nExclusion criteria for the trial include prior allogeneic transplant, receiving any other investigational agents, previous treatment with an HDAC inhibitor for lymphoma, known active CNS lymphoma, hypersensitivity to the drugs being tested, currently active second malignancy, uncontrolled illness, QTc interval greater than 0.470, and pregnancy or lactation.\n\nThe purpose of the trial is to assess the safety and efficacy of azacytidine and vorinostat in treating relapsed or resistant diffuse large B cell lymphoma.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are ovarian epithelial cancer stage III, stage IV ovarian cancer, and stage IV breast cancer. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial are lapatinib (gw572016), carboplatin, and paclitaxel. \n\nThe eligibility criteria for this trial include specific requirements for patients with relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma, and stage IV metastatic breast cancer. Patients must have failed no more than four previous chemotherapies for stage IV disease. They should also be able to swallow and retain oral medications and have measurable disease.\n\nThere are also exclusion criteria, which state that patients should not have received previous weekly carboplatin and paclitaxel treatments, nor any prior treatment with erbB targeting therapies such as erlotinib, gefitinib, and cetuximab. Additionally, patients should not have a concomitant requirement for medication classification as CYP3A4 inducers or inhibitors.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The disease being studied is type 2 diabetes mellitus, and its corresponding ICD-10 codes are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are gk1-399 (formerly ttp399) and placebo. The eligibility criteria for participants include being between the ages of 18 and 75, having a diagnosis of type 2 diabetes mellitus, being on a stable dose of diabetes medication, and having a body mass index (BMI) between 20 and 40 kg/m2. Exclusion criteria include having type 1 diabetes, experiencing a heart attack or stroke in the past 6 months, having uncontrolled blood pressure, or having significant kidney disease.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific disease being studied in this sample is atopic dermatitis. The corresponding ICD-10 codes for this disease are 'L20.89' and 'L20.9'. The drugs being tested in the trial are 'dpk-060 1% ointment' and 'placebo for dpk-060 ointment'. \n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a clinical diagnosis of atopic dermatitis, having a certain area of treatable eczematous lesions, and using appropriate contraception for female patients of childbearing potential. Exclusion criteria include having a recent significant clinical illness, previous antimicrobial therapy, certain medical conditions that may interfere with the drug, recent systemic or topical treatments for atopic dermatitis, and various other conditions or factors that may affect the outcome of the study.\n\nOverall, this sample provides information about the phase, disease, ICD-10 codes, drugs, and eligibility criteria for a clinical trial focused on atopic dermatitis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is pancreatic cancer. The ICDCodes associated with this disease are ['C25.3']. The drug being used in the trial is gemcitabine hydrochloride. \n\nThe eligibility criteria for this trial include the following:\n- The patient must have histologically confirmed adenocarcinoma of the pancreas or periampullary region that is unresectable or locally advanced.\n- The disease must be measurable or evaluable by CT scan or MRI.\n- There should be no evidence of metastatic disease outside of the planned irradiation field.\n- The patient's ECOG performance status should be between 0 and 2.\n- The patient's white blood cell count (WBC), absolute neutrophil count (ANC), platelet count, and hemoglobin levels should meet certain minimum requirements.\n- The levels of AST, ALT, bilirubin, and creatinine should be within specified limits.\n- The patient should not have any clinical indication of compromised function of the nonirradiated kidney.\n- The patient should not have had any secondary malignancies within the past 5 years, except for resected nonmelanoma skin cancer or carcinoma in situ of the cervix.\n- The patient should not be pregnant or nursing, and a negative pregnancy test is required.\n- Fertile patients must use effective contraception.\n\nThe exclusion criteria for this trial include the following:\n- The patient should not have acute hepatitis or known HIV infection.\n- The patient should not have any other active or uncontrolled infection.\n- The patient should not have a significant history of uncontrolled cardiac disease, including hypertension, unstable angina, myocardial infarction within the past 6 months, congestive heart failure, or cardiomyopathy with decreased ejection fraction.\n- The patient should not have had a prior severe infusion reaction to a monoclonal antibody.\n\nThe prior concurrent therapy requirements for this trial include the following:\n- The patient should not have had prior radiotherapy to the planned field of treatment.\n- The patient should not have had prior therapy that specifically and directly targets the EGFR pathway.\n- At least 14 days should have passed since the patient's prior surgery or biopsy.\n- At least 28 days should have passed since the patient's prior bypass procedures.\n- More than 5 years should have passed since the patient's prior chemotherapy, and no other concurrent chemotherapy is allowed.\n- No other concurrent investigational agent is allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is prostate cancer. The ICDCodes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drug being tested is an AR antagonist called BMS-641988. The eligibility criteria for this trial include having advanced castration-resistant prostate carcinoma with progressive disease, at least 4 weeks elapsed from major surgery, availability for follow-up, adequate liver and kidney function, and adequate blood values. The exclusion criteria include uncontrolled or significant heart disease, history of seizures, history of head injury, loss of consciousness, or stroke, patients undergoing alcohol withdrawal, any concurrent cancer, a serious uncontrolled medical disorder or active infection, and inability to swallow tablets.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is chronic hepatitis C. The ICDCodes associated with this disease are \"B18.2\", \"B18.0\", \"B18.1\", \"B18.8\", \"B18.9\", \"K71.3\", and \"K71.4\". The drugs being used in the trial are \"als-002200\" and \"placebo\". \n\nThe eligibility criteria for this trial include providing written consent, the ability to understand and comply with the protocol, being in good health, having a creatinine clearance greater than 50 mL/min, and being within a certain age range (18-55 years for healthy volunteers and 18-65 years for subjects with chronic hepatitis C). Other criteria include specific body mass index ranges, non-childbearing potential for females, and surgical sterilization or specific forms of birth control for males.\n\nAdditional inclusion criteria are specified for subjects with CHC genotype 1 infection, such as positive HCV antibody and RNA, documentation of CHC infection for more than 6 months, and specific liver biopsy or Fibroscan evaluation results. Exclusion criteria include various medical conditions, positive tests for certain antibodies, abnormal laboratory results, drug allergies, recent participation in other trials or receipt of investigational vaccines, significant blood loss or donation, regular tobacco use for healthy subjects, positive pre-study drug screen, and specific laboratory abnormalities.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"carcinoma, hepatocellular\" and \"liver neoplasms\". The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is \"talaporfin sodium\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include a diagnosis of primary Hepatocellular Carcinoma (HCC) based on imaging techniques, serum alpha-fetoprotein (AFP) level, or histological evidence. Other criteria include the number of liver lesions, Eastern Cooperative Oncology Group (ECOG) performance status, life expectancy, prior treatment failure, informed consent, age, and adequate hematologic, liver, and renal functions.\n\nExclusion criteria include being a candidate for surgery with curative intent, having large lesions or extensive disease involvement, known sensitivity to porphyrin type drugs, history of porphyria, presence of extrahepatic metastases, anticipated need for systemic chemotherapy, Child-Pugh C cirrhosis, diffuse HCC, concurrent participation in another clinical trial, and any concurrent disease or condition that may impair the subject's ability to complete the trial.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial related to hepatocellular carcinoma and liver neoplasms.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"glioblastoma multiforme.\" The ICDCodes associated with this disease are \"L51.0,\" \"L51.8,\" and \"L51.9.\" The drug being tested is \"mpc-6827 + carboplatin.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must have a histologically proven WHO Grade IV glioblastoma multiforme at the time of diagnosis or relapse, prior treatment with radiotherapy and temozolomide, evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI, and meet certain time requirements since prior surgical resection, major surgical procedure, radiation therapy, or cytotoxic chemotherapy. Participants must also have a Performance Scale of Karnofsky > 60%, ECOG < 2, or WHO < 2, and if steroids are needed, they should be on a stable or decreasing dose for at least 1 week.\n\nThe exclusion criteria state that participants should not have hypersensitivity to Cremophor EL, evidence of current/active intratumor hemorrhage by MRI, greater than second relapse, prior treatment with platinum-based chemotherapy, cardiovascular disease, cerebrovascular disease, uncontrolled hypertension, a cardiac ejection fraction < 50%, or Troponin-I elevated above the normal range.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of hepatocellular carcinoma, a type of liver cancer. The phase of the trial is a combination of phase 1 and phase 2. The diseases column specifies the disease being targeted, which in this case is hepatocellular carcinoma. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, which in this case is temsirolimus and sorafenib. The criteria column provides the eligibility criteria for participants in the trial, including age, life expectancy, confirmation of advanced HCC, tumor measurements, previous treatments, liver cirrhosis status, blood cell counts, liver function, and various other health factors. The exclusion criteria are also listed, which include factors such as concurrent treatments, previous use of investigational agents, certain medical conditions, and noncompliance with medical regimens.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is obesity, the ICDCodes are E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, the drugs are zgn-433 and normal saline, and the eligibility criteria are listed under inclusion and exclusion criteria. The inclusion criteria include being an obese but otherwise healthy female, having non-childbearing potential, having a BMI between 30 and 50 kg/m2, and having a stable body weight in the past month. The exclusion criteria include recent use of weight loss agents, a history of eating disorder, a history of gastric bypass surgery, and being a current smoker.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is pancreatic adenocarcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are temsirolimus and gemcitabine. \n\nThe eligibility criteria for this trial include having previously untreated metastatic pancreatic adenocarcinoma, measurable disease according to RECIST criteria, an ECOG Performance Status of 0 or 1, being 18 years of age or older, having a life expectancy of at least 12 weeks, specific blood test results within normal ranges, adequate glycemic control for subjects with diabetes, and agreeing to use birth control measures for patients of childbearing age. \n\nThe exclusion criteria for this trial include previous treatment with gemcitabine or chemoradiation, recent diagnosis of a second malignancy (except for certain types of skin cancer), certain cardiac dysrhythmias, immunodeficiency disorders or active infections, pregnancy or breastfeeding, brain metastases or other specific conditions, recent radiation therapy or major surgery, receiving other experimental or alternative therapies during the trial, and a history of hypersensitivity to polysorbate.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 1/phase 2. The trial is focused on studying the effects of a drug called \"ruxolitinib\" on patients with diseases such as myelofibrosis, polycythemia vera, and thrombocytosis. The diseases are identified by their corresponding ICD-10 codes, which are \"D75.81\", \"C94.41\", \"C94.42\", \"C94.40\", and \"D45\". The record also includes the eligibility criteria for the trial, including both inclusion and exclusion criteria. Inclusion criteria state that patients must be diagnosed with either primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF), require therapy for myelofibrosis, and have adequate bone marrow reserve. Exclusion criteria state that patients who have received anti-cancer medications or investigational therapy in the past 14 days are not eligible for the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease being studied is smoking cessation. The ICDCodes associated with this disease are Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, and Y36.891A. The drugs being tested in this trial are nicotine (2 mg) and nicotine (4 mg). The eligibility criteria for participants include being healthy smokers who usually smoke their first cigarette within 30 minutes of waking and having a Body Mass Index (BMI) within the range of 19-27 kilograms/meters^2. Participants who have used chewing tobacco or other tobacco products within 21 days of the screening visit are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are docetaxel, rad001, and dexamethasone. \n\nThe eligibility criteria for this trial include being 18 years of age or older, having a diagnosis of metastatic breast cancer with at least one measurable or evaluable lesion, and having no limit on the prior number of chemotherapies for Phase 1 or no more than one prior chemotherapy regimen for Phase 2. Patients must also provide signed informed consent, have adequate bone marrow function, normal renal function, and meet specific hepatic function variables. Additionally, patients must have a performance status of 0-2 on the World Health Organization scale.\n\nExclusion criteria for this trial include having received prior docetaxel treatment for metastatic breast cancer, a history of thromboembolism within the past 6 months or active thrombophlebitis, and grade 2 or higher neuropathy. Patients with treated brain metastasis stable for 3 months may be eligible for Phase 1 but excluded from Phase 2. Other exclusion criteria include uncontrolled infection, known history of HIV seropositivity, active bleeding diathesis, and concurrent severe or uncontrolled medical diseases. Patients with gastrointestinal impairment or disease, recent use of investigational drugs, or recent radiation therapy or surgery are also excluded. Finally, patients with a history of noncompliance to medical regimens or who are unwilling or unable to comply with the protocol are not eligible. Patients being treated with specific drugs or taking lithium chloride are also excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific disease being studied is \"idiopathic Parkinson's disease,\" and its corresponding ICD-10 code is \"G20.\" The drug being tested is a combination of safinamide and levodopa. \n\nThe eligibility criteria for participants in this trial are as follows:\n1. Participants can be male or female.\n2. Participants must be at least 30 years old.\n3. Participants must have a body mass index (BMI) between 18 and 32 kg/m2.\n4. Participants must have been diagnosed with idiopathic Parkinson's disease, with a Hoehn and Yahr (H&Y) stage of I-III.\n5. Participants must be responsive to levodopa treatment and currently taking a stable dose of levodopa/carbidopa.\n6. Participants' electrocardiogram (ECG) must be normal or have non-hazardous abnormalities, as determined by the investigator.\n7. Female participants must have a negative beta-HCG test, not be lactating, and use acceptable methods of contraception.\n8. Participants must be able to maintain an accurate dosing diary with the help of a caregiver.\n9. Participants must have given written informed consent before any study-related activities are carried out.\n\nThe exclusion criteria for participants in this trial are as follows:\n1. Participants cannot be taking other drugs that cause dopamine release or affect levodopa metabolism, except for AADC inhibitors.\n2. Participants cannot be taking other MAO inhibitors.\n3. Participants in a late stage of Parkinson's disease with severe dyskinesia or unpredictable symptoms are not eligible.\n4. Participants with forms of Parkinsonism other than idiopathic Parkinson's disease are not eligible.\n5. Participants cannot have taken drugs known to inhibit or induce drug-metabolizing enzymes within 4 weeks prior to the study.\n6. Participants cannot be receiving concomitant oral iron treatment.\n7. Participants with a history of hypersensitivity or contraindications to MAO-B inhibitors or levodopa are not eligible.\n8. Participants with clinically relevant allergies or significant hepatic or renal impairment are not eligible.\n9. Participants with gastrointestinal tract diseases or surgeries that could affect absorption or motility are not eligible.\n10. Participants with a diagnosis of HIV, acute Hepatitis B or C, or other clinically relevant diseases are not eligible.\n11. Participants with significant cardiovascular and lung diseases, narrow-angle glaucoma, or endocrinological diseases are not eligible.\n12. Participants with a current or recent neoplastic disorder are not eligible.\n13. Participants with active psychiatric diseases or a history of melanoma or current cancer are not eligible.\n14. Participants with signs of dementia or certain ophthalmologic conditions are not eligible.\n15. Participants who consume excessive amounts of caffeine or tobacco, have abnormal diets, or have participated in another clinical study within 30 days are not eligible.\n16. Participants with a history of alcohol or drug abuse within the past three years are not eligible.\n17. Participants who have received blood transfusions or donated blood within a certain timeframe are not eligible.\n18. Participants with signs or family history of transmissible spongiform encephalopathy are not eligible.\n\nThis description provides an overview of the sample record and the eligibility and exclusion criteria for participants in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in Phase 1, focusing on the disease called Hodgkin lymphoma. The ICD-10 codes associated with this disease are C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, and C81.70. The drugs being used in this trial are brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin, and brentuximab vedotin. The eligibility criteria for this trial include being a treatment-naive patient with Stage IIa or IIb-IV Hodgkin lymphoma, having measurable disease of at least 1.5 cm, and having an Eastern Cooperative Oncology Group performance status of less than 3. The exclusion criteria include having a history of another primary malignancy that has not been in remission for at least 3 years and having known cerebral/meningeal disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is hypertension. The ICDCodes associated with this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drugs being used in the trial are carvedilol cr capsules, placebo, and lisinopril. \n\nThe eligibility criteria for this trial include being male or female aged 65 years or older, having a body mass index (BMI) between 24 and 37 kg/m2, having a documented history of essential hypertension and being stable on treatment with an ACE inhibitor or angiotensin II receptor antagonist or renin antagonist, and no more than one other antihypertensive medication. \n\nThere are also exclusion criteria listed, such as having any clinically relevant abnormality, being a poor metabolizer of carvedilol based on CYP2D6 genotype, having persistent hyperkalemia or a history of hyperkalemia, having malignant hypertension or advanced hypertensive retinopathy, having a history of hepatic impairment or renal insufficiency, being treated for diabetes mellitus, having a history of angioedema, being treated with 3 or more antihypertensive medications, and more. \n\nThe sample also includes additional criteria related to ongoing treatment with certain medications, treatment with over-the-counter medications or herbal supplements, treatment with investigational drugs, and specific blood pressure measurements. It also mentions conditions such as uncontrollable or symptomatic arrhythmias, sick sinus syndrome, bradycardia, and history of myocardial infarction or stroke within 1 year of screening as exclusion criteria. \n\nLastly, the sample mentions criteria related to blood donation, history of asthma or hypersensitivity to beta-adrenergic blocking agents, history of sensitivity to study medications, history of anaphylaxis or severe allergic reactions to drugs, history of regular alcohol consumption, positive urine drug screen, and positive for Hepatitis B surface antigen or HIV as exclusion criteria. It also states that subjects must be willing and able to follow the procedures outlined in the protocol and provide written informed consent.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"renal function.\" The associated ICD-10 codes for this disease are \"N25.89\" and \"N25.9.\" The drugs being studied in this trial are \"aliskiren,\" \"placebo,\" and \"vtp-27999.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a healthy adult male or female between the ages of 18 and 75. Female subjects must be postmenopausal or surgically sterilized. Male subjects must be willing to use approved birth control methods for two weeks after the study. \n\nExclusion criteria include being under 18 or over 75 years old, having diabetes mellitus or kidney disease, experiencing a myocardial infarction, stroke, or cardiovascular revascularization/angioplasty within the last six months, having unstable angina pectoris or CAD requiring treatment with an excluded concomitant medication, having a history of congestive heart failure, hypertension, or left ventricular ejection fraction below 45%, being a current smoker or using nicotine patches, being pregnant or lactating, having cancer or any life-threatening illness with an expected death within two years or by the completion of the study, having certain abnormal blood test results, using specific medications, having a known hypersensitivity or contraindication to the study drugs or similar drugs, having any surgical or medical condition that may affect drug absorption, distribution, metabolism, or excretion, having a history of drug or alcohol abuse within the past 12 months, having acute infections or significant illness within three weeks of enrollment, having any medical condition that would render the subject unable to complete the study or pose significant risk, receiving any other investigational drug within 30 days of planned dosing, or having poor intravenous access as determined by the study staff.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"prostate neoplasms\" and its corresponding icd-10 codes are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being used in the trial are \"abiraterone acetate\", \"abiraterone acetate\", and \"prednisone/prednisolone or dexamethasone\". The eligibility criteria for this sample include various requirements such as histologically confirmed adenocarcinoma of the prostate, no prior chemotherapy for prostate cancer, ongoing androgen deprivation therapy, testosterone levels below 50 ng/dL, disease progression after antiandrogen withdrawal, and specific laboratory values within defined parameters. The criteria also include additional requirements for phase 2, such as the presence of target or non-target abnormalities on imaging and no prior treatment with ketoconazole for androgen-independent prostate cancer. The exclusion criteria for this sample include restrictions on prior hormonal therapy, bisphosphonate therapy, certain supplements or complementary medicines, recent radiation therapy, prior chemotherapy for hormone refractory prostate cancer, active second malignancy, uncontrolled medical conditions, certain blood pressure levels, congestive heart failure, recent myocardial infarction, serious infections or medical illnesses, active psychiatric illnesses or social situations that may limit compliance, and active or uncontrolled autoimmune disease. Phase 2 also includes an additional exclusion criterion related to abnormal electrocardiogram findings.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 combination. The trial focuses on several diseases, including severe combined immunodeficiency disease, severe primary immunodeficiency disorder, undefined T cell deficiency disorder, and Wiskott-Aldrich syndrome. The diseases are associated with specific ICD-10 codes. The trial involves the use of the drug fludarabine. \n\nThe eligibility criteria for the trial include patients with a diagnosis of severe combined immunodeficiency disease, which can be determined by gene specific mutations or clinical course with lymphocyte quantification and function assays. Additionally, patients with severe primary immunodeficiency disorder, including undefined T cell deficiency disorder and Wiskott-Aldrich syndrome, are eligible. The trial requires the availability of an HLA mismatched family member or an HLA matched or mismatched unrelated donor. Other criteria include a creatinine level below 2.5 times the normal for age, a life expectancy greater than 6 weeks, and a Lansky/Karnofsky score greater than or equal to 70%.\n\nExclusion criteria for the trial include patients with an HLA matched related donor, symptomatic cardiac disease or significant cardiac disease, known allergy to rat serum products, severe infection that precludes ablative chemotherapy or successful transplantation, HIV positive status, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"B-cell chronic lymphocytic leukemia\" and \"small lymphocytic lymphoma\". The corresponding ICDCodes for these diseases are \"C91.11\", \"C91.12\", \"C91.10\" for B-cell chronic lymphocytic leukemia, and \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\" for small lymphocytic lymphoma.\n\nThe drug being tested in this trial is \"pci-32765\". The eligibility criteria for participants in this trial include having histologically confirmed CLL or SLL and meeting at least one of the specified criteria for requiring treatment. Other criteria include having a certain number of prior treatment regimens, a specific ECOG performance status, being at least 18 years old, and being willing and able to participate in all required evaluations and procedures.\n\nThere are also exclusion criteria listed, which include recent use of certain therapies, concomitant use of specific medications, presence of certain medical conditions or organ dysfunctions, and abnormal laboratory values for ANC, platelet count, AST/SGOT, ALT/SGPT, creatinine, and creatinine clearance.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is listed as \"healthy.\" The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs involved in this trial are \"bi 691751\" and \"placebo.\" The eligibility criteria for this sample include being a healthy male subject, being able to understand and comply with study requirements, being between the ages of 18 and 55, having a BMI range of 18.5 to 29.9 kg/m2, and having a known genotype as specified in the study protocol. The exclusion criteria state that any relevant deviation from healthy conditions would exclude a subject from participating in the trial.",
    "The sample from the table represents a clinical trial for phase 1 of a drug called \"pf 03654746\" in patients with schizophrenia. The eligibility criteria for the trial are listed, including both inclusion and exclusion criteria. Inclusion criteria include being competent to provide informed consent, willingness to comply with study procedures, fluency in English, and having a BMI between 18 and 40. Psychiatric inclusion criteria specify that subjects must have a current diagnosis of schizophrenia and be receiving maintenance antipsychotic monotherapy with specific medications. They must also have stable control of symptoms, minimal extrapyramidal symptoms, and meet certain cognitive performance criteria. Exclusion criteria include females with childbearing potential, recent febrile illness, conditions affecting drug absorption, positive urine drug screen, excessive alcohol consumption, recent use of investigational drugs, abnormal ECG, use of disallowed concomitant medications, and various other conditions that may increase risk or interfere with trial results. The sample also includes exclusion criteria related to hepatitis, liver function, other psychiatric disorders, previous participation in a trial using the drug, substance dependence or abuse, evidence or history of mental retardation, risk of suicidal or violent behavior, poor compliance history, recent use of certain medications, history of seizures or head injury, and various medical disorders that may pose a risk or confound the study results.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on treating various stages of non-small cell lung cancer. The diseases mentioned include \"non small cell lung cancer,\" \"lung cancer,\" \"stage IIIB non small cell lung cancer,\" and \"stage IIIA non small cell lung cancer.\" The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe trial involves the use of a drug called \"s-3304.\" The eligibility criteria for participants are listed, including requirements such as being newly diagnosed with non-small cell lung cancer of stage IIIA or IIIB, having an ECOG performance status of 0-1, having adequate organ function, and being able to receive conventional chemoradiation therapy.\n\nThere are also exclusion criteria, which state that patients with a prior history of cancer (except for basal cell carcinoma after appropriate treatment) or prior systemic chemotherapy treatment are not eligible. Additionally, patients with other serious intercurrent illnesses, including HIV/AIDS, or those contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment, are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is insomnia. The ICDCodes associated with insomnia are listed as \"F51.01\", \"F51.02\", \"F51.03\", \"F51.04\", \"G47.00\", \"G47.09\", and \"A81.83\". The drugs being tested in this trial are zopiclone, zolpidem tartrate sublingual tablet, placebo (sublingual tablet), and placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male or female between the ages of 21 and 64, having good health based on medical history and examination, possessing valid driver's license for at least 3 years, having driving experience of at least 3000 km/year, and providing signed informed consent. \n\nExclusion criteria include having a history of drug addiction or substance abuse within the past 12 months, having restless legs syndrome, sleep apnea, narcolepsy, or other primary sleep disorder, having a known hypersensitivity to zolpidem or zopiclone, undergoing oral surgery or tooth extraction within 60 days prior to screening, using any medication to promote sleep within 14 days prior to screening, having a BMI greater than 29 Kg/M^2, currently using medication that affects driving performance, smoking more than 10 cigarettes per day, using tobacco products during nighttime awakening, consuming more than 6 cups of coffee per day, consuming more than 21 glasses of alcohol per week, receiving an investigational drug within 60 days or 5 half-lives prior to screening, and having any additional condition(s) that may affect sleep/wake function, prohibit completion of the study, or not be in the best interest of the subject to participate.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult mixed glioma, and recurrent adult brain tumor. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are ziv-aflibercept and temozolomide. The eligibility criteria for participants in this trial include various medical conditions, laboratory values, and prior medical history. These criteria ensure that the participants meet certain health requirements and do not have any conflicting medical conditions or treatments.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drugs being used in the trial are \"bay80-6946\" and \"bay80-6946.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Cancer patients\n- Japanese patients, who are at least 20 years of age\n- Histological or cytological documentation of non-hematologic, malignant solid tumors, excluding primary brain or spinal tumors, with no past or current involvement in the central nervous system (CNS)\n- At least one measurable lesion or evaluable disease according to RECIST (version 1.1)\n- Eastern Cooperative Oncology performance status (ECOG-PS) of 0 or 1\n- Life expectancy of at least 12 weeks\n- Advanced or refractory solid tumors not amenable to standard therapy, at the first screening examination/visit\n\nExclusion Criteria:\n- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of first study treatment. Patients must have recovered from the toxic effects of the previous anti-cancer chemotherapy or immunotherapy by the investigator (with the exception of alopecia).\n- Radiotherapy to target lesions during study or within 4 weeks of first study treatment\n- Investigational drug therapy outside of this trial during or within 4 weeks of first study treatment\n- Current diagnosis of Type I or II diabetes mellitus or fasting blood glucose level >125 mg/dL at screening, and/or HbA1c>/= 6.5%\n- Past and current histories of cardiac disease congestive heart failure > New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset of angina within 3 months prior to study entry or unstable angina or ventricular cardiac arrhythmias requiring anti-arrhythmic therapy\n- Active and clinically serious infections >Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 4.03)\n- Uncontrolled hypertension defined as systolic blood pressure >150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management\n- Patients undergoing renal dialysis\n- Pregnant or breastfeeding women",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"diabetes mellitus, type 2\". The ICDCodes associated with this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being tested in this trial are 'bi 10773 placebo' and 'bi 10773'. The eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". The inclusion criteria include requirements such as being a male or postmenopausal/hysterectomised female patient with a proven diagnosis of type 2 diabetes, having a certain level of HbA1c, age restrictions, and BMI range. The exclusion criteria include factors such as current use of insulin or glitazones, specific blood glucose levels, certain medical conditions, allergies, and history of certain cardiac conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is lupus nephritis. The ICDCodes associated with this disease are B26.83, A51.44, N11.8, N11.9, and N12. The drug being tested is nkt-01. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Males and females aged 18-70 years.\n- A diagnosis of SLE (Systemic Lupus Erythematosus) according to the ACR (American College of Rheumatology) criteria, with at least 4 out of 11 criteria.\n- Presence of sufficient signs to diagnose active SLE nephritis.\n- Serum creatinine concentration of <= 5.0 mg/dL.\n- Leucocyte counts >= 4000/uL.\n- Receiving OCS (Oral Corticosteroids) with a maximum dose of 1.0 mg/kg/day or 80 mg/day.\n- Prior treatment with cyclophosphamide, azathioprine, cyclosporin A, or any other immunosuppressive drugs.\n\nExclusion Criteria:\n- Chronic infection of HIV, Hepatitis B, or Hepatitis C.\n- Acute infection including fungal, viral, bacterial, or protozoal diseases.\n- Liver toxicity (WHO CTC class 2 and higher) or inadequate liver function.\n- Pregnant or lactating women.\n- Female patients of childbearing age without a safe method of contraception.\n- Anemia (hemoglobin < 8.0 g/dL), leucopenia (leucocytes < 4000/uL unless attributable to SLE), thrombocytopenia (platelets < 50000/uL).\n- Neutrophils below 1000/uL.\n- Hypogammaglobulinemia below 400 mg/dL of serum IgG.\n- Any other condition that, in the eyes of the investigator, might render the patient unsuitable for participation in the study. This includes major and active SLE organ involvement other than the kidney. Patients with SLE involvement of the central nervous system are not allowed to be included in the study.\n- History of malignancy.\n- Current participation in another trial or less than 6 months since participation in a similar trial.",
    "The sample provided is a phase 1 trial involving healthy volunteers. The trial is testing the drugs aleglitazar, placebo, and ibuprofen. The eligibility criteria for participants include being between the ages of 40 and 65, having a body mass index (BMI) between 18 and 35, and being a non-smoker or smoking less than 5 cigarettes per day. Female participants of child-bearing potential must be willing to use two forms of contraception. Additionally, participants should not have any clinically abnormal laboratory test results, should not have taken any medication within 2 weeks prior to the trial, and should not have a history of certain medical conditions or infections.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the diseases listed are \"bladder carcinoma,\" \"infiltrative bladder carcinoma,\" and \"cystectomy.\" The ICDCodes associated with these diseases are \"D09.0.\" The drug mentioned is \"lapatinib.\" The eligibility criteria include various factors such as age, life expectancy, performance status, clinical stage of bladder cancer, candidacy for radical cystectomy, cardiac function, ability to swallow medication, and more. The sample also includes exclusion criteria, which list conditions that would make a patient ineligible for the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"eosinophilic esophagitis,\" and its corresponding ICDCodes is \"K20.0.\" The drugs being tested in this trial are \"beclomethasone dipropionate\" and \"placebo.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria state that the subjects must be 18 years or older with a biopsy-proven diagnosis of EoE and willing to undergo repeat EGDs with esophageal biopsies and blood work. Exclusion criteria include subjects with suspected or proven inflammatory bowel disease, malignancy, and collagen-vascular disease, those who have used corticosteroids in the past 3 months, pregnant or breastfeeding individuals, those unable to swallow beclomethasone or intolerant to the medication, and individuals with a history of ischemic heart disease, diabetes, and dyslipidemia unless they have been stable in the last six months.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on ovarian cancer and primary peritoneal cancer.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial involves the use of pemetrexed and carboplatin in both phase 1 and phase 2.\n- Criteria: The eligibility criteria for the trial are listed, including requirements for diagnosis, previous treatments, and measurable disease. Exclusion criteria are also mentioned, such as limitations on the number of previous therapies and pregnancy/breastfeeding status. Additionally, there is a restriction on recent treatment with unapproved drugs.\n\nOverall, this sample provides specific information about a clinical trial, including the phase, diseases targeted, drugs used, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 1. The diseases being studied are pancreatic cancer and adenocarcinoma of the pancreas. The corresponding ICD-10 codes for these diseases are \"C25.3\" and \"C22.0\", \"C22.1\", \"C4A.9\", \"C7B.1\", \"D09.9\", \"C4A.0\", \"C4A.31\" respectively. The drugs being used in the trial are gemcitabine and sorafenib.\n\nThe eligibility criteria for participants are listed under \"criteria\". These criteria include confirmation of locally advanced unresectable or borderline unresectable pancreatic cancer, age of 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), tumor size of at least 2 cm, adequate organ function, biliary obstruction treatment if applicable, negative pregnancy test for women of childbearing potential, signed informed consent, curative treatment for previous malignancies, and other exclusion criteria such as prior treatment with gemcitabine or sorafenib, prior radiation therapy to the upper abdomen, evidence of metastatic disease, and various medical conditions or medications that may interfere with the study.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on pancreatic cancer and adenocarcinoma of the pancreas.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is ovarian cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is vandetanib. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histopathologically documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube, or peritoneum that is refractory to platinum-based chemotherapy or partially platinum sensitive.\n- The patient must be planned to receive therapy with pegylated liposomal doxorubicin 50 mg/m\u00b2 for recurrent platinum-refractory ovarian cancer.\n- Patients with a progression-free interval of 6 to 12 months after platinum-based chemotherapy are only eligible if further platinum-based combination chemotherapy is not possible.\n- Patients must have received at least one previous platinum- and taxane-based chemotherapy regimen.\n\nThe exclusion criteria for this trial include:\n- Patients with brain metastases or spinal cord compression, unless treated at least 4 weeks before the first dose and stable without steroid treatment for 10 days.\n- Patients taking concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function.\n- Patients who have been treated with mouse-antibodies in the last 3 months and have CA-125 progressive disease, unless they have measurable disease according to RECIST or cytological/histological proven relapse.\n- Patients who have undergone more than two prior lines of chemotherapy.\n- Patients who have received chemotherapy or other systemic anti-cancer therapy within four weeks prior to randomization.\n- Patients who have undergone radiation therapy within the last 4 weeks prior to randomization, except for palliative radiotherapy.",
    "The sample is a phase 1 clinical trial for patients with liver cirrhosis and hepatitis C. The trial is testing the drug bi 201335. The inclusion criteria for the trial include patients with histologically proven liver cirrhosis, compensated liver disease, age 18 or older, and specific requirements for male patients or female patients with certain conditions. The exclusion criteria include active HBV, HCV, or HIV infection, recent usage of drugs or investigational drugs, decompensated liver disease, abnormal liver function tests, certain types of liver cirrhosis, recent alcohol abuse, hypersensitivity to the study drug, pregnancy or breastfeeding, and other medical conditions that may interfere with the trial. The sample also includes additional criteria related to AFP levels, kidney function, hemoglobinopathy, and other concurrent illnesses or malignancies.",
    "The sample provided is for a Phase 1 clinical trial. The trial is focused on healthy male subjects. The inclusion criteria for the trial include being a healthy male, having signed written informed consent, being between the ages of 18 and 63, and having a BMI between 18.5 and 29.9 kg/m2. The exclusion criteria include any abnormal findings during the medical examination, any gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, oncological, or hormonal disorders, any history of surgery on the gastrointestinal tract (except appendectomy), any diseases of the central nervous system, psychiatric disorders, or neurological disorders, any relevant history of orthostatic hypotension, fainting spells, or blackouts, any chronic or relevant acute infections, any relevant history of allergy/hypersensitivity, any intake of drugs with a long half-life, any use of drugs that might influence the trial results, any participation in another trial with an investigational drug, being a smoker, having alcohol abuse, having drug abuse, having a recent blood donation or loss greater than 400 mL, and having clinically relevant laboratory abnormalities. The drugs being tested in the trial include \"birt 2584 xx - multiple escalating dose\", \"placebo\", and \"birt 2584 xx - single dose\".",
    "The sample from the table represents a phase 1 clinical trial for various types of leukemia. The diseases included in the trial range from different subtypes of acute myeloid leukemia (AML) to chronic myelogenous leukemia (CML) in accelerated or blastic phase. The trial also includes AML arising from myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD), as well as secondary or therapy-related AML. The eligibility criteria for the trial include having a confirmed diagnosis of one of these types of leukemia, excluding active CNS leukemia, and meeting certain performance status and laboratory test requirements. The trial also specifies that patients should not have certain medical conditions or be pregnant or nursing. The sample also mentions the use of specific drugs, such as vorinostat, cytarabine, and etoposide, and provides detailed inclusion criteria for patients to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are solid tumors and bladder cancer. The ICDCodes associated with these diseases are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drugs being used in the trial are cisplatin and carboplatin. The eligibility criteria for participants include being at least 18 years old, having a Karnofsky Performance Status of at least 70%, having an advanced/metastatic solid tumor that would typically be treated with gemcitabine plus carboplatin or gemcitabine plus cisplatin, and meeting certain laboratory value requirements for organ function. There are also exclusion criteria listed, such as having received more than three prior chemotherapy regimens, having active CNS metastases, and being pregnant or breastfeeding.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on studying the effects of a drug called \"bi 409306\" and a placebo on a group of healthy individuals. The participants in this sample are male Chinese and Japanese volunteers between the ages of 20 and 45, with a body mass index (BMI) between 18.5 and 25 kg/m2. They must have a known genotype as specified in the study protocol and be able to understand and comply with the study requirements. Any individuals with a deviation from a healthy condition are excluded from the trial. The diseases listed in this sample are \"healthy,\" which indicates that the trial is not specifically targeting any particular disease. The icd-10 codes provided, \"Z76.3\" and \"Z76.2,\" are likely related to the inclusion and exclusion criteria rather than specific diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"obstetric labour, premature.\" The ICDCodes associated with this disease are \"O71.9, O71.3, O71.7, O71.89, O90.2, O71.4, O90.1.\" The drugs mentioned in this sample are \"retosiban 100 mg, retosiban 800 mg, placebo, moxifloxacin 400 mg.\" The eligibility criteria for this trial include age requirements, gender specifications, health conditions, body weight and BMI range, written informed consent, ECG requirements, liver function parameters, exclusion criteria, and more.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on colon cancer. The ICD-10 codes associated with the disease are C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, and D12.3. The only drug being used in the trial is metformin. The eligibility criteria for participants include having histologically documented colorectal cancer, intending to undergo disease resection or biopsy at least 7 days from the treatment start date, being medically fit for resection or biopsy, being between the ages of 18 and 79, having adequate renal function and hepatic parameters, and being able to understand and sign a consent document. The exclusion criteria include intending to administer neoadjuvant chemotherapy or radiation therapy prior to surgery or biopsy, intending to perform surgery or biopsy within 7 days of study treatment start, having any situation where participation in the trial would alter or significantly risk altering the ability or timing of tumor resection, current use of metformin, having low blood glucose levels, having renal disease or dysfunction, having significant medical conditions such as cardiovascular collapse, acute myocardial infarction, septicemia, or metabolic acidosis, having a history of lactic acidosis or conditions associated with it, severe dehydration, clinical or laboratory evidence of hepatic disease, congestive heart failure requiring treatment, known hypersensitivity to metformin hydrochloride, being pregnant or lactating, and having a psychiatric illness or social situation that would limit compliance with study requirements or obscure results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is B-cell lymphoma. The ICDCodes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drug being tested is clofarabine. \n\nThe eligibility criteria for this trial include:\n- Patients must be at least 18 years old.\n- Patients must have histologically confirmed low grade or intermediate-grade B-cell lymphoma.\n- Patients must have relapsed or refractory to at least one standard chemotherapy regimen, excluding those who have only received Rituximab without a cytotoxic agent.\n- Patients must have measurable disease according to the Cheson lymphoma criteria.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n- Patients must have a life expectancy greater than 12 weeks.\n- Various laboratory values must meet specific criteria, such as ANC, WBC count, platelets, hemoglobin, total bilirubin, AST/ALT, and serum creatinine levels.\n- Patients must have normal cardiac function.\n- Patients must be capable of understanding the study's investigational nature and provide valid informed consent.\n- Female patients of childbearing potential must have a negative serum pregnancy test.\n- Both male and female patients must use effective contraception during the study and for at least 6 months after treatment.\n\nThe exclusion criteria for this trial include:\n- Patients with previously untreated B-cell lymphoma.\n- Patients who have received previous treatment with clofarabine.\n- Patients with known AIDS-related or HIV-positive lymphoma.\n- Patients who have undergone autologous bone marrow or stem cell transplant within 6 months of study entry.\n- Patients who have received prior radiotherapy to the only site of measurable disease.\n- Patients with certain medical conditions or use of medications that may interfere with the study.\n- Patients with active or untreated central nervous system (CNS) lymphoma.\n\nPregnant or lactating patients are also excluded from the trial. Additionally, any significant concurrent disease, illness, or psychiatric disorder that may compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results is considered an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is neoplasms. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in this trial are azd0530, carboplatin, and paclitaxel. The eligibility criteria for this trial include having a life expectancy of more than 12 weeks, being post-menopausal for women, and being a male or female patient with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel. The exclusion criteria include having inadequate bone marrow reserve, inadequate liver or renal function, or unresolved toxicity from previous anti-cancer therapy.",
    "The sample is a phase 1 clinical trial for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. The trial is testing the efficacy of oral azacitidine as a potential treatment. The eligibility criteria include being 18 years or older, having a diagnosis of one of the specified diseases, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and having adequate organ function. There are also specific criteria for females of childbearing potential and males with partners who are of childbearing potential. The sample also lists exclusion criteria, such as previous treatment with azacitidine, concurrent use of certain medications, and certain medical conditions that would prevent participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms\". The ICDCodes associated with this disease are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The drugs being used in this trial are \"rg4733\", \"rg4733\", and \"rg4733\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The trial is open to adult patients who are 18 years of age or older.\n- Patients must have advanced and/or metastatic solid tumor malignancy.\n- The disease must be measurable or evaluable.\n- Patients must have an ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n- Patients who have received chemotherapy, radiotherapy, or immunotherapy within 28 days prior to the first receipt of the study drug are not eligible.\n- Patients who have received corticosteroids as anti-cancer therapy within a minimum of 14 days prior to the first receipt of the study drug are not eligible, except for dexamethasone which may be allowed as part of supportive care measures.\n- Patients who have undergone major surgery within 28 days prior to the first receipt of the study drug are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is influenza, and the corresponding ICDCodes are ['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']. The drug being used in this trial is a placebo. \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male or non-pregnant female between the ages of 18 and 40, practicing adequate contraception for women of childbearing potential, being in good health, able to understand and comply with study procedures, and providing informed consent. Exclusion criteria include having allergies to vaccine components, being pregnant or breastfeeding, having immunosuppression, having neoplastic disease or a history of hematologic malignancy, using certain types of steroids, receiving immunoglobulin or other blood products within the past 3 months, receiving other licensed vaccines within a certain timeframe, having certain medical conditions or illnesses, having a history of severe reactions to influenza vaccines, having an acute illness, receiving experimental agents, planning to enroll in another clinical trial, having conditions that pose an unacceptable risk or interfere with the study, having certain psychiatric diagnoses or hospitalizations, receiving certain psychiatric drugs, having active HIV, hepatitis B, or hepatitis C infection, having a history of alcohol or drug abuse, planning to travel outside of the USA within a specific timeframe, having a history of Guillain-Barre syndrome, or having any condition that may interfere with the study according to the investigator's judgment.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for non-small cell lung cancer. The trial is open to patients who are 18 years or older and have been diagnosed with metastatic or recurrent non-small cell lung cancer that has failed at least one prior platinum-based chemotherapy treatment. Patients who have previously undergone surgery or radiation for their lung cancer can also participate in the trial. The trial is also open to patients who have received neoadjuvant or adjuvant therapy in the past.\n\nPatients with brain metastases are eligible if their disease has been treated and they are clinically stable, as confirmed by a stable or improved brain scan within 28 days prior to registration. The presence of measurable or non-measurable disease outside the area of surgical resection is required, and pleural effusions, ascites, and laboratory parameters alone are not acceptable as evidence of disease.\n\nOther criteria include progression after at least one prior platinum-based chemotherapy, a recovery period of more than 3 weeks since surgery, and adequate blood counts and liver function. Patients requiring lung radiation must have a certain level of lung function and pulmonary function tests.\n\nThe trial has certain exclusion criteria, such as no prior single-agent, weekly Docetaxel chemotherapy, peripheral neuropathy of grade 1 or higher, and a history of other malignancies except for specific cases. Pregnant or nursing women are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is a combination of phase 1 and phase 2.\n- Diseases: The list of diseases being studied, which in this case includes pancreatic neoplasms and bile duct neoplasms.\n- ICD Codes: The ICD-10 codes associated with the diseases, with the code \"C25.3\" corresponding to pancreatic neoplasms.\n- Drugs: The drugs being used in the trial, including oxaliplatin, capecitabine, and sorafenib.\n- Criteria: The eligibility criteria for participants in the trial, including age, performance status, organ and marrow function, presence of measurable lesions, and other factors. It also includes criteria related to pregnancy, breastfeeding, and informed consent. Additionally, there are exclusion criteria related to concomitant therapies, medical conditions, surgeries, drug interactions, and other factors.\n\nOverall, this sample provides specific information about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on pancreatic neoplasms and bile duct neoplasms.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on lung cancer.\n- ICD Codes: The ICD-10 codes associated with the lung cancer are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2.\n- Drugs: The drugs being tested in the trial are carboplatin, erlotinib hydrochloride, and paclitaxel.\n- Criteria: The eligibility criteria for the trial are listed under \"Disease Characteristics\" and \"Patient Characteristics.\" These criteria include specific requirements related to the diagnosis, stage, histology, performance status, blood counts, lung function, organ function, pregnancy status, and various other medical conditions. The criteria also mention prior concurrent therapies and procedures that the patient should not have undergone.\n\nOverall, this sample record provides information about a clinical trial for lung cancer, including the phase, diseases targeted, associated ICD codes, drugs being tested, and eligibility criteria for potential participants.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 1/phase 2. The diseases being studied are acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. The corresponding ICDCodes for these diseases are provided as well. The drug being tested is chr-2797 (tosedostat), which is an aminopeptidase inhibitor. The eligibility criteria for this trial include various factors such as signed informed consent, specific disease conditions, recovery from prior therapies, adequate bone marrow, hepatic and renal function, age requirement, performance status, estimated life-expectancy, and negative pregnancy test for female patients of reproductive potential. The sample also includes exclusion criteria such as recent anti-cancer therapy, certain medical conditions, psychiatric disorders, gastrointestinal disorders, low platelet count, recent blood transfusion, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are lymphoma, cancer, and thyroid carcinoma. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is XL184. The eligibility criteria for participants in this trial include having a confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable, having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, having a life expectancy of more than 3 months, and having adequate organ and marrow function, among other criteria. There are also exclusion criteria listed, such as recent chemotherapy, immunotherapy, or radiation treatment, known brain metastases, uncontrolled intercurrent illness, pregnancy or breastfeeding, and known allergies or hypersensitivity to the components of the XL184 formulation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent mantle cell lymphoma, and splenic marginal zone lymphoma. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are bendamustine hydrochloride and obatoclax mesylate. The eligibility criteria for participants include having histologically confirmed indolent B-cell non-Hodgkin lymphoma, having received at least one prior therapy, and having a certain performance status, blood counts, liver and kidney function, and no active hepatitis B infection.\n\nOther criteria include not being pregnant or nursing, using effective contraception if fertile, not having certain medical conditions or infections, and meeting specific criteria for HIV infection. The sample also mentions that prior use of bendamustine hydrochloride is allowed under certain conditions.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is prostate cancer. The icd-10 codes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drug being tested is called odm-201. The eligibility criteria for this trial include written informed consent, confirmed adenocarcinoma of the prostate, ongoing androgen deprivation therapy, progressive metastatic disease, and adequate bone marrow, hepatic, and renal function. The exclusion criteria include known brain metastases, history of other malignancy within the previous 5 years, known gastrointestinal disease or procedure that affects absorption, and inability to swallow the study drug.",
    "The sample from the table is for a clinical trial in phase 1/phase 2. The trial is focused on head and neck cancer. The ICD-10 codes associated with the disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being studied in the trial are cisplatin, fluorouracil, and iressa. The eligibility criteria for the trial include having histologically confirmed primary squamous cell carcinoma of the head and neck region, excluding certain locations like the nasopharynx, paranasal sinuses, and salivary glands. The patient should have locoregionally confined stage III or IV disease, with no evidence of nodal disease below the clavicles and no distant hematogenous metastases. Other patient characteristics include specific performance status, blood cell counts, kidney function, liver function, and absence of certain conditions like pregnancy, severe hypersensitivity to gefitinib, and clinically active interstitial lung disease. The patient should also not have certain medical conditions like unstable angina, clinically apparent jaundice, or active infection. Prior concurrent therapy should not include previous surgery, radiotherapy, chemotherapy, immunotherapy, or epidermal growth factor receptor inhibitors for head and neck cancer. The patient should not have taken investigational drugs within the past 30 days and should not be on concurrent CYP3A4 inducers. Concurrent surgery is allowed as long as gefitinib is not administered 2 weeks before and after the surgery. The patient should not be on concurrent aminoglycoside antibiotics.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are colorectal cancer and gastric cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are Xeloda, Oxaliplatin, and TKI258. The eligibility criteria for participants in this trial include having histologically confirmed gastric, gastro-oesophageal, or colorectal adenocarcinoma, being locally advanced unresectable or metastatic, being over 18 years old, having an ECOG performance status of less than 2, having a life expectancy of greater than 3 months, and meeting certain organ and marrow function requirements. The sample also includes exclusion criteria, such as not having a currently active malignancy, not being pregnant or breastfeeding, and not having certain medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and in this case, it is a combination of phase 1 and phase 2. The diseases being studied in this trial are \"primary erythromelalgia\" and \"inherited erythromelalgia.\" The diseases are also associated with ICD-10 codes, with the code \"I73.81\" being linked to these diseases. The trial involves testing the effectiveness of two drugs, namely \"xpf-001\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial include being between 18 and 75 years old, having inherited erythromelalgia, experiencing moderate pain caused by erythromelalgia (with a pain score of 4 out of 10), being generally healthy (except for the pain), and not being pregnant or breastfeeding. Participants are required to stop taking their usual pain medications for 9 days. \n\nThe role of participants in the trial includes an outpatient screening visit, a 9-day/8-night in-patient treatment visit at Nijmegen Medical Center (where they will be closely monitored), a follow-up phone call after returning home, taking the investigational medication daily, and recording their daily pain levels during their stay at the Medical Center. \n\nThere are also exclusion criteria that would disqualify individuals from participating in the trial. These include having another source of pain from different conditions, receiving professional psychological support for dealing with inherited erythromelalgia, recent treatment for significant depression, having active HIV, Hepatitis B or C, using prescription or over-the-counter medication between check-in and discharge, being pregnant or lactating without adequate contraception, having alcoholism or substance abuse issues, having a history of major psychiatric disturbance, being unwilling or unable to comply with dietary and activity restrictions, having any other condition or finding that may pose undue risk for participation, and using any other investigational drug in the 60 days prior to dosing.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular record, the phase of the trial is Phase 1. The diseases being studied are cancer of the esophagus, adenocarcinoma of the gastroesophageal junction, and cancer of the stomach. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are vandetanib, 5 fluorouracil (fu), carboplatin, and paclitaxel. The eligibility criteria for this trial include having histologically documented carcinoma of the esophagus, gastroesophageal junction, or stomach, being potentially resectable, having an Eastern Cooperative Oncology Group Performance Status of 0-2, having no evidence of distant metastases, being 18 years or older, providing signed informed consent, practicing adequate contraception for women of childbearing potential, and meeting various exclusion criteria such as not having previous radiation therapy to the chest or upper abdomen, not having severe or uncontrolled systemic disease, and not having impaired cardiac function or inadequate pulmonary and cardiac function to tolerate surgery. The record also includes laboratory result requirements such as adequate bone marrow function, specific serum bilirubin and creatinine levels, and normal levels of potassium, serum calcium, and magnesium.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Alzheimer's disease. The ICDCodes associated with this disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in this trial are pf-03654746 and placebo. The eligibility criteria for this trial include the inclusion criteria of having probable Alzheimer's disease, a Mini Mental State Examination score between 18 and 26 (inclusive), and being aged between 55 and 85. The exclusion criteria include having dementia other than Alzheimer's disease, clinically significant cardiovascular disease in the past 6 months prior to screening, and a creatinine clearance of less than 30 mL/min.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1. The diseases listed are \"metastases, neoplasm\", \"carcinoma, non-small cell lung\", \"renal cell carcinoma\", and \"neuroendocrine tumors\". The corresponding ICDCodes for these diseases are provided as well. The drugs being studied in this trial are \"ly2584702\" and \"erlotinib\". The eligibility criteria include having a diagnosis of advanced or metastatic cancer for which no proven effective therapy exists, having measurable or nonmeasurable disease, having adequate organ function, having a performance status of less than or equal to 1, and having discontinued previous cancer therapies for a certain period of time. There are also exclusion criteria listed, such as recent treatment with unapproved drugs, serious preexisting medical conditions, and certain medical conditions or treatments that would make a participant ineligible for the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases being studied are advanced solid tumors and lymphomas. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is called alisertib. The sample also includes the eligibility criteria for participants to be included or excluded from the trial. The inclusion criteria include factors such as age, confirmed diagnosis of metastatic or advanced tumors or lymphomas, performance status, expected survival, and contraceptive requirements for female and male participants. The exclusion criteria include factors such as pregnancy or lactation, recent treatment with certain medications, medical conditions, organ function, and other malignancies. The sample also mentions specific medical or psychiatric conditions, as well as HIV or hepatitis status.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on ovarian cancer. The ICD-10 codes associated with the disease are 'C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', and 'C17.2'. The drugs being studied in the trial are carboplatin, cyclophosphamide, etoposide, paclitaxel, and topotecan hydrochloride. \n\nThe eligibility criteria for the trial include having histologically proven stage IIIC ovarian epithelial cancer and being chemosensitive to 6-8 courses of standard dose adjuvant chemotherapy. Patients with residual disease (no greater than 1 cm) following second look laparotomy are eligible, but those with no microscopic disease present following induction chemotherapy or newly diagnosed stage IV ovarian epithelial cancer are ineligible. Patients who have achieved at least a partial response (80% or greater reduction in tumor by CT scan) following six courses of standard dose chemotherapy or have residual disease (no greater than 1 cm) or no disease determined at the time of second look laparotomy are also eligible. Patients with relapsed ovarian epithelial cancer following standard dose chemotherapy, who are chemosensitive and have achieved at least a partial response after 4-6 courses of salvage chemotherapy, are eligible as well. The trial also has specific criteria for age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. \n\nIn terms of prior concurrent therapy, there are no specific requirements for biologic therapy or endocrine therapy. Patients should not have received prior topotecan. There are no specific requirements for radiotherapy, but surgery should align with the disease characteristics. Patients should not be on concurrent nitroglycerin preparations or antiarrhythmic drugs.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is for a trial that includes both phase 1 and phase 2. The trial focuses on the treatment of malignant melanoma, a type of skin cancer. The ICD-10 codes associated with this disease are provided. The trial involves the use of two drugs, karenitecin and valproic acid. The eligibility criteria for participants are listed, including requirements such as having a documented diagnosis of metastatic malignant melanoma, being at least 18 years old, and having a certain performance status. Other criteria include specific laboratory parameters, the use of contraception, and the preference for subjects with biopsiable disease. The record also includes exclusion criteria for both phase 1 and phase 2, such as not having active infections, having adequate renal and hepatic function, and not being pregnant or nursing. Additional criteria for phase 2 include limitations on the number of prior chemotherapy regimens.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is lymphoma. The ICDCodes associated with the disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drug being tested is forodesine hydrochloride. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-small cell lung cancer and brain metastases. The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is icotinib. \n\nThe eligibility criteria for this trial include the following inclusion criteria: histological or cytological confirmation of non-small cell lung cancer, diagnosis of brain metastases on a Gadolinium-enhanced MRI with more than 3 sites of intracranial metastases or the longest diameter of the intracranial lesion being more than 3cm, and a positive EGFR mutation. \n\nThe exclusion criteria for this trial include previous usage of EGFR-TKI or antibody to EGFR (gefitinib, erlotinib, herceptin, erbitux), and CSF or MRI findings consistent with metastases of the spinal cord, meninges, or meningeal.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial is focused on ovarian cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in the trial are lenvatinib, carboplatin, and gemcitabine. The eligibility criteria for participants include being female and at least 18 years old, having a confirmed diagnosis of ovarian cancer that was treated with and was sensitive to one prior platinum-based chemotherapy regimen for Stage III or Stage IV disease, and meeting specific CA125 criteria for relapse. Other criteria include having a Gynecological Oncology Group performance status of 0 or 1, a life expectancy of at least 3 months, and adequate hematologic, renal, liver, and coagulation system function. Participants must also have recovered from any major surgery within 28 days prior to starting the study treatment. Exclusion criteria include being pregnant, breastfeeding, or not using appropriate contraception, having received certain prior treatments, having certain medical conditions or infections, and having hypersensitivity to the drugs being studied.",
    "The sample from the table is for a clinical trial in the early phase 1. The trial is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested in the trial is panobinostat (lbh589). \n\nThe eligibility criteria for the trial include being a female patient aged 18 or older, having stage IV tamoxifen-refractory breast cancer, not using any other HDAC inhibitors, having palpable disease, having an ECOG performance status of 2 or lower, providing written informed consent, not having received chemotherapy or radiation therapy recently, not having any major medical problems or untreated infections, not having CNS involvement by tumor, meeting specific laboratory criteria, having a baseline MUGA or ECHO demonstrating LVEF within the normal range, having normal TSH and free T4 levels, having an echocardiogram result above 50%, and having a negative serum pregnancy test for women of childbearing potential.\n\nThe exclusion criteria for the trial include having received prior HDAC, DAC, HSP90 inhibitors, or valproic acid for cancer treatment, needing valproic acid during the study, having impaired cardiac function, having uncontrolled hypertension, using drugs with a risk of causing torsades de pointes or CYP3A4 inhibitors, having unresolved diarrhea of grade 2 or higher, having gastrointestinal function impairment or disease that may affect the absorption of the drug, having other severe or uncontrolled medical conditions, having received chemotherapy, investigational drugs, or major surgery recently, using any anti-cancer therapy or radiation therapy, being pregnant or breastfeeding, not willing to use double barrier contraception, having a history of another primary malignancy within 5 years (except for certain cases), being HIV positive or having hepatitis C, having a history of non-compliance to medical regimens or inability to provide reliable informed consent, being unable to tolerate phlebotomy or biopsy, or being on any other hormonal or biological treatment drugs at the time of the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is tumors. The ICDCodes associated with the disease are E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, and C49.A3. The drugs being used in the trial are azd1152 part a and azd1152 part b. The eligibility criteria for this trial include the requirement of histological or cytological confirmation of a solid, malignant tumor, and the presence of at least one measurable or non-measurable site of disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The exclusion criteria include recent participation in an investigational drug study within the past 21 days or not having recovered from the effects of a previous investigational study drug, as well as recent major surgery within 4 weeks prior to entry into the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug being tested is \"bi 6727.\" \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that patients must have a confirmed diagnosis of advanced, non-resectable, and/or metastatic solid tumor. They must be male, aged between 18 and 70 years, and provide written informed consent. The Eastern Cooperative Oncology Group (ECOG) performance score must be less than or equal to 2, and patients must have recovered from therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapy.\n\nThe exclusion criteria state that patients with serious concomitant non-oncological diseases, active infectious diseases, viral hepatitis, HIV infection, clinical evidence of active brain metastasis in the past 6 months, or second malignancy currently requiring active therapy are not eligible. Additionally, patients with certain blood count abnormalities, liver function abnormalities, high serum creatinine levels, a history of QT/QTcF-prolongation, or who are sexually active without using contraception are excluded. Patients who have received other investigational drugs or participated in another clinical trial, undergone recent cancer therapy, have a history of alcohol abuse, have a life expectancy of less than 12 weeks, or are taking certain medications are also excluded. Finally, patients with a history of allergy/hypersensitivity are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is HIV infections, and the corresponding ICDCodes is \"Z21\". The drugs being used in the trial are raltegravir and emtricitabine/tenofovir disoproxil fumarate. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being HIV infected, antiretroviral treatment naive, having a viral load between 10,000 and 300,000 copies/ml within 42 days prior to study entry, and agreeing to use appropriate contraception. Exclusion criteria include having received HIV-specific immunizations or any immunizations within 6 months prior to study entry, having known allergies or sensitivities to the study drugs, having an acute AIDS-defining opportunistic infection that is not clinically stable or has not been treated for at least 30 days prior to study entry, recent treatment with immune modulators or investigational therapy, evidence of HIV seroconversion within 6 months prior to study entry, illness requiring systemic treatment or hospitalization, substance abuse that may interfere with adherence to study requirements, requirement for current medications that are prohibited with any study medication, evidence of major resistance-associated mutation, abnormal laboratory values, and being pregnant or breastfeeding.\n\nThis sample provides a detailed description of the trial phase, disease, drugs, and the criteria that participants must meet or exclude in order to be eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"antivirals/hiv\". The ICDCodes associated with this disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being tested in this trial are \"rifabutin\" and \"rifabutin + atazanavir + ritonavir\". The eligibility criteria for this trial include being a healthy male or female between the ages of 18 to 50 with a BMI of 18 to 32 kg/m\u00b2. Prior to enrollment, subjects must have normal physical and laboratory test findings, and women of childbearing potential must have a negative pregnancy test. Exclusion criteria include having any significant acute or chronic medical illness, evidence of organ dysfunction, or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations. Additionally, the use of prescription drugs or over-the-counter acid controllers within 4 weeks prior to the study drug administration, as well as the use of any other drugs or herbal preparations within 1 week prior to the study drug administration, are also exclusion criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The diseases being studied are listed as \"carcinoma, hepatocellular.\" The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in the trial are \"mapatumumab,\" \"placebo,\" and \"sorafenib.\" The eligibility criteria for participants in the trial are also included in the record. These criteria include specific medical conditions, such as Child-Pugh Class A, Barcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, and measurable disease demonstrating intratumoral arterial enhancement. Other criteria include adequate bone marrow, renal and liver function, performance status on the Eastern Cooperative Oncology Group (ECOG) Scale, age 18 years or older, and the ability to understand and comply with the study procedures. The record also lists exclusion criteria, such as co-morbid conditions that may increase the risk of treatment complications, previous treatment with certain therapies, history of organ allograft, and recent surgeries. Other exclusion criteria include certain medical conditions, infections, and use of specific medications. The record concludes with the requirement for negative pregnancy tests and the use of contraception for females, as well as the need for effective contraception for males during the study and for a period after the study.",
    "The sample provided is for a phase 1 trial. The disease being studied is pancreatic neoplasms. The corresponding ICD-10 code for this disease is C25.3. The drugs being used in the trial are nelfinavir and gemcitabine. The eligibility criteria for this sample is not provided, but it states that the trial is closed to accrual.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is colorectal neoplasms, and the corresponding ICD-10 codes for these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are bevacizumab, ag-013726, and ag-013736 (axitinib). The eligibility criteria for this trial include specific requirements for patients with solid/GI tumors, locally advanced or metastatic colorectal cancer, and previous treatments. There are also exclusion criteria that specify limitations on prior treatments and surgeries.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is ovarian cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are sorafenib and topotecan. \n\nThe eligibility criteria for this trial include having histologically-confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube cancer. Measurable disease or detectable disease is required for enrollment, which can be determined through RECIST criteria, CA-125 levels, ascites and/or pleural effusion, or radiographic imaging. Patients must have failed at least one prior platinum-based chemotherapeutic regimen and no more than three prior treatment regimens for epithelial ovarian cancer. Prior radiation therapy is allowed to a certain extent. Patients must also meet certain time requirements since their last anti-cancer treatment, radiation, or surgery. \n\nThere are also exclusion criteria, such as having known or suspected allergies to the drugs used in the trial, no prior treatment with anti-angiogenesis therapy, no active CNS metastases, and no recent treatment with investigational agents. Other exclusion criteria include no concurrent combination anti-retroviral therapy, no clinically significant infections, no evidence of bowel obstruction or other contraindications to oral medication, no serious non-healing wounds or fractures, no recent major surgery or traumatic injury, and no use of St. John's Wort or rifampin while on the trial. Additionally, patients must be able to swallow whole pills. \n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on ovarian cancer.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on multiple sclerosis. The ICD-10 codes associated with the disease are 'G35' and 'C81.18'. The drug being studied is smoked cannabis. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include a diagnosis of clinically definite multiple sclerosis, moderate or severe spasticity, and being 21 years or older. The exclusion criteria include preexisting pulmonary and cardiac conditions, inability to abstain from smoking or using certain medications, history of drug abuse, preexisting psychiatric illnesses, recent exacerbation of MS, current use of certain medications, arthritis or other disorders interfering with spasticity measures, inability to provide informed consent, and recent frequent cannabis use.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"acute myelogenous leukemia.\" The ICDCodes associated with this disease are \"C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01.\" The drug mentioned is \"clofarabine.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include patients with a diagnosis of relapsed or refractory Acute Myeloid Leukemia (AML) according to the World Health Organization (WHO) criteria or untreated AML patients (60 years to 74 years) for whom standard induction chemotherapy is unlikely to be of benefit. Other criteria include age requirements, Eastern Cooperative Oncology Group (ECOG) performance status, ability to comply with study procedures, and satisfying specific laboratory values criteria for hepatic, renal, pancreatic, and cardiac function.\n\nExclusion criteria include patients with a diagnosis of acute promyelocytic leukemia (APL), prior hematologic stem cell transplant, prior external beam radiation therapy to the pelvis, uncontrolled systemic infections, severe concurrent diseases, history of serious organ dysfunction or disease, diagnosis of another malignancy (with some exceptions), prior positive tests for certain viruses, clinically significant arrhythmia, central nervous system involvement with leukemia, psychiatric disorders that would interfere with study participation, prior treatment with the study drug or other chemotherapy/ investigational agents, current participation in another concurrent investigational protocol, pregnancy or lactation, and the requirement for fertile male and female patients to use effective birth control during the study period and for six months after the last dose of the study drug.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is chronic hepatitis C. The ICD-10 codes associated with the disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drugs being tested in the trial include sch 900518 biologic peginterferon alfa-2b (pegintron), sch 900518 biologic peginterferon alfa-2b, sch 900518 drug ritonavir (rtv) biologic peginterferon alfa-2b (pegintron), and sch 900518 drug ritonavir (rtv) drug ritonavir (rtv) biologic peginterferon alfa-2b (pegintron). \n\nThe eligibility criteria for the trial include being infected with HCV genotype 1, being treatment-na\u00efve or treatment-experienced (non-responder or relapser), having acceptable medical history and physical examination, having a viral load of >10^5 copies/mL, having a BMI of 18 to 40 kg/m^2, being between the ages of 18 and 65, and meeting certain requirements for contraception for females and males. \n\nThere are also exclusion criteria, such as having an unstable or uncontrolled medical illness, having received an organ transplant, having decompensated liver disease, having received an HCV NS3-specific protease inhibitor, and having certain abnormal laboratory values. Other exclusion criteria include having a history of significant infectious disease, having a partner who intends to become pregnant, being positive for HIV antibodies or hepatitis B surface antigen, having allergies or hypersensitivity to the investigational product, and having a history of auto-immune hepatitis. Additionally, subjects who have used investigational drugs or donated blood within a certain timeframe or received certain treatments for HCV infection are also excluded.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial focuses on patients with urinary bladder neoplasms. The icd-10 codes associated with these diseases are 'D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', and 'D41.4'. The drug being studied is lenalidomide. \n\nThe eligibility criteria for this trial include: \n1. Written informed consent and HIPAA authorization for release of personal health information.\n2. Age over 18 years at the time of consent.\n3. Karnofsky Performance Status of 70% or higher.\n4. Histological or cytological proof of transitional cell carcinoma of the urothelial tract, with transitional cell carcinoma being the predominant histology for patients with mixed histologies.\n5. Measurable disease according to RECIST or unresectable disease (cT4b).\n6. All study participants must be registered into the mandatory RevAssist\u00ae program and comply with its requirements.\n7. Females of childbearing potential must have a negative pregnancy test and commit to continued abstinence from heterosexual intercourse or use two acceptable methods of birth control.\n8. Able to take aspirin daily as prophylactic anticoagulation.\n9. Adequate organ function as determined by specific laboratory values.\n\nThe exclusion criteria for this trial include:\n1. Prior treatment with systemic chemotherapy for metastatic disease (prior intravesical therapy is permitted; prior neoadjuvant/adjuvant chemotherapy permitted if completed \u2265 1 year from study entry).\n2. Prior use of lenalidomide.\n3. Major surgery within 30 days of starting the study treatment.\n4. Certain cardiovascular events within the 6 months prior to study drug administration.\n5. Active CNS metastases.\n6. History of a prior malignancy.\n7. Recent receipt of anticancer therapy, radiation, or any investigational agent.\n8. Pregnant or breastfeeding.\n9. Clinically significant infection.\n10. Known seropositive for or active viral infection with HIV, HBV, or HCV.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"carcinoma, renal cell.\" The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drug mentioned is \"topotecan.\" The eligibility criteria for this trial include various inclusion and exclusion criteria, such as patients with histologically confirmed rectal cancer, candidates for preoperative radiotherapy, and patients with an Eastern Cooperative Oncology Group (ECOG) performance status less than 2. The sample also includes exclusion criteria, such as patients who have already had their primary tumor completely removed, recurrent rectal cancer that failed initial treatment, and patients who have been exposed to topotecan or have certain medical conditions that may affect absorption. Additionally, there are criteria related to pregnancy, contraception, and the use of investigational drugs.",
    "The sample from the table is for a phase 1 clinical trial for patients with metastatic renal cell carcinoma. The eligibility criteria for this trial include being of Chinese origin and at least 18 years old, having histologically or cytologically confirmed metastatic renal cell carcinoma, being intolerant of or having progression on or after stopping treatment with VEGF-targeted therapies within 6 months, having at least 1 measurable lesion according to RECIST Criteria Guidelines, being neurologically stable following definitive radiation or surgery for brain metastasis (if applicable), having a Karnofsky Performance Status of at least 70%, having adequate bone marrow, liver, and renal function, having a negative serum pregnancy test for women of childbearing potential, and giving written informed consent.\n\nThe exclusion criteria for this trial include having received chemotherapy, immunotherapy, radiotherapy, or any other investigational agent within 4 weeks of study entry, having previously received RAD001 or other mTOR inhibitors, having a known hypersensitivity to RAD001 or other rapamycin analogs, having a history of another primary malignancy within the past 3 years (except for non-melanoma skin cancer and carcinoma in situ of uterine cervix), receiving chronic and systemic treatment with corticosteroids or another immunosuppressive agent (except for low dose treatment for certain disorders), having a clinically significant active bleeding diathesis, having known HIV seropositivity, hepatitis B or C seropositivity, having undergone major surgery within 4 weeks prior to starting study drug or not having recovered from the side effects of previous surgeries or injuries, having any severe and/or uncontrolled medical conditions, being pregnant or breastfeeding, or not using effective birth control methods.\n\nThese are the specific inclusion and exclusion criteria for this phase 1 clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are rad001 and lenalidomide. \n\nThe eligibility criteria for this trial include being previously diagnosed with multiple myeloma, having relapsed or relapsed/refractory disease, being 18 years of age or older, having an ECOG Performance Status of 0 to 2, being able to take aspirin daily, and having necessary baseline studies obtained within 21 days prior to enrollment. Other criteria include being able to take bactrim, having a negative pregnancy test for females of childbearing potential, and not having certain medical conditions or prior treatments that would place the subject at unacceptable risk. \n\nExclusion criteria include renal insufficiency, concurrent therapy medications that include corticosteroids or other chemotherapy, evidence of bleeding or platelet refractory, poorly controlled diabetes, low ANC or hemoglobin levels, elevated AST or ALT levels, prior therapy with RAD001, known hypersensitivity to thalidomide or lenalidomide, and various other conditions or medical history that would make the subject ineligible for the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\". The diseases being studied in this trial are \"overactive bladder\" and \"overactive urinary bladder\". The corresponding ICD-10 code for these diseases is \"N32.81\". The drugs being used in the trial are \"vibegron\", \"tolterodine er\", and \"prophylactic antibiotic\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must not be able to bear children (either post-menopausal or have undergone procedures such as hysterectomy, oophorectomy, or tubal ligation). If they are of reproductive potential, they must not be pregnant (confirmed via blood test) and must agree to use two acceptable methods of birth control from at least 2 weeks before the first dose of the study drug until at least 2 weeks after the last dose.\n- Participants must have a body mass index (BMI) of \u226440 kg/m^2 (not morbidly obese).\n- Participants must have a clinical history of overactive bladder symptoms (OAB) for at least 3 months.\n- Participants must be capable of accurately completing a daily diary for reporting purposes.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants who are mentally or legally incapacitated, have significant emotional problems (other than situational depression), or have been diagnosed with a significant psychiatric disorder in the past 5-10 years.\n- Participants who have other types of urinary incontinence (such as stress or mixed).\n- Participants who have a history (current or past) of interstitial cystitis, painful bladder syndrome, chronic pelvic pain, or Stage III or greater pelvic organ prolapse.\n- Participants who have other types of kidney/urinary bladder disease/obstruction or infection, except for those with a history of uncomplicated kidney stones at the discretion of the investigator.\n- Participants who are unable to control bowel movements.\n- Participants who have a history of narrow-angle glaucoma, immunocompromise, stroke, chronic seizures, major neurological disorders, or other serious and chronic organ-system health conditions (such as heart disease).\n- Participants who have a urinary catheter, either permanent or intermittent placement.\n- Participants who do not meet the medication profile requirements or directives required for study eligibility.\n- Participants who have a condition for which there is a warning, contraindication, or precaution against the use of tolterodine ER or anticipate the use of prescription medications contraindicated with the use of tolterodine ER.\n- Participants whose daily alcohol or caffeine intake exceeds study requirements.\n- Participants who are unable to refrain from smoking throughout the study's duration.\n- Participants who engage in illicit drug use.\n- Participants who have recently undergone surgery or participated in another clinical trial.\n- Participants who have severe, frequent allergies or a history of life-threatening reactions or intolerability to prescription or non-prescription medications or food.\n- Participants who have an intended or unintended extended absence or exposure to a significant change in time zone or sleep schedule (such as transmeridian travel or shift work) that will interfere with accurate completion of scheduled daily diary entries.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are ovarian cancer, fallopian tube cancer, and peritoneal cancer. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is alemtuzumab. \n\nThe eligibility criteria for this trial include:\n1. Patients must have a confirmed diagnosis of ovarian, fallopian, or primary peritoneal cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy. This can be confirmed through radiologic studies or rising CA125 levels.\n2. There is no limit on prior courses of chemotherapy.\n3. Patients must have measurable disease or elevated CA125.\n4. Patients must be over 18 years old.\n5. Patients must have an ECOG performance status of less than 2 (Karnofsky 60%).\n6. Patients must have a life expectancy of greater than 12 weeks.\n7. Patients must have adequate organ and marrow function.\n8. Patients must be able to understand and sign a written informed consent document.\n9. Pre-study labs and measurements must be completed within 28 days of treatment Day 1.\n10. Patients with known immunosuppressive diseases, receiving other agents with therapeutic intent, or with certain medical conditions are excluded from the trial.\n\nThis sample provides a detailed description of the trial phase, diseases being studied, the drug being tested, and the specific eligibility criteria that patients must meet to participate in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease melanoma. The ICD-10 codes associated with melanoma are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being studied are lenalidomide and dacarbazine. The eligibility criteria for participants include being at least 18 years old, having a histological documentation of malignant melanoma with evidence of metastatic disease, and having an ECOG performance status of 0, 1, or 2. There are also specific laboratory test ranges that must be met, and certain exclusion criteria such as pregnancy, serious medical conditions, and prior treatment with systemic chemotherapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is chronic hepatitis B. The ICDCodes associated with this disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drugs being investigated in this trial are gs-7340 and tenofovir disoproxil fumarate.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being between 18 and 65 years of age, having a screening plasma HBV DNA level of at least 2x10^3 IU/mL, having chronic HBV infection for at least 6 months, having an estimated creatinine clearance (CLCr) of at least 70 mL/min, not being pregnant or nursing, and using recommended methods of birth control. Exclusion criteria include being pregnant or lactating, receiving anti-HBV nucleoside/nucleotide therapy, having co-infection with HIV, HCV, or HDV, having autoimmune disorders, having a history of liver disease other than Hepatitis B, having Gilbert's Disease, having decompensated liver disease, having known or suspected cirrhosis, having evidence of hepatocellular carcinoma, having cardiovascular disease or cardiac conduction abnormalities, having electrolyte abnormalities, having a history of treatment that permanently alters the gastric condition, having alcohol or substance abuse, having a history of bleeding diathesis, and having significant bone disease.",
    "The sample is a phase 1 trial with the disease \"essential hypertension\". The ICD-10 codes associated with this disease are \"I10\", \"O10.02\", \"O10.03\", \"O10.011\", \"O10.012\", \"O10.013\", and \"O10.019\". The drugs being tested in this trial are \"qgc001 [(3s,3's)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]\" and \"placebo\". The eligibility criteria for this trial include being a Caucasian male between the ages of 18 and 45, having a body weight of at least 50 kg and a body mass index between 18 and 27 kg/m2, and being in good health as determined by medical history, physical examination, laboratory tests, vital signs, and ECG readings. Exclusion criteria include having any significant medical conditions, recent acute illness or drug abuse, positive serologic findings for certain viruses, positive urine drug screen, history of drug allergy, recent use of investigational or prescription drugs, recent consumption of certain substances, and recent blood donation.",
    "The sample from the table represents a clinical trial for lung cancer patients in phase 1/phase 2. The trial aims to test the effectiveness of a combination of drugs including carboplatin, hydroxychloroquine, and paclitaxel. The eligibility criteria for patients include having histologically or cytologically confirmed advanced non-small cell lung cancer, with recurrent disease and no component of squamous cell carcinoma. The diagnosis should be established on a metastatic tumor aspirate or biopsy, and the patient should have stage IIIB disease with malignant pleural effusion or stage IV disease. Other criteria include having measurable disease, more than 1 year since post-operative adjuvant therapy, and no known CNS metastases. Patient characteristics include having an ECOG performance status of 0-1, specific blood counts and liver function within normal ranges, and no significant medical conditions or infections. Prior concurrent therapy should meet certain requirements, such as no prior cytotoxic chemotherapy or targeted therapy in the advanced or metastatic setting, and no concurrent treatment for rheumatoid arthritis or systemic lupus erythematosus.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is colorectal cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs mentioned are OSI-906 and irinotecan. The eligibility criteria include various conditions such as a histological or cytopathological diagnosis of advanced cancer, specific mutation status, previous treatments, age, performance status, and various health parameters. The sample also includes exclusion criteria and conditions related to prior therapies.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on the disease \"acute ischemic stroke\" and the corresponding ICD-10 codes for this disease are \"I25.5\", \"H47.013\", \"H93.013\", \"G45.9\", \"H47.011\", \"H47.012\", and \"H47.019\". The trial involves two drugs, namely \"mrx-801\" and \"placebo\". The eligibility criteria for this trial include having an acute ischemic stroke, occlusion demonstrated by transcranial Doppler ultrasound, and being eligible for tPA (tissue plasminogen activator). The exclusion criteria include having a right to left cardiac shunt, moderate to severe COPD (chronic obstructive pulmonary disease), and uncontrolled hypertension.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of type 1 diabetes mellitus. The trial uses the drug lisofylline. The eligibility criteria for participants are listed, including age requirements, ability to provide informed consent, compliance with the study protocol, and specific medical conditions and measurements such as body mass index, QTc interval, HbA1c levels, and serum creatinine levels. The sample also includes exclusion criteria, which list conditions and factors that would disqualify potential participants from the trial. These include various medical conditions, history of certain diseases, use of specific medications, and lifestyle factors such as smoking and alcohol consumption.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"recurrent childhood acute lymphoblastic leukemia.\" The ICDCodes associated with this disease are C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, and C83.53. The drugs being used in the trial include l-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, and leucovorin calcium. The eligibility criteria for this trial include specific diagnosis requirements, certain performance status levels, blood count limits, liver and kidney function requirements, cardiac health parameters, and restrictions on concurrent treatments.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the disease asthma. The ICD-10 codes associated with asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The trial involves two drugs, \"active\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as a specific body mass index (BMI) range, a limited smoking history, a documented history of mild bronchial asthma, and certain lung function measurements. The exclusion criteria are also provided, which include factors such as hypertension, recent respiratory tract infection or asthma exacerbation, and certain medical conditions or test results.",
    "The sample from the table represents a Phase 1 clinical trial for patients with advanced cancers. The diseases listed in this sample are \"advanced cancers\" and the corresponding ICD-10 codes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drugs being studied in this trial are \"azacitidine\", \"lenalidomide\", and \"grifola frondosa\". \n\nThe eligibility criteria for this trial include: \n1. Patients must have a confirmed diagnosis of an advanced solid tumor that is refractory to standard treatment or for which no standard therapy is available.\n2. Patients must have an ECOG performance status of 2 or better (0-2).\n3. Patients must have normal organ and marrow function, including specific blood count levels, liver function, and kidney function.\n4. Patients must be able to understand and sign an IRB-approved informed consent document.\n5. Female patients of childbearing potential must have a negative pregnancy test and agree to use two methods of birth control while taking lenalidomide.\n6. Patients must be 18 years of age or older, except for pediatric patients who are 13 years or older and have a body weight of more than 50 kg.\n7. Patients must have a life expectancy of greater than 3 months, as determined by the attending physician.\n8. All study participants must be registered in the mandatory RevAssist program and comply with its requirements.\n\nThe exclusion criteria for this trial include:\n1. Patients with uncontrolled ongoing or active infections, congestive heart failure, unstable angina, active bleeding, active thrombosis, or psychiatric illness/social situations that would limit compliance with the study requirements.\n2. Patients with a history of stroke, transient ischemic attack, significant vascular disease, or symptomatic peripheral vascular disease.\n3. Patients with a history of allergic reactions to the study drugs or their analogs.\n4. Patients who have received any tumor control treatment within specific timeframes prior to the study drug treatment.\n5. Patients using concurrent immunosuppressors.\n6. Patients who are unable to swallow oral medication.\n7. Pregnant or breastfeeding women.\n8. Patients concurrently enrolled in another research study.\n9. Patients with known hepatitis B and C infection, HIV infection, or autoimmune disorders.\n10. Patients with moderate or severe renal impairment (creatinine clearance < 60 ml/min) are excluded.\n\nThis sample provides an overview of the phase, diseases, icd codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease of asthma. The associated ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The trial involves two drugs, namely 'gw870086x' and 'placebo'. The eligibility criteria for this trial are listed under inclusion and exclusion criteria. Inclusion criteria include being a male aged 18-55 with a documented history of bronchial asthma, currently only being treated with short-acting beta-2-agonist therapy, having a documented sensitivity to adenosine mono phosphate (AMP), and demonstrating a repeatable and reproducible response to inhaled AMP. Exclusion criteria include having any significant illness or disease, a history of life-threatening asthma or respiratory tract infection, taking incompatible medications, being a smoker, being oversensitive to corticosteroids, having a history of drug or alcohol abuse, donating blood within the last 3 months, being involved in another clinical trial in the last 3 months, working night shifts, or undergoing de-sensitization therapy.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column lists the names of various diseases. The icdcodes column contains the corresponding ICD-10 codes for each disease. The drugs column lists the names of drugs being tested in the trial. The criteria column provides the eligibility criteria for patients to be enrolled in the study.\n\nIn the given sample, the phase is described as \"phase 1/phase 2\". The diseases listed include \"advanced nonhematological malignancies\", \"non-small cell lung cancer\", \"small cell lung cancer\", \"metastatic breast cancer\", \"head and neck squamous cell carcinoma\", and \"gastroesophageal adenocarcinoma\". The corresponding ICDCodes for these diseases are also provided.\n\nThe only drug mentioned in the sample is \"mln8237 (alisertib)\". The eligibility criteria are described in detail, including inclusion criteria such as age, confirmed diagnosis of metastatic or advanced solid tumor, specific disease requirements for phase 2, performance status, contraception requirements, consent, compliance with trial procedures, and measurable disease for phase 2. The exclusion criteria include pregnancy or lactation, medical or psychiatric illnesses that could interfere with the study, previous treatments, brain metastasis, cardiovascular conditions, infections, swallowing difficulties, history of HIV or hepatitis, anticoagulation requirements, sleep apnea, and recent use of enzyme inducers.\n\nOverall, the sample provides information about the trial phase, diseases, ICDCodes, drugs, and the eligibility criteria for patients to participate in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being used in the trial are \"lx4211\" and \"januvia\u00ae\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being an adult aged 18 to 65 years with a history of Type 2 Diabetes Mellitus for at least 3 months, specific HgbA1c values, and a certain C-peptide level. Other criteria include a specific body mass index (BMI), willingness to self-monitor blood glucose, and ability to provide written informed consent. \n\nExclusion criteria include a history of Type 1 diabetes mellitus, certain diabetic complications, use of certain medications, history of certain medical conditions, recent surgeries, active infections, and other factors that may interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is pancreatic cancer. The ICDCodes associated with this disease are ['C25.3']. The drug being tested is vandetanib. The eligibility criteria for this trial include having a confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma, having an ECOG performance status of less than 1, and having measurable disease. The exclusion criteria include having severe or uncontrolled systemic disease, having a clinically significant cardiac event such as a myocardial infarction, and taking any concomitant medication that may cause OTc prolongation, including Torsades de Pointes.",
    "The sample provided is a phase 1 trial for the treatment of advanced cancer, specifically carcinoma, non-small cell and neoplasm metastasis. The trial is investigating the drug pf-00299804. The eligibility criteria for inclusion in the trial include having histologically documented advanced cancer with an Eastern Cooperative Oncology Group (ECOG) score of 0-1, platelet count above 100,000, absolute neutrophil count (ANC) above 1500, and a creatinine clearance (Ccr) above 60 or serum creatinine below 1.5. For the non-small cell cancer cohort, the ECOG score can be 0-2, prior platinum therapy is allowed, and there should be less than 4 prior chemotherapy regimens. Additionally, the HgA1C level should be below 5.7%. The exclusion criteria include having active central nervous system (CNS) metastases, prior IGF1-R targeted therapy, and any history of unstable angina, myocardial infarction, or symptomatic congestive heart failure.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 1 and focuses on the disease \"type 2 diabetes mellitus (t2dm)\". The associated ICD-10 codes for this disease are ['E23.2', 'N25.1', 'P70.2', 'O24.92', 'Z83.3', 'Z86.32', 'E10.65']. The trial involves the use of two drugs: \"comparator: sitagliptin phosphate\" and \"comparator: placebo (unspecified)\". The eligibility criteria for participants are listed, including specific inclusion and exclusion criteria. Inclusion criteria include having type 2 diabetes mellitus, being male, being a female who is highly unlikely to become pregnant, and being poorly controlled without taking any or only one or two oral antidiabetic medications. Exclusion criteria include having a history of type 1 diabetes mellitus or ketoacidosis, requiring insulin therapy within the past 8 weeks, and being on or having taken TZDs such as Actos\u00ae (pioglitazone) or Avandia\u00ae (rosiglitazone) within the past 12 weeks of the screening visit.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"intermittent claudication,\" and the corresponding ICDCodes are provided as well. The drugs being studied are \"trans sodium crocetinate (tsc)\" and \"0.9% normal saline.\" The eligibility criteria for this trial include age requirements, a history of walking limitation or symptoms of intermittent claudication, a diagnosis of peripheral artery disease (PAD) secondary to atherosclerosis, specific measurements related to ankle-brachial index (ABI) and toe-brachial index (TBI), stable claudication severity, medication usage, exercise habits, and other medical conditions. The sample also includes exclusion criteria, such as pregnancy, critical limb ischemia, non-atherosclerotic co-morbid conditions, recent surgical interventions, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include \"diabetes mellitus type 1 and 2,\" \"diabetes mellitus complications,\" \"gastroparesis,\" and \"gastrointestinal motility disorder.\" The corresponding ICDCodes for these diseases are ['E10.9', 'E11.9', 'E13.9', 'E10.8', 'E11.8', 'E13.8', 'E08.9'] for diabetes mellitus, ['K31.84'] for diabetes mellitus complications, and ['A21.3', 'A22.2', 'B46.2', 'K92.2', 'K92.81', 'K91.0', 'P54.3'] for gastroparesis and gastrointestinal motility disorder.\n\nThe drugs being tested in this trial are \"rm-131\" and \"placebo.\" The eligibility criteria for participants include being able to provide written informed consent, having a diagnosis of Type 1 or 2 diabetic gastroparesis, having controlled Type 1 or 2 diabetes mellitus (HbA1c <10.1%), having stable concomitant medications, having a body mass index (BMI) of 18-40 kg/m\u00b2, and meeting certain exclusion criteria such as not having a history of gastric surgery, not having acute or chronic illnesses that could pose a threat, and not having any clinically significant abnormalities on screening laboratories.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"multiple myeloma and plasma cell neoplasm.\" The ICDCodes associated with this disease are \"C96.20,\" \"C96.29,\" and \"D47.09.\" The drugs being used in the trial are \"dexamethasone,\" \"sorafenib tosylate,\" and \"lenalidomide.\" The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy requirements. The criteria include details about the diagnosis of multiple myeloma, measurable disease criteria, patient performance status, blood counts, liver and kidney function, prior malignancies, pregnancy status, contraception requirements, and various other medical conditions that would exclude a patient from participating in the trial.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating two specific diseases: recurrent small cell lung cancer and unspecified adult solid tumor. The diseases are identified by their corresponding ICD-10 codes. The drugs being tested in the trial are obatoclax mesylate and topotecan hydrochloride. \n\nThe eligibility criteria for the trial include a confirmed diagnosis of either an advanced solid tumor or small cell lung cancer that has progressed after one prior platinum-based chemotherapy regimen. Patients with brain metastases are allowed to participate as long as they are neurologically stable and do not require steroids. Leptomeningeal involvement is not allowed. The trial is open to patients with an ECOG performance status of 0-1 or a Karnofsky performance status of 70-100%. \n\nOther criteria include specific ranges for leukocytes, absolute neutrophil count, and platelet count. Normal levels of total bilirubin, AST, ALT, and creatinine are required. Pregnant or nursing individuals are not eligible, and fertile patients must use effective contraception during and after the study. \n\nPatients must have completed chemotherapy and radiotherapy at least 4 weeks prior to participating in the trial. Concurrent use of combination antiretroviral therapy for HIV-positive patients is not allowed, and no other investigational agents or anticancer therapy can be used concurrently. \n\nExclusion criteria include a history of allergic reactions to similar compounds, uncontrolled illnesses such as ongoing infections, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements. Patients with a history of seizure disorder or other neurological dysfunction (except peripheral neuropathy) are also excluded.",
    "The sample is a phase 1 clinical trial for a drug called ZYGK1. The trial is focused on patients with diabetes. The eligibility criteria for participants include being between the ages of 18-45, mentally and physically capable of giving informed consent, and weighing between 50-75 kg for males and 45-75 kg for females. Participants must also be able to effectively communicate with the study personnel and be willing to adhere to the protocol requirements. For the gender effect study, only females with a history of sterility, at least one year of menopause, or the use of long-acting nonhormonal contraceptive measures will be recruited. Additionally, at least one panel in the trial will include subjects with type 2 diabetes as defined by the American Diabetes Association.\n\nThere are also exclusion criteria for potential participants. These include a history of hypersensitivity to any of the active or inactive ingredients of the ZYGK1 formulation, pancreatitis, severe gastrointestinal disease in the last 6 months, renal insufficiency, active liver disease, history or presence of other systemic disorders or diseases, abnormal bleeding or clotting times, recent medication use, significant alcoholism or drug abuse within the past year, significant smoking or tobacco consumption, difficulty with donating blood, abnormal blood pressure or pulse rate, clinically significant laboratory findings or electrocardiogram abnormalities during screening, major illness or surgery in the last 3 months, participation in any other drug research study within the past 3 months, and donation of blood in the past 3 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"leukemia, lymphocytic, acute\", \"leukemia, nonlymphocytic, acute\", \"leukemia, myeloid, chronic\", and \"myelodysplastic syndromes\". The corresponding ICDCodes for these diseases are ['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10'], ['C92.11', 'C92.12', 'C92.21', 'C92.22', 'C92.10', 'C92.20'], and ['D46.9', 'D46.C', 'D46.Z'] respectively. The drug being tested in this trial is \"vosaroxin\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion\" and \"Exclusion\" categories. Inclusion criteria include being able to understand and sign a consent document, having an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2, having received less than or equal to 3 induction/re-induction regimens for the specified diseases, and having relapsed or refractory leukemia for which no standard therapies are expected to result in a durable remission. \n\nExclusion criteria include prior exposure to SNS-595 (vosaroxin), being pregnant or breastfeeding, not using approved contraception, having active central nervous system (CNS) leukemia, acute or chronic graft-versus-host disease, active cancer (except for skin cancer), abnormal laboratory values, liver or kidney function outside specified limits, not yet recovered from previous cancer therapy side effects, recent myocardial infarction, cerebrovascular accident/transient ischemic attack (TIA) or thromboembolic event, requiring kidney dialysis, recent use of investigational agents, prior pelvic radiation therapy or radiation to a significant portion of bone marrow reserve, and any other medical, psychological, or social condition that would contraindicate participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is metastatic melanoma. The ICDCodes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drug being used in the trial is \"mpc-6827 + temozolomide\". The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria specify requirements such as histologically proven melanoma, measurable metastases, and specific performance scores. The exclusion criteria list conditions that would disqualify a participant from the trial, such as hypersensitivity to Cremophor EL, ocular melanoma, cardiovascular disease, and uncontrolled hypertension.",
    "The sample from the table represents a clinical trial for a combination therapy of the drug dasatinib in patients with chronic myeloid leukemia (CML) who have primary or acquired resistance to Imatinib mesylate or have intolerance to it. The trial is in phase 1/phase 2. The eligibility criteria include having Philadelphia chromosome positive or bcr-abl gene positive CML in the chronic phase, a performance status of 0-2 according to the Eastern Cooperative Oncology Group, and being between the ages of 20 and 75. Women of childbearing potential must use contraception throughout the study and for up to 3 months after. The exclusion criteria include subjects eligible and willing to undergo transplantation, pregnant or breastfeeding women, those with uncontrolled or significant cardiovascular disease, history of significant bleeding disorder unrelated to CML, and various other medical conditions and medications that may interfere with the study. Subjects who are compulsorily detained for legal or psychiatric reasons or for treatment of physical illnesses are also excluded from the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are hepatitis B and liver transplantation. The ICDCodes associated with these diseases are provided as well. The drug being used in the trial is a combination of adefovir dipivoxil and hepatitis B vaccination. The eligibility criteria for participants are listed, including both inclusion and exclusion criteria. Inclusion criteria include recipients who have received a liver transplantation with hepatitis B core antibody positive grafts, have undergone adefovir treatment post transplantation, and have not yet reached the 18-month post transplantation period. Exclusion criteria include recipients with hepatitis B surface antigen positivity prior to the transplant, grafts from hepatitis B surface antigen positive patients, previous intolerance to ADV therapy, pre-transplant creatinine levels above 1.6 mg/dL, patients younger than 21 years of age, and patients who are pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are adenocarcinoma and neoplasms. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 for adenocarcinoma, and C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for neoplasms.\n\nThe drug being tested in this trial is torisel. The eligibility criteria for this trial are listed, including inclusion and exclusion criteria. The inclusion criteria state that subjects must have a histological diagnosis of advanced cancer that is recurrent or refractory to standard therapy, or for whom standard therapy is not available. There are specific criteria for different parts of the trial, such as histologically confirmed diagnosis for certain diseases and the presence of measurable or evaluable disease.\n\nThe exclusion criteria mention subjects receiving enzyme-inducing anticonvulsants, pulmonary hypertension or pneumonitis, active infection or serious intercurrent illness, and other unspecified exclusions.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn the sample, the phase of the trial is described as \"phase 1/phase 2\". The diseases included in this trial are \"brain and central nervous system tumors\", \"melanoma\", and \"solid tumor\". The ICDCodes associated with these diseases are [\"C43.0\", \"C43.31\", \"D03.9\", \"C43.51\", \"C43.9\", \"D03.0\", \"C43.4\"].\n\nThe drugs used in the trial are \"ps-341 (velcade)\" and \"temozolomide\". The eligibility criteria for the trial are listed under the \"criteria\" field. The inclusion criteria for Phase I include histologically proven malignancy, no available effective therapy, adequate performance status, adequate baseline organ system function, agreement to use contraception, ability to understand and grant informed consent, and other specific requirements for patients with brain metastases or prior chemotherapy.\n\nThe exclusion criteria for Phase I include Grade 2 or greater peripheral neuropathy, previous administration of a maximum dose of CDDP, uncontrolled or serious infection, heart disease, recent myocardial infarction or pulmonary embolism, concurrent therapy for cancer, and inability to comply with protocol-specified procedures.\n\nThe inclusion criteria for Phase II include advanced and incurable melanoma, measurable disease, no other active malignancy, specific requirements for melanoma patients, ECOG 0-1 performance status, and adequate baseline organ system function. The exclusion criteria for Phase II are similar to those of Phase I, with additional criteria for patients with brain metastases and restrictions on previous administration of certain drugs.\n\nOverall, the sample provides a detailed description of the trial phases, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is leukemia, and the corresponding ICDCodes are ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']. The drugs being studied are clofarabine, cytarabine, and methotrexate. The eligibility criteria for this trial include specific disease characteristics, such as the percentage of blasts in the bone marrow, relapse or refractory status, and exclusion of certain types of leukemia. Patient characteristics, such as performance status, life expectancy, kidney and liver function, cardiac function, and absence of certain conditions, are also considered. Prior concurrent therapies and the timing of their completion are also specified.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is listed as \"phase 1/phase 2\". The disease being studied is \"lung cancer\" and its corresponding ICD-10 codes are provided as \"['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']\". The drugs being tested are \"bevacizumab\" and \"bortezomib\". The eligibility criteria for the trial are then listed, including requirements such as voluntary informed consent, specific performance status, absence of brain metastases, measurable disease, prior treatments received, certain laboratory values, and other medical conditions that may exclude a patient from participating in the trial.\n\nIt is important to note that this is just a single sample from the table, and there may be other records with different phases, diseases, drugs, and criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes are ['Z21']. The drugs being used in the trial are raltegravir poloxamer film coated tablet, raltegravir chewable tablet, and raltegravir oral granules for suspension (20 mg/ml), all of which are being tested in different forms. The eligibility criteria for participants include documentation of HIV-1 infection, being on a stable therapeutic regimen, having a certain level of HIV RNA, willingness to take the assigned raltegravir preparation, and meeting certain requirements for contraception. There are also exclusion criteria, such as having certain laboratory test results, a history of lactic acidosis, or prior treatment with another experimental HIV integrase inhibitor. Other exclusion criteria include certain medical conditions, participation in other investigational studies, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"relapsed acute lymphoblastic leukemia,\" \"allergy to peg E.coli asparaginase,\" and \"allergy to native E.coli asparaginase.\" The ICDCodes associated with these diseases are \"C83.57,\" \"C83.50,\" \"C91.01,\" \"C91.02,\" \"C83.52,\" \"C83.56,\" and \"C83.53.\" The drugs being used in the trial include \"erwinase,\" \"vincristine,\" \"dexamethasone,\" \"doxorubicin,\" \"cytarabine,\" \"methotrexate,\" \"triple intrathecal therapy,\" and \"dexrazoxane.\" The eligibility criteria for this trial include age restrictions, specific diagnosis requirements, history of allergic reactions to E.coli asparaginase, performance level criteria, recovery from prior therapies, reproductive function considerations, and exclusion criteria such as prior stroke, Down Syndrome, prior pancreatitis, renal and liver/pancreatic function, cardiac function, active infections, and restrictions on receiving other investigational agents or anti-cancer therapies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is malignant pleural mesothelioma. The ICDCodes associated with this disease are C45.9, C45.0, C45.1, C45.2, and C45.7. The drug being used in the trial is chemotherapy. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have a histologically or cytologically diagnosed malignant mesothelioma.\n- The patient must be over 18 years old.\n- The patient must be medically suitable for limited surgical intervention, such as pleural biopsies or limited pleurectomy.\n- Measurable or evaluable disease is not required.\n- The patient must be able to understand the study and give signed informed consent, including approval for a second thoracoscopic or surgical treatment after the third course.\n- The patient must not have received previous chemotherapy.\n- Radiotherapy is allowed for palliation, with certain conditions.\n- The patient's WHO performance status must be less than or equal to 2.\n- The patient must have adequate organ function, as evidenced by specific peripheral blood counts or serum chemistries.\n\nThe exclusion criteria for this trial include:\n- Active uncontrolled infection, severe cardiac dysfunction, or uncorrectable bleeding tendency.\n- Previous successful pleurodesis.\n- Uncontrolled hypertension.\n- Symptomatic peripheral neuropathy grade 2 or higher.\n- Presence of symptomatic CNS metastases.\n- Unstable peptic ulcer, unstable diabetes mellitus, or other serious disabling condition.\n- Concomitant administration of any other experimental drugs under investigation.\n- Impaired renal function.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of advanced solid tumors, specifically breast cancer, colon cancer, ovarian cancer, and endometrium cancer. The trial is investigating the drug \"bkm120\". The eligibility criteria for the trial include having histologically-confirmed advanced solid tumors, progressive and recurrent unresectable disease, a World Health Organization (WHO) performance status of 2 or lower, and no history of primary brain tumor or brain metastases. \n\nThere are additional criteria for the MTD Expansion part of the trial, which include having a genetic or molecular alteration of the PI3K pathway and no brain metastases unless asymptomatic and clinically stable for at least 3 months. \n\nThe exclusion criteria for the trial include prior treatment with a PI3K inhibitor, a history of major depressive episode, bipolar disorder, schizophrenia, or suicidal attempt or ideation, clinically manifest diabetes mellitus, acute or chronic renal disease, acute or chronic liver disease, acute or chronic pancreatitis, unresolved diarrhea, impaired cardiac function or significant cardiac diseases, acute myocardial infarction or unstable angina pectoris within the past 3 months, and being pregnant or nursing (fertile patients must use barrier contraceptives). \n\nIt is important to note that there may be other protocol-defined inclusion/exclusion criteria that apply to this trial.",
    "The sample is a phase 1 clinical trial for the treatment of cutaneous lupus and lupus. The trial is investigating the effectiveness of the drugs amg 557 and amg 557 placebo. The eligibility criteria for participants include being between the ages of 18 and 70, having a body mass index between 18 and 35, and being diagnosed with subacute cutaneous lupus erythematosus (SCLE) with or without systemic lupus erythematosus (SLE). Other criteria include having a history of skin biopsy consistent with SCLE, positive SS-A and/or SS-B antibodies, and intolerance or residual disease activity after anti-malarial therapy. Stable disease activity and medication doses are also required. Exclusion criteria include drug-induced SCLE, presence of other disorders or diseases that may interfere with the study, history of vasculitis or active CNS lupus, history of malignancy, recent infections, and use of certain medications.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"lymphoma, large-cell, anaplastic\", \"lymphoma, nk-cell\", and \"lymphoma, t-cell\". The corresponding ICDCodes for these diseases are \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", and \"S33.140S\". The drugs being used in the trial are \"brentuximab vedotin\", \"cyclophosphamide\", \"prednisone\", \"doxorubicin\", and \"vincristine\". The eligibility criteria for the trial include specific inclusion and exclusion criteria related to the disease, disease history, cardiac health, infections, and viral status.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are bortezomib, carboplatin, and docetaxel.\n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC.\n- The patient must be over 18 years of age.\n- The patient's ECOG PS (Eastern Cooperative Oncology Group Performance Status) must be less than 2.\n- The patient must not have received prior chemotherapy.\n- The patient must have measurable disease.\n- The patient must have signed informed consent.\n- The patient must have adequate bone marrow, renal, and hepatic function.\n\nExclusion Criteria:\n- The patient must not have untreated clinically active brain metastasis.\n- The patient must not have undergone radiotherapy within 2 weeks prior to starting the trial.\n- The patient must not have received any investigational therapy within 4 weeks prior to enrollment.\n- The patient must not have had any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years.\n- Patients of reproductive age must use effective birth control methods, and women of childbearing potential must have a negative pregnancy test.\n- The patient must not have undergone major surgery within 3 weeks prior to enrollment.\n- The patient must not be using immunosuppressive agents, including systemic corticosteroids, within 4 weeks prior to enrollment (except for physiological replacement therapy or supportive care for nausea and emesis).\n- The patient must not have a known history of Human immunodeficiency virus infection.\n- The patient must not have any co-morbidity or condition that would limit their ability to comply with the protocol, as assessed by the investigator.\n- The patient must not have any concurrent serious medical infection or illness, or psychiatric illness that would interfere with participation in the study.\n- The patient must not have a known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80, bortezomib, boron, or mannitol.\n- The patient must not have Grade 2 peripheral neuropathy within 14 days before enrollment.\n- The patient must not have had a myocardial infarction within 6 months prior to enrollment or have New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Any ECG abnormality at screening must be documented by the investigator as not medically relevant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Tourette's Syndrome, which is represented by the disease name and its corresponding ICD-10 code (F95.2). The drug being tested is called ecopipam. \n\nThe eligibility criteria for this sample include:\n- Subjects must have Tourette's Syndrome based on the clinician-administered DCI for TS.\n- Subjects must exhibit both motor and vocal tics.\n- Subjects must have exhibited tics for more than 5 years.\n- Subjects must have a minimum score of 20 on the Yale Global Tic Severity Score at both Screening and Baseline.\n- Subjects must be at least 18 years old.\n- Women must meet certain criteria related to contraception if they are of childbearing potential.\n- Sexually active male subjects must use a barrier method of contraception during the study.\n- Subjects must provide written informed consent.\n\nThe exclusion criteria for this sample include:\n- Subjects with unstable medical illness or clinically significant abnormalities on laboratory tests or ECG at Screening.\n- Subjects with a major depressive episode in the past 2 years.\n- Subjects with a history of attempted suicide or clinically significant suicidality.\n- Subjects with a first-degree relative with a major depressive episode resulting in psychiatric hospitalization, attempted or completed suicide.\n- Subjects with a history of seizures or myocardial infarction within 6 months.\n- Women of childbearing potential who are currently pregnant or lactating.\n- Subjects who require medication (other than ecopipam) that may affect TS symptoms or have unfavorable interactions with ecopipam.\n- Subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder.\n- Subjects with current or recent substance abuse or dependence (excluding nicotine).\n- Subjects with a positive urine drug screen for certain substances.\n- Subjects who have previously been treated with ecopipam or certain other medications.\n- Subjects who have had recent treatment with specific medications prior to screening.\n\nThis description provides an overview of the sample's characteristics and the eligibility and exclusion criteria for the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of cancer. The specific type of cancer being studied is advanced non-small cell lung cancer that is unresectable Stage IIIb or IV. The trial is for patients who have already undergone at least one chemotherapy regimen and have shown progression of the disease. The trial does not require measurable disease for enrollment.\n\nThe sample also includes a list of ICD-10 codes associated with the disease, which are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being studied in the trial are docetaxel and npi-2358 + docetaxel.\n\nThe sample provides the inclusion and exclusion criteria for the trial. Inclusion criteria include being male or female aged 18 or older, having an ECOG performance status of 1 or lower, and having confirmed advanced non-small cell lung cancer. The sample also lists exclusion criteria such as recent administration of certain treatments, significant cardiac history, prior treatment with tumor vascular disruptive agents, seizure disorder, brain metastases, active infections, and certain medical conditions.\n\nThe sample concludes by stating that pregnant or breastfeeding women, patients with concurrent active second malignancy (excluding certain types of cancer), and those unwilling or unable to comply with the procedures required in the trial are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is an unspecified adult solid tumor that is protocol-specific. The ICDCodes associated with this disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs being used in this trial are cisplatin and everolimus. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The disease characteristics include histologically confirmed diagnosis, advanced solid tumor or recurrent/metastatic disease, and measurable disease. The patient characteristics include Karnofsky performance status, blood counts, liver function, kidney function, pregnancy status, HIV status, and gastrointestinal function. The prior concurrent therapy restrictions include limitations on prior chemotherapy regimens, surgery, radiation therapy, systemic anticancer therapy, investigational drugs, everolimus or other mTOR-targeting agents, radiation therapy to bone marrow, radiation therapy to the whole pelvis and/or brain, chronic steroid treatment, immunosuppressive agents, and concurrent anticancer agents known to affect the CYP3A enzyme.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is non-small-cell lung carcinoma. The corresponding ICD-10 codes for this disease are D02.20, D02.21, and D02.22. The drugs being tested in this trial are azd2171, paclitaxel, and carboplatin. \n\nThe eligibility criteria for this trial include having histologically or cytologically confirmed non-small-cell lung carcinoma, being previously untreated with advanced/metastatic or recurrent NSCLC, and having a WHO performance status of 0-1. \n\nThe exclusion criteria for this trial include having untreated unstable brain or meningeal metastases, having inappropriate laboratory test values, and having poorly controlled hypertension.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, such as phase I, phase II, or phase III. The \"diseases\" column lists the names of various diseases. The \"icdcodes\" column contains the corresponding ICD-10 codes for the diseases. The \"drugs\" column lists the names of drugs used in the trial. The \"criteria\" column provides the eligibility criteria for the trial.\n\nIn the given sample, the phase is \"phase 1\". The diseases listed include various types of leukemia, lymphoma, and solid tumors. The corresponding ICDCodes are also provided. The drugs used in the trial are \"vorinostat\" and \"decitabine\". The eligibility criteria include specific diagnoses for each disease, performance status, life expectancy, normal blood counts, kidney function, liver function, absence of certain medical conditions, and previous treatments. There are also restrictions on concurrent medications and therapies.\n\nOverall, the sample provides detailed information about the trial phase, diseases, ICDCodes, drugs, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on rectal cancer and colon cancer. The associated ICD-10 codes for these diseases are provided. The trial involves the use of three drugs: folfox-4, amg 706, and folfiri. The eligibility criteria for participants are listed, including requirements such as being able to understand and sign an informed consent form, having a diagnosis of metastatic colorectal adenocarcinoma, and having certain levels of hematological, renal, and hepatic function. The sample also includes exclusion criteria, such as having received more than one prior chemotherapy regimen, having central nervous system metastases, and having a history of certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is xl765 (sar245409). \n\nThe eligibility criteria for this trial include having a histologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective. The subject's disease must be assessable by tumor marker, physical, or radiologic means. The subject must be at least 18 years old, weigh at least 40 kg, and have an Eastern Cooperative Oncology Group performance status of 0-2. Adequate organ and bone marrow function are also required. Additionally, the subject must have fasting plasma glucose < 120 mg/dL at screening.\n\nFor subjects who are to be enrolled in the Expanded MTD Cohort and Lower-Dose Tumor Genetic Alteration Subjects, they must have tumor tissue amenable to serial biopsy and provide additional informed consent. The subject must be capable of understanding the protocol and have signed the informed consent. Sexually active subjects must use medically acceptable methods of contraception during the study, and female subjects of childbearing potential must have a negative serum pregnancy test at screening.\n\nThere are also exclusion criteria, such as having received anticancer treatment within 30 days before the first dose of XL765, having uncontrolled intercurrent illness, or being pregnant or breastfeeding. Other exclusion criteria include having a known allergy or hypersensitivity to components of the XL765 formulation or a baseline corrected QT interval > 450 ms.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on lung cancer.\n- ICD Codes: The ICD-10 codes associated with the lung cancer are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2'].\n- Drugs: The drugs being tested in the trial are everolimus and gefitinib.\n- Criteria: The eligibility criteria for the trial are listed in a structured format, including disease characteristics, patient characteristics, prior concurrent therapy, and other requirements.\n\nThe eligibility criteria include specific disease characteristics such as histologically confirmed non-small cell lung cancer, specific stage criteria, and measurable or evaluable indicator lesions. It also includes patient characteristics such as age, performance status, and hematopoietic, hepatic, renal, and cardiovascular requirements. The criteria also mention prior concurrent therapy, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other factors. Finally, there are additional requirements such as recovery from prior therapy, no prior use of certain drugs, and no concurrent use of certain therapies.\n\nOverall, this sample record provides information about a clinical trial for lung cancer, including the phase, diseases, drugs, and eligibility criteria.",
    "The sample from the table represents a phase 1 clinical trial. The diseases being studied are tumors and lymphoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is called cnf2024. \n\nThe eligibility criteria for this trial include having a confirmed solid tumor that has failed standard therapies or for which effective therapy is not available. Participants must be at least 18 years old and meet certain hematological, hepatic, renal, coagulation, and adrenal function requirements. They must also have a normal electrocardiogram and an estimated life expectancy of at least 3 months. The Eastern Cooperative Oncology Group (ECOG) performance status must be 2 or lower.\n\nPatients of childbearing potential must use effective double-barrier contraception during the study and for 3 months after their last dose of the study drug. Pregnant or nursing women, as well as women of child-bearing age not using reliable contraception, are excluded from the trial. \n\nExclusion criteria also include recent radiotherapy or chemotherapy, participation in another investigational drug study within the past 28 days, active infection requiring intravenous antibiotic treatment, second malignancy requiring active treatment (except hormonal therapy), and concurrent severe or uncontrolled medical diseases. Patients with active symptomatic fungal, bacterial, or viral infections, including HIV or viral hepatitis, are also excluded. Other exclusion criteria involve specific gastrointestinal conditions, major surgery of the stomach or small intestine, and certain levels of adrenal dysfunction or diabetes.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on gastric cancer. The ICD-10 codes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being studied in the trial are capecitabine, cisplatin, and imatinib mesylate. The eligibility criteria for patients participating in the trial are listed, including disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"atherosclerotic vascular disease,\" and its corresponding ICDCodes are ['I25.10', 'I25.110', 'I25.119', 'I25.111', 'I25.118']. The drugs being tested are \"atorvastatin\" and \"placebo.\" The eligibility criteria for this sample include age requirements (30 to 80 years old) and the participant must either be on a low dose statin for at least 6 weeks prior to screening or be statin-naive at screening. The exclusion criteria include having HIV, Hepatitis B or C, using illegal drugs, having Type I diabetes, or having a history of claustrophobia.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is hypercholesterolemia. The icd-10 codes associated with this disease are 'E78.01', 'E78.00', and 'Z83.42'. The drugs being used in the trial are 'spc5001' and 'saline 0.9%'. \n\nThe eligibility criteria for this trial include being a healthy male or female subject, or a subject with heterozygous Familial Hypercholesterolemia. The age range for enrollment is 18 to 65 years for Cohorts 1 through 4, and 18 to 45 years for Cohort 5. The subjects must also have a BMI (Body Mass Index) between 18 and 33 kg/m2. \n\nScreening tests for overall good health include specific ranges for LDL (Low-Density Lipoprotein) and triglycerides levels. ALT (Alanine Aminotransferase) levels must be within normal limits for healthy subjects and below 2 times the Upper Limit of Normal (ULN) for FH (Familial Hypercholesterolemia) subjects.\n\nExclusion criteria for the trial include having any uncontrolled or active major systemic disease, active acute or chronic infection, recent use of prescription or non-prescription medications, and positive results on certain screening laboratory tests.\n\nOverall, this sample provides information about the phase, disease, icd-10 codes, drugs, and eligibility criteria for a clinical trial focused on hypercholesterolemia.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is diabetes mellitus, type 2. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are gk activator (2) and ethanol. The eligibility criteria for this trial include being an adult patient between the ages of 18 and 75, having type 2 diabetes, and having normal hepatic function or mild to moderate hepatic impairment. The exclusion criteria include having type 1 diabetes or latent autoimmune diabetes in adults, having diabetic neuropathy, retinopathy, or nephropathy, receiving treatment with insulin or PPAR gamma agonist within 6 weeks of screening, and having clinically significant cardiovascular disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is lymphoma, specifically various subtypes of B-cell non-Hodgkin's lymphoma. The ICDCodes associated with these diseases are listed as \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drug being tested is pegylated liposomal doxorubicin hydrochloride. \n\nThe eligibility criteria for this trial include a diagnosis of one of the specified indolent or aggressive B-cell non-Hodgkin's lymphoma subtypes, relapsed or refractory CD20-positive disease, measurable disease, and having received between 1 and 4 prior standard chemotherapy regimens. There are also specific exclusions, such as no Burkitt's lymphoma or precursor B-lymphoblastic lymphoma, no CNS lymphoma, and no other serious diseases that would prevent participation in the study.\n\nThe patient characteristics required for participation include a performance status of Karnofsky 60-100%, a life expectancy of at least 6 months, specific hematopoietic, hepatic, renal, and cardiovascular parameters within normal ranges, and no history of certain cardiac conditions. Other requirements include not being pregnant or nursing, negative pregnancy test, use of effective contraception for fertile patients, no known HIV positivity, no uncontrolled active infections, and no other primary malignancy within the past 5 years except for certain specified types.\n\nThe prior concurrent therapy section outlines requirements for prior biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other antitumor or investigational agents. Recovery from prior treatments is necessary, and there are specific restrictions and allowances for each type of therapy.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for a clinical trial related to lymphoma treatment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on studying the effectiveness of certain drugs in treating various diseases. The diseases included in this sample are ovarian cancer, peritoneal cancer, fallopian tube cancer, and bowel obstruction. The corresponding ICD-10 codes for these diseases are also provided. The drugs being studied are cisplatin and paclitaxel. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having a hospital admission and diagnosis of Malignant Bowel Obstruction, having a diagnosis of primary ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, experiencing at least two of the specified symptoms, and having CT findings suggestive of complete bowel obstruction. Other criteria include being a non-surgical candidate, being 18 years of age or older, having a certain performance status, and meeting certain hematological, renal, and hepatic function requirements.\n\nExclusion criteria include having Malignant Bowel Obstruction caused by a malignancy other than primary ovarian cancer, being a surgical candidate, being pregnant or breastfeeding, having a concomitant diagnosis of GI malignancy within the past 5 years, having a history of severe hypersensitivity reaction to the drugs being studied, having received chemotherapy within 2 weeks prior to enrollment, having uncontrolled Inflammatory Bowel Disease or concurrent active infections with Clostridium Difficile, and having certain medical conditions such as recent myocardial infarction, congestive heart failure, unstable angina, and others.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for participants in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase I, phase II, or phase III. The specific disease being studied is HIV infections. The ICD-10 code for this disease is \"Z21\". The drugs being used in the trial are tipranavir capsules and ritonavir capsules. The eligibility criteria for participants in the trial are listed, including requirements such as signed informed consent, age between 18 and 60, use of a barrier contraceptive method for female patients, ability to swallow capsules, a specific body mass index range, and a negative urine drug screen. Additional criteria include having a documented HIV-1 RNA load of less than 50 copies/mL for at least 3 months, being treatment-na\u00efve for tipranavir, and not having received a protease inhibitor-based regimen within 6 months. The exclusion criteria are also listed, which include being pregnant or planning to breast-feed, recent use of other investigational medicines or CYP3A4 altering drugs, recent ingestion of grapefruit or related products, recent blood or plasma donations, abnormal blood pressure or heart rate, history of certain illnesses or allergies, recent acute illness, current use of certain medications, hypersensitivity to certain drugs, abnormal laboratory values, non-compliance with background antiretroviral medications, recent use of other protease inhibitors, co-infection with active Hepatitis B and/or C, and use of certain anti-platelet medications.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on treating advanced cancer. The ICD-10 codes associated with the disease are 'K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', and 'H35.3123'. The drugs being studied in this trial are 'ly2228820', 'midazolam', and 'tamoxifen'. The record also includes the eligibility criteria for participants, including having a diagnosis of advanced or metastatic cancer, having measurable or nonmeasurable disease, and having adequate organ function. There are also exclusion criteria, such as not having received treatment with an unapproved drug within 14 days prior to the trial and not having certain medical conditions.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 1. The disease being studied is advanced cancer. The ICD-10 codes associated with the disease are K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, and H35.3123. The drugs being used in the trial are ly2090314, pemetrexed, and carboplatin. The eligibility criteria for participants in the trial are listed, including requirements for performance status, life expectancy, contraceptive use, cancer diagnosis, disease measurement, and adequate organ function. There are also exclusion criteria, such as recent treatment with unapproved drugs, preexisting medical conditions, certain cardiac conditions, and electrolyte disorders. The sample also mentions that pregnant or lactating females are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is ARQ 197. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Patients who did not respond or are refractory to available therapy or for whom no standard effective systemic therapy exists.\n- Karnofsky performance status (KPS) \u2265 70%, or Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n- Patients with adequate organ function.\n\nExclusion Criteria:\n- Anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of ARQ 197.\n- Known symptomatic brain metastases.\n- Pregnant or breastfeeding.\n- Uncontrolled intercurrent illness.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on two diseases, namely \"healthy\" and \"opioid-induced constipation\".\n- ICD Codes: The ICD-10 codes associated with the diseases are \"Z76.3\" and \"Z76.2\" for \"healthy\", and a list of codes including \"F11.14\", \"F11.181\", \"F11.182\", \"F11.188\", \"F11.19\", \"F11.24\", and \"F11.281\" for \"opioid-induced constipation\".\n- Drugs: The trial involves the drug \"td-1211\" and a placebo. The drug \"td-1211\" is mentioned multiple times.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age range, being healthy or having documented opioid-induced constipation, and willingness to stop all laxatives. Exclusion criteria include any clinically significant findings in healthy subjects, recent participation in another clinical trial, history of chronic constipation, and active medical disorders associated with diarrhea or intermittent loose stools in opioid-induced constipation subjects.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the diseases listed are \"glioma,\" \"brain neoplasms,\" and \"brain metastasis.\" The ICDCodes associated with these diseases are \"C71.7,\" \"C71.9,\" \"C79.31,\" \"D33.0,\" \"D33.1,\" \"D33.2,\" and \"D49.6.\" The drugs mentioned are \"vardenafil\" and \"carboplatin.\" The eligibility criteria for this trial include requirements such as patients having recurrent malignant glioma or metastatic brain cancer, a Karnofsky performance status of at least 60%, and normal hematologic, renal, and liver function. There are also exclusion criteria listed, such as patients with serious concurrent infections or medical illnesses, pregnant or breastfeeding patients, and patients receiving concurrent therapy for their tumor.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of metastatic colorectal cancer. The trial involves the use of drugs called cs-1008 and folfiri. The eligibility criteria for participants include having confirmed metastatic colorectal cancer that has progressed after first-line standard therapy, being at least 18 years old, having a performance status of 2 or lower, and meeting certain organ and bone marrow function requirements. Participants must also be willing to use effective contraception during the treatment and for 3 months after it ends. Female participants of childbearing potential must have a negative pregnancy test before starting the treatment. The sample also includes exclusion criteria, such as a history of certain medical conditions, recent treatments, active infections, and hypersensitivity reactions to certain components of the treatment. Additionally, it mentions that participants must not have certain genetic variations and deficiencies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include chronic lymphocytic leukemia, prolymphocytic leukemia, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, and various stages of chronic lymphocytic leukemia and small lymphocytic lymphoma. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are alvocidib hydrochloride and cyclophosphamide. The eligibility criteria for participants in this trial include specific requirements related to the type and stage of the disease, genetic markers, age, symptoms, and various health factors. There are also restrictions on concurrent medications and medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for the treatment of chronic hepatitis C. The trial focuses on patients with genotype 1 hepatitis C who have not responded to previous therapy with peginterferon alfa and ribavirin. The trial is specifically for adult Caucasian patients between the ages of 18 and 70.\n\nThe record includes the following details:\n- Phase: Phase 1\n- Diseases: The disease being studied is chronic hepatitis C.\n- ICD Codes: The ICD-10 codes associated with the disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4.\n- Drugs: The drugs being tested in the trial are peginterferon alfa 2a (brand name Pegasys).\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a non-responder to previous therapy, having compensated liver disease, and having a positive HCV test. Exclusion criteria include being treatment-na\u00efve, having a different genotype of HCV, having other infections, having liver disease of non-HCV origin, and various other factors.\n\nOverall, this record provides specific details about the phase 1 trial for chronic hepatitis C, including the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular sample belonging to phase 1. The trial focuses on the treatment of insomnia. The diseases column lists the specific disease being targeted, which in this case is insomnia. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being used in the trial, which are \"neu-p11\" and \"neu-p11 placebo\". The criteria column provides the eligibility criteria for participants in the trial, including specific conditions and requirements that must be met. The inclusion criteria include factors such as having primary insomnia, specific sleep patterns, age range, negative pregnancy test for women, good health, and not using certain medications. The exclusion criteria include factors such as having other sleep disorders, certain medical conditions, drug addiction, and not meeting specific health requirements.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular sample being from phase 1. The trial focuses on a specific disease, in this case, \"healthy.\" The disease is associated with ICD-10 codes, which are used for classification purposes. The trial also involves the administration of various drugs, including \"mylan fentanyl transdermal system 25 mcg/h + clinical procedure 1,\" \"mylan fentanyl transdermal system 25 mcg/h + clinical procedure 2,\" and \"duragesic 25 mcg/h + clinical procedure 3,\" among others.\n\nThe eligibility criteria for participants in this trial are outlined in the \"criteria\" section. Inclusion criteria include being 18 years or older, being male or a non-pregnant, non-lactating female, and meeting certain requirements for women of childbearing potential. These requirements include negative pregnancy tests, practicing abstinence or using acceptable forms of contraception, and not using hormonal contraceptives or hormone replacement therapy. Other inclusion criteria include meeting weight and BMI requirements and passing a pre-study medical evaluation.\n\nExclusion criteria for participants in this trial include being institutionalized, using tobacco products within the past year, consuming alcohol, caffeine, or xanthine-containing substances within 48 hours prior to the initial dose of study medication, and using certain medications or hormonal contraceptives within specific timeframes. Exclusion criteria also include having a history of significant diseases, acute illness, positive HIV, hepatitis B, or hepatitis C tests, abnormal laboratory test results, damaged skin at test sites, recent blood or plasma donation, recent use of investigational drugs, allergies or hypersensitivity to certain substances, and consumption of grapefruit or grapefruit-containing products within 7 days of drug administration.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are melanoma, recurrent melanoma, stage III melanoma, and stage IV melanoma. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are sorafenib tosylate and temsirolimus. The eligibility criteria for participants in this trial include having histologically or cytologically confirmed melanoma, meeting specific criteria related to the stage and origin of the tumor, having a certain performance status, normal levels of bilirubin and creatinine, not being pregnant or nursing, and meeting various other health-related requirements. The sample also includes additional criteria related to prior treatments, concurrent medications, and specific measurements for disease size and blood counts.",
    "The sample provided is for a Phase 1 clinical trial. The disease being studied is epilepsy, and the associated ICD-10 codes are G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, and G40.801. The drugs being tested in this trial are brivaracetam, levetiracetam, and lorazepam. \n\nThe eligibility criteria for this trial include being a healthy male or female volunteer between the ages of 18 and 50, having a body mass index (BMI) between 18.0 and 30.0 kg/m\u00b2, and being in good physical and mental health. Additionally, blood pressure and heart rate should be within the normal range, and electrocardiogram and laboratory tests should not show any clinically significant abnormalities.\n\nThe exclusion criteria for this trial include having an IQ of 80 or lower as determined by a test of non-verbal intelligence, having a Center for Epidemiological Studies Depression (CES-D) Scale score of 16 or higher, having a known allergy or intolerance to pyrrolidinone derivatives, having abnormalities on EEG recordings, being pregnant or lactating, having a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, or psychiatric disorders, and using any hepatic enzyme-inducing drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is leukemia, the ICDCodes are ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01'], the drug is dasatinib, and the eligibility criteria are listed in detail. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include \"Alzheimer's disease\", \"safety\", \"tolerability\", \"blood concentration\", and \"healthy volunteers\". The corresponding ICDCodes for these diseases are \"G30.8\", \"G30.9\", \"G30.0\", \"G30.1\", \"Z71.85\", \"Y38.4X1S\", \"Y38.9X1S\", \"Y38.4X1A\", \"Y38.4X1D\", \"Y38.5X1S\", and \"Y38.6X1S\".\n\nThe drugs being tested in this trial are \"azd3839\" and \"azd3839 placebo\". The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe \"Inclusion Criteria\" include being a healthy male or female volunteer aged 18 to 55 years, having suitable veins for cannulation or repeated venipuncture, having a body mass index (BMI) between 19 and 30 kg/m2, weighing between 50 kg and 100 kg, having a normal range of creatinine clearance, and having a serum potassium concentration of \u22653.8 mmol/L.\n\nThe \"Exclusion Criteria\" include having a history of clinically significant disease or disorder that may put the volunteer at risk or influence the results, having a history of psychotic disorder among first-degree relatives, experiencing significant orthostatic reaction at enrollment, having a prolonged or shortened QTcF interval or a family history of long QT syndrome or sudden death, and being a vegetarian or lactose intolerant (applicable only for healthy volunteers participating in Part 2).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drug being tested is \"abt-751\". The eligibility criteria for this trial include various requirements such as age, histologically proven adenocarcinoma of the prostate gland, evidence of metastatic disease, prior hormonal therapy, prior treatment with docetaxel, and specific hematologic, renal, and hepatic function levels. There are also exclusion criteria, such as no active angina pectoris, no brain metastases, no recent investigational therapy, and no serious concurrent medical illness or active infection.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"advanced solid tumors.\" The icd-10 codes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug mentioned is \"hydroxyurea.\" The eligibility criteria for this trial include having advanced or metastatic malignant solid tumors or lymphoma that has progressed on standard therapy, a Karnofsky Performance status of > 70, a predicted life expectancy of at least 3 months, measurable or evaluable disease, being at least 18 years old, providing written informed consent, and adhering to study visit schedules. Additional criteria include using a medically accepted method of contraception, having adequate renal and bone marrow function, and having adequate hepatic function. The sample also includes exclusion criteria such as hypersensitivity to hydroxyurea or SCH900776, recent use of certain medications, history of HIV infection or liver cirrhosis, certain heart conditions, recent major surgery, central nervous system or leptomeningeal metastases, and other medical or psychiatric conditions that may interfere with participation in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is related to the treatment of primary open-angle glaucoma and ocular hypertension. The ICD-10 codes associated with these diseases are ['H40.053', 'H40.051', 'H40.052', 'H40.059']. The drugs being tested in the trial are 'opa-6566', 'placebo', and 'latanoprost'. The eligibility criteria for participants include a diagnosis of bilateral primary open-angle glaucoma and ocular hypertension, while exclusion criteria include any form of glaucoma other than primary open-angle glaucoma and other ocular conditions as defined in the protocol.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is myocardial infarction. The ICD-10 codes associated with the disease are I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, and I23.8. The drugs being tested are lovaza\u00ae and a placebo containing 1 gram of corn oil in each capsule. \n\nThe eligibility criteria for participants in the trial are as follows:\n- The participant must have documented acute myocardial infarction, confirmed by typical symptoms, abnormal levels of cardiac biomarkers, and ECG findings.\n- The participant must have undergone urgent or emergent percutaneous coronary intervention (PCI).\n- The participant must have achieved a Thrombolysis In Myocardial Infarction (TIMI) flow grade of 3 post PCI.\n- The participant must have the capacity for informed consent and not have significant dementia or sedation from medication.\n- The participant must have ingested 325 mg of chewed aspirin as part of the acute coronary syndrome treatment protocol.\n\nThe exclusion criteria for participants in the trial are as follows:\n- The participant must not have provided informed consent.\n- The participant must not have been using daily aspirin prior to the index hospitalization.\n- The participant must not have a known prior myocardial infarction or be pregnant.\n- The participant must not have an allergy to fish, fish oil, or aspirin.\n- The participant must not have any active internal or non-superficial bleeding, bleeding disorder, coagulation defect, or thrombocytopenia.\n- The participant must not have undergone thrombolysis in the past 12 hours or received treatment with a IIbIIIa inhibitor during the index hospitalization.\n- The participant must not be in cardiogenic shock or have symptomatic hypotension or low sitting systolic blood pressure (SBP).\n- The participant must not have severe uncontrolled hypertension or hypertensive retinopathy.\n- The participant must not have a history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal or genitourinary bleeding in the past 6 weeks.\n- The participant must not have had a cerebrovascular attack within two years or a cerebrovascular attack with a significant residual neurological deficit.\n- The participant must not have a known arteriovenous malformation or aneurysm.\n- The participant must not have severe liver insufficiency or renal insufficiency requiring dialysis.\n- The participant must not have a known diagnosis of vasculitis or be participating in another clinical study.\n- The participant must not have a history of malignancy, except for disease-free individuals for more than 10 years or those with only basal or squamous cell skin carcinoma.\n- The participant must not be using oral contraceptives or daily NSAIDs.\n- The participant must not have a history of drug or alcohol abuse or consume more than 14 units of alcohol per week.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on the disease \"type 1 diabetes\". The associated ICD-10 codes for this disease are \"E10.65\", \"E10.9\", \"E10.21\", \"E10.36\", \"E10.41\", \"E10.42\", and \"E10.44\". The drugs being studied in this trial are \"insulin lispro\". \n\nThe record also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be between the ages of 18 and 70, have a body mass index (BMI) between 18 and 35 kg/m2, and have been diagnosed with type 1 diabetes for at least 1 year. \n\nThe exclusion criteria state that participants with type 2 diabetes mellitus, a serum C-peptide level greater than 1.0 ng/mL, or an HbA1c level greater than 10.0% are not eligible. Additionally, individuals with a history of hypersensitivity to any components of the study medication, recent use of other investigational drugs, current drug or alcohol abuse, or a history of drug or alcohol abuse that may impact subject safety or compliance are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"prostatic neoplasms\" and its corresponding ICDCodes are ['B38.81', 'N42.31', 'Z87.430', 'N40.0', 'N40.1']. The drug mentioned is \"tak-700\". The eligibility criteria for this trial include various conditions such as being male and at least 18 years old, having confirmed prostate adenocarcinoma with metastatic, progressive disease, having undergone orchiectomy or receiving luteinizing hormone-releasing hormone analogue therapy, and meeting specific laboratory values and physical examination results. There are also exclusion criteria listed, such as known hypersensitivity to TAK-700 or related compounds, prior therapy with aminoglutethimide or ketoconazole, prior chemotherapy for prostate cancer, and various other medical conditions or psychiatric illnesses that may affect life expectancy or make it difficult to follow the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are linifanib, carboplatin, and paclitaxel. \n\nThe eligibility criteria for this trial are as follows:\n- The subject must be 20 years of age or older.\n- The subject must have cytologically or histologically confirmed non-squamous NSCLC, with a preference for predominantly non-squamous histology.\n- The subject must have advanced or metastatic (Stage IV) disease that cannot be treated with surgery or radiation for cure.\n- The subject must not have received prior chemotherapy for NSCLC.\n- The subject must have measurable disease according to RECIST Version 1.1.\n- The subject must have an ECOG Performance Score of 0-1.\n- The subject must have adequate bone marrow, renal, and hepatic function.\n\nThe exclusion criteria for this trial are as follows:\n- The subject has hypersensitivity to paclitaxel or drugs formulated with polyethoxylated castor oil (Cremophor).\n- The subject has received any anti-cancer therapy for NSCLC, including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal or \"targeted\" agents, biologic therapy, or cytotoxic chemotherapy.\n- The subject has a history of another active cancer within the past 5 years, except for specific types.\n- The subject has active ulcerative colitis, Crohn's disease, celiac disease, or any other conditions that interfere with absorption.\n- The subject has a medical condition that places them at high risk for toxicities, according to the study investigator's opinion.\n- The subject is pregnant or breastfeeding.\n- The subject has NSCLC with a predominant squamous cell histology.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied in this trial are osteosarcoma, leukemia, and lymphoma. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are glucarpidase, high-dose methotrexate, and leucovorin, as well as high-dose methotrexate and leucovorin. The eligibility criteria for this trial include specific requirements for patients receiving high-dose methotrexate, such as the presence or absence of certain risks or conditions. There are also exclusion criteria for different arms of the trial, such as allergic reactions to lactose or delayed elimination of methotrexate.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"sepsis\". The ICD-10 codes associated with this disease are ['A02.1', 'A22.7', 'A26.7', 'A32.7', 'A42.7', 'A54.86', 'B37.7']. The trial involves two drugs, \"srt2379\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being healthy, male between 18 and 35 years old, capable of giving informed consent, having normal chemistry panel results, and agreeing to use double-barrier birth control or abstinence during the study. Exclusion criteria include having a major illness or chronic medical illness, history of malignancy (except basal cell cancer), gastrointestinal disease, positive tests for hepatitis C, hepatitis B, or HIV, liver disease or abnormalities, history of drug abuse, history of alcoholism or excessive alcohol consumption, recent participation in another clinical trial, use of certain medications or substances, difficulty in donating blood, tobacco use, abnormal 12-lead ECG results, and any other issues that could be harmful to the participant or compromise data interpretation. The sample also mentions that prior participation in a trial involving IV LPS is a criterion for exclusion.",
    "The sample from the table is a clinical trial for patients with non-small cell lung cancer. The trial is in phase 1/phase 2. The diseases column specifies the disease being studied, which is non-small cell lung cancer. The icdcodes column contains the ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, including \"docetaxel, cisplatin and sti571\", \"docetaxel\", and \"cisplatin\". The criteria column provides the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria specify the requirements for patients to be eligible for the trial, such as having histologically or cytologically recurrent or advanced NSCLC, expressing phosophorylated pdgf-rB by IHC, having measurable target lesions, and meeting certain laboratory parameters. The exclusion criteria specify the conditions or situations that would disqualify a patient from participating in the trial, such as prior treatment with certain drugs, concomitant malignancy (except non-melanoma skin cancer or in-situ carcinoma of the cervix), history of allergic reactions to specific compounds, certain medical conditions or illnesses, psychiatric illness or social situations that would limit compliance, hearing impairment, known HIV infection, and receiving other investigational agents.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"aplastic anemia,\" \"menorrhagia,\" and \"amenorrhea.\" The corresponding ICDCodes for these diseases are \"D61.3,\" \"D61.9,\" \"D61.09,\" \"D61.1,\" \"D61.2,\" and \"D61.89\" for aplastic anemia, and \"N91.0,\" \"N91.1,\" and \"N91.2\" for menorrhagia and amenorrhea.\n\nThe drugs being used in the trial are \"lo-ovral oral contraceptive pills\" and \"placebo - sugar pill.\" The eligibility criteria for participants in the trial are listed, including inclusion and exclusion criteria. \n\nThe inclusion criteria state that women aged 12-55 years who have a uterus and at least one functioning ovary are eligible. They should also have any active uterine bleeding more than spotting and be diagnosed with bone marrow failure or other diseases requiring treatment with chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters at study entry. Additionally, they should not desire pregnancy for the duration of the study, be willing and able to give informed consent, and comply with study requirements.\n\nThe exclusion criteria include age less than 12 years, postmenopausal women, hormone levels in the menopausal range, history of liver disease that precludes OCP use, history of thrombosis, thromboembolism, and/or thrombophilia, currently taking 2 or more tablets of any oral contraceptive pills per day at study entry, having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or a depo medroxyprogesterone acetate injection in the past 90 days, leuprolide acetate injection in the past 30 days, being a smoker over the age of 35, having estrogen-dependent tumors like breast cancer, being pregnant, having underlying sickle cell anemia, taking chemotherapeutic agents known to cause ovarian failure, and having allergies to any medication in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on two types of cancer, specifically head and neck cancer and squamous cell cancer.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial involves the use of two drugs, zalutumumab and cisplatin.\n- Criteria: The eligibility criteria for the trial are listed, including both inclusion and exclusion criteria. Inclusion criteria specify that patients must have locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Exclusion criteria include prior treatment with radiotherapy or chemotherapy in the head and neck area, prior treatment with similar drugs, and previous surgery with curative intent for head and neck cancer.",
    "The sample is a phase 1 clinical trial for breast cancer. The trial is specifically targeting patients with metastatic breast cancer who have negative estrogen and progesterone receptors but positive androgen receptors. The trial is open to postmenopausal women over the age of 60. The eligibility criteria include having an ECOG performance status between 0 and 3, certain blood count levels, normal bilirubin and liver enzyme levels, and normal kidney function or a creatinine clearance above 60 mL/min. Patients must have had at least 4 weeks since their last chemotherapy, biologic therapy, or radiotherapy, and at least 30 days since their last investigational agent. They should not be taking dehydroepiandrosterone or androstenedione supplements, and should not be receiving concurrent chemotherapy, radiotherapy, hormone therapy, or immunotherapy (including trastuzumab).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include breast cancer, lung cancer, colon cancer, pancreatic cancer, head and neck cancer, kidney cancer, sarcoma, and hepatocellular cancer. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are pazopanib and ixabepilone. The eligibility criteria for participants in this trial include having a diagnosis of advanced non-hematologic solid tumor malignancy, having measurable or evaluable disease, not having prior use of pazopanib or ixabepilone, and meeting certain organ function and health status requirements. There are also exclusion criteria listed, such as being pregnant or nursing, having a history of certain medical conditions, or having uncontrolled infections.",
    "The sample in the table is for a phase 1 clinical trial focused on type 2 diabetes. The diseases column specifies that the trial is targeting type 2 diabetes. The icdcodes column provides a list of ICD-10 codes associated with the disease. The drugs column lists the different drugs being tested in the trial, including a placebo and various doses of insulin glargine. The criteria column outlines the eligibility criteria for participants in the trial, including requirements such as having type 2 diabetes for at least six months, specific HgbA1c levels, age range, and BMI range. It also lists exclusion criteria, such as certain medical conditions, pregnancy or lactation, and history of alcoholism or drug abuse.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of rheumatoid arthritis. The trial includes patients who meet specific eligibility criteria, such as having active rheumatoid arthritis with low to moderate disease activity, being on stable doses of methotrexate for at least 12 weeks, and meeting certain age and weight requirements. Patients must also have a negative tuberculosis test and follow contraceptive measures if they are of childbearing potential. The trial excludes patients who have participated in another clinical trial, have certain medical conditions or diseases, use specific medications, have a history of drug abuse, or have abnormal laboratory parameters. Pregnant or lactating females are also excluded from the trial.",
    "The sample from the table represents a clinical trial for a drug called aliskiren in patients with type 2 diabetes and incipient or overt nephropathy. The trial is in phase 1/phase 2. The eligibility criteria for the trial include patients between the ages of 30-80 with type 2 diabetes, urinary albumin excretion between 100 and 2000 mg/day, and a glomerular filtration rate (GFR) of at least 40ml per minute. Patients must also have a blood pressure within a certain range and be on stable antihypertensive medications for at least 8 weeks prior to the study. Female patients must meet certain criteria related to menopause or surgical procedures. Other criteria include oral body temperature, ability to provide informed consent, ability to communicate well with the investigator, and willingness to discontinue certain medications. The exclusion criteria include the use of prohibited medications, severe hypertension, certain medical conditions, history of certain diseases or conditions, and other factors that may affect the evaluation of efficacy or safety.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on bladder cancer. The ICD-10 codes associated with the disease are 'D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', and 'D41.4'. The drugs being studied are mitomycin c and chemophase. The eligibility criteria for participants include having Stage Ta, T1, or Tis bladder cancer after transurethral resection of bladder tumor (TURBT), a Karnofsky Performance Status of at least 80%, a life expectancy of at least 3 years, being 18 years or older, having acceptable liver and renal function, and meeting certain hematologic and urinalysis requirements. Participants must also agree to use effective contraception during the study and provide signed, written informed consent. Exclusion criteria include a history of bladder fibrosis, low bladder capacity, severe urinary incontinence or irritative voiding symptoms, other active malignant diseases (except certain skin cancers), recent major surgery or infections, previous treatment with radiation therapy, surgery, chemotherapy, or investigational therapy, known infections with HIV, hepatitis B, or hepatitis C, serious diseases that could affect the study objectives, hypersensitivity or contraindication to mitomycin, allergies to bee or vespid venom, coagulation disorders or bleeding tendencies, treatment with heparin, and unwillingness or inability to comply with study procedures.",
    "The sample from the table is for a phase 1 trial. The disease being studied is \"healthy,\" which means that the trial is focused on healthy individuals. The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"bi 1026706 placebo\" and \"bi 1026706.\" The eligibility criteria for this trial include being a healthy male subject, while any relevant deviation from healthy conditions would be considered an exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"neoplasms malignant.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drugs mentioned in this sample are \"dalotuzumab,\" \"mk-0752,\" \"ridaforolimus,\" and \"mk-2206.\" \n\nThe eligibility criteria for this sample include various conditions that participants must meet to be included in the trial. These conditions include having no medical conditions that may impact compliance with the protocol, having a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (EGOG) Performance Scale, being able to swallow capsules, having no history of prior malignancy (with some exceptions), having at least one measurable metastatic or recurrent lesion, and meeting specific criteria for Part 1 and Part 2 of the trial.\n\nThe exclusion criteria for this sample include conditions that would exclude participants from the trial. These conditions include recent chemotherapy, radiotherapy, or biological therapy, current or recent participation in another study with an investigational compound or device, known central nervous system (CNS) metastases and/or carcinomatous meningitis, significant or uncontrolled cardiovascular disease, poorly controlled diabetes, pregnancy or breastfeeding, being HIV-positive, active Hepatitis B or C infection, symptomatic ascites or pleural effusion, requirement of certain medications or treatments, and the use of growth hormone or growth hormone inhibitors.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility and exclusion criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on individuals without any specific disease. The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"bi 1744 cl\" and \"placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a healthy male between the ages of 21 and 45, having a BMI between 18.5 and 30 kg/m2, and providing written informed consent. Exclusion criteria include any abnormal findings in medical examinations, evidence of concomitant diseases, various disorders and conditions, history of certain medical conditions, use of certain medications, participation in other trials, smoking, alcohol or drug abuse, recent blood donation, excessive physical activities, abnormal laboratory values, and inability to comply with the study's dietary regimen.\n\nAdditionally, there are specific exclusion criteria related to known side effects of \u00df2-mimetics, including asthma or history of pulmonary hyperreactivity, hyperthyroidism, allergic rhinitis requiring treatment, clinically relevant cardiac arrhythmia, and paroxysmal tachycardia.\n\nOverall, this sample provides information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a clinical trial focused on healthy individuals.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on healthy subjects. The ICD-10 codes associated with the diseases are \"Z76.3\" and \"Z76.2\". The drugs being tested are clopidogrel and placebo. The eligibility criteria for inclusion in the trial include being a healthy subject with a specific body weight and BMI range, as well as being classified into one of four groups based on CYP2C19 genotype. The exclusion criteria include having evidence of an inherited disorder of coagulation/hemostasis functions, smoking more than 10 cigarettes per day, and being unable to abstain from taking any drugs that affect hemostasis throughout the study duration. It is important to note that the provided information may not include all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on various diseases, including ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, and bladder cancer. The diseases are identified by their corresponding ICD-10 codes. The trial involves the administration of three drugs: belinostat, paclitaxel, and carboplatin. The eligibility criteria for participants include having signed consent from an Institutional Review Board, having histologically confirmed solid carcinomas with no known curative therapy, having a performance status of Eastern Cooperative Oncology Group (ECOG) \u2264 2, having a life expectancy of at least 3 months, being at least 18 years old, and meeting acceptable liver, renal, and bone marrow function criteria. Additional criteria include acceptable coagulation status, negative pregnancy test for women of childbearing potential, and serum potassium within the normal range. The sample also includes specific eligibility criteria for patients with epithelial ovarian cancer or urothelial carcinoma of the bladder. The exclusion criteria include recent treatment with investigational agents or anticancer therapy, co-existing active infection or medical conditions that may interfere with the study, significant cardiovascular disease, altered mental status, history of concurrent second malignancy, hypersensitivity to platinum or paclitaxel, and other specific criteria.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, which can be phase I, phase II, or phase III. The \"diseases\" column contains a list of disease names, while the \"icdcodes\" column contains a list of corresponding ICD-10 codes for the diseases. The \"drugs\" column contains a list of drug names. The \"criteria\" column contains the eligibility criteria for the trial.\n\nThe sample data in the table includes a phase of \"phase 1/phase 2\" and a list of diseases including \"recurrent pediatric all,\" \"relapsed pediatric all,\" \"acute lymphoblastic leukemia,\" and \"refractory pediatric all.\" The corresponding ICDCodes for these diseases are also provided. The drugs listed in the sample include \"abt-751,\" \"dexamethasone,\" \"peg-asparaginase,\" \"doxorubicin,\" \"cytarabine,\" \"methotrexate,\" \"cyclophosphamide,\" and \"6-thioguanine.\" The eligibility criteria are also included in the sample, including age requirements, diagnosis criteria, performance level, prior therapy conditions, reproductive function requirements, and exclusion criteria related to drug allergies, renal function, liver/pancreatic function, cardiac function, and infections.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the diseases mentioned are \"healthy\" and \"asthma\". The ICDCodes associated with these diseases are \"Z76.3\", \"Z76.2\" for \"healthy\" and \"J45.998\", \"J82.83\", \"J45.909\", \"J45.991\", \"J45.20\", \"J45.30\", \"J45.40\" for \"asthma\". The drugs mentioned in the sample are \"placebo to bi 1021958 qd\", \"bi 1021958 bid\", \"placebo to bi 1021958 bid\", and \"bi 1021958 qd\". The eligibility criteria state that the trial is open to healthy male and female subjects who are not of child-bearing potential. However, individuals with any relevant deviation from healthy conditions, except for mild controlled asthma, are excluded from the trial.",
    "The sample is a phase 1 clinical trial for the treatment of type 2 diabetes mellitus. The trial is testing a drug called gsk716155 for injection, as well as a placebo. The eligibility criteria for participants include having been diagnosed with type 2 diabetes for at least 3 months, with specific blood sugar and HbA1c levels. Participants must also have a BMI of 35kg/m2 or less and be between the ages of 20 and 70. Women must be unable to bear children. There are also exclusion criteria, such as testing positive for certain diseases, having certain medical conditions, or having a history of drug or alcohol abuse. Additionally, participants must not have previously used insulin or certain other medications.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drugs being used in the trial are gx15-070ms. The eligibility criteria for this trial include having histologically or cytologically confirmed B-CLL, previous standard systemic chemotherapy, age of 18 years or older, ECOG Performance Status of 1 or lower, and a life expectancy of more than 8 weeks. The exclusion criteria include patients receiving other investigational or commercial agents for their malignancy, patients with a history of seizure disorders, pregnant or breastfeeding women, and HIV-positive patients receiving combination anti-retroviral therapy.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on various diseases including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and others. The diseases are identified by their corresponding ICD-10 codes. The trial also involves the use of specific drugs such as cyclophosphamide and fludarabine phosphate. The eligibility criteria for participants include specific disease criteria for each disease, as well as requirements related to disease progression, response to previous therapies, and organ function. There are also exclusion criteria, such as the availability of a suitable matched sibling donor, eligibility for autologous transplantation, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is NK012. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having a histologically confirmed malignant solid tumor with no known effective treatments, having failed conventional therapy or having a malignancy for which conventional therapy does not exist, having recovered from prior therapies, having a life expectancy of at least 12 weeks and a performance status of 0 or 1, being 18 years of age or older, having adequate kidney, liver, and bone marrow function, and being willing to sign an informed consent document.\n\nExclusion criteria include having received chemotherapy or radiotherapy within the specified time frame, receiving any other investigational agent, having a history of brain metastases or spinal cord compression unless treated and stable, having a history of allergic reactions to compounds similar to NK012, having concurrent serious infections, being pregnant or not using contraception methods, having uncontrolled intercurrent illness or significant cardiac disease, having a history of serious ventricular arrhythmia, and testing positive for certain antibodies.\n\nOverall, this sample provides information about a Phase 1 clinical trial for cancer, specifically studying the drug NK012, and outlines the eligibility criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1. The diseases included in the trial are leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, and myelodysplastic syndromes. The corresponding ICDCodes for these diseases are also listed. The drugs being studied in this trial are busulfan, fludarabine phosphate, mycophenolate mofetil, and tacrolimus. The eligibility criteria for participants in this trial are described in detail, including specific disease characteristics and patient characteristics. The criteria include information about the advanced hematologic malignancies that qualify for the trial, such as acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, chronic myelogenous leukemia, multiple myeloma, lymphoma, and low-grade non-Hodgkin's lymphoma. The criteria also specify age requirements, the need for an umbilical cord blood donor, and various patient characteristics such as performance status, kidney function, liver function, and HIV status. The prior concurrent therapy section refers to the previous treatments received by the patients.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is tumors. The ICD-10 codes associated with the disease are E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, and C49.A3. The drug being tested is a combination of dasatinib and ketoconazole. \n\nThe eligibility criteria for this trial include having an ECOG status of 0-2, having advanced or metastatic disease that is unresponsive to standard treatment or for which no standard treatment exists, having a biopsy done before treatment, and having adequate bone marrow, liver, and kidney function. \n\nThe exclusion criteria for this trial include having serious cardiovascular disease, bleeding disorders, gastrointestinal tract disease, taking platelet inhibitors, and taking H2 blockers or proton pump inhibitors.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are leukemia and myelodysplastic syndromes. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are fludarabine and treosulfan. The eligibility criteria for participants include specific disease characteristics, such as the diagnosis of acute myeloid leukemia, lymphoblastic leukemia, or myelodysplastic syndrome, and the absence of CNS leukemic involvement. Other criteria include the need for bone marrow or peripheral blood stem cell transplantation, the availability of a suitable donor, and certain patient characteristics such as performance status, life expectancy, and various health parameters related to hematopoietic, hepatic, renal, cardiovascular, and pulmonary functions. The sample also includes information about prior concurrent therapies, including biologic therapy, chemotherapy, and radiotherapy, as well as restrictions on experimental drugs and concurrent enrollment in other protocols.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are colon cancer and rectal cancer. The ICDCodes associated with these diseases are C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, and D12.3 for colon cancer, and C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2 for rectal cancer. The drug being tested is lenalidomide. The eligibility criteria for this trial are listed under \"Inclusion\" and \"Exclusion\" categories. The inclusion criteria include having wild type metastatic colorectal cancer that failed on at least two treatment regimens, having a certain performance status, and meeting certain survival and medical condition requirements. The exclusion criteria include being pregnant or lactating, having certain medical conditions or psychiatric illnesses, recent use of certain medications, and having certain blood counts or liver function levels outside of the normal range.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as Phase 1. The diseases being studied in this trial are schizophrenia, Alzheimer's disease, and cognition disorders. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being used in the trial are \"jnj-39393406\" and \"placebo\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Male participants between the ages of 18 and 55.\n- Participants must have a known history of schizophrenia for at least 12 months, as confirmed by a referring psychiatrist.\n- Participants must meet the DSM-IV criteria for schizophrenia, including all subtypes.\n- Participants must have been on stable treatment for at least 3 months, with minor changes acceptable upon confirmation by the sponsor representative.\n- Participants must be medically stable based on physical examination, medical history, vital signs, and 12-lead ECG performed during screening. Any abnormalities must be consistent with the underlying illness being studied.\n- Participants must also be medically stable based on clinical laboratory tests performed during screening. If any abnormalities are found, they must be deemed not clinically significant or appropriate and reasonable for the study population by the investigator.\n- Participants must have a BMI between 18 and 35 kg/m\u00b2.\n- For the pharmacogenomic component of the study, participants must have signed a separate written informed consent indicating willingness to participate in genetic testing (Part 1), and indicate consent or refusal for DNA storage (Part 2). Participation in genetic testing is mandatory, while participation in DNA storage is voluntary.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants must not have any DSM-IV axis I diagnosis other than schizophrenia.\n- Participants must not have clinically significant abnormal values for clinical chemistry, hematology, or urinalysis at screening or admission. Minor deviations may be acceptable if not considered clinically significant by the investigator.\n- Participants must not have clinically significant abnormal physical examination, vital signs, or 12-lead ECG at screening. Minor deviations in ECG may be acceptable if not considered clinically significant by the investigator.\n- Participants must not have a QTcb (corrected QT interval) greater than 470ms.\n- Participants must not have a DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation, except for caffeine dependence. Participants with a positive drug screen at screening may be included if drug use does not lead to a diagnosis of substance dependence and the participant agrees to abstain from illegal drugs during the study.\n- Participants must not be treatment-resistant (failure to respond to two different antipsychotic drugs in the past).\n- Participants must not have PANSS scores (Positive and Negative Syndrome Scale) greater than 70.\n- Participants must not be at risk of suicide, as assessed by the investigator (e.g., prior suicide attempts, command hallucinations, hopelessness).\n- Participants must not have used clozapine within 3 months before screening until follow-up.\n- Participants must not have used more than two antipsychotic drugs within 3 months before dosing until follow-up.",
    "The sample from the table is for a phase 1 clinical trial. The diseases being studied are solid tumors and malignant lymphoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is enzastaurin. The eligibility criteria for participants include having a histologic or cytologic diagnosis of cancer with evidence of locally advanced and/or metastatic disease, no previous life-prolonging therapy available, and a performance status of 0 to 2 on the ECOG scale. Participants must also have adequate organ function and meet certain laboratory values. There are exclusion criteria as well, such as recent treatment with an experimental agent, certain medical conditions, and use of specific medications. The sample also includes detailed inclusion and exclusion criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"end stage renal disease.\" The ICDCodes associated with this disease are \"N18.6,\" \"I12.0,\" \"I13.11,\" and \"I13.2.\" The drug mentioned is \"aliskiren.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include requirements such as being a postmenopausal woman or surgically sterilized, having a certain weight and body mass index (BMI), having specific vital signs within normal ranges, being able to communicate well and understand the study requirements, and being in good health as determined by medical history, physical examination, and laboratory tests. \n\nExclusion criteria include factors such as smoking, recent use of aliskiren, recent participation in other clinical investigations, abnormal hemoglobin levels, a history or presence of diabetes mellitus, certain cardiovascular conditions, autonomic dysfunction, bronchospastic disease, drug or alcohol abuse, consumption of grapefruit or grapefruit juice, lactating or breastfeeding, history of head and neck angioedema, recent blood donation or loss, and certain medical conditions or test results. \n\nIt is important to note that there may be additional inclusion/exclusion criteria specific to the protocol of the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"graft versus host disease.\" The ICDCodes associated with this disease are \"D89.810,\" \"D89.811,\" \"D89.813,\" and \"D89.812.\" The drugs being used in the trial are \"rapamycin\" and \"tacrolimus.\" The eligibility criteria for this trial include being at least 18 years old, having received an allogeneic MSD or MUD PBSCT, being 24 weeks post SCT, currently on Tacrolimus for GVHD prophylaxis, and being deemed eligible for tapering off of Tacrolimus by the primary BMT physician. The exclusion criteria include having relapsed disease, ongoing GVHD, immunosuppression being stopped early to treat or prevent relapse, pure red cell aplasia due to ABO mismatched donor, ongoing thrombotic microangiopathy, allergy to rapamycin, and women of childbearing potential needing to have a negative serum pregnancy test before starting treatment.",
    "The sample from the table represents a clinical trial for the treatment of multiple myeloma. The trial is a combination of phase 1 and phase 2. The diseases being studied are limited to multiple myeloma. The corresponding ICD-10 codes for multiple myeloma are 'C90.01', 'C90.02', and 'C90.00'. The drugs being investigated in the trial are bortezomib and sorafenib. \n\nThe eligibility criteria for participants in the trial include being previously diagnosed with multiple myeloma and having received no more than 2 prior treatment regimens. Participants must also meet certain criteria to be defined as having relapsed or refractory disease. Other criteria include having an ECOG performance status of 0, 1, or 2, specific blood counts, normal kidney and liver function, and no other active malignancies or medical conditions that could interfere with participation in the trial.\n\nExclusion criteria for the trial include having grade 1 or higher peripheral neuropathy, recent thrombolic or embolic events, significant bleeding events, brain metastasis, other medical conditions that could interfere with participation, previous hypersensitivity to the drugs being studied, pregnancy or lactation in women, evidence of POEMS syndrome, certain cardiac conditions, uncontrolled hypertension, HIV infection or chronic Hepatitis B or C, and active clinically serious infection.\n\nOverall, the sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for participants in the clinical trial for the treatment of multiple myeloma.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"pulmonary disease, chronic obstructive.\" The ICDCodes associated with this disease are \"J44.9,\" \"J44.1,\" and \"J44.0.\" The drugs being tested in this trial are \"gsk573719 62.5 mcg (one strip),\" \"gsk573719 62.5 mcg (two strips),\" \"gsk573719 125 mcg (one strip),\" \"gsk573719 125 mcg (two strips),\" and \"placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include factors such as age (between 18 and 65 years), overall health, specific medical conditions, body weight, spirometry results, response to ipratropium bromide, liver function, ECG results, smoking history, ability to use the Novel DPI device, and willingness to provide informed consent. The exclusion criteria include factors such as abnormal heart rate or blood pressure, history of certain medical conditions, positive test results for hepatitis B or C, liver disease, positive drug/alcohol screen, HIV infection, excessive alcohol consumption, recent participation in other clinical trials, recent exposure to new chemical entities, use of certain medications, allergies or sensitivities to study medications, blood donation history, pregnancy or lactation, inability to follow study procedures, mental or legal incapacity, history of asthma or bronchoconstriction, recent tobacco use, and being in military service or institutionalized due to regulatory or juridical order.\n\nOverall, this sample provides detailed information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on various diseases, including melanoma, soft tissue sarcoma, parathyroid carcinoma, small cell carcinoma of the lung, and carcinoid tumors. The diseases are associated with specific ICD-10 codes. The trial involves the use of the drugs dacarbazine and bortezomib. The eligibility criteria for participants include having a histologic diagnosis of one of the specified diseases, having measurable or evaluable disease that cannot be treated with surgery or radiation, being at least 18 years old, having an ECOG Performance Status of 0 or 1, and meeting certain requirements for birth control. The exclusion criteria include having uncontrolled brain metastatic disease, low platelet count, low absolute neutrophil count, recent blood transfusion or use of hematopoietic growth factors, low creatinine clearance, elevated AST or bilirubin levels, peripheral neuropathy of grade 2 or higher, hypersensitivity to the drugs being used, being pregnant or nursing, recent use of other investigational drugs, and having any other medical or condition that could compromise the objectives of the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is \"kidney transplantation,\" the icd-10 codes associated with the disease are \"N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0,\" the drugs being studied are \"bleselumab\" and \"placebo,\" and the eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include requirements such as being a recipient of a de novo kidney transplant, having a decreased post-transplant serum creatinine value, and agreeing to use effective birth control. The exclusion criteria include factors such as receiving antibody induction therapy, having a positive T or B cell crossmatch, and having a current malignancy.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease mentioned in this sample is \"metastatic prostate cancer\". The corresponding ICD-10 codes for this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being studied in this trial are \"dasatinib\" and \"docetaxel\". The eligibility criteria for participants in this trial include having confirmed adenocarcinoma of the prostate that is resistant to hormone therapy, having evidence of progressive metastatic disease, and having measurable disease on imaging or a positive bone scan with a certain level of serum prostate specific antigen (PSA). There are also exclusion criteria, such as having known brain metastases, significant cardiovascular disease, or uncontrolled intercurrent illness. Prior treatments and medications are also mentioned, with certain restrictions on chemotherapy, radiotherapy, and hormonal therapy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on ovarian cancer, epithelial ovarian cancer, fallopian tube carcinoma, and primary peritoneal carcinoma. The corresponding ICD-10 codes for these diseases are provided. The drugs being studied in the trial are lenalidomide, liposomal doxorubicin, and bevacizumab, as well as revlimid, doxil, and avastin. The sample also includes the eligibility criteria for participants, including requirements such as being platinum resistant/refractory, having measurable or evaluable disease, and meeting certain creatinine clearance levels. Informed consent and participation in the RevAssist\u00ae program are also necessary. There are exclusion criteria as well, such as being pregnant or breastfeeding, having concurrent use of other anti-cancer agents, and having certain viral infections or hypersensitivity to Avastin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is \"graft versus host disease.\" The ICDCodes associated with this disease are \"D89.810,\" \"D89.811,\" \"D89.813,\" and \"D89.812.\" The drug being tested is \"everolimus.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include written informed consent, allogeneic HSCT from HLA-identical related or unrelated donors, clinically confirmed acute GVHD \u2265 grade II, age between 18 and 70 years, and Karnofsky performance status > 60%. Exclusion criteria include oral treatment not being feasible, severe hepatic impairment (Child-Pugh C), active cerebral epilepsy, renal failure (Creatinine clearance < 50 ml/min), life expectancy < 3 months, known hypersensitivity to everolimus, sirolimus, or any of the excipients, confirmed pregnancy (serum \u03b2-HCG), non-effective contraception for both male and female patients if the risk of conception exists, patients with limited legal capacity, and patients unwilling and unable to undergo study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include myelodysplastic syndrome, acute myeloid leukemia, myeloproliferative disorders, acute lymphocytic leukemia, acute promyelocytic leukemia, acute leukemia, chronic myelogenous leukemia, myelofibrosis, chronic myelomonocytic leukemia, and juvenile myelomonocytic leukemia. The corresponding ICDCodes for these diseases are also listed. The drugs being used in the trial are clofarabine and cyclophosphamide. The eligibility criteria for the trial include specific performance status, laboratory values, cardiac function, and exclusion criteria such as recent chemotherapy or major surgery, history of stem cell transplant, and certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the disease of obesity. The ICD-10 codes associated with obesity are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drug being studied is tesofensine. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being overweight to obese with a BMI of 28-35 kg/m\u00b2, being male between 18 and 50 years old, being able to comply with study procedures, and providing written informed consent. Exclusion criteria include the use of concomitant medication, recent smoking history, specific diseases that interfere with metabolism, certain medical conditions, known hypercholesterolemia or hypertriglyceridemia, malabsorptive intestinal disorders, mental or psychiatric disorders, systemic infections or inflammatory diseases, drug or alcohol abuse, hepatic or renal dysfunction, special diets, significant weight change, surgically treated obesity, significant cardiovascular disease, abnormal ECG values, hypotension or symptomatic orthostatic hypotension, hypertension, HIV infection, eye disorders, active hepatitis B or C, history of cancer within the past 5 years, previous treatment with tesofensine, and recent treatment with an investigational drug.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1/phase 2. The disease being studied is prostate cancer. The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being tested is temsirolimus. The eligibility criteria for the trial are listed under \"Inclusion\" and \"Exclusion\" categories. The \"Inclusion\" criteria include requirements such as patients having a confirmed diagnosis of adenocarcinoma of the prostate, evidence of chemotherapy-refractory metastatic castration-resistant prostate cancer (CRPC), and specific laboratory values within normal ranges. The \"Exclusion\" criteria include factors such as prior treatment with certain drugs, evidence of central nervous system metastases, significant cardiovascular disease, and other medical conditions that may affect participation in the trial.",
    "The sample from the table is for a phase 1 trial. The disease being studied is breast neoplasms. The corresponding ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being tested in this trial are lapatinib and docetaxel. The eligibility criteria for participants include having advanced solid tumors and being able to swallow oral medication.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1. The diseases being studied are metastatic renal cell carcinoma and advanced refractory solid tumors that have been histologically or cytologically confirmed. The corresponding ICD-10 codes for these diseases are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug being used in the trial is an association of bevacizumab (bvc) and pazopanib (pzp). \n\nThe eligibility criteria for the trial include being over 18 years old, providing written informed consent, having histologically progressive metastatic renal cell carcinoma or other advanced refractory solid tumors, having an ECOG performance status of 0 or 1, having at least one measurable site of disease, and meeting certain requirements for bone marrow, liver, coagulation, and renal function. Other criteria include the absence of proteinuria, the ability to swallow and retain oral medication, the use of adequate contraception methods, and mandatory affiliation with a health insurance company.\n\nThe exclusion criteria for the trial include prior treatment with pazopanib or bevacizumab, prior treatment with any tyrosine kinase inhibitor, participation in another clinical study with an experimental agent, experiencing grade 3 or 4 toxicity during prior bevacizumab therapy, experiencing grade 3-4 toxicity during prior systemic therapy regimens, having squamous non-small cell lung carcinoma, having high vascular and nephrologic risks, having brain metastases, having certain gastrointestinal abnormalities, having certain cardiovascular conditions, having certain bleeding or bleeding-related conditions, undergoing certain treatments or surgeries within a specific timeframe, receiving certain medications, having ongoing toxicity from prior anti-cancer therapy, having known hypersensitivity reactions to related drugs, having conditions that prevent compliance with the protocol, having inadequate venous access for PK sampling, and being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV-1 infection, and the corresponding ICDCodes are ['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']. The drugs being tested in the trial include 'tbr-652', 'tbr-652 matching placebo', 'tbr-652 50 mg', 'tbr-652 75 mg', 'tbr-652 100 mg', and 'tbr-652 150 mg'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as no clinically significant findings on screening evaluations, being antiretroviral treatment-experienced, having a CD4 cell count of at least 250 cells/mm3, and having qualifying plasma HIV 1 RNA levels. There are also specific criteria for females regarding reproductive potential and contraception.\n\nExclusion criteria include factors such as the presence of certain types of HIV 1 virus, active CDC category C disease (except for specific cases), history of hepatitis B or C, abnormal liver function, history of HIV-2, recent clinically significant infection, pregnancy or breastfeeding, recent use of certain medications or vaccines, positive pre-study drug screen, anticipated use of antacids, current alcohol or drug use, inability to comply with the protocol, recent use of experimental medications, and current or anticipated use of certain drugs or substances known to affect specific enzymes or transporters. There are also criteria related to various medical conditions and disorders.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the trial phase, disease, drugs, and detailed eligibility criteria for potential participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of hepatocellular carcinoma, a type of liver cancer. The trial is investigating the drug \"rad001\". The sample includes the eligibility criteria for participants, which include having unresectable or metastatic HCC, having measurable disease that has not been previously irradiated, and having a certain number of prior chemotherapy and biologic regimens. There are also criteria related to age, previous treatments, performance status, and various medical conditions. The sample also includes exclusion criteria, such as prior treatment with investigational drugs, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cervical cancer. The ICDCodes associated with this disease are \"M50.20\", \"M50.21\", \"M50.30\", \"M50.31\", \"M50.80\", \"M50.81\", and \"M50.90\". The drugs being used in the trial are carboplatin and docetaxel.\n\nThe eligibility criteria for this trial include specific disease characteristics such as histologically confirmed squamous cell carcinoma of the uterine cervix, advanced disease (stage IVB), and persistent or recurrent disease. Other criteria include age over 18, performance status of GOG 0-2, life expectancy of more than 6 months, and specific hematopoietic, hepatic, renal, and other health-related requirements.\n\nThe sample also includes information about prior concurrent therapies, such as biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery. It specifies the time since prior therapies and any restrictions on concurrent therapies.\n\nOverall, this sample provides a detailed description of the phase, disease, drugs, and eligibility criteria for a clinical trial focused on cervical cancer.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"b-cell chronic lymphocytic leukemia.\" The ICDCodes associated with this disease are \"C91.11,\" \"C91.12,\" and \"C91.10.\" The drug mentioned is \"forodesine.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria state that patients must have confirmed Binet Stage B or C B-CLL, have received up to 2 previous lines of treatment (including fludarabine-based therapy), be at least 18 years old with a life expectancy of more than 6 months, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Female patients must not be pregnant and both female and male patients must be willing to use effective contraception during the treatment and for 2 months after.\n\nExclusion criteria state that patients who have received more than 2 previous lines of treatment are not eligible for this study. Other groups of patients who may not participate include pregnant and/or nursing patients, patients on corticosteroid treatment, patients with active or severe infections, patients with certain medical conditions, patients who have participated in another clinical study within 6 weeks prior to this study, or patients with a known hypersensitivity to the study medication.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is breast cancer, and the corresponding ICDCodes are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is lyso-thermosensitive liposomal doxorubicin (thermodox). The eligibility criteria for this trial include specific disease characteristics, such as locally recurrent breast cancer involving the chest wall and/or its overlying skin, certain tumor measurements, and prior radiotherapy. Patient characteristics include being female, having a certain performance status, and meeting various health requirements. Prior concurrent therapies and medications that are not allowed during the trial are also specified. Concurrent bisphosphonates for palliation of bony metastasis are allowed.",
    "The sample from the table represents a clinical trial for the treatment of myeloma, a type of cancer. The trial is in phase 1/phase 2, meaning it is still in the early stages of testing. The trial is focused on patients who have primary refractory disease (did not respond to initial treatment), consolidation of a partial remission, or relapse after prior therapy. The eligibility criteria include being up to 75 years old, having a Zubrod performance status of less than 2, and having a left ventricular ejection fraction greater than 40%. Other criteria include having certain lung function measurements, normal liver function, being HIV-negative, and having a negative pregnancy test for women of childbearing potential. The sample also includes exclusion criteria, such as having a corrected QT interval greater than 470 msec, being in complete remission, or having non-secretory myeloma.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, which can be phase I, phase II, or phase III. The \"diseases\" column contains a list of disease names, while the \"icdcodes\" column contains a list of corresponding ICD-10 codes for the diseases. The \"drugs\" column contains a list of drug names. The \"criteria\" column contains the eligibility criteria for the clinical trial.\n\nIn the provided sample, the phase is \"phase 1\". The diseases listed include various types of leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. The corresponding ICD-10 codes for the diseases are also provided. The drugs mentioned in the sample are \"7-hydroxystaurosporine\" and \"perifosine\". The eligibility criteria include specific requirements related to the type of hematologic malignancy, previous treatments, age, cytogenetic abnormalities, and other medical conditions. The criteria also specify the exclusion of certain conditions, such as active CNS leukemia, active ischemia on EKG, poorly controlled diabetes mellitus, and HIV positivity. The sample also includes information about the timing of prior treatments and the exclusion of concurrent therapies.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are breast cancer and advanced malignant solid tumors. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are neratinib and vinorelbine. The eligibility criteria for the trial include confirmed pathologic diagnosis of a solid tumor that is not curable with available therapies, prior treatment with chemotherapy and trastuzumab-containing regimens, and the presence of at least one measurable lesion as defined by RECIST. There are also exclusion criteria, such as a limit on the number of prior antineoplastic treatment regimens and restrictions on prior treatment with certain drugs.",
    "The sample from the table is for a phase 1 clinical trial. The diseases being studied include adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult mixed glioma, and recurrent adult brain neoplasm. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being investigated in the trial are temozolomide and vorinostat. The eligibility criteria for the trial include specific requirements for patients' medical history, performance status, blood counts, liver and kidney function, and imaging scans. There are also specific criteria for patients in different parts of the study, depending on their disease status and prior treatments. The exclusion criteria include patients who have progressed on temozolomide, those with significant medical illnesses that cannot be controlled, active infections, pregnant women, patients with certain diseases that may affect drug metabolism, and those receiving other investigational agents.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is cancer, and the associated ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are vintafolide iv bolus and vintafolide iv infusion. \n\nThe eligibility criteria for this trial include having a histological or cytological diagnosis of neoplasm, no effective standard therapeutic options, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, being at least 4 weeks post therapeutic radiation or chemotherapy (6 weeks for nitrosoureas and mitomycin C) with recovery from associated toxicities, a negative serum pregnancy test for women of child-bearing potential, willingness to practice contraceptive methods, and adequate bone marrow reserve, renal, and hepatic function.\n\nThe exclusion criteria for this trial include having concurrent hematological malignancies, being pregnant or lactating, having evidence of symptomatic brain metastases, receiving concomitant anticancer therapy (excluding supportive care), and requiring palliative radiotherapy at the time of study entry.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is ulcerative colitis. The icd-10 codes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drug being used in the trial is adalimumab. \n\nThe eligibility criteria for this trial include being 18 years of age or older, utilizing a highly effective method of birth control for female subjects, having a diagnosis of ulcerative colitis for more than 3 months, confirming the diagnosis through endoscopy, having active ulcerative colitis with a Mayo Clinic Score of 6 to 12 points, and having moderately-to-severely active disease on sigmoidoscopy. Other criteria include being either anti-TNF agent na\u00efve or having a previous clinical response to infliximab therapy for ulcerative colitis with subsequent loss of response or inability to tolerate further infliximab therapy. Subjects must also be able and willing to give written informed consent and comply with the study protocol. Adequate cardiac, renal, and hepatic function is required as determined by screening laboratory evaluations, questionnaires, and physical examination results.\n\nExclusion criteria for this trial include a history of cancer or lymphoproliferative disease (except successfully treated squamous cell or basal cell carcinoma of the skin), history of certain infections or diseases (Listeria, Hepatitis B, CNS demyelinating disease, HIV, or previously untreated TB), Crohn's Disease, symptomatic obstructive strictures, previous colectomy surgeries, current total parenteral nutrition (TPN), recent use of investigational chemical agents, recent antibiotic treatment for systemic infection, pregnancy or breastfeeding for female subjects, history of drug or alcohol abuse, poorly controlled medical conditions, recent use of cyclosporine or tacrolimus, and recent use of methotrexate.",
    "The sample from the table is for a phase 1 trial. The disease being studied is \"healthy,\" which means that the trial is focused on individuals who do not have any specific disease. The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"ides\" and \"placebo.\" The eligibility criteria for participants include being able to understand and sign informed consent, having a BMI between 19 and 30. The exclusion criteria include having any clinically significant disease, testing positive for HIV, hepatitis B or C, having a history of drug abuse, being a smoker, and using any medication except paracetamol.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is diabetes mellitus, type 2. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs mentioned in this sample are bi 10773 low dose, placebo to bi 10773, bi 10773 medium dose, and bi 10773 high dose. The eligibility criteria for this trial include being a male or postmenopausal/hysterectomised female patient with type 2 diabetes, aged between 18 and 70 years, and having a BMI between 18.5 and 40 kg/m2. The exclusion criteria include not being on antidiabetic treatment with insulin or glitazones or more than one oral hypoglycemic agent, having a fasted blood glucose level above 240 mg/dl or a blood glucose level above 400 mg/dl postprandially, and having an HbA1c level above 8.5%.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer, and the associated ICDCodes are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are docetaxel and epirubicin hydrochloride. \n\nThe eligibility criteria for this trial include specific disease characteristics, such as histologically confirmed invasive adenocarcinoma of the breast meeting certain criteria, and no evidence of metastatic disease. Patient characteristics include age 16 and over, female sex, and not specified menopausal status. Other criteria include performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other health-related factors. \n\nThe sample also includes information about prior concurrent therapy, such as no prior immunotherapy, chemotherapy, hormonal therapy, radiotherapy, or surgery for breast cancer. Additionally, there should be no prior systemic therapy or concurrent use of investigational drugs or anticancer treatment. The sample also specifies that there should be no concurrent preventative IV antibiotics.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is melanoma (skin). The ICDCodes associated with this disease are C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, and D03.52. The drugs mentioned in this sample are buthionine sulfoximine and melphalan. The eligibility criteria for this trial include specific disease characteristics, such as histologically proven primary or recurrent in-transit melanoma of the extremity, stage IIIB or IIIC disease, and previous treatment with melphalan-based regional therapy. The sample also includes patient characteristics, such as ECOG/Zubrod performance status, serum creatinine level, WBC count, platelet count, and hemoglobin level. Additionally, it mentions prior concurrent therapy requirements, including recovery from prior therapy and specific time intervals since major surgery, antineoplastic therapy, radiotherapy, or any other investigational drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is chronic hepatitis B. The ICDCodes associated with this disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drug being tested is adefovir.\n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a documented positive HBsAg (Hepatitis B surface antigen) for at least 3 months at the time of screening.\n- The patient must have a positive HBeAg (Hepatitis B e antigen) at screening.\n- The patient should not have been treated with interferon alpha, lamivudine, or adefovir within 3 months prior to study entry.\n- The patient's HBV DNA (Hepatitis B virus DNA) levels should be more than 1x10^5 copies/mL as measured by the COBAS Amplicor HBV monitor assay or bDNA method at screening.\n- The patient's HBV DNA levels should have decreased by more than 10-fold compared to the baseline after 8 weeks of treatment with adefovir.\n- The patient's ALT (Alanine aminotransferase) value should be between ULN (Upper Limit of Normal) multiplied by 1.5 and ULN multiplied by 5 at screening.\n- The patient must have given written consent voluntarily.\n\nExclusion Criteria:\n- The patient should not have uncompensated liver disease.\n- The patient's serum creatinine levels should not be greater than ULN multiplied by 1.5.\n- The patient should not be positive for Hepatitis C, hepatitis D, or HIV infection (confirmed by ELISA assay).\n- The patient should not have had a previous liver or bone marrow transplant.\n- The patient should not be currently taking any immunosuppressant or immune modulatory drugs.\n- Pregnant or breastfeeding women should not participate in the trial.\n- Individuals planning to have a child during the study duration should not participate.\n- The patient should not have a history of severe adverse drug reactions or severe allergic diseases.\n- The patient should not have any severe diseases (e.g., heart failure, renal failure, pancreatitis, diabetes mellitus) that could affect the study, except for liver disease.\n- The patient should not have any other liver diseases besides hepatitis B (e.g., hemochromatosis, Wilson's disease, alcoholic/non-alcoholic liver disease).\n- The patient should not have intrahepatic tumors confirmed by imaging (liver biopsy) and abnormally increased alpha-fetoprotein.\n- The patient should not have any present malignant tumors, except for liver, or a history of such tumors.\n- Any other patients deemed inappropriate for the study at the discretion of the investigator are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is \"morbid obesity.\" The ICDCodes associated with this disease are \"E66.2\" and \"E66.01.\" The drug being tested is \"fondaparinux.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Age: 19-65\n- BMI: 35-65\n- Negative pregnancy test on the day of the study\n\nExclusion Criteria:\n- Blood Pressure \u2264 160/90\n- Temperature > 37.5\u00b0C (99.5\u00b0F)\n- Nursing a baby\n- Positive pregnancy test on the day of the study\n- Medications: History of regular treatment with anticoagulants or any anti-platelet agents including aspirin and other NSAIDs; use of aspirin or other NSAIDs within 1 month of the study\n\nPast Medical History:\n- Cerebrovascular accident (including transient ischemic attacks) within 6 months of the study\n- Diabetic retinopathy as documented by positive fundoscopy in the previous 3 months\n- Active peptic ulcer disease, by EGD or Ba meal, within 3 months of the study\n- Known bleeding disorder\n- Known thrombophilia\n- History of heparin-induced thrombocytopenia\n- History of bacterial endocarditis\n- Known hypersensitivity to fondaparinux\n- Ulcerative colitis\n- History of GI bleeding\n- History of hematuria\n- Recent surgery (in the previous 3 months)\n- Recent trauma - road traffic accident (previous 3 months)\n\nLaboratory Values:\n- Platelet count \u2264 100,000\n- Hemoglobin < 12g/dl for women or < 14g/dl for men\n- Prothrombin time > 13s\n- Activated partial thromboplastin time (APTT) > 35s\n- Liver function test parameters: ALT > 60u/L, AST > 40u/L, \u03b3-GT > 85u/L, Alkaline phosphatase > 251 u/L, or total bilirubin > 1.3 mg/dl\n- Estimated urinary creatinine clearance < 50 mls/min\n- Hematuria on urine dipstick",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is an unspecified childhood solid tumor that is protocol-specific. The ICDCodes associated with this disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs used in this trial are carboplatin, cyclophosphamide, etoposide, thiotepa, and topotecan hydrochloride. The eligibility criteria include specific disease characteristics, patient characteristics such as age and performance status, hematopoietic, hepatic, renal, cardiovascular, and neurologic requirements, as well as other factors like prior concurrent therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"kidney transplantation,\" and the associated ICDCodes are \"N26.2,\" \"Q63.0,\" \"Q63.2,\" \"Z52.4,\" \"I75.81,\" \"N19,\" and \"N20.0.\" The drug mentioned is \"aeb071.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion:\n- Male and female patients of any race who are 18 years or older.\n- Adult recipients of a kidney transplant from a deceased or living donor.\n- Recipients of a functioning kidney within 24 hours post-transplant.\n\nExclusion:\n- Patients who require medication prohibited by the protocol.\n- Patients or donors infected with Hepatitis B, C, or HIV.\n- Patients with a history of cancer within the last 5 years.\n- Patients with a history of significant cardiac disorder.\n- Patients with a high-risk immunological status.\n\nIt is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes is \"Z21\". The drug being tested is dapivirine (tmc120) vaginal gel. \n\nThe eligibility criteria for this sample include being HIV-negative, willing to participate and provide informed consent, willing to be tested for HIV and use an experimental vaginal gel, and being open to the possibility of being assigned to a placebo group. Participants must also be willing to use two forms of contraception during the study, undergo pelvic examinations with colposcopy and photographic documentation, and have a regular menstrual cycle. They must also abstain from using any vaginal product other than the study product or placebo and be sexually abstinent from randomization until completion of Day 7 evaluations.\n\nThe exclusion criteria for this sample include being currently pregnant or breastfeeding, having clinically detectable genital abnormalities, having laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis, having clinically diagnosed genital ulcer disease or active HSV-2 lesions, experiencing breakthrough bleeding or having gynecologic surgery within 60 days prior to randomization, having symptomatic bacterial vaginosis and being unwilling to undergo treatment, and requiring treatment for tuberculosis within 21 days prior to randomization.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is aee788. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The patient must have a histologically confirmed solid tumor.\n- Adequate hematologic, renal, and hepatic function is required.\n- The patient must be at least 18 years old.\n- The Karnofsky performance status score must be equal to or greater than 70%.\n- The patient must have a life expectancy of at least 12 weeks.\n\nExclusion Criteria:\n- Patients with active brain metastases are not eligible.\n- Peripheral neuropathy greater than grade 2 is not allowed.\n- Diarrhea greater than grade 1 is not allowed.\n- Patients with gastrointestinal (GI) dysfunction are excluded.\n- Compromised cardiac function is an exclusion criterion.\n- Patients with concurrent severe and/or uncontrolled medical conditions are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of small cell lung cancer. The phase of the trial is a combination of phase 1 and phase 2. The diseases column specifies the disease being studied, which in this case is small cell lung cancer. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being used in the trial, which are vorinostat, carboplatin, and etoposide. The criteria column provides the eligibility criteria for participants in the trial, including requirements such as confirmed diagnosis of small cell lung cancer, measurable disease, chemotherapy-naive status, certain organ and marrow function, and the ability to understand and sign an informed consent document. The exclusion criteria are also listed, which include recent chemotherapy or investigational agent use, recent radiotherapy, known brain metastases, previous treatment with an HDAC inhibitor, certain medical conditions, recent major surgery, history of other malignancies, pregnancy or breastfeeding, certain infections, use of systemic steroids, inability to absorb oral vorinostat, and known allergies or hypersensitivity to any study therapies.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being studied is celecoxib. The eligibility criteria for the trial include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The disease characteristics require histologically or cytologically confirmed non-small cell lung cancer that is either inoperable stage IIB or unresectable stage IIIA or IIIB, with no evidence of hematogenous metastases. The patient characteristics include being 18 years or older, having a Zubrod performance status of 2 and more than 5% weight loss over the past 3 months, or a Zubrod performance status of 0-1 and less than 5% weight loss over the past 3 months, and refusing chemotherapy or being medically unable to tolerate combined modality therapy. The patient's life expectancy is not specified. The eligibility criteria also include specific requirements for hematopoietic, hepatic, renal, and other health conditions. Prior concurrent therapy restrictions include no prior neoadjuvant chemotherapy, no concurrent chemotherapy, no concurrent corticosteroids, no prior thoracic radiotherapy, no prior complete or subtotal tumor resection, and restrictions on the use of certain medications. However, concurrent aspirin (325 mg/day) for cardioprotection is allowed.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is neoplasms. The corresponding ICD-10 codes for the diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are sunitinib, pemetrexed, cisplatin, and carboplatin. The eligibility criteria for inclusion in the trial are having a solid cancer that is not responsive to standard therapy or for which no standard therapy exists, and having a good performance status (ECOG 0 or 1). The exclusion criteria include prior treatment with either pemetrexed or SU011248, coughing up blood within 4 weeks before starting the study treatment (small amounts are okay), and having hypertension that cannot be controlled by medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: The list of diseases being studied in the trial, which includes \"non-Hodgkin's lymphoma\" and \"B-cell lymphoma\".\n- ICD Codes: The ICD-10 codes associated with the diseases, which are \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", and \"S33.140S\".\n- Drugs: The drugs being used in the trial, which are \"velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide\".\n- Criteria: The eligibility criteria for participants in the trial, including both inclusion and exclusion criteria.\n\nThe inclusion criteria specify the characteristics that potential participants must have, such as having aggressive B-cell non-Hodgkin lymphoma, being between the ages of 18 and 70, and having an ECOG performance status of 0-2. The exclusion criteria specify characteristics that would disqualify potential participants, such as having a platelet count of less than 75,000 or having a history of myocardial infarction within the past 6 months.\n\nOverall, this sample record provides information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include \"follicle development,\" \"ovarian follicle,\" \"follicle count,\" \"follicle size,\" and \"oral contraceptive.\" The ICDCodes associated with these diseases are [\"T38.4X1A\", \"T38.4X1D\", \"T38.4X1S\", \"T38.4X2A\", \"T38.4X2D\", \"T38.4X2S\", \"T38.4X3A\"].\n\nThe drugs being investigated in this trial are \"desogestrel/ethinyl estradiol and ethinyl estradiol,\" \"28-day drospirenone oral contraceptive,\" and \"28-day levonorgestrel oral contraceptive.\"\n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Participants must be premenopausal, non-pregnant, non-lactating women aged 18-35 years old.\n- Participants must have a Body Mass Index (BMI) of \u226518 kg/m\u00b2 and <30 kg/m\u00b2.\n- Participants must have a regular spontaneous menstrual cycle.\n- Other criteria may be specified by the Food and Drug Administration (FDA)-approved protocol.\n\nExclusion Criteria:\n- Participants with any condition that contraindicates the use of combination oral contraceptives are not eligible.\n- Participants with known thrombophlebitis or thromboembolic disorders, known or suspected clotting disorders, thrombogenic valvulopathies, or rhythm disorders are not eligible.\n- Participants with migraine headaches with focal, neurological symptoms are not eligible.\n- Other criteria may be specified by the FDA-approved protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for participating in the trial.\n\nIn this particular sample, the phase of the trial is phase 1. The diseases being studied are locally advanced breast cancer (labc) and metastatic breast cancer (mbc). The corresponding ICD-10 codes for these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being tested are bez235 + trastuzumab (phase l/phase ll) and lapatinib + capecitabine (phase II). \n\nThe eligibility criteria for this trial include being a female aged 18 or older, having a confirmed diagnosis of HER2-positive invasive breast cancer with inoperable locally advanced or metastatic disease, having controlled or asymptomatic CNS metastases, and having adequate bone marrow and organ functions. Other criteria include specific blood counts, liver function, bilirubin levels, creatinine levels, glucose levels, and prior treatment history. The patient's performance status, availability of tumor tissue for biomarker analysis, and previous treatment with taxane and trastuzumab are also considered.\n\nThe exclusion criteria for this trial include previous treatment with PI3K and/or mTOR inhibitors, symptomatic/uncontrolled CNS metastases, concurrent malignancy or malignancy within the last 3 years, recent radiotherapy, active cardiac disease, uncontrolled hypertension, gastrointestinal impairment, and contraindications to trastuzumab treatment. Additional exclusion criteria for phase II include previous treatment with capecitabine and lapatinib, intolerance or contraindications to capecitabine and lapatinib, previous treatment with HER-2 targeted agents other than trastuzumab or T-DM1, and peripheral neuropathy of grade 2 or higher.\n\nOverall, this sample provides information about a clinical trial for breast cancer patients, specifying the phase, diseases being studied, drugs being tested, and the eligibility and exclusion criteria for participation in the trial.",
    "The sample from the table is a clinical trial for rheumatoid arthritis, which is in phase 1/phase 2. The trial is looking for male and female patients aged 18-75 years with active rheumatoid arthritis who are already taking a stable dose of methotrexate. Post-menopausal or surgically sterile female patients are also allowed to participate. Women of child-bearing potential can participate if they are on a stable dose of methotrexate and practicing effective contraception. The trial requires patients to have a diagnosis of active rheumatoid arthritis of stages I, II, or III according to the ACR 1987 revised classification criteria, with a disease duration of at least 6 months prior to randomization.\n\nThere are also exclusion criteria, such as current treatment with anti-TNF-\u03b1 or anti IL-1 therapy, congestive heart failure, poorly controlled diabetes mellitus, presence of other major chronic inflammatory autoimmune diseases, history of renal trauma or glomerulonephritis, pregnancy or breastfeeding, and a positive tuberculin skin test.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is sickle cell disease, and the corresponding ICDCodes are ['D57.1', 'D57.20', 'D57.212', 'D57.219', 'D57.211', 'D57.213', 'D57.218']. The drugs involved in the trial are eptifibatide and placebo. The eligibility criteria for this trial include age between 18 and 55 years, confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia, specific serum creatinine and transaminase values, platelet count, normal baseline coagulation profile, sudden onset of pain, adequate intravenous access, understanding of study requirements, and willingness to give informed consent. There are also exclusion criteria listed, such as baseline hemoglobin levels, history of bleeding or acute chest syndrome, history of stroke, severe hypertension, recent major surgery, pregnancy or breastfeeding, chronic anticoagulation or antiplatelet therapy, history of metastatic cancer, recent blood transfusion, positive urine toxicology screen, history of alcohol abuse, and recent use of investigational drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is leukemia, specifically juvenile myelomonocytic leukemia (JMML). The ICDCodes associated with this disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drugs being used in the trial include cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, and cis-retinoic acid. The eligibility criteria for this trial include patients aged 0-18 with JMML who have relapsed or have residual disease after allogeneic hematopoietic cell transplant (HCT). The criteria also specify the required organ function levels, such as cardiac ejection fraction, pulmonary function, renal function, hepatic function, and performance status. The sample also mentions the need for written informed consent and excludes patients with active uncontrolled infection within one week of HCT.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is sickle cell disease. The ICDCodes associated with this disease are D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, and D57.218. The drug being tested in this trial is propranolol. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n1. The participant must have a diagnosis of HbSS or HbSBeta0Thal.\n2. The participant must be between the ages of 10 and 17 years.\n3. The participant must weigh 30kg or greater.\n4. The participant's Hb (hemoglobin) level must be 7mg/dL or greater.\n5. The participant must provide informed consent.\n\nExclusion Criteria:\n1. The participant must not have a history of vaso-occlusive crisis during the past 6 weeks or a history of transfusion during the past 3 months.\n2. The participant must not be pregnant.\n3. The participant must not have a history of heart failure, myocardial infarction, asthma, bradyarrhythmias, hypotension, thyroid disease, diabetes, or renal insufficiency.\n4. The participant must not be taking any antihypertensive medication, diuretics, thyroid replacement medications, arrhythmia medication, insulin, or hypoglycemic medication.\n5. The participant must not have a history of allergy to sulfonamides.\n6. The participant must not have elevated BUN (blood urea nitrogen) or creatinine levels.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"multiple myeloma\". The corresponding ICD-10 codes for this disease are \"C90.01\", \"C90.02\", and \"C90.00\". The drugs being studied in this trial are \"kw-2478\" and \"bortezomib\". The eligibility criteria for participants in this trial include having a confirmed diagnosis of multiple myeloma with a certain number of prior regimens, signing an informed consent form, having a specific performance status, a minimum life expectancy, and certain laboratory test results. Participants must also agree to follow pregnancy prevention methods if they are of reproductive potential. There are also exclusion criteria, such as not having received any anti-cancer treatment for a certain period of time and not having certain severe illnesses or concurrent malignancies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"brain neoplasms.\" The ICDCodes associated with this disease are \"C71.7,\" \"C71.9,\" \"C79.31,\" \"D33.0,\" \"D33.1,\" \"D33.2,\" and \"D49.6.\" The drug mentioned is \"temsirolimus (torisel).\" \n\nThe eligibility criteria for this trial include:\n1. Patients must be at least 18 years old.\n2. Patients must have histologically confirmed supratentorial grade III or IV astrocytoma and require a stereotactic biopsy for confirmation of tumor progression or differentiation.\n3. Patients must have a Karnofsky performance status of at least 50%.\n4. Patients must have had prior radiation therapy.\n5. The patient must be a candidate for temsirolimus as the next therapy for their tumor and must plan to continue temsirolimus chemotherapy after receiving the required dose for this study.\n6. Patients must have recovered from the toxicity of prior therapy.\n7. Patients must have adequate bone marrow, liver, and renal function.\n8. Patients must be able to provide written informed consent.\n9. Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods.\n10. Patients must not be allergic to temsirolimus or rapamycin.\n\nThe exclusion criteria for this trial include:\n1. Patients with serious concurrent infection or medical illness that would jeopardize their ability to receive the chemotherapy outlined in the protocol.\n2. Patients who are pregnant or breastfeeding.\n3. Patients without MRI or CT evidence of measurable, contrast-enhancing residual disease.\n4. Patients receiving concurrent chemotherapeutic or investigational agents.",
    "The sample provided is a record from a table that contains information about clinical trials for different phases of a trial (phase I, phase II, or phase III). The sample specifically pertains to a trial for the treatment of ischemic stroke. \n\nThe phase of the trial is described as \"phase 1/phase 2\". The disease being studied is \"ischemic stroke\". The corresponding ICD-10 codes for the disease are listed as \"['I25.5', 'H47.013', 'H93.013', 'G45.9', 'H47.011', 'H47.012', 'H47.019']\". The drug being tested is \"rp-1127 (glyburide for injection)\". \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria are as follows:\n- The patient must have a clinical diagnosis of acute ischemic stroke in the MCA or MCA/ACA territory.\n- The patient's pre-morbid mRS (modified Rankin Scale) score should be 0-1.\n- The patient's baseline DWI (Diffusion-Weighted Imaging) lesion on MRI should be between 82 cm3 and 210 cm3.\n- Patients treated with IV rtPA (intravenous recombinant tissue plasminogen activator) should meet the established criteria for IV rtPA administration within specific time periods.\n- The infusion of the study compound must start within 10 hours after the time of symptom onset.\n- The patient's age should be between 18 and 70 years.\n- The patient or their legally authorized representative must provide written informed consent according to institutional guidelines and national regulations.\n\nThe exclusion criteria for the trial are as follows:\n- Evidence from imaging or pre-enrollment investigation of any diagnosis other than acute ischemic stroke that could cause the presenting symptoms and signs.\n- Commitment to decompressive craniectomy (DC) prior to enrollment or after enrollment but before the start of the study compound.\n- Treatment with IA rtPA (intra-arterial recombinant tissue plasminogen activator) or mechanical means for clot disruption or with hypothermia.\n- Inability to tolerate MRI scanning, such as having pacemakers or automatic defibrillators.\n- Pre-morbid mRS score of 2 or higher.\n- Clinical signs of herniation or evidence of brain stem reflexes attributable to herniation.\n- CT or MRI evidence of hemorrhage or significant shift in the brain.\n- Rapidly improving symptoms.\n- Severe renal disorder or severe liver disease.\n- Blood glucose levels below 55 mg/dL or a history of hypoglycemia.\n- Diagnosis of decompensated heart failure.\n- Recent sulfonylurea treatment.\n- Known allergy to sulfa or specific allergy to sulfonylurea drugs.\n- Known G6PD enzyme deficiency.\n- Pregnancy or breastfeeding.\n- Enrollment in another non-observation-only stroke study, life expectancy less than 3 months unrelated to the current stroke, or unlikely to be compliant with follow-up.\n- Patients deemed unsuitable for the study by the investigator.\n\nThis information provides a detailed description of the sample record in natural language.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the diseases being studied are \"rubeosis iridis\" and \"proliferative diabetic retinopathy\". The ICDCodes associated with these diseases are \"H35.23\", \"H35.20\", \"H35.21\", \"H35.22\", \"E10.3553\", \"E11.3553\", and \"E13.3553\". The drug being tested is \"ranibizumab\". The sample also includes the inclusion and exclusion criteria for the trial, such as age requirements, diabetes mellitus, specific eye conditions, willingness to undergo cataract surgery, and HgbA1c level restrictions.",
    "The sample provided is for a phase 1 clinical trial for the treatment of rheumatoid arthritis (RA) using methotrexate (metoject\u00ae prefilled pen). The eligibility criteria for this trial include being a suitable candidate for methotrexate treatment, being 16 years of age or older, and not having any history of hypersensitivity to the investigational medicinal product. Exclusion criteria include being pregnant, trying to become pregnant, or breastfeeding, having any history of inflammatory arthritis or rheumatic autoimmune disease other than RA, and being unable to comprehend written labeling and training materials.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is \"phase 1\" and the diseases listed are \"acute renal failure\" and \"acute kidney injury\". The corresponding ICDCodes for these diseases are provided as well. The drugs being studied are \"i5np\" and \"placebo\". The eligibility criteria are listed under different categories such as \"Inclusion Criteria (before surgery)\", \"Inclusion Criteria (during surgery)\", \"Inclusion Criteria (after surgery)\", \"Exclusion Criteria (before surgery)\", \"Exclusion Criteria (during surgery)\", and \"Exclusion Criteria (after surgery)\".\n\nThe inclusion criteria include factors such as patient age, consent capability, willingness to comply with study procedures, undergoing major cardiac or vascular surgery, specific kidney injury risk factors, and up-to-date cancer screenings. The exclusion criteria include factors such as cancer history or predisposition, abnormal chest X-ray findings, elevated enzyme levels, women of childbearing potential, recent participation in experimental therapy, immunosuppressive therapy, and various pre-operative and post-operative complications.\n\nOverall, the sample provides a detailed description of the clinical trial phase, diseases being studied, drugs involved, and the specific eligibility criteria for participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 1. The disease mentioned is an unspecified adult solid tumor that is specific to the protocol. The ICD-10 codes associated with the disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drug being used in the trial is sunitinib malate. The eligibility criteria for the trial include various medical conditions and requirements such as histologically proven metastatic/unresectable adrenocortical carcinoma or melanoma, specific performance status, blood test results, absence of certain medical conditions, and more. The sample also includes restrictions on prior treatments and concurrent therapies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors\" and its corresponding ICDCodes are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug mentioned is \"px-866\". \n\nThe eligibility criteria for this trial include:\n- The patient must have a histologically or cytologically confirmed diagnosis of advanced solid tumor and has failed or is intolerant of standard therapy, or for whom standard therapy does not exist.\n- The patient must be 18 years of age or older.\n- The patient must have an ECOG performance status of 0 to 1.\n- The patient must have a predicted life expectancy of at least 12 weeks.\n- The patient must have discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of the study drug and recovered from the toxic effects of the prior treatment.\n- The patient must have discontinued any radiation therapy for at least four weeks and have recovered from all radiation-related toxicities prior to receiving the first dose of the study drug.\n- The patient must have adequate hematologic, hepatic, and renal function.\n- There are also exclusion criteria listed, such as having any active infection, known diabetes or high fasting blood glucose levels, known HIV, serious concomitant systemic disorders, recent surgery, significant central nervous system or psychiatric disorders, and other conditions that could jeopardize the safety of the patient and compliance with the protocol.\n\nIt is important to note that this is just a sample record from the table, and there may be more records with different phases, diseases, ICDCodes, drugs, and eligibility criteria in the actual table.",
    "The sample provided is for a Phase 1 clinical trial. The trial focuses on the treatment of obesity and lipid disorders. The trial drug is called ZYT1, and there is also a placebo tablet used for comparison. The eligibility criteria for participants include being between the ages of 18-45, mentally and physically capable of giving informed consent, and within a specific weight range. Other criteria include normal thyroid function, specific lipid levels, and for the gender effect study, only females with certain reproductive histories or contraceptive measures will be recruited.\n\nExclusion criteria include hypersensitivity to the drug, history of thyroid disorders, liver or renal disease, certain heart conditions, musculoskeletal disorders, and other systemic disorders or diseases. Participants must not be taking certain hormonal therapies or thyroid supplements, and must not have a history of coagulopathy or chronic medication use. Other exclusions include significant alcohol or drug abuse, smoking, difficulty with donating blood, abnormal blood pressure or pulse rate, abnormal X-ray or laboratory findings, and major illness or surgery within the past 3 months. Participants must also not have participated in any other drug research study within the past 3 months or donated blood within the past 3 months.\n\nFor the gender effect study, additional criteria for exclusion include recent pregnancy or lactation, not being protected against pregnancy, use of hormonal contraceptives or hormone replacement therapy, inability to provide assurance of protection against pregnancy, history of osteoporosis or recent fracture, and a positive urine pregnancy test on the day of check-in.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 1 trial and the diseases being studied are chronic lymphocytic leukemia and leukemia. The corresponding ICD-10 codes for these diseases are provided. The drug being tested in this trial is clofarabine. The eligibility criteria for this trial are listed, including requirements for patient characteristics such as blood counts, liver and renal function, and performance status. There are also exclusion criteria, which specify conditions or circumstances that would disqualify a patient from participating in the trial, such as certain heart diseases, pregnancy or breastfeeding, recent chemotherapy, and other significant medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is colorectal cancer, and the corresponding ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are (folpi) picoplatin with 5-fu and leucovorin, folpi, and folfox. \n\nThe eligibility criteria for this trial include having histologically or cytologically confirmed adenocarcinoma of the colon or rectum, having metastatic disease consistent with colorectal adenocarcinoma, and not being amenable to curative surgery. Other criteria include not having received prior systemic therapy for metastatic cancer, having an ECOG performance score of 0 or 1, and having a life expectancy of more than 3 months. \n\nAdditional criteria include having measurable disease according to the RECIST criteria, a certain time period having elapsed since prior surgery, radiotherapy, or a prior investigational agent. The sample also specifies certain blood count and liver function requirements, as well as negative pregnancy test results for women of childbearing potential. \n\nExclusion criteria for this trial include concurrent use of EGFR inhibitors or anti-VEGF agents, the presence of clinically significant obstructive symptoms or intestinal bleeding, and a history of serious cardiac disease. Other exclusion criteria include clinical evidence of brain metastases or central nervous system disease, symptomatic peripheral neuropathy, uncontrolled intercurrent illness, pregnancy or nursing, and serious medical or psychiatric illness that could interfere with the completion of the study treatment. Finally, the sample states that any malignancy other than colorectal carcinoma within the past 5 years, except for certain specified cases, would be an exclusion criterion.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and in this case, it is a combination of phase 1 and phase 2. The diseases being studied in this trial are \"primary erythromelalgia\" and \"inherited erythromelalgia.\" The corresponding ICD-10 code for these diseases is \"I73.81.\" The drugs being tested in the trial are \"xpf-002\" and \"placebo.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must have a Body Mass Index (BMI) within the range of 18-40 kg/m2, have primary or inherited erythromelalgia, experience flares of pain in their feet or hands caused by erythromelalgia, be generally healthy (apart from their pain), stop taking their usual pain medications and certain other medications for up to 11.5 weeks, not be pregnant or breastfeeding, and be able and willing to provide informed consent and comply with all study procedures and restrictions.\n\nOn the other hand, the exclusion criteria specify that participants must not be in constant pain, have any other source of pain from conditions that may interfere with the study interpretation, have HIV, Hepatitis B or C, have received treatment for significant depression within 6 months of screening, not be willing to use adequate contraception, have alcoholism or a history of alcohol or substance abuse, have a major psychiatric disturbance, have any other condition or finding that may pose undue risk for participation, have used any other investigational drug in the 30 days prior to dosing, have donated or lost a significant amount of whole blood or plasma within a certain timeframe, or be an employee or relative of an employee directly involved in the study.",
    "The sample from the table is a clinical trial for colorectal cancer patients in phase 1/phase 2. The trial aims to test the effectiveness of three drugs: capecitabine, gefitinib, and oxaliplatin. The eligibility criteria for patients include having histologically or cytologically confirmed colorectal cancer with metastatic disease, measurable disease, and no CNS metastases. Patients must be between the ages of 18 and 80, have an ECOG performance status of 0-1, and a life expectancy of more than 3 months. They should also meet certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Other criteria include not being pregnant or nursing, having no known hypersensitivity to the drugs, and not having any severe or uncontrolled systemic disease. Patients must be able to receive oral medication and should not have any other significant clinical disorder or laboratory finding that would prevent their participation in the study. The sample also includes information on prior concurrent therapies, such as chemotherapy, radiotherapy, and surgery, as well as restrictions on the use of certain medications during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the trial is in phase 1/phase 2 and is focused on treating myelodysplastic syndromes, acute myeloid leukemia, and leukemia. The ICDCodes associated with these diseases are provided as well. The drugs being studied in this trial are oxaliplatin, fludarabine, and cytarabine.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include confirmation of relapsed or refractory AML or high-risk myelodysplastic syndrome, a performance status of 0-2, specific levels of serum creatinine and bilirubin, and written informed consent. Exclusion criteria include no untreated or uncontrolled life-threatening infection, no intolerance to the specified drugs, no pregnancy or lactation, no recent chemotherapy or radiation therapy, and no other medical conditions that could interfere with the patient's ability to participate in the study or interpret the results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"irritable bowel syndrome constipation predominant,\" and its corresponding ICDCodes are ['K59.00', 'K59.09', 'K59.01', 'K59.02', 'K59.03', 'K59.04', 'K58.1']. The drugs being tested in this trial are 'rose-010' and 'placebo'. \n\nThe eligibility criteria for this trial are as follows:\n- Inclusion criteria:\n  1. Female aged 18-65 years old inclusive.\n  2. A previous diagnosis of IBS according to Rome III criteria, with recurrent abdominal pain or discomfort for at least six months prior to diagnosis, occurring at least three days per month in the last three months. The pain or discomfort should be associated with improvement upon defecation, onset associated with a change in the frequency of stool, or onset associated with a change in the form (appearance) of stool.\n  3. Constipation predominant type IBS, characterized by fewer than three spontaneous complete bowel movements per week, hard or lumpy stools more than 25% of the time, or straining during a bowel movement more than 25% of the time.\n  4. A normal rectal exam result on file within the past two years or performed at the screening to exclude the possibility of an evacuation disorder.\n  5. Females of childbearing potential must use an acceptable method of contraception during the study.\n  6. Able to provide written informed consent prior to any study procedures being performed.\n\n- Exclusion criteria:\n  1. Female patients who are pregnant or breastfeeding.\n  2. Patients with structural or metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal disorders other than C-IBS.\n  3. Patients unable to withdraw medications 48 hours prior to the study, including medications that alter GI transit, laxatives, antacids, prokinetics, certain antidepressants, analgesic drugs, GABAergic agents, and benzodiazepines.\n  4. Patients with clinical evidence or current clinically significant abnormal physical exam or laboratory test results that could indicate significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other diseases that interfere with the objectives of the study.\n  5. Patients who are considered alcoholics not in remission or known substance abusers.\n  6. Patients who have participated in another clinical study within the past 30 days.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug mentioned is rad001, which is used in addition to standard radiation and chemotherapy. The eligibility criteria for this trial include various factors such as histologically or cytologically confirmed NSCLC, disease stage, pleural effusion conditions, measurable and evaluable disease criteria, age, performance status, life expectancy, lung function, bone marrow function, liver function, renal function, cholesterol and triglyceride levels, informed consent, and radiation therapy requirements. The exclusion criteria include prior radiation or chemotherapy for NSCLC, recent major surgery or traumatic injury, prior treatment with investigational drugs, chronic systemic treatment with corticosteroids or immunosuppressive agents, recent immunization with live vaccines, other malignancies within the past 3 years, and various severe or uncontrolled medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Type 2 Diabetes. The ICDCodes associated with this disease are 'E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', and 'E11.44'. The drug being tested is chromium picolinate. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a diagnosis of Type 2 Diabetes for two years or less, being treated with metformin, and having a stable dose of metformin between 1000-2550 mg per day for at least two months. The HbA1c level should be between 7.0-10.5%.\n\nExclusion criteria include having a duration of metformin treatment longer than 1 year at the start of the study, using oral anti-diabetes medication (other than metformin) or insulin, having a history of myocardial infarction within the last 6 months, unstable angina, uncontrollable hypertension, or congestive heart failure. Other exclusion criteria include not receiving routine management for Type 2 Diabetes, not using standard birth control measures for women of child-bearing age, abnormal laboratory values for hemoglobin, hematocrit, WBC, platelets, serum creatinine, BUN, total bilirubin, LFTs, and having current use of nutritional supplements or certain lipid-lowering medications.\n\nIt is important to note that this is just a sample record from the table, and there may be more records with different phases, diseases, ICDCodes, drugs, and eligibility criteria in the actual table.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on treating metastatic breast cancer. The trial is specifically targeting patients with advanced breast tumors that have been confirmed through histologic or cytologic diagnosis with ER positive or the investigator believes they will benefit from the trial. The patients must have experienced relapse or failure from previous standard treatment. Other criteria include being female, aged between 18 and 65, having a BMI index between 19 and 30, and not having any serious heart, liver, lung, or kidney diseases. The patients must have received at least one anti-cancer treatment in the past, with the last treatment being at least four weeks before the study enrollment or more than 5 times the half-life. The life expectancy of the patients must be at least 12 weeks, and they must be able to cooperate in observing adverse events and efficacy. No other concurrent anti-cancer treatment is allowed, and a signed informed consent is required. The patients must have an ECOG Performance Status of 0 or 1, and women with childbearing potential must have a negative pregnancy test. The exclusion criteria include known hypersensitivity to flavonoid drugs, abnormal liver function, abnormal renal function, abnormal bone marrow function, abnormal PT/APTT values, history of thrombotic disease, high serum calcium levels, not having recovered from previous treatments or surgery, presence of serious or uncontrollable systemic disorders or active infections, CNS metastases or invasion requiring treatment, and no malabsorption or other diseases that may affect drug absorption, distribution, metabolism, and excretion. Concurrent other malignancies are generally not allowed, except for cervical cancer in situ or squamous Cell Carcinoma of the Skin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is acute leukemia. The ICDCodes associated with this disease are C91.01, C91.02, C92.01, C92.02, C92.41, C92.42, and C92.51. The drug being tested is ly2523355. \n\nThe eligibility criteria for this trial are divided into two periods: dose escalation and dose confirmation. For the dose escalation period, participants must have a confirmed diagnosis of acute leukemia, be 18 years or older, have a performance status of 0 or 1 on the ECOG scale, and females with childbearing potential must have a negative pregnancy test. \n\nFor the dose confirmation period, participants must have a confirmed diagnosis of untreated acute myeloblastic leukemia (AML) and not be a candidate for standard therapy. They should be 60 years or older, have a performance status of 0 or 1 on the ECOG scale, and females with childbearing potential must have a negative pregnancy test.\n\nThe exclusion criteria include having received treatment with an unapproved drug within 28 days prior to the study, having central nervous system (CNS) leukemia, having other active malignancies (except basal and squamous cell skin cancer), having had a bone marrow transplant within 3 months, having graft-versus-host disease, having uncontrolled systemic infection, being pregnant or lactating, and having positive test results for HIV, hepatitis B surface antigen, or hepatitis C antibodies.\n\nThis sample provides a detailed description of the trial phase, disease, ICDCodes, drug, and the eligibility and exclusion criteria for potential participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1. The specific disease being studied is \"multiple myeloma and plasma cell neoplasm.\" The corresponding ICD-10 codes for these diseases are \"C96.20,\" \"C96.29,\" and \"D47.09.\" The drugs being used in the trial are \"arsenic trioxide,\" \"bortezomib,\" and \"melphalan.\" \n\nThe eligibility criteria for the trial are listed under different categories. The \"Disease Characteristics\" section includes criteria such as a confirmed diagnosis of multiple myeloma, indication for therapy based on symptoms, stable disease or achieved remission to pre-transplant therapy, and being a candidate for high-dose chemotherapy with autologous stem cell transplantation. \n\nThe \"Patient Characteristics\" section includes criteria such as Karnofsky performance status, specific blood test results, bone marrow reserve, negative pregnancy test for females of childbearing potential, cardiac health, and lung function. \n\nThe \"Prior Concurrent Therapy\" section includes criteria related to previous radiation therapy and the use of bisphosphonates for lytic bone disease.\n\nThere are also exclusion criteria listed for each category, such as active plasma cell leukemia, relapsed refractory disease, progressive disease, peripheral neuropathy, history of second malignancy, and previous transplantation.\n\nOverall, this sample provides detailed information about the phase 1 clinical trial, including the diseases being studied, the drugs used, and the eligibility criteria for participants.",
    "The sample from the table represents a clinical trial for breast cancer treatment. The trial is in phase 1 and focuses on patients with stage IV breast cancer. The diseases column specifies the disease being studied, which in this case is \"neoplasms, breast.\" The icdcodes column contains a list of ICD-10 codes associated with the disease. In this sample, the icdcodes are ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60'].\n\nThe drugs column lists the drugs being used in the trial, which are 'lapatinib, docetaxel, trastuzumab' and 'docetaxel, trastuzumab'. The criteria column provides the eligibility criteria for the trial. It includes criteria for female subjects, such as age requirements and specific conditions related to child-bearing potential. Other criteria include performance status, confirmation of ErbB2 over-expression, availability of tumor tissue for biomarker evaluation, and adequate organ function.\n\nThe exclusion criteria specify conditions that would disqualify a subject from participating in the trial, such as peripheral neuropathy of grade 2 or higher, prior systemic therapy for metastatic disease, and uncontrolled heart conditions. The sample also includes additional exclusion criteria related to hypersensitivity to certain drugs and the use of prohibited medications.\n\nOverall, this sample provides information about the phase, diseases, icd codes, drugs, and eligibility criteria for a clinical trial focused on breast cancer treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are refractory solid tumors and leukemia. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are bevacizumab, sorafenib, and cyclophosphamide. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include a diagnosis of recurrent or refractory solid tumors or leukemia, age below or equal to 21 years at the time of diagnosis, a life expectancy of at least 8 weeks, specific performance status requirements, adequate organ and marrow function, recovery from prior therapy, and certain restrictions on medication use. \n\nThere are also additional criteria related to pregnancy, contraception, breastfeeding, wound healing, thrombosis, cardiovascular conditions, and informed consent. \n\nThe exclusion criteria include a body surface area below 0.3 m2, bleeding diathesis or coagulopathy, evidence of intra-tumoral central nervous system hemorrhage, hypersensitivity to other recombinant human antibodies, uncontrolled infection, and exclusion of patients with recurrent or refractory leukemia from the dose escalation component of the Phase 1 trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 1.\n- Diseases: The trial is focused on Type 1 Diabetes Mellitus.\n- ICD Codes: The ICD-10 codes associated with the disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44'].\n- Drugs: The drugs being tested in the trial are 'insulin glargine hoe901' and 'insulin glargine - new formulation hoe901'.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". The inclusion criteria include factors such as age, body weight, body mass index, stable insulin regimen, and overall health assessment. The exclusion criteria include factors such as presence of certain diseases, history of severe hypoglycemia, drug allergies, recent participation in other trials, and use of certain medications.\n\nPlease note that the provided information is not exhaustive and may not include all relevant considerations for potential participants in the clinical trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases being studied are breast cancer, triple negative breast cancer, and metastatic breast cancer. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are azd2281 and paclitaxel. The eligibility criteria for this trial include specific requirements for patients with metastatic triple negative breast cancer, normal organ and bone marrow function, ECOG performance status of no more than 2, and the availability of a tumour sample for testing. There are also exclusion criteria, such as recent chemotherapy or radiotherapy, major surgery within the past 4 weeks, and certain medications that may interfere with the trial. Additionally, patients with a second primary cancer are excluded, except for specific cases of adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors with no evidence of disease for at least 5 years.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for the disease \"melanoma\". The trial is focused on patients with metastatic melanoma who have an activating V600 BRAF mutation. The trial requires patients to have measurable tumors and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. \n\nThe sample also includes a list of ICD-10 codes associated with the disease, which are \"C43.0\", \"C43.31\", \"D03.9\", \"C43.51\", \"C43.9\", \"D03.0\", and \"C43.4\". Additionally, there is a list of drugs being used in the trial, which are \"ipilimumab (bms-734016)\" and \"vemurafenib\". \n\nThe eligibility criteria for the trial are provided, including both inclusion and exclusion criteria. Inclusion criteria include having metastatic melanoma with the specified BRAF mutation, a measurable tumor, and a specific performance status. Exclusion criteria include having autoimmune disease, active brain metastasis (unless stable after radiation for at least one month), and prior therapy with immune stimulating agents.\n\nThe sample also includes a website link for more information about participating in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is chronic pancreatitis. The ICD-10 codes associated with this disease are K86.1 and K86.0. The drug being tested is human secretin. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being between the ages of 18-70, having documented chronic pancreatitis, using contraception if female, and being willing to sign informed consent. Exclusion criteria include being under 18 or over 70 years old, having recent acute pancreatitis or symptoms of it, having severe cardiac, pulmonary, or renal disease, having a previous adverse reaction to secretin, ongoing illicit drug or alcohol use, recent use of certain medications, and having any medical condition that would make participation in the study medically inadvisable.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 1 trial for a drug called tki258 (dovitinib). The trial is focused on treating advanced solid tumors, excluding breast cancer, that have either progressed despite standard therapy or have no standard therapy available. The trial is open to patients with a World Health Organization (WHO) performance status of 2 or lower and who meet specific laboratory values outlined in the protocol.\n\nThe record also includes exclusion criteria, such as patients with brain cancer, those with severe or uncontrolled medical conditions that could affect their participation, patients who have not recovered from previous anti-cancer treatments, and female patients who are pregnant, breastfeeding, or unwilling to use effective birth control methods.\n\nIt's important to note that there may be additional inclusion and exclusion criteria defined by the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on stomach neoplasms (stomach cancer). The associated ICD-10 codes for the disease are ['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']. The trial involves the use of three drugs: 5-fluorouracil, cisplatin, and sunitinib malate. The eligibility criteria for participants are listed, including requirements such as a confirmed diagnosis of stomach cancer, advanced stage IV cancer, adequate blood chemistry and kidney function, and willingness to comply with study requirements and sign an informed consent document. The exclusion criteria include prior chemotherapy for advanced stomach cancer, excessive toxicities from previous therapies, and being pregnant or breastfeeding.",
    "The sample provided is for a Phase 1 clinical trial. The trial is focused on healthy males of Caucasian ethnicity, aged between 21 and 50 years, with a body mass index (BMI) ranging from 19 to 29.9 kg/m2. The trial requires volunteers to complete all study-related activities and provide written informed consent.\n\nThe inclusion criteria for the trial include being a healthy male, within the specified age and BMI range, and willing to participate. \n\nThe exclusion criteria include any abnormal findings in the medical examination, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders, clinically relevant electrolyte disturbances, diseases of the central nervous system, psychiatric disorders, neurological disorders, history of photosensitivity or recurrent rash, history of orthostatic hypotension, fainting spells, or blackouts, chronic or clinically relevant acute infections, history of relevant allergies or hypersensitivity, intake of drugs with a long half-life, use of drugs that may influence the trial results, vulnerable subjects, contraindications or hypersensitivity to specific medications, participation in another trial with an investigational drug, smoking, inability to refrain from smoking on trial days, alcohol abuse, drug abuse, recent blood donation, any laboratory values outside the reference range indicating underlying disease or poor health, excessive physical activities before or during the trial, hypersensitivity to treatment medication or related drugs, and a marked baseline prolongation of QT/QTc interval or specific enzyme polymorphism.\n\nThe drugs being tested in this trial include bi 207127 na, bi 201335 na, midazolam, and tolbutamide. The diseases being studied are listed as 'healthy', and the corresponding ICD-10 codes are ['Z76.3', 'Z76.2'].\n\nOverall, this sample provides detailed information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample from the table represents a clinical trial with multiple phases (phase I, phase II, and phase III) for the treatment of various diseases. The diseases included in this sample are recurrent childhood anaplastic astrocytoma, recurrent childhood brain stem glioma, recurrent childhood ependymoma, recurrent childhood giant cell glioblastoma, recurrent childhood glioblastoma, recurrent childhood gliosarcoma, recurrent childhood medulloblastoma, and recurrent childhood oligodendroglioma. The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe trial involves the use of a drug called lapatinib ditosylate. The eligibility criteria for the trial are also provided, including specific requirements for each phase of the trial. Inclusion criteria include having a histological diagnosis of a malignant CNS tumor, specific types of recurrent or refractory diseases, and measurable disease. Other criteria include performance scales, recovery from prior chemotherapy, time intervals for radiation and bone marrow transplants, seizure control, corticosteroid use, and discontinuation of certain medications.\n\nExclusion criteria include significant medical illnesses that cannot be controlled, diseases that may affect drug metabolism or obscure toxicity, and uncontrolled infection. Patients must also be willing to use a medically acceptable form of birth control and provide signed informed consent.\n\nOverall, the sample provides information about the phases of the trial, the diseases being targeted, the drug being used, and the eligibility criteria for participation.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on the disease \"proliferative diabetic retinopathy.\"\n- ICD Codes: The ICD-10 codes associated with the disease are \"H35.23,\" \"H35.20,\" \"H35.21,\" \"H35.22,\" \"E10.3553,\" \"E11.3553,\" and \"E13.3553.\"\n- Drugs: The drug being studied is \"ranibizumab.\"\n- Criteria: The eligibility criteria for participants in the trial are listed, including age, patient-related considerations (such as having diabetes mellitus and no sensitivity to ranibizumab), disease-related considerations (such as having diabetic neovascularization and no ocular inflammation), and other considerations (such as not being enrolled in another clinical study).\n\nThe exclusion criteria are also mentioned, which include pregnancy, uncontrolled glaucoma, prior enrollment in the study, any condition that may pose a significant hazard, and participation in another simultaneous medical investigation or trial.",
    "The sample is a phase 1 clinical trial for Parkinson's disease. The trial is testing the effectiveness of a drug called mk0657, as well as comparing it to a placebo (unspecified), levodopa, and carbidopa. The eligibility criteria for participants include being between the ages of 40 and 80, being in general good health, being willing to discontinue anti-Parkinson's medications before dosing, having levodopa-induced peak-dose dyskinesias, and not being heavy smokers or drinkers. The exclusion criteria include having atypical Parkinson's syndrome due to drugs or other disorders, having intolerance or hypersensitivity to levodopa or carbidopa, recent use of anticholinergics or memantine, having a history of certain medical conditions such as seizure disorder or cardiovascular disease, and having abnormal blood pressure levels.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is melanoma. The corresponding ICD-10 codes for the disease are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being used in the trial are sunitinib and dacarbazine. The eligibility criteria for participants are listed, including requirements such as having stage IV or unresectable stage III melanoma, resolving any acute toxic effects from previous treatments, and meeting certain organ function criteria. There are also exclusion criteria, such as recent major surgery or radiation therapy, history of certain medical conditions, and ongoing treatment on another clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on ovarian cancer. The ICD-10 codes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being studied are perifosine and docetaxel. The eligibility criteria for participants include having a confirmed diagnosis of epithelial cancer of the ovary, fallopian tube cancer, or gynecologic primary peritoneal cancer. Patients must also be platinum resistant or refractory, have accessible tumors for biopsy, and meet certain age and performance status requirements. Other criteria include willingness to comply with study procedures, use effective birth control, and have adequate liver, renal, and bone marrow function. There are also exclusion criteria, such as concurrent chemotherapy, certain medical conditions, hypersensitivity to study drugs, and recent treatments for tumor control.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"advanced solid tumors.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug being tested is \"darinaparsin.\" \n\nThe eligibility criteria for this trial include subjects with histological or cytological confirmation of advanced cancer that is refractory to standard therapies, men and women of at least 18 years of age, an ECOG performance score of 2 or lower, and the presence of at least one measurable lesion as defined by RECIST 1.1 guidelines. Other criteria include a life expectancy of at least 12 weeks, adequate bone marrow, liver, and renal function, adequate vascular access for blood sampling, agreement to use effective contraception, and written informed consent.\n\nThe exclusion criteria for this trial include an allergy to arsenic, a New York Heart Association functional class of 3 or higher myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, a QTc of 450 msec or higher, pregnancy or lactation, uncontrolled systemic infection, metastatic brain or meningeal tumors, seizure disorder requiring medication, history of confusion or dementia, anticancer chemotherapy or immunotherapy during the study or within four weeks of study entry, recent radiotherapy or major surgery, use of other investigational drug therapy within four weeks prior to study entry, history of invasive second primary malignancy within the previous 3 years (except for certain types of cancer), substance abuse or medical/psychological/social conditions that may interfere with participation in the study, and any unstable condition that could jeopardize the patient's safety or compliance in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are leukemia and lymphoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are pentostatin, tacrolimus, and methotrexate. \n\nThe eligibility criteria for this trial include:\n1. Patients who are receiving allogeneic hematopoietic transplants from an unrelated donor or one antigen mismatched related donors.\n2. Patients with AML, ALL, Hodgkin's disease, MDS (including CMML), CML in late chronic or accelerated phase or in blast crisis, and lymphoma in first or later relapses.\n3. Patients must have specific values for bilirubin, DLCO, LVEF, and performance status.\n4. Candidates must have a specific level of creatinine or creatinine clearance.\n\nThe exclusion criteria for this trial include:\n1. HIV seropositivity.\n2. Uncontrolled infection.\n3. Pregnancy.\n4. Candidates should not have received certain chemotherapy treatments within a specific timeframe.\n5. Diagnosis of myelofibrosis.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The trial involves the use of two drugs, melatonin and placebo. The eligibility criteria for participants are listed, including requirements such as having undergone a unilateral segmental mastectomy, being at least 40 years old, having a certain level of preoperative functioning, and being willing to provide informed consent and complete questionnaires. There are also exclusion criteria, which specify conditions or circumstances that would disqualify potential participants from the trial, such as having autoimmune diseases, being pregnant or lactating, having renal or hepatic failure, or having certain psychiatric disorders. Additionally, the use of certain medications, including benzodiazepines for insomnia and melatonin for sleep, is also listed as exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cystic fibrosis. The ICDCodes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drug being used in the trial is sodium chloride (7%). \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being male or female (non-pregnant, non-lactating), having a documented diagnosis of cystic fibrosis, and meeting certain severity of disease requirements such as FEV1 and oxygen saturation levels. The patient or their legally authorized representative must also agree to participate in the study by signing the informed consent form.\n\nExclusion criteria include having unstable lung disease, being unable or unwilling to withdraw from certain therapies prior to and during the study, being unable to withhold the use of certain medications, having received an investigational drug or therapy in the past 30 days, and having had radiation exposure within the past year that would exceed federal regulations.\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drug, and eligibility criteria for a clinical trial focused on cystic fibrosis.",
    "The sample from the table is a clinical trial for patients with metastatic melanoma. The trial is a combination of phase 1 and phase 2. The eligibility criteria for inclusion in the trial include having histologically confirmed malignant melanoma, stage IV disease with CNS metastases allowed, measurable disease, at least 1 prior systemic therapy, negative pregnancy test, and recovered from all toxic effects of prior therapy. The exclusion criteria include a life expectancy of less than 4 months, known HIV positivity, active infection requiring antibiotic therapy, other malignancy within the past 5 years (except surgically resected basal cell or squamous cell skin cancer), significant medical disease that may interfere with study completion, pregnancy or nursing, prior use of temozolomide or dacarbazine, investigational agent within 4 weeks prior to study entry, and concurrent use of certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is hyperparathyroidism, secondary. The corresponding ICDCodes for this disease are 'E21.1' and 'N25.81'. The drugs being tested in this trial are etelcalcetide and placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria state that the trial is open to males between the ages of 18 and 45 who have provided written informed consent and are in good health based on medical history, physical examination, and routine laboratory tests. \n\nExclusion criteria include a history or presence of any significant acute or chronic illness, ongoing medical conditions requiring prescription medication, history of asthma or severe allergies, clinically significant abnormalities on screening tests, and a history of drug or alcohol abuse.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is cancer, and the associated ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is \"decitabine and pegylated interferon-alfa 2b\". The eligibility criteria for this trial include having a biopsy-proven metastatic or unresectable cancer, having measurable disease by RECIST criteria, and not having untreated brain metastasis. Other criteria include specific performance status, time since previous treatments, liver and renal function, blood counts, informed consent, age, and exclusion criteria such as cardiac problems, uncontrolled medical conditions, pregnancy or nursing, and prior malignancies.",
    "The sample from the table represents a clinical trial for phase 1/phase 2 of a drug study. The trial focuses on patients with head and neck cancer. The diseases column specifies the disease name, while the icdcodes column provides the corresponding ICD-10 codes for the diseases. The drugs column lists the names of the drugs being studied, which include carboplatin, rad001, and paclitaxel. The criteria column outlines the eligibility criteria for patients to participate in the trial.\n\nThe eligibility criteria include specific disease characteristics such as histologically confirmed squamous cell carcinoma in certain areas of the oral cavity, oropharynx, larynx, or hypopharynx. The disease should be locally advanced and either unresectable or resectable with surgery contraindication. Patients with stage I, II, III, or IVc disease are not eligible. Measurable lesions are defined based on their size and imaging techniques.\n\nPatient characteristics include a WHO performance status of 0-2, a life expectancy of more than 3 months, and specific blood counts and levels within normal ranges. Other requirements include normal liver and kidney function, normal cholesterol levels, and the ability to swallow pills. Patients should not be pregnant or nursing, and fertile patients must use contraception during and after the study. Certain preexisting conditions and diseases are not allowed, and patients should not have a history of cancer within the past 5 years, except for specific types. Psychological, familial, sociological, or geographical conditions that may affect compliance with the study protocol are also considered.\n\nPrior concurrent therapy is not allowed, including prior therapy for the specific cancer being studied, prior chemotherapy (unless for another primary tumor in remission), prior investigational drug use, and recent participation in another therapeutic trial. Concurrent radiotherapy is generally not allowed, except for anterior radiotherapy for another primary tumor in remission. The use of certain medications, such as CYP3A4 strong inhibitors and anti-coagulant therapy, is also restricted during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include \"human epidermal growth factor 2 negative carcinoma of breast,\" \"male breast cancer,\" \"recurrent breast cancer,\" \"stage iiic breast cancer,\" and \"stage iv breast cancer.\" The corresponding ICDCodes for these diseases are provided as well.\n\nThe drug being tested in this trial is \"paclitaxel.\" The eligibility criteria for participants in this trial are listed, including requirements such as written informed consent, a life expectancy of at least 3 months, confirmed diagnosis of Her-2 negative breast cancer with evidence of metastatic disease, and specific medical parameters related to hematologic, renal, and hepatic function.\n\nExclusion criteria are also listed, which include factors such as a history of bleeding disorders, concurrent hormone therapy, grade 2 or higher peripheral neuropathy, recent chemotherapy or radiotherapy, allergies to certain substances, and various medical conditions or infections.\n\nOverall, this sample provides a snapshot of a clinical trial in Phase 1, focusing on breast cancer and the drug paclitaxel, with specific eligibility and exclusion criteria outlined.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are lymphoma and small intestine cancer. The ICDCodes associated with these diseases are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S' for lymphoma and 'C17.9', 'C78.4', 'D37.2', 'C17.8', 'D13.30', 'D13.39', 'Z12.13' for small intestine cancer. The drug being tested in this trial is vorinostat. The eligibility criteria for participants include specific disease characteristics and patient characteristics. The disease characteristics vary depending on the type of lymphoma, such as diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell non-Hodgkin lymphoma. The patient characteristics include performance status, blood counts, liver and kidney function, absence of certain medical conditions, and the ability to swallow capsules. Prior concurrent therapy and the use of certain medications are also considered.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on treating diseases such as adult glioblastoma, adult gliosarcoma, and recurrent adult brain neoplasm. The diseases are identified using ICD-10 codes. The trial involves the use of drugs like sorafenib tosylate and temsirolimus. The eligibility criteria for participants include having undergone central pathology review, having received a limited number of prior chemotherapy regimens, and having histological confirmation of grade 4 astrocytoma or gliosarcoma. Other criteria include evidence of tumor progression, measurable disease, specific performance status, and certain blood count and organ function requirements. The exclusion criteria include prior specific treatments, bleeding disorders, certain medication use, certain medical conditions, pregnancy or nursing, and other active malignancies or illnesses.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is renal cell carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drug being tested is \"tivozanib (av-951) plus temsirolimus\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include age requirements, confirmation of renal cell carcinoma, documented progressive disease, measurable disease, prior treatment history, performance status, and various medical conditions that may exclude a participant from the trial. Additionally, there is a list of prohibited medications and treatments during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being used in the trial are 'bibw 2992' and 'bibf 1120'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a male or female patient with a confirmed diagnosis of advanced, non-resectable and/or metastatic solid tumors, who have failed conventional treatment or for whom no proven therapy exists. Other criteria include being 18 years or older, having a life expectancy of at least three months, providing written informed consent, having an Eastern Cooperative Oncology Group performance score of 0, 1, or 2, and having recovered from previous therapies and surgeries.\n\nExclusion criteria include having an active infectious disease, gastrointestinal disorders that may interfere with drug absorption, serious illness or non-oncological diseases incompatible with the protocol, untreated or symptomatic brain metastases, cardiac left ventricular function with resting ejection fraction less than 50%, low blood cell counts, abnormal liver or kidney function, pregnancy or breastfeeding, recent treatment with other investigational drugs or therapies, inability to comply with the protocol, active alcohol or drug abuse, requirement for therapeutic anticoagulation or antiplatelet therapy (except Aspirin), and a history of hemorrhagic or thrombotic events in the past 12 months or known inherited predisposition to bleeding or thrombosis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"metastatic cancer\" and \"unspecified adult solid tumor, protocol specific\". The ICDCodes associated with these diseases are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", \"C17.2\" for metastatic cancer, and \"H01.009\", \"H02.209\", \"H02.009\", \"H02.109\", \"H04.209\", \"H05.409\", \"H10.509\" for unspecified adult solid tumor, protocol specific. The drug being used in the trial is \"riluzole\". \n\nThe eligibility criteria for this trial include specific disease characteristics such as having histologically confirmed solid tumor and having at least 2 brain metastases as demonstrated by baseline MRI. Patients with only 1 metastasis are eligible if it is too large for radiosurgery and not amenable to surgical resection. Patients should not be considered for surgical resection and should be eligible to undergo whole-brain radiotherapy (WBRT). \n\nThere are also patient characteristics that need to be met, including an ECOG performance status of 0-2, ANC (absolute neutrophil count) of at least 1,000/\u03bcL, platelet count of at least 50,000/\u03bcL, total bilirubin within 1.5 times the upper limit of normal (ULN), AST/ALT within 1.5 times ULN, INR (international normalized ratio) within 1.5 times ULN, normal sodium levels, normal thyroid-stimulating hormone levels, negative pregnancy test, and the use of effective contraception for fertile patients. \n\nThere are also exclusion criteria, such as no history of headaches, disequilibrium, vertigo, or dizziness, no known history of hepatitis B or C, and no concurrent serious systemic disorder that would compromise the safety of the patient or their ability to complete the study. Additionally, patients should have no history of allergic reactions attributed to riluzole. \n\nIn terms of prior concurrent therapy, patients should not have undergone whole-brain radiotherapy (WBRT) before, and there should be at least a 2-week gap since the last systemic chemotherapy. Systemic chemotherapy is not allowed during and for at least 3 weeks after completion of WBRT. Radiosurgical boosts to up to 3 metastases are allowed based on the discretion of the treating radiation oncologist.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is cancer, specifically advanced or metastatic solid tumors. The ICD-10 codes associated with these tumors are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is called bms-690514. The eligibility criteria for participants include having advanced or metastatic solid tumors that are not responding to standard treatment, as well as having adequate kidney, liver, and cardiac function.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on head and neck cancer. The ICD-10 codes associated with the disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being studied in the trial are carboplatin, cisplatin, docetaxel, fluorouracil, and lapatinib ditosylate. The eligibility criteria for the trial include specific disease characteristics such as histologically confirmed newly diagnosed squamous cell carcinoma of the larynx or hypopharynx, specific tumor stages, and nodal status. Other patient characteristics include WHO performance status, blood count levels, liver function, kidney function, cardiac function, and absence of certain medical conditions. Prior concurrent therapy and the use of certain medications are also considered in the eligibility criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1/phase 2. The disease being studied is rheumatoid arthritis. The ICD-10 codes associated with the disease are \"M06.9\", \"M05.9\", \"M06.08\", \"M06.00\", \"M06.011\", \"M06.012\", and \"M06.019\". The drug being tested is ccx 354-c. The sample also includes the eligibility criteria for participants in the trial, including age range, previous treatment requirements, medical history, and contraceptive use for participants of childbearing potential. Additionally, there are exclusion criteria listed, such as previous diagnoses, pregnancy, drug use, and certain medications that would disqualify potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-small cell lung cancer, lung cancer, and NSCLC (non-small cell lung cancer). The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial are etoposide and cisplatin. The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe inclusion criteria include requirements such as histologically or cytologically confirmed stage II or stage III non-small cell lung cancer, or stage IV non-small cell lung cancer that will be treated with curative intent, measurable disease, no active malignancy within the past 5 years (except for non-melanoma skin cancers or carcinoma in situ of the cervix), age of 18 years or older, life expectancy of greater than 6 months, Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, normal organ and marrow function, and forced expiratory volume (FEV1) of 1 L or greater OR 50% or greater of predicted.\n\nThe exclusion criteria include factors such as primary tumor size greater than 6cm, prior history of thoracic radiotherapy, not receiving any other study agents, history of pulmonary fibrosis, history of allergic reactions to compounds similar to cisplatin or etoposide, primary tumor located less than 1.5 cm beyond hilar lymphadenopathy and 1.5 cm from the proximal bronchial tree, uncontrolled intercurrent illness, pregnancy or breastfeeding, HIV-positive individuals on combination antiretroviral therapy, and patients planned to receive certain medications.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial related to non-small cell lung cancer.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on multiple sclerosis. The ICD-10 codes associated with the disease are 'G35' and 'C81.18'. The drugs being studied in the trial are inhaled cannabis, oral THC, oral placebo, and inhaled placebo. The eligibility criteria for participants are listed, including a diagnosis of clinically definite multiple sclerosis, moderate or severe spasticity, age 21 or older, and living close to the Sacramento, CA area. There are also exclusion criteria, such as preexisting pulmonary and cardiac conditions, inability to abstain from smoking or certain medications, history of drug abuse, and other psychiatric illnesses. Additional criteria include recent cannabis use, use of certain medications, arthritis or other disorders interfering with spasticity measures, inability to provide informed consent, and inability to comply with contraception for females of childbearing potential.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The specific disease being studied is metastatic pancreatic cancer. The ICD-10 code for this disease is C25.3. The trial involves two drugs: \"ipi-926 plus gemcitabine\" and \"placebo plus gemcitabine\". The eligibility criteria for participants are listed, including age, confirmation of metastatic pancreatic adenocarcinoma, presence of at least one evaluable metastatic lesion, ECOG performance status of 0 or 1, a life expectancy of at least 3 months, agreement to use birth control, ability to adhere to the study schedule, and voluntary consent. The exclusion criteria are also listed, which include specific types of pancreatic cancer, prior chemotherapy treatment for pancreatic cancer, central nervous system metastases, inadequate hematologic, hepatic, or renal function, external biliary drain, history of certain cardiovascular events, venous thromboembolic events, concurrent use of certain medications or foods, active infection or recent antibiotic use, significant co-morbid conditions, HIV positivity, known hypersensitivity to the drugs being studied, and pregnancy or lactation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are 'E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', and 'E11.44'. The drugs being tested in this trial are 'azd1656' and 'placebo'. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients must provide signed and dated, written informed consent before any study-specific procedures.\n- Male patients with Type 2 Diabetes Mellitus aged between 20 and 60 years.\n- Patients must have been treated with 1 to 2 Oral Antidiabetic Drugs (OADs) for at least 30 days prior to enrollment.\n- Patients should not have been treated with glitazones within 6 months prior to enrollment.\n- Male patients with Type 2 Diabetes Mellitus without known cardiovascular disease, except for Grade 1 hypertension without secondary organ involvement (e.g., no eye, kidney disease, or LVH documented).\n\nExclusion Criteria:\n- Patients with a history of ischemic heart disease, heart failure, stroke, transitory ischemic attack, or peripheral vascular disease.\n- Patients with a prolonged QTcF interval greater than 450 msec or a shortened QTcF interval less than 350 msec, or a family history of long QT syndrome.\n- Patients with any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG that may interfere with the interpretation of QTc interval changes.\n- Patients with systolic blood pressure greater than 159 mmHg or diastolic blood pressure greater than 99 mmHg at screening and on Day-1.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is atherosclerosis. The ICDCodes associated with this disease are \"I67.2\", \"I70.90\", \"I70.91\", \"I70.0\", \"I70.1\", \"I70.8\", and \"I25.83\". The drugs being used in the trial are darapladib and diltiazem. The eligibility criteria for participants include age between 18 and 65, being healthy based on medical evaluation, having a BMI within the range of 19-37 kg/m2, and meeting specific criteria for female participants regarding reproductive potential. The sample also includes exclusion criteria, such as a history of liver disease, sensitivity to study medications, contraindications for diltiazem administration, and other factors that may pose risks or interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is kidney cancer. The ICDCodes associated with this disease are D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, and D41.02. The drug being tested in this trial is sorafenib. \n\nThe eligibility criteria for this trial include having histologically or cytologically confirmed clear cell renal cell carcinoma (RCC), having measurable disease, and not having received any prior treatment except for sunitinib malate. Other criteria include specific patient characteristics such as ECOG performance status, life expectancy, Motzer prognostic status, blood counts, liver function, kidney function, cardiac function, and other medical conditions. \n\nThe prior concurrent therapy section outlines the treatments and procedures that patients should not have undergone before participating in the trial, such as prior treatment for RCC, systemic treatment for metastatic disease, organ allografts, recent surgeries, radiotherapy, steroid therapy, and the use of Hypericum perforatum (St. John's wort).",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is malignant melanoma. The ICDCodes associated with this disease are C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, and C43.10. The drugs being tested in this trial are imexon and dtic. The eligibility criteria for participants include having inoperable stage III or IV malignant melanoma, being able to perform daily activities, having a projected life expectancy of at least 4 months, not being pregnant or nursing (if female), being willing to use contraceptives, having blood cell counts and blood chemistries in or near normal range, not having prior radiation, not having any other serious illnesses, not having any other active malignancy, not having any serious infections, and not undergoing any other current drug therapy for cancer or steroid therapy. The exclusion criteria include not having prior chemotherapy for stage III or IV disease and not having brain metastases.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 1/phase 2.\n- Diseases: The trial is focused on leukemia and myelodysplastic syndromes.\n- ICD Codes: The ICD-10 codes associated with the diseases are ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01'] for leukemia and ['D46.9', 'D46.C', 'D46.Z'] for myelodysplastic syndromes.\n- Drugs: The trial involves the drug cytarabine.\n- Criteria: The eligibility criteria for the trial are listed, including disease characteristics, patient characteristics, and prior concurrent therapy requirements.\n\nThe disease characteristics include specific diagnostic criteria for acute myeloid leukemia and high-risk myelodysplastic syndromes. The patient characteristics include requirements for ECOG performance status, liver function, kidney function, pregnancy status, contraception use, history of other malignancies, gastrointestinal conditions, serious illnesses or medical conditions, cardiovascular health, hypersensitivity, preexisting hypothyroidism, and neuropathy. The prior concurrent therapy section outlines restrictions on prior chemotherapy, concurrent use of anticoagulants, and other experimental drugs or anticancer therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are breast cancer and brain metastases. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are lapatinib and herceptin. \n\nThe eligibility criteria for this trial include:\n- Histologically or cytologically-confirmed invasive breast cancer\n- HER2 overexpressing breast cancer defined as 3+ staining by immunohistochemistry or HER2 gene amplification by FISH\n- At least one parenchymal brain metastasis\n- Disease progression in the CNS as assessed by new neurological signs or symptoms, new lesions in the CNS on an imaging study, or progressive lesions on an imaging study\n- At least two weeks since prior radiotherapy, last chemotherapy, immunotherapy, biologic therapy, or major surgery for cancer\n- 18 years of age or older\n- Life expectancy of greater than 12 weeks\n- ECOG performance status 0-2\n- Normal organ and marrow function as described in the protocol\n- Left ventricular ejection fraction > 50%\n- Able to swallow and retain oral medications\n\nThe exclusion criteria for this trial include:\n- Prior whole brain radiation therapy (WBRT)\n- Receiving any other investigational agents\n- Concurrent chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for cancer treatment\n- History of grade 3 or 4 allergic reactions to compounds similar to herceptin or lapatinib\n- Leptomeningeal carcinomatosis as the only site of CNS involvement\n- Concurrent treatment with medications that are either inducers or inhibitors of CYP3A4\n- Malabsorption syndrome, significant gastrointestinal function disease, or previous stomach or small bowel resection or active ulcerative colitis\n- History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents\n- Other known contraindication to MRI\n- Uncontrolled intercurrent illness\n- History of other active malignancy except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix\n- Pregnant or breastfeeding women",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is metastatic pancreatic cancer. The ICDCodes associated with this disease are ['C25.3']. The drugs being used in the trial are gemcitabine and albumin-bound paclitaxel. The eligibility criteria for this trial include various factors such as confirmation of metastatic adenocarcinoma of the pancreas, age greater than or equal to 18, negative pregnancy test for female patients, no prior therapy for metastatic disease, specific blood counts and chemistry levels, acceptable coagulation status, Karnofsky performance status, measurable metastatic tumors, informed consent, and exclusion criteria such as brain metastases, certain infections, recent surgeries or therapies, allergies to the study drug, serious medical risk factors, and non-compliance with study procedures. It is also mentioned that the patient should not be enrolled in any other clinical protocol or investigational trial.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is rheumatoid arthritis, and its corresponding ICD-10 codes are provided. The drugs being tested in the trial are ocrelizumab and placebo. The eligibility criteria for participants are listed, including requirements such as having moderate to severe rheumatoid arthritis for at least 6 months, a positive serum rheumatoid factor, current treatment with rheumatoid arthritis medication, and treatment failure with one disease modifying anti-rheumatic drug or biologic. Other criteria include current treatment with methotrexate for at least 12 weeks, use of highly effective contraception, and exclusion of certain conditions or treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are fallopian tube cancer, malignant tumor of peritoneum, and recurrent ovarian epithelial cancer. The corresponding ICDCodes for these diseases are provided as well. The drug being used in the trial is docetaxel. \n\nThe eligibility criteria for this trial include the following:\n- The patient must have histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer.\n- The disease must be persistent or recurrent.\n- The patient must have measurable disease with at least one target lesion.\n- The patient must have received one prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound.\n- The patient must have a Zubrod performance status of 0-2.\n- The patient must meet certain blood count and liver function requirements.\n- The patient must not have certain medical conditions or history of allergic reactions.\n- The patient must not be pregnant or nursing.\n- The patient must use effective contraception during and after the study treatment.\n- The patient must not have certain cardiovascular or neurological conditions.\n- The patient must be able to undergo an MRI scan.\n- The patient must not have had any other invasive malignancy within the past 5 years.\n- The patient must have recovered from prior therapy.\n- The patient must not have received prior VEGF Trap treatment.\n- The patient must meet certain criteria regarding prior paclitaxel or docetaxel treatment.\n- The patient must meet certain criteria regarding the timing of prior surgeries, therapies, and dental procedures.\n- The patient must not be receiving concurrent major surgery, other anticancer therapy, or investigational agents.\n- The patient must not be receiving concurrent hematopoietic growth factors during the first phase of the trial.\n- Concurrent hormone replacement therapy is allowed.\n- The patient's white blood count must be at least 3,000/mm^3.\n\nThis description provides an overview of the sample record and the eligibility criteria for the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is chronic hepatitis B. The ICDCodes associated with the disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drugs being studied are dv-601 and entecavir. The eligibility criteria for this sample include age between 18 and 65, a diagnosis of chronic hepatitis B, normal renal function, and a negative pregnancy test for women of childbearing potential. There are also exclusion criteria such as liver disease other than chronic hepatitis B, co-infection with hepatitis A, C, or HIV, previous therapy with interferon alpha, and recent antiviral therapy for chronic hepatitis B. Other exclusion criteria include cirrhosis, certain scores related to liver function, significant acute or chronic illnesses, malignancy (except for specific cases), recent participation in other experimental protocols or therapies, and current substance or alcohol abuse that may interfere with compliance or interpretation of study results.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 trial phase. The disease being studied is non-small-cell lung carcinoma. The ICD-10 codes associated with the disease are 'D02.20', 'D02.21', and 'D02.22'. The drug being tested is patupilone. \n\nThe eligibility criteria for the trial include:\n- Patients must have histologic or cytologic confirmation of unresectable locally advanced or metastatic NSCLC.\n- Patients must have received prior treatment with a platinum-containing regimen.\n- Patients must be at least 18 years old and have a performance status of 0-1 on the WHO scale.\n- Patients must have a life expectancy of at least 3 months.\n- Patients must have at least one measurable lesion according to modified RECIST criteria.\n- Patients with controlled brain metastases are eligible to be enrolled in the trial.\n- Patients with brain metastases must have evidence of residual disease or progression since prior radiological or surgical therapy.\n- Patients must have adequate hematologic and blood chemistry laboratory values.\n- Female patients must have a negative serum pregnancy test and agree to use contraception during the study.\n- All patients must use a barrier method for contraception for sexual intercourse or avoid it for the first 5 days after patupilone infusion.\n- Written informed consent must be obtained.\n\nThe exclusion criteria for the trial include:\n- Patients who have received more than one prior chemotherapy regimen or any other systemic antineoplastic treatment.\n- Patients who have received any investigational compound within the past 28 days or plan to receive other investigational drugs while participating in the study.\n- Patients with brain metastases who have received any prior chemotherapy regimen or any other systemic antineoplastic treatment for brain metastases.\n- Patients with brain metastases who have experienced a dose increase of 25% or more above the previous dose in concomitant steroidal or anticonvulsive therapy within 14 days prior to study entry.\n- Patients with brain metastases who have leptomeningeal disease or extracranial metastases in more than two organs.\n- Patients with any peripheral polyneuropathy > Grade 1 or unresolved diarrhea > Grade 1.\n- Patients receiving hematopoietic growth factors except erythropoietin.\n- Patients with severe cardiac insufficiency, uncontrolled and/or unstable cardiac or coronary artery disease.\n- Patients taking warfarin or other agents containing warfarin, except for low dose warfarin administered prophylactically.\n- Patients who have not fully recovered from surgery or have received radiation therapy or chemotherapy within the last four weeks.\n- Patients with the presence of active or suspected acute or chronic uncontrolled infection, including abscess or fistulae.\n- Patients known to be HIV positive.\n- Patients with a history of another malignancy within 3 years prior to study entry, except curatively treated non-melanotic skin cancer or cervical cancer in situ.\n- For patients enrolling in the brain metastases cohort, there are additional exclusions to MRI imaging, such as having a cardiac pacemaker, ferromagnetic metal implants, claustrophobia, or obesity exceeding the limits of scanning equipment.\n- Pregnant or lactating females are excluded.\n- Patients with a history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits are excluded.\n\nOther protocol-dependent inclusion/exclusion criteria may also apply.",
    "The sample from the table is for a Phase 1 clinical trial. The disease being studied is diabetes mellitus, type 2. The ICD-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are placebo, insulin, glucose, and glucagon. The eligibility criteria for participants include being surgically sterile or postmenopausal for women, being reliable and willing to follow study procedures, having written informed consent, having certain serum creatinine and hemoglobin levels, and meeting specific criteria for healthy participants or participants with type 2 diabetes mellitus. The exclusion criteria include recent treatment with unapproved drugs, allergies to GLP-1 related compounds, previous participation in similar studies, regular use of drugs of abuse, presence of certain medical disorders, history of gastrointestinal disorder, poorly controlled hypertension, cardiac disease, hepatitis C or B, HIV, excessive alcohol consumption or smoking, use of corticosteroids, neuropsychiatric disease, recent blood donation, and any other condition that would prevent participation in the study. Additional exclusion criteria apply specifically to healthy participants and participants with type 2 diabetes mellitus.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the disease \"pre-hypertension.\" The corresponding ICD-10 codes for this disease are \"O11.1,\" \"O11.2,\" \"O11.3,\" \"O11.4,\" \"O11.9,\" \"O11.5,\" and \"O10.02.\" The drugs being studied in this trial are \"carvedilol phosphate,\" \"lisinopril,\" \"carvedilol phosphate and lisinopril,\" and \"placebo and placebo.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Males and females over 18 years old with pre-hypertensive or borderline blood pressures (systolic blood pressure \u2265 130 mmHg or diastolic blood pressure \u2265 85 mmHg) who are not in need of antihypertensive therapy. They must also have at least one additional risk factor for cardiovascular disease, such as LDL levels between 130 and 160 mg/dL, HDL levels below 40 mg/dL, fasting blood sugar levels between 100 and 126 mg/dL, a body mass index of 30 or higher, being a smoker, or having a family history of premature heart disease or hypertension.\n\nExclusion Criteria:\n- Patients with a history of cardiac, cerebral, or other vascular events within the previous 6 months will be excluded. Other exclusions include patients currently on beta blocker or ACE inhibitor therapy, those with known or suspected intolerance to beta blockers or ACE inhibitors, angiotensin receptor blocker therapy, or diabetes. Pregnant or lactating women, as well as women of child-bearing age who are not using an acceptable form of contraception, are also excluded from this study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of cancer. The trial is associated with specific ICD-10 codes related to cancer. The drug being studied is called gsk1120212. \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria specify that participants must be male and at least 18 years old, provide written informed consent, have a body weight of at least 45 kg and a BMI between 19 kg/m2 and 35 kg/m2, be able to swallow and retain oral medication, have a confirmed diagnosis of a solid tumor, have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, agree to use contraception during the study, have a history of regular bowel movements, and have adequate organ function.\n\nThe exclusion criteria state that participants should not be currently receiving cancer therapy, have serious or unstable pre-existing medical or psychiatric disorders, have undergone major surgery within the last four weeks, have unresolved toxicity from previous anti-cancer therapy, have had significant radiation exposure, have a history of interstitial lung disease or pneumonitis, have hypersensitivity to dimethyl sulfoxide (DMSO), be using prohibited medications, have a history of retinal vein occlusion (RVO) or central serous retinopathy (CSR), have symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression, be receiving enzyme-inducing anti-epileptic drugs (EIAEDs), have a history of acute coronary syndromes or significant uncontrolled arrhythmias, have congestive heart failure, have active gastrointestinal disease or certain gastrointestinal surgeries, have a history of HIV, Hepatitis B, or Hepatitis C, have a history of alcohol or drug abuse, have hypersensitivity to drugs related to the study drugs, have participated in another clinical trial recently, would donate excessive blood during the study, or be mentally or legally incapacitated.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"allergic asthma,\" and the corresponding ICDCodes associated with this disease are ['D69.0', 'L50.0', 'B44.81', 'J30.89', 'J30.9', 'L20.84', 'H10.45']. The drugs being tested in this trial are 'qge031', 'omalizumab', and 'placebo'. The eligibility criteria for this trial include various factors such as age (18 to 65 years), positive skin prick test to common airborne allergens, airway hyperresponsiveness, early asthmatic response, specific body weight and total IgE range, and exclusion criteria such as pregnancy, smoking, poorly controlled asthma, and recent asthma exacerbation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, and recurrent adult brain tumor. The ICDCodes associated with these diseases are G47.13, J01.41, K11.22, K12.0, N96, F33.8, and G03.2. The drugs being used in the trial are sorafenib tosylate, erlotinib hydrochloride, tipifarnib, and temsirolimus. The eligibility criteria for participants include having a confirmed diagnosis of intracranial glioblastoma multiforme or gliosarcoma, evidence of tumor progression, specific blood counts and levels, performance status, and various other medical conditions and requirements.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and the disease being studied is \"healthy\" (which seems to be a control group). The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". The trial involves testing various drugs, including \"placebo\", \"intact alo-02 60 mg/7.2 mg\", \"crushed alo-02 60 mg/7.2 mg\", \"crushed oxycodone ir 60 mg\", \"crushed alo-02 40 mg/4.8 mg\", and \"crushed oxycodone ir 40 mg\". The eligibility criteria for this sample include being a healthy subject and a non-dependent, recreational opioid user. The exclusion criteria include having a diagnosis of substance and/or alcohol dependence, participating in or seeking treatment for substance and/or alcohol-related disorder, having a history of sleep apnea, testing positive for drugs other than marijuana in a urine drug screen, and testing positive for Hepatitis B or C and HIV during screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors\" and its corresponding ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drug mentioned is \"lcl161\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a solid tumor, an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, meeting certain blood laboratory values, meeting criteria for time since the last dose of prior therapy, and providing written informed consent. \n\nExclusion criteria include having active and/or symptomatic brain tumors or brain metastases, unresolved nausea, vomiting, or diarrhea, any ongoing severe and/or uncontrolled medical condition that could compromise participation in the study (such as heart, lung, or inflammatory disease), any disease that may significantly alter the absorption of the study drug, currently receiving treatment with steroids or other immunosuppressive treatment that cannot be stopped prior to starting the study drug, currently receiving treatment with certain medications, having received radiation therapy or undergone major surgery within the last 4 weeks, being a pregnant or breastfeeding woman of child-bearing potential, having a known diagnosis of HIV infection or chronic active hepatitis B or C, and being unwilling or unable to follow the protocol.\n\nIt is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are docetaxel, epirubicin, and bevacizumab. The eligibility criteria for participants in this trial include having histologically- or cytologically-confirmed metastatic breast adenocarcinoma, no HER2 overexpression or gene amplification, no previous therapy for metastatic breast cancer, being between the ages of 18 and 75, having at least a 12-month interval since prior adjuvant therapy with taxanes and/or anthracyclines, having measurable disease, having a performance status (WHO) of 0-2, having adequate liver, renal, and bone marrow function, and providing written informed consent. The exclusion criteria include having an active infection, brain metastases, a history of significant cardiac disease, a history of stroke, being on anticoagulation therapy (except for low dose aspirin), having another invasive malignancy (except nonmelanoma skin cancer), having a psychiatric illness or social situation that would preclude study compliance, and being pregnant or lactating.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"extensive stage lung small cell carcinoma\" and \"recurrent lung small cell carcinoma\". The corresponding ICDCodes for these diseases are \"D02.20\", \"D02.21\", and \"D02.22\". The drugs being used in the trial are \"carboplatin\", \"cisplatin\", \"etoposide\", and \"sunitinib malate\". The eligibility criteria for this trial include having histologically or cytologically documented small cell lung cancer, measurable disease, no prior chemotherapy for small cell lung cancer, completed radiation therapy at least one week before starting the trial, specific performance status, no active second malignancy, no history of brain metastases or other specific conditions, and meeting certain medical criteria such as blood pressure control and blood parameters. Additionally, there are restrictions on the use of certain medications during the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on lung cancer. The ICD-10 codes associated with the disease are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drugs being studied in the trial are 'rad001' and 'docetaxel'. The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having histologically confirmed non-small cell lung cancer, a certain performance status, adequate bone marrow, renal and hepatic function, completed prior therapy, and meeting pre-entry requirements. Exclusion criteria include chronic treatment with systemic steroids or immunosuppressive agents, uncontrolled brain or leptomeningeal metastases, HIV seropositivity, gastrointestinal impairments, bleeding diathesis, hypersensitivity to certain drugs, pregnancy or breastfeeding, intercurrent illnesses, inability to swallow RAD001, history of other invasive malignancies, severe hypersensitivity reaction to docetaxel or other drugs, recent treatment with investigational agents, and final eligibility determined by health professionals conducting the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is non-small-cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is a combination of arq 197 and erlotinib. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include obtaining voluntary written informed consent, having a confirmed diagnosis of advanced/recurrent non-small-cell lung cancer, having a history of at least one prior chemotherapy regimen, having an ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1, and having a life expectancy of at least 3 months. \n\nExclusion criteria include recent treatment with anti-cancer chemotherapy, EGFR-TKI therapy, hormone therapy, radiotherapy, immunotherapy, investigational agents, or anti-cancer antibody therapy within 28 days prior to the administration of ARQ 197. Other exclusion criteria include recent cancer surgery, presence of active double cancer, symptomatic brain metastases, uncontrolled intercurrent illness, pregnancy or lactation, and subjects who wish to have a child but do not agree to use contraceptive measures.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase I, phase II, or phase III. The diseases being studied are Richter's transformation and leukemia. The diseases are also associated with specific ICD-10 codes. The drugs being used in the trial are oxaliplatin, fludarabine, cytarabine, rituximab, and pegfilgrastim. The record also includes the eligibility criteria for the trial, including age, performance status, renal and hepatic function, contraception use, and informed consent. Additionally, there are exclusion criteria such as untreated infections, intolerance to certain drugs, pregnancy or lactation, recent chemotherapy or radiation therapy, and medical conditions that may interfere with participation in the study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is diabetes mellitus, type 2. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drug mentioned is rosiglitazone maleate. The eligibility criteria for this sample include age requirements (18-65 years), specific requirements for females regarding pregnancy and contraception, and the inclusion of healthy normal or overweight control subjects, healthy obese subjects, or subjects with T2DM. The exclusion criteria include past or current significant medical conditions and abnormalities in vital signs or routine laboratory parameters.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is cachexia. The corresponding ICD-10 code for this disease is R64. The drugs being tested in the trial are gsk2849466 and placebo. The eligibility criteria for participants include being male between 18 and 50 years old, having a body weight of at least 50 kilograms and a BMI between 19 and 32 kg/m^2. Participants must also be in good health, as determined by a medical evaluation, and have a normal QT interval on an ECG. There are various exclusion criteria, such as a history of certain diseases or abnormalities, drug or alcohol abuse, and sensitivity to the study medications. Participants must also meet certain laboratory test ranges and refrain from certain medications and substances during the study.",
    "The sample from the table represents a clinical trial for patients with various types of B-cell non-Hodgkin lymphoma (NHL). The trial is divided into three phases: phase I, phase II, and phase III. The diseases included in the trial range from adult non-Hodgkin lymphoma to different stages and grades of follicular lymphoma, mantle cell lymphoma, and other B-cell lymphomas. The trial also includes patients with recurrent lymphomas and splenic marginal zone lymphoma.\n\nThe table provides the corresponding ICD-10 codes for each disease, which are used for classification and coding purposes. The only drug mentioned in the sample is lenalidomide, which is being investigated as a potential treatment option for these lymphomas.\n\nThe eligibility criteria for the trial are also provided. Inclusion criteria include having a histologic diagnosis of CD20+ B-cell NHL, having received high-dose chemotherapy with autologous stem cell transplantation (ASCT) within a specific timeframe, and having stable disease or a partial or complete response following ASCT. Other criteria include specific laboratory values, performance status, and the absence of certain medical conditions.\n\nExclusion criteria include pregnancy or breastfeeding, use of other experimental drugs or therapies, known hypersensitivity to thalidomide or rituximab, concurrent use of other anti-cancer agents or treatments, and certain medical conditions or laboratory abnormalities that would place the subject at unacceptable risk or confound the study results.\n\nOverall, the sample provides information about the diseases included in the trial, the corresponding ICD-10 codes, the investigational drug, and the eligibility criteria for participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on individuals who are not currently affected by any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" \n\nThe drugs being tested in this trial are \"dabigatran etexilate capsules,\" \"quinidine sulfate tablets,\" and \"fexofenadine tablets.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include being a healthy male or female between the ages of 18 and 55, having a BMI between 18.5 and 30 kg/m2, providing written informed consent, not being pregnant or breastfeeding, and using adequate contraception if female and of child-bearing potential. \n\nThe exclusion criteria include having any abnormal findings in the medical examination, having any clinically relevant concomitant disease, having gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders, having a history of relevant orthostatic hypotension, fainting spells, or blackouts, having chronic or relevant acute infections, having relevant allergies or hypersensitivity, taking drugs with a long half-life or drugs that might influence the trial results, participating in another trial with an investigational drug, being a smoker or unable to refrain from smoking on trial days, having alcohol or drug abuse, having recent blood donation or excessive physical activities, having any laboratory values outside the reference range, being unable to comply with the dietary regimen of the trial site, having a marked baseline prolongation of QT/QTc interval, having a history of additional risk factors for Torsades de Pointes, taking drugs known to be P-gp inhibitors or inducers, or having chronic use of oral contraception containing ethinyl estradiol as the only method of contraception.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as a combination of phase 1 and phase 2. The specific disease being studied in this trial is esophagus cancer. The corresponding ICD-10 codes for this disease are ['D13.0', 'C15.9', 'C15.3', 'C15.4', 'C15.5', 'C15.8', 'Z85.01']. The drugs being used in the trial are oxaliplatin, docetaxel, and capecitabine. \n\nThe sample also includes the eligibility criteria for participants. The inclusion criteria state that individuals must have adenocarcinoma or squamous cell carcinoma of the esophagus or G/E junction, be surgical candidates, have not received previous treatment for esophageal cancer, have measurable or evaluable disease, be able to perform daily activities with minimal to no assistance, have adequate bone marrow, liver, and kidney function, and provide written informed consent.\n\nOn the other hand, the exclusion criteria state that individuals cannot participate in the trial if they have tumor location in the proximal esophagus, metastatic disease or locally advanced cancer, moderate to severe peripheral neuropathy, serious pre-existing medical illnesses, significant heart disease, have been treated for an invasive cancer within the previous 5 years, are pregnant or breastfeeding, or are under the age of 18.\n\nIt is important to note that there may be additional inclusion and exclusion criteria that will be determined by the study center. If a participant does not meet the criteria, the study personnel will explain the reasons, and if they do qualify, the trial will be explained in detail, and any questions will be answered.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 1/phase 2.\n- Diseases: The trial is focused on lymphoma.\n- ICD Codes: The ICD-10 codes associated with the lymphoma are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'].\n- Drugs: The drugs being tested in the trial are bortezomib and gemcitabine hydrochloride.\n- Criteria: The eligibility criteria for participants in the trial are listed in a structured format, including disease characteristics, patient characteristics, and prior concurrent therapy requirements.\n\nThe disease characteristics include the diagnosis of B- or T-cell non-Hodgkin's lymphoma (NHL) and specific histology requirements. The patient characteristics include performance status, life expectancy, blood counts, liver and kidney function, and other medical conditions that would exclude participation. The prior concurrent therapy section outlines the allowed and disallowed treatments before participating in the trial.\n\nOverall, this sample provides information about a clinical trial for lymphoma patients in phase 1/phase 2, focusing on specific disease characteristics, drug treatments, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are leukemia and myelodysplastic syndromes. The corresponding ICDCodes for these diseases are ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01'] for leukemia and ['D46.9', 'D46.C', 'D46.Z'] for myelodysplastic syndromes. The drug being used in the trial is cyclophosphamide. \n\nThe eligibility criteria for this trial include a diagnosis of myelodysplastic syndromes (MDS) with an International Prognostic Scoring System (IPSS) score of at least intermediate-2, chronic myelomonocytic leukemia, or acute myeloid leukemia arising from MDS. Patients must have failed or be ineligible for or intolerant to treatment with azacitidine. Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or be ineligible for or intolerant to treatment with lenalidomide. Patients who are HLA-DR15-positive must have failed or be ineligible for pharmacologic immunosuppression. There should be no presence of cytotoxic antibodies against donor lymphocytes, and no HLA-identical donor available or eligible for HLA-identical allogeneic bone marrow transplantation. However, a HLA partially mismatched (haploidentical) related donor is available, including first-degree related donors or inherited recombinant haplotype from parents if the donor shares at least 1 HLA antigen at each of the HLA-A, -B, and DR loci. \n\nThe patient characteristics required for this trial include an ECOG performance status (PS) of 0-1 or Karnofsky PS of 80-100%, bilirubin levels below 3.0 mg/dL, AST and ALT levels within 4 times the upper limit of normal, creatinine levels below 3.0 mg/dL, and a left ventricular ejection fraction (LVEF) above 35%. \n\nRegarding prior concurrent therapy, patients must have recovered from prior therapy, not have received prior transfusions from the donor, and have at least 4 weeks since their last chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy. Additionally, no other concurrent investigational drugs should be used.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes details about the phase of the trial, which in this case is a combination of phase 1 and phase 2. The disease being studied is chronic lymphocytic leukemia (CLL), and the corresponding ICD-10 codes for CLL are provided. The drugs being used in the trial are bendamustine, rituximab, and lenalidomide. \n\nThe record also includes eligibility criteria for participants in the trial. These criteria include factors such as age, medical fitness, performance status, confirmed diagnosis of CLL, life expectancy, previous treatment regimens, timing of previous therapy, liver function, kidney function, blood counts, negative test results for hepatitis B, hepatitis C, and HIV, and contraception requirements for females of childbearing potential. \n\nAdditionally, there are exclusion criteria listed, which specify conditions or circumstances that would prevent someone from participating in the trial. These include factors such as previous treatment with more than three regimens for CLL, central nervous system involvement of CLL, certain aggressive B-cell cancers, history of anaphylaxis to study drugs, evidence of tumor lysis syndrome, participation in other clinical trials or use of investigational agents, presence of severe concurrent diseases, pregnancy or lactation, and other medical conditions or circumstances that would interfere with the study or follow-up. \n\nFinally, there are additional exclusions related to secondary malignancies, active infections, prolonged use of oral corticosteroids, cerebral dysfunction, contraindications to the study drugs, and employment by the sponsor or study sites, as well as being placed in an institution by legal or official order.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of acute myeloid leukemia. The trial uses a combination therapy using decitabine and midostaurin. The eligibility criteria for participants include being at least 60 years old with newly diagnosed AML that is not eligible for standard induction, or being at least 18 years old with relapsed/refractory AML. Other criteria include having a Karnofsky performance status of at least 70, specific lab values within normal range, giving written informed consent, and having a left ventricular ejection fraction of at least 50%. The exclusion criteria include having had a bone marrow or stem cell transplant within the past 2 months, having an uncontrolled active infection, having a known impairment of GI function or disease that may affect the absorption of midostaurin, being pregnant or breastfeeding, having certain medical conditions or diseases that could compromise participation in the study, having impaired cardiac function, having a confirmed diagnosis of HIV infection or active viral hepatitis, having received any investigational agent within the past 30 days, having had any surgical procedure within the past 14 days, and having a history of allergic reactions to similar compounds.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drug being investigated is cc-5013. \n\nThe eligibility criteria for this trial include being over 18 years old, able to adhere to the study visit schedule and other protocol requirements, diagnosed with active multiple myeloma with disease progression or relapse, having measurable myeloma paraprotein levels in serum or urine, having an Eastern Cooperative Group (ECOG) Performance Status of 0-2, and meeting certain laboratory parameters such as bilirubin, liver enzymes, bone marrow function, renal function, and echocardiogram results. \n\nThere are also exclusion criteria, which include severe infection requiring intravenous antibiotic treatment, a life expectancy of less than 3 months, prior malignancy (except for certain types), specific prior treatments, history of certain reactions or diseases, and other medical conditions that may prevent participation in the study. Pregnant or lactating females are also excluded.\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drug, and eligibility criteria for a clinical trial related to multiple myeloma.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on non-small cell lung cancer. The trial is specifically targeting patients with certain histological subtypes of lung cancer who have a high likelihood of responding to the drug gefitinib. The eligibility criteria for the trial include having a previous response to a similar drug, having a specific mutation in the EGFR gene, having recurrent or persistent disease, and meeting certain health and age requirements. The sample also includes exclusion criteria, such as previous severe toxicity to gefitinib, uncontrolled brain metastases, and other medical conditions that would make a patient ineligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is non-small cell lung cancer. The corresponding ICDCodes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are lapatinib and pemetrexed. \n\nThe eligibility criteria for this trial are as follows:\n\nINCLUSION CRITERIA:\n- Signed informed consent\n- Patients must be 18 years old\n- Subjects must have stage IIIB or IV NSCLC\n- Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy\n- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n- Life expectancy of 12 weeks\n- Have adequate organ function baseline laboratory values for inclusion\n\nEXCLUSION CRITERIA:\n- History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible\n- Known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment\n- Peripheral neuropathy of grade 3 or higher\n- Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization)\n- Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU prodrug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is pancreatic cancer, and its corresponding ICDCodes is C25.3. The drug being tested is pemetrexed disodium. The eligibility criteria for this trial include specific disease characteristics, such as histologically or cytologically confirmed carcinoma arising from the pancreas, different stages of the disease, and the absence of certain conditions like neuroendocrine tumor of the pancreas or brain metastasis. The patient characteristics required for participation in the trial include specific performance status, life expectancy, blood counts, liver function, kidney function, and other factors. Prior concurrent therapy and medication restrictions are also mentioned.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied include carcinoma, fallopian tube cancer, ovarian cancer, and primary peritoneal cancer. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are amg 386, paclitaxel, and carboplatin. The eligibility criteria for participants in this trial are listed, including age requirements, specific cancer stages, previous surgeries, organ and hematological function requirements, and exclusion criteria such as prior use of anticancer therapy, history of thromboembolism, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of ovarian neoplasms. The trial involves the use of a drug called sb-485232 (interleukin 18) in combination with pegylated liposomal doxorubicin. The eligibility criteria for participants include being female and at least 18 years old, having a confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, and being a candidate for pegylated liposomal doxorubicin treatment. Other criteria include having measurable lesions, a certain performance status, a predicted life expectancy of at least 4 months, and not having received certain types of therapies within a specific timeframe. The sample also includes exclusion criteria, such as having certain medical conditions, a history of hypersensitivity reactions to certain drugs, being pregnant or breastfeeding, and having certain infections or disorders.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is arthritis, specifically rheumatoid arthritis. The ICD-10 codes associated with the disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs being tested in the trial are otelixizumab and a matching placebo. The eligibility criteria for participants include being between 18 and 75 years old, having a body mass index between 18.5 and 35 kg/m2, and having a diagnosis of rheumatoid arthritis according to the American College of Rheumatology criteria. Other criteria include having active disease with swollen and tender joints, meeting certain laboratory criteria, and not having previously received otelixizumab or any other anti-CD3 monoclonal antibody. There are also exclusion criteria, such as having significant systemic involvement secondary to rheumatoid arthritis, having certain infections or medical conditions, and having undergone major surgery recently.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is lymphoma, and the corresponding ICDCodes are listed as \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drugs being used in the trial are cyclophosphamide, doxorubicin, vincristine, and prednisone. \n\nThe eligibility criteria for this trial include:\n1. Patients with newly diagnosed stage I and II nasal Natural Killer (NK) cell lymphoma.\n2. Adequate blood cell counts at baseline or willingness to accept supportive measures.\n3. Adequate liver function and renal function.\n4. Left ventricular ejection fraction must be at least 50%.\n5. Male patients must use a barrier method of contraception or abstain from heterosexual activity.\n6. Female patients must use two adequate barrier methods of contraception or abstain from heterosexual activity, or be postmenopausal or surgically sterilized.\n7. Female patients of childbearing potential must have a negative pregnancy test.\n8. Patients must have the ability to give informed consent.\n\nThe exclusion criteria for this trial include:\n1. Patients with active Hepatitis B and/or Hepatitis C infection.\n2. Patients with active infections requiring specific anti-infective therapy.\n3. Patients known to be HIV positive.\n4. Patients with pre-existing cardiovascular disease requiring ongoing treatment.\n5. Patients with prior exposure to anthracyclines.\n6. Patients who are pregnant or breastfeeding.\n7. Patients with psychiatric illness and/or social situations that would limit compliance with the study medication and requirements.\n8. Prior radiation to the site of current primary disease, if re-treatment would violate known radiation dose tolerance limits for that site.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are thrombosis and heparin-induced thrombocytopenia. The corresponding ICDCodes for these diseases are \"I81\", \"K64.5\", \"I51.3\", \"I67.6\", \"I74.11\", \"I74.5\", \"I74.8\" for thrombosis and \"D75.82\" for heparin-induced thrombocytopenia. The drug being tested is fondaparinux.\n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Children between 1 year and 18 years of age.\n- The presence of documented venous or arterial thrombosis confirmed by diagnostic imaging.\n- Weight greater than 8.3 kg.\n- Signed informed consent/assent.\n\nExclusion Criteria:\n- Patients with active bleeding.\n- Patients with planned invasive procedures less than 2 weeks from the time of enrollment.\n- Patients with a contraindication to anticoagulation.\n- Patients receiving thrombolytic agents.\n- Patients with an INR>1.5 or an activated partial thromboplastin time (PTT)>40 seconds.\n- Patients with a creatinine level above 1.2 times the upper limit of normal expected for age.\n- Children <1 year of age.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied in this phase include head and neck cancer, liver cancer, breast cancer, gastric cancer, and non-small cell lung cancer. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in this trial are \"cudc-101\" and \"cudc-101\". The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe inclusion criteria include having a confirmed diagnosis of advanced breast, gastric, head and neck, liver, or non-small cell lung cancer. For non-small cell lung cancer, additional criteria include having a radiographic partial or complete response to erlotinib treatment and a documented mutation in EGFR exons 19 or 21. Other criteria include having no further standard of care options or refusing standard therapy, measurable or evaluable disease, age \u2265 18 years, ECOG performance < 2, life expectancy \u2265 3 months, and meeting certain laboratory values.\n\nThe exclusion criteria include recent anticancer therapy or use of investigational agents, history of cardiac disease, known infection with HIV, hepatitis B, or hepatitis C (except for liver cancer and hepatitis cases).\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are related to kidney diseases and transplantation, including kidney transplant, renal transplantation, and renal transplant. The ICDCodes associated with these diseases include codes such as I12.9, N18.9, Q61.9, and others.\n\nThe drugs being used in the trial include daclizumab, mycophenolate mofetil (mmf), prednisone, tacrolimus, ganciclovir, valganciclovir, and trimethoprim and sulfamethoxazole.\n\nThe eligibility criteria for participants in this trial are listed under inclusion and exclusion criteria. Inclusion criteria include being the primary recipient of a kidney transplant, meeting site-specific transplant criteria, having a Panel Reactive Antibody (PRA) of 20% or less, being willing to use acceptable forms of contraception, and having a parent or guardian willing to provide informed consent if applicable.\n\nExclusion criteria include previous treatment with steroids within 6 months prior to transplantation, receiving a kidney that does not meet protocol-specified requirements, receiving an organ from an HLA identical or non-heart-beating donor, receiving a solid organ other than a kidney, receiving a bone marrow or hematopoietic stem cell transplant, receiving a repeat kidney transplant, currently receiving an investigational pharmacologic or biologic agent, being HIV infected or infected with another immunodeficiency virus, having hypersensitivity to murine products or the study drugs or their formulations, inability to measure height accurately, and being pregnant or breastfeeding.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 study design. The trial focuses on the treatment of non-small-cell lung carcinoma. The trial includes patients with histologically and/or pathologically confirmed NSCLC, including various subtypes. Patients must have stage IIIB (with pleural effusion), stage IV, or recurrent metastatic disease. They should have experienced disease progression or relapse after platinum-based chemotherapy. The trial has two study phases, and patients in phase B must have measurable disease according to RECIST criteria. Prior radiation to the measurable site(s) of disease is not allowed unless disease progression has been documented. Patients who have had extensive radiotherapy are excluded. Prior surgery is allowed if completed at least 4 weeks prior to enrollment and the patient has recovered. Patients with primary brain, metastatic brain, or meningeal tumors or clinical signs or symptoms of brain metastases are not eligible. Patients must be able to understand and sign an informed consent document, be at least 18 years old, and have a predicted life expectancy of more than 3 months. The trial also has specific criteria for Eastern Cooperative Oncology Group (ECOG) performance status and laboratory values. Female patients with reproductive potential must have a negative pregnancy test and agree to use contraception. The exclusion criteria include various therapies, medical conditions, and medical history. Major surgery within 4 weeks prior to enrollment, significant weight loss, pregnancy or lactation, rapidly deteriorating liver function tests, dementia or altered mental status, and known allergies to study medication are among the exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is diabetes mellitus, type 2. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are canagliflozin 50 mg, canagliflozin 100 mg, canagliflozin 300 mg, and a placebo. \n\nThe eligibility criteria for this trial include:\n- Patients must have a diagnosis of type 2 diabetes mellitus for at least 1 year, but not more than 12 years prior to the study.\n- Patients must be medically stable based on physical examination, medical history, laboratory safety test results, vital signs, and electrocardiogram performed during the screening process.\n- Patients must have been on a generally stable approved anti-hyperglycemic agent regimen for at least 2 months prior to the screening visit.\n- Patients must have fasting plasma glucose concentrations between 7.8 mM (140 mg/dL) and 15 mM (270 mg/dL) on Day -2.\n\nThe exclusion criteria for this trial include:\n- Patients with a history of clinically significant diabetic complications such as retinopathy, nephropathy, macro albuminuria, neuropathy, gastroparesis, or diabetic ketoacidosis.\n- Patients with a history of type 1 diabetes mellitus.\n- Patients with a history of repeated severe hypoglycemic episodes before screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is \"phase 1/phase 2\". The disease being studied is \"multiple myeloma\". The ICDCodes associated with this disease are \"['C90.01', 'C90.02', 'C90.00']\". The drugs being used in the trial are \"ixazomib\", \"lenalidomide\", and \"dexamethasone\". The eligibility criteria for this trial include requirements such as being 18 years or older, having previously untreated multiple myeloma, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. There are also exclusion criteria listed, such as having peripheral neuropathy greater or equal to Grade 2, being pregnant or lactating, and having certain medical conditions or illnesses that could interfere with the completion of treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Hepatitis C. The ICDCodes associated with this disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being tested in this trial are Imo-2125 and a saline placebo. The eligibility criteria for this trial include being HCV-positive and a nonresponder to standard-dose pegylated interferon-\u03b1-2a or -\u03b1-2b in combination with standard-dose ribavirin. Exclusion criteria include having HIV or hepatitis B surface antigen (HbsAg), inadequate bone marrow, liver, and renal function, recent treatment with interferon-based or other experimental or antiviral therapies, other significant medical diseases, and a history of alcohol or drug abuse within the past 12 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"healthy volunteers\" and \"hepatitis C virus.\" The ICDCodes associated with these diseases are \"B00.81,\" \"B25.1,\" \"B26.81,\" \"B58.1,\" \"K75.4,\" \"A51.45,\" and \"B17.2.\" The drug being tested is \"ro5024048.\" The eligibility criteria for participants include being aged 18 to 65 years, diagnosed with chronic hepatitis C infection, having specific genotypes, being otherwise healthy, meeting certain laboratory measurements, having a specific liver biopsy result, and meeting various other medical and lifestyle requirements. There are also exclusion criteria listed, which include having certain medical conditions, abnormal test results, or a history of certain diseases or allergies.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is Autistic Disorder. The ICDCodes associated with this disease are F84.0. The drugs mentioned are placebo and ro5028442. The eligibility criteria for this trial include being a male adult between the ages of 18 and 45, having an IQ greater than 70, having a body mass index (BMI) between 18 and 35 kg/m2, and having an Aberrant Behavior Checklist (ABC) - Irritability subscale score of 13 or less. The exclusion criteria include testing positive for drugs of abuse, having alcohol and/or substance abuse/dependence in the last 12 months, testing positive for hepatitis B, hepatitis C, or HIV infection, having relevant cardiovascular, renal, hepatic, or hematologic diseases or disorders, having active inflammatory pulmonary disease, having a history of epilepsy/seizure disorder (except for simple febrile seizures), initiating new or major changes in psychosocial intervention within 4 weeks prior to randomization, being treated with any investigational agent within 90 days prior to screening, and having a history of hypersensitivity or allergic reactions.",
    "The sample from the table represents a clinical trial for breast cancer patients. The trial is a combination of phase 1 and phase 2. The diseases included in the trial are male breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, and stage IV breast cancer. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in the trial are vorinostat and paclitaxel. \n\nThe eligibility criteria for the trial include having histologically or cytologically confirmed adenocarcinoma of the breast, stage IV disease or locally recurrent inoperable chest wall disease, specific performance status, certain blood counts and liver function within normal limits, normal kidney function or specific clearance levels, specific urine protein levels, normal cardiac function, and not being pregnant or lactating. \n\nThe exclusion criteria for the trial include recent chemotherapy or radiotherapy, use of other investigational agents, history of allergic reactions to similar compounds, and presence of uncontrolled intercurrent illnesses or conditions that may limit compliance with the study requirements.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"friedreich ataxia,\" and its corresponding ICDCodes is \"G11.11.\" The drug mentioned is \"resveratrol.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria state that adults with Friedreich ataxia due to homozygosity for the GAA repeat expansion in intron 1 of the FXN gene are eligible, and they should have a functional stage on the Ataxia subscale of the FARS of 1 or higher. Exclusion criteria include being pregnant or lactating, having active arrhythmias or significant cardiac insufficiency, using idebenone, Coenzyme Q, or vitamin E within 30 days prior to enrollment, and using amiodarone or other medications with clinically significant drug interactions that cannot be safely monitored.",
    "The sample from the table is a clinical trial in phase 1/phase 2. The disease being studied is acute lymphoblastic leukemia. The corresponding ICD-10 codes for this disease are C91.01, C91.02, and C91.00. The drug being tested is native l asparaginase. The eligibility criteria for this trial include being between 1 and 55 years old, having relapsed after first remission of acute lymphoblastic leukemia or lymphoblastic lymphoma (excluding Burkitt lymphoma), being refractory to first-line chemotherapy for acute lymphoblastic leukemia, and providing written informed consent (or consent from both parents for children). The exclusion criteria are not specified in the given sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"untreated childhood brain stem glioma.\" The ICDCodes associated with this disease are \"F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2.\" The drug being tested is \"tipifarnib.\" \n\nThe eligibility criteria for this trial include:\n- Newly diagnosed non-disseminated intrinsic diffuse brainstem glioma\n- Karnofsky performance scale (KPS) or Lansky performance score (LPS) must be greater than or equal to 50, assessed within two weeks prior to registration\n- No prior chemo or radiation therapy allowed\n- No prior bone marrow transplant\n- Patients receiving enzyme-inducing anticonvulsant drugs are not eligible, but they can switch to non-enzyme-inducing anticonvulsant drugs for at least 7 days prior to registration\n- Off all colony forming growth factor(s) for more than 2 weeks prior to registration\n- Certain blood count and laboratory values must meet specific criteria\n- Female patients of childbearing potential must have a negative pregnancy test and must not be pregnant or breastfeeding\n- Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control\n- Signed informed consent according to institutional guidelines must be obtained\n\nThe exclusion criteria for this trial include:\n- Patients with significant medical illnesses that cannot be adequately controlled or would compromise their ability to tolerate the therapy\n- Patients with disseminated intrinsic diffuse brainstem glioma\n- Patients taking enzyme-inducing anticonvulsant drugs\n- Patients with known allergy to certain imidazoles\n- Patients receiving any other anticancer or experimental drug therapy\n- Patients with uncontrolled infection.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is indicated as \"phase 1/phase 2\". The diseases being studied are \"prostate cancer\" and \"prostatic neoplasms\". The corresponding ICD-10 codes for these diseases are provided as well. The drugs being used in the trial are \"docetaxel\" and \"imatinib mesylate\". The eligibility criteria for the trial are listed, including age requirements, specific diagnosis criteria for prostate cancer, previous treatments received, performance status, and various medical parameters that need to be within certain ranges. The sample also includes exclusion criteria, such as recent use of other investigational agents, presence of certain medical conditions, and previous treatments or surgeries within specific timeframes.\n\nOverall, this sample provides a detailed description of a clinical trial, including the phase, diseases being studied, drugs used, and the eligibility and exclusion criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on studying the effects of drugs on patients with hypertension and renal transplant. The diseases are represented by their corresponding ICD-10 codes. The drugs being tested are placebo and allopurinol. The sample also includes the eligibility criteria for participants, including age, gender, weight, and specific medical conditions. There are also exclusion criteria listed, such as certain medications being taken, laboratory abnormalities, and other medical conditions. The sample concludes with criteria related to pregnancy, previous drug use, and compliance with study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are rectal cancer and colorectal cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are cetuximab, oxaliplatin, capecitabine, and diphenhydramine hydrochloride (HCL). \n\nThe eligibility criteria for this trial include having histologically-confirmed adenocarcinoma of the rectum with clinical stages T3, T4, or N1. The age requirement is 18 years or older, and the Karnofsky performance status (KPS) should be 70 or higher. Other criteria include specific blood counts, liver enzyme levels, bilirubin levels, and kidney function. The ability to swallow pills without difficulty is also required. Women of child-bearing potential must have a negative pregnancy test and use contraception throughout the treatment. \n\nThe exclusion criteria for this trial include having metastatic or stage IV disease, prior treatment with cetuximab or other therapy targeting EGFR, prior history of anti-cancer murine monoclonal antibody therapy, prior pelvic or whole abdominal radiotherapy, and uncontrolled intercurrent illnesses. Patients with concurrent or previous malignancies within 5 years, except for specific exceptions, will be excluded. Other exclusion criteria include inability to sign written consent, pregnancy or breastfeeding, and unwillingness or inability to use effective contraception.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial is focused on head and neck cancer. The ICD-10 codes associated with the disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being studied in the trial are cisplatin, doxorubicin hydrochloride, and fosbretabulin disodium. The eligibility criteria for the trial include specific disease characteristics such as histologically confirmed anaplastic or poorly differentiated variant thyroid carcinoma, regionally advanced disease confined to the neck and/or superior mediastinum, and completely resected disease without measurable or evaluable disease. Other criteria include age 18 and over, ECOG performance status of 0-2, life expectancy of at least 12 weeks, and various hematopoietic, hepatic, renal, and cardiovascular requirements. The sample also includes information on prior concurrent therapy restrictions for biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other cytotoxic or investigational therapies. Additionally, there are specific requirements regarding concurrent medications known to prolong the QTc interval.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is rectal cancer, and its corresponding ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are azd6244 and cediranib (azd2171). \n\nThe eligibility criteria for this trial are listed under \"Inc Criteria\" and \"Exc Criteria.\" The inclusion criteria include having histologically confirmed rectal adenocarcinoma, locally advanced rectal cancer as defined by MRI and triphasic CT, and other specific medical conditions and test results. The exclusion criteria include having concurrent uncontrolled medical illness, being under 18 years old, being pregnant or lactating without adequate contraception, having previous chemotherapy or radiotherapy for rectal cancer, having metastatic disease, and having certain cardiac, respiratory, or other medical conditions.\n\nThere are also additional exclusion criteria specific to the AZD6244 and Cediranib cohorts, which include specific genetic markers, prior treatment with a MEK inhibitor, and certain baseline measurements and medical conditions.\n\nOverall, this sample provides information about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on rectal cancer.",
    "The sample from the table represents a clinical trial for a combination treatment for breakthrough nausea and vomiting in patients with unspecified adult solid tumors. The trial is in phase 1/phase 2. The diseases included in the trial are breakthrough nausea and vomiting and unspecified adult solid tumors. The corresponding ICD-10 codes for the diseases are provided. The drugs being tested in the trial are fosaprepitant dimeglumine and systemic chemotherapy. The eligibility criteria for the trial include a diagnosis of cancer, scheduled inpatient chemotherapy with moderately emetogenic agents, and the use of a 5-HT3 receptor antagonist antiemetic on the day of chemotherapy. Patients must also have self-reported at least mild nausea or moderate nausea, or have experienced at least one episode of emesis since receiving chemotherapy. There should be no history of chronic nausea and/or vomiting, anticipatory nausea and/or vomiting, or emesis within 24 hours before chemotherapy. Patients must be able to understand English, not be pregnant or nursing, have a negative pregnancy test, and have no clinical evidence of current or impending bowel obstruction. They should also have no allergy or intolerance to the study drugs. Prior chemotherapy is allowed, but the use of aprepitant as prophylaxis or rescue treatment during the current course of chemotherapy (other than as part of the study therapy) is not permitted. Patients should not be scheduled to receive a dopamine antagonist after chemotherapy.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial in this sample is in phase 1 and focuses on the disease \"type 2 diabetes mellitus\". The corresponding ICD-10 codes for this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being studied in this trial are \"mk-0941\", \"placebo\", and \"lantus insulin\". \n\nThe sample also includes the eligibility criteria for participants. The inclusion criteria state that participants must be males or females (of non-childbearing potential) between the ages of 18 and 70. They should have a diagnosis of Type 2 Diabetes and currently be treated with basal insulin. Smokers are allowed to participate but are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules.\n\nThe exclusion criteria state that individuals with a history of Type 1 diabetes, those treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to the study start, those with a history of severe hypoglycemia, and those allergic to insulin are not eligible to participate in the trial.",
    "The sample in the table is for a phase 1 clinical trial. The disease being studied is chronic hepatitis C infection. The ICD-10 codes associated with this disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs being tested in this trial are ach-0143102 and ribavirin. The eligibility criteria for participants include being 18 years or older, having a clinical diagnosis of hepatitis C with genotype 1b, being treatment naive for chronic hepatitis C, having IL28B genotype CC, having HCV RNA levels greater than 10000 IU/mL at screening, and meeting certain contraception requirements for females and males. There are also exclusion criteria such as having a BMI greater than 36, being pregnant or nursing, having clinically significant laboratory abnormalities, previous participation in a clinical trial with protease inhibitor and/or NS5A inhibitor, having HIV infection or other liver diseases, testing positive for Hepatitis B Surface Antigen, having liver cirrhosis, having uncontrolled psychiatric disease, having clinical evidence of chronic cardiac disease, and having a history of malignancy within the past 5 years.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is non-small cell lung cancer. The icd-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug mentioned for this trial is sunitinib and rapamycin, and it states that the drug will be held. The eligibility criteria for this trial include having a histologically or cytologically proven NSCLC, being at least 18 years old, having an ECOG score of 0-2, having a life expectancy of at least 3 months, and meeting certain requirements regarding prior therapy, surgery, intercurrent illness, cardiovascular conditions, spinal cord compression, psychiatric conditions, laboratory abnormalities, bone marrow function, liver function, renal function, serum calcium levels, hypersensitivity reactions, contraception, and written consent. The trial is open to both men and women of all racial and ethnic subgroups, but pregnant and nursing women are not eligible.",
    "The sample from the table is for a phase 1 trial. The disease being studied is renal cell carcinoma. The ICD-10 codes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being tested in this trial are cp-675,206 and su011248. The eligibility criteria for this trial include having histologically proven renal cell carcinoma with metastases and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The exclusion criteria include having received more than one systemic therapy for metastatic renal cell carcinoma and having a history of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening CT or MRI scan.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is diabetes mellitus, type 2. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are pf-05161704 or placebo. The eligibility criteria for participants include being a healthy male or female between the ages of 18 and 55, having a BMI between 24.5 and 35.5 kg/m2, and a total body weight of over 50 kg. Exclusion criteria include having any clinically significant diseases or conditions that may affect drug absorption, a history of excessive alcohol consumption or tobacco/nicotine use within a certain timeframe.",
    "The sample in the table is for a phase 1 clinical trial. The disease being studied is \"healthy\", which means the trial is focused on individuals who are generally healthy. The ICD-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"darifenacin\", \"tolterodine\", and \"placebo\". The eligibility criteria for participants include being males and females aged 50 years or older, having a body mass index between 18.5 kg/m2 and 35.0 kg/m2. There are also exclusion criteria, such as having allergies to tolterodine ER or darifenacin, having irregular day and night patterns, having medical problems that affect heart rate, taking medications that affect heart rate, having a history of malignancy within the past 5 years (except for localized basal cell carcinoma of the skin), being pregnant or nursing, and having certain diseases like urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, severe renal insufficiency, etc. Additionally, there may be other inclusion/exclusion criteria defined by the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"drug/agent toxicity by tissue/organ\" and \"multiple myeloma and plasma cell neoplasm\". The corresponding ICDCodes for these diseases are \"['T86.91', 'T86.92', 'T86.93', 'Z52.9', 'Z94.89', 'Z94.9', 'T86.90']\" and \"['C96.20', 'C96.29', 'D47.09']\" respectively. The drugs being used in the trial are \"amifostine trihydrate\" and \"melphalan\". \n\nThe eligibility criteria for this trial include specific disease characteristics such as histologically confirmed amyloidosis, presence of monoclonal protein, and absence of primary amyloidosis manifested only by carpal tunnel syndrome or purpura. Other criteria include age between 18 and 70, ECOG performance status of 0-1, specific hematopoietic, hepatic, renal, and cardiovascular requirements, as well as restrictions on concurrent therapies and prior treatments.\n\nOverall, this sample provides a snapshot of the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on patients with stage IV pancreatic cancer. The eligibility criteria include having histologically or cytologically confirmed pancreatic adenocarcinoma, unresectable disease, and compatible histologic diagnosis based on a metastatic site. Patients should not have endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer. They should also not have macroscopic residual disease post-resection as the only site of disease, clinically significant ascites, or known brain metastases. Other criteria include specific performance status, blood counts, liver and kidney function, glucose levels, and coagulation factors. Patients should not be pregnant or nursing, and fertile patients must use effective contraception. They should be willing to submit previously collected tumor tissue specimens. There are also restrictions on prior treatments, including no prior chemotherapy, hormonal therapy, immunotherapy, or chemoradiotherapy for advanced or locally advanced pancreatic cancer. Patients should not have plans to receive concurrent therapy for cancer treatment. There are also specific restrictions on prior medications and concurrent use of certain medications. Anticoagulation is allowed under certain conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are diabetes and diabetes mellitus, type 1. The ICDCodes associated with these diseases are E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65 for the first disease, and E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44 for the second disease.\n\nThe drugs being tested in this trial are liraglutide and placebo. The eligibility criteria for participants are as follows:\n\nInclusion Criteria:\n- The participant must have been clinically diagnosed with Type 1 diabetes mellitus for at least 12 months prior to randomization.\n- The participant's body mass index (BMI) must be between 20.0 and 28.0 kg/m^2 (inclusive).\n\nExclusion Criteria:\n- The participant must not have used liraglutide or exenatide within 3 months of randomization.\n- The participant must not have experienced recurrent severe hypoglycemia (more than 1 severe hypoglycemic event in the last 12 months) or have hypoglycemic unawareness as determined by the trial physician. Additionally, the participant must not have been hospitalized for diabetic ketoacidosis in the previous 6 months.\n- The participant must not have donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is lung cancer, non-small cell. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs mentioned in this record are pazopanib, erlotinib, and pemetrexed. The eligibility criteria for this trial include various factors such as written informed consent, confirmed diagnosis of advanced solid tumor, age above 18, ECOG performance status of 1 or lower, and adequate organ system function. The criteria also specify requirements for hematologic, hepatic, and renal functions, as well as the presence of measurable disease on a CT scan. Additionally, there are specific criteria for female subjects regarding pregnancy and contraception. The exclusion criteria include prior use of the mentioned drugs, history of central nervous system metastases, gastrointestinal abnormalities, uncontrolled infection, certain cardiovascular conditions, recent cerebrovascular accidents or deep venous thrombosis, major surgery or trauma, active bleeding, and various other medical or psychiatric conditions that could interfere with the study. The criteria also mention the discontinuation of certain medications and the exclusion of subjects who have used investigational agents or cancer therapies within a specific timeframe.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases listed are diabetes and diabetes mellitus, type 2. The ICDCodes associated with these diseases are provided as well. The drug mentioned in this sample is insulin degludec. The eligibility criteria for this trial are listed under both inclusion and exclusion criteria, including age, nationality, diabetes diagnosis duration, insulin treatment duration, BMI, HbA1c levels, fasting C-peptide levels, and various exclusion factors such as recent use of certain medications, blood or plasma donation, smoking, and specific blood pressure thresholds.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on ovarian cancer. The ICD-10 codes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being studied are cc-5013 and topotecan. The eligibility criteria for participants are listed, including requirements such as age over 18, documented advanced ovarian or primary peritoneal carcinoma, measurable disease, previous treatment with platinum and paclitaxel, and a performance status of 0 or 1. The exclusion criteria are also listed, which include various laboratory abnormalities, serious medical conditions or psychiatric illnesses, prior history of malignancy (except certain types), brain or leptomeningeal disease, prior use of certain drugs, and concurrent use of other anti-cancer agents.",
    "The sample in the table represents a clinical trial for the treatment of psoriasis. The trial is in phase 1/phase 2, meaning it is still in the early stages of testing. The disease being studied is psoriasis, and the corresponding ICD-10 codes for psoriasis are provided. The drugs being tested in the trial include ciclosporin formulations, betamethasone, calcipotriol, and another formulation. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Subjects must have chronic plaque type psoriasis.\n- Sexually active females of childbearing potential must either be surgically sterile or use a highly effective contraceptive method.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Local treatment with antipsoriatics (except for salicylic acid in vaseline) in the 4 weeks preceding and during the study (corticosteroids 8 weeks).\n- Systemic treatment with antipsoriatics or therapy with PUVA, selected ultraviolet photo therapy in the three months preceding and during the study.\n- Treatment with systemic or locally acting medications that might counter or influence the study aim.\n- Previous therapy with methotrexate over many years.\n- Therapy with nephrotoxic medication.\n- Therapy with digoxin, colchicin, and statins.\n- Medications that might influence the potassium metabolism.\n- Subjects with known dysfunction of the calcium metabolism.\n- Subjects with increased uric acid or potassium serum levels.\n- Erythrodermic psoriasis, psoriasis punctata and pustular psoriasis, or extended chronic stationary forms of psoriasis.\n- Subjects with acute virus infection.\n- Subjects with acne, anogenital pruritus, rosacea, perioral dermatitis, specific skin problems (skin tuberculosis, luetic skin diseases), vaccination reactions, skin infections caused by bacteria or viruses.\n- Symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study.",
    "The sample from the table represents a clinical trial for the treatment of various brain tumors and meningiomas. The trial is divided into different phases, with phase 1/phase 2 being mentioned in this sample. The diseases included in the trial are adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult grade i meningioma, adult grade ii meningioma, adult grade iii meningioma, and recurrent adult brain tumor.\n\nThe corresponding ICD-10 codes for these diseases are also provided. The only drug mentioned in this sample is erlotinib hydrochloride. The eligibility criteria for the trial are listed, including the requirement of a confirmed diagnosis of intracranial malignant glioma or recurrent/progressive benign or malignant meningioma. Other criteria include measurable or evaluable disease, specific performance status, blood count requirements, absence of certain ophthalmic abnormalities, absence of active infection or other serious concurrent medical illness, and more.\n\nThe sample also mentions specific time intervals since prior treatments, such as chemotherapy, radiotherapy, and surgery, as well as restrictions on the use of certain medications. The sample concludes with the exclusion of patients on concurrent combination antiretroviral therapy for HIV-positive patients.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"pain, neuropathic.\" The associated ICD-10 codes for this disease are ['E85.1', 'E85.0', 'N31.0', 'N31.1', 'N31.2', 'E10.610', 'E11.610']. The drugs being studied in this trial are 'gabapentin lower dose', 'donepezil', and 'gabapentin higher dose'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male between 18 and 55 years old, having a body weight of at least 50 kilograms and a BMI within the range of 18.5-29.9 kilograms per square meter. The participant must also be deemed healthy based on medical evaluations, including medical history, physical examination, psychiatric evaluation, laboratory tests, and cardiac monitoring. Certain parameters such as AST, ALT, alkaline phosphatase, bilirubin, and QT duration corrected for heart rate must also fall within specified ranges.\n\nExclusion criteria include having a previous or current medical condition that may compromise safety or affect the interpretation of efficacy data. Other factors such as a history of seizures, abnormal ECG results, abnormal blood pressure, sensitivity to study medications, regular alcohol consumption, positive drug/alcohol screen, excessive caffeine consumption, excessive smoking, recent use of prescription/non-prescription drugs or supplements, use of topical steroids or capsaicin preparations, needle phobia, inability to tolerate certain stimulation, absence of allodynia or hyperalgesia, significant suicide risk, recent participation in another clinical trial, blood donation within a specific period, and positive Hepatitis B or Hepatitis C results are also considered exclusion criteria.\n\nOverall, this sample provides a snapshot of the phase, diseases, associated ICD-10 codes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2, and the disease being studied is multiple myeloma. The corresponding ICD-10 codes for multiple myeloma are ['C90.01', 'C90.02', 'C90.00']. The drugs being used in the trial are cci-779 and bortezomib. \n\nThe eligibility criteria for this trial include being 18 years of age or older, having received prior therapy for myeloma and experiencing relapse or relapsed/refractory multiple myeloma. The patient must also have certain levels of monoclonal protein or light chain in their serum or urine, or measurable light chains by free light chain assay, or measurable plasmacytoma. The patient's ECOG Performance Status should be 0, 1, or 2, and their laboratory values should meet the requirements outlined in the protocol.\n\nThere are also exclusion criteria, such as having an uncontrolled infection, recent cytotoxic chemotherapy, biologic therapy, or corticosteroid use, being pregnant or nursing, unwillingness to use adequate contraception, receiving other concurrent investigational therapies, being HIV positive, having recent myocardial infarction or severe heart failure, having hypersensitivity to bortezomib, boron, or mannitol, having a serious medical or psychiatric illness that may interfere with participation in the trial, and receiving or needing live vaccines for immunization.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is sarcoma. The ICDCodes associated with this disease are C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, and C92.32. The drug being used in the trial is chemotherapy. The eligibility criteria for participants include having a biopsy-proven soft tissue sarcoma of the extremity, meeting certain disease characteristics such as being a high-grade tumor or a low-grade tumor at high risk for local recurrence, and meeting certain patient characteristics such as having specific blood counts, liver function, and no concurrent diseases that would prevent them from tolerating treatment. Additionally, participants must have had at least 30 days since their last therapy for sarcoma.",
    "The sample from the table represents a phase 1 clinical trial. The disease being studied is an unspecified adult solid tumor. The corresponding ICD-10 codes for this disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs being investigated in this trial are cyclophosphamide and imatinib. \n\nThe eligibility criteria for this trial include a diagnosis of advanced or metastatic solid tumor, refractory to standard therapy or no standard therapy available. Patients with advanced ovarian cancer, peritoneal carcinomatosis, or metastases causing significant ascites are excluded. Lung malignancies with certain characteristics such as proximity to major vessels, central location, cavitary nature, squamous histology, or hemoptysis greater than \u00bd teaspoon per day are also excluded.\n\nOther patient characteristics required for participation in the trial include an ECOG performance status of 0-1, platelet count of at least 100,000/mm^3, absolute neutrophil count of at least 1,500/mm^3, bilirubin level below 2 mg/dL, AST or ALT levels below 3 times the upper limit of normal, creatinine level below 2 mg/dL, urine protein to creatinine ratio of 1.0 or less, not being pregnant or nursing, negative pregnancy test, use of effective contraception for fertile patients, ability to tolerate oral therapy, absence of bleeding disorders or coagulopathy, and no impairment of gastrointestinal function or diseases that may affect the absorption of the drugs.\n\nAdditional exclusion criteria include no abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months, no uncontrolled hypertension (blood pressure above 150/100 mm Hg), no uncontrolled cardiovascular disease, and no arterial thromboses within the past year. Patients with interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung, serious nonhealing wounds, ulcers, or bone fractures, active second malignancies (except nonmelanoma skin cancer or cervical carcinoma in situ), active infection or known HIV infection, history of severe allergic reactions to similar compounds, noncompliance with medical regimens, intolerance or hypersensitivity to the study drugs, significant medical or psychiatric illnesses, or social situations that may limit compliance with study requirements are also excluded. Patients who are unable to provide reliable informed consent or have undergone major surgery within the past 28 days or are expected to undergo major surgery during the study treatment are also not eligible for participation.",
    "The sample from the table is for a phase 1 clinical trial. The diseases being studied include \"healthy\" and \"otherwise healthy volunteers with mild or moderate hepatic dysfunction\". The corresponding ICD-10 codes for these diseases are \"Z76.3\" and \"Z76.2\". The drugs being tested in the trial are \"dacomitinib\". The eligibility criteria for inclusion in the trial include being a healthy male or female between the ages of 18 and 75, having a BMI between 18 and 35 kg/m2, providing informed consent, and being willing to comply with the study procedures. For subjects with hepatic impairment, they must meet specific criteria related to their liver function and medication/treatment regimen. Exclusion criteria include conditions that may affect drug absorption, a positive urine drug screen, and females of childbearing potential unless they meet specific age and postmenopausal criteria. Subjects with certain conditions related to hepatic impairment, such as hepatic carcinoma or hepatorenal syndrome, porta-caval shunt surgery, or recent gastrointestinal hemorrhage, will also be excluded from the trial.",
    "The sample provided is for a clinical trial in Phase 1. The trial focuses on two diseases: \"carcinoma, non-small-cell lung\" and \"neoplasm metastasis\". The corresponding ICD-10 codes for these diseases are \"D02.20\", \"D02.21\", \"D02.22\" for the first disease, and \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", \"C17.2\" for the second disease. The trial involves the drug \"cetuximab\". The eligibility criteria for this trial include having measurable disease tumor available for biopsies and a life expectancy of at least 3 months. The exclusion criteria state that individuals with known or documented brain metastases prior to Cetuximab therapy are not eligible for the trial.",
    "The sample is a clinical trial for the treatment of non-Hodgkin's lymphoma, specifically diffuse large B cell or mantle cell lymphoma. The trial is in phase 1/phase 2. The eligibility criteria for participants include having a confirmed diagnosis of the specified types of lymphoma, not having received any prior anti-cancer therapy for lymphoma, having tumor tissue that expresses the CD20 antigen, having measurable disease with a tumor mass larger than 1.5 cm, being in stage II, III, or IV of the disease, being over 18 years old, and meeting certain blood count and organ function requirements. The exclusion criteria include having central nervous system involvement by lymphoma, having HIV disease, being pregnant or nursing, having had major surgery within the last 3 weeks, receiving other investigational drugs, and having peripheral neuropathy greater than Grade 2.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include brain and central nervous system tumors, cognitive/functional effects, neurotoxicity, and solid tumors. The ICDCodes associated with these diseases are G92.00, G92.01, G92.02, G92.03, G92.04, and G92.05. The drug being used in the trial is lithium carbonate. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having histopathologically confirmed extracranial primary malignancy, having multiple brain metastases or less than 3 metastases with at least 1 metastasis larger than 4.0 cm in diameter, and not being eligible for radiosurgery. Exclusion criteria include having a Zubrod performance status of 0-2, having a life expectancy of at least 8 weeks, having a platelet count greater than 100,000/mm^3, having an ANC (absolute neutrophil count) greater than 1,500/mm^3, having a hemoglobin level of at least 10 g/dL, having a BUN (blood urea nitrogen) level less than 25 mg/dL, having a creatinine level less than 1.5 mg/dL, having a bilirubin level less than 1.5 mg/dL, having an ALT (alanine aminotransferase) level less than or equal to 2 times the normal value, having a sodium level greater than 136 mg/dL, not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, being neurologically stable without seizure disorders or seizures due to brain metastases, not having medical illnesses or psychiatric conditions that would prevent completion of study treatment, not having sensory neuropathy greater than or equal to grade 2, not having bipolar disorder, not having thyroid disease, and not having QTc interval prolongation.\n\nThe prior concurrent therapy section states that there should be more than 2 weeks since prior and no concurrent chemotherapy, at least 2 weeks since prior and no concurrent use of certain medications, no prior radiotherapy to the head and neck area, no prior radiosurgery, no concurrent radiotherapy to other sites, no concurrent use of anticonvulsants due to brain metastases, no concurrent use of psychoactive drugs, no concurrent use of thyroid medications, and no concurrent use of amifostine.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on treating solid tumors and lymphoma. The diseases are represented by their corresponding ICD-10 codes. The drug being tested is called kx2-391. The sample also includes the eligibility criteria for participants in the trial, including age, performance status, life expectancy, and various health parameters. It also lists the exclusion criteria, such as unresolved toxicity from previous treatments, recent use of investigational or anti-cancer agents, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1 and focuses on type 1 diabetes. The ICD-10 codes associated with the disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44']. The drugs being studied are 'sar341402', 'insulin aspart', and 'insulin aspart'. The eligibility criteria for this trial include having type 1 diabetes for more than one year, a total insulin dose of less than 1.2 U/kg/day, fasting negative serum C-peptide, a glycohemoglobin (HbA1c) level of less than or equal to 9%, a stable insulin regimen for at least 2 months prior to the study, and normal findings in medical history, physical examination, vital signs, electrocardiogram (ECG), and safety lab. The exclusion criteria include having any clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness. Other exclusion criteria include a history of severe hypoglycemia, frequent headaches or migraines, symptomatic or asymptomatic postural hypotension, drug hypersensitivity or allergic disease, likelihood of requiring treatment with drugs not permitted by the study protocol, recent medication or vaccination, and positive results on certain tests. It is important to note that the provided information may not include all relevant considerations for potential participation in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is a tumor. The ICDCodes associated with this disease are \"E88.3\", \"R97.8\", \"C49.A0\", \"C49.A1\", \"C49.A2\", \"C49.A5\", and \"C49.A3\". The drug being tested is called \"fruquintinib\". \n\nThe eligibility criteria for this trial are as follows:\n- The participant must be between 18 and 70 years old.\n- They must have a histological or cytological confirmed solid malignant tumor.\n- Their ECOG performance status should be 0-1.\n- Standard treatment options have failed or are not available.\n- The participant is expected to have a life expectancy of more than 12 weeks.\n- Their left ventricular ejection fraction (LVEF) should be equal to or greater than 50%.\n- The duration since the last therapy is more than 4 weeks for surgery or radiotherapy, and more than 4 weeks for prior systemic treatment.\n- The participant must have adequate hepatic, renal, heart, and hematologic functions.\n- They should have at least one measurable lesion larger than 10 mm in diameter by spiral CT scan.\n- The participant must provide signed and dated informed consent and be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nThe exclusion criteria for this trial are as follows:\n- Pregnant or lactating women are not eligible.\n- Any factors that affect oral administration may exclude a participant.\n- Evidence of uncontrolled central nervous system (CNS) metastasis is an exclusion factor.\n- Participants with non-controlled hypertension, coronary artery disease, arrhythmia, and heart failure are not eligible.\n- Abuse of alcohol or drugs is an exclusion criterion.\n- Participants who have participated in another clinical trial within the last 4 weeks are not eligible.\n- Previous treatment with VEGF/VEGFR inhibition is an exclusion factor.\n- Serious uncontrolled intercurrent infection or proteinuria \u2265 2+ may exclude a participant.\n- Uncontrolled hemorrhage in the gastrointestinal (GI) tract is an exclusion criterion.\n- Participants who have experienced arterial/venous thromboembolic events, such as cerebral vascular accidents, within the last 12 months are not eligible.\n- Participants who have had acute myocardial infarction, acute coronary syndrome, or coronary artery bypass grafting (CABG) within the last 6 months are excluded.\n- Bone fractures or wounds that have not healed for a long time are exclusion factors.\n- Coagulation dysfunction, hemorrhagic tendency, or receiving anticoagulant therapy may exclude a participant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include solid tumors, breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer. The corresponding ICDCodes for these diseases are also listed. The drug being tested is called ati-1123, with the active drug being docetaxel. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as signing an informed consent form, having a confirmed solid tumor, having progressive disease or no alternative therapy available, specific performance status, age requirements, negative pregnancy test for females, acceptable liver and kidney function, acceptable blood counts, recovery from prior treatments, use of contraception, and exclusion of certain medical conditions or treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is tumors. The ICDCodes associated with this disease are E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, and C49.A3. The drug being tested in this trial is gefitinib. The eligibility criteria for this trial include having a histologically confirmed solid tumor that is refractory to conventional treatment or for which no standard treatment exists, a life expectancy of more than 12 weeks, and a World Health Organization (WHO) performance status of less than 2. The exclusion criteria include severe hypersensitivity to gefitinib or any of its components, completion of prior chemotherapy or radiation therapy within the last 4 weeks (except for nitrosoureas or mitomycin-C, which require a 6-week washout period), and incomplete healing from previous oncologic or major surgery.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this particular sample, the phase of the trial is listed as \"phase 1/phase 2\". The diseases being studied are \"recurrent melanoma\", \"stage iii melanoma\", \"stage iv melanoma\", and \"unspecified adult solid tumor, protocol specific\". The corresponding ICD-10 codes for these diseases are also provided. The drug being tested is \"imatinib mesylate\". The eligibility criteria for participants in the trial are listed in detail, including requirements related to the diagnosis, disease stage, medical history, laboratory values, and other factors.\n\nOverall, this sample provides information about a clinical trial that is studying the effectiveness of imatinib mesylate in treating various types of melanoma and other solid tumors.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease cystic fibrosis. The ICD-10 codes associated with this disease are \"E84.9\", \"Z14.1\", \"E84.0\", \"E84.11\", \"E84.8\", \"E84.19\", and \"P09.4\". The drugs being studied in this trial are \"arikayce\u2122 560 mg\", \"placebo for 560 mg\", \"arikayce\u2122 70 mg\", \"arikayce\u2122 140 mg\", and \"placebo for 70 mg / 140 mg\". The eligibility criteria for participants include being adults (\u2265 6 years of age), having a confirmed diagnosis of CF, a history of chronic infection with P.aeruginosa, FEV1 \u226540% of predicted at Screening, ability to comply with study medication use, study visits and procedures, and ability to produce 0.5 grams of sputum. There are also exclusion criteria listed, such as recent administration of any investigational drug, recent emergency room visit or hospitalization for CF or respiratory-related illness, history of alcohol, medication or illicit drug abuse, history of lung transplantation, and others.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are refractory multiple myeloma, stage I multiple myeloma, stage II multiple myeloma, and stage III multiple myeloma. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are obatoclax mesylate and bortezomib. The eligibility criteria for participants in this trial include having symptomatic multiple myeloma, measurable diseases, progressive disease after prior therapy, specific treatment history with bortezomib, certain health conditions and laboratory values within normal ranges, and no concurrent illnesses or medications that may interfere with the trial.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on two diseases, namely Fanconi anemia and severe aplastic anemia. The corresponding ICD-10 codes for these diseases are ['D61.3', 'D61.9', 'D61.09', 'D61.1', 'D61.2', 'D61.89']. The trial involves the use of the drug fludarabine. The eligibility criteria for participants include a diagnosis of Fanconi anemia or other suspected DNA breakage/chromosomal instability syndromes, severe aplastic anemia, availability of an HLA matched or mismatched family member or unrelated HLA matched stem cell donor, life expectancy greater than 6 weeks limited by diseases other than Fanconi anemia, creatinine levels within normal range, and a Karnofsky score of 70% or more. Exclusion criteria include symptomatic cardiac disease, allergy to rat serum products, severe infection, severe personality disorder or mental illness, documented HIV positivity, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"non-small cell lung cancer.\" The ICDCodes associated with this disease are \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2.\" The drugs being studied in this trial are \"erlotinib\" and \"hydroxychloroquine.\" The eligibility criteria for this trial include various conditions such as confirmed diagnosis of non-small cell lung cancer, specific cancer staging, prior treatment with certain drugs, age requirement, measurable disease, performance status, time since prior treatments, organ function, approval for hydroxychloroquine treatment by an eye doctor, willingness to comply with protocol procedures, and more. The exclusion criteria include current use of hydroxychloroquine, known hypersensitivity to certain drugs, G6PD deficiency, certain eye conditions, pregnancy or breastfeeding, CNS metastases, prior radiation therapy, interstitial lung disease, recent malignancies, and other significant clinical disorders or laboratory findings. The use of non-FDA approved or investigational agents within a specific timeframe and penicillamine use are also mentioned as exclusion criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on kidney transplantation. The associated diseases are listed as \"kidney transplantation\" with corresponding ICD-10 codes. The drugs being studied are \"c1 esterase inhibitor\" and \"placebos\". The eligibility criteria for participants are provided, including inclusion criteria such as having end-stage renal disease, being within a certain age range, and having specific antibody requirements. Exclusion criteria are also listed, such as being pregnant or lactating, having certain infections or medical conditions, or having received certain vaccines or medications within a specified timeframe. The sample provides detailed information about the trial's requirements and restrictions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug being used in this trial is \"temsirolimus and capecitabine.\" \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have histologically proven adenocarcinoma with measurable or evaluable disease.\n- The disease for which capecitabine is approved or compendia listed.\n- The patient must have advanced unresectable and/or metastatic disease for which there is no known curative therapy.\n- The patient must have a performance status of 0-2.\n- The patient must have adequate hepatic, bone marrow, and renal function.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have brain metastases that are not under control for at least 3 months.\n- The patient must not have an active severe infection or known chronic infection with HIV, hepatitis B virus, or hepatitis C virus.\n- The patient must not have cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months.\n- The patient must not have life-threatening visceral disease or other severe concurrent disease.\n- Women who are pregnant or breastfeeding are not eligible for this trial.\n- The anticipated patient survival must be under 3 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drugs being used in the trial are gemcitabine and bosutinib. The eligibility criteria for participants in this trial include having histologically proven adenocarcinoma of the pancreas, having undergone complete resection surgery for pancreatic cancer, having no measurable disease, having an ECOG performance status of 0-1, being at least 18 years old, being able to start adjuvant therapy within 8 weeks after surgery, having a CA 19-9 level \u2264 2.5 times the upper limit of normal, having an ANC (absolute neutrophil count) \u2265 1500/\u03bcL, having a hemoglobin level \u2265 9 gm/dL, having a platelet count \u2265 100,000/\u03bcL, having an INR \u2264 1.5 (except for those on full-dose warfarin), having a total bilirubin level \u2264 2.0 mg/dL, having AST and ALT levels \u2264 2.5 times the upper limit of normal, having a serum creatinine level \u2264 2.0, having a negative pregnancy test for women of childbearing potential, providing informed consent, agreeing to use effective contraception during treatment and for 6 months afterwards, and having at least one paraffin block from the patient's pancreatic cancer surgery available for analysis. The exclusion criteria include having received any prior systemic or investigational therapy for pancreatic cancer, having grossly positive surgical margins, experiencing certain post-operative complications, having a history of major psychiatric disorder or chronic medical illness that contraindicates the use of the investigational drugs, having a serious active ongoing infection, having a currently active second malignancy other than non-melanoma skin cancer, being pregnant or lactating, having known central nervous system disease, being unable to swallow pills or tolerate oral intake, and being unable to comply with study and/or follow-up procedures.",
    "The sample provided is for a phase 1 clinical trial. The trial focuses on postmenopausal individuals with osteopenia, which is characterized by low bone mineral density. The trial aims to study the effects of the drugs romosozumab and placebo. \n\nThe inclusion criteria for participants include being healthy males or postmenopausal females between the ages of 45 and 80. They should have low bone mineral density, as indicated by specific T-scores for the lumbar spine or total hip. Additionally, participants should have a minimum level of 25-hydroxyvitamin D and meet certain weight and height requirements.\n\nOn the other hand, the exclusion criteria state that individuals with osteoporosis, diagnosed bone metabolism conditions, or previous exposure to AMG 785 are not eligible to participate in the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are melanoma and advanced melanoma. The ICDCodes associated with these diseases are provided as well. The drug being tested is a combination of gleevec and temozolomide. The eligibility criteria for participants are listed, including requirements such as confirmed melanoma, prior treatment history, measurable disease, performance status, and life expectancy. There are also exclusion criteria, such as no prior treatment with temozolomide or imatinib mesylate, organ allografts, and history of second cancer. The sample provides detailed information about the trial and the requirements for participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include b-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, prolymphocytic leukemia, and Richter's transformation. The corresponding ICDCodes for these diseases are also provided. The drugs being investigated in this trial are pci-32765 and ofatumumab. The eligibility criteria for participants in this trial include specific medical conditions, prior treatment history, CD20 expression level, performance status, life expectancy, organ and marrow function, and other factors. There are also exclusion criteria listed, which outline conditions that would disqualify a participant from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 1/phase 2.\n- Diseases: The trial is focused on chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.\n- ICD Codes: The ICD-10 codes associated with the diseases are ['D47.1'], ['D89.810', 'D89.811', 'D89.813', 'D89.812'], ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01'], ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'], ['C96.20', 'C96.29', 'D47.09'], and ['D46.9', 'D46.C', 'D46.Z'].\n- Drugs: The trial involves the use of methotrexate, sirolimus, and tacrolimus.\n- Criteria: The eligibility criteria for the trial are listed, including disease characteristics, patient characteristics, and prior concurrent therapy. The criteria cover various aspects such as diagnosis, age, performance status, life expectancy, organ function, prior treatments, and other factors.\n\nOverall, this sample record provides information about a clinical trial in phases 1 and 2, focusing on specific diseases, involving certain drugs, and having specific eligibility criteria.",
    "The sample from the table is a clinical trial for a drug called he3286, which is being tested for the treatment of rheumatoid arthritis. The trial is a combination of phase 1 and phase 2. The eligibility criteria for participants include being between 18-75 years old, having stable or active disease on a stable dose of methotrexate, having normal thyroid stimulating hormone levels, and being willing to abstain from consuming grapefruit products during the study. Participants should not have a history of renal or liver disease, acute cardiac disease within the past 6 months, or any systemic autoimmune disorder. They should also not have received certain immunosuppressive drugs within specific timeframes. Other exclusion criteria include having functional status class IV, a history of cardiovascular, hepatic, respiratory, or endocrine disorders, active tuberculosis, or inflammatory joint disease other than rheumatoid arthritis. Participants should not be bed or wheelchair bound and should not have taken prednisone or certain medications within specific timeframes. Additionally, any clinically significant abnormalities in laboratory results at screening would exclude a participant from the trial.",
    "The sample is a phase 1 clinical trial for patients with malignant glioma, specifically glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma. The trial is for patients whose tumors have progressed or recurred after radiation therapy and chemotherapy. The trial includes the drugs erlotinib hydrochloride and isotretinoin. The eligibility criteria include having a Karnofsky performance status of at least 60%, practicing contraception for patients with reproductive potential, providing informed consent, having a Mini Mental Status Exam score of at least 15, meeting certain laboratory test requirements, and having recovered from prior therapy. The exclusion criteria include being pregnant or breastfeeding, having uncontrolled intercurrent illness, a history of inflammatory bowel disease or uncontrolled depression, receiving concurrent therapy for the tumor (except steroids), and having certain medication or allergy history.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The icd-10 codes associated with this disease are C90.01, C90.02, and C90.00. The drug being used in the trial is lbh589. \n\nThe eligibility criteria for this trial include:\n1. Patients must have a diagnosis of active multiple myeloma and require treatment.\n2. Patients must have received at least one prior line of therapy, including autologous stem cell transplantation.\n3. Patients must be suitable for treatment with BTZ (presumably another drug).\n4. Patients must have measurable M component at entry according to specific criteria.\n5. Patients must be adults aged 18 or older.\n6. Patients must have an ECOG Performance Status of 2 or lower.\n7. Patients must have a life expectancy of more than 12 weeks.\n8. Patients must meet specific laboratory value requirements for ANC, platelets, calculated CrCl, AST and ALT, serum bilirubin, serum potassium, magnesium, phosphorous, and total calcium.\n9. Patients must have a baseline MUGA or ECHO demonstrating LVEF within the institutional normal range.\n10. Patients must be willing to undergo bone marrow aspirate sampling at baseline and potentially later in the study.\n11. Patients must be able to sign informed consent and comply with the protocol.\n12. Patients must be able to swallow capsules.\n\nThe exclusion criteria for this trial include:\n1. Prior exposure to a HDAC inhibitor compound used in the treatment of MM.\n2. Patients with refractory MM who have not responded to prior therapies or whose disease progressed within 60 days of last dose of therapy.\n3. Patients who have had prior allogeneic stem cell transplantation and show evidence of active graft-versus-host disease.\n4. Patients with peripheral neuropathy of certain grades.\n5. Patients with impaired cardiac function or clinically significant cardiac diseases.\n6. Patients with impairment of GI function or GI disease that may significantly alter the absorption of PAN (presumably another drug).\n7. Patients with unresolved diarrhea of a certain grade.\n8. Patients with other concurrent severe and/or uncontrolled medical conditions.\n9. Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes.\n10. Patients who need valproic acid for any medical condition during the study or within 5 days prior to the first PAN treatment.\n11. Patients who have received targeted agents, immunotherapy, chemotherapy, or radiation therapy within specific timeframes.\n12. Patients who have received steroids within a certain timeframe.\n13. Patients who have undergone major surgery within a specific timeframe.\n14. Women who are pregnant or breastfeeding, or women of childbearing potential not willing to use a double method of contraception.\n15. Male patients whose sexual partners are women of childbearing potential not using a double method of contraception.\n16. Patients with a prior malignancy within the last 3 years, except for specific types.\n17. Patients with a significant history of non-compliance to medical regimens or unwillingness/unable to comply with study instructions.\n18. Patients who have shown intolerance to specific drugs or have contraindications to them.\n\nPlease note that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 1. The diseases being studied are metastatic non-small cell lung cancer and metastatic breast cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being used in the trial are pazopanib and vinorelbine. The eligibility criteria for the trial are listed, including age requirements, specific diagnoses, and the need for evaluable disease. Inclusion and exclusion criteria are also provided, such as restrictions on pregnancy and lactation, prior exposure to certain drugs, and limitations on previous therapies. The sample also mentions the need for informed consent and lists additional criteria related to allergies, prior chemotherapy regimens, and the absence of uncontrolled illnesses.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are advanced solid tumors and lymphoma. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is called px-478. The eligibility criteria for participants in this trial include factors such as age, performance status, predicted life expectancy, previous treatments, hematologic function, hepatic function, renal function, and contraception use for women of childbearing potential. The exclusion criteria include factors such as active infections, serious systemic disorders, recent surgery, central nervous system or psychiatric disorders, brain metastases, history of seizures or arterial thrombosis, cardiac conditions, pregnancy or breastfeeding, gastrectomy or bowel obstruction, and any condition that could jeopardize patient safety or compliance with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is prostate cancer. The ICDCodes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. \n\nThe drugs being used in this trial are bicalutamide and cp-675,206 (tremelimumab). The eligibility criteria for participants in this trial include being at least 18 years old, having a histologic diagnosis of adenocarcinoma of the prostate, having completed surgery or radiation at least 8 weeks prior with the removal of all visible disease, having clinical Stage D0 prostate cancer with rising PSA and PSA >2ng/ml, having an ECOG performance score of less than 2, and having normal hematologic, renal, and liver function.\n\nThe exclusion criteria for this trial include not having evidence of immunosuppression or being treated with immunosuppressive therapy, not having prior treatment with an LHRH agonist or nonsteroidal antiandrogen such as casodex or flutamide, not having evidence of metastatic disease per bone scan or CT scan of the abdomen and pelvis, not having prior treatment with anti-CTLA 4 monoclonal antibody, not having a history of known autoimmune disorder or HIV, hepatitis B, or hepatitis C, not having known brain metastases, and not having a history of inflammatory bowel conditions including diverticulitis, ulcerative colitis, etc.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are \u03b2-thalassemia and transfusional iron overload. The ICDCodes associated with these diseases are ['E87.70', 'E87.79', 'E87.71']. The drug being tested in this trial is deferasirox. The eligibility criteria for this sample include various inclusion and exclusion criteria. Inclusion criteria include being a male or female patient aged 18 or older without prior history of deferasirox treatment, being a \u03b2-thalassemia patient receiving regular transfusions every 2-5 weeks, and having a transfusion history of at least 20 units of packed red blood cells. Exclusion criteria include having abnormal renal function at baseline, ALT (alanine aminotransferase) levels greater than 5 times the upper limit of normal at screening, and having underlying cardiac disease requiring continuous iron chelation therapy. It is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"neoplasms,\" and the corresponding ICDCodes are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug mentioned is \"bibw 2992.\" The eligibility criteria for this trial include various factors such as confirmed diagnosis of advanced, non-resectable and/or metastatic solid tumors, age 18 years or older, life expectancy of at least three months, written informed consent, Eastern Cooperative Oncology Group (ECOG) performance score 0, 1, or 2, recovery from previous therapies, and more. There are also exclusion criteria listed, such as active infectious disease, gastrointestinal disorders that may interfere with drug absorption, serious illness or non-oncological disease incompatible with the protocol, untreated or symptomatic brain metastases, and various laboratory values outside the specified ranges. Additionally, there are criteria for re-treatment eligibility and recovery from dose-limiting toxicity.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is kidney neoplasms. The ICDCodes associated with this disease are D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, and D41.02. The drugs being used in the trial are il-2 (interleukin-2), okt3, cyclophosphamide, fludarabine, and mesna. \n\nThe eligibility criteria for this trial are divided into two sections: Cell Harvest and Cell Infusion. \n\nFor the Cell Harvest criteria, patients must have metastatic renal cell cancer, be at least 18 years old, have a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, have a life expectancy of more than three months, be seronegative for HIV antibody and hepatitis B antigen, be seropositive for Epstein-Barr Virus (EBV), have a normal stress cardiac test if they have EKG abnormalities, symptoms of cardiac ischemia, arrhythmias, or are over 50 years old, and have pulmonary function testing with an FEV(1) greater than 60% predicted if they have a recent prolonged history of cigarette smoking or symptoms of respiratory dysfunction. \n\nFor the Cell Infusion criteria, patients must have measurable metastatic renal cell cancer and tumor progression after therapy with interleukin-2 (IL-2), have a clinical performance status of ECOG 0 or 1, have a platelet count greater than 100,000/mm^3, have serum ALT/AST levels less than three times the upper limit of normal, have serum creatinine less than or equal to 1.6 mg/dl, have total bilirubin less than or equal to 1.6 mg/dl or direct bilirubin less than or equal to 0.5 mg/dl, have a life expectancy of more than three months, have a T-cell population that has met the attached Certificate of Analysis for tumor recognition and safety testing at the time of T-cell transfer, sign a durable power of attorney if receiving IL-2, be willing to practice contraception during the treatment phase of the study, and may be considered eligible if they have asymptomatic brain metastases. \n\nThe exclusion criteria for both Cell Harvest and Cell Infusion include active systemic infections, coagulation disorders, contraindications to receiving IL-2, major medical illnesses of the cardiovascular, respiratory, or immune system, potentially effective therapy for renal cell cancer within four weeks of T-cell transfer (except for local irradiation to non-evaluated sites), requirement for steroid therapy, and exclusion of pregnant patients and nursing mothers due to unknown effects on the fetus or nursing infant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"advanced solid tumors.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug mentioned is \"bevacizumab, everolimus, and lbh589.\" The eligibility criteria for this trial include various factors such as age, performance status, bone marrow function, liver function, renal function, cholesterol levels, blood sugar levels, cardiac health, medical history, and more.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The disease being studied is chronic hepatitis C. The ICD-10 codes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drugs being tested in this trial are daclatasvir and placebo. The eligibility criteria for participants include being chronically infected with hepatitis C virus genotype 1, being treatment naive or non-responders or intolerant to previous treatments, not co-infected with HIV or hepatitis B virus, having a hepatitis C virus RNA viral load of at least 10^5 IU/mL, and having a BMI between 18 and 35 kg/m\u00b2. The exclusion criteria include having any significant acute or chronic medical illness that is not stable or controlled with medication and is not consistent with hepatitis C virus infection, having had major surgery within 4 weeks of study drug administration, and having had any gastrointestinal surgery that could impact the absorption of the study drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Crohn's disease. The ICDCodes associated with Crohn's disease are listed as ['K50.90', 'K50.913', 'K50.914', 'K50.911', 'K50.912', 'K50.918', 'K50.919']. The drug being tested is a comparison between delayed release 6mp or calcitriol versus purinethol. \n\nThe eligibility criteria for this trial are as follows:\n- The trial is open to both male and female patients aged 18-75 years with moderate Crohn's Disease, as determined by a CDAI score between 220 and 400 at screening. \n- The patients may or may not be receiving adjunctive mesalamine treatment. \n- The patients must have a definitive diagnosis of active inflammatory Crohn's Disease, ruling out fibrostenosing and/or fistulizing/perforating types based on clinical, radiological, endoscopic, or pathological findings within the previous 6 months. \n\nThere are also exclusion criteria, which include:\n- Body weight below 42.5 kg\n- Recent use of methotrexate, cyclosporine, anti-TNFalpha (infliximab, Remicade), or anti-integrin (namixilab) within the past 3 months\n- Use of allopurinol, sulfasalazine, valerian, warfarin, corticosteroids (including budesonide and prednisone) within 28 days prior to and throughout the study\n- Previous bowel resection or colostomy, ileostomy, or colectomy with ileorectal anastomosis\n- Symptomatic stenosis or ileal strictures, or x-ray evidence of fibrosed bowel\n- Presence of ulcerative colitis or short bowel syndrome\n- History of persistent intestinal obstruction, bowel perforation, uncontrolled GI bleed, abdominal abscess or infection, or toxic megacolon\n- Fistulizing Crohn's Disease or isolated small bowel Crohn's Disease\n- Evidence of other serious infectious, autoimmune, hepatic, nephritic, or systemic disease, or compromised organ function\n- History of GI tract malignancy or IBD-associated malignant changes in the intestines.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are paclitaxel and neratinib. The eligibility criteria for this trial include factors such as co-morbid conditions, reproductive potential, ECOG performance status, ability to swallow oral medication, histologic or cytologic confirmation of invasive adenocarcinoma of the breast, evidence of metastatic breast cancer, hormone receptor analysis, HER2 positivity, blood counts, hepatic function, serum creatinine levels, LVEF assessment, and various exclusion criteria such as previous therapy with neratinib, brain metastases, active hepatitis, lung disease, active infection, malabsorption syndrome, persistent diarrhea, neuropathy, corticosteroid treatment, uncontrolled hypertension, cardiac disease, nonmalignant systemic disease, pregnancy or lactation, psychiatric or addictive disorders, and recent use of investigational agents.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which is indicated as \"phase 1/phase 2\".\n- Diseases: A list of disease names related to the trial, including \"breast cancer\", \"metastatic breast cancer\", \"her-2 positive breast cancer\", and \"er positive breast cancer\".\n- ICD Codes: A list of ICD-10 codes associated with the diseases mentioned above.\n- Drugs: A list of drug names, with \"auy922\" being the only drug mentioned in this sample.\n- Criteria: The eligibility criteria for participating in the trial, which are divided into inclusion and exclusion criteria.\n\nThe inclusion criteria include factors such as age, ability to sign informed consent, specific laboratory values, normal potassium, calcium, phosphorus, and magnesium levels, certain liver enzyme levels, negative pregnancy test, confirmed HER2+ and HR+ breast cancer, stage of disease, prior treatments, presence of measurable lesions, HER-2 gene amplifications, performance status, and life expectancy.\n\nThe exclusion criteria include factors such as unresolved diarrhea, pregnancy or lactation, impaired cardiac function, history of long QT syndrome or ischemic heart disease, HIV positive status, hypersensitivity to study drugs, and participation in another clinical study within 30 days prior to the first study treatment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular sample being from phase 1. The diseases being studied in this trial include nausea and vomiting, pain, sleep disorders, and an unspecified adult solid tumor. The diseases are also associated with specific ICD-10 codes. The drug being investigated in this trial is methadone hydrochloride. \n\nThe eligibility criteria for participants in this trial include being diagnosed with cancer and experiencing chronic neuropathic pain syndrome. The pain syndrome must be related to the effects of cancer or its treatment. Patients must meet certain criteria such as needing to be started on strong opioids or requiring an increase in opioid dose. They must also have been experiencing pain for at least 4 weeks with a certain level of pain score. Other criteria include specific patient characteristics such as Karnofsky performance status, laboratory values, language proficiency, and ability to complete study requirements. \n\nThere are also criteria related to prior concurrent therapy, such as the timing of previous treatments and the use of other medications. Certain conditions and diseases are listed as contraindications for study participation. Additionally, patients with a history of substance abuse or who live alone without access to a caregiver are excluded. The sample also includes information about prior concurrent therapy and restrictions on certain medications and procedures during the study period.",
    "The sample is a record from a table that contains information about clinical trials. It is for a trial that is in both phase 1 and phase 2. The trial is focused on the disease \"rheumatoid arthritis\" and the associated ICD-10 codes are provided. The drugs being studied are \"ask8007\" and a placebo. The eligibility criteria for participants are listed, including meeting specific criteria for the classification of rheumatoid arthritis, being treated with certain medications for a specified period of time, and having active poly-arthritis. There are also exclusion criteria, such as recent treatment with other investigational drugs or TNF\u03b1-blockers, and the presence of certain medical illnesses that could pose a safety risk or affect the efficacy measures.",
    "The sample from the table is a clinical trial in phase 1/phase 2 for patients with hematological malignancies. The trial is focused on patients who have undergone either ablative or non-myeloablative allogeneic stem cell transplantation, using peripheral blood stem cells as the source. The patients must have received transplantation from donors who are identical at 6 HLA loci, or mismatched at no more than 1 locus. For patients who have undergone a non-myeloablative stem cell transplant, they must have more than 80% donor hematopoiesis within 30 days of study enrollment. The inclusion criteria also specify that patients must be 18 years of age or older, have a performance status of 0-2, and a life expectancy of more than 100 days. Subjects with CLL are eligible if there is no more than 20% residual leukemia in the bone marrow at the time of study entry. \n\nThe exclusion criteria include evidence of relapsed or residual malignancy within 30 days of trial entry, highly aggressive B cell malignancy, allogeneic stem cell transplantation using umbilical cord blood units or bone marrow, evidence of active uncontrolled infection or exposure to Hepatitis B, Hepatitis C, or HIV, ongoing gastrointestinal or hepatic acute GVHD, GVHD with chronic features diagnosed prior to day +100 or prior to enrollment, participation in another clinical trial evaluating a preventative strategy for chronic GVHD or ongoing participation in a clinical trial for therapy of acute GVHD, no plans for Donor Lymphocyte Infusion (DLI) prior to day 100 and not plans for a DLI in the upcoming 30 days, uncontrolled heart failure, and pregnancy or lactation.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase is \"Phase 1\" and the diseases listed are \"fallopian tube cancer,\" \"ovarian cancer,\" and \"primary peritoneal cavity cancer.\" The corresponding ICDCodes for these diseases are also provided. The drugs mentioned are \"docetaxel\" and \"idronoxil.\" \n\nThe eligibility criteria for this trial include specific disease characteristics such as a confirmed diagnosis of ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer, as well as recurrent advanced disease. The patient must also meet certain criteria related to blood levels, measurable disease, and the absence of active CNS metastases. \n\nThere are additional patient characteristics that must be met, including a Karnofsky performance score of at least 60%, not being pregnant or nursing, and having a negative pregnancy test. Other criteria include specific laboratory values, such as creatinine levels, transaminases, bilirubin, platelet count, WBC count, neutrophil count, and hemoglobin levels. The patient should also have peripheral neuropathy no higher than grade 1 and meet certain criteria related to AST, ALT, and alkaline phosphatase levels. \n\nThere are also restrictions on concurrent medical conditions, such as active infections or severe and/or uncontrolled medical diseases. The patient should not have a history of chronic active hepatitis or cirrhosis, and should not have a severe hypersensitivity to docetaxel or other drugs formulated with polysorbate 80. \n\nThe prior concurrent therapy section outlines requirements for previous treatments, investigational agents, antineoplastic therapy, and other concurrent medications. It also mentions that concurrent localized radiation therapy is allowed for control of local disease complications. However, concurrent grapefruit or grapefruit juice and amifostine are not allowed.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1. The disease being studied is asthma, and the corresponding ICD-10 codes for asthma are provided. The drugs being used in the trial are \"gsk2269557\" and \"gsk2269557 matching placebo\". The eligibility criteria for participants are listed, including requirements such as being healthy, male between 18 and 55 years old, having a certain body weight and BMI range, and being capable of giving informed consent. There are also additional inclusion criteria for healthy smokers. The exclusion criteria include factors such as having certain medical conditions, positive test results for hepatitis B, hepatitis C, HIV, or drug/alcohol use, recent participation in other clinical trials, and sensitivity to study medications. The sample also mentions restrictions on blood donation, following study procedures, and mental or legal incapacitation. Additionally, it states that individuals with asthma or a history of asthma are excluded, as well as those who have consumed certain foods or beverages within a specific timeframe.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on kidney diseases, specifically those with ICD-10 codes I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, and N18.5. The drugs being tested in the trial are yspsl and placebo. The eligibility criteria for the trial include patients undergoing primary cadaver renal transplants. However, there are also exclusion criteria, such as patients who have planned transplants from non-heart beating donors, dual kidney transplants, donors under 6 years of age, donors who have received investigational therapies, patients planned to receive living donor kidneys, or patients planned to receive ABO-incompatible donor kidneys.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is \"phase 1\" and the disease is \"Alzheimer's disease\". The icd-10 code associated with Alzheimer's disease is \"G30.8, G30.9, G30.0, G30.1\". The drugs being tested in this trial are \"active comparator: a\", \"placebo comparator b\", \"active comparator b\", and \"placebo comparator a\". The eligibility criteria for this trial include specific requirements for inclusion and exclusion. For inclusion, the criteria include a clinical diagnosis of probable mild to moderate Alzheimer's disease, a specific range of Mini Mental State Examination (MMSE) scores, stable treatment for Alzheimer's disease, and stable doses of other prescribed medications. The exclusion criteria include any neurological condition that could contribute to cognitive impairment, psychiatric diagnoses or symptoms that could interfere with cognition assessment, recent history of transient ischemic attack, stroke, or seizures, evidence of other clinically significant lesions or conditions on brain magnetic resonance imaging (MRI), and other pathological findings on brain MRI.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of non-small-cell lung cancer using the drug gefitinib. The trial is focused on patients who require low dose palliative thoracic irradiation. The inclusion criteria for the trial include patients who have provided written informed consent, have histologically or cytologically confirmed non-small cell lung cancer, and are 18 years of age or older. The exclusion criteria include patients who have previously undergone thoracic radiotherapy, have any condition that may predispose them to suffer a drug-related dose limiting toxicity event, or have a known hypersensitivity to any component of the study medication.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on the disease \"ulcerative colitis.\" The ICD-10 codes associated with this disease are provided as well. The drugs being studied in this trial are \"mesalamine.\" \n\nThe eligibility criteria for this trial are listed, including age requirements, the severity of ulcerative colitis, general health conditions, ability to swallow specific tablets, and willingness to participate. \n\nThere are also exclusion criteria listed, such as a history of cancer, intestinal surgery or malabsorption, renal insufficiency, allergies to certain medications, and other medical conditions that may interfere with the study or pose a risk to the patient's safety. \n\nAdditional criteria include specific laboratory test values, the use of certain medications, pregnancy status, drug abuse, and recent participation in other clinical trials.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 design. The trial is focused on hematologic malignancies, specifically acute myeloid leukemia (AML). The trial is investigating the use of a drug called CP-4055, both as a single agent and in combination with idarubicin. \n\nThe eligibility criteria for the trial include patients who have relapsed or refractory leukemias for which standard therapies are not expected to result in a durable response, or patients who have failed potentially curative therapy, or patients who refuse or are considered unsuitable for standard therapy. Patients must be 18 years of age or older and have an ECOG performance status of 0-2. Women of child-bearing potential must have a negative pregnancy test and both male and female patients must use acceptable contraceptive methods during the study. \n\nThe interval from prior treatment to the administration of the study drug should be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Patients must also meet certain clinical laboratory values, including serum creatinine, total bilirubin, and liver enzyme levels. \n\nFor phase 2 of the trial, patients must have a confirmed diagnosis of AML and have received cytotoxic chemotherapy. \n\nThere are also exclusion criteria for both phase 1 and phase 2, including a history of allergic reactions to similar compounds, positive status for HIV or hepatitis B or C, pregnancy or nursing, uncontrolled intercurrent illness, active heart disease, receiving other cytotoxic treatments, and any medical condition that places the patient at high risk for toxicities. In arm C of the trial, there is an additional exclusion criterion for patients with hypersensitivity to idarubicin or other anthracyclines or anthracenediones.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of lymphoma, specifically T-cell cutaneous lymphoma. The trial involves the use of different drugs, including a placebo, with the drug name \"shape (shp-141)\" at different concentrations. The eligibility criteria for participants include having a confirmed diagnosis of CTCL through a biopsy report, being in clinical Stage IA, IB, or IIA, having at least 3% of the body surface area affected by skin lesions that can be accessed for topical application of the study drug and biopsy, and having an ECOG performance status of 0-2. There are also exclusion criteria, such as having certain variants or transformed forms of CTCL, severe pruritus, palpable lymph nodes of a certain size, coexisting second malignancies, and various other medical conditions. The presence of active Hepatitis B or C or HIV, as well as circulating atypical cells above a certain threshold, are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are leukemia, lymphoma, and myeloma. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial include rituximab, cyclophosphamide, fludarabine, mesna, and sirolimus. \n\nThe eligibility criteria for this trial are as follows:\n- The patient must be between the ages of 18 and 70.\n- The patient must have a confirmed diagnosis of follicular lymphoma, mantle cell lymphoma, chronic lymphocyte leukemia/small lymphocytic lymphoma, or multiple myeloma. They must have had persistent or progressive disease despite initial chemotherapy and achieved a partial or complete response to their most recent chemotherapy.\n- The patient must have an HLA-matched related donor who is seropositive against Epstein Barr virus and capable of donating peripheral blood mononuclear cells and peripheral blood progenitor cells.\n- The patient must be completely mismatched for HLA class I loci (A, B, and C) with the third-party stimulator cells.\n- The patient must have a Zubrod Performance Scale (PS) of 0 or 1.\n- The patient's creatinine level must be less than 1.8 mg/dl.\n- The patient's ejection fraction must be greater than or equal to 40%.\n- The patient's Corrected Carbon Monoxide Diffusing Capacity (DLCO) must be greater than or equal to 45% predicted.\n- The patient's serum bilirubin must be less than or equal to 1.5 mg/dl, unless it is due to Gilbert's syndrome.\n\nThere are also exclusion criteria, which include:\n- Uncontrolled infection.\n- Being HIV positive, hepatitis B surface antigen positive, or hepatitis C seropositive.\n- Having a serum glutamic-pyruvic transaminase (SGPT) level greater than 200 IU/ml.\n- Being pregnant or lactating, as indicated by a positive Beta human chorionic gonadotrophin (hCG) test in a woman with childbearing potential. Childbearing potential is defined as not being post-menopausal for 12 months or not having undergone previous surgical sterilization.",
    "The sample from the table is for a phase 1 trial for the treatment of gastroparesis. The trial includes the drug GSK1322888 and a placebo. The eligibility criteria for participants include having certain liver enzyme levels within a specific range, being in good health, being between the ages of 18 and 65, and having a certain body weight and BMI. Participants must also be capable of giving informed consent and have a certain QTc interval duration. Japanese participants must have Japanese ancestry. Exclusion criteria include having hepatitis B or C, a history of liver disease, a positive drug/alcohol screen, being HIV positive, recent alcohol consumption, recent exposure to multiple new drugs, recent use of prescription or non-prescription drugs, sensitivity to the study medications, and other factors outlined in the protocol. Pregnant females, those unwilling or unable to follow the study procedures, those who are mentally or legally incapacitated, and those who regularly use tobacco or nicotine-containing products are also excluded. Additionally, consumption of certain foods and beverages is restricted, and individuals with rapid gastric emptying rates will be excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"non-small-cell lung carcinoma\" and \"carcinoma, non-small cell lung\". The corresponding ICDCodes for these diseases are \"['D02.20', 'D02.21', 'D02.22']\" and \"['D02.20', 'D02.21', 'D02.22']\" respectively. The drugs being tested in this trial are \"entinostat\", \"sndx-275\", and \"erlotinib\". \n\nThe eligibility criteria for this trial include various requirements such as confirmed stage IIIb or IV NSCLC, a certain number of prior chemotherapy or chemoradiotherapy regimens, measurable lesions, specific performance score and life expectancy, availability of a tumor specimen, age requirement, certain blood counts, liver and kidney function, normal levels of certain substances, willingness to use contraception, written informed consent, and more. \n\nThere are also exclusion criteria listed, which include factors such as prior stem cell transplant, CNS involvement, previous treatment with HDAC or EGFR inhibitors, current use of certain medications, prior exposure to SNDX-275, recent treatments or radiotherapy, presence of other malignancies, certain medical conditions, allergies, pregnancy or breastfeeding, participation in other investigational drug studies, and any medical, psychiatric, or behavioral disorders that may affect participation in the study.",
    "The sample from the table is for a clinical trial in the early phase 1. The trial is focused on chronic hepatitis C, specifically genotype 1 and relapse cases. The trial involves the use of drugs such as betaine, peginterferon alpha 2a, and ribavirin. The eligibility criteria for participants include being willing to give informed consent, having a history of chronic hepatitis C genotype 1, and being between 18-70 years old. Other criteria include having a recent liver biopsy confirming the diagnosis, meeting certain hematologic and biochemical criteria, and having no radiologic evidence of hepatoma or ascites. There are also exclusion criteria, such as being pregnant or nursing, having a history of treatment non-compliance, and participating in other clinical trials. Various other medical conditions and substance abuse are also considered for exclusion.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific trial in this sample focuses on breast cancer. The International Classification of Diseases (ICD-10) codes associated with the disease are also included. The table also includes a list of drugs being used in the trial. In this case, the drugs are \"bibf + paclitaxel\" and \"paclitaxel\". The eligibility criteria for participants are also provided, including requirements such as signed informed consent, age over 18, specific tumor size and characteristics, negative HER2 status, and various health parameters. The sample also includes exclusion criteria, which outline conditions or circumstances that would disqualify a participant from the trial. These criteria include factors such as metastatic breast cancer, previous or concurrent treatments, pregnancy or breastfeeding, and various medical conditions.",
    "The sample is a phase 1/phase 2 clinical trial for patients with type 2 diabetes. The trial is investigating the effectiveness of the drug aliskiren in treating diabetic nephropathy. The inclusion criteria for the trial include being between the ages of 30-80 with a diagnosis of type 2 diabetes, having a body mass index (BMI) within the range of 20 and 32, having incipient or overt diabetic nephropathy, and having a glomerular filtration rate (GFR) of at least 40 ml/min. Patients must also meet certain blood pressure requirements and be on stable hypoglycemic medications. Female patients must meet certain reproductive criteria. Exclusion criteria include severe hypertension, certain medications, kidney disease not caused by diabetes or hypertension, abnormal potassium levels, and various cardiovascular conditions. Other criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is listed as \"phase 1/phase 2\". The disease being studied is \"pancreatic cancer\" and its corresponding ICD-10 code is \"C25.3\". The drug being used in the trial is \"gemcitabine hydrochloride\". The eligibility criteria for the trial are then listed, including specific disease characteristics, patient characteristics, and prior concurrent therapy requirements.\n\nThe disease characteristics include the requirement of histologically or cytologically confirmed adenocarcinoma of the pancreas, completely resected disease, and specific surgical procedures that were performed. The patient characteristics include criteria such as ECOG performance status, pregnancy status, CA 19-9 levels, blood counts, liver function, renal function, and absence of certain complications or medical conditions. The prior concurrent therapy section specifies that no prior chemotherapy or radiotherapy for pancreatic cancer should have been received, among other requirements.\n\nOverall, this sample provides a detailed description of the phase, disease, drug, and eligibility criteria for a clinical trial focused on pancreatic cancer.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on metastatic breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied are lapatinib and docetaxel. The eligibility criteria for participants include being over 18 years old, having an ECOG Performance Status of 0 to 2, having histological or cytological confirmed breast cancer that is HER positive, and not being eligible for an alternative curative strategy in the first-line metastatic setting. Other criteria include receiving hormonotherapy or chemotherapy in the adjuvant setting, not having received the last injection of trastuzumab within the past six weeks, having completed prior radiotherapy treatment at least four weeks prior to enrollment, and having adequate haematological, hepatic, and renal function. The sample also includes exclusion criteria such as elevations of transaminase levels, recent chemotherapy or radiotherapy, prior treatment with EGFR targeting therapies, known brain metastases, and uncontrolled inter-current illness. Pregnant women and HIV-positive patients receiving combination anti-retroviral therapy are also excluded. Additionally, patients with certain gastrointestinal, hepatic, or cardiac conditions are excluded from the study.",
    "The sample from the table is for a phase 1 clinical trial for the treatment of plasmodium falciparum malaria. The eligibility criteria for participants include being between 18 and 40 years old, not having been exposed to or infected with malaria, and being in good health. Women of childbearing potential must have a negative pregnancy test and agree to practice adequate contraception. Participants must be able to understand and comply with the study procedures, provide informed consent, and be available for all study visits. Exclusion criteria include a history of travel to a malaria-endemic area, previous malaria infection, planned travel to a malaria-endemic area during the study, and certain medical conditions or medications that may interfere with the study.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The diseases being studied are \"peripheral T-cell lymphomas\" and \"non-Hodgkin lymphoma\". The corresponding ICD-10 codes for these diseases are \"['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']\". The drug being tested is \"velcade\". The eligibility criteria for this trial include histologically confirmed PTCLs and NK/T cell lymphomas (excluding ALK-positive anaplastic large cell T-cell lymphomas), performance status (ECOG) of 3 or lower, age of 65 or lower, presence of at least one measurable lesion, specific laboratory values within normal range, informed consent, and being in Ann Arbor stage III or IV. The exclusion criteria include having any other malignancies within the past 5 years (except basal cell skin cancer or CIS of the cervix), serious comorbid diseases, and being pregnant or breastfeeding. Any exceptions to these criteria must be approved by the investigator and the sponsor on a case-by-case basis.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is advanced solid tumors, specifically colorectal cancer in the Biomarker Expansion Cohort. The trial is focused on patients whose cancer is advanced and refractory to established forms of therapy or for which no effective therapy exists. The eligibility criteria include having a histologically or cytologically documented malignancy, an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, and a life expectancy of at least 12 weeks. Prior chemotherapy and tyrosine kinase inhibitor therapy are permitted, as long as a minimum of 3 weeks has elapsed and patients have recovered from any treatment-related toxicities. Prior hormonal therapy is also allowed, except for prostate cancer patients who have been on hormone therapy for at least 3 months. Prior radiation therapy and surgery are permitted, as long as patients have recovered from the toxic effects and wound healing has occurred. Other criteria include specific glucose levels, normal potassium, calcium, and magnesium levels, and certain blood counts and liver function tests within normal limits. Patients must also be accessible for repeat dosing and follow-up, practice effective contraceptive measures, and provide written informed consent. The exclusion criteria include a history of stroke, psychiatric conditions that may impair participation, allergic reactions to similar compounds, active seizure disorder, previously diagnosed brain metastases, concurrent anticancer therapy, active or uncontrolled infections or serious illnesses, pregnancy or breastfeeding, documented history of diabetes mellitus (except for the Diabetic Expansion Cohort), use of drugs that may prolong the QT interval or glucocorticoids within a certain timeframe, and significant cardiac disease unless well controlled.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and the diseases being studied are \"hypertension\" and \"metabolic syndrome\". The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in this trial is \"aliskerin/valsartan and rampiril\". \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being African American men or women between the ages of 18 and 80, having appropriate therapy for high blood pressure with no more than 2 antihypertensives, and having at least one marker of Metabolic Syndrome such as low HDL cholesterol, high triglycerides, high fasting glucose, or a specific waist circumference measurement. Other criteria include having a recent copy of an EKG and women of childbearing potential using reliable contraception throughout the study.\n\nExclusion criteria include having uncontrolled hypertension, having undergone an organ transplant, having hypersensitivity to any study medications, having high systolic or diastolic blood pressure, having experienced cardiovascular events within the last 6 months, having high serum potassium levels, having certain heart conditions or renal impairments, having conditions that may affect medication absorption, and having any condition that may put the patient at higher risk or jeopardize the evaluation of efficacy or safety. Other exclusion criteria include recent use of investigational study medications, unwillingness or inability to take regular medications or comply with the study protocol, and being pregnant or nursing without using reliable contraception.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is melanoma (skin). The ICDCodes associated with this disease are C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, and D03.52. The drugs used in this trial are busulfan, cyclophosphamide, cyclosporine, and methotrexate. The eligibility criteria for this trial include having biopsy-proven relapsed malignant melanoma that has failed prior standard regimen for metastatic disease, requiring an HLA-matched or related bone marrow donor, and having specific age, performance status, life expectancy, and various health conditions. Additionally, the patient should have received at least one prior standard regimen for metastatic disease.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of multiple myeloma, a type of cancer. The ICD-10 codes associated with the disease are 'C90.01', 'C90.02', and 'C90.00'. The drugs being studied in the trial are lenalidomide, bortezomib, dexamethasone, and doxil. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be at least 18 years old at the time of consent.\n- They must have measurable disease.\n- All necessary baseline studies must be completed.\n- The left ventricular ejection fraction (LVEF) must be greater than or equal to 50 percent by MUGA or ECHO.\n- Participants must be able to adhere to the study visit schedule.\n\nThere are also exclusion criteria, which include:\n- Grade 2 or higher peripheral neuropathy within 14 days of enrollment.\n- Renal insufficiency.\n- Evidence of mucosal or internal bleeding and/or platelet refractory.\n- Absolute neutrophil count less than 1000 cells/mm^2 within 14 days of enrollment.\n- Acceptable lab results.\n- Concomitant medications that include corticosteroids.\n- Recent myocardial infarction, uncontrolled angina, or severe uncontrolled ventricular arrhythmias.\n- Clinically relevant active infection or serious medical condition that puts the subject at risk.\n- Any condition or laboratory values that put the subject at an unacceptable risk.\n- Another malignancy within 3 years, except for certain exceptions.\n- Hypersensitivity to bortezomib, boron, mannitol, or any components of DOXIL.\n- Female subjects who are pregnant or breastfeeding.\n- Recent use of other investigational drugs within 14 days of enrollment.\n- Serious medical or psychiatric illness.\n- Uncontrolled diabetes mellitus.\n- Hypersensitivity to acyclovir or similar antiviral drugs.\n- Presence of POEMS (plasma cell dyscrasia with polyneuropathy).\n- Known HIV infection.\n- Known hepatitis B or C infection.\n- Known intolerance to steroid therapy.\n- Known hypersensitivity to required prophylactic medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are lung cancer and non-small-cell lung cancer (NSCLC). The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. \n\nThe drugs being tested in this trial are abt-751, pemetrexed, and a placebo. \n\nThe eligibility criteria for participants in this trial include having pathologically documented NSCLC, being in the locally advanced (Stage III) or metastatic (Stage IV) stage of NSCLC, having received only one prior anti-tumor treatment regimen in the non-curative and curative settings, having progressive disease following the previous treatment, having measurable disease according to RECIST criteria, having stable and well-controlled brain metastasis, having an ECOG performance score of 0-2, discontinuing all anti-tumor therapy at least 3 weeks prior to study entry, having resolved or stable adverse events from prior treatment, having adequate hematologic, renal, and hepatic function, not being pregnant and willing to take measures to prevent pregnancy, having a life expectancy of at least 3 months, being able to complete the Quality of Life questionnaire, and voluntarily signing informed consent. \n\nThe exclusion criteria for this trial include having greater than Grade 1 neurological findings, having an allergy to sulfa medications, having previous treatment with ABT-751 or pemetrexed, receiving more than one investigational agent for NSCLC, experiencing significant weight loss (>10%) within 6 weeks of study entry, having glucose-6-phosphate dehydrogenase deficiency or porphyria, having significant systemic disease that would adversely affect participation, having a Class 3-4 New York Heart Association classification status, and having other cancers except for in situ carcinoma of the cervix, basal or squamous cell skin cancer, or any other cancer considered adequately treated and cured by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being used in the trial is dasatinib. \n\nThe eligibility criteria for patients to be enrolled in the study are listed, including requirements such as histologically or pathologically confirmed adenocarcinoma of the prostate, intermediate, high, or very high-risk disease, no prior pelvic or prostate radiation or chemotherapy, clinically negative lymph nodes, bone scan within 12 weeks, ECOG performance status 0-1, age over 18, required entry laboratory parameters, life expectancy of at least 1 year, no concurrent anticancer therapy, peripheral neuropathy must be \u2264 Grade 2, adequate contraception for male subjects of fathering potential, ability to take oral medication, and a signed study-specific consent form.\n\nThe sample also includes conditions for patient ineligibility, such as evidence of distant metastases, prior radical prostatectomy or other treatments, PSA > 150, pathologically positive lymph nodes, major medical or psychiatric illness, prior systemic chemotherapy for the study cancer, prior radiotherapy to the region of the study cancer, and concurrent medical conditions that may increase the risk of toxicity.\n\nOverall, this sample provides specific information about the phase, disease, ICDCodes, drug, and eligibility criteria for a clinical trial related to prostate cancer.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The trial involves the use of two drugs, hydroxychloroquine and ixabepilone. The eligibility criteria for the trial include having histologically or cytologically confirmed breast cancer, measurable disease according to RECIST criteria, having received 2 prior chemotherapy regimens for metastatic breast cancer, and being resistant to anthracycline and taxane treatments. The patient characteristics include having an ECOG performance status of 0-2, specific blood counts and liver function within certain ranges, not being pregnant or nursing, and not having any other active malignancy. The sample also includes information on prior concurrent therapy and restrictions on concurrent treatments during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"multiple myeloma and plasma cell neoplasm.\" The corresponding ICDCodes for this disease are \"C96.20,\" \"C96.29,\" and \"D47.09.\" The drugs being studied in this trial are \"paricalcitol\" and \"zoledronic acid.\" \n\nThe eligibility criteria for this trial include specific requirements for the disease characteristics, patient characteristics, and prior concurrent therapy. For disease characteristics, the patient must have a diagnosis of relapsed or refractory multiple myeloma or other plasma cell disorder, and at least one previous treatment for the disease is required. \n\nRegarding patient characteristics, the performance status can be measured using either the ECOG scale (0-2) or the Karnofsky scale (60-100%). The patient must have a life expectancy of at least 3 months. \n\nIn terms of hematopoietic, hepatic, renal, and cardiovascular conditions, there are no specific requirements mentioned. However, for renal conditions, the patient's calcium level should be less than or equal to 10.5 mg/dL, and there should be no history of renal stone formation or calculi in the urinary tract. \n\nOther eligibility criteria include not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, not having osteonecrosis of the jaw, not having a history of allergic reactions to similar compounds, not having any uncontrolled intercurrent illness or ongoing infection, and not having any psychiatric illness or social situation that may affect study compliance. \n\nIn terms of prior concurrent therapy, the patient should not have received chemotherapy within the past 4 weeks, high-dose steroids within the past 4 weeks, or any other concurrent investigational agents or therapies for multiple myeloma or plasma cell disorders. Additionally, concurrent use of digoxin is not allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"uveitis, posterior\" and \"glaucoma\". The corresponding icd-10 codes for these diseases are \"G83.83\", \"H15.033\", \"H30.23\", \"G46.2\", \"H15.031\", \"H15.032\", \"H15.039\" for \"uveitis, posterior\" and \"H40.9\", \"Q15.0\", \"B73.02\", \"H40.823\", \"H40.89\", \"H44.513\", \"H40.821\" for \"glaucoma\". The drug being tested is \"anecortave acetate\". The eligibility criteria for this sample include being at least 12 years of age, having had a Retisert implant in the last 12 weeks, and meeting certain medical conditions such as not having a history of scleral thinning or allergies to steroids.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on non-Hodgkin's lymphoma. The ICD-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being studied in the trial are rituximab, dhap, tec, and autologous stem cell transplantation. The sample also includes the eligibility criteria for the trial, including requirements such as having first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage I-IV, pretreatment with systemic therapy, being between 18-65 years of age, having a certain performance status, and meeting certain blood count and liver function requirements. The sample also lists the exclusion criteria, which include having a history of second neoplasia (except for specific types), CNS involvement by lymphoma, respiratory or cardiac insufficiency, severe neurological or psychiatric disease, pregnancy, HIV positivity or active virus hepatitis, bacterial infection, and not ensuring follow-up procedures.",
    "The sample from the table represents a clinical trial for patients with non-small cell lung cancer. The trial is in phase 1/phase 2. The diseases being studied are stage IIIA, stage IIIB, and stage IV non-small cell lung cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being investigated in the trial are paclitaxel, carboplatin, and vorinostat. The eligibility criteria for the trial include having histologically confirmed non-small cell lung cancer, no prior chemotherapy for advanced or metastatic disease, ECOG performance status of 0 or 1, measurable disease, life expectancy of greater than 12 weeks, specific blood count requirements, normal liver and kidney function, ability to understand and sign informed consent, and meeting certain exclusion criteria such as not receiving other investigational agents, not having untreated brain metastases, and not having certain medical conditions. Pregnant women and HIV-positive patients receiving combination antiretroviral therapy are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drug being tested is \"jnj-38877605.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a confirmed advanced or refractory solid tumor that is no longer eligible for approved therapies.\n- The patient's Eastern Cooperative Oncology Group performance status test score must be <=2.\n- The patient must meet the protocol lab criteria, which includes lab assessment of adequate bone marrow function, liver function, and renal function.\n\nExclusion Criteria:\n- The patient should not have any medical condition that requires wound healing during the study, such as chronic leg ulcers or gastric ulcer disease, or be expected to undergo major surgery.\n- The patient should not have decreased or deficient coagulability of blood or compliance problems with anticoagulants.\n- The patient should not have received chemotherapy, radiotherapy, immunotherapy, or any other investigational agent within 3 weeks before the study drug administration.\n- The patient should not have received antibody therapy within 3 months before the administration of JNJ-38877605.\n- The patient should not have brain metastases.\n- The patient should not have a history of uncontrolled heart disease within 12 months before enrollment or any protocol-defined cardiovascular abnormalities.\n- The patient should not have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"heart failure\" and \"asymptomatic systolic dysfunction\". The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial are \"nesiritide\" and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having an ejection fraction of less than 45%, no clinical signs or symptoms of congestive heart failure, ability to walk a minimal distance of more than 450 meters on a 6-minute walk, and being on stable doses of an angiotensin converting enzyme (ACE) inhibitor for two weeks prior to the study date. Therapy with other vasodilators, beta-receptor antagonists, digoxin, and antiarrhythmic medications is allowed, but all medications must be at stable doses two weeks prior to the study date.\n\nExclusion criteria include having a myocardial infarction within 3 months of screening, unstable angina within 14 days of screening, significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy-proven active myocarditis, severe congenital heart diseases, sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening, second or third-degree heart block without a permanent cardiac pacemaker, stroke within 3 months of screening or other evidence of significantly compromised central nervous system (CNS) perfusion, total bilirubin of more than 1.5 mg/dL or other liver enzymes more than 1.5 times the upper limit of normal, serum creatinine of more than 3.0 mg/dL, serum sodium of less than 125 milliequivalent (mEq)/dL or more than 160 mEq/dL, serum potassium of less than 3.5 mEq/dL or more than 5.0 mEq/dL, serum digoxin level of more than 2.0 ng/ml, systolic pressure of less than 85 mmHg, and hemoglobin less than 10 gm/dl.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is \"advanced cancer,\" the ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123'], the drug is \"rdea119,\" and the eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include requirements such as histological or cytological confirmation of a solid tumor, advanced metastatic or locally recurrent disease with no proven effective therapy, ECOG performance status of 0-1, and more. The exclusion criteria include factors such as recent use of investigational agents or devices, major surgery within 30 days, uncontrolled active infections, and other medical or psychiatric illnesses.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is myelodysplastic syndrome (MDS). The ICDCodes associated with this disease are ['D46.Z', 'D46.9', 'C94.6', 'D46.C']. The drug being tested is txa127. \n\nThe eligibility criteria for this trial include a diagnosis of MDS using the World Health Organization classification and Low or Intermediate-1 risk MDS using the IPSS. The platelet count must be \u226450 x 109/L, with no individual non-transfused count >60 x 109/L. The subject must be at least 18 years old and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Adequate liver function, as evidenced by specific laboratory values, and a serum creatinine concentration \u22642 mg/dL are also required.\n\nThere are also exclusion criteria, such as currently receiving any treatment for MDS other than transfusions, a history of bone marrow transplantation, and certain cardiovascular conditions. Other exclusions include recent use of specific medications, history of thrombosis, pregnancy or breastfeeding for female subjects, and various other conditions that may interfere with the study requirements.\n\nIt is important to note that this is just a sample record, and there may be additional records in the table with different phases, diseases, drugs, and criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"advanced cancer.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug being tested is \"sgx523 capsules.\" \n\nThe eligibility criteria for this trial include the subject's ability to understand and comply with study procedures, having pathologic evidence of a solid tumor, having failed standard therapy and being deemed suitable for participation by the investigator. The subject's laboratory values should meet certain criteria, such as ANC (Absolute Neutrophil Count) being greater than or equal to 1.5 \u00d7 109/L, platelets being greater than or equal to 100 \u00d7 109/L, and hemoglobin being greater than or equal to 10.0 g/dL. Other criteria include having no residual toxic effects of previous therapy, having IHC evidence of phospho-MET expression on tumor material, and undergoing a washout period from previous therapy.\n\nExclusion criteria for this trial include being pregnant, having cardiac disease requiring medical therapy, having had major surgery within 4 weeks prior to the study, having an active, uncontrolled bacterial, viral, or fungal infection, having a known active infection with HIV, hepatitis B or C, having psychiatric or seizure disorders that would require therapy or interfere with study participation, having severe concurrent nonmalignant disease that could compromise protocol objectives, and receiving prohibited medications as listed in Appendix E. Additionally, patients with known allergies to the SGX523 formulation or its excipients and those receiving anti-coagulant therapy are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: The specific disease being targeted in the trial, which is \"carcinoma, non-small-cell lung.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are ['D02.20', 'D02.21', 'D02.22'].\n- Drugs: The drugs being used in the trial, which are 'cetuximab', 'cetuximab', 'bibw 2992', and 'bibw 2992'.\n- Criteria: The eligibility criteria for participants in the trial.\n\nThe eligibility criteria are divided into inclusion and exclusion criteria. The inclusion criteria specify the requirements for patients to be eligible for the trial, such as having confirmed Stage IIIB/IV non-small cell lung cancer or recurrent disease, having specific tumor mutations, and having shown clinical benefit from previous treatment. The exclusion criteria list factors that would disqualify patients from participating, such as prior treatment with certain antibodies, recent surgery or radiotherapy, and other concurrent treatments or medical conditions.\n\nOverall, this sample provides a snapshot of a clinical trial focused on non-small cell lung cancer, detailing the phase, disease, drugs, and eligibility criteria for potential participants.",
    "The sample from the table is for a phase 1 clinical trial for the treatment of myeloma, a type of cancer. The trial is open to patients who have previously been treated with at least one cycle of a specific therapy and have shown progressive or refractory disease. The eligibility criteria include having histologically or cytologically confirmed symptomatic multiple myeloma, measurable levels of monoclonal protein, lytic bone disease, and normal organ and marrow function. Patients must not be pregnant or breastfeeding and must agree to avoid conception during the study. The sample also includes exclusion criteria such as recent chemotherapy or radiotherapy, known brain metastases, allergic reactions to certain compounds, and serious cardiac conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"amyotrophic lateral sclerosis\" (ALS). The corresponding ICD-10 code for ALS is \"G12.21\". The drug being studied is \"zinc and copper\". \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be between the ages of 18 and 85, clinically diagnosed with ALS according to the El Escorial criteria, have an ALS-FRS score greater than 25, and be capable of providing informed consent and complying with trial procedures. \n\nThe exclusion criteria specify that patients with a forced vital capacity (FVC) below 50%, a history of liver disease, severe renal failure, creatinine levels greater than or equal to 1.5 mg/dL, intolerance to zinc or copper, evidence of motor neuron disease for more than 5 years, any other co-morbid condition that would make completion of the trial unlikely, pregnancy or breastfeeding for female participants, unwillingness to use birth control for those of childbearing age, use of other trial medications, history of significant anemia, elevated levels of zinc at baseline, or copper levels below normal at baseline are not eligible to participate in the trial.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is \"rectal cancer\". The corresponding ICD-10 codes for the disease are \"C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2\". The drug being tested is \"capecitabine\". \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that patients must have clinical stage T4 or recurrent adenocarcinoma of the rectum, confirmed by histology review. They must not have distant metastatic disease in specific areas and must have a performance status of 70% or greater. There are no age restrictions. Patients must also meet certain blood test values and sign an informed consent form.\n\nThe exclusion criteria state that patients who have previously received radiotherapy to the pelvis, pregnant or lactating women, and patients with certain medical conditions or illnesses are not eligible for the trial. Other criteria include recent treatment for other carcinomas, major surgery within 4 weeks, and known hypersensitivity to the drug being tested.\n\nThe sample also mentions specific requirements for patients on coumadin and antacids, as well as an age restriction of 18 years or older.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial focuses on locally advanced or metastatic, unresectable soft tissue sarcoma, sarcoma, and soft tissue sarcoma.\n- ICD Codes: The ICD-10 codes associated with the diseases are ['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32'] for the first disease and ['C46.1'] for the second disease.\n- Drugs: The trial involves the use of amg 655 and doxorubicin.\n- Criteria: The eligibility criteria for the trial include histologically or cytologically confirmed soft tissue sarcoma, locally advanced, recurrent, or metastatic, unresectable disease, measurable disease according to modified RECIST, ECOG performance status of 0 or 1, age of at least 18 years, and adequate hematological, renal, hepatic, and coagulation function. The exclusion criteria include prior treatment with anthracyclines and uncontrolled cardiovascular disease.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: A list of diseases being studied in the trial, including \"diabetes,\" \"diabetes mellitus, type 2,\" and \"healthy.\"\n- ICD Codes: The corresponding ICD-10 codes for the diseases, such as \"E23.2,\" \"N25.1,\" and \"P70.2\" for diabetes.\n- Drugs: The drugs being tested in the trial, which are \"semaglutide\" and \"placebo.\"\n- Criteria: The eligibility criteria for participants in the trial, including both inclusion and exclusion criteria.\n\nThe inclusion criteria state that participants must provide informed consent, be male, aged between 18 and 65 years, have a body mass index (BMI) below 35.0 kg/m^2, and be in good general health based on medical history, physical examination, ECG, and laboratory analysis.\n\nThe exclusion criteria state that participants should not have participated in any other clinical trial involving investigational products in the last 3 months, should not have had a myocardial infarction in the last 12 months, and should not be taking certain medications unless on a stable dose for more than 6 weeks prior to the study. Other exclusion criteria include the presence of certain gastrointestinal diseases, certain medications, excessive tea/coffee consumption, history of drug or alcohol abuse, certain medical conditions, and recent blood donation or significant blood loss.\n\nThe sample also includes additional criteria related to contraception, smoking, hepatitis B/C, impaired hepatic and renal function, cardiac problems, blood pressure, allergies, mental capacity, blood donation, and any other condition that may interfere with the study.\n\nFinally, there are restrictions on the use of non-prescription drugs and strenuous exercise during the trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 design. The trial is focused on the treatment of acute lymphoblastic leukemia (ALL). The ICD-10 codes associated with the disease are 'C91.01', 'C91.02', and 'C91.00'. The drug being studied is clofarabine. \n\nThe eligibility criteria for the trial include:\n1. Patients must provide signed written informed consent, or if under 18 years old, their parent or guardian must provide consent.\n2. Patients must have a diagnosis of ALL (B or T lineage) and have received therapy with at least 1 but not more than 3 prior different induction regimens. The phase II component of the study is limited to patients who have had 2 different prior induction regimens if they are older than 30 years.\n3. ALL lymphoblasts must have CD52 expression on at least 10% of lymphoblasts.\n4. Patients must be 16 years of age or older.\n5. Patients must have an ECOG performance status of 0-2.\n6. Patients must have adequate renal and hepatic functions.\n7. Patients or their guardian must be capable of understanding the nature of the study and provide valid informed consent.\n8. Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.\n9. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment. Patients aged 16 and 17 must also adhere to effective contraception methods or abstinence, and this must be documented.\n10. Patients must be CMV PCR negative prior to enrollment.\n\nThe exclusion criteria for the trial include:\n1. Patients currently receiving concomitant chemotherapy, radiation therapy, or immunotherapy, unless specified in the protocol.\n2. Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry, except for specific exceptions mentioned in the protocol.\n3. Patients with no bone marrow or blood involvement by leukemia, such as a documented CNS or testicular only relapse.\n4. Patients with severe concurrent diseases, a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may put them at risk during treatment.\n5. Patients with known or suspected Hepatitis B, C, and HIV infections.\n6. Patients with uncontrolled systemic fungal, bacterial, viral, or other infections.\n7. Pregnant or lactating patients.\n8. Patients with any significant concurrent disease, illness, or psychiatric disorder that may compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is advanced solid tumors. The ICD-10 codes associated with these tumors are K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, and H35.3123. The drug being tested is g-202. The eligibility criteria for participants include having a histologically-confirmed malignancy that is metastatic or unresectable, having measurable or evaluable disease according to RECIST criteria, having an ECOG Performance Status of 2 or lower, having a life expectancy of at least 3 months, and meeting certain liver, kidney, hematologic, and coagulation function requirements. Other criteria include not having certain medical conditions, not being pregnant or lactating, and not having any conditions that could interfere with compliance with the study protocol. Participants must also agree to use an effective method of birth control if they are of childbearing potential.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is E7107. \n\nThe eligibility criteria for this trial are outlined in the sample. Inclusion criteria include patients with confirmed solid tumors who have progressed after receiving approved therapies and for whom no effective therapies are available. Other criteria include completing surgery and radiotherapy at least four weeks prior to the study, having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, and providing written informed consent. \n\nExclusion criteria include patients with symptomatic or progressive brain tumors, certain laboratory parameters outside the specified ranges, positive history of HIV or active hepatitis, significant cardiac impairment, bleeding or thrombotic disorders, history of alcoholism or drug addiction, pregnancy or breastfeeding, and other medical conditions that would exclude the patient from the study. Additionally, patients are not allowed to take certain drugs or substances during the trial.",
    "The sample is a phase 1 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is evaluating the effectiveness of a drug called pur0200, along with a placebo and an active comparator. The eligibility criteria for the trial include being a current or ex-smoker with at least 10 pack-year smoking history, having a moderate to severe COPD diagnosis, and meeting specific lung function criteria. There are also exclusion criteria, such as having other clinically significant or unstable diseases, a current diagnosis of asthma, or a history of certain respiratory infections. The sample provides a detailed description of the inclusion and exclusion criteria for the trial.",
    "The sample from the table represents a clinical trial for the treatment of metastatic colorectal cancer. The trial is in phase 1/phase 2. The diseases being studied are specified as metastatic colorectal cancer. The corresponding ICD-10 codes for these diseases are provided as ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being tested in the trial include tivantinib, placebo, cetuximab, and irinotecan. \n\nThe eligibility criteria for participants in the trial are as follows:\n1. Participants must have surgically unresectable locally advanced or metastatic disease and have received one prior line of chemotherapy.\n2. Participants must express the wild-type form of the gene KRAS.\n3. Participants must have measurable disease according to RECIST criteria.\n4. Participants must be 18 years of age or older.\n5. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Participants must have resolved any toxic effects of prior therapy to a certain grade.\n7. Participants must have adequate bone marrow, liver, and renal functions.\n8. Male and female participants of child-bearing potential must agree to use contraceptive measures.\n9. Female participants of childbearing potential must have a negative pregnancy test before starting treatment.\n10. Participants must be fully informed about the study and provide informed consent.\n\nThe exclusion criteria for participants in the trial are as follows:\n1. Participants who have received prior therapy with an Epidermal Growth Factor Receptor (EGFR) inhibitor.\n2. Participants with a history of malignancy other than colorectal cancer, unless certain conditions are met.\n3. Participants who anticipate the need for major surgery or radiation therapy during the study.\n4. Participants who have received certain types of treatment within 4 weeks prior to the start of study treatment.\n5. Participants with a history of certain cardiac diseases.\n6. Participants with certain gastrointestinal conditions.\n7. Participants with known metastatic brain or meningeal tumors, unless certain conditions are met.\n8. Participants with certain neurological conditions.\n9. Participants with certain fluid-related conditions.\n10. Participants with clinically significant active infection.\n11. Participants who have previously received ARQ 197.\n12. Participants with substance abuse or medical, psychological, or social conditions that may interfere with the trial.\n13. Participants with certain unstable conditions or infections.\n14. Participants who are unable to swallow oral medications.\n15. Pregnant or nursing females.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is multiple sclerosis. The ICDCodes associated with this disease are 'G35' and 'C81.18'. The drugs being used in the trial are acth and methylprednisolone. The eligibility criteria for this trial include being clinically diagnosed with multiple sclerosis, being between the ages of 18-65, understanding and signing the informed consent form, complying with the required scheduling and assessments, having a negative pregnancy test (for women of childbearing potential), experiencing at least one MS relapse within the last year and/or having at least one new T2 or Gadolinium-enhanced lesion on MRI while on stable interferon therapy, having an EDSS score of 3.0 - 6.5, and currently being on one of the approved beta-interferon drugs (Avonex, Betaseron, or Rebif) for a minimum of 6 months. The exclusion criteria include being pregnant or breastfeeding, having uncontrolled hypertension, clinically significant cardiac arrhythmias, gastrointestinal ulcer, uncontrolled diabetes mellitus, osteoporosis, any stage of renal failure, psychiatric disorders, or any other clinically significant general health conditions that may interfere with the trial participation. Other exclusion criteria include a history of drug or alcohol abuse within the past year, recent corticosteroid treatment, starting new medication within the last 30 days, being on Tysabri treatment presently or within 6 months of screening, being on Novantrone, Cellcept, Rituxan, or other chemotherapeutic treatment presently or within 6 months of screening, being a participant in another research project, and having contraindications for either ACTH or MP administration.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on two diseases, inflammation and rheumatoid arthritis. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of three drugs: nnc0215-0384, placebo, and nnc0215-0384. The eligibility criteria for participants are listed, including requirements for active rheumatoid arthritis and concomitant treatment with MTX. There are also exclusion criteria, such as having other chronic inflammatory autoimmune diseases or a history of certain joint diseases. Additionally, subjects with certain medical conditions, such as cardiac disease or past or current malignancy, are excluded. The presence of latent or active tuberculosis is also considered in the eligibility criteria.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is obesity. The ICDCodes associated with obesity are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drug being tested is 'zgn-433'. The eligibility criteria for this trial include being an obese, otherwise healthy female who is post-menopausal or infertile, weighs at least 50 kg, and has a BMI between 32 and 45 kg/m2. The exclusion criteria include a history of using weight loss agents in the past month, eating disorders, diabetes or other endocrine disorders, gastric bypass surgery, being a current smoker, and having an unstable body weight in the past 3 months.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1/phase 2 and focuses on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drugs being studied in this trial are gefitinib and gemcitabine. The eligibility criteria for participants are listed, including requirements such as histologically confirmed pancreatic cancer, tumor volume less than 500 cc, age between 18 and 75, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or lower, life expectancy of more than 12 weeks, and willingness to practice reliable methods of birth control for women of child-bearing potential. The exclusion criteria are also listed, which include previous radiotherapy or chemotherapy for malignant disease, presence of other malignancies within the last 5 years (except for basal cell carcinoma or cervical cancer in situ), severe or uncontrolled systemic diseases, abnormal blood counts or liver function, active dermatoses, concomitant use of certain medications, and severe hypersensitivity to ZD1839 or any of its excipients.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is hepatocellular carcinoma. The ICDCodes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being used in the trial are ro5323441 and sorafenib. \n\nThe eligibility criteria for this trial include being an adult patient aged 21 or older, having advanced or metastatic and/or unresectable hepatocellular carcinoma, having at least one measurable lesion according to RECIST criteria, having the primary tumor in situ (Expansion Cohort Part I, Part II), having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and having adequate bone marrow, liver, and renal function.\n\nThe exclusion criteria for this trial include having received prior systemic treatment for metastatic hepatocellular carcinoma or having had the tumor removed (Expansion Cohort Part I, Part II), having undergone major surgery within the previous 4 weeks or planning a major surgical procedure during the course of the study, having received radiation therapy within 28 days prior to the start of study treatment, having a serious non-healing wound, ulcer, or bone fracture, having a history of uncontrolled seizures or encephalopathy within the last 6 months, having current central nervous system (CNS) metastases or spinal cord compression, having a history of gastrointestinal perforation or esophageal/gastric bleeding within 6 months prior to study enrollment, having a history of another primary malignancy and being off treatment for 3 years or less (except for non-melanoma skin cancer and carcinoma in situ of the cervix), having undergone a liver transplant in the past, having inadequately controlled hypertension or a prior history of hypertensive crisis or hypertensive encephalopathy, and having an active bleeding diathesis.",
    "The sample provided is for a Phase 1 clinical trial. The trial is focused on healthy individuals, as indicated by the \"diseases\" field containing the value \"healthy\". The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". \n\nThe trial involves two drugs, namely \"advagraf\u00ae\" and \"prograf\u00ae\". The eligibility criteria for participants are listed under the \"criteria\" field. The inclusion criteria include being Caucasian, having no history of various diseases or disorders, having a normal 12-lead Electrocardiogram (ECG), and meeting certain blood pressure and smoking requirements. Participants must also be willing to abstain from alcohol during the study.\n\nThe exclusion criteria include testing positive for illicit drugs or alcohol consumption, having certain infections or a history of cancer, having a positive tuberculin skin test or history of tuberculosis, and having a history of head injuries, seizures, or eating disorders. Other exclusion criteria include specific body mass index (BMI) ranges, history of renal dysfunction or abnormal liver function, recent plasma or blood donation, drug or alcohol abuse within the past year, recent steroid injections, and recent live vaccine administration.\n\nOverall, this sample represents the eligibility criteria and details for participants in a Phase 1 clinical trial focused on healthy individuals.",
    "The sample from the table represents a phase 1 clinical trial. The disease being studied is neoplasms, and the corresponding ICD-10 codes for these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is batracylin. \n\nThe eligibility criteria for this trial include patients with histologically confirmed solid tumor malignancy or lymphoma that is metastatic or unresectable, and for which standard curative measures do not exist or provide minimal survival benefit. Patients must have measurable or evaluable disease and must have completed any prior chemotherapy or biologic therapy at least 4 weeks prior to entering the study. Other criteria include age greater than or equal to 18 years, Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2, and a life expectancy of greater than 3 months. \n\nPatients must also have normal or adequate organ and marrow function, including specific criteria for absolute neutrophil count, platelets, total bilirubin, AST/ALT levels, and creatinine levels. Women of child-bearing potential and men must agree to use adequate contraception during the study and for 2 months after discontinuation. Patients must have a specific slow acetylator NAT2 genotype and must be able to understand and sign a written informed consent document.\n\nExclusion criteria include patients receiving any other investigational agents, patients with known brain metastases (unless stable for at least 6 months without steroids or anti-seizure medications), and patients with clinically significant illnesses that could compromise participation in the study.\n\nBoth men and women, as well as members of all races and ethnic groups, are eligible for this trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is hormone refractory prostate cancer. The icd-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are picoplatin and docetaxel. The eligibility criteria for participants in this trial include having histologically or cytologically confirmed adenocarcinoma of the prostate, radiologic evidence of metastatic disease, disease progression or recurrence, receiving androgen ablation therapy, adequate hormonal therapy, specific age requirements, ECOG performance score, stable levels of pain, life expectancy, specific time intervals since prior treatments, certain blood count and liver function requirements, and agreement to use birth control methods. The exclusion criteria include prior treatment with certain agents, evidence of brain or leptomeningeal metastases, symptomatic peripheral neuropathy, history of other cancers within the past 5 years, hypersensitivity to certain drugs, prior radiotherapy affecting a significant portion of the bone marrow, uncontrolled intercurrent illness, serious medical or psychiatric illness that could interfere with the study treatment, and history of serious cardiac disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied in this trial are sarcoma, neuroblastoma, Wilms tumor, osteosarcoma, and brain tumor. The corresponding ICDCodes for these diseases are also provided. The drug being tested in this trial is pazopanib (gw786034). \n\nThe eligibility criteria for this trial are outlined in a bullet point format. The criteria include age restrictions, specific tumor types, histologic verification, and the requirement of certain performance scores. Additionally, patients must have fully recovered from previous therapies and have adequate organ function as determined by laboratory evaluation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"alveolitis\" and \"systemic sclerosis\". The ICDCodes associated with these diseases are \"M34.0\", \"M34.89\", \"M34.9\", \"M34.82\", \"M34.83\", \"M34.81\", and \"M34.2\". The drugs being used in the trial are \"imatinib\". \n\nThe eligibility criteria for this trial include:\n1. Patients must fulfill the criteria for systemic sclerosis (SSc) according to the ACR criteria.\n2. Patients must be at least 18 years old.\n3. Forced Vital Capacity (FVC) must be less than 85% of predicted.\n4. Patients must be able to complete the 6-minute walk test with a walking distance of at least 150 meters.\n5. Patients must have dyspnea on exertion (grade 2 or higher on the Mahler Modified Dyspnea Index).\n6. Patients must have had SSc for 10 years or less, with the onset defined as the date of the first non-Raynaud manifestation typical of systemic sclerosis.\n7. Patients may have limited or diffuse cutaneous SSc.\n8. Patients must show evidence of alveolitis through HRCT of the lung or bronchoalveolar lavage (BAL).\n9. Female patients of childbearing potential must have a negative pregnancy test.\n10. Patients must be able to provide written voluntary informed consent.\n\nThere are also exclusion criteria listed, which include factors such as severe lung disease, significant abnormalities on HRCT not related to SSc, clinically significant pulmonary hypertension, persistent unexplained hematuria, history of leukopenia, and various other medical conditions and medications that would exclude a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on the disease \"hepatitis C, chronic.\"\n- ICD Codes: The ICD-10 codes associated with the disease are \"B18.2,\" \"B18.0,\" \"B18.1,\" \"B18.8,\" \"B18.9,\" \"K71.3,\" and \"K71.4.\"\n- Drugs: The trial involves the drugs \"idx719\" and \"placebo.\"\n- Criteria: The eligibility criteria for participants are listed, including general health requirements, the use of birth control, and the specific requirements for participants with chronic HCV infection. There are also exclusion criteria, such as pregnancy or breastfeeding, prior HCV treatment, and co-infection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on non-small-cell lung carcinoma. The ICD-10 codes associated with this disease are 'D02.20', 'D02.21', and 'D02.22'. The drug being tested in this trial is called \"pt-523 for injection\". \n\nThe eligibility criteria for this trial include being at least 18 years old, having histologically or cytologically confirmed NSCLC that is stage III or stage IV, or recurrent disease, and having failed therapy with a standard first line (Phase I/II) as well as second line chemotherapy regimen (Phase I), or being intolerant of standard chemotherapy. Patients who have received one additional prior chemotherapy regimen for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant are also allowed. A prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK) antagonist is allowable for Phase II. \n\nOther inclusion criteria include being asymptomatic or having treated brain metastases (including steroids) if the last therapy was received more than 4 weeks from study entry and is deemed by the investigator to have a low likelihood of rapid deterioration. Patients should have an ECOG performance status of 0 - 2 and adequate organ function and bone marrow reserve. They should also be using an appropriate contraceptive method and have signed the patient informed consent.\n\nExclusion criteria for this trial include the use of investigational agents within 30 days prior to Day 1 of the study, known symptomatic or uncontrolled brain metastases, uncontrolled intercurrent illness, known human immunodeficiency virus (HIV), hepatitis A, B, C, D and E, uncontrolled pleural effusions, and having received nitrosoureas or mitomycin-C within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1 and focuses on various types of cancer, including breast cancer, ovarian cancer, prostate cancer, colon cancer, and renal cancer. The diseases are represented by their respective ICD-10 codes. The trial involves the use of a drug called cyclophosphamide & zyc300, which is administered with pre-dosing of cyclophosphamide. \n\nThe eligibility criteria for the trial are listed, including requirements such as having advanced stage malignancies, evidence of measurable disease, being at least 18 years old, having a certain performance status, and a life expectancy of more than 6 months. Adequate hematological, renal, and hepatic functions are also required. Additional criteria include negative brain MRI results, negative pregnancy test, agreement to use contraception, and signing an informed consent form approved by the Institutional Review Board.\n\nExclusion criteria are also provided, which specify conditions that would disqualify a patient from participating in the trial. These include a history of brain metastases, recent treatments such as chemotherapy or radiation therapy, use of certain medications, history of bone marrow or stem cell transplantation, and various other factors.\n\nIt is important to note that there may be additional inclusion and exclusion criteria determined by the study center. Patients who do not meet the criteria will be informed of the reasons, while those who qualify will receive a detailed explanation of the trial and have the opportunity to ask questions before deciding whether to participate.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drug being used in the trial is a combination of gleevec and chlorambucil. \n\nThe eligibility criteria for this trial include:\n- Patients must have B-cell chronic lymphocytic leukemia, either Rai stage 0-II with an indication for treatment by NCI Working Group Criteria, or Rai stage III or IV.\n- Patients must have received at least one prior chemotherapy regimen, and prior treatment with corticosteroids, immunotherapies, monoclonal antibodies, or radiation therapy is allowed.\n- Patients must have a white blood cell count greater than 25 x 10^9/L.\n- Patients must have an ECOG performance status of 0, 1, or 2.\n- Patients must have adequate renal and hepatic function.\n- Patients must have platelets greater than 75 x 10^9/L and be transfusion independent.\n- Patients must have neutrophils greater than 1.0 x 10^9/L and be transfusion independent.\n\nThe exclusion criteria for this trial include:\n- Patients with documented prolymphocytic leukemia (PLL) with prolymphocytes comprising 55% of the blood.\n- Patients with active cardiovascular disease categorized as NYHA class III-IV.\n- Patients with an intercurrent illness or medical condition that would prevent the safe administration of ribavirin.\n- Patients currently using chronic steroids, except as replacement therapy for adrenal insufficiency.\n- Patients with known infection with HIV, Hepatitis B, or Hepatitis C.\n- Patients with any concurrent malignancy, except for resected basal or squamous cell skin cancers or in-situ carcinoma.\n- Patients who have received any previous therapy for CLL within 28 days prior to study entry.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 1. The diseases being studied include breast cancer, colorectal cancer, gastric cancer, lung cancer, ovarian cancer, pancreatic cancer, and unspecified adult solid tumor, protocol specific. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial are cyclophosphamide and fludarabine phosphate. The eligibility criteria for the trial are listed, including requirements for disease characteristics, patient characteristics, and prior concurrent therapy.\n\nOverall, this sample provides specific details about a clinical trial, including the phase, diseases being studied, drugs being used, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include extensive stage small cell lung cancer, recurrent colon cancer, recurrent non-small cell lung cancer, recurrent rectal cancer, recurrent small cell lung cancer, stage IV colon cancer, stage IV non-small cell lung cancer, and stage IV rectal cancer. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are recombinant fowlpox-cea(6d)/tricom vaccine, recombinant vaccinia-cea(6d)-tricom vaccine, docetaxel, and sargramostim. The eligibility criteria for participants in this trial include having histologically confirmed lung or colorectal cancer, incurable metastatic disease, no clinically active brain metastases, and meeting various medical and health requirements.",
    "The sample provided is a phase 1 clinical trial for patients with central nervous system neoplasms, neoplasm metastasis, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, primary CNS lymphoma, or malignant disease metastatic to the CNS. The trial aims to evaluate the effectiveness of the drug temozolomide in patients who have not responded or experienced recurrence after previous chemotherapy or radiation therapy. \n\nTo be eligible for the trial, patients or their health care proxies must be able to provide consent. They must also meet certain criteria, including being candidates for high dose chemotherapy and autologous stem cell transplant. Other criteria include age between 18 and 70 years, left ventricular ejection fraction greater than or equal to 45%, adequate pulmonary function, specific blood test results within normal ranges, ECOG performance status between 0 and 2, and at least 4 weeks since last cytoreductive chemotherapy. Patients are also required to have an expected survival of at least 3 months.\n\nThere are several exclusion criteria for the trial, such as uncontrolled metastatic disease outside of the CNS, uncontrolled seizures, recent history of myocardial infarction or significant arrhythmia, uncontrolled hypertension or congestive heart failure, unstable angina, pregnancy or lactation, failure to practice approved methods of birth control, uncontrolled active infection, and HIV infection.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are melanoma and malignant melanoma. The corresponding icd-10 codes for these diseases are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4'] and ['C43.0', 'C43.31', 'C43.51', 'C43.9', 'C43.4', 'C43.52', 'C43.10'] respectively. The drug being tested is lbh589. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having histologically or cytologically confirmed metastatic melanoma, measurable disease, being 18 years of age or older, having an ECOG performance status of 0, 1, or 2, normal organ and marrow function, negative serum pregnancy test for women of childbearing potential, being clinically euthyroid, and having biopsiable disease. \n\nExclusion criteria include recent chemotherapy or radiotherapy, not recovered from adverse events of previous treatments, not receiving any other study agents or anti-cancer therapy, having known or previous brain metastases, history of allergic reactions to similar compounds, concomitant use of drugs with a risk of causing torsades de pointes, previous use of HDAC, DAC, HSP90 inhibitors or valproic acid for cancer treatment, impaired cardiac function, uncontrolled hypertension, unresolved diarrhea grade 2 or greater, gastrointestinal function impairment, pregnancy or breastfeeding, history of different malignancy (except for specific circumstances), positivity for HIV or hepatitis C, significant history of non-compliance to medical regimens, and uncontrolled or severe intercurrent illness.\n\nThis sample provides a detailed description of the trial phase, diseases being studied, icd-10 codes, drug being tested, and the specific eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are myelodysplastic syndrome and acute myelogenous leukemia. The corresponding icd-10 codes for these diseases are provided as well. The drug being tested in this trial is called mgcd0103. The eligibility criteria for this trial include having high-risk MDS or AML, specific subtypes of MDS or AML, certain performance status, age requirement, and meeting laboratory requirements. There are also exclusion criteria listed, such as having another active cancer, being pregnant or lactating, having uncontrolled illness or infections, and having certain medical conditions or history that may interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on colorectal cancer.\n- ICD Codes: The ICD-10 codes associated with the colorectal cancer are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'].\n- Drugs: The drugs being tested in the trial are bevacizumab, oxaliplatin, and capecitabine.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age range (20-74 years), confirmed diagnosis of colorectal cancer, metastatic and/or locally advanced colorectal cancer that has not been previously treated with chemotherapy for metastatic disease, and the presence of at least one measurable lesion according to RECIST. Exclusion criteria include the presence of clinically detectable ascites, recent major surgical procedures or biopsies, bleeding diathesis or coagulopathy, non-healing wounds or fractures, and the use of certain medications known to predispose to gastrointestinal ulceration, such as chronic daily aspirin or anticoagulants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on diseases related to metabolism and nutrition disorder and obesity. The ICD-10 codes associated with these diseases are provided. The trial involves the use of drugs, including \"nnc 0070-0002-0453\", \"'2-0453\", and a placebo. The eligibility criteria for the trial are also listed, including requirements for body mass index (BMI) and general health. There are also exclusion criteria, such as recent aggressive diet attempts, history of certain mental health disorders, and substance abuse history.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is head and neck cancer. The ICDCodes associated with this disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being used in the trial are bortezomib and cisplatin. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy requirements. The disease characteristics include the type and stage of the cancer, eligibility for full-dose radiotherapy, absence of clinically measurable distant disease, and no previously untreated nasopharyngeal cancer. The patient characteristics include performance status, blood counts, liver and kidney function, pregnancy status, contraception use, cognitive and neurologic function, and absence of certain medical conditions. The prior concurrent therapy requirements include recovery from previous treatments, specific time intervals since prior chemotherapy, cisplatin, radiotherapy to the head and neck, systemic EGFR inhibitors, and bortezomib. Additionally, there should be no concurrent use of investigational agents, other anticancer therapy, antiretroviral therapy, prophylactic filgrastim or sargramostim, or amifostine.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is \"prostatic neoplasms\". The corresponding ICD-10 codes for the disease are \"B38.81\", \"N42.31\", \"Z87.430\", \"N40.0\", and \"N40.1\". The drug being tested is \"samarium sm-153 lexidronam + docetaxel\". \n\nThe eligibility criteria for this trial include having histological evidence of adenocarcinoma of the prostate, progressive castrate metastatic disease, castrate levels of testosterone, evidence of at least 3 bone metastases on a bone scan, and showing progression of disease following withdrawal of anti-androgen treatment. Patients who have undergone prior bisphosphonate treatments or received one prior treatment with 153Sm lexidronam or 89Sr are also eligible. Other requirements include a life expectancy of at least 12 weeks, a KPS score greater than 60, and specific lab requirements such as white blood count, absolute neutrophil count, platelet count, hemoglobin level, bilirubin level, ALT/AST levels, and serum creatinine level. Patients must also sign an informed consent form.\n\nExclusion criteria for this trial include patients with small cell carcinoma, patients with predominant visceral metastases or symptomatic lymphadenopathy, patients who have received more than one course of external beam radiation therapy directed at bone lesions, patients with clinically significant cardiac disease, patients with a history of other malignancies (unless in complete remission or off therapy for at least five years), and patients who have participated in another research study or clinical trial within 30 days of the baseline visit.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is psoriasis. The ICDCodes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being tested in this trial are 'mapracorat (zk 245186, bay 86-5319)', 'prednicarbate 0.25% ointment', 'clobetasol 0.05% ointment', 'calcipotriene 0.005% ointment', and 'calcipotriene 0.005%/betamethasone dipropionate 0.05% ointment'. The eligibility criteria for this trial include various inclusion and exclusion criteria, such as age range, plaque size, absence of certain diseases, and previous treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"carcinoma, non-small cell-lung,\" \"lung neoplasms,\" \"lung cancer,\" and \"respiratory tract neoplasms.\" The corresponding ICDCodes for these diseases are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2'].\n\nThe drug being tested in this trial is \"gefitinib.\" The eligibility criteria for participants in this trial include being of Asian ethnicity, having an ECOG performance status of 0-2, and having a diagnosis of unresectable NSCLC with or without prior therapy advanced solid tumor that progressed after standard therapy (for phase 1b only). For phase 2, the criteria include having histologic or cytologic confirmation of unresectable locally advanced or metastatic stage IIIB/IV lung adenocarcinoma with at least one measurable lesion, being a never smoker or light ex-smoker, and having available tumor tissue for determination of EGFR mutational status and immunohistochemistry analysis.\n\nOther criteria include having adequate hematologic, hepatic, renal, and coagulation function, no active central nervous system metastases, and agreement to use effective contraception. Prior radiotherapy is allowed if 14 days from the first dose of the study drug and toxicity is resolved. Additionally, in phase 2, subjects on the Gefitinib monotherapy arm must have documented CR, PR, or SD for \u226512 weeks prior to disease progression in order to cross over to the combination therapy arm.\n\nExclusion criteria include prior chemotherapy or prior treatment with EGFR inhibitor (for phase 2 only), history of neoplasm other than the entry diagnosis, pregnancy or lactation, myocardial infarction within 6 months prior to initiation of study treatment, serious active infection, known human immunodeficiency virus infection, serious underlying medical condition that would impair the ability to receive protocol treatment, major surgical procedure, open biopsy, or significant traumatic injury, thrombotic or embolic events, known or suspected allergy/hypersensitivity to any agent given in the course of this trial, any condition that impairs absorption of oral agents or the subject's ability to swallow whole pills, diarrhea \u2265 Grade 2 or active Inflammatory Bowel Disease, severe acute or chronic medical, psychiatric, or behavioral condition or laboratory abnormality, diagnosis of interstitial lung disease, and any medications or treatments prohibited by the protocol.",
    "The sample is a phase 1 clinical trial for patients with type 1 diabetes. The trial is testing the effectiveness of the drug pramlintide acetate in achieving glycemic goals for patients who have not been successful with insulin therapy. The inclusion criteria for the trial include being between 18 and 70 years old, having a diagnosis of type 1 diabetes for at least 1 year, having an HbA1c level between 7.0% and 9.0%, and having a body mass index (BMI) below 30 kg/m2. The exclusion criteria include a history of severe hypoglycemia, hypoglycemia unawareness, gastroparesis, and the use of certain medications that affect gastrointestinal motility or nutrient absorption. Patients with certain medical conditions or allergies, as well as those who have recently donated blood or undergone surgery, are also excluded. Additionally, individuals who have previously been treated with pramlintide or participated in a pramlintide clinical study within the past 3 months are not eligible. The trial is not open to immediate family members of study personnel or employees of Amylin Pharmaceuticals, Inc.",
    "The sample from the table is for a clinical trial that is in both phase 1 and phase 2. The trial is focused on the disease \"essential tremor\" which is identified by the ICD-10 code \"G25.0\". The trial involves the use of two drugs, \"levetiracetam\" and \"placebo\". The eligibility criteria for participants include having a history of tremor for 5 or more years and not having any other neurological problems. The exclusion criteria include having a prior stroke or other neurological disease, psychiatric problems, a history of renal disease, and being pregnant.",
    "The sample is a phase 1 trial for hypertension. The diseases being studied are hypertension. The icd-10 codes associated with the diseases are I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, and I10. The drugs being tested include a reference treatment of 5 mg amlodipine + 50 mg losartan, a reference treatment of 5 mg amlodipine + 100 mg losartan, a fixed-dose combination of 5/50 amlodipine/losartan, and a fixed-dose combination of 5/100 amlodipine/losartan. The eligibility criteria for participants include being between 18 and 65 years old, having a body weight of at least 50 kg and a BMI between 18.5 and 24.9 kg/m\u00b2, having normal liver function, having a normal ECG, being a non-pregnant female or using contraception, being in good health, and being capable of giving informed consent. The exclusion criteria include having a positive drug/alcohol screen, having low blood pressure, having liver disease or abnormalities, having a positive pre-study drug/alcohol test, abusing alcohol, participating in another clinical trial recently, being unable to refrain from using certain medications, having allergies to the study medications, donating a large amount of blood recently, being pregnant or lactating, being unwilling or unable to follow the study procedures, being mentally or legally incapacitated, having a sensitivity to heparin, having used tobacco or nicotine-containing products recently, having asthma, and consuming certain foods or beverages.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are tumors and neoplasm metastasis. The corresponding ICDCodes for these diseases are ['E88.3', 'R97.8', 'C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3'] and ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'], respectively. The drugs being used in the trial are brivanib. \n\nThe eligibility criteria for this trial include:\n- Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors\n- No tumor spread to the brain\n- Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)\n- Available tumor tissue sample from prior surgery\n- 4-6 weeks since prior therapy and recovered from prior therapy\n- Men and women, ages 18 and above\n- Women must not be pregnant or breastfeeding\n- Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer\n- Measurable disease on scans (at least one)",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on the disease \"non-Hodgkin B-cell lymphoma.\" The corresponding ICD-10 codes for this disease are listed as \"S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S.\" The drug being studied in this trial is \"aflibercept.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Patients must have non-Hodgkin B-cell lymphoma, be in good condition, and have not been previously treated.\n\nExclusion Criteria:\n- Patients with contraindications to any drug contained in the R-CHOP regimen (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate) are excluded.\n- Patients who have undergone major surgery within the past 42 days (or other surgery within the past 28 days) are excluded.\n- Patients with cerebral or leptomeningeal involvement are excluded.\n- Patients with a history of another neoplasm, except for adequately treated basal cell or squamous cell skin cancers, carcinoma in situ of the cervix, or any other cancer from which the patient has been disease-free for more than 5 years, are excluded.\n- Patients who are currently participating in another clinical trial or receiving concurrent treatment with any investigational drug within 30 days prior to the first drug intake are excluded.\n- Patients with any acute or chronic medical condition that could impair their ability to participate in the study or interfere with the interpretation of study results are excluded.\n- Patients with uncontrolled diabetes mellitus, uncontrolled hypertension, abnormal kidney function, clinically significant bleeding diathesis, non-healing wound, or underlying coagulopathy are excluded.\n- Pregnant or breastfeeding women, as well as patients with reproductive potential (male or female) without an effective method of contraception, are excluded.\n- Patients with a history of hypersensitivity to any Trap agents or recombinant proteins are excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is described as \"phase 1/phase 2\". The diseases being studied include \"adenocarcinoma of the colon\", \"adenocarcinoma of the rectum\", \"recurrent colon cancer\", \"recurrent rectal cancer\", \"stage iii colon cancer\", \"stage iii rectal cancer\", \"stage iv colon cancer\", and \"stage iv rectal cancer\". The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drug being used in the trial is \"irinotecan hydrochloride\". The eligibility criteria for participants are listed in a detailed format, including requirements related to the patient's medical history, tumor specimens, KRAS mutation status, disease stage, prior treatments, measurable disease, performance status, blood counts, organ function, pregnancy status, cardiac health, infection status, bowel disorders, psychiatric illness, prior or concurrent malignancies, allergies, surgical history, radiotherapy history, and medication use.\n\nOverall, this sample provides a comprehensive description of a clinical trial, including the phase, diseases being studied, drugs used, and the specific eligibility criteria for participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are arthritis and rheumatoid arthritis. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested are cdp 6038 sc and methotrexate. The eligibility criteria for participants are listed, including criteria for inclusion and exclusion. Inclusion criteria include having rheumatoid arthritis for at least 6 months, a specific number of swollen and tender joints, and a minimum screening CRP level. Exclusion criteria include previous participation or treatment with certain agents, certain medical conditions, pregnancy, positive tests for tuberculosis or HIV, and drug addiction or alcohol abuse.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is \"healthy.\" The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this phase are \"pf-03654764 2.5mg plus fexofenadine 60mg,\" \"pf-03654764 5mg plus fexofenadine 60mg,\" and \"placebo.\" The eligibility criteria for this sample include inclusion and exclusion criteria. The inclusion criteria state that the trial is looking for healthy subjects with no clinically relevant abnormalities. The exclusion criteria include various medical conditions, a positive urine drug screen, and recent treatment with an investigational drug.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"relapsing multiple sclerosis\". The ICD-10 codes associated with this disease are \"M94.1\", \"A68.9\", \"A68.0\", \"A68.1\", and \"M35.6\". The drugs being tested in the trial are \"cdp323\" and \"placebo\". The eligibility criteria for participants include being aged 18-65, having a relapsing form of MS with at least one clinical relapse in the 24 months prior to screening, having a screening EDSS score of 0-6.5, being fully immunocompetent, and female subjects of childbearing potential must agree to practice contraception methods. The exclusion criteria include any conditions that could interfere with the contrast-enhanced MRI, any clinically significant disease state or findings other than MS, any clinically significant deviation from the pre-defined ranges for laboratory tests, and concomitant treatment with MS disease modifying drugs.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is type 2 diabetes mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested are ta-7284 and a placebo of ta-7284. The eligibility criteria for this trial include having clinically stable type 2 diabetes mellitus, being a female without childbearing potential, having a body mass index (BMI) between 18.5 kg/m2 and 39.9 kg/m2, having hemoglobin A1c levels between 6.5% and 10%, having fasting blood glucose levels between 140 mg/dL and 270 mg/dL, having specific ranges for systolic and diastolic blood pressure, not having been administered anti-diabetic medication within 2 weeks prior to dosing, having stable dosage of necessary medicines for hypertension or dyslipidemia for at least 3 months, and having unchanged treatment with diet and exercise for more than 3 months. The exclusion criteria include having type 1 diabetes mellitus or secondary diabetic mellitus, having a history of diabetic complications that require treatment, having been treated with insulin, thiazolidinediones, thiazide diuretics, beta blockers, or systemic steroids within 3 months prior to informed consent, having serum creatinine levels above the upper limit of the normal range, and having significant complications.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is essential hypertension. The ICD-10 codes associated with this disease are I10, O10.02, O10.03, O10.011, O10.012, O10.013, and O10.019. The drugs being tested in this trial are vasomera (pb1046) and 0.9% sodium chloride. The eligibility criteria for participants include being willing and able to provide informed consent, being between the ages of 18 and 70, practicing effective contraception for females of childbearing potential, having a diagnosis of essential hypertension with specific blood pressure ranges, having a BMI between 20 and 40 kg/m2, and being in generally stable health. There are also exclusion criteria, such as having certain blood pressure readings, having unstable cardiovascular disease or uncontrolled type 2 diabetes mellitus, having significant renal or hepatic dysfunction, using certain medications, being pregnant or lactating, having a history of drug or alcohol abuse, and having certain medical or psychiatric conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being tested in this trial are ODM-201 tablet A, ODM-201 tablet B, and ODM-201 capsule formulation. The eligibility criteria for this trial include requirements such as written informed consent, confirmed adenocarcinoma of the prostate, progressive metastatic disease, ongoing androgen deprivation therapy, adequate bone marrow, hepatic and renal function, and the ability to swallow the ODM-201 treatment. The exclusion criteria include previous chemotherapy for prostate cancer, known brain metastases, history of other malignancy within the previous 5 years (except basal cell carcinoma of the skin), and known gastrointestinal conditions that may affect the absorption of the study treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is called npi-2358. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having an ECOG performance status of 2 or lower, having a confirmed solid tumor malignancy, not being eligible for other treatment regimens known to be beneficial, having resolved adverse events from previous treatments, having adequate bone marrow reserve, hepatic and renal function, and having signed informed consent.\n\nExclusion criteria include not having received chemotherapy, biological, immunotherapy, or investigational agents within 21 days prior to the study, not having major surgery within 6 weeks before the study, not having received radiotherapy within 4 weeks, not having significant cardiac history or findings, not having underlying conditions or medications associated with bleeding diathesis or significant vascular pathology, not having lung cancer with central chest tumors, not having prior treatment with vascular disruptive agents, not having a seizure disorder requiring anticonvulsant therapy or prior transient ischemic attack or cerebrovascular accident, not having brain metastases, not having severe chronic obstructive pulmonary disease (COPD) with hypoxemia, not having an active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy, not having known infection with HIV, active hepatitis A, B, or C, not having a prior hypersensitivity reaction to any product containing Solutol and/or propylene glycol, not being pregnant or breastfeeding, and not having a concurrent, active second malignancy for which the patient is receiving therapy (excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix).",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is an unspecified childhood solid tumor that is specific to the protocol. The associated ICD-10 codes for the disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs being used in the trial are temsirolimus, temozolomide, and irinotecan hydrochloride. The eligibility criteria for the trial include having a histologically verified malignancy, either measurable or evaluable disease, and a current disease state for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life. Other criteria include specific performance scores, recovery from prior chemotherapy, certain blood counts and kidney function, and various other medical conditions and medications that may exclude a patient from participating in the trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on patients with multiple myeloma, a type of cancer. The trial includes patients who have been previously diagnosed with multiple myeloma and have received at least one but less than four lines of therapy. These patients are currently in need of further treatment due to relapse from complete response or progressive disease.\n\nInclusion criteria for the trial include being over 18 years old, willing and able to comply with the protocol requirements, and having given voluntary written informed consent. Female patients of child-bearing potential and male patients with female partners of child-bearing potential must agree to use two simultaneous methods of contraception. Additionally, patients must have measurable disease, a Karnofsky performance status of at least 80%, and a life expectancy of more than 3 months.\n\nThe sample also provides specific laboratory values that patients must meet within 14 days before receiving the study drug. These values include platelet count, hemoglobin level, absolute neutrophil count, corrected serum calcium, serum potassium, serum magnesium, aspartate transaminase, alanine transaminase, total bilirubin, and calculated or measured creatinine clearance.\n\nExclusion criteria for the trial include prior severe allergic reactions to specific drugs, neuropathy of a certain grade, and various cardiac risk factors such as long QT syndrome, certain ECG abnormalities, congestive heart failure, and uncontrolled hypertension. Female patients who are pregnant are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is migraine. The icd-10 codes associated with migraine are listed as ['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']. The drug being used in this trial is a placebo. \n\nThe eligibility criteria for this trial include a diagnosis of migraine at or before the age of 50, a history of migraine for at least 12 months, a specific number of migraine days within a 28-day period, limited use of acute migraine medications, and specific contraceptive requirements for women of child-bearing potential. The criteria also include restrictions on posting personal medical data related to the trial on social media sites until the trial is completed.\n\nThe exclusion criteria for this trial include the presence of confounding pain syndromes, certain types of headaches other than migraine, regular use of prophylactic headache medication or onabotulinumtoxin A within specific timeframes, recent cardiac surgery or symptoms, suspected or diagnosed hypertension, any ongoing co-morbidity that may interfere with participation, a high body mass index (BMI), pregnancy or breastfeeding, and the use of opioids for pain treatment within specific timeframes.\n\nOverall, this sample provides a snapshot of the trial phase, the specific disease being studied, the associated icd-10 codes, the drug being used, and the eligibility and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease of pain. The associated ICD-10 codes for this disease are ['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']. The trial involves two drugs, namely 'ppc-5650' and 'placebo'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include factors such as signed informed consent, specific age range, pain intensity level, hypersensitivity measurement, ability to cooperate, stable medication, and not taking over-the-counter medication 24 hours before the study sessions. Exclusion criteria include factors such as any conditions or medications that may affect gastrointestinal function, abnormal laboratory test results, presence of chronic extraintestinal pain, known digestive tract abnormalities, previous major intra-abdominal surgery, planned surgical interventions, recent participation in other clinical trials, and alcohol or drug abuse.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are acute myeloid leukemia and essential thrombocythemia. The ICDCodes associated with these diseases are C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60 for acute myeloid leukemia and D47.3 for essential thrombocythemia. The drug being tested is LY573636-sodium. The eligibility criteria for participants include having a diagnosis of either essential thrombocythemia or relapsed/refractory acute myeloid leukemia, being at least 18 years old, having given written informed consent, having adequate hepatic and renal function, and having discontinued previous cancer therapies for a certain period of time. There are also exclusion criteria listed, such as recent treatment with unapproved drugs, presence of other myeloproliferative disorders, recent stem cell transplant, and various medical conditions that would preclude participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is \"renal insufficiency, chronic.\" The ICDCodes associated with this disease are ['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']. The drug mentioned in this sample is \"dabigatran etexilate.\" \n\nThe eligibility criteria for this trial are listed under inclusion and exclusion criteria. Inclusion criteria include being a male or female patient aged 18 years or older, having impaired renal function within a specific range, and using either aspirin or Vitamin K Antagonists. The provision of informed consent is also required.\n\nExclusion criteria include having unstable renal function, being treated with two or more platelet aggregation inhibitors, having a need for therapeutic heparin, having prosthetic heart valves, having a hemorrhagic disorder or bleeding diathesis, having a low platelet count, and participating in another drug trial within the last 30 days before screening.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are small cell carcinoma and lung cancer. The icd-10 codes associated with these diseases are provided. The drugs being used in the trial are topotecan and sorafenib. The eligibility criteria for this trial include specific requirements for patients, such as having histologically proven small cell carcinoma, receiving previous chemotherapy, having documented disease recurrence or progression, and having certain organ function levels. There are also criteria related to pregnancy, contraception, brain metastases, coagulation, and informed consent. The exclusion criteria include factors such as pregnancy, recent myocardial infarction or cerebrovascular accident, uncontrolled hypertension, history of other active invasive malignancy, recent major surgery or chemotherapy, cardiac disease, bleeding disorders, serious infections, and various other conditions that may affect the patient's ability to participate in the trial.",
    "The sample from the table represents a phase 1 clinical trial for Parkinson's disease (PD). The trial includes a list of diseases, with Parkinson's disease being the only disease mentioned in this sample. The corresponding ICD-10 code for Parkinson's disease is \"G20\". The trial also involves the administration of various drugs, including \"bia 9-1067 5 mg\", \"bia 9-1067 25 mg\", \"levodopa/carbidopa 100/25\", \"placebo\", and \"levodopa/benserazide 100/25 mg\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must be willing to provide written informed consent.\n- Both male and female subjects are eligible.\n- Participants must be between the ages of 18 and 45.\n- Body mass index (BMI) should be between 18 and 30 kg/m2.\n- Participants should be deemed healthy based on medical history, physical examination, clinical laboratory tests, vital signs, neurological examination, and electrocardiogram (ECG).\n- Negative tests for hepatitis B, hepatitis C, HIV-1, and HIV-2 are required.\n- Participants should test negative for drugs of abuse and alcohol.\n- Non-smokers or ex-smokers for at least 3 months are eligible.\n- If sexually active, participants must agree to use medically acceptable contraception throughout the study.\n- Female participants of childbearing potential must have a negative pregnancy test.\n\nExclusion criteria for participants in this trial include:\n- Failure to meet the inclusion criteria or having a clinically relevant surgical history, family history, or history of relevant atopy.\n- Presence of significant infection, known inflammatory process, or acute gastrointestinal symptoms at screening or admission to the treatment period.\n- Being a vegetarian, vegan, or having medical dietary restrictions.\n- Inability to communicate reliably with the investigator.\n- Unwillingness to cooperate with the study requirements or history of hypersensitivity to specific drugs.\n- Presence of significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatological, hematological, neurologic, or psychiatric disease.\n- Any clinically significant illness within the previous 28 days before the study.\n- History of drug abuse or alcoholism within the past year.\n- Consumption of more than 50 g of ethanol per day.\n- Poor motivation, intellectual problems, or inability to cooperate or understand the instructions of the physician.\n- Blood donation within 60 days before the study.\n- Positive urine screening for alcohol or drugs of abuse upon admission to the treatment period.\n- History of tuberculosis or positive results for HIV, hepatitis B surface antigen (HBsAg), or anti-HCV tests.\n- Previous participation in a clinical study with BIA 9 1067.\n- Pregnancy or breastfeeding for female participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is ischemic stroke. The ICDCodes associated with this disease are \"I25.5\", \"H47.013\", \"H93.013\", \"G45.9\", \"H47.011\", \"H47.012\", and \"H47.019\". The drugs being investigated in this trial are aspirin and warfarin. The eligibility criteria for this trial include the inclusion criteria of having a clinical and imaging diagnosis of cervicocephalic arterial dissection within 3 months, and the exclusion criteria of having any contraindication to aspirin or warfarin.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is neoplasms. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs mentioned are mk0683 and vorinostat. The eligibility criteria for this trial include being a chemotherapy-naive patient with histologically or cytologically diagnosed NSCLC (non-small cell lung cancer) in stage IIIB or stage IV. Additionally, the patient should have normal organ and bone marrow function. The exclusion criteria include having received radical thoracic radiation for NSCLC or radiation for other than the original lesion within the past 3 weeks, having peripheral neuropathy above grade 2, having ascites, pleural effusion, or pericardiac effusion requiring treatment, having any uncontrolled concomitant illness, and being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"diabetes mellitus,\" \"diabetes mellitus, type 2,\" and \"glucose metabolism disorders.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being tested in this trial are \"pf-04991532\" and \"placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include patients with type 2 diabetes mellitus who are taking metformin only, with stable treatment for the past 2 months. Other criteria include specific body mass index (BMI) and weight requirements, fasting C-peptide levels, and HbA1c levels. \n\nExclusion criteria include a history of various medical conditions, such as hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic diseases. Other exclusion criteria include a history of certain medical events, conditions affecting drug absorption, and specific laboratory values. \n\nCertain lifestyle factors, such as tobacco or nicotine use, alcohol consumption, and concomitant medications, are also considered in the exclusion criteria. Pregnant or nursing females and females of childbearing potential are also excluded from the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on individuals without any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"glpg0778\" and \"placebo.\" The eligibility criteria for participants include being a healthy male between the ages of 18 and 50, having a body mass index (BMI) between 18 and 30 kg/m\u00b2, and not having significantly abnormal platelet function or coagulopathy, smoking, drug or alcohol abuse, or hypersensitivity to any of the test substances.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is an unspecified adult solid tumor that is specific to the protocol. The ICDCodes associated with this disease are \"H01.009\", \"H02.209\", \"H02.009\", \"H02.109\", \"H04.209\", \"H05.409\", and \"H10.509\". The drug mentioned in this sample is \"decitabine\". \n\nThe eligibility criteria for this trial include:\n- The patient must have a biopsy-proven solid tumor.\n- The tumor must be metastatic or unresectable.\n- The tumor must be amenable to biopsy.\n- There should be no curative or more effective treatment available for this disease, according to the investigator's opinion.\n- The disease must be measurable by scans using RECIST criteria.\n- The patient should not have any untreated brain metastasis and should no longer be receiving steroid therapy for previously treated brain metastasis.\n- The patient's Zubrod performance status should be between 0-2.\n- The levels of bilirubin, SGOT or SGPT, and serum creatinine should be within certain limits.\n- The patient's creatinine clearance, ANC, platelet count, and hemoglobin levels should also meet certain criteria.\n- The patient should not have severe and/or uncontrolled concurrent medical diseases, such as uncontrolled diabetes, chronic renal or liver disease, or active uncontrolled infection (e.g., HIV).\n- The patient should not be pregnant or nursing, and a negative pregnancy test is required.\n- Fertile patients must use effective barrier contraception during and for 3 months after completing the study therapy.\n- The patient must be willing to undergo biopsies.\n- The patient should not have any medical or psychological conditions that, in the investigator's opinion, may hinder their ability to tolerate or complete the treatment or provide reliable informed consent.\n- The patient should not have any other prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I, II, or III cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.\n- The patient should not have had prior extensive pelvic irradiation or prolonged nucleoside analogue pretreatment.\n- There should be at least 28 days since prior and no concurrent chemotherapy, radiotherapy, surgery, biological therapy, anticancer agent, or other investigational drug.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1. The diseases being studied are autism and pervasive developmental disorder. The corresponding ICD-10 code for these diseases is \"Z13.41\". The drug being tested is oral zinc and vitamin C supplements. The eligibility criteria for this trial include being between the ages of 3 and 8, having a diagnosis of autism spectrum disorder, and having a serum copper/zinc ratio greater than 2.0 or as determined in phase 1 of the study. The exclusion criteria state that individuals with known chromosomal disorders or neurological disorders other than autism are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Hepatitis C. The ICDCodes associated with this disease are ['B18.2', 'B17.10', 'B17.11', 'B19.20', 'B19.21', 'B15.0', 'B15.9']. The drugs being tested in this trial are 'mk-3281' and 'placebo to mk-3281'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being in good health, having no significant abnormalities on an electrocardiogram, using contraception if applicable, and having a clinical diagnosis of chronic HCV infection. Exclusion criteria include a history of stroke, seizures, major neurological disorders, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is B-cell lymphoma. The ICD-10 codes associated with this disease are S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, and S33.131S. The drugs being tested in this trial are inotuzumab ozogamicin (cmc-544) and rituximab (rituxan). The eligibility criteria for this trial include having CD20 and CD22-positive B-cell NHL that has progressed after 1 or 2 prior therapies, having received at least one dose of Rituximab therapy in the past, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, not having received previous radioimmunotherapy, being tolerant to Rituximab, and not having received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before the first dose of the test article. The exclusion criteria include being a candidate for potentially curative therapies, having received previous radioimmunotherapy, and having undergone autologous hematopoietic stem cell transplant within the last 6 months.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial is focused on non-small cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being studied is irinotecan. \n\nThe eligibility criteria for participants include being 18 years of age or older, having received prior chemotherapy for advanced non-small cell lung cancer (up to 3 prior treatments), displaying high ISG15 levels in tumors, having a life expectancy of at least 12 weeks, and having an ECOG/Zubrod performance status of 0-2. Adequate bone marrow function, hepatic function, and renal function are also required.\n\nExclusion criteria include having symptomatic brain metastases, being pregnant or nursing, not using adequate contraception for patients of childbearing potential, receiving concurrent chemotherapy or radiation therapy, having severe medical problems such as uncontrolled diabetes or cardiovascular disease, and having a previous hypersensitivity reaction to camptothecins.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is neoplasms. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are afatinib 20mg, afatinib 40mg, and vinorelbine iv 25 or 20mg/m2. \n\nThe eligibility criteria for this trial are as follows:\nInclusion criteria:\n- The patient must have a histologically confirmed diagnosis of malignancy that is advanced and for which standard therapies do not exist or are no longer effective.\n- The patient must have a life expectancy of at least 12 weeks.\n- The patient's Eastern Cooperative Oncology Group Performance Status must be 0 or 1.\n- The patient must have adequate hepatic, renal, hematologic, and other organ function.\n- The patient must provide written informed consent.\n\nExclusion criteria:\n- The patient must not have undergone chemotherapy, immunotherapy, surgery, or radiotherapy within the past 4 weeks.\n- The patient must not have received prior treatment with afatinib and/or vinorelbine.\n- The patient must not have any clinically significant active infectious disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cutaneous T-cell lymphoma. The ICDCodes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drug being tested in this trial is pralatrexate. \n\nThe eligibility criteria for this trial include having confirmed relapsed or refractory cutaneous T-cell lymphoma, no curative treatment options, progression of disease or relapse after previous systemic therapy, Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 2, life expectancy of at least 3 months, adequate blood, liver, and kidney function, specific serum concentration levels, and the use of contraception for women of childbearing potential. \n\nThere are also exclusion criteria, such as having an active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix), congestive heart failure Class III/IV, uncontrolled hypertension, HIV-positive diagnosis with a low CD4 count or detectable viral load, symptomatic central nervous system metastases, active uncontrolled infection, major surgery within 2 weeks of treatment, recent receipt of chemotherapy or radiation therapy, use of corticosteroids or topical corticosteroids, use of investigational drugs or devices, recent receipt of a monoclonal antibody, previous exposure to pralatrexate, and re-entering patients who have received subsequent therapy for CTCL during the time off initial study treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is pancreatic cancer. The ICDCodes associated with this disease are ['C25.3']. The drugs being used in the trial are 'as703569/gemcitabine' and 'as703569/gemcitabine'. The eligibility criteria for participants include having a confirmed diagnosis of measurable or assessable malignancy, being at least 18 years old, having a life expectancy of at least 3 months, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of less than 2, having received no more than 3 prior chemotherapy regimens for advanced/metastatic disease, and having a certain time period since the last treatment or therapy. Adequate renal, hepatic, and bone marrow functions are also required.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is HIV-1 infection. The ICDCodes associated with this disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being used in the trial are interleukin-2, gm-csf, and growth hormone. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being documented HIV-1 positive, stable on HAART (Highly Active Antiretroviral Therapy), having two consecutive screening viral loads of less than 50 cps/ml, a CD4 T cell count of more than 400 cells/ul, a nadir CD4 T cell count of more than 200 cells/ul, being over 18 years of age, willing and able to provide informed consent, not being pregnant or lactating (for female subjects), and using adequate double barrier method of contraception as appropriate.\n\nExclusion criteria include having prior therapeutic vaccination, experiencing acute illness within 2 weeks of the study start, receiving prior immunomodulatory therapy (such as IL-2, rhGH, GCSF, GM-CSF, HU), taking immunosuppressive medication (such as steroids), participating in other vaccine trials currently, having diabetes mellitus type 2, having cardiac abnormalities, having pre-existing autoimmune disease, having active neoplasia, and having evidence of any progression or recurrence of an underlying intra-cranial lesion.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as an early phase 1 trial. The diseases being studied in this trial are \"injuries\" and \"shock, traumatic\". The corresponding ICD-10 codes for these diseases are \"P15.8\", \"T07.XXXS\", \"P12.89\", \"P13.1\", \"P14.3\", \"T07.XXXA\", \"T07.XXXD\" for the first disease, and \"T79.4XXS\", \"T79.4XXA\", \"T79.4XXD\" for the second disease. The drugs being used in the trial are \"normal saline control\" and \"vasopressin\". The eligibility criteria for the trial are listed, including inclusion criteria such as being at least 18 years old, having a systolic blood pressure below 90 mmHg, and having clinical evidence of acute traumatic injury. Exclusion criteria are also provided, such as being admitted to the study hospital's Emergency Department more than six hours after the injury, receiving more than 4 liters of fluid since the time of injury, being enrolled in another shock trial, being asystolic or requiring CPR prior to randomization, being pregnant, or having \"Do Not Resuscitate\" orders or visible/identifiable objection to participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is metastatic melanoma. The ICDCodes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drug being tested is raf265. The sample also includes the eligibility criteria for participants to be included or excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes for this disease are 'Z21'. The drugs being used in the trial are 'tenofovir df' and 'tenofovir alafenamide'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as having HIV-1 RNA levels greater than or equal to 30,000 copies/mL, a CD4 count greater than or equal to 200 cells/mm3, and various other health parameters within specific ranges. Exclusion criteria include factors such as prior treatment with antiretroviral therapy, recent immunization, the presence of a new AIDS defining condition, and the use of certain medications.\n\nOverall, this sample provides a snapshot of a clinical trial that focuses on HIV infections, with specific eligibility criteria and drugs being investigated.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of anxiety in patients with advanced-stage cancer. The trial uses the drug psilocybin. The inclusion criteria for participants include having advanced-stage cancer and anxiety, and being between the ages of 18 and 70. The trial takes place in Los Angeles, California, with two treatment sessions scheduled three to six weeks apart, each requiring an overnight hospital stay. \n\nThe exclusion criteria state that participants should not have cancer affecting the central nervous system or brain function, no history of major psychiatric disorder, and no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease (including untreated hypertension). Participants should also not be taking certain medications, except for PRN benzodiazepines up to 3 days before the session. Prozac should not have been taken for the previous 5 weeks. \n\nOn the day of and the day after treatment sessions, participants should not take any medications except ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration. Alcohol consumption is not allowed the day before, the day of, and the day after a session. Female participants of childbearing potential must have a negative pregnancy test and agree to use effective birth control.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"prostatic neoplasms\" and its corresponding ICDCodes are ['B38.81', 'N42.31', 'Z87.430', 'N40.0', 'N40.1']. The drugs involved in the trial are 'abiraterone acetate', 'abiraterone acetate mtd', and 'dexamethasone'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include having histologically documented adenocarcinoma of the prostate, evidence of progressive prostate cancer, specific PSA levels, Eastern Cooperative Oncology Group (ECOG) performance status score, and a life expectancy of at least 12 weeks. The exclusion criteria include having central nervous system disease or brain metastases, currently active second malignancy other than non-melanoma skin cancer, recent myocardial infarction, active or uncontrolled autoimmune disease, and major surgery or traumatic injury within 4 weeks of the study start.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is focused on pancreatic cancer and is in either phase 1 or phase 2. The diseases column specifies the disease being studied, which in this case is pancreatic cancer. The icdcodes column contains the ICD-10 code for the disease, which is \"C25.3\" in this sample. The drugs column lists the names of the drugs being used in the trial, including gemcitabine, capecitabine, erlotinib, and bevacizumab. The criteria column provides eligibility criteria for patients participating in the trial, including disease characteristics, patient characteristics, and prior concurrent therapy. The criteria specify requirements such as histologically confirmed adenocarcinoma of the pancreas, certain performance status, life expectancy, hematopoietic and hepatic conditions, renal function, cardiovascular health, and other factors. The criteria also outline restrictions on prior treatments and medications.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is small cell lung cancer. The corresponding ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are at-101 and topotecan. The eligibility criteria for participants are listed, including requirements such as confirmed diagnosis of small cell lung cancer, progression of disease after one prior platinum-containing chemotherapy regimen, measurable disease, ECOG performance status of 0-1, and adequate hematologic, liver, and renal function. There are also exclusion criteria, such as having more than one prior chemotherapy regimen or prior regimen without a platinum agent, prior chemotherapy regimen containing irinotecan, active secondary malignancy, unstable or progressive brain metastases, and uncontrolled concurrent illnesses.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"multiple myeloma\" and \"multiple myeloma in relapse\". The corresponding ICDCodes for these diseases are \"C90.01\", \"C90.02\", and \"C90.00\" for the first disease, and \"C90.02\" for the second disease. The drugs being used in the trial are \"perifosine\", \"bortezomib\", and \"dexamethasone\". The eligibility criteria for this trial include various conditions and requirements such as previous diagnosis of multiple myeloma, specific diagnostic criteria, relapsed or refractory disease, previous treatment with bortezomib, age requirement, performance status, ability to adhere to the study schedule, and signing an informed consent document. There are also exclusion criteria listed, which include certain medical conditions, medication history, laboratory abnormalities, pregnancy or breastfeeding, and plasma cell leukemia at the time of study entry.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors\" and its corresponding ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drug mentioned is \"tki258\". The eligibility criteria for this trial include various factors such as obtaining written informed consent, having an ECOG performance status of 0 or 1, a life expectancy of at least 3 months, and agreement to remain hospitalized. There are also exclusion criteria listed, such as recent receipt of investigational compounds or other antineoplastic therapies, presence of certain diseases or conditions, and use of certain medications. It is important to note that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial is testing the drug MN-221 in three different dose groups. The eligibility criteria for participants include being between 40-65 years old, having a history of physician-diagnosed COPD, and meeting certain lung function requirements. Other criteria include negative pregnancy and drug tests, no evidence of heart disease, and obtaining informed consent. Exclusion criteria include recent use of certain medications, significant heart or respiratory conditions, and allergies to the drug or other beta agonists. Participants must also not have participated in another clinical study with an investigational drug within the past 30 days.",
    "The sample is a record from a table that contains information about clinical trials. It is for a trial that is in both phase 1 and phase 2. The trial is focused on the treatment of non-small-cell lung carcinoma. The trial uses the drugs vorinostat and erlotinib. The eligibility criteria for participants include being 18 years or older, having a confirmed diagnosis of non-small-cell lung cancer, and having failed at least one prior treatment for the disease. Other criteria include having normal lab results, not being pregnant, and agreeing to practice birth control during the study. Exclusion criteria include prior treatment with vorinostat or erlotinib, as well as having certain conditions such as active infections, brain metastases, heart problems, or pregnancy.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are solid tumors and non-Hodgkin's lymphoma. The ICDCodes associated with these diseases are S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, and S33.140S. The drug being tested is cep-18770. The eligibility criteria for this trial include a diagnosis of relapsed or refractory solid tumor or non-Hodgkin's lymphoma, unresponsiveness or poor response to accepted treatments, expected survival of at least 12 weeks, Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, recovery from prior surgical procedures and reversible side effects of previous cancer therapies, specific time intervals since last cancer therapy, no more than 3 previous chemotherapies for advanced disease, good overall health as determined by medical evaluations, use of contraception for women of childbearing potential and birth control for men, willingness and ability to comply with study requirements. The exclusion criteria include specific hematologic and hepatic function values, high serum creatinine value, known cerebral metastases or active CNS disease, signs of major bone marrow involvement, significant neurotoxicity, concomitant cancer-related treatment, treatment with steroids, previous high-dose chemotherapy with PBSC support, recent use of investigational drugs or medications that interact with CYP3A4, known hypersensitivity to boronic acid derivatives or excipients in the CEP-18770 formulation, and any other condition that may pose undue risk or interfere with the study results.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is acute coronary syndrome. The icd-10 code associated with this disease is I24.0. The drugs being used in this trial are lc23-1306, placebo, and ticagrelor. The eligibility criteria for participants in this trial include being a healthy male between the ages of 20 and 50, having a BMI between 18.0 and 27.0 kg/m2, and weighing between 55 kg and 90 kg. Additionally, the participant must be informed about the nature of the study, voluntarily agree to participate, and provide informed consent approved by the Institutional Review Board. The participant's medical history, physical examination, and laboratory results should also fall within acceptable ranges.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is cystic fibrosis. The ICD-10 codes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being tested in this trial are tiotropium bromide low, tiotropium bromide medium, tiotropium bromide high, and placebo. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as age, diagnosis of cystic fibrosis, spirometric measurements, and ability to inhale medication properly. The exclusion criteria include factors such as allergies, participation in other trials, substance abuse, pregnancy or lactation, and certain medical conditions. These criteria are used to determine if a patient is eligible to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is choroidal neovascularization. The ICDCodes associated with this disease are 'H44.2A1', 'H44.2A2', 'H44.2A3', 'H44.2A9', 'H35.3231', 'H35.3232', and 'H35.3211'. The drugs being used in the trial are ranibizumab. The eligibility criteria for this trial include the ability to provide written informed consent, having predominantly hemorrhagic subfoveal CNV from age-related macular degeneration resulting in visual acuity of 20/40 or worse, being over 50 years of age, and having clear media for fundus photography, fluorescein angiography, and optical coherence tomography. The exclusion criteria include known hypersensitivity to humanized monoclonal antibodies, history or evidence of severe cardiac disease, history of stroke within 6 months, current acute ocular or periocular infection, recent major surgical procedure, serious allergies to fluorescein dye, previous participation in a clinical trial involving anti-angiogenic drugs within the last 6 months, previous intravitreal drug delivery in the study eye within the last 6 months, history of subfoveal laser treatment in the study eye, history of other visually-limiting conditions, ocular inflammation in the study eye, and inability to comply with study or follow-up procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"inflammation,\" \"rheumatoid arthritis,\" and \"healthy.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are \"nnc0114-0000-0005\" and \"placebo.\" \n\nThe eligibility criteria for the trial are listed under \"criteria.\" The inclusion criteria include requirements for male subjects to use contraception and refrain from sperm donation. For healthy subjects, additional criteria include being male, aged between 18 and 60 years, and in good health. For subjects with rheumatoid arthritis, additional criteria include being diagnosed with RA for at least 3 months, having active RA, and using effective contraception. \n\nThe exclusion criteria include limitations on body mass index, positive pregnancy test for females, history of excessive alcohol consumption, recent blood donation or loss, and other specific criteria for healthy subjects and subjects with rheumatoid arthritis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is malignant melanoma. The icd-10 codes associated with this disease are C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, and C43.10. The drug being used in the trial is vemurafenib. \n\nThe eligibility criteria for this trial include being a Chinese male or female participant who is 18 years of age or older. The participant must have histologically confirmed metastatic melanoma that is surgically unresectable Stage IIIC or Stage IV. They can be treatment-na\u00efve or have received prior systemic treatments for metastatic melanoma. The participant must also have a positive BRAF V600 mutation result and measurable disease. \n\nOther criteria include completing previous chemotherapy, immunotherapy, or radiation therapy at least 2 weeks prior to the study, recovering from major surgery or significant traumatic injury at least 14 days before the first dose of the study treatment, and having adequate hematologic, renal, and liver function. Fertile men and women must use contraception during treatment and for at least 6 months after completion of treatment. The participant's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1, and their life expectancy must be greater than 3 months. They must also be able to swallow pills.\n\nExclusion criteria for this trial include having active central nervous system (CNS) lesions, history of spinal cord compression or carcinomatous meningitis, ongoing administration of anti-cancer therapies other than those in the study, active squamous cell carcinoma (SCC) that has not been excised or adequately healed post excision, being pregnant or lactating, having conditions that would preclude adequate absorption of vemurafenib, and having certain cardiovascular or infectious conditions. \n\nOther exclusion criteria include history of bone marrow or organ transplantation, previous malignancy within the past 5 years (except for specific types of skin cancer or curatively treated cancer), previous treatment with a BRAF or MEK inhibitor, previous doses of vemurafenib in a previous clinical trial, being HIV positive or having AIDS-related illness, and being a carrier of hepatitis B or hepatitis C virus. Finally, participants who have received any investigational treatment within 4 weeks of the study drug start are also excluded.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is \"lung cancer\" and its corresponding ICD-10 codes are \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2\". The drug being tested is \"paclitaxel albumin-stabilized nanoparticle formulation\". The eligibility criteria for the trial are listed, including disease characteristics such as stage IV non-small cell lung cancer with evidence of inoperable local recurrence or metastasis, measurable disease documented radiographically, and no active brain metastases or leptomeningeal involvement. Patient characteristics include being 18 years or older, having an ECOG performance status of 0-1 or Karnofsky score of 80-100%, and a life expectancy of more than 12 weeks. Various laboratory values and medical conditions are also specified as eligibility criteria. The sample also includes information about prior concurrent therapies that are allowed or not allowed during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is asthma. The ICDCodes associated with asthma are listed as ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in this trial are 'gw805858' and 'placebo'. \n\nThe eligibility criteria for this trial are then listed, with both inclusion and exclusion criteria. The inclusion criteria state that the trial is open to men and women between the ages of 18 and 60, who are not capable of bearing children. The subjects must also meet certain weight and BMI requirements, be non-smokers, provide informed consent, and be able to understand and comply with the trial's requirements. If the subject has asthma, they must be clinically stable.\n\nThe exclusion criteria list factors that would disqualify a subject from participating in the trial. These include allergies to the inhaler ingredients, recent participation in other research trials or use of certain medications, excessive alcohol intake, history of breathing problems, infections with hepatitis B, hepatitis C, or HIV, recent respiratory tract infections or worsening of asthma, presence of other diseases that may affect the trial's outcome, history of life-threatening asthma, recent use of steroids, inability to abstain from interfering drugs, and ongoing rhinitis requiring treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"recurrence of solid tumor,\" \"glioblastoma multiforme,\" and \"melanoma.\" The corresponding ICDCodes for these diseases are \"L51.0, L51.8, L51.9\" and \"C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4\" respectively. The drugs being used in the trial are \"mk-4827\" and \"temozolomide.\" \n\nThe eligibility criteria for this trial are divided into different parts. In Part A, participants must have advanced solid tumors that have failed to respond to standard therapy, progressed on standard therapy, or for whom standard therapy does not exist. In Part B, participants must have recurrent glioblastoma multiforme (GBM) or recurrent or metastatic melanoma. Participants in both parts must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, adequate organ function, and must agree to use contraception. They must also meet certain criteria related to their medical history and have at least one measurable metastatic or recurrent lesion.\n\nThe exclusion criteria include recent chemotherapy, radiotherapy, or biological therapy, symptomatic or progressive Central Nervous System (CNS) metastases and/or carcinomatous meningitis, prior exposure to PARP inhibitors, significant or uncontrolled cardiovascular disease, breastfeeding, being HIV-positive, having active Hepatitis B or C, symptomatic ascites or pleural effusion, requiring concurrent treatment with immunosuppressive agents, prior radiation therapy to more than 30% of the bone marrow, and prior stem cell or bone marrow transplant.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on non-small cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in this trial are docetaxel and pemetrexed. The eligibility criteria for participants include having histologically confirmed inoperable NSCLC, providing written informed consent, having prior chemotherapy with platinum compounds, not having been previously treated with docetaxel and pemetrexed, having measurable disease according to RECIST criteria, being at least 18 years old, having a World Health Organization performance status of 0-2, having a life expectancy of at least 12 weeks, and meeting certain laboratory values such as serum bilirubin, AST and ALT levels, serum creatinine, neutrophil count, and platelet count. The exclusion criteria include having other co-existing malignancies within the last 5 years (except for basal cell carcinoma or cervical cancer in situ), having severe uncontrolled concomitant disease, having unresolved chronic toxicity from previous anticancer therapy, having unstable central nervous system metastases, experiencing malnutrition, having a performance status of 4, having psychiatric illness or a social situation that would hinder study compliance, and being pregnant or lactating.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: A list of disease names associated with the trial, including \"adult anaplastic astrocytoma,\" \"adult anaplastic oligodendroglioma,\" \"adult giant cell glioblastoma,\" \"adult gliosarcoma,\" and \"recurrent adult brain tumor.\"\n- ICD Codes: A list of ICD-10 codes corresponding to the diseases mentioned. The codes include \"C84.67,\" \"C84.77,\" \"C84.7A,\" \"C84.60,\" \"C84.70,\" \"C84.62,\" \"C84.66,\" \"G47.13,\" \"J01.41,\" \"K11.22,\" \"K12.0,\" \"N96,\" \"F33.8,\" and \"G03.2.\"\n- Drugs: A list of drug names associated with the trial, which in this case is \"sorafenib tosylate.\"\n- Criteria: The eligibility criteria for participating in the trial, including both inclusion and exclusion criteria. The inclusion criteria specify requirements such as having a histologically proven malignant glioma, measurable progressive or recurrent glioma, recovery from prior therapy, a certain performance status, specific blood counts and laboratory values, ability to provide informed consent, and other factors. The exclusion criteria specify conditions that would make a patient ineligible for the trial, such as serious concurrent infections or medical illnesses, pregnancy or breastfeeding, having received more than two prior treatments, receiving concurrent therapy for the tumor (except steroids), having a concurrent malignancy (unless certain conditions are met), evidence of bleeding diathesis, and being on therapeutic anticoagulation.\n\nOverall, this sample record provides information about a Phase 1 clinical trial for malignant glioma, including the specific diseases, ICD codes, drug, and eligibility criteria associated with the trial.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is \"phase 1\" and the disease is \"type 2 diabetes mellitus\". The ICDCodes associated with the disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being tested in the trial are 'asp1941' and 'placebo'. The eligibility criteria for the trial are listed under the \"criteria\" column.\n\nThe inclusion criteria are divided into different parts: Part A for healthy subjects and Part A & Part B for subjects with type 2 diabetes mellitus. The criteria include factors such as fasting plasma glucose levels, body mass index (BMI), serum creatinine levels, and HbA1c levels.\n\nThe exclusion criteria are also divided into different parts: Part A for healthy subjects and Part A & Part B for subjects with type 2 diabetes mellitus. The criteria include factors such as liver function tests, QTc interval, pulse and blood pressure measurements, eGFR levels, type 1 diabetes mellitus, insulin therapy, urinary microalbumin/creatinine ratio, ALT and AST levels, urinary tract infections, hypertension, cardiovascular disease, and eGFR levels.\n\nOverall, the sample provides a glimpse into the structure and content of the table, including the phases, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on the disease \"knee osteoarthritis\". The ICD-10 codes associated with this disease are listed as \"M17.9\", \"M17.0\", \"M17.10\", \"M17.11\", \"M17.12\", \"M17.2\", and \"M17.30\". The drugs being tested in this trial are \"sar113945\" and \"placebo\". The eligibility criteria for this trial are listed, including both inclusion and exclusion criteria. The inclusion criteria specify that patients must have a diagnosis of primary knee osteoarthritis based on X-ray or MRI evidence, be classified as Kellgren and Lawrence II/III, and have a total WOMAC score between 24 and 72. The exclusion criteria include factors such as age, gender, presence of other types of osteoarthritis, skin abnormalities, and recent intra-articular injections. It is important to note that the provided information may not include all relevant considerations for potential participation in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, high-risk myelodysplastic syndrome, chronic lymphocytic leukemia, and advanced myelofibrosis. The corresponding ICDCodes for these diseases are also listed. The drug being tested in this trial is \"th-302\". The eligibility criteria for participants in this trial include being at least 18 years old, having relapsed or refractory leukemias with no anticipated standard therapy options, and meeting specific criteria for each disease. There are also additional criteria related to age, organ function, pregnancy, and other medical conditions. Exclusion criteria are also listed, which include certain cardiac conditions, seizure disorders, severe chronic obstructive pulmonary disease, recent major surgery, active uncontrolled infection, and other factors that could interfere with the study or pose risks to the participants.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1. The disease being studied is hepatocellular carcinoma. The ICD-10 codes associated with the disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being used in the trial are lenalidomide and sorafenib. The eligibility criteria for participants in the trial are listed, including requirements such as a diagnosis of unresectable hepatocellular carcinoma, previous discontinuation of cancer therapy, specific liver function class, performance status, and laboratory test results within specified ranges. There are also exclusion criteria, such as no serious medical conditions or psychiatric illnesses that would prevent signing the informed consent form, no pregnant or breastfeeding females, and no use of other experimental drugs or therapies within a certain timeframe.",
    "The sample from the table represents a clinical trial for patients with acute myeloid leukemia (AML). The trial is in phase 1/phase 2. The diseases column specifies the disease name, which in this case is \"acute myeloid leukemia.\" The icdcodes column provides the corresponding ICD-10 codes for the disease, which are ['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60'].\n\nThe drugs column lists the drugs being used in the trial, which are 'cytarabine' and 'lovastatin'. The criteria column contains the eligibility criteria for the trial. The inclusion criteria include patients with primary refractory AML (no prior remission) and patients with relapsed AML. The exclusion criteria include serious illnesses with a limited survival prognosis, psychiatric conditions affecting compliance, uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or infection, and currently active second malignancy other than non-melanoma skin cancers. Additionally, patients who have received any investigational agent within the prior 4 weeks are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"HIV-1 infection,\" \"HIV infection,\" and \"healthy volunteers.\" The corresponding ICDCodes for these diseases are \"B20,\" \"Z71.7,\" \"O98.72,\" \"Z21,\" \"O98.73,\" \"R75,\" \"Z11.4,\" and \"Z21.\" The drugs being used in the trial are \"dcvax-001,\" \"poly-iclc,\" and \"placebo.\" The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include factors such as age, willingness to comply with the study requirements, low risk of HIV infection, use of contraception, absence of HIV infection, absence of certain medical conditions, and exclusion from other clinical studies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drug being used in the trial is a combination of arsenic trioxide, ascorbic acid, and bortezomib. \n\nThe eligibility criteria for this trial include a diagnosis of relapsed/refractory multiple myeloma, measurable disease, adequate organ function, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and specific serum potassium and magnesium levels. \n\nThere are also exclusion criteria, such as not receiving any other investigational agents, history of allergic reactions to similar compounds, specific QT interval and cardiac arrhythmia requirements, and an ejection fraction less than 35% as determined by a MUGA scan.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being used in the trial are bicalutamide, docetaxel, and gnrh analog. The eligibility criteria for this trial include various factors such as histologically confirmed adenocarcinoma of the prostate, no prior radiation therapy or chemotherapy for prostate cancer, acceptable lab values, and a performance status of 0-2. Additionally, men of childbearing potential must be willing to use effective contraception during the treatment and for at least 3 months afterward. The exclusion criteria state that individuals with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80 are not eligible for the trial.",
    "The sample from the table is for a Phase 1 trial. The disease being studied is HIV infection, and the corresponding ICD-10 code is Z21. The drug being tested is called gsk1265744. The eligibility criteria for this trial include being a healthy male or female between the ages of 18 and 55, having a body weight within a certain range, and providing written informed consent. For the HIV-infected cohort, additional criteria include having a CD4 cell count of at least 200 cells/mm3 and a plasma HIV-1 RNA level of at least 5,000 copies/mL. The exclusion criteria include having certain medical conditions, such as hepatitis B or C, regular alcohol consumption, or a history of drug allergies. Other factors that would exclude a subject from participating in the trial include recent participation in another research trial, certain cardiac or pulmonary conditions, and use of certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"small cell lung cancer\" and \"small cell lung carcinoma\". The corresponding ICDCodes for these diseases are \"C78.00\", \"C78.01\", \"C78.02\", \"D14.30\", \"D14.31\", \"D14.32\", \"C34.2\" for the first disease, and \"D02.20\", \"D02.21\", \"D02.22\" for the second disease. The drug being tested is \"abt-263\".\n\nThe eligibility criteria for this trial include being at least 18 years old, having a documented diagnosis of small cell lung cancer or other non-hematological malignancy, having received prior chemotherapy treatment, having refractory or progressive disease, having clinically controlled brain metastases, having a certain performance score, receiving a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants, and meeting certain bone marrow, renal, and hepatic function requirements.\n\nThe sample also includes exclusion criteria, such as having a bleeding condition, recent history of thrombocytopenia-associated bleeding, active peptic ulcer disease, active immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia (AIHA), receiving anticoagulation therapy, recent anti-cancer therapy, and having certain medical conditions or diseases.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is major depressive disorder, and the corresponding ICDCodes are ['F33.0', 'F33.1', 'F33.9', 'F32.0', 'F32.1', 'F32.9', 'F33.40']. The drugs being tested are 'alks 5461' and 'placebo'. The eligibility criteria for this trial include being between 18 and 65 years old, meeting the DSM-IV-TR criteria for MDD, having a current episode lasting at least 8 weeks with an inadequate/partial response to a stable dose of an SSRI or SNRI, and meeting specific criteria related to depressive symptom severity and clinical impression. There are also exclusion criteria listed, such as having certain Axis I or Axis II diagnoses, experiencing certain symptoms, using certain medications, or having certain allergies or hypersensitivities.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied are cnf2024 and cnf2024 + trastuzumab. The eligibility criteria for this trial include age \u226518 years, confirmed HER2 adenocarcinoma of the breast with advanced disease, evaluable disease, ECOG \u22642, specific laboratory values, normal electrocardiogram, and negative pregnancy test for female subjects of childbearing potential. The sample also includes exclusion criteria such as prior antitumor therapies, active infection, history of prior malignancies, concurrent severe or uncontrolled diabetes, problems with swallowing or malabsorption, history of major surgery, prior treatment with Hsp90 inhibitors, and history of central nervous system metastasis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is chronic hepatitis C. The icd-10 codes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drugs being tested in this trial are als-002158 and placebo. \n\nThe eligibility criteria for this trial include providing written consent, being in good health, having a creatinine clearance greater than 50 mL/min, being within a certain age range (18-55 years for healthy volunteers and 18-65 years for subjects with chronic hepatitis C), having a specific body mass index (BMI) range, and meeting certain requirements for females of childbearing potential and males. \n\nThere are additional inclusion criteria specific to subjects with chronic hepatitis C genotype 1 infection, such as having a positive HCV antibody and HCV RNA, documentation of infection duration, specific viral load range, recent liver biopsy or Fibroscan evaluation, absence of hepatocellular carcinoma, no prior treatment for chronic hepatitis C, absence of hepatic decompensation, and specific laboratory values within normal ranges. \n\nExclusion criteria for this trial include having certain medical illnesses or psychiatric disorders, testing positive for certain antibodies, having abnormal screening laboratory results, having drug allergies, recent participation in other trials or receipt of investigational drugs or vaccines, significant blood loss or donation, and specific laboratory abnormalities. \n\nFor healthy volunteers, a history of regular tobacco use and a positive pre-study drug screen are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include myelodysplastic and myeloproliferative disorders, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, multiple myeloma, plasma cell dyscrasia, lymphoproliferative disorders, and other hematologic diseases. The corresponding ICDCodes for these diseases are also listed.\n\nThe drugs being used in the trial are campath, busulfan, fludarabine, and fk-506. The eligibility criteria for participants in the trial are listed, including requirements such as a specific diagnosis, performance status, ejection fraction, liver function, lung function, age range, and various conditions that may increase treatment-related mortality.\n\nThe inclusion criteria also specify the need for a healthy donor without any contraindications for donation, either related or unrelated. The patient or responsible person must be able to understand and sign consent, and women of childbearing potential must have a negative pregnancy test.\n\nThe exclusion criteria list factors that would disqualify a patient from participating in the trial, such as pregnancy or lactation, HIV positivity, uncontrolled infections, refractory AML or ALL, untreated blast crisis for CML, unstable angina or congestive heart failure, severe chronic pulmonary disease, hemodialysis dependence, active hepatitis or cirrhosis, high serum creatinine levels, unstable cerebral vascular disease or recent hemorrhagic stroke, and active CNS disease from a hematological disorder.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors\" and its corresponding ICDCodes are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug mentioned is \"osi-930 and erlotinib\". The eligibility criteria for this trial include various factors such as histology or cytologically documented malignancy, age, ECOG PS, ANC, bilirubin levels, AST and ALT levels, creatinine levels, predicted life expectancy, prior chemotherapy and tyrosine kinase inhibitor therapy, recovery from treatment-related toxicities, prior hormonal therapy, prior radiation therapy, prior surgery, contraceptive measures, written informed consent, accessibility for repeat dosing and follow-up, and adequate hematopoietic, hepatic, and renal function. The exclusion criteria include significant cardiac disease, current or former smokers, active or uncontrolled infections or serious illnesses, history of unacceptable toxicity with previous EGFR inhibitor therapy, history of psychiatric conditions, use of CYP3A4 inducers/inhibitors, pregnancy or breastfeeding, symptomatic brain metastases, history of allergic reaction to a similar compound, GI abnormalities, and clinically significant ophthalmologic abnormalities.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are colorectal cancer and unspecified adult solid tumor, protocol specific. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for colorectal cancer and H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509 for the unspecified adult solid tumor. The drugs being used in the trial are capecitabine, irinotecan hydrochloride, and oxaliplatin.\n\nThe eligibility criteria for this trial are listed under \"criteria\" and include specific requirements for disease characteristics and patient characteristics. For example, patients must have histologically or cytologically confirmed solid tumors, either metastatic or locally advanced unresectable disease. They must also have measurable or evaluable disease, with specific size requirements for measurable disease. Additionally, there are various patient characteristics that must be met, such as Karnofsky performance status, blood counts, liver and kidney function, and pregnancy status.\n\nThe sample also includes information about prior concurrent therapy, specifying the time since previous treatments and the recovery status required. It also mentions specific exclusions, such as prior treatment for advanced or metastatic colorectal cancer and concurrent use of certain medications.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are cancer and lymphoma. The ICDCodes associated with these diseases are provided as well. The drugs being tested in this trial are xl147 (sar245408). The eligibility criteria for participants in this trial include having a confirmed solid tumor that is metastatic or unresectable, having a confirmed diagnosis of relapsed or refractory lymphoma, and meeting various other criteria such as age, weight, performance status, organ function, and ability to understand and comply with the protocol. There are also exclusion criteria listed, which specify conditions or situations that would disqualify a participant from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drugs being used in the trial are \"bi 6727\" and \"bibf 1120.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria include patients with advanced, non-resectable, and/or metastatic solid tumors who have failed conventional treatment and have no other proven effective therapy available. Other criteria include being at least 18 years old, having a performance status of 2 or lower, providing written informed consent, and recovering from previous therapy-related toxicities.\n\nExclusion criteria include having a serious illness or non-oncological disease that is incompatible with the trial, known hypersensitivity to the trial drugs, recent participation in other interventional trials, active infectious disease or HIV, requiring another anti-cancer therapy, and evidence of symptomatic progressive brain or leptomeningeal disease in the past 6 months, among others.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria associated with a clinical trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 trial phase. The trial is focused on the disease cystic fibrosis. The ICD-10 codes associated with the disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being studied are 'oligog cf-5/20' and 'saline'. The eligibility criteria for participants include having a confirmed diagnosis of cystic fibrosis, being 18 years or older, providing samples for microbiological evaluation, having a positive microbiological finding of Pseudomonas aeruginosa, and having a FEV1 (forced expiratory volume in 1 second) between 35%-80% of the predicted normal value. There are also exclusion criteria, such as recent changes in therapy, pulmonary exacerbation, positive microbiological finding of Burkholderia sp., and history of organ transplantation. Other exclusion criteria include ongoing acute illness, allergic bronchopulmonary aspergillosis, requirement for continuous oxygen supplementation, and recent initiation of cycled, inhaled tobramycin. The sample also includes criteria related to laboratory findings, ability to perform pulmonary function tests, pregnancy or breastfeeding, participation in other clinical trials, and allergies or intolerance to alginates. Additionally, subjects with current malignant disease or any serious or active medical or psychiatric illness that would interfere with the study are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"renal impairment,\" and the corresponding ICDCodes are ['M10.38', 'M10.30', 'M10.311', 'M10.312', 'M10.319', 'M10.321', 'M10.322']. The drug mentioned is \"varespladib methyl.\" \n\nThe eligibility criteria for this sample include:\n- Participants must be males or non-pregnant, non-lactating females aged 18 years or older with a BMI between 18 and 40 kg/m2.\n- Renal function will be assessed using the MDRD and Cockcroft-Gault formulae, and subjects will be classified as having normal renal function or suffering from mild, moderate, or severe renal impairment.\n\nThe exclusion criteria for this sample include:\n- Any disease, condition, or chronic medications that may compromise various bodily systems or interfere with the distribution, metabolism, or excretion of the study drug, or pose an increased risk to the subject.\n- Evidence of significant respiratory, gastrointestinal, or hepatic disease at the screening.\n- Positive screening results for hepatitis B surface antigen or HIV.\n- Positive test results for drugs of abuse or alcohol upon admission to the clinic.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and the disease being studied is \"healthy\" (which seems to be a control group). The ICD-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial include \"yh4808 30mg\", \"yh4808 50mg\", \"yh4808 100mg\", \"yh4808 200mg\", \"yh4808\", \"yh4808 100mg (repeat dose)\", \"yh4808 200mg (repeat dose)\", \"yh4808 600mg\", \"yh4808 800mg (single dose)\", \"yh4808 400 mg (repeat doses)\", \"placebo\", and \"esomeprazole 40mg\".\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a healthy male volunteer between the ages of 20 to 45, meeting certain weight requirements, and providing written consent after receiving a thorough explanation of the trial. Exclusion criteria include having significant disorders or medical history related to various body systems, hypersensitivity to drugs, abnormal blood chemistry values, drug abuse history, recent use of prescription or over-the-counter drugs, recent participation in another clinical trial, recent blood donation, excessive alcohol consumption, recent smoking cessation, consumption of grapefruit or caffeine, positive H.pylori test results, and being deemed unsuitable based on medical judgment.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample from the table represents a phase 1 clinical trial for various childhood and adult central nervous system (CNS) malignancies. The diseases included in the trial range from childhood brain tumors like medulloblastoma and ependymoma to adult CNS tumors like gliomas and paraganglioma. The trial also allows for the inclusion of patients with recurrent or refractory spinal cord tumors. The drugs being studied in this trial are vorinostat and temozolomide.\n\nThe eligibility criteria for the trial include having a histologically confirmed CNS malignancy at the original diagnosis or relapse, with exceptions for certain types of tumors. Patients must have measurable or evaluable disease and should not have any known curative therapy or therapy proven to prolong survival with an acceptable quality of life. The performance status of the patients should be between 50-100% based on age-specific scales. Other criteria include specific blood counts, kidney function, liver function, and the absence of certain medical conditions. Patients must also be fully recovered from prior treatments and meet specific time intervals since the last treatment. Certain concurrent medications and treatments are not allowed during the trial.\n\nOverall, this sample represents the inclusion criteria and details of a phase 1 clinical trial for CNS malignancies, including the diseases being studied, the drugs being tested, and the eligibility requirements for participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is HIV infections. The corresponding ICDCodes for this disease are ['Z21']. The drugs being tested in this trial are nevirapine, amprenavir, and abacavir. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age between 18 and 65 years, plasma HIV-1 RNA level of at least 5000 copies/mL, CD4+ cell count of at least 100 cells/mm\u00b3, and meeting specific laboratory parameters such as lymphocyte count, hemoglobin level, platelet count, alkaline phosphatase level, SGOT and SGPT levels, total bilirubin level, and creatinine level. Female patients of reproductive potential must be willing to use a reliable method of double-barrier contraception. Patients must also be informed of the investigational nature of the study and provide written consent.\n\nExclusion criteria include being pregnant or breastfeeding, intending to change contraception method, requiring treatment with prohibited medications, taking certain inhibitors or inducers of Cytochrome P450 metabolic enzymes, receiving immunomodulatory agents, and having previous exposure to certain antiretroviral drugs. Other exclusion criteria include receiving investigational drugs or systemic corticosteroids within a certain timeframe, having malabsorption or severe chronic diarrhea, currently abusing alcohol or substances, undergoing treatment for an active infection, having hepatic or renal insufficiency, being a heavy smoker, and being deemed unreliable or at risk for non-compliance with the study.\n\nThis sample provides a detailed description of the eligibility criteria for this particular phase 1 trial on HIV infections, including specific laboratory parameters and restrictions on medications and medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"prostatic neoplasms.\" The ICDCodes associated with this disease are \"B38.81,\" \"N42.31,\" \"Z87.430,\" \"N40.0,\" and \"N40.1.\" The drugs being used in the trial are \"radium-223 dichloride (xofigo, bay88-8223).\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a male aged 20 or above, having confirmed adenocarcinoma of the prostate, having at least 2 bone metastases confirmed by imaging, and having progressive castration-resistant metastatic disease. Exclusion criteria include recent or planned use of investigational drugs, recent chemo-, immuno-, or radiotherapy, prior hemibody external radiotherapy, immediate need for external radiotherapy, recent use of specific systemic radiotherapies, and recent changes in bisphosphonate dosage.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include acute myeloid leukemia, adult acute myeloid leukemia with specific abnormalities, adult acute promyelocytic leukemia, and recurrent adult acute myeloid leukemia. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are clofarabine and cytarabine. The eligibility criteria for participants include having an ECOG performance status of 0-2, understanding the risks and benefits of the study, providing informed consent, having a negative pregnancy test for female patients, using effective contraception, meeting certain blood test criteria, being diagnosed with acute myeloid leukemia or acute promyelocytic leukemia, and meeting certain kidney and liver function criteria.\n\nThere are also exclusion criteria, which include recent use of investigational agents or other anticancer therapies, uncontrolled infections, pregnancy or lactation, significant concurrent diseases or psychiatric disorders, severe organ dysfunction, restrictions on concomitant cytotoxic or investigational therapy, restrictions on nephrotoxic or hepatotoxic agents, ongoing chemotherapy, radiation therapy, or immunotherapy, and specific criteria for patients who have undergone allogeneic transplants.\n\nOverall, this sample provides information about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on the treatment of chronic hepatitis C. The diseases listed in the sample are specifically related to hepatitis C. The icd-10 codes provided are associated with the diseases mentioned. The drugs being tested in the trial are \"bilb 1941 zw\" and a placebo. The eligibility criteria for the trial are listed, including age requirements, confirmation of chronic HCV infection, specific liver biopsy results, HCV RNA load, and willingness to abstain from alcohol. The exclusion criteria are also provided, which include factors such as inadequate contraception, presence of other liver diseases, positive tests for HIV or Hepatitis B, history of alcohol or drug abuse, concurrent medical illnesses or treatments, and various laboratory abnormalities. The sample also mentions specific exclusions related to previous treatment with interferon and/or ribavirin, planned or concurrent usage of other pharmacological therapies, known hypersensitivity to drugs or excipients, and inability to comply with the protocol.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease being studied is Alzheimer's disease. The ICDCodes associated with this disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested are \"drug: e2609\" and a placebo. The eligibility criteria for this sample include being a healthy male or female, aged 30 to 55 years for cohorts 1 through 5, and aged 65 to 85 years for cohort 6. The body mass index (BMI) should be between 18 and 32kg/m^2 at screening. There are additional inclusion criteria for cohort 6, which are not specified in the sample. The exclusion criteria include females of child-bearing potential, individuals with personal or family history of neurological abnormalities, any clinical abnormality of the electrocardiogram (ECG) at screening and check-in, a family history of cardiac abnormalities, and thyroid abnormalities.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on treating central nervous system lymphoma and intraocular lymphoma. The diseases are identified by their respective ICD-10 codes. The drug being tested is intraventricular rituximab plus mtx. The eligibility criteria for the trial are listed, including requirements for patients to have relapsed or refractory lymphoma, CD20+ tumors, an Ommaya reservoir, and sufficient baseline hematologic function. There are also exclusion criteria, such as a history of certain treatments or a HIV infection.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on small cell lung cancer and carcinoma, small cell (SCLC).\n- ICD Codes: The ICD-10 codes associated with the diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2.\n- Drugs: The drugs being studied in the trial are pemetrexed and cisplatin.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having measurable disease with a diagnosis of SCLC, a performance status of 0 to 1, being at least 18 years old with a life expectancy of at least 12 weeks, and not having received prior chemotherapy or thoracic radiotherapy. Exclusion criteria include recent myocardial infarction, serious concomitant systemic disorder, prior radiotherapy to specific regions, significant weight loss, and concurrent administration of other antitumor therapy.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on healthy individuals, as indicated by the \"diseases\" field containing the value \"healthy\". The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". The trial involves two drugs, namely \"trv130a\" and \"dextrose in water\". The eligibility criteria for participants include being a healthy adult male between the ages of 19 and 50, having a body weight of at least 50 kg, and being capable of providing written informed consent. Exclusion criteria include having any clinically significant diseases or conditions that may pose a risk to the participant or interfere with the study's safety, tolerability, or pharmacodynamic evaluations. Additionally, individuals with positive laboratory tests for HIV, Hepatitis B virus surface antigen, Hepatitis C virus antibody, aspartate aminotransferase or alanine aminotransferase elevations, positive drug or alcohol tests, or positive urine tests for cotinine are excluded. Finally, individuals who have undergone major surgery within 4 weeks of screening are also excluded from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1. The disease being studied is cancer of the liver. The ICD-10 codes associated with the disease are D13.4, Z85.05, C22.8, C78.7, D37.6, and C22.9. The drug being used in the trial is capecitabine (xeloda). The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as age, performance status, confirmation of the disease, presence of measurable lesions, laboratory values, and other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include advanced solid tumor cancers, medulloblastoma, and basal cell carcinoma. The ICDCodes associated with these diseases are C44.510, C44.91, C44.01, C44.311, C44.511, C44.81, and C44.41. The drug being tested in this trial is lde225. The eligibility criteria for this trial include a confirmed diagnosis of advanced solid tumor (including medulloblastoma and basal cell carcinoma) and specific blood work criteria. The exclusion criteria include a history of brain tumor (except recurrent medulloblastoma) or brain metastases, positive HIV, hepatitis B or C, impaired intestinal function, impaired heart function, and being pregnant or breastfeeding. Additional protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is listed as \"phase 1/phase 2\". The disease being studied is \"non-small-cell lung carcinoma\". The corresponding ICD-10 codes for this disease are listed as \"['D02.20', 'D02.21', 'D02.22']\". The drugs being used in the trial are \"cisplatinum\" and \"docetaxel\". \n\nThe eligibility criteria for participants are then listed, including requirements such as informed consent, confirmation of NSCLC diagnosis, specific stage of the disease, age range, life expectancy, performance status, weight loss, and various laboratory and lung function tests. The exclusion criteria are also provided, which include factors such as diagnosis of small cell lung cancer, certain stages of NSCLC, pregnancy or lactation, prior treatments, certain medical conditions, and other factors that may affect participation in the trial.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on non-small-cell lung carcinoma.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of relapsed multiple myeloma. The trial includes patients who have previously received one to three therapeutic treatments for multiple myeloma, which may have included drugs like bortezomib, lenalidomide, and thalidomide. The eligibility criteria include having measurable disease, a life expectancy of more than three months, and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. The patients must also meet certain laboratory requirements, such as having adequate hepatic function, specific blood counts, and a calculated or measured creatinine clearance of at least 50 mL/minute. Ethical requirements include providing written informed consent and adhering to the study visit schedule. Female participants of childbearing potential must agree to ongoing pregnancy testing and use reliable birth control methods. Male participants must agree to use condoms during sexual contact with females who can become pregnant. The exclusion criteria include certain types of multiple myeloma, recent use of experimental drugs or therapies, and various concurrent conditions such as pregnancy, major surgery, congestive heart failure, and uncontrolled hypertension.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is hypertension. The ICDCodes associated with this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drugs being tested in this trial are \"mk-7145\", \"hydrochlorothiazide (hctz)\", \"placebo to mk-7145\", and \"placebo to hctz\". \n\nThe eligibility criteria for this trial are divided into inclusion and exclusion criteria. The inclusion criteria include a diagnosis of essential hypertension, a body mass index (BMI) of \u226435 kg/m^2, being in general good health, no history of clinically significant arrhythmias or abnormality on electrocardiogram (ECG), no history of clinically significant cardiac disease, being treatment-na\u00efve or taking up to 2 antihypertensive therapeutic agents, and being a non-smoker or not having used nicotine or nicotine-containing products for at least 6 months.\n\nThe exclusion criteria include having low plasma potassium, a history of stroke, chronic seizures, or major neurological disorder, a history of clinically significant abnormalities or diseases in various body systems, a history of osteoporosis, active or history of certain kidney conditions, orthostatic changes in vital signs, functional disability that interferes with standing up, a history of malignant neoplastic disease (with some exceptions), inability to refrain from certain medications, current use of certain medications, excessive alcohol or caffeine consumption, recent major surgery or participation in another study, history of significant allergies or intolerability to drugs or food, regular use of illicit drugs or history of drug abuse, and dehydration or volume-depletion.\n\nThis sample provides a detailed description of the trial phase, disease, ICDCodes, drugs, and the eligibility criteria for participants.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, such as phase I, phase II, or phase III. The \"diseases\" column lists the names of various diseases. The \"icdcodes\" column contains the corresponding ICD-10 codes for the diseases. The \"drugs\" column lists the names of drugs being used in the trial. The \"criteria\" column provides the eligibility criteria for participants in the trial.\n\nIn the given sample, the phase is \"phase 1\". The diseases being studied include \"accelerated phase of disease\", \"adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11\", \"adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11\", and many others. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are \"belinostat\" and \"azacitidine\". The eligibility criteria include specific diagnoses, previous treatment history, performance status, laboratory values, and other factors.\n\nOverall, the sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is chronic obstructive pulmonary disease (COPD), and the corresponding ICDCodes are J44.9, J44.1, and J44.0. The drugs being tested are mn-221 and placebo. \n\nThe eligibility criteria for this sample include being male or female between the ages of 40 and 75, having a history of physician-diagnosed COPD, meeting specific lung function criteria, having a negative pregnancy test (unless post-menopausal or surgically sterile), passing urine drug and alcohol tests, having a normal ECG, being able to stop certain medications for a specified period, providing informed consent, and being willing and able to comply with the study procedures.\n\nThe exclusion criteria for this sample include recent use of certain medications, recent exacerbation or hospitalization due to COPD, recent antibiotic therapy for respiratory infection, presence of active respiratory diseases, low potassium levels, significant laboratory abnormalities, significant systemic diseases, uncontrolled hypertension, recent myocardial infarction, pregnancy or lactation, recent participation in another clinical study, home oxygen requirements, known allergies to the MN-221 drug or other beta agonists, and current use of medications with a risk of Torsades de Pointes.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"infections, bacterial.\" The ICDCodes associated with this disease are \"A49.9,\" \"A04.9,\" \"A04.8,\" and \"A49.8.\" The drugs being tested in this trial include \"gsk1322322 initial fit for purpose tablets,\" \"gsk1322322 over granulated tablets,\" \"gsk1322322 intended commercial tablets,\" \"placebo tablets,\" \"13c-gsk1322322 stable isotope powder,\" \"gsk1322322 for injection,\" and \"placebo injection.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include specific laboratory values, being in good health, age requirements, and other factors such as language proficiency and dietary habits. Exclusion criteria include factors such as certain medical conditions, drug/alcohol use, participation in other clinical trials, and sensitivity/allergies to study medications. Additionally, there are specific criteria for different parts of the trial, such as gender restrictions and smoking history.\n\nThe sample also mentions additional exclusion criteria related to previous myocardial infarction, conduction abnormalities, and specific ECG measurements.\n\nOverall, this sample provides a snapshot of the information stored in the table, including details about the trial phase, diseases, drugs, and the criteria for participant eligibility.",
    "The sample from the table represents a clinical trial for the treatment of multiple myeloma. The trial is divided into different phases, with this sample being from phase 1/phase 2. The diseases being studied are multiple myeloma. The icd-10 codes associated with the diseases are ['C90.01', 'C90.02', 'C90.00']. The drugs being used in the trial are lenalidomide, pioglitazone, dexamethasone, and treosulfan. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of multiple myeloma that is progressing or has relapsed after at least two different anti-myeloma treatments, and having certain laboratory results within normal ranges. There are also specific criteria related to previous treatments, bone marrow function, performance status, and other medical conditions. Female participants of childbearing potential must agree to use effective contraception. There are also exclusion criteria, such as certain medical conditions, prior treatments, and pregnancy or lactation.",
    "The sample from the table represents a clinical trial for the treatment of hepatocellular carcinoma (HCC), a type of liver cancer. The trial is in phase 1/phase 2 and focuses on evaluating the effectiveness of a drug called denspm. The eligibility criteria for participants include having histologically proven HCC or meeting specific criteria if a biopsy is not possible, having radiographic evidence of progression for recurrent HCC, and not being suitable for curative therapy or refusing it. Participants must also have measurable disease, meet certain laboratory values, have a Karnofsky Performance Status of at least 60%, and use effective contraception if female and of childbearing potential. Exclusion criteria include receiving localized therapy or other systemic therapy for HCC within specific timeframes, receiving another investigational therapy within 30 days prior to the study, having unstable serious or life-threatening medical conditions, and having certain medical conditions or contraindications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is gastrointestinal stromal tumor. The ICD-10 codes associated with this disease are C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, and C49.A9. The drugs being used in the trial are imatinib mesylate and sunitinib malate. The eligibility criteria for this trial include having a biopsy-proven gastrointestinal stromal tumor, measurable lesions, and an ECOG performance status of 0-2, among other requirements. The record also includes information about prior concurrent therapy and exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 1, focusing on the disease \"neoplasms\" (which includes various types of cancer). The ICD-10 codes associated with these diseases are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug being tested in this trial is \"ombrabulin (ave8062)\". The eligibility criteria for participants are listed, including requirements such as having advanced neoplastic disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and not receiving concurrent treatment with other anticancer therapies. The sample also includes exclusion criteria and additional information about the trial.",
    "The sample provided is for a phase 1 trial. The disease being studied is depressive disorder, specifically Major Depressive Disorder (MDD) with a seasonal pattern. The icd-10 codes associated with this disease are F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, and F32.9. The drug being tested is extended-release bupropion hydrochloride. The eligibility criteria for this trial include a history of MDD with a seasonal pattern, while exclusion criteria include a current or past history of seizure disorder or brain injury, a history or current diagnosis of anorexia nervosa or bulimia, recurrent summer depression more frequently than winter depression, primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Post-traumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder, or other psychotic disorders, and initiation of psychotherapy within the last 3 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is colorectal carcinoma. The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs used in this trial are irinotecan, levofolinate, and 5-fluorouracil (5-fu). The eligibility criteria for participants include being Japanese, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having histologically or cytologically confirmed colorectal carcinoma, having metastatic disease that is not amenable to potentially curative resection, having received no more than 2 prior systemic chemotherapy regimens, and meeting other specific requirements related to prior treatment and medical conditions. There are also exclusion criteria listed, which specify conditions or circumstances that would disqualify a participant from the trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The disease being studied is amenorrhea, which is indicated by the presence of the icd-10 codes N91.0, N91.1, and N91.2. The drug being tested is called proellex. \n\nThe eligibility criteria for participants in this trial include being a healthy adult female between the ages of 18 and 50. Women with conditions such as excessive menstrual bleeding, menstrual pain, uterine fibroids, and endometriosis are also included. Other criteria include having a normal menstrual cycle of 26-32 days, agreeing not to attempt to become pregnant, limiting alcohol consumption, being able to swallow gelatin capsules, completing a daily subject diary, discontinuing hormonal contraceptives, and having a negative pregnancy test. Participants should also have a BMI between 18 and 39, be available for all treatment and follow-up visits, and meet certain exclusion criteria such as not being post-menopausal, not being pregnant or lactating, and not having abnormal liver enzymes or liver disease.",
    "The sample from the table is for a phase 1 clinical trial. The diseases being studied are hematologic malignancies, multiple myeloma, lymphoma, and Hodgkin lymphoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is called mln4924. The eligibility criteria for the trial include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, a confirmed diagnosis of lymphoma or multiple myeloma that is relapsed and/or refractory after at least 2 prior standard chemotherapeutic regimens, and having evaluable tumor by radiography, serum or urine electrophoresis, or clinical evaluations. There are also specific criteria for patients in the expansion cohort. The exclusion criteria include recent systemic antineoplastic therapy, corticosteroid treatment, radiation therapy involving a significant portion of bone marrow, and certain medication interactions. There are also criteria related to blood counts and kidney function.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The disease being studied is uveitis. The corresponding ICD-10 codes for uveitis are 'H44.133', 'H44.131', 'H44.132', and 'H44.139'. The drug being tested is apremilast. The eligibility criteria for this trial include patients with vision-threatening autoimmune uveitis who have not responded to prednisone and at least one other systemic immunosuppressive medication, or who cannot tolerate such medications due to side effects. The exclusion criteria include having a serious concomitant illness that could interfere with participation, previous or current use of an alkylating agent, use of CYP3A4 inhibitors during the trial, and use of TNF blockers within 8 weeks prior to enrollment.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases, \"icdcodes\" which lists the icd-10 codes associated with the diseases, \"drugs\" which lists the names of drugs, and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe sample data in the table includes three different phases of the trial: phase 1/phase 2. The diseases mentioned in the sample are \"prostate cancer\". The icd-10 codes associated with prostate cancer are listed as \"['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']\". The drugs mentioned in the sample are \"arn-509 (phase 1)\" and \"arn-509 (phase 2)\". The eligibility criteria for the trial are provided under the \"criteria\" column, including inclusion and exclusion criteria for different phases and types of prostate cancer.\n\nOverall, the sample data provides information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for a clinical trial related to prostate cancer.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on mesothelioma.\n- ICD Codes: The ICD-10 codes associated with mesothelioma are ['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7'].\n- Drugs: The drugs being used in the trial are carboplatin, bevacizumab, and pemetrexed.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" These criteria include requirements related to the diagnosis of malignant pleural mesothelioma, measurable disease, performance status, renal function, hepatic function, bone marrow function, previous medical procedures, ability to take certain medications, informed consent, and exclusion criteria such as hypercalcemia, history of certain medical conditions, and inability to comply with study procedures. The record also includes laboratory values related to renal function, hepatic function, and bone marrow function.\n\nOverall, this sample provides information about a clinical trial for mesothelioma, including the phase, diseases being studied, drugs being used, and the eligibility criteria for participants.",
    "The sample from the table is for a clinical trial in phase 1/phase 2. The trial is focused on non-small cell lung cancer (NSCLC) and the eligibility criteria for participants are listed. Inclusion criteria include having a confirmed diagnosis of NSCLC, experiencing recurrent or progressive disease after receiving at least one chemotherapy regimen for advanced or metastatic NSCLC, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, being at least 18 years old, and having recovered from any reversible acute effects of prior anti-cancer therapy. Other criteria include the ability to comply with the study procedures, ability to take oral medication, availability of archival tumor tissue for testing, and a life expectancy of at least 3 months. Exclusion criteria include prior treatment with an investigational or marketed agent for inhibiting epidermal growth factor receptor (EGFR), recent chemotherapy or radiotherapy, inability to take oral medications, uncontrolled diabetes, unstable systemic diseases, pregnancy or lactation, history of another malignancy in the past 2 years (unless adequately treated and associated with a high survival rate), claustrophobia, and any other condition that the investigator deems inappropriate for the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is ridaforolimus. \n\nThe eligibility criteria for this trial include being a male or female patient aged 18 or older with a histological/cytological diagnosis of unresectable or metastatic cancer that is refractory to standard therapies or for which no standard therapy exists. Patients must have measurable or nonmeasurable lesions that can be assessed using radiographical procedures such as CT or MRI scans. Fertile male or female patients must agree to use approved barrier methods of contraception. The Eastern Cooperative Oncology Group (ECOG) performance status should be \u2264 2. Adequate renal and hepatic function, as well as bone marrow function, are required. Serum cholesterol and triglyceride levels should be within specified ranges. The anticipated life expectancy should be at least 3 months, and the patient must be able to give and understand a written informed consent.\n\nFor the Phase IIa segment, additional criteria include a histological/cytological diagnosis of metastatic and/or unresectable sarcoma within specific histological subgroups such as bone sarcomas, leiomyosarcomas, and liposarcomas. The presence of at least one measurable lesion meeting certain size criteria is also required, and the ECOG performance status should be \u2264 1.\n\nExclusion criteria for this trial include patients with active central nervous system (CNS) metastases or leptomeningeal disease, prior therapy with rapamycin or rapamycin analogs, prior anticancer treatment within specific timeframes, concomitant treatment with certain medications, ongoing toxicity associated with prior anticancer therapy, and other medical conditions or organ system dysfunctions that could compromise patient safety or interfere with the evaluation of the study drug.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is Hepatitis C. The icd-10 codes associated with this disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being used in the trial are pf-00868554 and placebo. The eligibility criteria for this sample include having an HCV RNA level of at least 100,000 IU/mL at screening and having genotype 1a or 1b. The exclusion criteria include not having received previous treatment with IFN and/or RBV and not having evidence of decompensated liver disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is prostate cancer. The ICDCodes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being used in the trial are 'tak-700', 'docetaxel', and 'prednisone'. The eligibility criteria for this trial include various requirements such as voluntary written consent, being a male patient aged 18 or older, having a life expectancy of 6 months or more, having a confirmed diagnosis of prostate adenocarcinoma, having radiograph-documented metastatic disease, and meeting certain performance status and physical examination findings. There are also exclusion criteria listed, which specify conditions or circumstances that would prevent a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are bevacizumab (drug) and herceptin (drug). \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have metastatic or relapsed locally advanced breast cancer.\n- The patient must be HER2-positive as determined by FISH.\n- The patient must not have received prior chemotherapy for metastatic disease.\n- The patient's ECOG performance status must be between 0 and 2.\n- The patient must have a normal left ventricular ejection fraction.\n- The patient must have bidimensionally measurable disease.\n- The patient's oxygen saturation must be greater than 90% on room air.\n\nExclusion Criteria:\n- The patient must not have had any other invasive malignancy within the past 5 years.\n- The patient must not have more than 3 different metastatic sites.\n- The patient must not have more than 50% liver involvement by metastasis.\n- The patient must not have newly diagnosed untreated Stage IIIB breast cancer.\n- The patient must not have received prior chemotherapy for metastatic disease.\n- The patient must not have clinically significant cardiovascular disease.\n- The patient must not have a history or evidence of CNS disease.\n- The patient must not have undergone major surgery within 28 days prior to day 0.\n- The patient must not be currently or recently using parenteral anticoagulants.\n- The patient's WBC count must not be less than 3,000/uL.\n- The patient's platelet count must not be less than 75,000/uL.\n- The patient's hemoglobin level must not be less than 9.0 g/dL.\n- The patient's total bilirubin level must not be greater than 2.0 mg/dL.\n- The patient's AST or ALT levels must not be greater than 5 times the upper limit of normal for subjects with documented liver metastases or greater than 2.5 times the upper limit of normal for subjects without evidence of liver metastases.\n- The patient must not have proteinuria (> 1g protein/24 hours at baseline).\n- The patient must not have received prior therapy with Herceptin or rhuMAb VEGF (bevacizumab).",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is esophageal neoplasms. The ICDCodes associated with this disease are K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, and I85.10. The drug being tested in this trial is capecitabine (xeloda). The eligibility criteria for inclusion in the trial include having locally advanced and surgically resectable esophageal or gastroesophageal junction cancer (stage II or III) with no prior therapy and adequate organ function. The exclusion criteria include evidence of metastasis (except for celiac axis lymph nodes), cervical esophageal tumors, and peripheral or auditory neuropathy grade 2 or higher.",
    "The sample from the table is a clinical trial for patients with metastatic breast cancer. The trial is a combination of phase 1 and phase 2. The diseases column specifies the disease being studied, which in this case is metastatic breast cancer. The icdcodes column provides the ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, including dasatinib, trastuzumab, and paclitaxel. The criteria column contains the eligibility criteria for participating in the trial, including requirements such as histologically confirmed breast cancer with documented metastasis, HER2 overexpression, performance status, previous therapies, organ function, ability to take oral medication, and concomitant medications. The exclusion criteria are also listed, which include factors such as pregnancy, central nervous system metastases, medical history, allergies, prohibited treatments, and other exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is described as \"phase 1/phase 2\". The disease mentioned in this sample is \"glioblastoma multiforme\". The corresponding ICD-10 codes for this disease are \"L51.0\", \"L51.8\", and \"L51.9\". The drug mentioned in this sample is \"aee788\". \n\nThe sample also includes eligibility criteria for the trial. The inclusion criteria state that the patient must have histologically confirmed GBM in first or second recurrence or relapse, adequate hematologic, hepatic and renal function, be at least 18 years old, have a Karnofsky performance status score of at least 70%, and a life expectancy of at least 12 weeks. \n\nThe exclusion criteria state that patients with peripheral neuropathy greater than grade 1, diarrhea greater than grade 1, gastrointestinal dysfunction, compromised cardiac function, or concurrent severe and/or uncontrolled medical conditions are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drugs being used in the trial are \"bibw 2992\" and \"bibw 2992.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria include patients with a confirmed diagnosis of non-resectable and/or metastatic cancer, preferably squamous cell carcinomas of the head and neck, esophagus, lung, or cervix. Other criteria include age 18 years or older, a life expectancy of at least three months, written informed consent, an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2, and recovery from previous therapies and surgeries.\n\nExclusion criteria include active infectious disease, gastrointestinal disorders that may interfere with drug absorption, serious illness or non-oncological diseases incompatible with the protocol, untreated or symptomatic brain metastases, cardiac left ventricular function with a resting ejection fraction less than 50%, and various abnormal blood counts and liver function tests. Other exclusion criteria include pregnancy or breastfeeding, treatment with other investigational drugs or anti-cancer therapies within the past four weeks, treatment with EGFR- or HER2-inhibiting drugs within the past four weeks (two weeks for trastuzumab), inability to comply with the protocol, and active alcohol or drug abuse.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on patients with symptomatic multiple myeloma requiring treatment. The eligibility criteria include being approved for single or tandem autologous transplant, being 65 years of age or older or having renal insufficiency, not having a history of chronic obstructive or chronic restrictive pulmonary disease, having adequate pulmonary function, having a left ventricular ejection fraction (LVEF) greater than 40%, having bilirubin, SGOT, and SGPT levels within normal limits, having evaluable myeloma markers for response, being able to receive full doses of DT-PACE (except for cisplatin), having a performance status of 0-2, and providing informed consent. The exclusion criteria include having elevated serum transaminases and direct bilirubin levels, being HIV positive or having active Hepatitis B or Hepatitis C infection, having a prior malignancy that is more likely to determine life expectancy than the myeloma, currently receiving therapy for a prior malignancy, being pregnant or nursing, and not using effective contraception for women/men of reproductive potential.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is osteoarthritis. The ICDCodes associated with this disease are \"M15.4\", \"M15.0\", \"M16.9\", \"M17.9\", \"M19.011\", \"M19.012\", and \"M19.019\". The drug being used in the trial is normal saline.\n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The participant must have painful osteoarthritis in the study knee.\n- The participant must be able to walk without assistive walking devices, perform usual daily activities, and agree to maintain a similar activity level throughout the study.\n\nExclusion Criteria:\n- The participant must not have any chronic pain conditions other than knee osteoarthritis.\n- The participant must not have bursitis, meniscus tear, ligament tear, or significant injury to the study knee within the past year.\n- The participant must not have undergone surgery on the study knee within the past 24 weeks.\n- The participant must not have received treatment with hyaluronic acid in the study knee within the past 24 weeks.\n- The participant must not have received treatment with corticosteroids in the study knee within the past 12 weeks.\n- The participant must not have a diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.\n- The participant must not have received previous treatment with botulinum toxin of any serotype for any reason.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes is \"Z21\". The drug being tested is tmc278la. \n\nThe sample also includes the eligibility criteria for participants to be included in the trial. These criteria include: \n- Subjects must provide informed consent and comply with all study requirements.\n- Participants can be male or non-pregnant, non-lactating females of different ethnic backgrounds.\n- Age must be between 18 to 50 years.\n- Body Mass Index (BMI) must be between 16 to 35 kg/m2.\n- Participants should not have any significant health problems based on screening procedures, including medical history, physical examination, vital signs, and ECG.\n- Laboratory abnormalities should not be clinically significant.\n- Participants must be willing to undergo HIV testing and discussion, as well as receive HIV test results.\n- Women of childbearing potential must use an adequate method of contraception to avoid pregnancy throughout the study and for at least four months after the study follow-up visit.\n- Sexually active males must use an effective method of contraception, such as condoms, from the day of enrollment until at least four months after the follow-up visit.\n- Participants must be likely to remain in the UK for the duration of the study and follow-up period.\n- Personal details will be entered into The Overvolunteering Prevention Scheme (TOPS) database.\n- Participants must provide photographic identification at each visit.\n- Participants must be registered with a GP in the UK.\n\nThe sample also includes exclusion criteria, which are conditions that would prevent individuals from participating in the study. These criteria include:\n- Any significant acute or chronic medical illness.\n- Evidence of organ dysfunction or clinically significant deviations from normal in physical examination, vital signs, ECG, or clinical laboratory determinations.\n- Positive blood screen for syphilis, hepatitis A, B, or C antibodies.\n- Positive blood screen for HIV-1 and/or HIV-2 antibodies.\n- High-risk behavior for HIV infection within six months before the study, such as unprotected sex with an HIV-infected person or a casual partner, engaging in sex work, acquiring a sexually transmitted disease, or having a high-risk partner.\n- Clinically relevant alcohol or drug use or history of alcohol or drug use that may hinder compliance with treatment, follow-up procedures, or evaluation of adverse events.\n- Exposure to any investigational drug or placebo within 30 days of the first dose of the study drug.\n- History of severe drug allergy that may increase the risk of developing an allergic reaction to the study drug.\n- Use of any drug, including over-the-counter medications and herbal preparations, within two weeks prior to the first dose of the study drug, unless approved by the Investigator.\n- Pregnant or lactating females.\n- Females of childbearing potential not using effective non-hormonal birth control methods or not willing to practice these methods for at least four months after the study follow-up visit.\n- Males unwilling to use an effective method of contraception, such as condoms, from the day of enrollment until at least four months after the follow-up visit.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on treating mantle cell lymphoma. The ICD-10 codes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being used in the trial are temsirolimus and bendamustine. The eligibility criteria for participants include being 18 years or older, having mantle cell lymphoma according to REAL/WHO classification, and being in the first or second relapse or experiencing progression during therapy. There are additional criteria related to previous treatments, bone marrow function, performance status, measurable disease, life expectancy, and written informed consent. The exclusion criteria include prior treatment with any m-TOR inhibitor, unstable or severe uncontrolled medical conditions, abnormal liver or renal function, previous malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix, concurrent treatment with certain medications, pregnancy or breastfeeding, recent major surgery or minor procedures, previous therapy with investigational agents, concomitant immunotherapy or chemotherapy other than bendamustine, central nervous system lymphomatous involvement, HIV positivity, current or chronic hepatitis B or hepatitis C infection, severe psychiatric illness, and inability to comply with study requirements.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease of asthma. The associated ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being studied in this trial are 'rns60', 'normal saline', and 'budesonide'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a non-smoker between the ages of 18 and 65, having a clinical diagnosis of mild to moderate asthma, and currently using an inhaled corticosteroid medication for at least 1 month. Exclusion criteria include having chronic or acute diseases that may interfere with the evaluation of the drug, being pregnant or breastfeeding, having certain viral infections, and having significant organ dysfunction. The sample also includes additional details about the study, such as the need for informed consent and the prohibition of certain medications during the study period.",
    "The sample is a record from a table that contains information about clinical trials. It represents a trial in phase 1/phase 2. The trial is focused on the diseases glaucoma and ocular hypertension. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in the trial are ino-8875 and placebo. The sample also includes the eligibility criteria for the trial, including inclusion criteria such as having a diagnosis of ocular hypertension or primary open-angle glaucoma, being aged 18 to 75 years, and having a mean intraocular pressure (IOP) within a specific range. The exclusion criteria include factors such as no significant visual field loss, cup-to-disc ratio, central corneal thickness, and certain medical conditions that could affect the study data.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is breast cancer. The ICDCodes associated with breast cancer are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs mentioned in this sample are ixabepilone and capecitabine. The eligibility criteria for this trial include being a woman aged 20 or above and having a confirmed diagnosis of adenocarcinoma originating in the breast. The exclusion criteria state that individuals who have undergone three or more lines of chemotherapy treatment in the metastatic setting are not eligible for this trial.",
    "The sample is a phase 1 clinical trial for patients with malignant advanced solid tumors and carcinoma, renal cell. The trial is testing the combination of axitinib plus everolimus as a potential treatment. The eligibility criteria include having histologically proven advanced adult solid tumors (excluding lymphoma), failure or contra-indication of standard therapies (except for advanced renal cell carcinoma patients who are treatment-na\u00efve), age over 18, ECOG performance status of 0-1, life expectancy of more than 3 months, and measurable/evaluable disease according to RECIST criteria version 1.0. Other criteria include acceptable biological values, specific laboratory values within normal ranges, specific blood pressure levels, a washout period from previous anticancer therapy, written informed consent, use of effective contraception for women of child-bearing age, and being a patient with French social security. There are also additional inclusion criteria before the combination treatment period. Exclusion criteria include brain metastasis, severe underlying cardiovascular disease, hepatitis B or C carrier or at a chronic state, uncontrolled hypertension or diabetes, inability to swallow pills, unresolved pneumopathy, and any medical or social condition that could jeopardize patient safety or compliance with the protocol. Hypersensitivity to axitinib or everolimus, participation in another clinical trial or use of unapproved medication within 4 weeks prior to the study, and pregnancy or lactation are also exclusion criteria.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on lung cancer, specifically non-small cell lung cancer. The trial is investigating the use of three drugs: pazopanib (gw786034), gemcitabine, and cisplatin. The eligibility criteria for participants in the trial are listed, including requirements such as having a confirmed advanced solid tumor, being at least 18 years old, having a performance status of ECOG 0-1, and having adequate organ function. There are also exclusion criteria listed, such as a history of central nervous system metastases, certain cardiovascular conditions, and ongoing toxicity from prior anti-cancer therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are brain tumors and central nervous system tumors. The corresponding ICDCodes for these diseases are ['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6'] for brain tumors and ['C72.9', 'D33.9', 'D43.9', 'D33.7', 'D43.8'] for central nervous system tumors. \n\nThe drugs being used in the trial are cyclosporine, etoposide, and vincristine sulfate. \n\nThe eligibility criteria for this trial include specific disease characteristics such as being newly diagnosed with diffuse intrinsic brain stem glioma by MRI biopsy, having at least two-thirds of the tumor in the pons, and the origin of the tumor being clearly in the pons. The patient must be registered within 28 days of diagnosis and have a clinical history of less than 6 months duration with no diffuse leptomeningeal disease. \n\nPatient characteristics include an age range of 3 to 21, a performance status of Karnofsky or Lansky 50-100%, a life expectancy of at least 6 weeks, and specific hematopoietic, hepatic, and renal requirements. \n\nPrior concurrent therapy restrictions include no prior biologic therapy, no prior chemotherapy, no other concurrent chemotherapy, prior steroids at stable or decreasing doses allowed for endocrine therapy, no prior radiotherapy, no specified prior surgery, and no other concurrent investigational agents.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The diseases being studied are \"anterior cruciate ligament injury\" and \"osteoarthritis\". The corresponding ICD-10 codes for these diseases are [\"M15.4\", \"M15.0\", \"M16.9\", \"M17.9\", \"M19.011\", \"M19.012\", \"M19.019\"]. The drug being tested is \"hyaluronan\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n1. Participants must be males or females aged 18 to 40.\n2. They must have an ACL injury requiring reconstruction.\n3. Participants must have undergone unilateral ACL reconstruction surgery within six months of the injury.\n4. They must be willing and able to undertake a standardized rehabilitation protocol.\n5. The ACL graft used must be autograft.\n6. Participants must be willing to participate in follow-up for 24 months from the time of initial treatment.\n7. They must have the ability to understand and be willing to sign a consent form.\n\nExclusion Criteria:\n1. Women who are pregnant, breastfeeding, or planning to become pregnant during the study are excluded.\n2. Participants with a previous allergic reaction to hyaluronan are excluded.\n3. Those with a systemic or local infection at the screening visit or at the time of the study injection are excluded.\n4. Individuals with a history of any autoimmune disease, such as systemic lupus erythematosus, Addison's disease, Crohn's disease, or rheumatoid arthritis, are excluded.\n5. Participants who have received immunosuppression therapy within 6 months prior to the screening visit are excluded.\n6. Those with an acute or chronic infectious disease, including HIV, are excluded.\n7. Individuals who have received treatment or uncompleted follow-up treatment of any investigational therapy within 6 months before the procedure, or intend to participate in any other investigational drug or cell therapy study during the 24-month follow-up period of this study, are excluded.\n8. Participants who have received prior allogeneic stem cell/progenitor cell therapy are excluded.\n9. Those undergoing a simultaneous procedure on the opposite knee are excluded.\n10. Individuals with a 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or have antibody specificities to donor HLA antigens are excluded.\n11. Participants with known sensitivities to bovine (cow), murine (mouse), chicken products, and/or dimethylsulfoxide (DMSO), or a previous allergic reaction to hyaluronan, are excluded.\n12. Individuals with a history or current evidence of alcohol or drug abuse, or who are recreational users of illicit drugs or prescription medications, are excluded.\n13. Those with a history of prior surgery to the study knee joint are excluded.\n14. Individuals with a history of malignancy (excluding successfully excised basal cell carcinoma) are excluded.\n15. Participants with chondral lesions noted at the time of surgical reconstruction greater than Grade 1a on any surfaces are excluded.",
    "The sample provided is for a phase 1 clinical trial focused on Parkinson's disease. The trial is investigating the drug rotigotine. The eligibility criteria for participants include being between the ages of 19 and 45, being in good health, having a normal body weight, and being of Korean descent. Exclusion criteria include a history of drug or alcohol abuse, recent history of stroke or transient ischemic attack, epilepsy or seizures, skin hypersensitivity or dermatitis, pregnancy or lactation, any medical or psychiatric condition that could affect participation, abnormal ECG findings, abnormal physical examination or laboratory results, hepatic dysfunction, positive tests for HIV, Hepatitis B or C, alcohol or drugs, excessive alcohol consumption, recent blood donation or significant blood loss, smoking, allergies, current medication use (excluding oral contraceptives), symptomatic orthostatic hypotension, abnormal resting pulse rate or blood pressure, history of motor disturbance or neurodegenerative disease, recent herbal medicine therapy, and excessive caffeine consumption.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is malaria. The ICDCodes associated with the disease are ['B54', 'B53.0', 'P37.3', 'P37.4', 'B50.9', 'Z86.13', 'B51.9']. The drug being used in this trial is a placebo. The eligibility criteria for participants include providing informed consent, being between the ages of 18 and 45, practicing adequate contraception, being in good health, and complying with the protocol requirements. There are also exclusion criteria, such as recent treatment with corticosteroids or immunosuppressive agents, abnormal screening laboratory values, history of drug abuse, and various medical conditions. Pregnant or breastfeeding women, individuals with certain infections or illnesses, and those who have previously received a malaria vaccine or a recombinant adenovirus vector vaccine are also excluded from the study.",
    "The sample from the table represents a clinical trial in phase 1. The trial focuses on the treatment of peripheral vascular diseases. The ICD-10 codes associated with these diseases are 'I73.9' and 'I73.89'. The drugs being tested in this trial are 'mk-0736' and a placebo (unspecified). The eligibility criteria for participants include having peripheral arterial disease, being between 18 and 85 years old, and females must be postmenopausal or sterile. Participants with hepatic, HIV, endocrine, connective tissue, psychiatric disorders, or uncontrolled hypertension are excluded from the trial.",
    "The sample from the table represents a clinical trial in phase 1. The trial is focused on treating various diseases, including Hodgkin's disease, large-cell anaplastic lymphoma, and non-Hodgkin's lymphoma. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of a drug called brentuximab vedotin. The eligibility criteria for participants include having a relapsed or refractory CD30-positive malignancy, adequate organ function, and an ECOG performance status of less than 2. However, there are also exclusion criteria, such as having cardiac abnormalities, a current diagnosis of primary cutaneous ALCL, or a history of acute or chronic graft-versus-host disease. Additionally, participants who have undergone a hematopoietic stem cell transplant within a specified timeframe are also excluded from the trial.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nThe \"phase\" column indicates the phase of the trial, which can be phase I, phase II, or phase III. \n\nThe \"diseases\" column contains a list of disease names associated with the trial. In the sample, the diseases mentioned are leukemia, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive, philadelphia chromosome, and hematologic diseases. \n\nThe \"icdcodes\" column contains a list of ICDCodes (ICD-10 codes) associated with the diseases mentioned. In the sample, the ICDCodes provided are associated with the respective diseases. \n\nThe \"drugs\" column contains a list of drug names associated with the trial. In the sample, the drug mentioned is radotinib. \n\nThe \"criteria\" column contains the eligibility criteria for the trial. In the sample, the inclusion and exclusion criteria are provided for both phase I and phase II of the trial. The criteria include age requirements, disease-specific conditions, performance status, laboratory values, medical history, and other relevant factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"relapse\" and \"refractory multiple myeloma.\" The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is \"revlimid.\" \n\nThe eligibility criteria for this trial include various conditions that subjects must meet to be enrolled. These criteria include being over 18 years old, having multiple myeloma with Durie-Salmon stage II or III, having disease progression after at least one previous anti-myeloma regimen, and not having received more than three previous anti-myeloma regimens. Other criteria include having measurable levels of myeloma paraprotein, a certain performance status score, and a negative pregnancy test for women of childbearing potential. \n\nThere are also exclusion criteria listed, which would prevent a subject from being enrolled in the study. These include having certain medical conditions, being pregnant or lactating, having heart failure, and having certain laboratory abnormalities. Other exclusion criteria include a history of other malignancies, hypersensitivity to certain medications, prior use of Revlimid, and recent use of other anti-myeloma drug therapy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on age-related macular degeneration and choroidal neovascularization. The ICD-10 codes associated with these diseases are provided. The drug being studied is ibi-20089/lucentis. The eligibility criteria for participants are listed, including age requirements, specific diagnosis, and visual acuity range. There are also exclusion criteria, such as recent corticosteroid use, uncontrolled glaucoma, recent ocular surgery, and active ocular infections. Other medical or psychological conditions that could affect patient safety or study validity are also considered. Participation in other clinical trials and allergies to corticosteroids are additional exclusion criteria. Pregnant or lactating women are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in this trial are ic83/ly2603618 and pemetrexed. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must have at least one lesion that can be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST).\n- The participant must have fully recovered from any toxicities caused by local radiation therapy or surgery.\n- The participant must have a life expectancy of at least 3 months.\n- The participant must have a negative serum pregnancy test.\n\nExclusion Criteria:\n- Pregnant or breastfeeding individuals are not eligible for the trial.\n- Women of childbearing potential who are unwilling to use an approved and effective means of contraception are not eligible.\n- Men of childbearing potential who are unwilling to use an approved and effective means of contraception are not eligible.\n- Individuals with a history of brain metastases, unless adequately treated and without radiologic evidence of progressive disease for at least 3 months after completion of therapy, are not eligible.\n- Individuals with a known active infection are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on healthy individuals rather than specific diseases. The ICDCodes associated with this trial are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial include \"map0004,\" \"iv placebo (saline),\" \"placebo inhaler,\" and \"iv dihydroergotamine mesylate (DHE).\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include requirements such as providing informed consent, being a healthy non-smoking adult between 18 and 45 years old, practicing adequate contraception (for female subjects), having a stable cardiac status, normal hemoglobin values, normal echocardiogram, normal or not clinically significant 12-lead electrocardiogram, demonstrated ability to use the Tempo\u00ae Inhaler properly, and not having donated blood in the last 56 days. Exclusion criteria include contraindication to dihydroergotamine mesylate (DHE), use of any excluded concomitant medications within the 10 days prior to Visit 1, history of hemiplegic or basilar migraine, and participation in another investigational trial during the 30 days prior to Visit 1.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on HIV infection. The trial is investigating the drug panobinostat. The eligibility criteria for participants are listed, including requirements such as being over 18 years old, having documented HIV-1 infection, having a low HIV-1 plasma RNA level, and receiving specific antiretroviral therapy. There are also exclusion criteria, such as having certain medical illnesses, active AIDS-defining opportunistic infections, or gastrointestinal issues that could affect the absorption of the drug. The sample also includes specific laboratory values that must be within acceptable ranges, as well as restrictions on certain medications and substances. Other exclusion criteria include having hepatitis B or C infection, a history of cardiac disease, malignancy or transplantation, diabetes mellitus, or known resistance to certain antiretroviral therapies. There are also restrictions for pregnant or breastfeeding women and requirements for contraception use. The sample concludes with a requirement for barrier contraception during sexual intercourse for the entire study period.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 1. The disease mentioned is \"neoplastic meningitis\" and its corresponding icd-10 codes are \"I78.1\", \"D63.0\", \"M36.1\", \"Q82.5\", \"R53.0\", \"G73.1\", and \"M36.0\". The drugs being studied are \"depocyt\" and \"temozolomide\". The eligibility criteria for this trial include age requirement, histologic diagnosis of systemic malignancy, Karnofsky performance status, recovery from prior treatments, platelet count and ANC requirements, liver and renal function, informed consent, and the presence of ventricular access devices. The exclusion criteria include receiving other therapy for leptomeningeal disease, evidence of obstructive hydrocephalus or compartmentalization of CSF flow, presence of a ventriculoperitoneal or ventriculoatrial shunt without an on/off device, pregnancy or lactation, uncontrolled infection, use of other investigational drugs, inability to undergo magnetic resonance testing, and prior treatment with Temozolomide.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include hermansky-pudlak syndrome (HPS), pulmonary fibrosis, oculocutaneous albinism, platelet storage pool deficiency, and metabolic disease. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are losartan, zileuton, n-acetylcysteine, pravastatin, and erythromycin. The eligibility criteria for participants are listed, including requirements such as having a molecular diagnosis of HPS-1 or HPS-4, being within the age range of 18-70, having severe pulmonary fibrosis, and being available for regular visits to the NIH Clinical Center. There are also exclusion criteria listed, such as having other explanations for interstitial lung disease, being pregnant or lactating, having a history of substance abuse, and having certain medical complications or laboratory abnormalities. The sample provides detailed information about the trial and the criteria for participant eligibility.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on the treatment of advanced solid tumors. The trial is associated with specific diseases, which are listed as \"advanced solid tumors\" in this case. The diseases are also identified by their corresponding ICD-10 codes, which in this sample are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\".\n\nThe trial involves the use of a drug called \"ixabepilone (oral formulation)\". The eligibility criteria for participants are listed, including requirements such as being 18 years or older, having a confirmed diagnosis of a solid tumor malignancy, having measurable or non-measurable disease according to RECIST criteria, and having a Karnofsky Performance Status (KPS) score of 70-100. Participants should also have recovered from any toxicities resulting from previous therapies.\n\nThere are also exclusion criteria, which specify conditions that would disqualify potential participants from the trial. These include having undergone more than three prior cytotoxic regimens in the metastatic setting, having current or recent gastrointestinal (GI) disease that would affect the absorption of the study drug, being unable to swallow whole capsules, having inadequate hepatic and renal function, and having been previously exposed to any epothilone.\n\nOverall, this sample provides a snapshot of a phase 1 clinical trial focusing on the treatment of advanced solid tumors, with specific eligibility and exclusion criteria.",
    "The sample from the table represents a clinical trial in the early phase 1. The trial focuses on the treatment of nausea and vomiting. The diseases included in the trial are nausea and vomiting. The corresponding ICD-10 codes for these diseases are 'R11.0', 'R11.11', 'R11.2' for nausea and 'R11.10', 'R11.12', 'R11.14', 'R11.11', 'K91.0', 'O21.2', 'O21.8' for vomiting. The drugs being tested in the trial are haloperidol and placebo. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Age: patients must be 18 years or older and less than 70 years of age.\n- Provision of informed consent.\n- No previous adverse reaction to haloperidol.\n- No current use of haloperidol.\n- Good health.\n- No alcohol consumption within 24 hours of the study.\n- No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal, hepatic, or pulmonary disease.\n- Normal neurologic exam.\n\nThe exclusionary criteria for participants in the trial are as follows:\n- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study.\n- Recent cerebral trauma.\n- Women who are pregnant and/or nursing will be excluded from the study.\n- Women who are of childbearing potential must have a negative urine pregnancy test.\n- History of seizures.\n- Taking medications that can interact with haloperidol.\n- Subjects with significant cardiovascular (cardiac conduction deficits), gastrointestinal, hematologic, neurologic, renal, hepatic, or pulmonary disease.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 1.\n- Diseases: The disease mentioned in this record is \"atrial fibrillation\".\n- ICD Codes: The ICD-10 codes associated with the disease are \"I48.0\", \"I48.21\", \"I48.91\", \"I48.11\", \"I48.19\", and \"I48.20\".\n- Drugs: The drugs being tested in this trial are \"mangosteen juice\" and \"placebo juice\".\n- Criteria: The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include age over 18, documented atrial fibrillation, anticoagulation with therapeutic INR or PTT, and provision of written informed consent. The exclusion criteria include conditions such as atrial fibrillation secondary to a reversible cause, recent myocardial infarction or cardiac surgery, presence of certain medical devices, history of bleeding disorders, active infection or inflammation, current use of corticosteroids, recent gastrointestinal or genitourinary bleed, presence of certain medical illnesses, known allergy to juice components, inability or refusal to cooperate with study procedures, and unsuccessful cardioversion.\n\nOverall, this record provides information about a Phase 1 clinical trial for the treatment of atrial fibrillation using mangosteen juice and placebo juice. It also outlines the eligibility criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"esophagogastric junction adenocarcinoma,\" \"gastric cancer,\" and \"esophageal cancer.\" The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being investigated in this trial are \"capecitabine,\" \"epirubicin,\" \"amg 102,\" \"cisplatin,\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial include having a confirmed diagnosis of unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma. The criteria also specify that tumors of the distal esophagus within 5 cm of the EGJ are eligible. Other criteria include having an ECOG performance status of 0 or 1 and being 18 years of age or older.\n\nExclusion criteria for this trial include previous systemic therapy for the specified diseases, recent completion of neoadjuvant or adjuvant chemotherapy or chemoradiotherapy, resectable disease or suitability for definitive chemoradiation, certain medical conditions such as persistent gastric outlet obstruction or dysphagia, and other factors like tumors of squamous cell histology, central nervous system metastases, recent upper gastrointestinal bleeding, and serious or non-healing wounds.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the diseases listed are cervical cancer and precancerous conditions. The ICDCodes associated with these diseases are provided as well. The drug mentioned in this sample is zoledronate. The eligibility criteria for this trial include specific disease characteristics such as biopsy confirmation of cervical intraepithelial neoplasia (CIN) 2/3 or 3, visible lesion by colposcopy, and no suspicion of invasive cervical cancer. There are also patient characteristics listed, such as normal creatinine levels, screening laboratory values within the normal range, not being pregnant or nursing, and negative pregnancy test. Other criteria include the ability to read and speak English or Spanish, no known hypersensitivity to bisphosphonates, not being immunocompromised or HIV positive, no aspirin-sensitive asthma, and no unexplained abnormal vaginal bleeding. The prior concurrent therapy section states that there should be no concurrent use of loop diuretics, aminoglycosides, other nephrotoxic drugs, immunosuppressive drugs, or other investigational agents.",
    "The sample from the table represents a clinical trial for prostate cancer patients in phase 1/phase 2. The trial aims to evaluate the effectiveness of the drugs docetaxel, prednisone, and vatalanib in treating the disease. The eligibility criteria for participants include having histologically documented adenocarcinoma of the prostate that has progressed despite castrate levels of testosterone. Patients must have measurable disease or nonmeasurable disease with a PSA level of at least 5 ng/mL. They must also have castrate levels of testosterone and demonstrate disease progression after discontinuation of antiandrogen therapy. Other criteria include specific patient characteristics such as Karnofsky performance status, life expectancy, blood counts, kidney and liver function, and absence of certain medical conditions. Prior concurrent therapies and medications are also considered, and certain exclusions apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on kidney transplantation.\n- ICD Codes: The ICD-10 codes associated with the diseases are ['N26.2', 'Q63.0', 'Q63.2', 'Z52.4', 'I75.81', 'N19', 'N20.0'].\n- Drugs: The drugs being studied in the trial are 'aeb071' and 'mycophenolic acid'.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". The inclusion criteria include being a male or female patient of any race who is 18 years or older, having received a kidney transplant from a deceased or living donor, and having a functioning kidney graft within 36 hours of transplantation. The exclusion criteria include the need for prohibited medication, infection with hepatitis B or C or HIV, a history of cancer, severe systemic infections, and heart diseases associated with an increased risk for arrhythmias. Additional inclusion/exclusion criteria may also apply as defined by the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on HIV infections. The ICD-10 code for this disease is \"Z21\". The drug being studied is \"gm-csf\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being HIV uninfected, having good general health, specific major histocompatibility alleles, acceptable contraception methods for females, and negative test results for hepatitis B and hepatitis C. Exclusion criteria include previous participation in HIV vaccine trials, recent use of immunosuppressive medications or blood products, recent administration of live attenuated or subunit/killed vaccines, current tuberculosis prophylaxis or therapy, and various other medical conditions or circumstances that may interfere with the study. Pregnant or breastfeeding individuals are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are solid tumors and metastatic cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are cisplatin and pazopanib. The eligibility criteria for this trial include having documented metastatic solid malignancies, being a candidate for a cisplatin-based regimen, having measurable or evaluable disease, having a WHO performance status of \u2264 1, having a negative dipstick proteinuria test or proteinuria <1g/24h, having a corrected QT interval (QTc) \u2264 480 msecs, and meeting certain exclusion criteria such as not having prior treatment with cisplatin reaching a cumulative dose > 300 mg/m2, not having HER2 positive breast cancer, not being at high risk of bleeding, and not having other concurrent severe and/or uncontrolled medical diseases that could compromise participation in the study.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on treating metastatic colorectal cancer, colon cancer, colorectal cancer, and rectal cancer. The diseases are identified using ICD-10 codes. The drugs being tested in the trial include placebo, amg 655, modified folfox6, and bevacizumab. The eligibility criteria for participants include having histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, measurable or unmeasurable disease, an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1, being at least 18 years old, and having adequate hematologic, renal, hepatic, and coagulation function. Exclusion criteria include a history or known presence of central nervous system (CNS) metastases, prior chemotherapy or other systemic therapy for advanced or metastatic CRC, any investigational agent or therapy for advanced or metastatic CRC, clinically significant cardiac disease, clinically significant peripheral neuropathy, active inflammatory bowel disease, recent gastrointestinal ulcer or hemorrhage, recent arterial thrombotic event or pulmonary embolus, recent history of clinically significant bleeding, bleeding diathesis, or coagulopathy, and recent major surgical procedure or not yet recovered from major surgery.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is \"phase 1\" and the diseases listed are \"Waldenstrom's macroglobulinemia\", \"non-Hodgkin's lymphoma\", \"Hodgkin's disease\", and \"multiple myeloma\". The corresponding ICDCodes for these diseases are [\"C88.0\"], [\"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\"], [\"C81.77\", \"C81.97\", \"C81.17\", \"C81.27\", \"C81.37\", \"C81.47\", \"C81.70\"], and [\"C90.01\", \"C90.02\", \"C90.00\"].\n\nThe drugs mentioned in the sample are \"carfilzomib\" and \"dexamethasone\". The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. The inclusion criteria include factors such as written informed consent, age requirement, confirmed diagnosis of specific hematologic malignancies, previous therapies, performance status, and various health parameters. The exclusion criteria include factors such as pregnancy or lactation, transfusion dependency, recent steroid therapy, recent radiation/chemotherapy/immunotherapy, previous stem cell transplant therapy, and various other medical conditions.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is described as \"phase 1/phase 2\". The diseases being studied are \"aml\" (acute myeloid leukemia), \"acute myeloid leukemia\", and \"myelodysplastic disorders\". The corresponding ICD-10 codes for these diseases are listed as \"['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']\". The drugs being used in the trial are \"idarubicin\", \"sorafenib\", and \"ara-c\". \n\nThe eligibility criteria for participants are then provided, including criteria for inclusion and exclusion. The inclusion criteria state that patients must have a diagnosis of AML or high-risk MDS (myelodysplastic disorders) with specific blast percentages. The age range for eligible patients is 15 to 60 years, with exceptions for patients over 60 who are deemed fit for intensive chemotherapy. The criteria also mention specific serum biochemical values, the ability to take oral medication, and the ability to provide informed consent. Other criteria include baseline ejection fraction, performance status, and exclusion of patients with certain medical conditions or coexisting conditions.\n\nOverall, this sample provides a snapshot of a clinical trial record, including information about the trial phase, diseases being studied, drugs being used, and eligibility criteria for participants.",
    "The sample from the table represents a phase 1 clinical trial for breast cancer. The trial is focused on patients with advanced breast cancer, including those who have undergone adjuvant treatment for high-risk disease. The eligibility criteria include no symptomatic evidence or history of brain metastases or leptomeningeal metastases. The hormone receptor status is not specified. \n\nThe patient characteristics required for participation in the trial include being between the ages of 18 and 69, female, and not specified menopausal status. The performance status should be WHO 0-2 or Karnofsky 60-100%. There is no specific requirement for life expectancy.\n\nIn terms of hematopoietic criteria, the patient should have a neutrophil count of at least 2,000/mm^3, a platelet count greater than 100,000/mm^3, and a hemoglobin level greater than 10 g/dL. \n\nFor hepatic criteria, the bilirubin level should be less than the upper limit of normal (ULN), and the AST and ALT levels should not be greater than 2.5 times ULN (1.5 times ULN if alkaline phosphatase is greater than 2.5 times ULN). The alkaline phosphatase level should not be greater than 5 times ULN.\n\nIn terms of renal criteria, the patient should have normal creatinine levels or a creatinine clearance of at least 60 mL/min.\n\nCardiovascular criteria include having a left ventricular ejection fraction (LVEF) or shortening fraction greater than the lower limit of normal by MUGA or echocardiography, normal cardiac function, and no history of congestive heart failure, unstable angina pectoris, myocardial infarction within the past year, uncontrolled hypertension, or high-risk uncontrolled arrhythmia.\n\nOther criteria include not being pregnant or nursing, having a negative pregnancy test, using effective nonhormonal contraception for fertile patients, having no active uncontrolled infection or peptic ulcer, no unstable diabetes mellitus, no other serious illness or medical condition, no contraindication to corticosteroids, no pre-existing grade 2 or greater motor or sensory neurotoxicity, no psychological, social, familial, or geographical reasons that would preclude study follow-up, and no history of significant neurologic or psychiatric disorder that would preclude understanding and giving informed consent. \n\nThe prior concurrent therapy includes no specified biologic therapy, at least 6 months since prior anthracycline or taxoid therapy, and no prior cumulative anthracycline dose greater than 240 mg/m^2. Concurrent corticosteroid treatment is allowed if initiated more than 6 months before study entry and at a dose of less than 20 mg of methylprednisolone or equivalent. No concurrent ovarian hormonal replacement therapy is allowed.\n\nThere are no specific requirements for radiotherapy. It should be more than 2 weeks since prior major surgery. Other criteria include more than 30 days since prior participation in another clinical trial with any investigational drug or device, no other concurrent experimental drugs, no other concurrent systemic anticancer therapy, and no concurrent aminoglycoside antibiotics.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors\" and its corresponding ICDCodes are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug mentioned is \"osi-906\". The eligibility criteria for this trial include various conditions such as having a documented malignancy that is advanced and refractory to established therapies, having a predicted life expectancy of at least 12 weeks, and having certain laboratory values within normal limits. There are also exclusion criteria listed, such as having a history of diabetes mellitus, significant cardiac disease, or active seizure disorder. Additionally, the sample includes information about prior therapies, fasting glucose levels, and contraceptive measures for patients of reproductive potential.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on HIV infection. The trial is studying the effectiveness of a drug called HAART. The eligibility criteria for participants include having documented HIV-1 infection, being on a stable antiretroviral regimen for at least 12 weeks, having a low plasma HIV-1 RNA level, and having certain laboratory values within normal ranges. Female participants must have a negative pregnancy test and use contraception during the trial. The sample also includes exclusion criteria such as having a high viral load, active skin disease, recent use of corticosteroids or vaccines, and allergies to the study vaccine products.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1/phase 2 and focuses on pancreatic cancer and pancreatic ductal adenocarcinoma. The diseases are represented by their respective ICD-10 codes. The drugs being studied in this trial are bevacizumab, 5-fluorouracil, oxaliplatin, and gemcitabine.\n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must have histologically and radiologically confirmed locally advanced pancreatic ductal adenocarcinoma and have not received prior therapy.\n- The disease must be measurable by CT scan.\n- Participants must be at least 18 years old and have a life expectancy of 4 months or longer.\n- Certain blood counts and levels must meet specific criteria, such as ANC (absolute neutrophil count), hemoglobin, platelet count, total bilirubin, SGOT/SGPT (liver enzymes), and serum creatinine.\n- Participants must not have evidence of metastatic disease by laparoscopy.\n\nThere are also exclusion criteria that would disqualify participants from the trial, such as having other diseases or conditions that contraindicate the use of an investigational drug, having secondary malignancies within the past 5 years, having pre-existing peripheral neuropathy of grade 2 or greater, being pregnant or lactating, and having participated in another experimental drug study within the past 4 weeks.\n\nOther exclusion criteria include specific medical conditions like high blood pressure, unstable angina, congestive heart failure, recent history of myocardial infarction or stroke, peripheral vascular disease, bleeding disorders, central nervous system or brain metastases, recent major surgical procedures or biopsies, abnormal urine protein creatinine ratio, history of abdominal fistula or abscess, and serious non-healing wounds, ulcers, or bone fractures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"aplastic anemia.\" The ICDCodes associated with this disease are \"D61.3,\" \"D61.9,\" \"D61.09,\" \"D61.1,\" \"D61.2,\" and \"D61.89.\" The drugs being used in the trial are \"cyclophosphamide,\" \"cyclosporine,\" and \"mycophenolate mofetil.\" \n\nThe eligibility criteria for this trial include several inclusion and exclusion criteria. Inclusion criteria state that patients must have life-threatening marrow failure of nonmalignant etiology meeting specific criteria related to granulocytes, reticulocyte count, and platelet count. They must also have failed to respond to the best available immunosuppressive treatment protocol within 75 days and lack an HLA-identical family member or closely matched unrelated marrow donor. The donor requirements for unrelated UCB units and related UCB units are also specified.\n\nExclusion criteria state that patients with severe diseases other than aplastic anemia, HIV seropositive patients, patients with clonal cytogenetic abnormalities or myelodysplastic syndrome, patients with paroxysmal nocturnal hemoglobinuria or Fanconi anemia, and patients over 40 years of age are not eligible for the trial. Additionally, related or unrelated cord blood units with insufficient total nucleated cells per kg recipient weight and units without full testing and negative results for certain viruses are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease mentioned is \"advanced cancer.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug mentioned is \"sgx523 capsules.\" \n\nThe eligibility criteria for this sample include the subject's ability to understand and comply with study procedures, having pathologic evidence of a solid tumor, having failed standard therapy and deemed suitable for participation by the investigator, and meeting specific laboratory values such as ANC, platelets, hemoglobin, bilirubin, AST, ALT, alkaline phosphatase, serum creatinine, and PT/PTT/INR. Additionally, having IHC evidence of phospho-MET expression on tumor material within the last 12 months is required for entry into the MTD dose expansion phase. \n\nThe exclusion criteria include being pregnant, lactating, or at risk of becoming pregnant, having cardiac disease requiring medical therapy, having had major surgery within 4 weeks prior to the study, having an active, uncontrolled bacterial, viral, or fungal infection, having a known active infection with HIV, hepatitis B or C, having psychiatric or seizure disorders that would require therapy or interfere with study participation, having severe concurrent nonmalignant disease that could compromise protocol objectives, including malabsorptive conditions, receiving prohibited medications, having known allergy to SGX523 formulation or its excipients, and receiving anti-coagulant therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"hematologic malignancies.\" The ICDCodes associated with this disease are ['E70.338', 'E70.339', 'P09.3', 'O28.0', 'P61.8', 'P61.9', 'T45.8X1A']. The drug mentioned is \"clofarabine.\" \n\nThe eligibility criteria for this trial include documentation of the disease, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplasia, chronic myelogenous leukemia (CML), or aggressive non-Hodgkin's lymphoma (NHL). There are specific criteria for each disease type, including primary refractory to induction chemotherapy, relapsed and refractory disease, or being in complete remission. Other criteria include patient age (18-60 years), availability of a consenting HLA-matched donor, performance status, absence of active infection or HIV disease, non-pregnancy or nursing, and specific baseline laboratory values.\n\nThe exclusion criteria state that patients who relapse less than 6 months following autologous stem cell transplantation are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied in this trial are lymphoma, sarcoma, wilmstumor, and neuroblastoma. The corresponding ICDCodes for these diseases are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'] for lymphoma and ['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32'] for sarcoma.\n\nThe drugs being used in this trial are vorinostat (saha) and velcade (ps-341, bortezomib). The eligibility criteria for this trial include patients who are older than 12 months and less than or equal to 21 years of age with a diagnosis and histologic verification of relapsed or refractory solid tumors, including CNS tumors and lymphomas. The patients must have a current disease state for which there is no known curative therapy or therapy proven to prolong survival. They must also have a performance score of Karnofsky greater than or equal to 60% for patients older than 16 years of age or Lansky greater than or equal to 60 for patients less than or equal to 16 years of age. Additionally, the patients must have fully recovered from any acute toxic effects of prior therapy and have adequate organ function as determined by laboratory evaluation.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of solid tumors, specifically cancer. The trial is for patients who have advanced, histologically-confirmed solid tumors that are refractory to standard therapy or for which no standard therapy exists. The patients must have evidence of disease progression since their prior therapy and must have measurable or evaluable disease.\n\nThe patients must not have received chemotherapy or radiation for at least 4 weeks prior to the first dose of the study drug. However, they may have received radiation therapy involving up to 30% of the bone marrow, as long as it was administered at least 4 weeks prior to the first dose of the study drug and the patient has recovered from the acute toxic effects of the treatment. Patients with a history of treated brain metastases that have been clinically stable for at least 4 weeks prior to the first dose of the study drug may also be enrolled, as long as they are not currently receiving dexamethasone.\n\nOther criteria for inclusion in the trial include an ECOG performance status of less than 2, a life expectancy of greater than 12 weeks, acceptable organ and marrow function, and an electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia. Women of childbearing potential must agree to use adequate contraception during the study.\n\nExclusion criteria for the trial include pregnancy or nursing, recent chemotherapy or radiotherapy, congestive heart failure requiring medical therapy, elevated serum amylase or lipase levels, previous high dose chemotherapy with autologous stem cell rescue bone marrow transplantation, recent use of any investigational agent or drug, metastatic disease to the central nervous system requiring treatment or radiation therapy, untreated or unstable brain metastases, uncontrolled intercurrent illness, active coagulation disorder, marked baseline prolongation of QT/QTc interval, prior treatment with a topoisomerase I inhibitor, major surgery within 4 weeks prior to the first dose of the study drug, and concurrent use of G-CSF or growth factors at the time of initiation of the study drug.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drug being studied is vorinostat. The sample also includes the eligibility criteria for the trial, which include factors such as the patient's age, performance status, proof of adenocarcinoma of the pancreas, and staging with physical exams and imaging tests. The sample also lists exclusion criteria, such as prior abdominal radiotherapy, participation in other experimental drug studies, and certain medical conditions or infections.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 1 and is focused on the disease called cystic fibrosis. The ICD-10 codes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being tested in this trial are recombinant human igf-1 and a placebo. The eligibility criteria for participants are listed, including requirements such as a diagnosis of cystic fibrosis, age of 18 years or older, and specific Tanner stage for males and females. There are also exclusion criteria, which include conditions such as high hemoglobin A1C levels, diabetic retinopathy, and respiratory failure requiring mechanical ventilation. Other exclusions include previous pulmonary transplantation, recent use of human growth hormone, pregnancy or breastfeeding, and allergies to components in the IGF-I preparation.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 design. The trial is focused on various types of lymphoid malignancies, including B-cell, T-cell, and Hodgkin's disease. The diseases are specified using their names and corresponding ICD-10 codes. The trial also involves the use of specific drugs, such as vorinostat, ifosfamide, carboplatin, and etoposide.\n\nThe eligibility criteria for the trial include having relapsed or primary refractory lymphoid malignancy, measurable disease, specific performance status, certain blood counts and laboratory values, and the ability to complete at least 2 cycles of chemotherapy. There are also exclusion criteria, such as being HIV positive, pregnancy or nursing, refractory to certain chemotherapy regimens, and having certain medical conditions or prior treatments.\n\nOverall, the sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a clinical trial focused on lymphoid malignancies.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is urothelial carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug mentioned is ipilimumab. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include previously untreated urothelial cancer requiring surgery for treatment, ineligibility for chemotherapy, and adequate hematologic, kidney, and liver function. The exclusion criteria include various factors such as being sexually active and fertile without using birth control, pregnancy or breastfeeding, prior treatment with ipilimumab or other anti-CTLA4 antibody, concurrent malignancy (except for certain cases), autoimmune diseases, ineligibility for surgery, recent non-oncology vaccine therapy, concomitant therapy with specific medications, prior radiation therapy for urothelial cancer, and positive screening tests for HIV, Hepatitis B, or Hepatitis C.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 1/phase 2. The disease being studied is \"carcinoma, non-small-cell lung.\" The corresponding ICD-10 codes for this disease are \"D02.20,\" \"D02.21,\" and \"D02.22.\" The drugs being tested in this trial are \"tlk286,\" \"carboplatin,\" and \"paclitaxel.\" \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be 18 years of age or older.\n- They must have histologically confirmed non-small cell lung cancer (NSCLC).\n- The disease must be at stage IV or IIIB, which means it is not eligible for combined modality chemotherapy and radiation.\n- Participants must have measurable disease according to RECIST criteria.\n- Their ECOG status (a measure of performance status) must be 0-1.\n- They must have adequate liver and renal function.\n- Adequate bone marrow reserves are required.\n\nThe exclusion criteria for this trial are:\n- Participants who have received prior chemotherapy, immunotherapy, or biologic therapy for metastatic NSCLC are not eligible.\n- Up to one prior adjuvant or neoadjuvant chemotherapy is allowed.\n- Individuals with a history of bone marrow transplantation or stem cell support are excluded.\n- Pregnant or lactating women are not eligible to participate.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on liver carcinoma.\n- ICD Codes: The ICD-10 codes associated with the liver carcinoma are 'C22.0', 'D01.5', and 'C22.7'.\n- Drugs: The drugs being used in the trial are 'ave1642', 'sorafenib', and 'erlotinib'.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include patients who are not eligible for surgical resection, liver transplantation, local ablation techniques, or chemoembolisation. They should have histologically proven liver carcinoma or a combination of radiologically documented hypervascular liver tumor and \u03b1 foeto protein level \u2265 400 ng/ml. The exclusion criteria include patients with an ECOG performance status > 2, inadequate organ function, no measurable or evaluable tumoral lesion, patients not eligible for sorafenib therapy, prior exposure to an anti-IGF-1R class compound, and other specific conditions mentioned in the criteria.\n\nPlease note that the provided information is not exhaustive and may not include all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are \"diabetes mellitus, type 2\" and \"plasma volume.\" The ICDCodes associated with these diseases are \"E11.65,\" \"E11.9,\" \"E11.21,\" \"E11.36,\" \"E11.41,\" \"E11.42,\" and \"E11.44.\" The drugs being used in the trial are \"canagliflozin\" and \"placebo.\" The eligibility criteria for inclusion in the trial include having a diagnosis of type 2 diabetes mellitus with inadequate glycemic control, being on metformin monotherapy, and receiving therapy with an antihypertensive agent (an ACEI or ARB) for at least 4 weeks prior to screening. The exclusion criteria include a history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is cetuximab. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have histologically confirmed non-small cell lung cancer.\n- The patient must have inoperable stage III (UICC 2002; sixth edition) without pleural effusion.\n- The patient's WHO performance status must be 0 or 1.\n- The patient must have had less than 10% weight loss in the last 6 months.\n- The patient's lung function must be at least 50% of the predicted value for FEV1 and DLCO.\n- The patient must not have any recent severe cardiac disease.\n- The patient must have adequate bone marrow, renal, and hepatic function.\n- The patient's life expectancy must be more than 6 months.\n- The patient must have measurable cancer.\n- The patient must be willing and able to comply with study prescriptions.\n- The patient must be 18 years or older.\n- The patient must not be pregnant or breastfeeding.\n- The patient must provide written informed consent.\n- The patient must not have received previous radiotherapy to the chest.\n\nExclusion Criteria:\n- The patient must not have non-small cell lung cancer histology.\n- The patient must not have mixed pathology.\n- The patient must not have a history of prior chest radiotherapy.\n- The patient must not have had a recent (<3 months) myocardial infarction.\n- The patient must not have an uncontrolled infectious disease.\n- The patient must be less than 18 years old.\n- The patient must have inadequate pulmonary function.\n- The patient must not have any other active malignancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"non small cell lung cancer\" and its corresponding ICDCodes are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drugs being tested in this trial are 'pemetrexed', 'cisplatin', and 'ly2603618'. The eligibility criteria for participants are listed, including specific requirements for each phase of the trial. Exclusion criteria are also mentioned, which outline conditions that would prevent a participant from being eligible for the trial.",
    "The sample from the table is for a phase 1 trial. The diseases being studied are lymphoma, NHL (non-Hodgkin lymphoma), and non-Hodgkin lymphoma. The corresponding ICD-10 codes for these diseases are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'] and ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'] respectively. The drug being tested is azd4877. The eligibility criteria for this trial include having advanced solid tumors (including lymphoma without bone marrow involvement) for which standard treatment doesn't exist or is no longer effective, having B-cell non-Hodgkin lymphoma that is not eligible for curative therapy or has relapsed, and being in relatively good overall health other than the cancer. The exclusion criteria include having poor bone marrow function (not producing enough blood cells), serious heart conditions, and poor liver or kidney function.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is snx-5422. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must be over 18 years old.\n- The participant must have a histologically confirmed solid tumor malignancy.\n- The participant must be refractory to available therapy or have no therapy available.\n- The participant must have adequate organ function.\n\nExclusion Criteria:\n- The participant must not have a CNS malignancy.\n- The participant must not have significant GI disease.\n- The participant must not be at risk for a prolonged QT interval.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are breast neoplasm, colon neoplasm, pancreatic neoplasm, and bladder neoplasm. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is MLN8054. The eligibility criteria for this trial include having confirmed metastatic and/or advanced solid tumors, being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having an expected survival of more than 3 months, having suitable venous access for blood sampling, having recovered from prior antineoplastic therapy, and meeting certain contraceptive requirements. The exclusion criteria include being pregnant or lactating, having had major surgery or serious infection within the past 28 days, having a life-threatening illness unrelated to cancer, experiencing ongoing nausea or vomiting, having grade 1 or higher diarrhea, having a known gastrointestinal disease that could interfere with the absorption or tolerance of MLN8054, having difficulty swallowing capsules, being unable to fast overnight before taking MLN8054, having received more than 4 previous cytotoxic chemotherapeutic regimens, having received high-dose chemotherapy or radiation therapy involving a significant amount of bone marrow, having clinical or radiographic evidence of cerebral metastases, having clinically significant abnormalities or arrhythmias on an ECG, having known or suspected HIV or hepatitis B or C infection, having a disorder of bilirubin metabolism or excretion, having participated in an investigational drug trial in the past 4 weeks, and admitting to alcohol abuse or being unable to restrict alcohol consumption during the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is a combination of phase 1 and phase 2.\n- Diseases: The specific disease being targeted in the trial, which is \"metastatic colorectal cancer\".\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\".\n- Drugs: The drugs being used in the trial, which are \"pimasertib\", \"placebo\", and \"folfiri\".\n- Criteria: The eligibility criteria for participants in the trial, including both inclusion and exclusion criteria.\n\nThe inclusion criteria state that participants must have histologically confirmed K-Ras mutated colon/rectum cancer that has progressed after a first-line treatment with oxaliplatin and fluoropyrimidines based chemotherapy. They must also have measurable metastatic disease and be at least 18 years old. Additionally, women of childbearing potential must have a negative pregnancy test and be willing to avoid pregnancy during the trial.\n\nThe exclusion criteria include various medical conditions and impairments, such as bone marrow impairment, renal impairment, liver function abnormalities, and history of central nervous system metastases. Other exclusions include certain medical history, prior treatments, cardiac abnormalities, pregnancy or nursing, retinal degenerative disease, and hypersensitivity to the trial treatments.\n\nOverall, this record provides information about a clinical trial targeting metastatic colorectal cancer and outlines the criteria for participant eligibility.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of psoriasis and psoriasis vulgaris. The ICD-10 codes associated with these diseases are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50' for the first disease and 'L40.0' for the second disease. The drugs being studied are 'hat1 topical solution' and 'calcipotriol'. The eligibility criteria for participants are listed, including requirements such as having a clinical diagnosis of psoriasis with a specific severity index score, being within a certain age range, and not having certain medical conditions or taking specific medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is tumors. The ICDCodes associated with the disease are ['E88.3', 'R97.8', 'C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3']. The drug being tested is cudc-101. \n\nThe eligibility criteria for this trial include:\n- Subjects must have advanced, refractory solid tumors with a confirmed diagnosis.\n- Subjects must have exhausted all standard treatment options or have refused them.\n- Measurable or evaluable disease is required.\n- Subjects must be at least 18 years old.\n- ECOG performance should be less than 2.\n- Life expectancy should be at least 3 months.\n- Pregnant or lactating females are not eligible.\n- If of childbearing potential, adequate birth control must be used.\n- Certain blood count and liver function parameters must be within specified limits.\n- Prothrombin time should be within a certain range, unless the subject is receiving therapeutic anticoagulation.\n- Serum magnesium and potassium levels should be within normal limits.\n- Subjects with controlled brain metastases on a stable dose of prednisone or equivalent steroids are eligible.\n- Subjects must be able to provide informed consent and follow the protocol requirements.\n\nThere are also exclusion criteria, which include:\n- Recent anticancer therapy within 4 weeks of study entry, except for prostate cancer subjects on LHRH hormonal therapy.\n- Use of investigational agents within 30 days of study entry.\n- History of certain cardiac diseases or serious arrhythmias.\n- Known infection with HIV, hepatitis B, or hepatitis C.\n- Caution should be exercised if subjects are receiving certain concomitant medications or if they are taking warfarin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is tumors. The ICDCodes associated with the disease are E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, and C49.A3. The drug being tested is bms-275183. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a non-hematologic malignancy that has either progressed or for which no standard therapy is known.\n- The patient must be at least four weeks from their last chemotherapy treatment or two weeks from their last non-cytotoxic therapy.\n- The patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n- The patient must have had no more than three prior chemotherapy regimens in the advanced/metastatic setting.\n- The patient must have an absolute neutrophil count of at least 1,500/mm3 and platelets of at least 100,000/mm3.\n- The patient's bilirubin levels must be less than or equal to 1.5 times the Upper Limit of Normal (ULN), and their aspartate aminotransferase levels must be less than or equal to 2.5 times the ULN.\n- The patient's serum creatinine levels must be less than or equal to 1.5 times the ULN.\n- The patient must be at least 18 years old.\n- Women of Child Bearing Potential (WOCBP) must use an adequate method of contraception throughout the study and for up to 4 weeks after.\n\nExclusion Criteria:\n- Women of Child Bearing Potential (WOCBP) and men who are not using an adequate method of birth control.\n- WOCBP who are pregnant or breastfeeding.\n- Patients with prior radiation treatment that involved at least 25% of the bone marrow-containing skeleton.\n- Patients with uncontrolled, significant, or active cardiovascular or pulmonary disease, infection, or psychiatric disorder.\n- Patients with neuropathy.\n- Patients with active brain metastases.\n- Patients who are unable to swallow capsules.\n- Patients with a history of gastrointestinal disease, surgery, malabsorption, or requiring the use of a feeding tube.\n- Patients receiving concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are recurrent non-small cell lung cancer, stage IIIA non-small cell lung cancer, and stage IIIB non-small cell lung cancer. The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2.\n\nThe drugs being used in the trial are bortezomib, paclitaxel, and carboplatin. The eligibility criteria for participants in this trial include having histologically or cytologically confirmed non-small cell lung cancer, locally advanced stage IIIA or IIIB disease that is considered unresectable, and no stage IV disease. Other criteria include specific blood counts, liver function, heart health, lung function, weight loss, pregnancy status, and previous medical history.\n\nThere are also contraindications for participation in the trial, such as being pregnant or nursing, unwillingness to use contraception, prior radiation therapy to the chest, prior systemic chemotherapy for NSCLC, New York Heart Association classification III or IV, uncontrolled infection, recent major surgery or unhealed wound, and history of malignancy within the past 5 years.\n\nOverall, this sample provides detailed information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial related to non-small cell lung cancer.",
    "The sample is a phase 1 clinical trial for rectal cancer. The trial is investigating the effectiveness of three drugs - bevacizumab, capecitabine, and erlotinib. The eligibility criteria for participants include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, being at least 18 years old, having histologically confirmed adenocarcinoma of the rectum, and having clinical stage II-III disease. Other criteria include not having distant metastatic disease, having certain blood counts and kidney function within normal ranges, and having signed informed consent. Exclusion criteria include prior radiotherapy or chemotherapy to the pelvis, prior use of certain targeted therapies, current or planned participation in other experimental drug studies, pregnancy or lactation, uncontrolled infections, and certain medical conditions such as hypertension, heart failure, and impaired renal function.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: The specific disease being targeted in the trial, which is \"non small cell lung cancer\".\n- ICD Codes: The ICD-10 codes associated with the disease, which are \"C78.00\", \"C78.01\", \"C78.02\", \"D14.30\", \"D14.31\", \"D14.32\", and \"C34.2\".\n- Drugs: The drug being tested in the trial, which is \"axl1717\".\n- Criteria: The eligibility criteria for participants in the trial, including inclusion and exclusion criteria.\n\nThe inclusion criteria state that participants must be at least 18 years old and have a confirmed diagnosis of locally advanced or metastatic squamous non-small-cell lung cancer. They should also have preserved major organ functions and meet specific blood count and biochemical criteria. Additionally, participants must provide signed written informed consent.\n\nThe exclusion criteria list various conditions or circumstances that would exclude a patient from participating in the study. These include ongoing infections or major diseases that pose a risk, certain gastrointestinal conditions, known malignancy in the central nervous system, dementia and neuropathy above a certain grade, recent major surgical procedures, prior anti-tumor therapy, pregnancy or lactation, current participation in another clinical trial, poor performance status, a life expectancy of less than 3 months, contraindications to the investigational product, and any other reason that the investigator deems unsuitable for participation.\n\nOverall, this sample provides specific information about a Phase 1 clinical trial targeting non small cell lung cancer, including the disease, drug, and eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 1. The diseases being studied are \"advanced solid tumors\", \"tumors\", and \"cancer\". The corresponding ICD-10 codes for these diseases are provided as well. The drugs being used in the trial are \"mk-2206\", \"paclitaxel\", and \"trastuzumab\". The eligibility criteria for participants are listed, including requirements such as confirmed metastatic or locally advanced HER2+ cancer, specific laboratory values within normal ranges, ability to swallow capsules, and prior treatment history.\n\nThe sample also includes exclusion criteria, which outline conditions or factors that would disqualify a participant from the trial. These include recent chemotherapy, radiotherapy, or hormonal therapy, active CNS metastases, significant heart disease, uncontrolled hypertension, and various other medical conditions or history that may interfere with the study.\n\nOverall, this sample provides a snapshot of the information contained in the table, including the phase of the trial, the diseases being studied, the drugs being used, and the eligibility and exclusion criteria for participants.",
    "The sample is a phase 1 clinical trial for patients with mild to moderate persistent allergic asthma. The trial focuses on the effectiveness of a drug called fluticasone compared to a placebo. The eligibility criteria for participants include having a history of asthma with typical symptoms, being in good health, being able to perform pulmonary function tests, demonstrating an allergic response to house dust mite allergen, and being a nonsmoker or having quit smoking for at least 10 months. Participants must also be willing to avoid strenuous physical activity before each visit and allergen challenge. Exclusion criteria include having any illness that could affect the study results or pose additional risk, recent use of corticosteroids, a history of stroke or major neurological disorder, and various other medical conditions. Participants must also refrain from using any medication not permitted in the study and avoid excessive alcohol and caffeine consumption.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and the disease being studied is \"healthy\" (which likely refers to a control group). The ICD-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being used in the trial are \"bibr 796 bs\" and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a healthy male or female subject, providing written informed consent, meeting certain age and body mass index requirements, and having laboratory values within a normal range. Exclusion criteria include having any abnormal medical examination findings, having certain medical disorders or conditions, having a history of certain medical conditions or surgeries, taking certain medications, participating in other trials with investigational drugs, and having certain lifestyle habits or behaviors.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria of a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are chronic lymphocytic leukemia and small lymphocytic lymphoma. The corresponding ICDCodes for these diseases are C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, and S33.131S. The drug being tested is dinaciclib.\n\nThe eligibility criteria for this trial include having received at least one prior therapy that includes fludarabine or an equivalent nucleoside analogue, a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an Eastern Cooperative Oncology Group (ECOG) Performance status of \u2264 2, and a life expectancy of at least 12 weeks.\n\nExclusion criteria for this trial include having symptomatic brain metastases or primary central nervous system malignancy, recent treatment with chemotherapy or biologic therapy, non-hematological toxicities from prior therapy, serious or uncontrolled infection, known HIV infection or HIV-related malignancy, clinically active hepatitis B or C, pregnancy or intent to become pregnant, prior allogeneic bone marrow transplant, prior malignancy (except for certain types), recent use of investigational drugs, concurrent participation in another clinical study, previous treatment with a cyclin dependent kinase (CDK) inhibitor, and active autoimmune anemia or idiopathic thrombocytopenic purpura (ITP) unless stable.\n\nThis information provides details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for this particular clinical trial sample.",
    "The sample is a phase 1 clinical trial with the following details:\n- Phase: Phase 1\n- Diseases: The trial is focused on lymphoma and unspecified adult solid tumors that are protocol specific.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The drug being tested in the trial is called \"cdki at7519\".\n- Criteria: The eligibility criteria for participants in the trial are listed, including disease characteristics, patient characteristics, and prior concurrent therapy requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drug being used in the trial is gemcitabine hydrochloride. The eligibility criteria for this trial include specific disease characteristics such as confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas, ampulla of Vater, or distal bile duct. The patient should have locally advanced disease that is medically inoperable, unresectable, or borderline resectable. They should not have previously had resected disease. Other criteria include specific patient characteristics such as Karnofsky performance status, blood counts, bilirubin levels, liver function, and pregnancy status. The patient should also not have any active malignancy within the past 3 years and should not have severe, active comorbidities. Prior concurrent therapy is also mentioned, stating that the patient should not have had prior chemotherapy or radiotherapy to any upper abdominal site, and should not be receiving concurrent prophylactic colony-stimulating factors, warfarin, or any other concurrent cancer therapies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are esophageal neoplasms, carcinoma, squamous cell, adenocarcinoma, and esophageal cancer. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial are capecitabine (xeloda), [18-f] fluorodeoxyglucose (fdg), 5-fluorouracil (5-fu), and carboplatin.\n\nThe eligibility criteria for this trial include having a confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus, evidence of tumor penetration through the esophageal wall or involvement of regional lymph nodes without distant metastasis, no prior chest radiation therapy or chemotherapy for esophageal cancer, being over 18 years of age, having acceptable liver, kidney, and bone marrow function, not having any infections requiring antibiotic treatment, being able to care for oneself, and agreeing to use adequate contraception for women of child-bearing potential and men.\n\nThe exclusion criteria for this trial include receiving any other investigational agents, evidence of distant metastases, uncontrolled medical illness, any malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix, and being pregnant or breastfeeding. HIV-positive patients are also excluded from this trial.",
    "The sample from the table represents a clinical trial for patients with Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia and recurrent adult acute lymphoblastic leukemia. The trial is in phase 1/phase 2. The diseases are identified by their names and corresponding ICD-10 codes. The drugs being studied are entinostat and imatinib mesylate. The eligibility criteria for the trial include having confirmed BCR-ABL1 associated acute lymphoblastic leukemia, prior treatment with tyrosine kinase inhibitors, specific performance status, certain blood and organ function levels, and meeting other requirements related to previous treatments and medical conditions. There are also exclusion criteria, such as not receiving any other investigational agents, having active CNS leukemia, and having a history of allergic reactions to similar compounds. Pregnant women and HIV-positive patients on antiretroviral therapy are also excluded from the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are colorectal cancer, lung cancer, and head and neck cancer. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is a combination of cetuximab and lapatinib.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having at least one measurable lesion, being able to undergo a biopsy, being over 18 years old, having progressed after standard therapy, and meeting certain health requirements. Exclusion criteria include recent chemotherapy or surgery, prior therapy with lapatinib, untreated brain metastasis, and various other medical conditions or medications that could affect participation in the study.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on the disease \"systemic sclerosis\" and the corresponding ICD-10 codes for this disease are ['M34.0', 'M34.89', 'M34.9', 'M34.82', 'M34.83', 'M34.81', 'M34.2']. The drugs being studied in this trial are \"rapamycin\" and \"methotrexate\". The eligibility criteria for participants in this trial include satisfying the American College of Rheumatology classification criteria for systemic sclerosis, having skin thickening proximal to the elbows and/or knees (diffuse scleroderma), and having cutaneous involvement for less than 5 years from the onset of the first non-Raynaud's manifestation. The exclusion criteria include severe intractable malabsorption, chronic debilitation from any underlying disease, and being off putative disease modifying therapies for one month prior to entry.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, such as phase I, phase II, or phase III. The sample specifically belongs to a trial that combines phase I and phase II. The diseases being studied in this trial are \"malignant pleural mesothelioma\" and \"solid tumors\". The diseases are also associated with specific ICD-10 codes, which in this case are \"C45.9\", \"C45.0\", \"C45.1\", \"C45.2\", and \"C45.7\". The drugs being used in the trial are \"pemetrexed, cisplatin and cbp501\" and \"pemetrexed and cisplatin\". The eligibility criteria for participants in the trial are listed, including requirements such as signed informed consent, specific disease diagnoses, measurable disease, age, performance status, previous treatment discontinuation, life expectancy, organ function, contraception use, and ability to cooperate with treatment and follow-up. The exclusion criteria are also listed, which include factors such as previous radiation therapy, specific types of mesothelioma, absence of measurable lesions, certain medical conditions, previous malignancies, central nervous system or psychiatric disorders, peripheral neuropathy, recent participation in other trials, pregnancy or breastfeeding, HIV/HBV/HCV infection, and presence of central nervous system metastases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is pancreatic cancer, and its corresponding ICDCodes is C25.3. The drugs being studied in this trial are gemcitabine and imatinib mesylate. \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have histologically confirmed pancreatic cancer, which can be locally advanced, metastatic, or recurrent.\n- The disease should be measurable or evaluable through physical exams, radiographs, CT scans, or MRI.\n- Patients with brain metastases are not eligible.\n- The patient's ECOG performance status should be between 0 and 2.\n- The patient's life expectancy should be at least 12 weeks.\n- The patient's absolute neutrophil count should be equal to or greater than 1,500/mm^3.\n- The patient's platelet count should be equal to or greater than 100,000/mm^3.\n- The patient's bilirubin levels should be less than or equal to 1.5 times the upper limit of normal (ULN).\n- The patient's AST levels should be less than or equal to 2.5 times ULN (or 5 times ULN if liver metastases are present).\n- Patients with chronic liver disease, chronic renal disease, uncontrolled diabetes, active uncontrolled infection, or other severe and/or uncontrolled medical diseases are not eligible.\n- The patient should be HIV negative.\n- Patients with other malignancies within the past 5 years, except for basal cell skin cancer or carcinoma in situ of the cervix, are not eligible.\n- Pregnant or nursing patients are not eligible, and a negative pregnancy test is required.\n- Fertile patients must use effective barrier-method contraception during the study treatment and for at least 3 months after its completion.\n- Patients who have not received prior therapy for metastatic disease are eligible, except for prior fluorouracil as a radiosensitizer for adjuvant therapy after surgery or for locally advanced disease. In such cases, local disease recurrence or progression must have occurred at least 3 months after completion of therapy or the disease should be present outside the radiation field.\n- At least 2 weeks should have passed since the patient's last major surgery.\n- Patients should avoid concurrent consumption of grapefruit or grapefruit juice.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are soft tissue sarcoma and mesothelioma. The ICDCodes associated with these diseases are \"C46.1\" for soft tissue sarcoma and a list of codes including \"C45.9\", \"C45.0\", \"C45.1\", \"C45.2\", and \"C45.7\" for mesothelioma. The drug being used in the trial is \"azacitidine in combination with temozolomide\". \n\nThe eligibility criteria for this trial include:\n- Histologically confirmed soft tissue sarcoma or mesothelioma.\n- Ineligibility for other high priority national or institutional studies.\n- Non-pregnant and non-lactating.\n- Recurrent or progressive disease that is not amenable to definitive surgical therapy.\n- Measurable disease that can be measured in at least one dimension.\n- Prior chemotherapy is allowed, except for prior treatment with Temozolomide or Azacitidine.\n- Prior radiation therapy is allowed.\n- A certain time period since prior chemotherapy or radiation therapy.\n- Patients may have had another cancer, but the sarcoma must be the disease requiring intervention.\n- Certain clinical parameters such as life expectancy, age, and performance status.\n- Required initial laboratory data including blood counts, bilirubin levels, liver function, and creatinine levels.\n- Women of child-bearing potential must have a negative pregnancy test and both men and women must be willing to use contraception.\n- Patients must be capable of providing written, informed consent.\n- No serious medical or psychiatric illness preventing informed consent or intensive treatment.\n- No uncontrolled central nervous system metastases.\n\nThe exclusion criteria for this trial include:\n- Known or suspected hypersensitivity to azacitidine or mannitol.\n- Pregnancy or breastfeeding.\n- Histology other than soft tissue sarcoma or mesothelioma.\n- Active or uncontrolled infection or other serious systemic disease.\n- Prior treatment with temozolomide or azacitidine.\n- Uncontrolled central nervous system metastases.\n- Liver metastases.\n- Patients who do not wish to participate in the second biopsy for tissue evaluation.\n- Subjects who have not had prior chemotherapy.",
    "The sample from the table represents a phase 1 clinical trial for patients with various types of solid tumors or lymphomas. The diseases included in the sample range from adult grade III lymphomatoid granulomatosis to Waldenstr\u00f6m macroglobulinemia. The corresponding ICD-10 codes for these diseases are also provided. The trial is investigating the use of the drugs tanespimycin and bortezomib. The eligibility criteria for the trial include having a histologically confirmed tumor or lymphoma that is refractory to standard treatment or for which no potentially curative or life-prolonging treatment exists. Other criteria include specific laboratory values, cardiac and pulmonary health, absence of certain medical conditions, and previous treatment history. The sample does not provide information on the number of participants or any outcomes of the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is peripheral arterial disease. The ICDCodes associated with this disease are A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, and I73.9. The drugs being tested in this trial are \"biwh 3\" and \"placebo\". The eligibility criteria for inclusion in the trial include having severe PAOD with Chronic Critical Limb Ischaemia, being at least 18 years old, giving written informed consent, and having a life expectancy of at least six months. There are also exclusion criteria listed, such as recent episodes of TIA, CVA, MI, or unstable angina, certain ophthalmologic conditions, clinically significant diseases that may put the patient at risk or influence the study results, abnormal ECG results, history of malignant disease, certain laboratory abnormalities, concurrent infectious diseases, severe renal insufficiency, and various other factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are colorectal cancer, colorectal carcinoma, colorectal tumors, and neoplasms of the colorectal region. The corresponding ICDCodes for these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31.\n\nThe drugs being used in the trial are rad001, cetuximab, and irinotecan. \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria include being between the ages of 18 and 65, having metastatic colorectal cancer confirmed by histological or cytological specimen, having progressed despite prior therapy with FOLFOX plus bevacizumab or XELOX plus bevacizumab, having at least one measurable lesion, and having a WHO performance status of 0 or 1. Exclusion criteria include having Gilbert's syndrome or any other syndrome associated with deficient glucoronidation of bilirubin, being homozygous for the UGT1A1*28 allele, having received previous irinotecan-based therapy, and having prior treatment with an mTOR inhibitor.\n\nIt is important to note that there may be additional protocol-defined inclusion/exclusion criteria that apply to this trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on treating advanced cancer. The trial is investigating a drug called enmd-2076. The eligibility criteria for participants are listed, including having histologic proof of advanced cancer that has progressed after treatment and having no standard therapy that is curative or provides clinical benefit. Other criteria include age, liver and kidney function, blood counts, performance status, and the ability to understand and comply with the study requirements. The sample also includes exclusion criteria, such as pregnancy or nursing, recent radiotherapy or chemotherapy, participation in other clinical trials, and various medical conditions that could interfere with the administration of the drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"acute lymphoblastic leukemia\" and its corresponding ICDCodes are \"C91.01\", \"C91.02\", and \"C91.00\". The drugs being used in the trial are \"bortezomib\", \"dexamethasone\", \"peg-asparaginase\", \"doxorubicin\", \"cytarabine\", \"methotrexate\", \"vincristine\", and \"triple it therapy\". The eligibility criteria for this trial include age restrictions, specific diagnosis requirements, performance level criteria, prior therapy considerations, reproductive function requirements, exclusion criteria related to drug allergies, renal and liver/pancreatic function, cardiac function, Down Syndrome, infection, neuropathy, use of other investigational agents or anti-cancer therapies, and compliance with safety monitoring requirements.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on patients with mucositis and head and neck cancer. The diseases are identified by their corresponding ICD-10 codes. The drugs being studied in the trial are placebo, palifermin, and cisplatin. \n\nThe eligibility criteria for the trial include having a newly diagnosed histologically confirmed squamous cell carcinoma in the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx. The patient should have undergone surgical resection and be scheduled to receive adjuvant concurrent chemoradiation treatment within 12 weeks of surgery. High-risk subjects are defined by specific criteria such as R1 resection margins, T3 or T4 tumor stage, 3 or more positive lymph node metastases, or <3 lymph node metastases with extracapsular extension of the disease. The radiation treatment field should receive a planned dose of at least 50Gy to areas of the oral cavity/oropharynx mucosa that can be visualized.\n\nExclusion criteria for the trial include tumors of the lips, paranasal sinuses, salivary glands, or unknown primary tumors, metastatic disease (M1) or Stage IV C, presence or history of any other primary malignancy, history of pancreatitis, prior radiotherapy or chemotherapy to the site of disease, and participation in other investigational procedures or clinical trials within the last 30 days.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and involves the study of diseases related to pain and healthy individuals. The diseases are represented by a list of names, and each disease has associated ICD-10 codes. The drugs being tested in the trial are listed, including a drug called \"bi 660848\" and a placebo. \n\nThe eligibility criteria for participants in the trial are also provided. The inclusion criteria specify that participants must be healthy males between the ages of 21 and 50, with a BMI between 18.5 and 30 kg/m2. They must also provide written informed consent and have no clinically relevant concomitant diseases. \n\nOn the other hand, the exclusion criteria outline various conditions that would disqualify individuals from participating in the trial. These include any abnormal findings in medical examinations, presence of clinically relevant concomitant diseases, and various disorders affecting different bodily systems. Other factors such as history of certain medical conditions, drug intake, participation in other trials, smoking, alcohol or drug abuse, recent blood donation, excessive physical activities, and abnormal laboratory values are also considered as exclusion criteria. Additionally, participants must be able to comply with the dietary regimen of the study center.\n\nOverall, this sample provides a snapshot of the phase 1 clinical trial, including the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 design. The trial focuses on bladder cancer and includes patients with a diagnosis of transitional cell carcinoma (TCC) of the urinary bladder that has recurred after standard intravesical therapy. The inclusion criteria specify that patients must have superficial recurrent bladder cancer (stage Ta, T1, Tis) and exclude those with muscle invasion (T2). High-grade histology is required for patients with stage Ta. All visible disease must be fully resected, and pathologic stage confirmation is necessary. Patients must have experienced disease recurrence after receiving standard intravesical therapy such as BCG, mitomycin, interferon, or a combination of these treatments.\n\nOther inclusion criteria include being over 18 years old, able to read, understand, and sign informed consent, having an ECOG performance status of 0 or 1, having peripheral neuropathy below grade 1, and meeting certain hematologic and hepatic requirements. Hematologic requirements include an absolute neutrophil count > 1,500/mm3, hemoglobin > 9.0 g/dl, and platelet count > 100,000/mm3. Hepatic requirements include total bilirubin within normal limits, adequate renal function with serum creatinine \u2264 2.0 mg/dL, and specific limits for AST, ALT, and alkaline phosphatase. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 3 months after participation ends. Other exclusion criteria include prior systemic docetaxel or paclitaxel therapy, any other malignancy diagnosed within 2 years (except certain types), concurrent treatment with any chemotherapeutic agent, pregnancy or lactation, history of vesicoureteral reflux or indwelling urinary stent, recent participation in another research protocol involving an investigational agent, and history of neuropathy of any cause.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on pancreatic cancer.\n- ICD Codes: The ICD-10 code for pancreatic cancer is C25.3.\n- Drugs: The drugs being studied in the trial are oxaliplatin, 5fu, and folfox 6.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements such as having a confirmed diagnosis of unresectable pancreatic adenocarcinoma, not having received prior chemotherapy or abdominal radiation therapy, having a certain performance status, and meeting various health and age requirements. The criteria also include exclusions, such as having an active infection, metastatic disease, inadequate organ function, or being pregnant.\n\nOverall, this sample record provides information about a clinical trial focused on pancreatic cancer, including the phase, specific disease, drugs being studied, and eligibility criteria for participants.",
    "The sample from the table is for a Phase 1 clinical trial. The disease being studied is acute coronary syndrome, which is identified by the ICD-10 code I24.0. The drugs being tested in the trial are losmapimod, moxifloxacin, losmapimod matched placebo, and moxifloxacin placebo. \n\nThe eligibility criteria for participants in the trial include being healthy, as determined by a medical evaluation, and being between 18 and 65 years old. Female participants must meet certain criteria related to their reproductive potential and agree to use contraception during the study. Participants must also meet specific criteria related to body weight, body mass index, and liver function. \n\nThere are also exclusion criteria, which include having certain cardiac conduction abnormalities, having any clinically relevant abnormalities identified during screening, and having a personal or family history of certain cardiac conditions. Other exclusion criteria include hypersensitivity to the drugs being tested, certain medical conditions, positive test results for hepatitis B or C, and positive drug/alcohol screens. \n\nParticipants must not have participated in another clinical trial within a certain time period, and they must be able to refrain from using certain medications and substances during the study. Other exclusion criteria include restrictions on blood donation, pregnancy or lactation, unwillingness or inability to follow the study procedures, and mental or legal incapacitation.",
    "The sample from the table is a clinical trial that is in phase 1/phase 2. The trial is focused on squamous cell cancer. The ICD-10 codes associated with this disease are C96.20, C96.29, and D47.09. The trial involves several drugs, including cilengitide (2000 mg once weekly and twice weekly), cetuximab, 5-fluorouracil (5-fu), and cisplatin. The eligibility criteria for participants include having a confirmed diagnosis of SCCHN, at least one measurable lesion, and a Karnofsky performance status (KPS) of greater than or equal to 70 or an eastern cooperative oncology group performance status (ECOG PS) of 0-1 at trial entry. There are also exclusion criteria, such as prior systemic chemotherapy within the last 6 months, recent surgery or irradiation, presence of nasopharyngeal carcinoma, documented or symptomatic brain or leptomeningeal metastasis, and previous treatment with epidermal growth factor receptor (EGFR) targeting therapy or signal transduction inhibitors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"leukemia, myelocytic, acute myelodysplastic syndromes\" and \"myelodysplastic syndromes\". The corresponding ICDCodes for these diseases are \"D46.9\", \"D46.C\", and \"D46.Z\". The drugs being used in the trial are \"vorinostat\" and \"decitabine\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being at least 18 years old with refractory/relapsed AML, being older than 60 years old and not a candidate for standard chemotherapy if untreated AML, being at least 4 weeks from prior treatment and having recovered from all prior treatment side effects, having no known liver or kidney problems, being able to receive transfusions of blood clotting cells (platelets), being able to swallow capsules, and being willing to practice birth control during the study for both male and female patients. \n\nExclusion criteria include having received prior treatment with valproic acid, decitabine, or azacitidine, being less than 18 years of age or below 60 years of age if untreated AML, being a pregnant or breastfeeding woman, having an active infection that requires antibiotics, having uncontrolled illnesses such as heart problems, inflammation of the pancreas, or mental/social conditions that may interfere with following study procedures, having a known HIV infection or HIV-related malignancy, having a history of hepatitis B or C infection, currently having another active cancer other than certain types of skin cancer, and being heterosexual, able to have a child, and unwilling to practice birth control during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms.\" The ICDCodes associated with this disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs being used in this trial are 'bay86-9766'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a Japanese patient who is at least 18 years old, having advanced or refractory solid tumors that cannot be treated with standard therapy, having histological or cytological documentation of non-hematologic malignant solid tumors (excluding primary brain or spinal tumors), having at least one measurable lesion or evaluable disease, having an Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1, and having a life expectancy of at least 12 weeks.\n\nExclusion criteria include recent use of any anti-cancer therapy within 4 weeks of the first dose of study medication, uncontrolled hypertension, known HIV infection or chronic active hepatitis B or C, inadequate bone marrow, liver, or renal function, inability to swallow oral medications, and concomitant treatment with specific cytochrome P450 isoenzymes inhibitors/inducers.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on colorectal cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in the trial are zd6474, cetuximab, and irinotecan. The eligibility criteria for participants are listed, including requirements such as having histologically or cytologically documented locally advanced or metastatic colorectal cancer, having received 1-2 prior therapies for metastatic colorectal cancer, being K-ras wildtype, having measurable disease according to RECIST criteria, being 18 years of age or older, having an ECOG Performance Status of 0-2, and meeting various other health and medical criteria. There are also exclusion criteria listed, such as having a history of prior malignancy within the past 3 years (with some exceptions), having a known hypersensitivity to any of the drugs, being pregnant or lactating, having certain medical conditions or diseases, and having certain cardiac conditions or abnormalities.",
    "The sample is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on three types of diseases - melanoma, colonic neoplasms, and breast neoplasms.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial is testing a drug called \"pd-0325901\".\n- Criteria: The eligibility criteria for participants are listed, including age, tumor accessibility for biopsy, prior treatment history, adequate organ function, hemoglobin levels, reproductive potential, ECOG status, ability to swallow medication, ability to follow instructions, and written informed consent. The exclusion criteria are also mentioned, such as no parathyroid disorder, no recent radiation or other therapies, no serious infections or life-threatening illnesses, no history of other cancers (except nonmelanoma skin cancer or carcinoma in situ of the cervix), and no untreated brain metastases.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being studied is sorafenib. The eligibility criteria for participants include being previously untreated or systemically treated poor prognosis NSCLC patients, having evaluable radiographic evidence of the primary tumor and/or regional lymphatic metastases, being 18 years or older, having an ECOG Performance Status of 0-2, and meeting certain requirements for bone marrow, liver, and renal function. Other criteria include not having received prior radiation to the thorax, having distant metastasis, having a negative pregnancy test for women of childbearing potential, and agreeing to use contraception during the study. Participants must also have the ability to understand and sign a written informed consent. Exclusion criteria include having certain cardiac diseases, hemorrhagic brain metastasis, cardiac ventricular arrhythmias requiring treatment, uncontrolled hypertension, HIV infection or chronic Hepatitis B or C, active serious infections, recent thrombolic or embolic events, pulmonary hemorrhage/bleeding events, non-healing wounds or fractures, bleeding diathesis or coagulopathy, recent major surgery or traumatic injury, current use of St. John's Wort or rifampin, known or suspected allergy to sorafenib, malabsorption problems, and having squamous cell carcinoma.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is arthritis, rheumatoid. The ICDCodes associated with this disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs being tested in this trial are cp-690,550 or placebo, and placebo alone. The eligibility criteria for this trial include meeting the American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis, having active disease at screening and on the first day of the trial, and having an inadequate response to at least one disease-modifying antirheumatic drug (DMARD). There are also exclusion criteria, such as being pregnant or lactating, having serious medical conditions that may make treatment with CP-690,550 unsafe, and having a history of asthma, multiple allergies, or severe allergy to certain substances.",
    "The sample from the table is a clinical trial for the treatment of non-small cell lung cancer. The trial is in phase 1/phase 2. The diseases being studied are non-small cell lung cancer. The corresponding ICD-10 codes for the diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in the trial are carboplatin, paclitaxel, and medi-575. \n\nThe eligibility criteria for participants in the trial include having histologically confirmed inoperable Stage IIIB or Stage IV non-small cell lung cancer, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having a life expectancy of at least 3 months, and having suitable organ and hematologic function. Participants must also be suitable candidates for therapy with carboplatin/paclitaxel, have at least 1 measurable lesion, and be willing to allow collection of archived NSCLC tumor samples. \n\nThere are additional criteria for female participants of childbearing potential, including having a negative serum beta-human chorionic gonadotropin (beta-hCG) test and using 2 effective methods of birth control. Male participants must also use 2 effective methods of birth control with a female partner. \n\nExclusion criteria for the trial include concurrent enrollment in another clinical study, concurrent use of chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, previous monoclonal antibody treatment specifically directed against platelet-derived growth factor (PDGF) or PDGF receptors, and previous systemic anticancer therapies for advanced or metastatic disease. Other exclusion criteria include certain medical conditions, history of certain illnesses or infections, use of immunosuppressive medication, history of active HIV or hepatitis B or C infection, pregnancy or lactation, and any condition that would prevent effective cooperation or participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied in this trial include preleukemia, myeloproliferative disorders, lymphoma, myeloma, and graft versus host disease. The corresponding ICDCodes for these diseases are D47.1, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00, D89.810, D89.811, D89.813, and D89.812.\n\nThe drugs being used in this trial are fludarabine, melphalan, and campath. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include various types of leukemia (relapsed or refractory acute myelogenous or lymphoid leukemia, acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence, chronic myelogenous leukemia in accelerated phase or blast-crisis, chronic myelogenous leukemia in second or subsequent chronic phase), recurrent or refractory malignant lymphoma or Hodgkin's disease, multiple myeloma at high risk for disease recurrence, chronic lymphocytic leukemia (relapsed or with poor prognostic features), and myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.\n\nThe exclusion criteria include clinical progression and contra-indications for vaccination.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is metastatic breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are ct-p6, herceptin, and paclitaxel. The eligibility criteria for this trial include being a female, having Her 2 over-expression, and having an ECOG score of 0 or 1. The exclusion criteria include not having current clinical or radiographic evidence of CNS metastases, not having a current known infection, and not being a pregnant or nursing mother.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on treating head and neck neoplasms and cancer of the head and neck. The diseases are identified using ICD-10 codes. The drugs being tested in the trial are carboplatin, cetuximab, and rad001. \n\nThe eligibility criteria for the trial include having at least one measurable site of disease that has not been previously irradiated, being diagnosed with squamous cell carcinoma of the head and neck, and having failed to respond to or relapsed from prior chemoradiotherapy. Patients must also have evaluable locoregional and/or metastatic disease that is not suitable for surgical resection or radiotherapy. Other criteria include age 18 or older, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and a life expectancy of at least 4 months. Adequate bone marrow, liver, and renal function are also required.\n\nExclusion criteria for the trial include a history of prior malignancy within the past 5 years (except for certain types of skin cancer and localized prostate cancer), uncontrolled brain or leptomeningeal metastases, and current or recent use of anticancer therapies. Other exclusion criteria include prior treatment with investigational drugs, hypersensitivity to the drugs being tested, and certain medical conditions that could affect participation in the trial.\n\nFemale patients of childbearing potential must have a negative pregnancy test and use effective birth control methods during the study. Informed consent is required from all participants.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease being studied is \"healthy.\" The icd-10 codes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"glpg1205 single ascending doses, oral suspension,\" \"placebo single ascending doses, oral suspension,\" \"glpg1205, multiple ascending doses, oral suspension,\" and \"placebo, multiple ascending doses, oral suspension.\" The eligibility criteria for this trial include being a healthy male between the ages of 18-50 with a BMI between 18-30 kg/m2. The exclusion criteria include any condition that might interfere with the study procedures or tests, drug or alcohol abuse, and smoking.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is pancreatic neoplasms, and its corresponding ICD-10 code is C25.3. The drug being tested is a combination of bay86-9766 and gemcitabine. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must be 18 years of age or older.\n- They must have histologically or cytologically confirmed locally advanced, inoperable, or metastatic pancreatic adenocarcinoma that cannot be treated with curative radiotherapy or surgery.\n- Patients must have at least one measurable lesion according to RECIST, Version 1.1.\n- Any acute toxic effects from previous local treatment must have resolved to Grade 1 or lower according to CTCAE.\n- The patient's Eastern Cooperative Oncology Group performance status (ECOG PS) must be 2 or lower.\n- The patient's cardiac function must be within the normal range as measured by an echocardiogram.\n\nThe exclusion criteria for this trial are as follows:\n- Patients with a known history of or symptomatic metastatic brain or meningeal tumors.\n- Patients with a history of cardiac disease.\n- Patients with active clinically serious infections.\n- Patients with clinically significant peripheral vascular disease.\n- Pregnant or lactating women, or women of childbearing potential who are not using adequate contraception.\n- Patients using strong inhibitors or inducers of CYP3A4.\n- Patients who have received prior systemic therapy for metastatic or locally advanced, unresectable pancreatic cancer, or any other malignancy.\n- Patients who have received gemcitabine or 5-fluorouracil (5-FU) concurrently with radiation therapy in an adjuvant setting within 6 months prior to the start of the study treatment.\n- Patients who have experienced thrombotic or embolic events within 6 months prior to the start of the study treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are lung cancer, pancreatic cancer, and esophageal cancer. The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2 for lung cancer, C25.3 for pancreatic cancer, and K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10 for esophageal cancer.\n\nThe drugs being used in the trial are amg 706, gemcitabine, and cisplatin. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The subject must be competent to comprehend, sign, and date an Institutional Review Board (IRB) approved informed consent form.\n- The subject must have advanced cancer in which the gemcitabine and cisplatin chemotherapy regimen is clinically indicated.\n- The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n- The subject must have adequate hematological, renal, and hepatic function.\n- The subject must have a life expectancy of greater than or equal to 3 months as documented by the investigator.\n\nExclusion Criteria:\n- The subject must not have received more than 1 prior chemotherapy regimen.\n- The subject must not have a history of venous thrombosis.\n- The subject must not have had a myocardial infarction, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, or unstable angina within 1 year before study enrollment.\n- The subject must not have a history of interstitial pneumonitis or pulmonary fibrosis, or evidence of interstitial pneumonitis or pulmonary fibrosis on screening chest computed tomograph (CT) scan.\n- The subject must not have an average systolic blood pressure of greater than 145 mm Hg or average diastolic blood pressure of greater than 85 mm Hg.\n- The subject must not have received radiotherapy within 28 days of study enrollment or within 14 days of study enrollment for peripheral lesions.\n- The subject must not have received prior AMG 706, panitumumab, or another anti-EGFr monoclonal antibody (mAb) (e.g., cetuximab [Erbitux\u00ae] or EMD 72000).\n- The subject must not have received systemic chemotherapy within 28 days before study enrollment.\n- The subject must not have undergone major surgery within 28 days or minor surgery within 14 days of study enrollment.\n- The subject must not have central nervous system metastases, unless they have been treated and are clinically stable for at least 30 days before study enrollment.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 1 and focuses on the treatment of inflammation and psoriasis. The ICD-10 codes associated with these diseases are provided. The trial involves the use of the drugs \"anti-il-20\" and \"placebo\". The eligibility criteria for participants are also listed, including requirements such as having moderate to severe chronic plaque psoriasis, a certain affected body surface area, and a physician's global assessment score. There are also exclusion criteria, such as not being able to have concomitant anti-psoriatic treatment and having certain medical conditions or a history of malignancy.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is acute myeloid leukemia (AML). The ICD-10 codes associated with AML are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drug being tested is rad001 (everolimus). The eligibility criteria for the trial include untreated AML patients over the age of 60 or relapsed/refractory AML patients over the age of 18 who have received up to 2 previous lines of intensive chemotherapy. There are additional criteria such as no prior failure with certain medications, provision of informed consent, specific performance status, normal electrolyte levels, adequate hepatic and renal function, absence of uncontrolled active infection, and cessation of hydroxyurea prior to the study therapy. The exclusion criteria include serious medical or psychiatric conditions that may interfere with participation, history of non-compliance to medication, evidence of CNS leukemia, uncontrolled viral infections, currently active gastrointestinal disease or other conditions that prevent oral medication, and other severe or uncontrolled medical conditions. Male participants with female partners of childbearing potential must agree to use effective contraception methods throughout the study and for 6 months after the last dose.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"friedreich's ataxia\". The corresponding ICD-10 code for this disease is \"G11.11\". The drugs being studied in the trial are \"placebo\" and \"deferiprone\", with multiple instances of each. The eligibility criteria for participants in the trial are listed, including requirements related to diagnosis, age, exposure to certain medications, neurological testing, contraception, and informed consent. There are also exclusion criteria listed, such as iron deficiency, certain physical and laboratory abnormalities, previous use of deferiprone, and various medical and personal factors.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is dry eye. The ICDCodes associated with this disease are H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, and H35.3121. The drugs being tested in this trial are ebi-005-1 and ebi-005-1 placebo. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The trial is open to healthy adult males and/or females between the ages of 18 and 65 years.\n- Participants must be medically healthy.\n- Best corrected vision should be greater than or equal to 20/40 in each eye.\n- Participants should not have used tobacco/nicotine-containing products for at least 6 months prior to dosing.\n- Participants should be able to tolerate topical administration to the eye.\n- Participants must have signed and dated an Institutional Review Board (IRB) approved informed consent form (ICF) before any protocol-specific screening procedures.\n\nExclusion Criteria:\n- Participants with a history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease, or any other clinically significant disease not deemed acceptable by the Principal Investigator (PI) are not eligible.\n- Participants with a history of any primary malignancy, except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ, or other malignancies that have been curatively treated and show no evidence of disease for at least 5 years are not eligible.\n- Participants with active seasonal allergies, including ocular allergies, are not eligible.\n- Participants with abnormalities found during an ophthalmological examination, such as corneal abnormalities, ocular inflammation, glaucoma, optic neuropathy, or a history of laser refractive surgery, corneal transplantation, dry eyes, or radiotherapy to the eyes are not eligible.\n- Participants who currently use contact lenses or have used them within the past year are not eligible.\n- Participants with positive urine drug/alcohol or cotinine testing are not eligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is non-Hodgkin's lymphoma. The ICDCodes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being used in the trial is bendamustine hydrochloride. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must have histologically or cytologically confirmed indolent B cell non-Hodgkin's lymphoma.\n- Patients should not have received treatment (chemotherapy, antibody therapy, and radiation/radiotherapy) for more than 4 weeks following prior therapy and should show no effect from the prior therapy.\n- Patients must be aged between 20 and less than 75 years.\n- Patients must agree to in-patient treatment during the first course of therapy.\n- Patients must have provided written consent to participate in the study.\n\nThe exclusion criteria for this trial are as follows:\n- Patients with apparent infections.\n- Patients with serious complications such as hepatic failure or renal failure.\n- Patients with a complication or history of serious heart failure (e.g., cardiac infarction, ischemic heart disease).\n- Patients with serious digestive symptoms like nausea, vomiting, or diarrhea.\n- Patients who are known to be positive for HBV, HCV, or HIC.\n- Patients who have received other investigational drugs within 3 months before registration in the study.\n- Patients who have undergone allogenic transplant.\n- Women who are pregnant, of childbearing potential, or lactating.\n- Patients who do not agree to contraception.\n- Otherwise, patients who are deemed unsuitable for inclusion in the study by the investigator.",
    "The sample is a record from a table that contains information about clinical trials. It is for a trial that is in both phase 1 and phase 2. The trial is focused on lung cancer, specifically Stage IIIb or Stage IV non-small cell lung cancer (NSCLC) with malignant pleural or pericardial effusion. The trial requires patients to have a confirmed diagnosis and measurable disease according to RECIST criteria. \n\nThe sample also includes exclusion criteria, which are conditions that would disqualify a patient from participating in the trial. These include recent treatment with any approved or investigational product for NSCLC, inadequate hematologic, renal, or hepatic function, and previous treatment with specific Hsp90 inhibitors.\n\nThe sample also provides additional information such as the ICD-10 codes associated with the lung cancer diagnosis and the drug being tested in the trial, which is called IPI-504.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is Acute Myeloid Leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drug being tested is tki258. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Confirmed diagnosis of Acute Myeloid Leukemia\n- Eighteen years of age or older\n- Life expectancy of at least 2 months\n\nExclusion Criteria:\n- Intracranial disease or epidural disease\n- Clinically significant cardiac disease\n- Diabetes mellitus uncontrolled with medication\n- Pregnant or breastfeeding women\n- Dementia or altered mental status\n- Known pre-existing clinically significant or uncontrolled disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands\n- Previous pericarditis\n- Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea, diarrhea, vomiting",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are breast cancer and neoplasm metastasis. The ICDCodes associated with these diseases are provided as well. The drugs being investigated in this trial are trastuzumab and rad001. The eligibility criteria for participants in this trial include having a history of biopsy-proven HER-2-overexpressing breast cancer with radiographic evidence of metastatic disease, trastuzumab resistance, specific performance status, certain blood counts and levels, age requirement, not being pregnant, signing an informed consent document, having measurable disease, not receiving any other investigational agents, and having a left ventricular ejection fraction of 50% or higher. The exclusion criteria include uncontrolled intercurrent illness, prior treatment with investigational drugs, chronic treatment with systemic steroids or immunosuppressive agents, uncontrolled brain or leptomeningeal metastases, other malignancies within the past 3 years (except for specific cases), a known history of HIV seropositivity, gastrointestinal impairments or diseases, bleeding diathesis or oral anti-vitamin K medication, prior treatment with an mTor inhibitor, history of noncompliance to medical regimens, unwillingness or inability to comply with the protocol, receiving any other investigational agents, and exhibiting confusion, disorientation, or a history of major psychiatric illness that may impair understanding of the informed consent.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase I, phase II, or phase III. The diseases being studied are \"advanced metastatic gastric cancer\" and \"recurrent gastric cancer\". The corresponding ICD-10 codes for these diseases are \"G47.13\", \"J01.41\", \"K11.22\", \"K12.0\", \"N96\", \"F33.8\", and \"G03.2\". The drug being tested is \"paclitaxel\". The eligibility criteria for the trial include having a diagnosis of advanced solid cancer, having advanced/metastatic/recurred gastric cancer, having an ECOG performance status of \u2264 2, and meeting certain requirements for bone marrow, kidney, liver function, and heart and lung function. There are also exclusion criteria, such as having blood tumor, uncontrolled infectious disease, neurologic disorders, metastasis to CNS or ileus, or having received or planning to receive a bone marrow transplant. Additionally, patients with a history of certain heart conditions or recent myocardial infarction are excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on the treatment of renal cell carcinoma. The trial includes patients with metastatic or unresectable renal cell carcinoma that contains predominantly clear cell histology. The eligibility criteria include having measurable disease according to RECIST criteria, being at least 21 years old, having an ECOG performance status of 0-1, and meeting certain requirements for bone marrow, hepatic, and renal function. The patients should also be able to swallow oral medications, have resolved any pre-existing toxicity from prior therapy, and have signed an informed consent document. They should be willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other study procedures. The exclusion criteria include certain types of renal cell carcinoma, prior treatment with specific drugs, prior surgery or radiation therapy within 4 weeks of starting the study treatment, history of brain metastasis or other brain diseases, certain cardiovascular conditions, uncontrolled hypertension, HIV or AIDS-related illness, currently active second malignancy, current treatment on another clinical trial, pregnancy or breastfeeding, chronic treatment with systemic steroids or immunosuppressive agents, and other pre-existing medical or psychiatric conditions that could interfere with subject safety or obtaining informed consent.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 1. The diseases being studied are breast cancer and nausea and vomiting. The corresponding ICD-10 codes for these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60 for breast cancer, and R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8 for nausea and vomiting. The drugs being used in the trial are aprepitant and cyclophosphamide. The eligibility criteria for the trial include a diagnosis of breast cancer, planning to receive cyclophosphamide infusion, certain patient characteristics such as life expectancy, ANC, platelet count, hemoglobin, serum creatinine, AST/ALT levels, and no pregnancy or nursing. The prior concurrent therapy includes no concurrent medications that are CYP3A4 substrates, inhibitors, and/or inducers, except for dexamethasone as part of the standard antiemetic regimen.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the trial is in phase 1/phase 2. The diseases being studied include cardiovascular diseases, dilated cardiomyopathy, heart diseases, and congestive heart failure. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being investigated in this trial are allopurinol and dobutamine. \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include a diagnosis of idiopathic cardiomyopathy with an ejection fraction of less than or equal to 35%, New York Heart Association (NYHA) Class I - II heart failure, stable heart failure medication for at least 1 month, and the ability to lie flat for 45 minutes. \n\nExclusion criteria include a history of poorly controlled hypertension with concentric left ventricular hypertrophy, biopsy-proven myocarditis, peripartum cardiomyopathy, recent allopurinol therapy, allopurinol allergy, contraindications to allopurinol due to concomitant therapy with certain medications, acute gout, low creatinine clearance, high total bilirubin, elevated AST or ALT levels, low white blood cell count, low platelet count, low hemoglobin, use of intravenous inotropes, history of untreated symptomatic ventricular tachycardia, history of sustained ventricular tachycardia induced by dobutamine, contraindications to MRI due to certain medical devices or conditions, and recent hospitalization.\n\nThis sample provides a snapshot of the information stored in the table, giving details about the trial phase, diseases, drugs, and the specific eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are neoplasm, cancer, and tumors. The corresponding ICDCodes for these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, and C49.A3. The drug being tested is tki258. The eligibility criteria for this trial include patients with an advanced solid tumor that has progressed despite standard therapy or for which no standard therapy exists. Patients must have a World Health Organization (WHO) performance status of 2 or lower and meet specific laboratory values as specified in the protocol. Exclusion criteria include patients with brain cancer, those with severe and/or uncontrolled medical conditions that could affect participation, those who have not recovered from previous anti-cancer therapies, and female patients who are pregnant, breastfeeding, or not willing to use effective birth control. Additional inclusion/exclusion criteria may also apply as defined by the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1 and is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drug being tested in this trial is a combination of cp-675,206 and gemcitabine. The eligibility criteria for this trial include having metastatic pancreatic cancer, adequate bone marrow, liver, and kidney function, an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, being chemotherapy naive, and having inoperable pancreatic cancer. The exclusion criteria state that patients should not have received prior systemic therapy for pancreatic cancer, should not have previously received anti-CTLA4 therapy, and should not have a history of chronic inflammatory or autoimmune disease.",
    "The sample provided is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 1. The disease being studied is hypercholesterolemia. The ICD-10 codes associated with this disease are 'E78.01', 'E78.00', and 'Z83.42'. The drugs being tested in this trial are alirocumab, ezetimibe, ezetimibe placebo, and fenofibrate.\n\nThe eligibility criteria for this trial are as follows:\n- The trial is open to both healthy male and female subjects.\n- The age range for participants is 18 to 65 years old.\n- Participants must have LDL-C (low-density lipoprotein cholesterol) levels higher than 130 mg/dL.\n- Participants should not be currently receiving any lipid lowering therapy.\n\nThere are also exclusion criteria, which include:\n- Healthy subjects with a history or presence of clinically relevant illness are not eligible.\n- Subjects who are currently taking statins, ezetimibe, or fenofibrate are excluded from the trial.\n\nIt is important to note that the provided information may not include all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on prostate cancer. The ICD-10 codes associated with the disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being studied in the trial are docetaxel and gemcitabine. The sample also includes the eligibility criteria for the trial, including requirements such as histologically verified adenocarcinoma of the prostate, hormone refractory prostate cancer, stage IV disease, PSA levels, castrate level of testosterone, satisfactory hepatic and renal function, ECOG performance status, life expectancy, ability to adhere to protocol requirements, and written informed consent. The exclusion criteria are also listed, which include previous treatments, serious medical conditions, symptomatic cerebral metastases, and ECOG performance status greater than 2.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 1 and focuses on the diseases of inflammation and rheumatoid arthritis. The associated ICD-10 codes for these diseases are also provided. The trial involves the use of the drugs \"anti-il-20\" and \"placebo\". The eligibility criteria for participants are listed, including requirements such as informed consent, a diagnosis of rheumatoid arthritis, a certain level of disease activity, and prior treatment with methotrexate. There are also exclusion criteria, such as specific BMI ranges, other autoimmune diseases, infectious diseases, and certain medical conditions. The record specifies that breastfeeding women are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is migraine. The ICDCodes associated with this disease are G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, and G43.419. The drug being used in the trial is sumatriptan. \n\nThe eligibility criteria for this trial include being between the ages of 18 and 55, being healthy with no significant medical abnormalities, having a BMI between 18 and 32, and a body weight of at least 50 kg. For females of childbearing potential, they must either be sexually inactive for 14 days prior to the first dose and throughout the study or use acceptable birth control methods. \n\nOther criteria include having certain sterilization procedures for females of non-childbearing potential, having a negative pregnancy test, abstaining from alcohol and limiting caffeine intake, avoiding certain foods and beverages, having verified airflow through both nostrils, being able to use a specific device correctly, understanding English, and agreeing to adhere to the study schedule and requirements.\n\nExclusion criteria include having significant medical conditions, chronic diseases requiring prescription medications, a history of migraines, allergies to any drug compounds, recent surgeries or hospitalizations, abnormal screening ECG results, history of substance abuse, abnormal laboratory values, positive serology tests, recent blood donation, use of certain medications, participation in other investigational studies, recent febrile illness, breastfeeding or planning to become pregnant, restrictions on physical activity and sunbathing, abnormalities regarding the sense of smell and taste, respiratory diseases or nasal obstructions, chronic nosebleeds, current nasopharyngeal illness, known velum insufficiency, and any other condition that may complicate or compromise the study or the well-being of the subject. Employees of the investigator/study center or the sponsor are also excluded from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 1.\n- Diseases: The trial is focused on advanced solid tumors.\n- ICD Codes: The ICD-10 codes associated with the diseases are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\".\n- Drugs: The drugs being tested in the trial are \"arry-520, ksp(eg5) inhibitor; intravenous\" and \"filgrastim, granulocyte-colony stimulating factor (g-csf); subcutaneous\".\n- Criteria: The eligibility criteria for the trial are listed under \"Key Inclusion Criteria\" and \"Key Exclusion Criteria\". The inclusion criteria include histological or cytological evidence of malignancy, advanced solid tumors that have recurred or progressed following standard therapy, Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and adequate hematology counts and serum chemistry values. The exclusion criteria include recent treatment with investigational products or anti-neoplastic therapy, major surgery, radiotherapy (except if local to <5% of the bone marrow), known positive serology for HIV, hepatitis C, and/or active hepatitis B, and additional criteria that are not specified in the sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied include estrogen receptor negative, her2/neu negative, male breast carcinoma, progesterone receptor negative, recurrent breast carcinoma, stage iv breast cancer ajcc v6 and v7, and triple-negative breast carcinoma. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in this trial are dinaciclib and epirubicin hydrochloride. The eligibility criteria for participants in this trial are listed, including requirements such as confirmed diagnosis of estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) negative breast cancer, Eastern Cooperative Oncology Group (ECOG) performance status, prior chemotherapy regimens, life expectancy, blood counts, liver function, kidney function, prior malignancy history, measurable or evaluable disease, prior therapy with dinaciclib, concurrent use of hormonal therapy or radiation therapy, completion of prior chemotherapy, contraception, and ability to provide informed consent.\n\nExclusion criteria are also listed, including recent chemotherapy or radiotherapy, use of other investigational agents, untreated brain metastases, history of allergic reactions to similar compounds, use of medications that affect cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), uncontrolled intercurrent illness, pregnancy or breastfeeding, HIV-positive patients on antiretroviral therapy, prior organ allograft or immunosuppressive therapy, cumulative dose of doxorubicin or epirubicin, history of heart failure or cardiovascular events, low left ventricular ejection fraction (LVEF), and history of PR prolongation or atrioventricular (AV) block.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 1 and is focused on the disease \"type 2 diabetes mellitus\". The ICD-10 codes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drug being studied in this trial is \"dapagliflozin\". \n\nThe record also includes eligibility criteria for participants. The inclusion criteria state that participants must already be on voglibose treatment with a steady dosage for at least 8 weeks, provide informed consent, and be diagnosed with type 2 diabetes. The exclusion criteria state that participants should not have clinically relevant medical history or concurrent diseases such as cardiovascular disease, renal disease, retinopathy, hepatic disease, and hematological disease. Additionally, the investigator(s) may judge that a subject should not participate based on screening tests or medical history.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"sjogren's syndrome,\" and its corresponding ICDCodes are listed as [\"M35.00\", \"M35.01\", \"M35.03\", \"M35.0B\", \"M35.02\", \"M35.05\", \"M35.08\"]. The drug being used in the trial is \"rituximab (anti-cd20)\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as stimulated whole saliva secretion of at least 0.15 ml/min, being male or female over 18 years old, having primary SS according to the revised European - U.S. criteria, positive autoantibodies (IgM-Rf > 10 and SS-A and/or SS-B), having a parotid gland biopsy with characteristic features of SS performed within the last 12 months, using a reliable method of contraception during the study, and providing written informed consent.\n\nExclusion criteria include factors such as the presence of any other connective tissue disease, previous treatment with anti-TNF or other monoclonal antibodies, recent use of certain medications (prednisone, hydroxychloroquine, MTX, cyclophosphamide, cyclosporin, azathioprine, and other DMARDS), abnormal laboratory values (serum creatine, ASAT or ALAT, Hb, neutrophil granulocytes, and platelet count), positive pregnancy test or breastfeeding, history of alcohol or drug abuse, serious infections, underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases, immune deficiency, or history of any malignancy (except completely resected basal cell carcinoma of the skin).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is an unspecified adult solid tumor, protocol specific. The ICDCodes associated with this disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drug mentioned is enzastaurin hydrochloride. The eligibility criteria for this trial include various disease characteristics and patient characteristics. The disease characteristics include a histologic or cytologic diagnosis of locally advanced or metastatic cancer with no preferable therapy available, measurable or nonmeasurable disease, and no CNS metastases or primary CNS tumor. The patient characteristics include an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, specific blood counts and levels within normal ranges, no proteinuria, no second primary malignancy, no concurrent serious systemic disorder, no known hypersensitivity to the drugs, no prior bevacizumab-related toxicity, no clinically significant cardiac disease, no bleeding diathesis or coagulopathy, no nonhealing cutaneous wound or gastrointestinal ulcer, no history of certain conditions or risk factors, able to comply with study procedures, able to swallow tablets, exhibits compliance and geographic proximity for follow-up, not pregnant or nursing, negative pregnancy test, and fertile patients must use effective contraception during and after the study treatment. The prior concurrent therapy includes specific time intervals since prior treatments, no prior participation in this or any other study involving enzastaurin hydrochloride, and no concurrent use of certain medications or therapies.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is ovarian carcinoma. The ICDCodes associated with the disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug mentioned is fondaparinux. The eligibility criteria for this sample include age restrictions (18 to 75 years), biopsy-proven ovarian, tubal, or primary peritoneal epithelial adenocarcinomas, specific performance status (ECOG 0 or 1), patients at high risk of clinical relapse, and patients in remission with specific criteria. The sample also includes exclusion criteria such as specific performance status (ECOG 2, 3, or 4), patients on warfarin or prior therapeutic anticoagulation, presence of another primary malignancy within 5 years, severe and/or uncontrolled medical diseases, recent major surgery, specific lab abnormalities, and known bleeding disorder.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases included are papillary thyroid cancer, follicular thyroid cancer, huerthle cell thyroid cancer, and renal cell carcinoma. The ICDCodes associated with these diseases are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs mentioned are rosiglitazone and xl184. The eligibility criteria for this trial include having a diagnosis of a metastatic or unresectable solid tumor that is refractory to or progressed following standard therapies, having a measurable lesion on CT or MRI scan, having a BMI between 18 and 33 kg/m2, having a Karnofsky Performance Status of 70 or higher, having adequate organ and marrow function, being able to reside in the clinic for two one-day confinement periods, and refraining from consuming certain foods. The sample also includes exclusion criteria such as restrictions on prior treatments, recent hematemesis or hemoptysis, not recovered from prior therapies, presence of primary brain tumor or brain metastases, abnormal PT/INR or PTT levels, uncontrolled intercurrent illness, bleeding diathesis or coagulopathy, pregnancy or breastfeeding, HIV, Hepatitis B or C, allergy or hypersensitivity to study treatments, history of medical or surgical conditions that may interfere with drug absorption, history of pancreatic injury or pancreatitis, hepatic impairment, use of certain drugs, poor peripheral venous access, receiving warfarin or dialysis.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is non-Hodgkin lymphoma. The ICD-10 codes associated with the disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', and 'S33.140S'. The drugs being tested in the trial are sb-485232 and rituximab. The eligibility criteria for participants include having a confirmed diagnosis of CD20+ B cell NHL, disease progression after standard therapy or no effective standard therapy, prior treatment with rituximab completed at least six months before enrollment, being 18 years or older, having measurable or evaluable disease, predicted life expectancy of at least 12 weeks, ECOG Performance Status of 0 or 1, no recent chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer, and being able to understand and comply with the study requirements. There are also additional criteria related to female participants and contraceptive methods. Exclusion criteria include pregnancy or breastfeeding, significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal, or autoimmune conditions, poor glycemic control in diabetes mellitus, history of HIV or other immunodeficiency disease, positive Hepatitis B surface antigen, prolonged corrected QT interval, history of severe infusion related reaction or tumor lysis syndrome following treatment with rituximab, high circulating malignant cell count, known anaphylaxis or hypersensitivity to murine proteins, acute or severe infections, serious medical or psychiatric disorders, leptomeningeal disease or metastatic brain disease, concurrent use of chemotherapy, immunotherapy, radiotherapy, or investigational therapy, recent use of oral corticosteroids, history of alcohol abuse, history of ventricular arrhythmias, unresolved or unstable serious toxicity from prior investigational drug use, recent use of any investigational drug, and recent blood donation exceeding 500 mL within a 56-day period.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"carcinoma, renal cell,\" and its corresponding ICDCodes are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs involved in the trial are 'pazopanib' and 'lapatinib'. The eligibility criteria for this trial include signed informed consent, a confirmed diagnosis of an advanced solid tumor, the ability to practice acceptable methods of birth control, an ECOG performance status of 0 or 1, adequate bone marrow reserve and hepato-renal function, the ability to swallow and retain oral medication, and a left ventricular ejection fraction within the normal range or above 50% for the combo part. The exclusion criteria include prior treatment with pazopanib and lapatinib for the combo part, clinically significant gastrointestinal abnormalities, severe diseases or conditions other than cancer, poorly controlled hypertension, use of warfarin for therapeutic anticoagulation, use of other anti-angiogenesis agents, and other ErbB inhibitors for the combo part, unresolved and/or unstable toxicities, and being pregnant or lactating.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of chronic lymphocytic leukemia (CLL). The trial is investigating the effectiveness of a combination of drugs including fludarabine, obinutuzumab, bendamustine, and cyclophosphamide. The eligibility criteria for participants include a confirmed diagnosis of CD20-positive B-CLL, Rai Stage III/IV or Binet Stage C disease, or Rai Stage I/II or Binet Stage B disease that requires treatment. Other criteria include adequate baseline bone marrow function, no previous treatment for CLL, Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and a life expectancy of greater than 6 months. Exclusion criteria include recent participation in another clinical trial, transformation of CLL to aggressive B-cell malignancy, certain levels of creatinine clearance, AST or ALT levels above a certain threshold, and other significant concomitant diseases or infections. Pregnant or lactating women, as well as fertile men or women of childbearing potential without adequate contraception, are also excluded. The sample provides detailed inclusion and exclusion criteria for potential participants in the clinical trial.",
    "The sample from the table is for a phase 1 clinical trial for metastatic melanoma. The diseases column lists only one disease, which is metastatic melanoma. The icdcodes column contains a list of icd-10 codes associated with the disease. The drugs column lists two drugs, disulfiram and arsenic trioxide. The criteria column provides the eligibility criteria for the trial, including requirements for measurable disease, imaging tests, previous treatments, performance status, and ECG results. The sample also includes exclusion criteria, such as pregnancy or nursing, severe myocardial disease, psychoses, hypersensitivity to disulfiram, and inability to abstain from alcohol intake during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases listed include prostate cancer, adenocarcinoma of the prostate, recurrent prostate cancer, stage i prostate cancer, stage iii prostate cancer, and stage iv prostate cancer. The ICDCodes associated with these diseases are also provided.\n\nThe drugs mentioned in the sample are sunitinib malate, docetaxel, and prednisone. The eligibility criteria for this trial include having a histological diagnosis of adenocarcinoma of the prostate, being at least 18 years old, having metastatic prostate cancer that is unresponsive or refractory to hormone therapy, and meeting various other medical and health criteria.\n\nThe sample also includes exclusion criteria, such as not having received chemotherapy or other investigational drugs within the past 28 days, not having ongoing problems with bowel obstruction or malabsorptive disorders, and not having severe hypersensitivity reactions to certain drugs.\n\nOverall, this sample provides specific details about the trial phase, diseases, drugs, and eligibility criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"solid tumor or lymphoma,\" and the corresponding ICDCodes are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being studied is \"lenvatinib.\" \n\nThe eligibility criteria for this trial are outlined in the sample. Inclusion criteria include patients with confirmed solid tumor or lymphoma who are resistant/refractory to approved therapies or for whom no appropriate therapies are available. Other criteria include completion of previous treatments, being at least 18 years old, having a Karnofsky performance status of 70% or higher, and providing written informed consent.\n\nExclusion criteria include patients with brain tumors or brain/leptomeningeal metastases, certain abnormal laboratory parameters, uncontrolled infections, significant cardiac impairment or unstable ischemic heart disease, recent treatment with investigational drugs, pregnancy or lactation, certain medical conditions, and other factors that may impair study compliance.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is chronic lymphocytic leukemia. The ICD-10 codes associated with this disease are C91.11, C91.12, and C91.10. The drugs being tested in this trial are rituximab and alemtuzumab. The eligibility criteria for participants include being diagnosed with B-CLL/SLL, having relapsed after a fludarabine-containing regimen, and having measurable disease. Other criteria include age over 18, a WHO performance status of 2 or lower, and a life expectancy of more than 3 months. Exclusion criteria include a history of HIV, active uncontrolled infection, known CNS involvement with CLL, pregnancy or lactation, and recent anti-neoplastic therapy. Prior use of rituximab or alemtuzumab does not exclude patients from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease mentioned in this record is \"Crohn's disease\". The corresponding ICD-10 codes for this disease are \"K50.90\", \"K50.913\", \"K50.914\", \"K50.911\", \"K50.912\", \"K50.918\", and \"K50.919\". The drug mentioned in this record is \"chondroitin sulfate\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n1. The patient must have been diagnosed with colonic or ileocolonic Crohn's disease for at least 3 months.\n2. The patient must have active Crohn's disease, with a Crohn's Disease Activity Index (CDAI) score greater than 200 but less than 320 at the time of entry into the study.\n3. The patient must be above 18 years of age.\n4. Patients receiving oral or topical 5-aminosalicylates must be on a stable dose for four weeks prior to enrollment.\n5. Patients on azathioprine, 6-mercaptopurine, or methotrexate must be on stable doses for 14 weeks prior to enrollment.\n6. Patients on corticosteroids must be on stable doses for 2 weeks prior to enrollment.\n7. Patients receiving corticosteroid enemas must be on a stable dose for 3 weeks prior to enrollment.\n8. Patients on biologic therapy with infliximab, adalimumab, or certolizumab must be on stable therapy for 12 weeks prior to enrollment.\n9. The patient must sign informed consent.\n\nExclusion Criteria:\n1. Patients with only small bowel Crohn's disease, fistulizing Crohn's disease, or gastroduodenal Crohn's disease without colonic involvement.\n2. Patients with known ulcerative colitis.\n3. Patients expected to require surgery within 30 days for complications of Crohn's disease.\n4. Patients with Crohn's disease and an intraabdominal abscess.\n5. Patients requiring continuous antibiotics; antibiotics may be taken up to the point of enrollment into the study.\n6. Patients with severe cardiac, pulmonary, or renal disease.\n7. Patients with a history of malignancy other than resected basal cell carcinoma of the skin.\n8. Patients who have participated in another clinical research study in the past 8 weeks.\n9. Patients who are pregnant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is a tumor. The ICDCodes associated with the disease are \"E88.3\", \"R97.8\", \"C49.A0\", \"C49.A1\", \"C49.A2\", \"C49.A5\", and \"C49.A3\". The drugs being used in the trial are \"belinostat\" and \"5-fluorouracil (5-fu)\". \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically confirmed solid tumors.\n- The patient must have advanced colorectal cancer or other adenocarcinomas.\n- The tumor must have progressed after standard chemotherapy or have no approved treatment yet.\n- The patient must have at least one measurable lesion.\n- The patient's Karnofsky performance score must be greater than or equal to 70%.\n- The patient must have a life expectancy of at least 3 months.\n- The patient must be 18 years or older.\n- The patient must have signed, written Institutional Review Board (IRB)-approved informed consent.\n- The patient must have acceptable liver function, with bilirubin levels within a certain range and AST (SGOT) and ALT (SGPT) levels within a certain range.\n- The patient must have acceptable renal function, with serum creatinine within normal limits or calculated creatinine clearance above a certain threshold.\n- The patient must have acceptable hematologic status, with certain minimum values for absolute neutrophil count, platelet count, and hemoglobin.\n- The patient's urinalysis should not show any clinically significant abnormalities.\n- The patient must have acceptable coagulation status, with prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits or within therapeutic range for patients on anticoagulation therapy.\n- For men and women of child-producing potential, effective contraception must be used.\n- The patient's tumors must be accessible for needle biopsy.\n\nThe exclusion criteria for this trial include:\n- Significant cardiovascular disease.\n- A marked baseline prolongation of QT/QTc interval.\n- Long QT syndrome.\n- Required use of medication on dosing days that may cause torsade de pointes.\n- Infections requiring intravenous (IV) systemic therapy.\n- Pregnant or nursing women.\n- Treatment with chemotherapy or investigational therapy less than 4 weeks (28 days) prior to study entry (6 weeks for nitrosoureas, mitomycin C, or Avastin).\n- Treatment with radiation therapy or surgery either within 2 weeks prior to study entry or not yet recovered if 2-4 weeks prior to study entry.\n- Unwillingness or inability to comply with protocol procedures.\n- Known active uncontrolled infection with HIV, hepatitis B, or hepatitis C.\n- Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.\n- Concurrent use of other investigational agent(s).\n- Serious concurrent medical illness.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are bevacizumab, erlotinib, and pemetrexed. \n\nThe eligibility criteria for this trial include:\n- Patients must have a histologically proven diagnosis of Non-Squamous NSCLC, specifically adenocarcinoma, large cell carcinoma, adeno-squamous carcinoma, and bronchioloalveolar carcinoma (BAC).\n- Patients must be 70 years of age or older.\n- Patients must have either stage IIIB disease with malignant pleural effusion or stage IV disease with measurable disease.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1.\n- Patients must have adequate renal function, hepatic function, and bone marrow function.\n- Patients must meet certain time requirements since prior biopsies or surgeries.\n- Patients must be able to take dexamethasone, folic acid, and vitamin B-12 supplementation.\n- Patients must sign an informed consent form.\n\nThe exclusion criteria for this trial include:\n- Patients with lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel.\n- Patients with hypercalcemia, history of hemoptysis, hematemesis, coagulopathy, thrombosis, or requiring anticoagulation.\n- Patients with recent acute infection or history of palliative radiation therapy within 2 weeks.\n- Patients with high blood pressure, unstable angina, congestive heart failure, myocardial infarction, stroke, peripheral vascular disease, or central nervous system or brain metastases.\n- Patients with recent major surgical procedures, open biopsy, or traumatic injury.\n- Pregnant or lactating women.\n- Patients with certain kidney or abdominal conditions, serious wounds, or inability to comply with study procedures.\n\nThis information provides details about the phase, disease, ICDCodes, drugs, and eligibility criteria for this particular sample in the table.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drugs being used in the trial include busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, and mycophenolate mofetil. The eligibility criteria for this trial include specific disease characteristics, such as a diagnosis of B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma, poor prognostic features, and low probability of successful autografting. Other patient characteristics, such as ECOG performance status, kidney function, liver function, cardiac function, lung function, absence of infections, absence of other concurrent malignant diseases, and absence of impaired organ function, are also considered. Additionally, certain conditions, such as uncontrolled diabetes, uncontrolled hypertension, pregnancy or nursing, HIV infection, hepatitis B or C infection, concurrent alcohol or drug abuse, and dementia or altered mental status, would exclude a patient from participating in the trial. The prior concurrent therapy is not specified in this sample.",
    "The sample from the table represents a clinical trial for prostate cancer. The trial is in phase 1/phase 2, indicating that it is a combination of both phases. The diseases being studied include prostate cancer, prostate neoplasms, and castration-resistant prostate cancer (CRPC). The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe trial focuses on a drug called mdv3100. The eligibility criteria for participants include having histologically or cytologically confirmed adenocarcinoma of the prostate, ongoing androgen deprivation therapy, and progressive disease after prior androgen deprivation therapy. For the expansion cohort, patients must have had no more than two prior chemotherapy regimens, with at least one regimen containing docetaxel. Additionally, measurable lesions by RECIST are required for the expansion cohort.\n\nThere are also exclusion criteria, such as having metastases in the brain, a history of another malignancy within the previous 5 years (except for adenocarcinoma of the prostate), recent use of bicalutamide or radiation therapy, and evidence of serious drug hypersensitivity. These criteria are used to determine the eligibility of participants for the trial.",
    "The sample from the table represents a clinical trial for the treatment of acute myeloid leukemia (AML). The trial is in phase 1/phase 2. The eligibility criteria for the trial include patients with relapsed or refractory AML subtypes (excluding acute promyelocytic leukemia) who have been treated with one to three induction/reinduction AML regimens. The patients should have at least 10% blasts in their bone marrow biopsy or aspirate and an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. They should also meet certain clinical laboratory values for serum creatinine, total bilirubin, and aspartate aminotransferase (AST) or alkaline phosphatase.\n\nThe exclusion criteria for the trial include patients who have undergone allogenic bone marrow transplant/stem cell transplant, have persistent chronic toxicities from prior AML therapy, have acute promyelocytic leukemia, have disseminated intravascular coagulation, have active infections, have active central nervous system involvement by AML, have other active malignancies or malignancies within the last 12 months (except nonmelanoma skin cancer or cervical intraepithelial neoplasia), require hemodialysis or peritoneal dialysis, have a history of myocardial infarction or cerebrovascular accident/transient ischemic attack within the specified time frame, have had a thromboembolic event within 28 days before treatment, have taken investigational products or non-investigational cancer therapies/radiation therapy within the specified time frames, have a known intolerance or allergy to certain substances used in the treatment, have prior exposure to the specific drug being tested, or have any other medical, psychological, or social condition that would contraindicate their participation in the trial.\n\nAdditionally, women who are pregnant or breastfeeding, women of childbearing potential, or male patients with partners of childbearing potential who are unwilling to use approved contraception methods are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 1/phase 2.\n- Diseases: The trial is focused on treating \"b-cell chronic lymphocytic leukemia\" and \"small lymphocytic lymphoma\".\n- ICD Codes: The ICD-10 codes associated with the diseases are \"C91.11\", \"C91.12\", \"C91.10\" for b-cell chronic lymphocytic leukemia and \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\" for small lymphocytic lymphoma.\n- Drugs: The drug being tested in the trial is \"pci-32765\".\n- Criteria: The eligibility criteria for participants in the trial are listed, including age requirements, previous treatment history, performance status, ability to participate in evaluations, and procedures. There are also exclusion criteria, such as prior malignancy, recent therapies, CNS involvement, and certain medical conditions.\n\nOverall, this sample record provides information about a clinical trial in phases 1 and 2, targeting specific diseases, using a particular drug, and outlining the eligibility and exclusion criteria for participants.",
    "The sample from the table represents a clinical trial study with a combination of phase 1 and phase 2. The diseases being studied are breast neoplasms and metastases, neoplasm. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being investigated in the trial include cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, and mesna. \n\nThe eligibility criteria for the trial are listed, including the requirement for patients to have a diagnosis of metastatic infiltrating carcinoma of the breast, with confirmation of at least one site of metastatic disease. Pathologic material must be reviewed by the Pathology Laboratory of the National Cancer Institute before treatment. The tumor must also stain positive for CEA (carcinoembryonic antigen). \n\nPatients may be newly diagnosed with metastatic breast carcinoma or known to have breast carcinoma. If newly diagnosed, they should not have received any chemotherapy for this disease before entering the study. If previously treated, chemotherapy or radiation may have been received as adjuvant treatment, but not in the previous 18 months. Patients on hormonal therapy for stage IV disease are also eligible if they have experienced disease progression on hormonal therapy alone.\n\nOther eligibility criteria include a Karnofsky performance status of greater than or equal to 70%, normal ejection fraction, adequate kidney function, normal liver function, normal blood counts, and normal lung function. Patients must also be able to avoid close contact with certain individuals for a period of time after initial vaccination. Informed consent is required for participation in the trial.\n\nExclusion criteria include age less than 18 years, urgent or emergent clinical situations that do not allow for the necessary delay in initiating concurrent therapy, chronic immunosuppressive therapy, autoimmune diseases, abnormal test results suggestive of an autoimmune disease, active inflammatory bowel disease, significant cardiomyopathy or congestive heart failure, positive tests for HIV or hepatitis B or C, pregnancy or unwillingness to discontinue breastfeeding, lack of effective contraception for patients of childbearing age, brain metastases, active second malignancy (excluding treated skin cancers or carcinoma in-situ), life expectancy of less than 6 months, and other factors that may pose unacceptable medical or psychiatric risks.\n\nThere are also specific exclusion criteria related to the administration of the recombinant vaccinia vaccine, including certain skin conditions, pregnancy, age under 3 years, immunodeficiency or immunosuppression, history of seizures, encephalitis, or multiple sclerosis, and history of allergy or complications with past vaccinia vaccination.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The disease being studied is breast cancer, and the corresponding ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being investigated in the trial is trastuzumab (herceptin\u00ae). The eligibility criteria for participants include being women with Her-2 positive and ER-negative or ER-low breast cancer that has not spread to other parts of the body. Participants must have had a biopsy of their breast cancer but have not yet undergone definitive breast surgery. They should not have a BRCA mutation and should not have received prior treatment for their breast cancer, including chemotherapy, hormonal therapy, or trastuzumab.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on the disease of female infertility. The ICD-10 codes associated with this disease are 'N97.9', 'N97.0', 'N97.1', 'N97.2', 'N97.8', and 'Z31.81'. The drugs being studied in this trial are 'g-csf' and 'saline'. The eligibility criteria for inclusion in the trial are patients who are preparing for in vitro fertilization and embryo transfer with endometrial growth of less than 7 mm, unresponsive to standard treatment. The exclusion criteria include patients with sickle cell disease, renal insufficiency, upper respiratory infection or pneumonia, chronic neutropenia, and known past or present malignancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are lapatinib ditosylate and doxil. \n\nThe eligibility criteria for this trial include the following disease characteristics: histologically confirmed adenocarcinoma of the breast with evidence of metastatic disease, measurable disease, no known brain metastases or leptomeningeal disease, and hormone receptor status not specified. \n\nThe patient characteristics required for participation in the trial include being male or female, having a life expectancy of at least 12 weeks, having an ECOG performance status of 0-1, and meeting certain blood count and liver function requirements. Other criteria include not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, being able to swallow and retain oral medication, and not having a history of allergic reactions to compounds similar to lapatinib. \n\nThere are also criteria related to gastrointestinal health, prior treatments, and concurrent medications. For example, prior trastuzumab (Herceptin) and anthracyclines are allowed, but there are specific dose limitations. The sample also mentions time requirements since prior surgeries, therapies, and the use of certain medications. Concurrent use of certain medications, such as CYP3A4 inhibitors and inducers, gastric pH modifiers, and herbal medications, is not allowed. Additionally, concurrent use of other investigational agents or anticancer therapy is not permitted.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is an unspecified adult solid tumor that is specific to the protocol. The ICDCodes associated with this disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs being used in this trial are pr-104, docetaxel, and gemcitabine hydrochloride. The eligibility criteria for this trial include specific disease characteristics, such as histologically confirmed solid tumor malignancy, and measurable or evaluable disease. It also includes patient characteristics, such as an ECOG performance status of 0-1, certain blood counts, normal bilirubin levels, and normal liver and kidney function. Other criteria include not being pregnant or nursing, using effective contraception, and not having any other significant medical disorders. The sample also mentions prior concurrent therapy restrictions, such as no prior radiotherapy to more than 25% of bone marrow, no prior high-dose chemotherapy, and a limit of three prior chemotherapy regimens. It also specifies the time since prior major surgery and prior investigational or traditional anticancer therapy. Certain medications and treatments are not permitted during the trial, while others, like concurrent systemic steroids and androgen-deprivation therapy, are allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include cancer, neuroendocrine, ovarian cancer, and colon cancer. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are ji-101 and everolimus. The eligibility criteria for participants are listed, including requirements such as age, tumor measurement, previous treatments, organ and marrow function, blood pressure, thyroid function, cardiac function, pregnancy status, contraception use, and written consent. The exclusion criteria are also listed, which include conditions such as brain metastases, gastrointestinal conditions, recent surgeries or therapies, bleeding disorders, pregnancy or breastfeeding, allergies to the investigational products, drug or alcohol abuse history, viral infections, cardiac abnormalities, gastrointestinal abnormalities, and other medical conditions that may interfere with study participation.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 1/phase 2, focusing on the treatment of chronic hepatitis C. The trial includes patients who are chronically infected with HCV genotype 1 and have not received any previous treatment or have not responded to previous treatment, or are intolerant to treatment. The patients must have a HCV RNA viral load of at least 10^5 IU/mL and a body mass index (BMI) between 18 and 35 kg/m\u00b2.\n\nThe trial has certain inclusion criteria, such as being chronically infected with HCV genotype 1, treatment history, viral load, and BMI range. There are also exclusion criteria, including having any significant acute or chronic medical illness that is not stable or controlled with medication and is not consistent with HCV infection, recent major surgery or gastrointestinal surgery that could affect the absorption of the study drug, and co-infection with HIV or HBV.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include brain and central nervous system tumors, childhood germ cell tumor, chordoma, kidney cancer, liver cancer, neuroblastoma, ovarian cancer, retinoblastoma, and sarcoma. The corresponding ICDCodes for these diseases are also listed.\n\nThe drugs being used in the trial are amifostine trihydrate, busulfan, filgrastim, melphalan, and thiotepa. \n\nThe eligibility criteria for participants in this trial include having histologically confirmed high-risk or relapsed solid tumors or brain tumors, being between the ages of 1 and 45, having a performance status of Karnofsky 70-100%, and meeting certain blood count and organ function requirements. There are also exclusion criteria listed, such as having osteogenic sarcoma, being less than 4 months old, having uncontrolled bleeding or congestive heart failure, and being pregnant or nursing, among others.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in the early phase 1 and focuses on the treatment of hepatocellular carcinoma, a type of liver cancer. The trial uses the drug Nexavar. The eligibility criteria for participants are listed, including age, confirmation of diagnosis, performance status, liver function, and other medical factors. There are also exclusion criteria, such as prior use of sorafenib (the generic name for Nexavar), cardiac disease, brain metastasis, and other medical conditions that would make a patient ineligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in the early phase 1 and focuses on the disease of asthma. The ICD-10 codes associated with asthma are provided. The drug being studied is iloprost. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include being between the ages of 18-60, having a history of asthma controlled by inhaled rescue medication or inhaled corticosteroids, being able to give informed consent, being able to perform pulmonary function tests, being able to tolerate the initial Ventavis inhalation, and being able to comply with the study protocol. The exclusion criteria include cigarette smoking, having serious concomitant diseases such as diabetes, hypertension, coronary heart disease, other lung disease, or cancer (except skin cancer), being pregnant or lacking contraception, having allergies or intolerance to inhaled iloprost, participating in other ongoing research studies, having any psychological problems that may interfere with the investigation, having a history of bleeding disorder or using anticoagulants, having a viral upper respiratory tract infection within the last 6 weeks, and having certain high doses of inhaled corticosteroids or using other specific medications. Any screening laboratory blood test value outside the normal range would also exclude an individual from the study, although an isolated abnormal value could be retested after at least a week.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is prostate cancer, and the corresponding ICDCodes are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being tested is he3235. The eligibility criteria for this sample include requirements such as being a male patient over 18 years old, having metastatic disease, having failed at least one taxane regimen, or being chemotherapy-naive with symptomatic or asymptomatic CRPC. Other criteria include having confirmed adenocarcinoma of the prostate, disease progression despite hormone therapy, and specific performance status. The sample also includes exclusion criteria related to brain metastases, active infection, cardiovascular or other significant medical conditions, abnormal laboratory results, and neurological or psychiatric conditions. Additionally, there are mentions of additional criteria applicable to expansion cohorts.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The sample includes a specific entry for a trial related to renal cell carcinoma. \n\nIn this trial, the phase is described as \"phase 1/phase 2.\" The disease being studied is renal cell carcinoma. The ICDCodes associated with this disease are listed as \"['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8'].\" The drug being used in the trial is a combination of temsirolimus and sunitinib. \n\nThe eligibility criteria for the dose escalation phase include requirements such as histologically confirmed advanced RCC, a maximum of 2 prior systemic regimens for RCC, and the presence of at least 1 measurable lesion. The exclusion criteria for this phase include subjects with known active central nervous system malignancy, prior therapy with sirolimus, temsirolimus or sunitinib, and subjects receiving certain Cytochrome P450 (CYP)3A4 isoenzyme inhibitors and/or inducers.\n\nThe inclusion criteria for the expanded cohort phase include subjects with histologically confirmed advanced RCC regardless of nephrectomy status, who have received no prior systemic therapies for their disease. The exclusion criteria for this phase include subjects with a history of CNS malignancy or metastatic disease to the CNS, prior anti-vascular endothelial growth factor therapies, and subjects receiving certain CYP3A4 isoenzyme inhibitors and/or inducers.\n\nOverall, the sample provides information about the trial phase, the disease being studied, the associated ICDCodes, the drug being used, and the eligibility criteria for both the dose escalation and expanded cohort phases.",
    "The sample from the table represents a phase 1 clinical trial for advanced solid tumors or lymphoma. The trial includes patients with diseases such as anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, and extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, among others. The trial also includes patients with specific ICD-10 codes associated with these diseases. The drugs being studied in the trial are gemcitabine hydrochloride and triapine. The eligibility criteria for the trial include factors such as confirmed diagnosis, ECOG performance status, blood counts, liver and kidney function, pregnancy status, and previous treatments. The sample also specifies the time intervals since prior treatments and the exclusion of certain concurrent therapies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is asthma. The ICDCodes associated with asthma are listed as \"J45.998\", \"J82.83\", \"J45.909\", \"J45.991\", \"J45.20\", \"J45.30\", and \"J45.40\". The drugs being used in the trial are \"gsk679586\" and \"placebo\". \n\nThe eligibility criteria for this trial include age restrictions for both men and women, with specific requirements for female subjects to be of non-childbearing potential. Male subjects must agree to abstain from sexual intercourse or use contraception during sexual intercourse with pregnant or lactating females. Other criteria include body weight and BMI ranges, non-smoking status, ability to complete all study measurements, and proficiency in reading, comprehending, and writing English. Written informed consent is also required.\n\nAdditional inclusion criteria are specified for subjects in Part I and Part II of the trial. For Part I, subjects must be determined healthy based on medical evaluation, including history, physical examination, laboratory tests, and cardiac monitoring. For Part II, subjects must have a history of asthma for at least 6 months, with specific requirements for treatment and lung function measurements. A positive skin prick test for an appropriate allergen is also required.\n\nExclusion criteria include being deemed unsuitable for the study based on medical evaluation, history of sensitivity or allergy to study medications, previous exposure to humanized antibody therapy, family history of Th1 cytokine-related inflammatory disorders, history of tuberculosis or chronic infections, recent vaccination, recent participation in another clinical trial, restrictions on blood donation, exposure to multiple new chemical entities, recent use of prescription or non-prescription drugs, history of alcohol or drug abuse, positive test results for hepatitis B, hepatitis C, or HIV, positive urine drug/alcohol screen, abnormal ECG results, risk of non-compliance with study procedures, history of parasitic infection, and inability to refrain from traveling to countries with a high prevalence of infectious diseases during the trial period.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is HIV infections, which is represented by the ICD-10 code 'Z21'. The drug being tested is maraviroc. The eligibility criteria for participants include being at least 16 years old, having an HIV RNA level of at least 1000 copies/mL, and potentially receiving another investigational antiretroviral compound in a separate clinical study. The participant must also have at least 3 active drugs other than maraviroc in their new optimized background therapy (OBT) based on genotypic resistance testing. There are also exclusion criteria, such as having a potentially life-threatening laboratory abnormality or medical condition, severe hepatic impairment, or end-stage renal disease requiring dialysis therapy.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on the treatment of glioblastoma, glioblastoma multiforme, and gliosarcoma. The diseases are identified by their respective ICD-10 codes. The drugs being studied are enzastaurin and temozolomide. \n\nThe inclusion criteria for the trial state that patients must have a confirmed diagnosis of intracranial glioblastoma multiforme or gliosarcoma, with a biopsy or resection performed within the last 5 weeks. An MRI or CT scan must have been obtained within 14 days prior to treatment. Patients should not have received prior drug therapy for brain tumors and must have adequate organ function as demonstrated by lab tests.\n\nThe exclusion criteria state that patients who are unable to swallow tablets, unable to discontinue the use of certain antiepileptic drugs, have an active infection, have a significant medical illness that cannot be controlled, or are concurrently receiving anticoagulant therapy will be excluded from the trial. However, if a patient requires anticoagulant therapy after starting treatment, they may remain in the study but should be closely monitored.",
    "The sample is a phase 1 trial for the treatment of respiratory syncytial virus infections. The trial is testing the drugs rv568 and placebo. The eligibility criteria for participants include being healthy males aged 18-45 years, using adequate contraception, testing negative for hepatitis B, hepatitis C, HIV, drugs of abuse, alcohol, and nicotine, providing written informed consent, having low titres of RSV neutralising antibody, and meeting various exclusion criteria such as not having any acute or chronic illness, not having febrile illness or respiratory tract infection symptoms in the 28 days prior to the trial, not having a history of asthma or other lung conditions, not having diabetes or autoimmune diseases, and not having certain anatomical or neurological abnormalities. Other exclusion criteria include not having abnormal pulmonary function, abnormal laboratory or ECG results, not using medication for nasal congestion, not using prescription drugs, herbal supplements, or over-the-counter medication prior to the trial, not receiving certain treatments or participating in other clinical trials, not having allergies or adverse reactions to the challenge virus preparation or gentamicin, not having certain nasal or sinus conditions, not planning to travel to high-risk infection countries during the trial, not being a healthcare worker with patient contact, not having household members or close contacts with certain medical conditions, not being an employee or relative of the organizations conducting the trial, and not having any other findings or opinions from the general practitioner or investigator that deem the subject unsuitable for the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"neoplasms,\" and the corresponding ICDCodes are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drug mentioned is \"regorafenib (stivarga, bay73-4506)\". The eligibility criteria for this trial include various factors such as age, confirmation of advanced solid tumors, refractory to standard treatment, Eastern Cooperative Oncology Group performance status, adequate bone marrow, liver and renal function, and a life expectancy of at least 3 months. The exclusion criteria include conditions like unstable/uncontrolled cardiac disease, history of arterial or venous thrombotic or embolic events, malabsorption condition, severe renal impairment, symptomatic metastatic brain or meningeal tumors, and clinically significant bleeding within 30 days before starting the study medication.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is vincristine sulfate liposome injection plus rituximab. The eligibility criteria for participants include having histologically-confirmed diffuse large B-cell non-Hodgkin's lymphoma, confirmation of CD20 expression on lymphoma cells, an Eastern Cooperative Oncology Group (ECOG) score of 2 or lower, having received one or more prior chemotherapy regimens, having measurable disease in at least one site, and meeting certain laboratory values. There are also exclusion criteria listed, such as having a known transformation from an indolent lymphoma, being eligible for conventional or high-dose chemotherapy with curative intent, recent radiotherapy or chemotherapy, and various medical history and allergy restrictions.",
    "The sample from the table is a clinical trial for phase 1/phase 2 of a treatment for relapsed CD20-positive B-cell non-Hodgkin's lymphoma. The trial is looking for patients who are chemosensitive (at least in partial remission) and have not started any anti-cancer therapy within the past three weeks. Patients should also not have had prior radioimmunoconjugate therapy or more than 25% bone marrow involvement if they had prior radiation. Other eligibility criteria include age between 18 and 65, acceptable hematologic status, a prestudy performance status of 0, 1, or 2, and not being pregnant or lactating for female patients. Patients who have previously been treated with Phase II drugs can also be included if there are no long-term toxicities expected and they have been off the drug for four or more weeks with no significant post-treatment toxicities observed. The trial also has exclusion criteria, such as impaired bone marrow reserve, prior radioimmunotherapy, presence of central nervous system lymphoma, chronic lymphocytic lymphoma, HIV or AIDS-related lymphoma, abnormal liver or renal function, prior external beam radiation therapy to more than 25% of active bone marrow, and other serious nonmalignant diseases or infections that could compromise the objectives of the trial.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, which can be phase I, phase II, or phase III. The \"diseases\" column lists the names of diseases being studied in the trial. The \"icdcodes\" column contains the corresponding ICD-10 codes for each disease. The \"drugs\" column lists the names of drugs being tested in the trial. The \"criteria\" column provides the eligibility criteria for patients to participate in the trial.\n\nThe sample data in the table includes an example of a phase 1 trial. The diseases being studied are \"advanced cancer,\" \"solid tumors,\" \"cancer,\" and \"neoplasms.\" The corresponding ICD-10 codes for these diseases are provided in the \"icdcodes\" column. The drug being tested is \"rigosertib sodium.\" The eligibility criteria for this trial include having a confirmed metastatic or unresectable malignancy, not responding to standard treatments, and meeting various medical criteria such as blood counts, liver function, and performance status. There are also exclusion criteria, such as recent major surgery or ongoing infections, that would disqualify a patient from participating in the trial. Pregnant and nursing women, as well as HIV-positive patients receiving combination anti-retroviral therapy, are also excluded from the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on studying the effects of a drug called bavituximab. The trial is targeting patients with hepatitis C virus and HIV infections. The diseases are represented by their names and corresponding ICD-10 codes. The sample also includes the eligibility criteria for the trial, including requirements for written informed consent, age, HIV infection confirmation, CD4+ cell count, hepatitis C infection confirmation, liver function, blood counts, renal function, and normal blood clotting. The sample also lists exclusion criteria, such as recent antiviral therapy, prior exposure to certain antibodies, liver diseases other than chronic hepatitis C, bleeding disorders, history of thromboembolic events, concurrent use of certain medications, recent surgery, pregnancy or nursing, uncontrolled intercurrent diseases, history of cardiovascular conditions, and other conditions or therapies that may affect immunologic function.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, which can be phase I, phase II, or phase III. The \"diseases\" column contains a list of disease names, while the \"icdcodes\" column contains a list of corresponding ICD-10 codes for the diseases. The \"drugs\" column contains a list of drug names. The \"criteria\" column contains the eligibility criteria for the trial.\n\nIn the provided sample, the phase is \"phase 1\". The diseases listed include \"extensive stage small cell lung cancer\", \"hereditary paraganglioma\", \"male breast cancer\", and many others. The corresponding ICDCodes for these diseases are also provided. The drugs mentioned in the sample are \"temsirolimus\" and \"vinorelbine ditartrate\". The eligibility criteria are listed under \"criteria\" and include requirements such as histologically confirmed metastatic or unresectable solid tumors, specific performance status, projected life expectancy, provision of informed consent, negative pregnancy test for women, and various other medical conditions and parameters.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are erlotinib and rad001. The eligibility criteria for this trial include specific disease characteristics, such as histologically confirmed adenocarcinoma of the breast, evaluable metastatic disease, and previous anthracycline and taxane therapy. There are also patient characteristics and prior concurrent therapy requirements outlined in the criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are carcinoma and lymphoma. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 for carcinoma, and S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S for lymphoma.\n\nThe drug being tested in this trial is intravenous ezn-2968 (anti-hif-1\u03b1 lna as-odn). The eligibility criteria for patients to participate in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe inclusion criteria include having a confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma, having failed standard therapy with no other effective treatment options available, having measurable or evaluable disease, and being 18 years or older. \n\nThe exclusion criteria include having a concurrent serious medical illness, having a known or suspected history of central nervous system (CNS) tumor involvement, having received chemotherapy, immunotherapy, investigational agents, or other cancer treatments within a specific timeframe before the scheduled administration of EZN-2968, and certain restrictions on hormone therapy for patients with hormone refractory prostate cancer.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on the treatment of neoplasms (cancer).\n- ICD Codes: The specific ICD-10 codes associated with the neoplasms are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'].\n- Drugs: The drugs being used in the trial are 'adh-1' and 'melphalan'.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as age, diagnosis, disease site, previous treatments, medical history, and organ function.\n\nOverall, this sample record provides information about a clinical trial that combines phase 1 and phase 2, focusing on the treatment of neoplasms using the drugs adh-1 and melphalan. It also outlines the specific eligibility criteria that participants must meet to be included or excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is \"diabetes mellitus, type 2\". The ICDCodes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being used in the trial are \"bi10773\" and \"placebo\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion criteria:\n1. Chinese male and female patients with a proven diagnosis of type 2 diabetes mellitus, treated with diet and exercise only or on a maximum of two oral antidiabetic agents (except thiazolidinediones) with at least one agent taken at 50% of its maximum dose or less, unchanged for at least 12 weeks before randomization.\n2. Glycosylated haemoglobin A1(HbA1c) <= 8.5% and >= 7.0% at screening, age >= 21 and age <= 70 years (male and female patients), BMI >= 19 and <= 40 kg/m2.\n3. Signed and dated written informed consent by the date of Visit 1 in accordance with GCP and local legislation.\n\nExclusion criteria:\n1. Patients who did not discontinue the antidiabetic treatment with insulin or glitazones, DPP-IV at least 12 weeks before randomization.\n2. Uncontrolled hyperglycemia with a glucose level > 240 mg/dl (>13.3 mmol/L) after an overnight fast at the screening visit.\n3. Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidemia, and medically treated hypertension, such as:\n   - Any late-stage complication of diabetes (e.g., retinopathy, polyneuropathy, vegetative disorders, diabetic foot).\n   - Renal insufficiency (calculated creatinine clearance < 80 ml/min/1.73m\u00b2).\n   - Cardiac insufficiency NYHA II-IV, myocardial infarction, other known cardiovascular diseases including hypertension > 160/95mmHg (measured at training visit and each of the timepoints of Day -1), stroke, and TIA.\n   - Neurological disorders (such as epilepsy) or psychiatric disorders.\n   - Acute or relevant chronic infections (e.g., HIV, repeated urogenital infections).\n   - Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder.\n   - History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients).\n   - A marked baseline prolongation of QT/QTc interval (e.g., ECG demonstration of a QTc interval > 450 ms) at the screening visit.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs mentioned in this sample are cisplatin (cddp) and vinorelbine. The eligibility criteria for this trial include various conditions such as written informed consent, age of 18 or older, specific stage of NSCLC, expression of MAGE-A3, absence of distant metastasis, and other specific requirements based on different cohorts. Additionally, there are exclusion criteria listed, which include previous or concomitant malignancies, pregnancy or lactation, severe medical problems, psychiatric or addictive disorders, HIV-positive status, and other factors that may limit compliance or pose risks to the patient.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is HIV. The icd-10 codes associated with HIV are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drug being tested is rilpivirine. \n\nThe eligibility criteria for this trial include being an HIV-1 infected male subject, having signed informed consent, being willing to switch therapy as per the study protocol, having no previous exposure to rilpivirine, having a plasma HIV RNA level below 50 copies/mL at screening and on at least one other occasion over the last 3 months, currently receiving a stable antiretroviral regimen comprising of TDF/FTC with nevirapine with no antiretroviral drug switches for at least 3 months, having no clinically-significant resistance documented on any prior HIV-1 genotypic resistance testing, being in good health based on medical history, physical exam, and laboratory testing, having a BMI above or equal to 18 and below 32, and using two forms of barrier contraception during heterosexual intercourse if the male subject is heterosexually active.\n\nThe sample also includes exclusion criteria, such as current alcohol abuse or drug dependence, positive urine drug of abuse screening, active opportunistic infection or significant co-morbidities, current disallowed concomitant medication, contraindication to MR examination or lumbar puncture examination, and recent head injury or chronic ongoing neurological diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drug mentioned is dapagliflozin. \n\nThe eligibility criteria for this trial are described for two groups: individuals with Type 2 Diabetes Mellitus and healthy subjects. The inclusion criteria for individuals with Type 2 Diabetes Mellitus include having a diagnosis of T2DM and being on specific therapies such as diet therapy alone, diet plus a sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin. Subjects taking metformin and/or sulfonylurea must be on a stable dose for at least 2 months prior to the study. Additionally, they must have a fasting plasma glucose concentration of \u2264 200 mg/dl and HbA1C \u2264 10%.\n\nThe inclusion criteria for healthy subjects state that they should have no clinically significant deviation from normal in their medical history, physical examination, ECGs, and clinical laboratory determinations.\n\nThere are also inclusion criteria applicable to all subjects, including having an estimated glomerular filtration rate (eGFR) between 60 and 160 mL/min/1.73m\u00b2 and urinary albumin excretion < 300 mg/g creatinine. The body mass index (BMI) should be between 18 and 38 kg/m\u00b2, and the age range for both men and women is 18 to 65 years.\n\nThe exclusion criteria for all subjects include having Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus. Subjects with T2DM should not have a fasting plasma glucose level above 200 mg/dL, and healthy subjects should not have a fasting plasma glucose level above 105 mg/dL. Additionally, subjects with T2DM should not have an HbA1C level above 10.0%, and healthy subjects should not have an HbA1C level above 6.8%.",
    "The sample provided is for a clinical trial in phase 1. The trial focuses on the disease \"lymphoma\" and the corresponding ICD-10 codes are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being tested is \"azd4877\". \n\nThe eligibility criteria for this trial include patients with AML, a certain type of ALL, NHL, and MM. It also includes certain types of cancer of the lymph nodes and certain types of leukemias (blood cancers). The patients should have failed with other treatments and should be in relatively good overall health other than their cancer.\n\nThe exclusion criteria for this trial include poor bone marrow function (not producing enough blood cells), serious heart conditions, and poor liver or kidney function.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are diabetes and diabetes mellitus, type 2. The ICDCodes associated with these diseases are E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65 for the first disease, and E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44 for the second disease. The drug being tested is insulin degludec. The eligibility criteria for this trial include having type 2 diabetes mellitus for at least 12 months, having a body mass index (BMI) below or equal to 35.0 kg/m2, not having donated blood or plasma in the past month or more than 500 mL within 3 months prior to screening, not being a smoker (defined as smoking more than 5 cigarettes or the equivalent per day), and being able and willing to refrain from smoking and the use of nicotine gum or transdermal nicotine patches during the inpatient period.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of Phase 1 and Phase 2.\n- Diseases: The trial is focused on two types of leukemia - chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.\n- ICD Codes: The ICD-10 codes associated with the diseases are ['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01'].\n- Drugs: The drug being tested in the trial is dasatinib.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include subjects who have completed a previous Phase I and II study and are recommended by the principal investigator to continue with the study drug. Exclusion criteria include pregnant or breastfeeding women, subjects willing to undergo transplantation, and subjects who had non-hematologic intolerance to dasatinib in a previous Phase I and II study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are lymphoma and non-Hodgkin's lymphoma. The ICDCodes associated with these diseases are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being used in the trial is a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone.\n\nThe eligibility criteria for this trial are as follows:\n- Patients must have previously untreated aggressive non-Hodgkin's lymphoma, including specific histologies.\n- Patients must have measurable or evaluable disease.\n- Patients at stage I-IV are eligible.\n- Patients must be 18 years or older.\n- Patients should not have evidence of grade 3 or more neurosensory or neuromotor dysfunction.\n- Written consent is required.\n\nThe exclusion criteria for this trial are as follows:\n- HIV positive patients and those with Hepatitis B or C are excluded.\n- Patients with inadequate bone marrow and organ function, as defined by specific criteria, are excluded.\n- Patients with CNS involvement by lymphoma are excluded.\n- Patients with uncontrolled intercurrent diseases, active infection, or fever above 38.2 degrees Celsius (unless due to lymphoma) are excluded.\n- Patients who are not using adequate contraceptive precautions, pregnant, or breastfeeding are excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 1.\n- Diseases: The trial is focused on recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, and recurrent primary peritoneal cavity cancer.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The drugs being used in the trial are decitabine and pegylated liposomal doxorubicin hydrochloride.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements related to previous treatments, performance status, laboratory results, and other factors. Exclusion criteria are also provided, such as the presence of certain illnesses or conditions, recent treatments, and participation in other clinical trials.\n\nOverall, this sample provides specific information about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on Alzheimer's disease. The trial involves the use of a drug called \"gsk933776\" and a placebo. The eligibility criteria for participants include having a clinical diagnosis of probable Alzheimer's disease, being between the ages of 55 and 80, and having a Mini Mental State Examination (MMSE) score of 18-26. Female participants must be post-menopausal or surgically sterile, and male participants with partners of child-bearing potential must use contraception. Participants must also have the ability to comply with testing procedures and be fluent in the language used for cognitive tests. They must live with or have substantial contact with a permanent caregiver who will oversee compliance with the study protocol. Informed consent is required from both the participant and the caregiver. Exclusion criteria include having any other central nervous system disorder that could be a cause of dementia, living in a nursing home, being unable to provide informed consent due to cognitive status, and having certain conditions on a brain MRI. Other exclusion criteria include having significant psychiatric or neurological illnesses, a history of stroke or diabetes, drug or alcohol abuse, autoimmune diseases, seizures, or significant systemic illness or infection. Participants must not be on certain medications or have certain medical conditions. They must also not have participated in other clinical investigations involving certain medications or devices within a certain timeframe. Contraindications for MRI and smoking more than 20 cigarettes per day are also listed as exclusion criteria.",
    "The sample provided is for a Phase 1 clinical trial. The trial is focused on healthy male volunteers between the ages of 20 and 54. The trial aims to investigate the effects of the drug \"hm10560a\" compared to a placebo. The eligibility criteria for participants include being medically healthy, having a body mass index (BMI) between 19 and 26, and having normal blood pressure and pulse rate. Participants must also abstain from alcohol and smoking during the study period and agree to use contraception for two months after the study ends.\n\nThere are several exclusion criteria, such as recent acute infection, hypersensitivity to recombinant human growth hormone, and positive test results for certain infections. Participants with significant medical conditions or a history of certain disorders or treatments are also excluded. Other exclusion criteria include substance abuse, history of hemophilia or anticoagulant treatment, and aversion to syringe needles. Participants must not have a history of drug abuse or recent blood or plasma donation. They should also not have used herbal products, prescription medication, or over-the-counter medication within specific timeframes prior to the start of the study. Lastly, participants must be willing and able to comply with the study requirements, instructions, and restrictions.\n\nOverall, the sample describes the eligibility and exclusion criteria for participants in a Phase 1 clinical trial, including the specific diseases, drugs, and medical conditions involved.",
    "The sample in the table represents a clinical trial for breast cancer patients. The trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer, and the corresponding ICD-10 codes for the disease are provided. The drugs being tested in the trial are ptk787 and trastuzumab. \n\nThe eligibility criteria for the trial are as follows:\n- Patients must have a histologic or cytologic diagnosis of breast cancer that is either unresectable, locally recurrent, or metastatic.\n- The disease should not involve more than 3 metastatic sites, and the patient should not have symptomatic pulmonary metastasis or liver metastasis involving more than 50% of the liver.\n- The patient must have HER2 gene amplification confirmed by FISH testing. HER protein overexpression alone is not sufficient for entry into the trial.\n- A negative pregnancy test is required.\n\nThe exclusion criteria for the trial are as follows:\n- Patients should not have received prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic disease.\n- Patients should not have received any prior treatment with VEGF inhibiting agents.\n- Patients should not have a history or presence of central nervous system (CNS) disease.\n- Patients should not have received any other forms of cancer therapy, including radiation, chemotherapy, and hormonal therapy, within 21 days prior to being registered for the trial.\n- Patients should not have undergone major surgery within 28 days prior to being registered for the trial.\n- Patients should not have uncontrolled hypertension, a history of labile hypertension, or a history of poor compliance with antihypertensive therapy.\n- Patients should not require therapeutic anticoagulation, regular aspirin (> 325 mg/day) or NSAID use.\n- Patients should not be currently breastfeeding.\n- Patients should not have any impairment of gastrointestinal (GI) function that may significantly alter the absorption of PTK787.\n- Patients should not have evidence of other serious concomitant systemic disorders that are incompatible with the study, as determined by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are \"healthy\" and \"adult\". The ICDCodes associated with these diseases are \"Z76.3\" and \"Z76.2\". The drugs being tested are \"sam-531\" and \"donepezil\". The eligibility criteria for this sample include specific requirements such as age, body mass index, body weight, and overall health. There are also exclusion criteria listed, which include various medical conditions, abnormal EEG results, and recent consumption of caffeine or alcohol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is colorectal cancer, and the corresponding ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are zd1839 and oxaliplatin. \n\nThe eligibility criteria for this trial include the following disease characteristics: the patient must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is not amenable to potentially curative surgical resection, metastatic or locally recurrent disease, and a tumor in the liver or lung accessible to needle biopsy. The patient must also have at least one measurable lesion that meets certain size criteria. \n\nOther eligibility criteria include having failed prior therapy with fluorouracil, leucovorin calcium, and irinotecan, no known brain metastases, being 18 years or older, having an ECOG performance status of 0-2, a life expectancy of at least 3 months, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. \n\nAdditional criteria include not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, not having peripheral neuropathy greater than grade 1, not having any concurrent uncontrolled illness or psychiatric illness that would preclude study participation, and not having any ongoing or active infection. \n\nPrior concurrent therapy restrictions include not having received prior epidermal growth factor inhibitor therapy, not receiving concurrent colony-stimulating factors during the first course of study therapy, and meeting certain requirements for prior chemotherapy, endocrine therapy, radiotherapy, surgery, and other investigational or commercial agents or therapies for malignancy.",
    "The sample from the table is for a phase 1 clinical trial for breast cancer. The eligibility criteria for the trial include patients with histologic confirmation of invasive, non-inflammatory carcinoma of the breast. Patients with stage I (T1N0) are not eligible for the neo-adjuvant portion of the protocol. High-risk patients with stage I disease, such as those with high proliferation rate, poorly differentiated tumors, ER/PR negative, or lymphovascular invasion, are eligible for adjuvant therapy. Patients with pure mucinous carcinomas, tubular carcinomas, or pure medullary carcinomas are eligible if the tumor is larger than 3 cm or if there is lymph node involvement. Patients with bilateral breast cancers are also eligible. Patients with pN2a or pN3a axillary lymph node involvement are eligible, but those with infraclavicular lymph node involvement are not eligible. Patients must have clinically measurable disease to be treated in the neoadjuvant setting. The sample also includes exclusion criteria, such as patients with N2 or N3 nodal disease, inflammatory breast cancer, or metastatic disease. Patients with severe hypersensitivity reactions to the study medications, history of other malignancies (except non-melanoma skin cancer and non-invasive cervical cancer), uncompensated congestive heart failure, recent myocardial infarction, pregnancy or lactation, organ allograft, serious concurrent infections, pre-existing peripheral neuropathy > grade 1, or sexually active male patients unwilling to practice contraception during the study are also ineligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is melanoma. The ICDCodes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in this trial are genasense\u00ae (oblimersen), abraxane\u00ae (paclitaxel protein-bound particles for injectable suspension), and temodar\u00ae (temozolomide). \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Subjects with progressive, unresectable, or advanced melanoma who are considered candidates for systemic treatment with chemotherapy.\n- Subjects must have measurable disease, an Eastern Cooperative Oncology Group Performance Status less than or equal to 2, and serum LDH less than or equal to 1.1 times the upper limit of normal. They should not have previously received cytotoxic chemotherapy.\n- Prior immunotherapy, radiotherapy, or cytokine, biologic, or vaccine therapy is permitted in the adjuvant and/or metastatic setting.\n\nExclusion Criteria:\n- Prior treatment with cytotoxic chemotherapy, including regional perfusion, or with Genasense\u00ae (oblimersen sodium) Injection.\n- Nonmeasurable disease only.\n- History or presence of brain metastasis or leptomeningeal disease.\n- Significant medical disease other than cancer.\n- Known human immunodeficiency virus infection.\n- Pregnant or lactating.\n- Known hypersensitivity to temozolomide, phosphorothioate-containing oligonucleotides, or products containing human albumin.\n- Use of any experimental therapy within 3 weeks prior to baseline evaluations, other anticancer treatment (such as chemotherapy, radiation, or biologic or investigational therapies) while receiving therapy in this study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of HCV infection. The trial involves the use of two drugs, \"vch 916\" and \"placebo\". The eligibility criteria for participants are listed, including age range, liver condition, HCV genotype, overall health, and contraception requirements for females. The sample also includes exclusion criteria, such as participation in other clinical trials, drug or alcohol use, liver cirrhosis, other liver diseases, and certain medical conditions. Coinfection with hepatitis B and/or HIV is also listed as an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are ovarian cancer, peritoneal cancer, and fallopian tube cancer. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are intravenous docetaxel with intraperitoneal oxaliplatin and intravenous oxaliplatin with intraperitoneal docetaxel. The eligibility criteria for participants in this trial include having recurrent histologically confirmed platinum-sensitive or platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer, not having had more than 3 prior regimens, and not having received platinum or taxane agents within the past 6 months. Other criteria include having an ECOG Performance Score of \u22642, adequate bone marrow, renal function, and hepatic function, being recovered from prior surgeries or therapies, and being able to provide informed consent. The sample also includes exclusion criteria such as active infections, extra-abdominal metastases, active CNS metastases, and known hypersensitivity to the drugs being used. Other exclusion criteria include receiving concurrent or recent investigational therapy, having peripheral neuropathy above Grade 2, being pregnant or lactating, having a history of allogeneic transplant, and having known HIV or Hepatitis B or C.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"neonatal seizures,\" and the corresponding ICDCodes are ['E71.511', 'P29.11', 'P29.12', 'P29.2', 'P37.5', 'P54.0', 'P54.1']. The drug mentioned is \"bumetanide.\" \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The participant must be a male or female term baby with a gestational age of 37-43 weeks and a postnatal age of less than 48 hours.\n- The participant must meet one or more of the following conditions: APGAR score less than 5 at 5 minutes, umbilical cord or first arterial blood sample pH less than 7.1 or base deficit greater than 16 mmol/L, postnatal resuscitation still required 10 minutes after birth, clinically evolving encephalopathy, received one dose of standard anticonvulsive therapy (phenobarbitone, 20mg/kg) for clinical or electrographic seizures, EEG showing equal to or more than 3 minutes cumulative seizures or 2 or more seizures of more than 30 seconds duration over a 2-hour period within the first 48 hours of life, written informed consent of parent or guardian, and EEG monitoring commenced within the first 48 hours of birth.\n\nThe exclusion criteria for this trial include the following:\n- Suspected or confirmed brain malformation, inborn error of metabolism, genetic syndrome, or major congenital malformation.\n- Congenital (in utero) infection (TORCH).\n- Babies who have received diuretics such as furosemide or bumetanide in routine clinical management within the last 24 hours.\n- Total serum bilirubin greater than 15 mg/dl (255 micromol/l) at inclusion.\n- On any other anticonvulsive medication other than phenobarbitone or bolus of midazolam/pentobarbitone for intubation.\n- Anuria/renal failure defined as serum creatinine greater than 200 micromol/l.\n- Severe electrolyte depletion (Na less than 120 mmol/L, K less than 3.0 mmol/L).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is cancer, and the ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are gsk1120212 and gsk2110183. \n\nThe eligibility criteria for this part of the trial include being at least 18 years old, having a confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy, and having certain organ system functions within normal ranges. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, agreeing to serial PK sampling and collection of samples for evaluation of circulating free DNA (cfDNA), and being able to swallow and retain orally administered medication. \n\nFor Part 2A of the trial, the eligibility criteria are similar to Part 1, but with the addition of a histologically confirmed diagnosis of secretory multiple myeloma and specific organ system function requirements. \n\nFor Part 2B of the trial, the eligibility criteria are similar to Part 1, but with the addition of a histologically or cytologically confirmed diagnosis of endometrial cancer or ER-/PR-/HER2- breast cancer, and specific disease progression and treatment history requirements. \n\nThere are also exclusion criteria listed, such as recent use of chemotherapy or other anti-cancer therapy, history of certain medical conditions, active infections, and certain cardiac conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 1.\n- Diseases: The trial is focused on Type 1 Diabetes Mellitus.\n- ICD Codes: The ICD-10 codes associated with the disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44'].\n- Drugs: The drugs being tested in the trial are 'insulin glargine (hoe901)' and 'insulin glargine- new formulation (hoe901)'.\n- Criteria: The eligibility criteria for the trial are listed, including inclusion and exclusion criteria. Inclusion criteria state that Japanese patients with Type 1 Diabetes Mellitus who are on treatment with basal-bolus insulin are eligible. Exclusion criteria include age below 20 years, HbA1c levels below 6.5% or above 10.0%, presence of diabetes mellitus other than Type 1, BMI above 35.0 kg/m2, contraindications to the use of insulin glargine, and a history of hypoglycemia unawareness or metabolic acidosis. The provided information is not exhaustive and may not cover all considerations for potential participation in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (in this case, it is \"early phase 1\"), \"diseases\" which lists the disease names (in this case, it is \"breast cancer\"), \"icdcodes\" which lists the ICD-10 codes associated with the diseases (in this case, it is \"['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']\"), \"drugs\" which lists the drug names (in this case, it is \"lapatinib ditosylate\" and \"paclitaxel albumin-stabilized nanoparticle formulation\"), and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe eligibility criteria for this sample trial are described in detail. The criteria include specific disease characteristics such as histologically confirmed breast cancer, clinical stage I-III disease, measurable disease, and HER2/neu status. The patient characteristics include factors like menopausal status, life expectancy, performance status, blood counts, liver and kidney function, cardiac health, and other medical conditions. The criteria also mention prior concurrent therapies that are not allowed, such as previous treatments for breast cancer or epidermal growth factor receptor targeting therapies. Additionally, there are restrictions on the use of certain medications and the presence of other concurrent illnesses or therapies.\n\nIt is important to note that this description is based on the provided sample and may not represent the complete information or structure of the entire table.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 1.\n- Diseases: The trial is focused on the disease \"dementia\".\n- ICD Codes: The ICD-10 codes associated with the disease are \"G31.09\", \"G31.83\", \"F01.50\", \"F01.51\", \"F03.90\", \"F03.91\", and \"F18.17\".\n- Drugs: The trial involves several drugs, including a placebo to match donepezil and mk-3134, a placebo to match scopolamine, mk-3134 25 mg, donepezil 10 mg, and a combination of donepezil 10 mg, mk-3134 25 mg, and scopolamine 0.5 mg.\n- Criteria: The eligibility criteria for participants in the study include being male between 18 and 40 years of age, being a non-smoker in good health, and willing to follow study-related procedures. Participants are not eligible if they have a history of illness that could affect the study results or pose additional risks, if they are taking any medication except for acetaminophen, or if they have a history of significant head injury or trauma."
]